data_2v31_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2v31 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.4 tp . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.803 0.335 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 90.1 p -151.56 167.05 29.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.04 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -157.15 164.7 37.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.962 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -109.89 154.55 22.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.013 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 90.3 t -99.92 123.2 52.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.794 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 31.2 t -100.14 -31.45 11.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.118 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -169.14 135.12 1.65 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 11.0 p -142.56 149.37 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.027 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 81.6 p -107.34 149.46 27.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.921 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -95.91 79.48 3.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.402 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -129.07 -161.43 1.11 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.789 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -152.49 87.51 4.15 Favored Pre-proline 0 C--N 1.331 -0.203 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.292 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.402 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 74.6 Cg_endo -82.7 169.6 59.52 Favored 'Cis proline' 0 C--N 1.348 0.513 0 C-N-CA 123.49 -1.462 . . . . 0.0 112.271 -0.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -111.9 153.01 17.57 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.24 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.87 121.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.83 0.348 . . . . 0.0 111.018 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.463 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 3.3 p -117.27 156.68 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.133 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.403 ' N ' ' CG2' ' A' ' 232' ' ' VAL . 87.8 m -122.2 160.6 24.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.564 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.6 m -99.9 170.04 8.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.816 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.67 140.93 36.88 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.848 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -53.6 -36.02 61.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.39 . . . . 0.0 110.823 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -94.09 44.85 1.13 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.074 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -159.85 159.59 32.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.218 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -127.47 146.59 50.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.007 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -101.28 149.42 24.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.776 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -143.83 43.74 0.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.688 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.41 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 1.6 m-85 -127.1 145.32 50.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.712 0.291 . . . . 0.0 110.651 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -108.65 173.29 6.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.974 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -59.58 94.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.62 -15.58 3.84 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.714 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -63.13 -178.36 0.23 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.738 0.304 . . . . 0.0 110.859 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 265' ' ' MET . 33.6 m-85 -131.79 146.46 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.985 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 19.5 m -144.85 150.43 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.282 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.0 p -120.86 164.28 16.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.414 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 4.2 m-30 -99.74 143.59 29.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.75 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 251' ' ' SER . . . . . 0.411 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 58.1 m -99.97 -90.77 0.31 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.408 -179.702 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.5 OUTLIER -116.3 88.75 2.96 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 120.505 0.193 . . . . 0.0 111.109 -179.851 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.411 HG21 ' HA3' ' A' ' 290' ' ' GLY . 2.4 t -100.24 155.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.977 0.418 . . . . 0.0 111.268 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -111.61 102.59 10.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.901 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.7 -53.71 0.81 Allowed Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.553 -178.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 39.2 ttm -93.04 49.35 1.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.982 0.42 . . . . 0.0 110.483 179.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -79.19 -34.01 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.78 -179.557 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.6 mm-40 -39.33 -34.74 0.22 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.936 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.414 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.8 mm? -59.7 -45.28 92.58 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.325 . . . . 0.0 110.792 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 47.3 t30 -64.02 -34.93 79.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.24 39.6 2.79 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.292 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.3 t -151.54 30.53 0.6 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.686 0.279 . . . . 0.0 110.945 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 61.31 156.16 0.11 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.545 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.1 168.06 6.57 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.37 2.046 . . . . 0.0 112.035 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.435 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.8 OUTLIER -132.67 -175.24 3.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.769 -179.859 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -99.67 134.85 41.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.543 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.41 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -103.8 172.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.627 0.727 . . . . 0.0 112.311 -179.239 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.591 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 10.0 ttpp -140.34 127.42 20.91 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.641 178.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 6.4 m -97.58 115.0 36.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 0.0 111.709 -178.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 51.1 mt -92.93 -28.83 16.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.385 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.23 -167.92 26.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.543 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.98 -49.6 9.38 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.534 2.156 . . . . 0.0 111.921 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -115.06 14.15 17.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.915 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.7 p -120.04 147.28 45.01 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.623 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.591 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.9 p90 -177.87 161.74 1.62 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.98 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.66 170.08 9.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.946 0.403 . . . . 0.0 111.113 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.7 pp -133.41 176.89 7.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.931 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 31.0 p -58.83 -177.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.922 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -66.63 110.12 3.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 10.2 t -108.03 31.71 5.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.6 m -87.12 -15.49 38.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.194 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.06 33.6 1.7 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.771 0.319 . . . . 0.0 111.021 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.405 ' CE2' HD12 ' A' ' 259' ' ' LEU . 26.1 m-85 -144.05 175.64 9.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.797 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.61 174.27 6.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.729 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -83.56 137.11 33.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -64.97 121.32 14.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.866 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 23.0 mt -105.99 -55.59 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 6.9 mtt180 -158.98 -171.33 3.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.378 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 53.34 177.62 0.08 OUTLIER Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.344 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 116.05 106.01 2.5 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.98 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.411 ' HB ' ' HB2' ' A' ' 251' ' ' SER . 7.6 mm -114.58 129.69 70.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 9.1 p -99.74 117.89 45.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.982 0.42 . . . . 0.0 111.484 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -120.45 175.72 5.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.629 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.054 0 CA-C-O 120.828 0.347 . . . . 0.0 110.875 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 2.2 m -157.6 134.42 9.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -136.71 159.6 41.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.038 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.2 mtt -105.09 155.36 19.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 45.2 t -100.67 137.02 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.002 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.2 t -112.18 -37.8 4.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.72 150.77 25.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.92 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 11.2 p -159.96 142.79 5.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.047 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 51.5 p -106.62 146.33 30.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.948 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 31.1 tttt -90.72 64.57 5.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.425 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -106.32 -156.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.811 -179.92 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -157.07 89.52 2.55 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.567 0.223 . . . . 0.0 111.389 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.425 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 91.2 Cg_endo -77.69 169.12 74.5 Favored 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 123.347 -1.522 . . . . 0.0 112.012 -0.273 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.72 148.67 16.54 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.429 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 30.7 t -99.92 120.48 49.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.907 0.384 . . . . 0.0 111.029 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.453 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.6 p -112.99 155.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.12 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.83 162.23 19.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.63 179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.9 m -99.95 166.58 10.99 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.954 0.407 . . . . 0.0 110.935 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 11.2 tp -59.28 153.66 18.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.701 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -51.68 -27.12 10.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.095 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -134.79 42.69 2.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.853 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -91.32 -176.65 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 1.3 tpm_? -130.62 135.46 47.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 38.5 p-80 -109.66 110.67 21.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -126.13 -0.48 7.53 Favored Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.991 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -80.45 139.67 36.33 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.866 0.365 . . . . 0.0 110.705 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.49 169.4 10.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.928 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 4.6 m -59.83 91.57 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.85 23.98 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.685 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -78.74 170.03 17.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 110.879 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 265' ' ' MET . 47.9 m-85 -104.36 122.39 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.903 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 30.2 m -128.07 143.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.345 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.2 p -119.82 165.85 14.04 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.739 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.492 ' CD2' HG22 ' A' ' 253' ' ' VAL . 4.0 m-30 -99.58 145.24 27.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.96 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -105.0 -88.29 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.988 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.606 ' O ' ' CG ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.63 90.99 3.45 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.233 0.54 . . . . 0.0 109.769 179.765 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.492 HG22 ' CD2' ' A' ' 250' ' ' PHE . 17.3 t -116.08 139.26 43.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.607 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 119.68 38.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.219 179.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.09 -65.67 0.5 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.778 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 6.4 ttm -85.75 59.73 5.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.089 0.471 . . . . 0.0 110.396 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 29.9 pt -80.14 -33.39 14.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.977 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.405 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.1 OUTLIER -38.94 -34.72 0.17 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.897 -178.87 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.474 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.1 mm? -75.15 -44.71 45.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.838 0.351 . . . . 0.0 110.614 179.587 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -57.45 -34.89 69.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.892 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.71 38.64 3.07 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.43 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -158.46 165.2 35.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.755 0.312 . . . . 0.0 110.759 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -56.55 167.66 0.94 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.669 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -67.98 169.37 16.58 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.335 2.023 . . . . 0.0 111.999 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.446 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.7 OUTLIER -129.39 -176.99 4.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.716 179.929 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.37 140.7 33.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.757 0.313 . . . . 0.0 110.649 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.2 pp -106.77 171.91 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.55 0.691 . . . . 0.0 112.212 -179.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.602 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -143.05 125.58 15.78 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.617 178.797 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.66 115.53 37.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.598 0.714 . . . . 0.0 111.43 -178.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 50.1 mt -94.27 -27.7 15.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.789 -1.096 . . . . 0.0 110.503 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -163.9 -170.67 29.14 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -62.96 -35.34 66.99 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.52 2.147 . . . . 0.0 112.056 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -123.93 2.44 8.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.169 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -112.24 149.94 31.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.798 0.333 . . . . 0.0 110.791 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.602 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.9 p90 -177.44 162.27 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.767 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 5.1 t -118.19 170.17 9.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.933 0.397 . . . . 0.0 111.332 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.2 pp -133.95 179.3 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.947 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.2 m -58.51 -173.41 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.9 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . 0.407 ' O ' ' CE2' ' A' ' 283' ' ' PHE . 1.7 m-20 -54.12 126.58 23.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.98 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -110.02 -30.15 7.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.968 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 2.9 m -59.44 -30.49 68.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.019 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -71.8 -31.01 66.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.998 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.427 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 50.7 m-85 -89.51 -172.92 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 75.4 m -78.63 -178.32 5.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.993 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -93.26 135.39 34.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.855 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.415 ' CE2' HG11 ' A' ' 253' ' ' VAL . 39.3 t80 -74.94 138.09 42.1 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.746 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.2 mt -117.05 -66.81 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.197 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 -152.65 170.68 19.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.664 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.77 149.72 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.143 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 142.81 116.64 1.18 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.801 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 3.9 mp -117.44 133.56 63.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.755 0.312 . . . . 0.0 110.711 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.8 p -99.88 122.08 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.219 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.7 m -131.48 158.19 41.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.94 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 29.7 tp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.844 0.355 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 13.7 t -147.42 154.71 41.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.834 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.44 155.98 40.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.043 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -94.26 143.44 26.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 39.1 t -99.92 145.04 11.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.058 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 38.7 t -112.79 -32.96 6.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.073 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 14.7 ptm -169.5 159.05 8.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.427 HG13 ' CD1' ' A' ' 286' ' ' TYR . 8.5 p -158.87 149.21 7.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.062 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 63.3 p -99.46 147.56 25.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.948 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.04 81.44 3.7 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.428 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.6 t0 -127.76 -157.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.796 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 1.6 p30 -154.68 90.59 3.09 Favored Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 97.3 Cg_endo -77.13 169.39 74.38 Favored 'Cis proline' 0 C--N 1.347 0.477 0 C-N-CA 123.369 -1.513 . . . . 0.0 112.011 -0.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.76 151.3 17.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.45 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.6 t -99.87 140.25 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.843 0.354 . . . . 0.0 111.008 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.421 HG12 ' CE2' ' A' ' 275' ' ' PHE . 3.3 p -130.88 151.96 36.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.141 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 4.9 m -114.19 158.12 21.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.67 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.1 m -99.97 166.64 10.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 7.2 tp -59.11 152.25 20.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.789 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -50.95 -27.21 7.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.143 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -132.79 38.35 3.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -87.68 -169.0 2.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.158 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.2 ttm180 -145.35 106.84 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.924 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.492 ' CE1' ' CD2' ' A' ' 275' ' ' PHE . 27.5 t60 -107.61 143.64 35.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.82 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 177.04 68.79 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.678 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.452 ' CE2' ' CE1' ' A' ' 240' ' ' HIS . 15.3 m-85 -116.32 149.26 39.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.861 0.362 . . . . 0.0 110.762 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -69.28 151.33 46.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.5 m -57.86 97.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.78 15.35 9.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.721 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -64.9 -178.67 0.45 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.657 0.265 . . . . 0.0 110.743 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.482 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.8 m-85 -120.24 132.06 55.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.789 0.328 . . . . 0.0 110.982 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 17.8 m -137.32 154.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.421 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.4 p -125.59 165.0 19.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.556 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.463 ' CD2' HG22 ' A' ' 253' ' ' VAL . 4.6 m-30 -99.74 140.59 33.73 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.041 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 62.2 m -99.96 -94.09 0.26 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.033 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.54 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.2 OUTLIER -109.66 87.74 2.58 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 121.27 -0.172 . . . . 0.0 110.636 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.463 HG22 ' CD2' ' A' ' 250' ' ' PHE . 15.5 t -107.21 144.72 15.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.928 0.394 . . . . 0.0 111.726 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -107.92 114.94 29.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.912 179.161 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.6 -63.52 0.51 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.671 -0.776 . . . . 0.0 111.458 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 2.9 ttm -89.24 54.57 3.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.133 0.492 . . . . 0.0 110.152 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 14.2 pt -79.04 -33.35 15.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.045 -179.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -38.76 -34.71 0.16 Allowed 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.933 -178.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.45 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.2 mm? -71.08 -47.03 60.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.943 0.401 . . . . 0.0 110.49 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -55.86 -34.85 65.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.896 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.14 46.37 3.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -169.1 166.34 10.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.784 0.326 . . . . 0.0 110.663 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -55.91 164.19 1.83 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.9 168.54 13.43 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.242 1.961 . . . . 0.0 112.078 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.482 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.7 ptp -128.35 -172.29 2.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.516 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -99.37 151.43 21.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.758 0.313 . . . . 0.0 110.654 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 2.1 pp -123.1 174.0 8.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.593 0.711 . . . . 0.0 112.316 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.547 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.2 OUTLIER -147.43 127.77 13.95 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.738 178.919 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 34.9 m -97.88 112.75 30.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.434 0.635 . . . . 0.0 111.539 -178.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 17.6 mt -89.04 -28.0 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.449 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.63 -164.17 24.9 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.583 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 -44.25 9.06 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.586 2.191 . . . . 0.0 112.099 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -117.03 18.34 14.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.029 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.97 146.66 51.67 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.92 0.391 . . . . 0.0 110.794 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.547 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.2 p90 -178.62 154.12 0.74 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.639 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.7 t -105.58 170.06 8.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.014 0.435 . . . . 0.0 111.441 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.61 -178.02 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.84 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.31 175.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.987 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.38 133.2 50.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 62.9 p -118.07 28.57 8.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.06 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 80.3 p -82.21 -30.05 31.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.921 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . 0.405 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 77.5 m-20 -100.1 31.23 3.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.999 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.444 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 24.9 m-85 -138.12 -175.05 3.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.04 178.78 6.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.94 150.88 21.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.929 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.427 ' CD1' HG13 ' A' ' 224' ' ' VAL . 67.3 t80 -81.43 136.39 35.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.5 mt -120.0 -56.81 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.199 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.8 mmt85 -162.48 178.11 8.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.372 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.29 162.58 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.269 -0.967 . . . . 0.0 111.932 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 130.8 116.37 1.81 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.793 179.002 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.2 mt -120.51 133.59 66.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.747 0.308 . . . . 0.0 110.597 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 12.1 p -99.6 117.21 44.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.325 -179.448 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.31 142.54 50.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.812 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.927 -179.938 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 4.0 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.89 0.376 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 63.8 m -134.02 160.22 38.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.991 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -148.0 153.25 38.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.57 155.97 17.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.055 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 41.0 t -105.19 135.31 43.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.021 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.6 t -111.52 -34.75 6.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -164.53 151.91 11.67 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.82 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.44 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 9.8 p -157.86 148.58 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.023 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 64.5 p -101.96 145.36 29.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.913 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -93.65 77.92 4.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.729 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.5 t70 -121.59 -153.68 0.56 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.773 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 37.1 t-20 -157.39 90.19 2.43 Favored Pre-proline 0 CA--C 1.531 0.232 0 CA-C-O 120.452 0.168 . . . . 0.0 111.256 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.401 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 97.4 Cg_endo -76.97 169.8 73.43 Favored 'Cis proline' 0 C--N 1.348 0.5 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.15 -0.253 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.4 149.58 16.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.458 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.2 t -99.88 138.72 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.832 0.348 . . . . 0.0 110.874 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.448 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 3.6 p -131.63 156.9 43.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.406 ' N ' ' CG2' ' A' ' 232' ' ' VAL . 94.3 m -120.92 161.68 21.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.368 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.4 m -99.9 169.86 8.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.908 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 3.2 tp -68.08 153.67 43.24 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.807 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -53.67 -28.3 32.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.97 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -121.68 30.64 6.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.891 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -92.14 -176.42 4.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.122 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -124.87 -175.89 3.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 6.2 t-80 -174.12 113.32 0.18 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -144.78 25.71 1.94 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.819 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.405 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 0.5 OUTLIER -99.04 138.64 35.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.861 0.362 . . . . 0.0 110.595 179.808 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -92.78 168.8 10.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 58.7 p -59.44 102.39 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 120.6 11.7 6.46 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.898 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -73.83 -176.14 2.34 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.732 0.301 . . . . 0.0 110.767 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -132.75 121.82 23.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.798 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 20.2 m -129.1 154.84 40.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 0.0 111.325 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.8 p -123.76 165.51 17.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.862 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.48 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.0 m-30 -99.61 144.27 28.89 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.96 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 28.7 t -102.88 -94.35 0.31 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.011 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -110.29 88.29 2.73 Favored 'General case' 0 C--O 1.225 -0.195 0 CA-C-O 120.511 0.196 . . . . 0.0 110.54 179.684 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.48 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 2.9 t -104.32 143.54 15.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.988 0.423 . . . . 0.0 111.745 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.06 110.81 23.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.924 179.152 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.73 -63.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.701 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 2.1 ttm -86.25 58.58 5.13 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 110.33 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 16.2 pt -79.32 -33.33 15.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.9 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.435 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 4.2 mp0 -38.99 -34.59 0.16 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.859 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.454 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.0 mm? -73.16 -46.82 48.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.938 0.399 . . . . 0.0 110.495 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -58.38 -34.94 71.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.788 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.62 45.35 2.74 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.346 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -165.92 163.96 18.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.775 0.321 . . . . 0.0 110.714 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -56.01 167.65 0.83 Allowed Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.599 179.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -68.68 154.39 71.47 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.302 2.002 . . . . 0.0 112.017 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.429 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.1 ptp -115.11 -177.03 3.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.574 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -99.7 138.67 36.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.773 0.321 . . . . 0.0 110.784 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.405 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -106.79 174.72 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.573 0.702 . . . . 0.0 112.2 -179.473 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -144.04 128.77 18.27 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.508 178.716 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 27.7 m -97.43 118.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.523 0.678 . . . . 0.0 111.495 -178.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 44.5 mt -92.42 -30.78 15.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.662 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.44 -158.99 32.17 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.312 -0.947 . . . . 0.0 113.097 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -63.89 112.13 1.74 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.71 2.273 . . . . 0.0 112.338 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 66.27 14.99 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.08 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -128.73 138.33 52.06 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.484 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.688 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.4 p90 -174.21 169.42 3.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.872 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.0 t -123.42 170.11 10.68 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.98 0.419 . . . . 0.0 111.415 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 11.6 pt -123.58 -177.53 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.802 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 m -57.5 -82.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.983 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -150.15 140.69 22.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.801 0.334 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 71.5 p -113.22 -26.92 8.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.146 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 t -54.53 -24.21 19.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.292 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . 0.401 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 3.3 m120 -94.47 20.91 7.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.23 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.453 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 35.7 m-85 -143.78 -179.61 6.57 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.774 0.321 . . . . 0.0 110.825 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.81 -171.79 0.74 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.893 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -98.87 125.86 44.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.44 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 26.9 t80 -69.98 120.67 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.797 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.2 mt -106.88 -68.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.185 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -138.48 -178.84 5.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.508 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.81 166.67 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.238 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 122.87 111.32 2.05 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.532 -0.842 . . . . 0.0 113.126 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.8 mp -118.69 128.35 75.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 12.6 p -99.55 113.1 33.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.017 0.437 . . . . 0.0 111.531 -179.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.4 m -115.28 -176.81 2.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.641 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.826 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.806 0.336 . . . . 0.0 110.832 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.2 p -168.52 97.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.024 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -102.49 167.49 9.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.986 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 4.5 mmt -105.54 146.46 29.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.015 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.446 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 96.0 t -100.06 130.58 49.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 40.0 t -109.39 -34.88 6.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.066 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -157.0 148.29 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.043 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.433 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.0 p -155.93 113.09 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.005 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 68.8 p -70.81 135.69 48.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.05 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.54 82.96 6.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.726 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -129.85 -147.94 0.35 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.498 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -145.96 102.77 4.16 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 120.342 0.115 . . . . 0.0 110.881 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.414 ' HB2' ' O ' ' A' ' 277' ' ' ILE . 36.2 Cg_endo -68.24 -74.26 0.0 OUTLIER 'Cis proline' 0 C--N 1.349 0.555 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.656 0.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 154.42 139.73 2.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.18 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.3 t -99.83 127.85 52.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.895 0.378 . . . . 0.0 111.025 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.451 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.7 p -116.85 153.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.165 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 90.3 m -117.93 157.86 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.508 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -99.97 168.65 9.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 3.5 tp -68.95 150.81 47.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.781 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -48.5 -28.38 3.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.176 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -133.75 47.42 2.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.85 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -90.85 174.19 7.58 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.163 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -118.38 107.4 13.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.912 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 12.9 p80 -92.57 131.58 37.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.824 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -151.4 26.36 0.97 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.566 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.424 ' CD1' ' HG3' ' A' ' 294' ' ' GLN . 1.4 m-85 -112.3 140.86 46.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 110.719 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.66 175.48 5.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -61.18 88.67 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.773 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.18 -16.47 3.9 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.818 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.09 165.39 3.41 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.658 0.266 . . . . 0.0 110.708 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.498 ' HA ' ' O ' ' A' ' 265' ' ' MET . 5.0 m-85 -113.61 150.15 33.52 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.883 0.373 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.4 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 10.1 m -147.48 144.31 19.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.21 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 p -115.78 163.67 15.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.671 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.454 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 2.0 m-30 -99.44 142.78 30.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.77 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 65.3 m -99.82 -100.12 0.24 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.108 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 1.7 pt-20 -103.1 88.01 3.04 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.605 0.24 . . . . 0.0 110.641 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.45 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 9.8 t -100.9 136.71 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.853 0.358 . . . . 0.0 111.522 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -99.92 107.88 19.98 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.883 179.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.65 -66.02 0.46 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.79 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 32.1 ttm -84.04 59.65 5.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.164 0.506 . . . . 0.0 110.673 179.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 12.4 pt -80.23 -33.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.989 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -38.57 -34.5 0.14 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.454 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.4 mm? -61.64 -53.9 49.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.907 0.384 . . . . 0.0 110.613 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -57.39 -34.94 69.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.884 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.05 46.09 2.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 2.2 t -162.06 30.2 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.69 0.281 . . . . 0.0 110.981 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . 0.401 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 2.4 mt-30 58.33 167.66 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.773 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.401 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 30.1 Cg_endo -63.39 165.8 16.69 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.31 2.007 . . . . 0.0 112.067 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.498 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.7 ptp -134.52 -171.69 2.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.643 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -99.68 138.63 36.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.857 0.36 . . . . 0.0 110.568 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.6 pp -109.71 172.72 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.5 0.666 . . . . 0.0 112.181 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.538 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 8.5 tttm -143.54 125.51 15.29 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.788 -1.096 . . . . 0.0 108.833 178.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 27.4 m -97.61 108.9 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.459 0.647 . . . . 0.0 111.525 -178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.1 mt -86.02 -30.57 22.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.451 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.61 -168.53 27.91 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.615 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -60.1 -50.57 7.14 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.59 2.194 . . . . 0.0 111.816 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -112.91 21.87 15.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.723 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -130.33 145.93 51.85 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.736 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.538 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -179.18 155.68 0.73 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.4 t -104.3 170.08 8.11 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.162 0.506 . . . . 0.0 111.35 -179.249 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.414 ' O ' ' HB2' ' A' ' 229' ' ' PRO . 3.8 pt -124.67 -171.22 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.643 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -74.27 -168.46 0.65 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.623 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -69.77 105.6 2.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.412 ' HA ' ' CD1' ' A' ' 283' ' ' PHE . 4.4 t -132.89 74.25 1.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.932 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 10.1 p -125.76 -33.51 2.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.593 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 -95.14 25.4 4.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.647 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.412 ' CD1' ' HA ' ' A' ' 280' ' ' THR . 21.6 m-85 -117.36 -167.48 1.32 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.739 0.304 . . . . 0.0 110.739 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 31.0 t -74.56 175.95 7.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.842 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -99.4 131.71 45.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.433 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 24.7 t80 -69.01 117.56 10.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.029 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 6.0 mt -102.98 -60.06 3.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.47 -178.75 6.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.459 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . 0.401 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 57.87 158.31 0.02 OUTLIER Glycine 0 C--N 1.331 0.29 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.427 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 129.37 106.13 1.21 Allowed Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.513 -0.851 . . . . 0.0 112.865 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.7 mp -111.54 135.87 49.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.4 ' CG2' ' HB ' ' A' ' 248' ' ' VAL . 12.2 p -99.64 112.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.964 0.411 . . . . 0.0 111.549 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 49.8 m -107.2 171.91 7.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.701 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.424 ' HG3' ' CD1' ' A' ' 242' ' ' PHE . 2.2 tt0 . . . . . 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.086 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 8.1 tp . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.793 0.33 . . . . 0.0 110.834 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 25.6 p -145.25 172.28 13.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -162.98 169.95 18.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.05 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.3 156.08 22.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.939 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 41.0 t -108.21 127.39 64.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.003 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 17.2 t -106.06 -34.68 7.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.974 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.76 137.33 10.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 11.1 p -142.8 122.08 8.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.064 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 31.0 p -81.7 138.67 35.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.112 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -90.56 78.32 6.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.77 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.415 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.9 t0 -123.07 -150.96 0.46 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.723 -179.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -159.44 90.49 1.93 Allowed Pre-proline 0 CA--C 1.532 0.255 0 CA-C-O 120.471 0.177 . . . . 0.0 111.202 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.415 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 81.2 Cg_endo -75.13 169.34 74.82 Favored 'Cis proline' 0 C--N 1.347 0.451 0 C-N-CA 123.322 -1.533 . . . . 0.0 111.937 -0.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -103.86 146.13 16.29 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.377 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.1 t -99.76 125.35 53.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.464 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.7 p -122.55 155.25 27.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.214 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 4.7 m -123.52 166.9 14.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.577 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -100.0 170.05 8.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.745 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.16 160.46 32.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.7 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -55.08 -29.81 58.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.992 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -119.13 34.64 5.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.829 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.94 159.6 15.22 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.019 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -124.65 140.02 53.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.977 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.4 t60 -118.76 144.19 46.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.82 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -159.57 26.39 0.34 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.739 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.407 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 1.6 m-85 -100.53 142.34 32.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.66 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -95.94 170.07 9.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.24 101.07 0.11 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.8 19.26 5.35 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.696 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -84.9 169.27 14.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.758 0.313 . . . . 0.0 110.702 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.441 ' HA ' ' O ' ' A' ' 265' ' ' MET . 62.5 m-85 -108.28 141.81 39.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.912 0.387 . . . . 0.0 111.033 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 32.5 m -146.21 143.5 21.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.1 179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.5 p -121.24 162.52 20.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.425 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 4.0 m-30 -99.76 149.61 23.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.1 m -108.5 -85.17 0.53 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.919 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.602 ' O ' ' CG ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.72 92.58 3.85 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.128 0.49 . . . . 0.0 109.828 179.678 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.422 HG23 ' CD2' ' A' ' 250' ' ' PHE . 3.3 t -112.46 140.63 31.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.479 -179.196 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 68.3 mt-30 -103.79 110.84 23.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.091 179.331 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.88 -57.75 0.64 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.591 -179.021 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -90.27 53.78 2.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.11 0.481 . . . . 0.0 110.353 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 18.8 pt -78.91 -33.79 16.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.843 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -39.24 -34.73 0.2 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.294 -0.412 . . . . 0.0 112.068 -178.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.425 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.5 mm? -66.47 -45.07 80.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 110.685 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -57.68 -38.86 75.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.994 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.7 50.22 1.14 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.511 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.2 t -161.67 30.12 0.13 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.711 0.291 . . . . 0.0 110.905 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 10.2 mt-30 58.82 166.22 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.762 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.34 166.01 13.94 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.441 2.094 . . . . 0.0 112.148 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.441 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.2 ptp -130.97 -174.84 3.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.713 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.52 136.53 39.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.801 0.334 . . . . 0.0 110.616 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.407 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.2 pp -103.15 175.77 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.662 0.744 . . . . 0.0 112.315 -179.317 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.626 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -148.89 128.84 13.46 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.621 178.805 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 26.1 m -97.73 122.89 49.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.528 0.68 . . . . 0.0 111.577 -178.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 48.4 mt -101.95 -29.1 12.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.504 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.49 -172.35 27.64 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.513 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.56 -33.98 65.79 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.556 2.171 . . . . 0.0 112.053 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -124.63 1.92 8.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.166 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -113.98 153.3 29.57 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.85 0.357 . . . . 0.0 110.805 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.626 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.53 169.05 2.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.831 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -124.1 170.08 11.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.993 0.425 . . . . 0.0 111.242 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.3 pt -125.73 -179.21 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.773 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.04 -173.37 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.865 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.67 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.827 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -99.85 33.47 2.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.979 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 31.2 t -109.21 30.78 6.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . 0.406 ' OD1' ' CZ ' ' A' ' 283' ' ' PHE . 28.2 p30 -150.09 30.71 0.7 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.851 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.406 ' CZ ' ' OD1' ' A' ' 282' ' ' ASN . 20.0 m-85 -138.04 -168.42 2.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -91.61 175.25 6.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.84 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -85.43 121.04 27.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -56.67 136.52 54.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.879 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . 0.449 HD11 HG22 ' A' ' 287' ' ' ILE . 30.9 mt -114.16 -59.83 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.301 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.01 173.3 11.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.734 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.36 150.51 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.31 112.53 0.95 Allowed Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.895 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.2 mp -109.22 128.87 64.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.806 0.336 . . . . 0.0 110.614 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.7 p -99.88 114.93 39.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.359 -179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 75.6 m -109.42 -178.03 3.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.638 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 31.9 tt0 . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.001 -179.905 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.745 0.307 . . . . 0.0 110.774 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.7 m -162.19 169.6 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.972 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -162.25 148.39 13.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.951 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.4 mtt -93.45 160.93 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.002 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.422 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 47.9 t -108.73 123.88 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.025 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 28.8 t -102.22 -30.68 10.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.52 143.21 5.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.955 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.401 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.2 p -149.2 137.33 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.087 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 43.8 p -90.22 145.51 24.95 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.83 78.28 4.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.813 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.71 -160.74 1.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.824 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 7.3 p-10 -154.4 90.04 3.22 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.277 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -80.1 169.72 68.61 Favored 'Cis proline' 0 C--N 1.348 0.503 0 C-N-CA 123.501 -1.458 . . . . 0.0 112.168 -0.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -113.76 157.13 15.16 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.334 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.0 t -99.79 125.45 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.858 0.361 . . . . 0.0 110.911 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.461 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.5 p -123.72 155.79 30.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.196 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.407 ' N ' ' CG2' ' A' ' 232' ' ' VAL . 89.1 m -124.16 159.11 30.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.615 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.0 m -99.97 165.9 11.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.86 0.362 . . . . 0.0 110.905 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 3.7 tp -59.92 150.12 29.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.741 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -52.24 -27.79 16.22 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.261 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -99.92 -26.74 13.9 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.04 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . 0.405 ' O ' ' CE2' ' A' ' 273' ' ' TYR . . . -74.4 140.81 44.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.243 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 27.5 ttt180 -120.59 145.31 47.5 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.902 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -86.24 131.53 34.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.935 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -119.52 -19.38 4.19 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.995 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.415 ' CE1' ' HB2' ' A' ' 294' ' ' GLN . 0.2 OUTLIER -78.9 145.93 33.85 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.777 0.322 . . . . 0.0 110.737 -179.879 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -101.92 179.66 4.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -63.72 105.44 0.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.997 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 128.24 -5.39 6.78 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.967 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -80.21 172.34 13.9 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.841 0.353 . . . . 0.0 110.98 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.437 ' HA ' ' O ' ' A' ' 265' ' ' MET . 4.4 m-85 -122.19 152.75 39.64 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.055 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.422 ' CG2' ' CG2' ' A' ' 292' ' ' VAL . 19.5 m -156.55 154.76 5.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.256 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 t -125.61 170.19 11.73 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.725 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.429 ' CD2' HG23 ' A' ' 253' ' ' VAL . 5.5 m-30 -99.6 159.45 15.03 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.13 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 29.3 t -113.37 -87.66 0.56 Allowed 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.065 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -114.66 88.57 2.89 Favored 'General case' 0 CA--C 1.521 -0.15 0 CA-C-O 120.54 0.209 . . . . 0.0 110.852 179.785 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.429 HG23 ' CD2' ' A' ' 250' ' ' PHE . 5.0 t -99.96 158.36 3.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.004 0.431 . . . . 0.0 111.462 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.2 mm-40 -119.04 106.11 12.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.941 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -56.55 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.482 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 2.2 ttm -96.59 51.53 1.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.153 0.502 . . . . 0.0 110.315 179.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.7 pp -75.74 -33.66 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.563 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.415 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 5.1 mm-40 -39.25 -34.64 0.2 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.695 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.425 HD12 ' CE2' ' A' ' 283' ' ' PHE . 3.4 mm? -59.22 -47.32 85.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 110.59 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -57.54 -46.41 83.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.871 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.82 47.56 2.98 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.538 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 5.1 t -152.14 34.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 59.74 168.49 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -67.55 151.34 79.77 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.349 2.033 . . . . 0.0 112.067 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.437 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 3.1 ptp -118.69 -178.01 3.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.711 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -99.75 157.25 16.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.504 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.8 pp -125.93 170.5 15.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.625 0.726 . . . . 0.0 112.312 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.612 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 14.4 mtpt -145.06 126.79 15.25 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.564 -1.198 . . . . 0.0 108.532 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 29.4 m -97.54 120.36 46.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.595 0.712 . . . . 0.0 111.587 -178.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.2 mt -99.11 -30.25 12.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.809 -1.087 . . . . 0.0 110.601 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -162.31 -173.81 31.44 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.565 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.82 -59.27 1.31 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.611 2.208 . . . . 0.0 112.243 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CE2' ' O ' ' A' ' 238' ' ' ALA . 10.0 m-85 -109.39 5.19 23.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.3 p -106.57 149.5 27.1 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.612 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -177.65 166.88 2.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.755 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.4 t -117.21 170.09 8.95 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.7 pt -131.11 179.89 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.16 -179.55 0.78 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.89 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.34 109.23 0.83 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.799 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.6 t -122.5 30.08 6.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.026 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 p -98.66 31.42 2.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.942 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.26 -45.95 1.0 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.425 ' CE2' HD12 ' A' ' 259' ' ' LEU . 30.5 m-85 -59.81 -168.21 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.878 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.2 176.77 9.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.913 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -83.79 125.99 32.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.976 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.401 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 20.7 t80 -61.12 135.04 57.64 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.81 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.7 mt -118.26 -64.71 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.008 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.85 -173.74 4.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.438 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.14 170.38 0.1 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.251 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 118.95 106.83 2.25 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.0 179.261 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 2.9 mp -116.94 125.3 73.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.739 0.304 . . . . 0.0 110.191 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.422 ' CG2' ' CG2' ' A' ' 248' ' ' VAL . 9.8 p -99.68 120.1 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.551 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.5 m -125.58 170.23 11.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.726 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.415 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 27.7 tt0 . . . . . 0 C--N 1.329 -0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.896 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.7 tp . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.872 0.368 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 36.3 p -152.53 146.39 25.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -141.8 145.24 34.5 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.026 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -82.8 151.27 26.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.983 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 83.7 t -104.25 143.85 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.065 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.2 t -117.32 -38.52 3.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.774 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.7 mtp -159.63 143.61 14.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.433 HG11 ' CD2' ' A' ' 286' ' ' TYR . 10.5 p -143.68 121.32 6.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.028 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 32.9 p -79.89 142.76 34.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.007 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.56 78.54 4.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.799 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.422 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 4.7 t0 -127.84 -158.91 0.91 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.749 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -153.53 90.8 3.37 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.543 0.211 . . . . 0.0 111.325 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.422 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 96.9 Cg_endo -77.23 169.17 74.85 Favored 'Cis proline' 0 C--N 1.348 0.512 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.949 -0.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.27 17.53 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.453 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 21.4 t -99.84 136.09 32.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.844 0.355 . . . . 0.0 111.19 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.452 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 6.3 p -127.67 138.12 55.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.014 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.46 162.33 13.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.65 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.99 165.88 11.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.887 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -58.76 158.0 8.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.701 179.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.76 -27.64 29.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.109 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.32 38.51 3.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.804 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -99.22 169.54 9.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.096 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 4.0 tpt180 -150.02 135.71 18.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.001 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.428 ' HB2' ' CE2' ' A' ' 242' ' ' PHE . 27.1 p-80 -137.78 135.96 36.82 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.766 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -122.15 65.07 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.669 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.428 ' CE2' ' HB2' ' A' ' 240' ' ' HIS . 0.9 OUTLIER -111.87 142.1 44.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.848 0.356 . . . . 0.0 110.656 179.856 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.55 172.26 9.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 27.0 m -64.17 99.54 0.28 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.003 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.26 17.89 6.97 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.902 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.01 -175.46 2.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.704 0.288 . . . . 0.0 110.687 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.0 m-85 -120.93 151.95 39.08 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.909 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 35.0 m -156.04 152.2 8.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.374 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.9 p -128.45 168.91 14.95 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.462 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.5 m-30 -99.79 140.94 33.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.135 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.8 m -104.09 -81.38 0.52 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.899 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.572 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -119.56 88.17 2.88 Favored 'General case' 0 C--O 1.216 -0.661 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.61 179.567 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.462 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 9.2 t -114.72 134.17 58.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 120.934 0.397 . . . . 0.0 111.882 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 64.2 mt-30 -99.65 119.82 38.7 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.028 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -62.91 0.51 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.366 -178.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 2.3 ttm -87.9 58.84 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.156 0.503 . . . . 0.0 110.162 179.032 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . 0.433 ' O ' ' N ' ' A' ' 260' ' ' ASN . 1.0 OUTLIER -77.46 -33.34 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.961 -179.437 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.422 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 37.9 mm-40 -39.14 -34.65 0.18 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.444 ' CD1' ' CE2' ' A' ' 283' ' ' PHE . 2.7 mm? -76.87 -39.89 49.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.873 0.368 . . . . 0.0 110.69 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.433 ' N ' ' O ' ' A' ' 257' ' ' ILE . 0.6 OUTLIER -57.09 -36.99 71.27 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.91 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.54 29.1 10.15 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.325 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -144.18 158.42 43.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.767 0.317 . . . . 0.0 110.762 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 12.7 mt-30 -54.42 165.75 0.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.754 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -64.05 174.63 3.8 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.427 2.085 . . . . 0.0 111.826 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.3 OUTLIER -133.86 -177.75 4.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.753 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -99.51 132.83 44.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.455 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.2 pp -102.61 172.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.8 0.81 . . . . 0.0 112.591 -179.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.577 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 43.8 mmtt -142.13 129.69 21.41 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.302 -1.317 . . . . 0.0 108.299 178.484 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 5.8 m -97.48 113.55 32.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.457 0.646 . . . . 0.0 111.567 -178.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.8 mt -93.77 -27.77 16.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.707 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.59 -170.93 34.68 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.811 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -66.99 -27.25 42.89 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.636 2.224 . . . . 0.0 112.309 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 44.5 m-85 -129.42 18.31 5.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.03 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.79 148.85 47.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.843 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.577 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 6.6 p90 -178.55 149.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.611 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 268' ' ' LYS . 1.6 t -107.49 170.14 8.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.275 -179.353 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.7 pp -123.7 -175.85 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.739 179.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 42.7 t -56.87 -77.36 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.038 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -150.06 133.39 16.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.06 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.2 -28.23 5.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.195 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 22.5 p -60.38 -18.61 51.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.373 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -94.49 29.72 2.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.213 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.444 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 58.4 m-85 -150.07 -174.89 4.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.944 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.5 m -70.74 175.32 5.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.967 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -90.98 136.91 32.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.961 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.433 ' CD2' HG11 ' A' ' 224' ' ' VAL . 11.9 t80 -64.73 142.88 58.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.77 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.7 -61.72 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 2.1 mmt-85 -165.35 171.45 13.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.405 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 62.53 153.04 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.095 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.28 132.96 2.86 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.299 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 3.2 mt -135.45 136.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.566 -0.317 . . . . 0.0 110.3 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 11.8 p -99.83 127.2 52.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.192 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.4 m -130.7 135.43 47.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.85 -179.987 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.826 0.346 . . . . 0.0 110.819 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.8 m -146.43 176.84 9.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.002 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -164.15 141.99 7.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.073 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 7.6 mtm -79.32 156.47 28.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.994 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 58.9 t -100.23 137.3 28.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.996 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.4 t -109.75 -31.21 7.53 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.824 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -171.9 131.66 0.67 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.425 HG11 ' CG ' ' A' ' 286' ' ' TYR . 11.9 p -133.91 115.88 22.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.118 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 34.0 p -75.43 141.77 43.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.079 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.77 87.39 6.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.869 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.411 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.8 OUTLIER -136.96 -160.41 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.765 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.402 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 37.4 t-20 -155.77 92.58 2.65 Favored Pre-proline 0 CA--C 1.531 0.228 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.263 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.411 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 87.1 Cg_endo -76.11 169.59 74.08 Favored 'Cis proline' 0 C--N 1.348 0.549 0 C-N-CA 123.389 -1.504 . . . . 0.0 112.098 -0.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.56 145.74 18.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.335 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 28.1 t -99.84 125.92 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.99 0.424 . . . . 0.0 111.067 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.452 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 4.1 p -115.82 157.29 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.4 ' N ' ' CG2' ' A' ' 232' ' ' VAL . 86.5 m -119.56 161.85 19.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.503 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.4 m -99.87 164.75 11.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 110.867 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 24.1 tp -57.44 157.88 6.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -53.88 -26.91 27.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.046 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -125.28 29.75 5.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.946 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -90.81 -178.13 5.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.193 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 3.6 tpt85 -150.09 139.42 21.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 10.5 t-160 -106.64 127.26 53.2 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.746 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -135.8 24.57 3.3 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.967 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.414 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 0.2 OUTLIER -106.9 138.66 42.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.575 179.774 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -90.81 172.45 8.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.977 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.2 p -63.54 101.62 0.35 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.802 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 119.66 7.14 9.92 Favored Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.851 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.58 -174.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.723 0.297 . . . . 0.0 110.769 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 265' ' ' MET . 90.1 m-85 -129.85 142.64 50.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.881 0.372 . . . . 0.0 111.167 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 18.6 m -151.32 154.71 7.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.63 170.5 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.879 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.477 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.3 m-30 -99.1 142.47 30.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.4 m -100.39 -82.49 0.45 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.944 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.6 ' O ' ' CG ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -123.75 91.17 3.41 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.299 0.571 . . . . 0.0 109.793 179.575 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.477 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 2.6 t -114.39 138.05 45.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.568 -178.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -101.57 118.1 36.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.094 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.54 -62.43 0.54 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.858 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.414 ' HG3' HD21 ' A' ' 259' ' ' LEU . 23.3 tpp -88.54 57.45 4.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.167 0.508 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . 0.472 HG22 HD11 ' A' ' 257' ' ' ILE . 0.2 OUTLIER -77.09 -33.3 20.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.977 -179.355 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.41 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.5 OUTLIER -39.03 -34.7 0.17 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.983 -178.756 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.433 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 2.8 mm? -74.76 -43.16 56.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.035 0.445 . . . . 0.0 110.385 179.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.417 ' N ' ' O ' ' A' ' 257' ' ' ILE . 0.6 OUTLIER -50.49 -40.01 49.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.112 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -106.79 46.5 1.16 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 12.9 t -144.07 26.38 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.313 . . . . 0.0 111.085 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 58.14 166.41 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.835 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -61.4 144.9 98.53 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.421 2.081 . . . . 0.0 112.102 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.442 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.3 ptp -115.36 -171.85 2.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.51 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -99.81 149.74 23.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.761 0.315 . . . . 0.0 110.572 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.2 pp -119.87 175.76 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.569 0.7 . . . . 0.0 112.441 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.679 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 2.2 tttp -146.18 131.27 18.32 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.6 -1.182 . . . . 0.0 108.475 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 27.5 m -97.55 119.77 46.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.369 0.604 . . . . 0.0 111.537 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.5 mt -95.48 -29.51 14.35 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.779 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 165.71 -159.81 33.1 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 113.108 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.84 112.66 1.88 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.81 2.34 . . . . 0.0 112.301 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 65.46 15.8 10.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.104 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -130.74 134.66 47.08 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.494 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.679 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.2 p90 -171.85 169.86 5.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.94 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.8 t -124.74 170.07 11.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.6 pp -135.28 -179.87 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.928 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 29.8 p -55.77 -172.47 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.005 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -62.14 119.68 9.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 10.0 t -135.33 30.74 3.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.956 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 35.3 t -97.37 -34.06 11.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.923 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -70.21 -25.39 63.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.055 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.41 ' CD1' ' HB3' ' A' ' 258' ' ' GLN . 20.7 m-85 -77.48 -170.66 1.86 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.918 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.27 -160.54 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.762 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -117.98 131.18 56.51 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.839 0.352 . . . . 0.0 110.715 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.425 ' CG ' HG11 ' A' ' 224' ' ' VAL . 17.3 t80 -57.82 131.05 49.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.983 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.0 mt -111.89 -64.85 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.031 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.06 164.84 36.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.724 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.81 151.73 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.199 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.06 122.29 1.84 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.721 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 26.8 mt -125.85 131.6 71.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.776 0.322 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 13.2 p -99.98 108.82 23.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.031 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 62.3 m -103.51 169.12 8.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.82 179.97 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.781 0.324 . . . . 0.0 110.85 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.8 p -137.79 152.08 48.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.951 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -137.34 147.82 45.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.06 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -86.57 151.17 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.887 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 59.0 t -99.94 136.24 32.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.009 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.0 t -111.61 -34.27 6.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.974 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.4 mtp -163.99 153.75 14.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.992 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 11.0 p -157.14 135.61 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.05 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.3 140.75 29.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -86.75 74.06 9.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.861 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.422 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.4 t0 -122.09 -156.73 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.68 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -158.91 91.18 2.01 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-O 120.516 0.198 . . . . 0.0 111.307 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.422 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 80.2 Cg_endo -76.06 169.72 73.71 Favored 'Cis proline' 0 C--N 1.348 0.527 0 C-N-CA 123.451 -1.479 . . . . 0.0 112.074 -0.108 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.21 151.8 17.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.501 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.9 t -99.98 114.69 39.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 0.0 111.109 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.434 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 4.3 p -106.15 157.1 6.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.108 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 1.7 m -121.81 165.02 16.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.581 179.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.03 169.98 8.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.908 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -68.86 158.66 34.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.754 179.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -54.21 -33.53 58.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.044 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -122.38 29.98 6.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.892 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -82.24 -175.66 5.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -148.45 107.62 3.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.952 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.462 ' CE1' ' CD2' ' A' ' 242' ' ' PHE . 34.5 t-80 -97.29 136.64 37.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.767 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -164.48 62.94 0.24 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.697 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.462 ' CD2' ' CE1' ' A' ' 240' ' ' HIS . 3.8 m-85 -122.6 143.81 49.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.817 0.341 . . . . 0.0 110.759 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.26 156.7 36.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 5.7 m -58.48 97.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.96 10.37 12.34 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.826 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -60.04 174.11 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.747 0.274 . . . . 0.0 110.724 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.447 ' HA ' ' O ' ' A' ' 265' ' ' MET . 54.7 m-85 -115.99 130.93 57.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.813 0.34 . . . . 0.0 111.066 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 15.0 m -144.96 159.36 13.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.019 0.438 . . . . 0.0 111.399 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.21 170.71 14.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.453 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 3.6 m-30 -99.08 145.49 27.07 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.967 -179.581 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -100.37 -86.6 0.39 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.088 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -119.33 88.32 2.91 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-O 120.535 0.207 . . . . 0.0 110.664 179.627 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.453 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 2.8 t -102.16 149.9 6.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.55 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.59 30.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.811 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 100.1 -73.29 0.45 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.431 -178.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 3.3 tpp -83.71 60.28 5.65 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.2 0.524 . . . . 0.0 110.215 179.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 16.1 pt -78.63 -33.0 16.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.498 -0.774 . . . . 0.0 112.001 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -38.32 -34.39 0.13 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.897 -178.669 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -63.7 -50.25 69.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.979 0.419 . . . . 0.0 110.239 179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -53.32 -34.73 58.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.998 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -85.84 45.06 3.42 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.808 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 4.6 t -165.78 150.21 8.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.743 0.306 . . . . 0.0 110.767 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.64 159.95 0.5 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.849 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -53.35 149.13 30.62 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.449 2.099 . . . . 0.0 111.87 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.447 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 5.7 ptp -111.91 -173.04 2.16 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.476 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -99.75 155.32 17.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.762 0.315 . . . . 0.0 110.792 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.8 pp -123.47 169.64 14.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.5 0.667 . . . . 0.0 112.127 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.584 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -142.36 125.44 16.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.825 -1.079 . . . . 0.0 108.818 178.707 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.415 HG11 ' CE1' ' A' ' 240' ' ' HIS . 33.0 m -97.65 112.61 30.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.53 0.681 . . . . 0.0 111.499 -178.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.5 mt -90.77 -27.72 18.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.522 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -167.31 -166.24 26.06 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.582 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.55 -52.88 3.31 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.573 2.182 . . . . 0.0 111.857 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 20.8 m-85 -112.86 18.92 17.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.87 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.88 145.65 49.7 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.67 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.584 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.8 p90 -178.07 159.2 1.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -108.92 170.05 8.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.158 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.2 pt -131.2 -179.98 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.803 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.33 172.85 1.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.905 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.74 118.91 7.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.857 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.9 t -141.17 51.2 1.6 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.984 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 7.2 p -102.69 -22.08 14.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.171 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -96.51 31.4 2.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.748 0.309 . . . . 0.0 111.089 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -128.77 -175.47 3.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.777 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.04 125.76 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.717 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.56 149.17 0.19 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.553 -179.688 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -78.14 137.36 38.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.853 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.3 mt -119.11 -65.18 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.102 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -148.71 -174.48 4.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.44 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 55.76 169.02 0.07 OUTLIER Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.258 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 122.09 116.75 2.4 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.981 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 2.8 mp -128.79 127.31 66.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.729 0.3 . . . . 0.0 110.252 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.7 p -99.65 111.06 28.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.992 0.425 . . . . 0.0 111.369 -179.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -106.36 158.31 16.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.706 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.968 -179.828 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.6 tp . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.819 0.342 . . . . 0.0 110.828 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 55.9 p -158.0 160.51 37.57 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.025 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -159.11 170.08 22.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.079 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 6.6 mtm -105.88 157.04 17.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.8 t -109.51 130.6 62.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.836 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 22.9 t -109.94 -35.1 6.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.162 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.46 148.51 27.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.936 0.398 . . . . 0.0 111.067 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.447 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.3 p -158.31 137.04 3.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.969 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 144.63 29.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.01 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.2 ttmt -89.68 72.63 7.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.815 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -122.49 -160.77 0.9 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.858 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 8.0 p-10 -156.08 90.91 2.7 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.175 -179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -78.87 169.9 70.92 Favored 'Cis proline' 0 C--N 1.349 0.577 0 C-N-CA 123.495 -1.46 . . . . 0.0 112.179 -0.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.17 153.01 17.87 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.444 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.3 t -99.85 122.35 51.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.883 0.373 . . . . 0.0 111.0 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.434 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.8 p -114.34 153.81 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.165 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 1.7 m -123.33 155.73 36.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.486 179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.85 170.02 8.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.83 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -71.83 143.43 49.46 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.764 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -24.86 30.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.399 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -100.54 -18.07 16.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.364 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -79.57 168.01 19.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.824 0.345 . . . . 0.0 111.247 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.08 -167.83 1.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.864 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 9.3 p80 -171.96 155.33 3.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.847 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 179.26 54.33 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.872 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.404 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 1.1 m-85 -103.74 141.05 36.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.823 0.344 . . . . 0.0 110.575 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -71.69 153.44 42.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.7 m -57.08 97.44 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.12 9.44 15.67 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.746 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.17 -165.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.772 0.286 . . . . 0.0 110.545 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.548 ' HA ' ' O ' ' A' ' 265' ' ' MET . 86.9 m-85 -128.9 143.06 50.78 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.916 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.404 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 15.9 m -149.58 134.87 10.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.731 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.1 p -111.95 166.47 11.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.434 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.478 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.7 m-30 -99.85 143.93 29.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.02 -179.853 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 25.7 m -99.93 -86.28 0.39 Allowed 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.988 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.598 ' O ' ' CG ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -120.02 92.76 3.85 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.266 0.555 . . . . 0.0 110.006 179.896 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.478 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 4.6 t -111.43 139.02 37.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.383 -179.264 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -99.93 116.27 31.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.194 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.23 -65.53 0.5 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.629 -0.795 . . . . 0.0 111.897 -179.253 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 1.5 ttt -89.91 59.38 4.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.487 . . . . 0.0 110.534 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 15.0 pt -77.99 -33.94 18.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.67 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.7 mm100 -39.24 -34.64 0.2 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.81 -179.091 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.454 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.3 mm? -60.6 -49.54 77.12 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.884 0.373 . . . . 0.0 110.576 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -64.75 -34.82 79.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.835 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -93.1 39.38 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.496 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.5 t -159.26 34.25 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 0.0 110.716 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 61.88 168.41 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.597 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -61.46 -153.15 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 111.702 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.548 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.9 ptp -172.78 -175.89 1.36 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.805 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.58 147.37 25.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.656 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.404 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.2 pp -119.73 174.99 4.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.675 0.75 . . . . 0.0 112.482 -179.49 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.652 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.0 mttt -147.33 131.07 16.95 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.401 178.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 34.6 m -97.54 122.33 49.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.433 0.635 . . . . 0.0 111.63 -178.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 15.0 mt -96.77 -30.87 12.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.651 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.29 -171.81 42.09 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.245 -0.979 . . . . 0.0 113.214 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_exo -51.75 112.96 0.96 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.793 2.328 . . . . 0.0 112.475 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 64.71 19.41 11.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.054 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.5 p -133.0 139.35 47.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.459 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.652 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.3 p90 -176.97 166.48 2.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 -179.57 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -118.56 170.05 9.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.992 0.425 . . . . 0.0 111.161 -179.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -134.62 -178.63 2.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.848 179.814 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 29.9 p -57.35 -177.55 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -72.56 124.06 24.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.416 ' HA ' ' CD1' ' A' ' 283' ' ' PHE . 8.6 t -137.69 51.88 1.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.971 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 96.5 p -88.37 -54.8 4.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -67.4 -19.62 65.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.192 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.434 ' CE2' HD12 ' A' ' 259' ' ' LEU . 23.5 m-85 -59.49 -176.94 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.748 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 48.1 t -78.18 -175.81 4.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.895 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.79 127.25 48.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.907 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.447 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 65.4 t80 -72.21 140.97 48.99 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 26.1 mt -125.45 -63.51 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.09 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 5.7 mmt180 -153.94 175.56 13.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.655 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.48 149.65 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.424 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.06 115.47 1.19 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.768 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 18.4 mm -114.29 133.43 60.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 120.743 0.306 . . . . 0.0 110.821 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.404 ' CG2' ' HB ' ' A' ' 248' ' ' VAL . 14.1 p -99.89 114.65 38.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.035 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.3 m -119.56 154.44 33.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.051 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 12.9 tt0 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.962 179.898 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.851 0.357 . . . . 0.0 110.747 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 50.2 p -136.21 127.87 28.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -122.18 148.8 44.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.079 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -78.31 145.97 35.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.948 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.0 t -99.94 140.6 18.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 6.5 t -105.93 -29.66 9.83 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.016 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.81 158.69 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.027 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.453 ' CG1' ' CD2' ' A' ' 286' ' ' TYR . 11.6 p -160.93 122.08 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 65.0 p -84.31 143.25 29.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.037 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.42 56.34 3.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.461 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.6 t0 -91.61 -151.02 0.26 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.818 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -159.85 90.57 1.84 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-O 120.489 0.185 . . . . 0.0 111.372 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.461 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 71.8 Cg_endo -73.24 169.11 74.02 Favored 'Cis proline' 0 C--N 1.347 0.493 0 C-N-CA 123.244 -1.565 . . . . 0.0 111.836 -0.132 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -101.41 147.28 17.59 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.436 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.1 t -99.81 145.65 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.87 0.367 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.448 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 4.4 p -139.2 151.15 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.22 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 63.6 m -122.5 161.01 24.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.412 179.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.1 m -99.84 169.29 9.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.879 0.371 . . . . 0.0 110.86 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 2.9 tp -70.69 148.16 48.32 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.834 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -56.26 -30.83 62.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -106.36 50.76 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -178.35 152.79 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.25 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 20.7 ttm105 -135.89 155.41 50.34 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.857 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 23.4 p-80 -111.23 148.37 32.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.792 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -130.27 70.4 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.723 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.426 ' CE1' ' HB2' ' A' ' 294' ' ' GLN . 0.9 OUTLIER -126.55 141.54 51.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.766 0.317 . . . . 0.0 110.746 179.78 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.61 166.97 12.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.941 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 13.2 m -59.58 100.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.9 18.42 5.58 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.856 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.52 174.75 10.78 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.715 0.293 . . . . 0.0 110.767 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.431 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.4 m-85 -114.3 134.06 55.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 19.1 m -138.24 153.44 26.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.053 0.454 . . . . 0.0 111.359 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 11.1 p -124.2 165.11 18.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.577 179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.489 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 1.9 m-30 -99.8 141.3 32.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.045 -179.69 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 251' ' ' SER . . . . . 0.4 ' CB ' ' HB ' ' A' ' 291' ' ' ILE . 31.3 t -99.91 -101.65 0.23 Allowed 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.7 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' A' ' 290' ' ' GLY . 3.3 pt-20 -102.52 87.58 3.04 Favored 'General case' 0 C--O 1.223 -0.333 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.489 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 5.4 t -105.74 134.38 47.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.869 0.366 . . . . 0.0 111.786 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 18.8 mt-30 -99.9 116.02 30.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.777 178.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.35 -69.02 0.42 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.542 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 10.8 tpp -82.74 62.18 6.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.111 0.481 . . . . 0.0 110.235 179.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 37.2 pt -80.09 -33.34 14.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.274 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -38.64 -34.63 0.15 Allowed 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -178.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.466 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.2 mm? -72.8 -46.48 52.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.892 0.377 . . . . 0.0 110.703 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 24.2 t30 -57.57 -34.92 69.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.934 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.83 46.27 2.5 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.367 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.66 161.66 13.61 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.858 0.361 . . . . 0.0 110.898 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -54.99 156.83 6.44 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.682 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -57.38 157.11 23.17 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.508 2.138 . . . . 0.0 111.941 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.431 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.7 ptp -117.07 -171.19 1.98 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -99.48 153.17 19.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.755 0.312 . . . . 0.0 110.615 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.7 pp -121.84 173.62 7.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.643 0.735 . . . . 0.0 112.312 -179.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.588 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 6.1 tttt -144.43 127.14 16.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.749 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 15.5 m -97.75 115.18 37.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.436 0.636 . . . . 0.0 111.598 -178.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 15.7 mt -94.96 -28.14 15.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.49 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.53 -178.95 39.5 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.576 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -50.61 -48.5 20.21 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.635 2.223 . . . . 0.0 112.217 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 80.8 m-85 -115.95 15.09 16.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.112 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.92 147.72 45.66 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.692 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.588 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.5 p90 -178.35 159.59 1.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.725 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 9.4 t -114.3 170.13 8.53 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.975 0.417 . . . . 0.0 111.32 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.06 -179.17 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.929 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 179.96 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.934 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -60.92 134.49 57.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 1.1 p -116.25 -19.92 10.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.372 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 93.0 p -52.92 -27.63 19.69 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 111.332 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -77.76 -25.87 49.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.142 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.451 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 13.1 m-85 -91.09 -168.3 2.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.976 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 8.5 p -83.4 -147.09 0.08 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.568 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -119.07 147.11 44.5 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.831 0.348 . . . . 0.0 110.844 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.453 ' CD2' ' CG1' ' A' ' 224' ' ' VAL . 44.5 t80 -80.02 141.49 35.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 30.3 mt -120.45 -59.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.998 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 4.3 mmt85 -163.32 176.63 9.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.408 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.02 155.55 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.935 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.64 119.24 1.77 Allowed Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.867 178.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.4 ' HB ' ' CB ' ' A' ' 251' ' ' SER . 10.9 mt -122.25 134.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.812 0.339 . . . . 0.0 110.557 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 13.4 p -99.73 107.35 20.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.252 -179.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 71.0 m -115.12 123.22 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.771 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.426 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.025 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 3.9 tp . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.806 0.336 . . . . 0.0 110.857 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.5 p -162.34 107.7 1.21 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -100.08 153.77 18.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.978 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 38.8 mtt -90.68 145.77 24.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.935 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.42 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 98.8 t -99.87 136.62 30.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.815 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.1 t -105.95 -35.75 7.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.024 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -163.21 143.6 9.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 12.8 p -146.5 130.58 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.053 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 11.4 p -92.29 146.18 23.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.043 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.8 tttm -92.17 86.61 5.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.732 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.413 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.5 OUTLIER -132.96 -158.07 0.86 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.787 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 9.5 p-10 -158.73 91.87 2.01 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-O 120.503 0.192 . . . . 0.0 111.203 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.413 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 86.9 Cg_endo -75.86 169.52 74.28 Favored 'Cis proline' 0 C--N 1.347 0.498 0 C-N-CA 123.327 -1.53 . . . . 0.0 112.083 -0.265 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.97 146.9 17.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.471 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.9 t -99.85 126.87 53.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.973 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.454 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 3.8 p -121.09 155.32 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.275 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 6.7 m -118.25 161.3 20.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.648 179.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.85 161.68 13.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.881 0.372 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 8.2 tp -60.26 154.35 20.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.825 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -52.62 -27.12 15.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.032 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -128.48 37.37 4.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -94.77 -167.41 1.64 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.151 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.62 176.57 8.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.011 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -155.08 114.0 3.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.711 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -133.28 26.38 3.54 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.817 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.446 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 0.1 OUTLIER -106.4 135.32 48.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 179.799 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -89.85 174.34 7.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.071 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.28 101.33 0.3 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 113.97 15.86 8.27 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.732 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -76.4 -175.75 3.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.728 0.299 . . . . 0.0 110.653 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.47 ' HA ' ' O ' ' A' ' 265' ' ' MET . 63.1 m-85 -121.95 141.45 51.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.983 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 22.5 m -137.4 155.28 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.504 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.2 p -129.29 161.42 30.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.693 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.508 ' CD2' HG22 ' A' ' 253' ' ' VAL . 2.6 m-30 -99.85 137.11 38.76 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.999 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 72.4 m -99.77 -104.85 0.22 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.671 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.3 OUTLIER -100.18 87.47 3.46 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.508 HG22 ' CD2' ' A' ' 250' ' ' PHE . 21.8 t -109.91 138.1 39.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.883 0.373 . . . . 0.0 111.707 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -100.73 118.66 37.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.935 179.145 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.45 -65.57 0.48 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.673 -179.049 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 6.3 ttm -85.11 58.95 5.32 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.053 0.454 . . . . 0.0 110.357 179.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 4.8 pt -79.99 -33.36 14.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.037 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -39.06 -34.75 0.18 Allowed 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.5 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 2.7 mm? -79.86 -42.09 24.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.872 0.368 . . . . 0.0 110.701 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 44.8 t30 -54.99 -34.88 63.78 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.063 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.88 28.22 13.41 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.293 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -142.24 165.08 28.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 110.753 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -58.04 166.26 2.14 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.595 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.48 158.39 53.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.363 2.042 . . . . 0.0 112.094 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.1 ptp -116.61 -174.17 2.52 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.517 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -99.56 151.26 21.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.719 0.295 . . . . 0.0 110.705 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.8 pp -122.22 174.96 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.612 0.72 . . . . 0.0 112.376 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.604 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.3 tptt -146.86 130.71 17.1 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.576 -1.193 . . . . 0.0 108.5 178.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 31.0 m -97.74 120.17 46.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.494 0.664 . . . . 0.0 111.585 -178.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.4 mt -98.2 -29.99 12.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.462 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.55 -175.3 36.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.524 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.85 -53.91 6.01 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.638 2.226 . . . . 0.0 112.387 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -112.77 23.22 13.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -133.23 148.45 52.0 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.751 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.604 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -175.33 167.3 3.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -117.58 170.15 8.98 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 14.3 pt -133.09 -179.38 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.843 179.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 32.0 p -63.6 171.0 2.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.83 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.9 p-10 -58.73 112.22 1.55 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.966 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 11.2 p -115.81 24.94 11.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.058 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 91.6 p -90.48 9.78 27.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.357 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 62.4 m-20 -111.38 -32.05 6.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.348 . . . . 0.0 110.801 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -78.17 -165.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.802 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.96 -179.78 6.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.868 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -94.1 130.86 40.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 54.4 t80 -60.12 136.33 57.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.838 179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 47.7 mt -115.73 -67.92 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.09 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -151.91 174.01 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.297 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.82 155.98 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.911 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 138.78 116.12 1.38 Allowed Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.901 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.1 mp -121.98 138.33 52.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.8 0.334 . . . . 0.0 110.573 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 13.4 p -99.7 124.95 53.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.517 -179.404 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -121.76 131.94 54.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.528 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.446 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.317 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.1 mp . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.8 0.333 . . . . 0.0 110.747 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.87 150.11 22.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.086 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -156.63 154.19 29.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.075 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 3.4 mtt -95.23 164.19 12.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.112 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 36.5 t -114.72 140.43 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 4.3 t -114.42 -26.33 8.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.255 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -166.73 162.63 16.33 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.851 0.358 . . . . 0.0 111.042 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.444 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.8 p -168.02 151.64 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.176 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 40.1 p -113.93 150.53 33.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 7.5 ttmt -92.53 84.82 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.859 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.405 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.3 t0 -134.67 -160.16 1.03 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.823 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 14.1 p-10 -156.28 89.7 2.74 Favored Pre-proline 0 CA--C 1.531 0.233 0 CA-C-O 120.506 0.193 . . . . 0.0 111.371 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.405 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 85.1 Cg_endo -79.36 169.45 71.28 Favored 'Cis proline' 0 C--N 1.349 0.591 0 C-N-CA 123.448 -1.48 . . . . 0.0 112.202 -0.078 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.65 155.24 16.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.391 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.5 t -99.87 111.09 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.9 0.381 . . . . 0.0 111.028 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.458 ' CG1' ' CZ ' ' A' ' 275' ' ' PHE . 2.0 p -102.9 151.95 5.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.059 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.12 139.73 52.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.312 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 61.3 m -99.91 170.07 8.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.023 0.44 . . . . 0.0 111.133 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.487 ' HB3' ' CB ' ' A' ' 238' ' ' ALA . 3.6 tt -49.68 161.27 0.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.923 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -42.05 -31.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.242 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -165.5 51.1 0.1 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.816 0.341 . . . . 0.0 111.239 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . 0.487 ' CB ' ' HB3' ' A' ' 235' ' ' LEU . . . -121.33 30.99 6.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.484 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -150.15 131.76 14.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.866 0.365 . . . . 0.0 111.121 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 170.04 90.16 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.852 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 179.79 -35.69 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.779 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -85.63 134.5 33.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.922 0.391 . . . . 0.0 110.719 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -105.61 171.39 7.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.83 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 62.8 m -53.06 102.03 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.37 25.36 4.7 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.593 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -93.89 166.61 12.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.777 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.447 ' HA ' ' O ' ' A' ' 265' ' ' MET . 94.6 m-85 -110.86 135.48 51.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.832 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 14.7 m -143.18 145.58 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.436 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 16.9 p -116.27 170.27 8.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.571 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.471 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.5 m-30 -99.46 139.61 34.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.938 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -104.73 -87.95 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.222 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -108.14 88.06 2.64 Favored 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 116.848 -0.16 . . . . 0.0 110.826 179.802 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.471 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 11.2 t -113.95 132.13 63.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.945 0.403 . . . . 0.0 111.803 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -99.77 115.89 30.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.925 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.94 -59.55 0.59 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.552 -178.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 2.5 ttm -92.14 54.63 2.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.107 0.479 . . . . 0.0 110.163 179.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 33.2 pt -77.21 -33.55 20.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.763 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -39.14 -34.66 0.18 Allowed 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.835 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.425 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.5 mm? -66.65 -47.11 73.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.915 0.388 . . . . 0.0 110.618 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -56.37 -34.78 66.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.909 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.54 46.24 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.318 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.7 t -167.61 163.83 14.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.749 0.309 . . . . 0.0 110.596 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.28 166.33 0.9 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.586 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -68.82 178.61 3.83 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.311 2.007 . . . . 0.0 112.013 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.447 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.0 OUTLIER -136.89 176.18 8.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.78 -179.957 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -99.49 125.07 45.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.4 pp -88.7 163.88 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.546 0.689 . . . . 0.0 112.229 -179.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.639 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.5 OUTLIER -137.88 125.52 22.25 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.744 -1.117 . . . . 0.0 108.586 178.445 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 30.3 m -97.29 114.77 35.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.547 0.689 . . . . 0.0 111.573 -178.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.0 mt -92.03 -28.45 17.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.494 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -161.59 -163.52 14.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.589 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.47 -48.67 4.15 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.572 2.182 . . . . 0.0 112.111 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -115.27 7.77 15.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.212 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.67 152.73 30.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.764 0.316 . . . . 0.0 110.676 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.639 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.1 p90 -179.78 162.44 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.821 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.7 t -118.64 169.99 9.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.07 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.3 pp -134.22 -177.51 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.911 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -54.88 -176.4 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 0.0 111.048 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -71.89 99.77 2.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 3.2 t -102.83 56.57 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 59.8 p -104.85 -26.38 12.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.988 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -96.54 31.53 2.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.98 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -126.08 -175.66 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.79 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.45 170.97 12.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.91 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -83.96 122.09 28.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.444 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 37.5 t80 -59.25 142.81 50.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.722 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . 0.438 HG23 HD11 ' A' ' 287' ' ' ILE . 33.7 mt -119.92 -69.21 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.237 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.2 173.82 14.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.729 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.41 153.81 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.216 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.0 124.38 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.904 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 30.8 mt -123.04 134.45 66.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.789 0.328 . . . . 0.0 110.797 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.4 ' O ' ' CG1' ' A' ' 292' ' ' VAL . 13.1 p -99.94 102.42 13.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.963 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.7 m -113.72 150.89 32.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.022 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.916 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.808 0.337 . . . . 0.0 110.7 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 52.8 p -124.47 146.91 48.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.04 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -128.38 167.05 17.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.001 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 11.6 mtt -94.09 148.56 22.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.923 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 49.1 t -99.91 139.32 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.953 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.3 t -106.77 -32.94 7.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.053 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.4 mtp -168.89 144.28 3.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.973 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.446 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 10.8 p -142.78 140.87 27.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.047 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 15.6 p -95.91 144.31 26.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.028 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.6 tttt -94.1 83.01 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.445 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.2 t0 -128.67 -158.17 0.87 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.738 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 1.6 p30 -154.27 89.62 3.3 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-O 120.472 0.177 . . . . 0.0 111.336 -179.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.445 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 93.7 Cg_endo -77.71 169.16 74.37 Favored 'Cis proline' 0 C--N 1.347 0.491 0 C-N-CA 123.437 -1.485 . . . . 0.0 111.996 -0.162 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.76 149.77 17.01 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.598 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.8 141.81 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.72 0.295 . . . . 0.0 110.905 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.424 ' CG1' ' CZ ' ' A' ' 275' ' ' PHE . 5.3 p -134.43 157.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.246 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 91.8 m -122.11 156.79 32.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.582 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.94 166.14 11.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.919 0.39 . . . . 0.0 110.721 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 2.5 tp -66.98 148.15 52.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.785 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -55.38 -26.73 43.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -98.05 -26.28 14.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.016 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -68.85 172.68 6.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.21 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -145.97 145.25 30.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.967 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.4 ' NE2' ' CD2' ' A' ' 242' ' ' PHE . 17.2 t-80 -98.36 135.65 39.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -137.09 27.82 2.86 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.525 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.459 ' CE1' ' HB2' ' A' ' 294' ' ' GLN . 0.1 OUTLIER -116.34 146.34 42.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.584 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -102.55 173.26 6.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.141 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 80.6 p -59.87 103.17 0.19 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.84 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 127.87 -17.78 6.0 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.531 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.09 -178.8 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.739 0.304 . . . . 0.0 110.808 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.463 ' HA ' ' O ' ' A' ' 265' ' ' MET . 49.1 m-85 -122.99 162.08 23.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.07 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.41 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 28.8 m -151.74 155.06 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.5 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.8 p -129.66 159.31 36.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.501 179.627 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.483 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 2.3 m-30 -99.65 136.3 39.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.0 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 35.1 t -99.78 -92.49 0.28 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.543 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.73 87.77 2.61 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.468 179.499 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.474 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 3.9 t -106.3 137.59 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.939 0.4 . . . . 0.0 111.809 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -99.97 112.83 25.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.813 179.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.04 -60.28 0.56 Allowed Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.69 -178.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 3.0 ttm -87.88 59.15 5.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.144 0.497 . . . . 0.0 110.478 179.297 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 28.7 pt -79.95 -33.57 14.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.922 -179.432 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -38.89 -34.64 0.16 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.36 -0.382 . . . . 0.0 112.021 -178.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.483 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.1 mm? -73.01 -46.01 54.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.901 0.381 . . . . 0.0 110.634 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -56.23 -34.85 66.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.864 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.03 46.61 2.89 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.351 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -170.35 160.99 7.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -56.22 156.26 11.17 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.704 179.792 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.22 171.76 1.61 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.318 2.012 . . . . 0.0 112.062 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.463 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.6 OUTLIER -131.75 -174.36 3.39 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.628 -179.892 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -99.51 148.86 23.82 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.724 0.297 . . . . 0.0 110.698 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.4 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -118.64 177.36 2.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.637 0.732 . . . . 0.0 112.376 -179.2 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.638 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.44 130.27 19.27 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.473 -1.239 . . . . 0.0 108.27 178.585 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 31.9 m -97.49 117.61 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.588 0.708 . . . . 0.0 111.691 -178.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.3 mt -91.16 -28.31 17.95 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.846 -1.07 . . . . 0.0 110.545 -179.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 162.64 -166.57 36.75 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.224 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -52.83 112.66 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.785 2.323 . . . . 0.0 112.506 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 62.4 m-85 63.07 18.02 10.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.107 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -128.42 136.95 51.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.454 179.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.638 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.77 160.64 1.94 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.806 -179.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.1 t -112.61 170.11 8.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.998 0.428 . . . . 0.0 111.179 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -130.88 -179.5 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.919 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -55.5 -173.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.983 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -58.67 122.56 13.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.5 24.19 13.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.081 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 34.0 t -98.31 -26.6 14.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.031 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . 0.404 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 17.8 t30 -97.41 34.83 1.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.969 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.447 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 24.5 m-85 -137.75 -175.5 4.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.852 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 28.7 t -86.35 176.98 7.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -85.62 132.2 34.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.964 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.446 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 16.3 t80 -77.49 144.44 37.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.66 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 35.7 mt -126.24 -68.43 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -146.91 -179.87 7.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.602 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.5 161.57 0.05 OUTLIER Glycine 0 C--N 1.332 0.324 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.27 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 132.56 116.22 1.73 Allowed Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.919 178.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 20.6 mt -118.66 133.92 63.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.798 0.332 . . . . 0.0 110.592 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.41 ' CG2' ' HB ' ' A' ' 248' ' ' VAL . 12.5 p -99.77 120.9 49.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.567 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 20.8 m -119.64 136.69 54.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.67 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.459 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 7.4 tt0 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.187 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.938 0.399 . . . . 0.0 111.056 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.4 m -138.37 103.62 4.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.507 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -102.12 157.7 16.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.973 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 34.1 mtp -101.73 167.98 9.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.9 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.39 128.6 70.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.992 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.6 t -104.31 -29.42 10.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -167.5 152.66 7.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.001 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.444 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 12.0 p -158.72 145.37 7.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 7.1 p -106.52 146.38 30.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.853 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.31 80.57 3.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.838 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.427 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.6 OUTLIER -126.22 -157.9 0.82 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -154.02 91.0 3.22 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.355 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.427 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 80.2 Cg_endo -76.3 169.07 75.44 Favored 'Cis proline' 0 C--N 1.348 0.516 0 C-N-CA 123.345 -1.523 . . . . 0.0 112.044 -0.143 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.9 151.9 17.59 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.494 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.1 t -99.98 145.86 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 111.135 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.456 ' CG1' ' CZ ' ' A' ' 275' ' ' PHE . 2.7 p -142.7 150.2 18.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.097 -179.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 81.0 m -124.98 143.27 50.98 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.492 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 26.2 m -100.0 170.07 8.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.977 0.418 . . . . 0.0 111.054 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 1.2 tp -56.5 140.49 45.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.996 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -54.16 -26.7 29.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.984 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.6 mt-10 -114.84 34.49 4.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -166.41 76.44 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.204 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . 0.404 ' O ' ' CG ' ' A' ' 240' ' ' HIS . 38.3 tpt85 -150.06 87.07 1.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.828 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.404 ' CG ' ' O ' ' A' ' 239' ' ' ARG . 1.0 OUTLIER -178.8 106.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.107 179.986 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 162.11 -14.96 0.14 Allowed Glycine 0 CA--C 1.52 0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 113.562 179.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.432 ' CZ ' HG12 ' A' ' 292' ' ' VAL . 0.0 OUTLIER -131.75 132.19 43.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 117.17 0.485 . . . . 0.0 111.258 -179.41 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -124.09 -169.58 1.99 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.778 179.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.2 m -61.32 106.07 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.068 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 100.67 26.94 7.79 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.684 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.55 169.75 8.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.765 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 265' ' ' MET . 76.8 m-85 -108.17 148.96 29.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.803 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.424 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 34.3 m -149.71 144.26 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 111.578 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.7 p -123.67 156.88 35.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.462 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.447 ' CD2' HG22 ' A' ' 253' ' ' VAL . 4.8 m-30 -99.52 139.09 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -99.7 -91.86 0.29 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.11 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.06 87.74 2.59 Favored 'General case' 0 C--O 1.224 -0.278 0 C-N-CA 121.21 -0.196 . . . . 0.0 110.822 179.703 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.447 HG22 ' CD2' ' A' ' 250' ' ' PHE . 21.2 t -109.31 143.69 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.871 0.367 . . . . 0.0 111.491 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -105.72 114.93 29.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.087 179.326 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.36 -64.07 0.52 Allowed Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.596 -179.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 31.1 ttm -88.91 54.54 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.165 0.507 . . . . 0.0 110.283 179.271 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 2.2 pp -80.04 -33.76 14.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.928 -179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.442 ' HB3' ' CE2' ' A' ' 283' ' ' PHE . 5.7 mm-40 -39.07 -34.47 0.17 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 112.006 -178.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.45 HD23 ' CD2' ' A' ' 283' ' ' PHE . 2.9 mm? -64.02 -48.36 76.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.839 0.352 . . . . 0.0 110.682 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.0 t-20 -55.66 -35.06 65.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.94 49.38 1.02 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.71 28.96 0.13 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.104 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 60.86 156.67 0.11 Allowed Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.525 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -55.77 176.33 0.17 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.35 2.033 . . . . 0.0 111.991 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.5 ptp -142.76 -173.9 4.01 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.632 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -99.39 137.33 38.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.345 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.1 pt -106.07 176.45 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.727 0.775 . . . . 0.0 112.472 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.669 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.5 tttt -148.21 129.95 15.11 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.162 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 29.0 m -97.3 123.83 49.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.583 0.706 . . . . 0.0 111.423 -178.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 55.1 mt -96.41 -28.17 14.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.82 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 169.59 -160.78 34.06 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.417 -0.897 . . . . 0.0 113.14 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.7 111.49 1.92 Allowed 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.711 2.274 . . . . 0.0 112.294 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 71.1 9.37 6.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.23 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.6 p -124.52 145.0 49.81 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.754 0.312 . . . . 0.0 110.617 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.669 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -178.61 170.04 1.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.744 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.9 t -120.35 169.93 9.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.15 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.1 pp -138.54 -177.91 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.025 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -54.89 163.65 0.96 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.974 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -58.41 140.4 53.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.007 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 6.2 t -145.67 31.83 1.06 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 19.9 p -71.24 -46.8 60.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.89 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 12.1 t30 -76.98 -22.53 53.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.059 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.45 ' CD2' HD23 ' A' ' 259' ' ' LEU . 3.3 m-85 -67.83 -176.15 0.63 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.3 m -87.29 151.14 23.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.2 142.23 50.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.006 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.444 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 17.6 t80 -72.1 144.96 48.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.88 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.5 mt -124.49 -63.96 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.4 mmt180 -152.8 178.85 9.19 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.434 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.33 164.53 0.08 OUTLIER Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.283 -0.961 . . . . 0.0 112.085 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 127.89 114.97 1.86 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.038 178.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.409 ' CD1' ' N ' ' A' ' 291' ' ' ILE . 3.2 mp -121.56 131.06 73.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.79 0.329 . . . . 0.0 110.151 179.228 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.432 HG12 ' CZ ' ' A' ' 242' ' ' PHE . 12.9 p -99.83 118.13 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.389 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 58.0 m -121.32 146.95 46.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 6.6 tm0? . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.962 -179.928 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.352 . . . . 0.0 110.816 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.3 m -125.22 159.95 30.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.038 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.96 162.0 37.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.031 179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.72 146.39 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.065 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.0 137.59 27.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.91 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.6 t -108.84 -42.07 4.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -151.03 153.74 35.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.109 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.442 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.5 p -161.87 140.28 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.989 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 1.5 p -95.32 148.13 22.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.08 55.86 2.42 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.435 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -102.79 -158.32 0.66 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.708 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -156.97 91.81 2.43 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 120.504 0.193 . . . . 0.0 111.307 -179.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.435 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 73.3 Cg_endo -75.54 169.6 74.08 Favored 'Cis proline' 0 C--N 1.348 0.529 0 C-N-CA 123.436 -1.485 . . . . 0.0 112.002 -0.182 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.54 17.47 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.558 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.98 124.69 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.885 0.374 . . . . 0.0 110.974 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.428 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.9 p -117.51 154.39 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.207 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 1.3 m -120.57 155.51 33.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.567 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.0 m -99.94 162.58 12.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.844 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 4.3 tp -60.11 147.69 38.64 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.794 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -64.94 -26.95 68.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.084 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -95.47 -15.12 23.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.054 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -97.15 171.07 8.69 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.865 0.364 . . . . 0.0 111.172 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -135.1 160.58 37.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.923 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.5 p-80 -96.81 146.81 24.57 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -138.12 25.05 2.93 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.69 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.404 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 0.4 OUTLIER -128.3 147.57 50.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.803 0.335 . . . . 0.0 110.732 179.875 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -105.13 174.78 5.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.972 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.6 t -62.49 97.23 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.82 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 137.44 -17.43 3.53 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.561 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.54 -171.24 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.753 0.311 . . . . 0.0 110.8 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.479 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -138.46 141.99 39.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.787 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.421 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 33.8 m -148.71 146.03 17.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.039 0.447 . . . . 0.0 111.545 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 21.3 p -112.73 170.08 8.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.33 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.415 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 4.2 m-30 -99.62 143.07 30.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.082 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -99.97 -86.64 0.38 Allowed 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.134 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.6 ' O ' ' CG ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.84 92.62 3.85 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-O 121.127 0.489 . . . . 0.0 110.008 179.997 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.417 HG11 ' CE2' ' A' ' 286' ' ' TYR . 5.0 t -109.15 149.03 12.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.349 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 288' ' ' ARG . 18.1 mm-40 -110.36 109.33 19.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.026 179.136 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.57 -53.47 0.83 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.6 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 11.0 ttm -95.63 54.03 1.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.988 0.423 . . . . 0.0 110.333 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 43.7 pt -80.03 -34.35 15.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.71 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.0 mp0 -39.63 -34.62 0.25 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.748 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.415 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 2.3 mm? -61.02 -46.44 90.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.38 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -61.55 -36.43 80.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.893 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.5 42.93 2.26 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.362 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.4 t -156.06 31.06 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.817 0.342 . . . . 0.0 110.934 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . 0.414 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 0.4 OUTLIER 59.67 168.03 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.622 -179.898 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.414 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 28.9 Cg_endo -62.78 -173.03 0.13 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.372 2.048 . . . . 0.0 112.04 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.479 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.4 OUTLIER -156.03 -177.95 6.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.635 -179.917 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -99.85 135.07 41.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.611 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.404 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -105.67 178.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 0.0 112.087 -179.604 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.66 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 29.7 mttt -149.01 131.02 15.3 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.659 178.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 10.5 m -97.33 121.8 48.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.473 0.654 . . . . 0.0 111.367 -178.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 15.3 mt -96.81 -30.29 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.868 -179.527 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 164.76 -166.79 38.21 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.074 -1.06 . . . . 0.0 113.404 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_exo -51.16 112.93 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.897 2.398 . . . . 0.0 112.696 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 60.37 20.59 10.17 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.036 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -130.86 139.47 50.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.586 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.66 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.6 p90 -177.17 166.13 2.35 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.734 -179.615 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.9 t -114.83 170.08 8.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.997 0.427 . . . . 0.0 111.133 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -138.56 -179.69 2.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.916 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.44 160.5 3.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.999 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 13.5 p30 -56.81 138.03 53.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.024 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.424 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.6 p -133.09 27.11 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.954 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -69.54 -30.31 68.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.95 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -84.94 -31.11 23.78 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.424 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 21.3 m-85 -70.1 -175.51 0.97 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.829 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.99 179.83 6.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -89.63 124.93 35.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.442 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 15.1 t80 -59.41 139.55 56.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.776 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.8 mt -117.33 -62.2 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.021 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.41 ' O ' ' HB2' ' A' ' 254' ' ' GLN . 2.8 mmt180 -158.2 175.8 13.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.581 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.52 151.44 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.443 -0.884 . . . . 0.0 112.408 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.23 115.66 1.31 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.642 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 3.4 mp -113.24 134.12 56.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.797 0.332 . . . . 0.0 110.954 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.421 ' CG2' ' HB ' ' A' ' 248' ' ' VAL . 13.5 p -99.81 115.04 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.124 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.0 m -119.05 143.49 47.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.15 -179.665 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 . . . . . 0 C--N 1.331 -0.205 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.948 179.871 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.052 0 CA-C-O 120.785 0.326 . . . . 0.0 110.837 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.5 p -149.52 124.21 9.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -115.7 170.06 8.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.56 165.76 11.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.895 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.403 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 88.0 t -115.4 125.96 72.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 27.9 t -108.13 -31.15 8.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.27 135.1 7.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 11.5 p -142.86 150.26 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 66.3 p -107.42 148.16 29.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.1 tmtt? -99.28 70.18 1.73 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -120.52 -159.64 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 20.4 p30 -153.6 91.03 3.32 Favored Pre-proline 0 CA--C 1.531 0.234 0 CA-C-N 116.717 -0.22 . . . . 0.0 111.328 -179.645 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -78.21 169.75 72.14 Favored 'Cis proline' 0 C--N 1.348 0.535 0 C-N-CA 123.422 -1.491 . . . . 0.0 112.112 -0.142 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.8 149.84 18.78 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.74 140.13 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.878 0.371 . . . . 0.0 110.999 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.443 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 5.3 p -134.6 158.04 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.264 -179.691 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.401 ' N ' ' CG2' ' A' ' 232' ' ' VAL . 0.6 OUTLIER -125.01 160.26 29.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.516 179.697 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.83 167.31 10.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.874 0.369 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.01 159.83 10.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.731 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -55.36 -29.87 59.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.014 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -117.48 32.35 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -78.19 -176.94 4.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.111 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 -144.16 148.02 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.943 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -96.99 141.84 29.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.822 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -163.07 29.94 0.26 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.595 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.402 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 0.1 OUTLIER -147.74 130.56 16.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.752 0.31 . . . . 0.0 110.755 179.991 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.67 179.17 4.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.998 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.67 104.7 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.891 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 123.81 -13.64 8.11 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.757 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -67.67 172.98 4.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.809 0.338 . . . . 0.0 110.777 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -123.31 158.24 31.44 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 19.8 m -155.11 142.66 12.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.198 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 p -109.99 166.13 11.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.303 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.434 ' CD2' HG23 ' A' ' 253' ' ' VAL . 2.4 m-30 -99.66 152.24 20.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.863 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 61.3 m -108.5 -98.77 0.38 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.072 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.498 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.6 OUTLIER -107.09 88.25 2.69 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.592 0.234 . . . . 0.0 110.666 179.892 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.434 HG23 ' CD2' ' A' ' 250' ' ' PHE . 4.1 t -100.93 148.28 7.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.042 0.449 . . . . 0.0 111.625 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.41 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.0 OUTLIER -111.1 108.59 18.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.576 178.955 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.35 -59.92 0.55 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.276 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 21.2 ttm -92.19 54.88 2.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.177 0.513 . . . . 0.0 110.061 179.08 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 9.0 pt -79.25 -33.23 15.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.598 -0.728 . . . . 0.0 112.22 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.409 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 2.5 mm100 -38.64 -34.54 0.15 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.86 -178.677 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.432 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.3 mm? -67.69 -49.68 61.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.979 0.418 . . . . 0.0 110.474 179.403 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -58.65 -34.83 71.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.78 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.43 44.38 2.92 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.468 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.9 t -164.99 162.97 20.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.6 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -54.5 156.73 5.77 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.553 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -63.05 169.53 8.96 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.272 1.982 . . . . 0.0 111.821 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 265' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -134.55 -175.59 3.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.856 -179.69 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -99.66 154.66 18.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.417 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.402 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -123.02 174.94 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.66 0.743 . . . . 0.0 112.194 -179.271 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.569 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 32.1 mmtm -143.27 129.07 19.39 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.705 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 22.3 m -97.54 112.91 30.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.473 0.654 . . . . 0.0 111.48 -178.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 13.3 mt -91.02 -27.06 18.88 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.569 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.45 -164.01 21.21 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.627 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -63.34 -50.62 3.35 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.585 2.19 . . . . 0.0 112.027 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -114.1 12.47 17.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.047 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -118.83 147.32 44.06 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.636 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.569 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 10.4 p90 -177.95 158.54 1.26 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.959 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.0 t -112.84 170.12 8.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.5 pp -135.93 -179.01 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.986 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -55.56 -178.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.891 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -68.13 110.32 3.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.43 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.9 t -110.33 32.97 4.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.4 m -87.78 -22.6 24.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -95.43 38.0 1.17 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.984 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.43 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 25.0 m-85 -137.76 -171.48 3.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.728 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -88.85 -166.93 1.72 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.83 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -96.75 145.23 26.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -85.89 139.58 31.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.733 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 68.4 mt -124.27 -71.16 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.41 ' O ' ' N ' ' A' ' 254' ' ' GLN . 3.4 mpt_? -138.93 -178.22 5.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.421 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 57.16 160.59 0.02 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.389 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 128.99 102.11 1.04 Allowed Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.923 179.109 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.5 mp -109.25 129.04 64.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.738 0.304 . . . . 0.0 110.193 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.3 p -99.61 108.83 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.051 0.453 . . . . 0.0 111.474 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -109.11 173.15 6.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.585 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 . . . . . 0 C--N 1.328 -0.368 0 CA-C-O 120.998 0.428 . . . . 0.0 111.032 -179.937 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.748 0.308 . . . . 0.0 110.947 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 p -162.57 141.74 9.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.948 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -137.4 154.66 49.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.101 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.7 mmm -101.23 156.61 17.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 44.6 t -100.67 138.94 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.973 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 15.0 t -110.24 -39.99 4.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.898 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.3 mmm -169.37 138.96 2.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 8.2 p -139.26 151.17 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.08 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.8 p -102.06 148.08 25.82 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.005 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? -92.19 85.55 5.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.747 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.438 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.8 t0 -132.31 -154.79 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.758 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 31.4 p30 -159.04 90.77 2.0 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-O 120.445 0.164 . . . . 0.0 111.234 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.438 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 72.8 Cg_endo -74.96 169.03 75.65 Favored 'Cis proline' 0 C--N 1.348 0.543 0 C-N-CA 123.387 -1.505 . . . . 0.0 112.081 -0.282 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.42 151.31 17.14 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 16.9 t -99.9 131.86 46.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 111.074 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.456 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 6.3 p -128.87 158.02 41.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.253 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.77 164.59 18.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.686 179.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.3 m -99.94 168.81 9.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.871 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 5.8 tp -64.88 151.25 46.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -58.71 -26.23 63.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.197 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -114.91 32.23 6.16 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -133.07 155.91 48.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.256 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.29 158.6 33.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.883 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -92.31 145.16 24.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -136.97 42.45 1.31 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.579 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -137.99 138.92 39.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.779 0.323 . . . . 0.0 110.775 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -88.68 171.9 9.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.924 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.5 m -62.72 101.88 0.29 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.868 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 117.24 0.32 18.9 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.85 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.6 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.658 0.266 . . . . 0.0 110.777 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.545 ' HA ' ' O ' ' A' ' 265' ' ' MET . 38.2 m-85 -134.41 143.37 47.55 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.896 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.414 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 3.4 m -149.99 142.33 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.609 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 25.1 p -115.79 165.91 12.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.452 179.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.45 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 3.9 m-30 -99.71 148.67 24.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.992 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.7 m -99.89 -90.32 0.31 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.09 -179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.496 ' O ' ' N ' ' A' ' 290' ' ' GLY . 5.1 pt-20 -113.22 88.03 2.74 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 120.519 0.199 . . . . 0.0 110.768 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.444 HG23 ' CD2' ' A' ' 250' ' ' PHE . 12.1 t -100.02 148.09 6.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 111.6 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.406 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.9 OUTLIER -116.24 110.45 18.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.77 -62.21 0.53 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.627 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 25.9 ttm -91.79 61.78 4.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.227 0.537 . . . . 0.0 110.225 179.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 23.8 pt -80.03 -32.3 13.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.336 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.438 ' HB2' ' CZ ' ' A' ' 283' ' ' PHE . 3.8 tp-100 -37.61 -34.44 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -178.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.45 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.1 mm? -67.65 -52.08 42.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.973 0.416 . . . . 0.0 110.414 179.457 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -64.61 -34.95 79.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.119 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.27 38.56 3.16 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.836 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 3.2 t -157.99 36.39 0.25 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.766 0.317 . . . . 0.0 111.08 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . 0.442 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 11.8 mt-30 59.05 169.16 0.07 OUTLIER Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.488 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.442 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 14.2 Cg_endo -56.97 -164.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.253 1.969 . . . . 0.0 111.593 179.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.545 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.0 OUTLIER -169.44 -173.2 1.63 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.791 -179.713 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.55 143.23 30.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.407 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.1 pp -118.59 176.81 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.665 0.745 . . . . 0.0 112.388 -179.225 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.501 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -149.87 129.64 13.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.374 178.596 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 29.3 m -97.59 112.11 28.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.507 0.67 . . . . 0.0 111.546 -178.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 40.4 mt -86.14 -29.78 23.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.476 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.9 -167.23 21.09 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -61.61 -43.52 26.54 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.508 2.139 . . . . 0.0 111.826 179.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -117.5 -5.1 11.23 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.049 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.3 p -100.2 148.26 24.81 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.841 0.353 . . . . 0.0 111.006 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.501 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 6.7 p90 -178.58 162.62 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.566 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.7 t -112.39 167.37 10.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.993 0.425 . . . . 0.0 111.354 -179.395 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.2 pp -137.9 -173.42 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.751 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -52.0 179.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.932 0.396 . . . . 0.0 111.159 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -94.69 140.59 29.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.998 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 11.7 t -151.21 39.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.78 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 28.9 t -73.93 -7.57 52.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.574 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -108.33 5.94 25.99 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.522 0.201 . . . . 0.0 111.53 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.438 ' CZ ' ' HB2' ' A' ' 258' ' ' GLN . 0.2 OUTLIER -110.73 -158.44 0.65 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.594 0.235 . . . . 0.0 110.883 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 2.2 m -96.49 156.62 16.26 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.856 0.36 . . . . 0.0 111.077 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -74.29 151.9 39.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.406 ' CE2' ' O ' ' A' ' 289' ' ' GLY . 32.1 t80 -58.86 124.48 19.99 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.927 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 29.5 mt -102.77 -47.79 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.005 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.406 ' O ' ' N ' ' A' ' 254' ' ' GLN . 1.1 mmt-85 -176.97 175.37 1.59 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.167 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . 0.406 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 60.39 158.42 0.06 OUTLIER Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.178 -1.01 . . . . 0.0 111.966 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 131.76 115.84 1.73 Allowed Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.723 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.7 mp -125.26 128.38 72.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.775 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.414 ' CG2' ' HB ' ' A' ' 248' ' ' VAL . 14.5 p -100.0 118.79 47.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.175 -179.685 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.9 m -129.58 168.19 16.79 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.121 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 . . . . . 0 C--N 1.33 -0.265 0 CA-C-O 121.104 0.478 . . . . 0.0 111.034 -179.993 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.806 0.336 . . . . 0.0 110.926 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 11.2 t -166.53 155.67 11.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.796 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -149.1 166.8 27.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.019 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 10.9 mtp -107.63 147.48 30.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 40.5 t -105.93 139.56 26.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.995 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 8.3 t -106.61 -31.9 8.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.976 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.1 ptm -168.16 163.94 13.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.968 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.421 HG11 ' CG ' ' A' ' 286' ' ' TYR . 12.6 p -162.36 118.62 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.037 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 76.9 p -76.48 140.59 41.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.828 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -90.17 68.15 7.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.795 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -106.69 -148.0 0.41 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.781 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -160.26 88.88 1.82 Allowed Pre-proline 0 CA--C 1.531 0.227 0 CA-C-O 120.536 0.208 . . . . 0.0 111.305 -179.67 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -76.4 169.52 74.23 Favored 'Cis proline' 0 C--N 1.347 0.488 0 C-N-CA 123.27 -1.554 . . . . 0.0 111.945 -0.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -100.43 147.63 18.08 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.501 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.2 t -99.81 118.89 47.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.847 0.356 . . . . 0.0 111.058 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.457 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.8 p -110.37 154.24 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.058 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.32 161.8 28.56 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.691 179.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -100.04 169.63 9.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.92 0.39 . . . . 0.0 110.845 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.26 161.6 6.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.794 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -54.63 -32.86 59.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.074 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -119.16 32.19 6.24 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.824 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -82.81 -175.74 5.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.082 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.41 136.12 23.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.933 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 2.8 t60 -105.9 137.24 44.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -149.83 26.73 1.17 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.674 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -114.52 138.39 50.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.813 0.339 . . . . 0.0 110.679 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 165.0 14.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.03 87.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 138.51 -12.72 3.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.718 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -57.46 -179.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.771 0.32 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 265' ' ' MET . 51.1 m-85 -125.07 146.77 49.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.057 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 19.5 m -148.47 147.86 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.173 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.5 p -115.95 167.88 10.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.623 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.489 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.6 m-30 -99.64 146.65 26.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.077 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 53.8 m -109.46 -89.94 0.47 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.77 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.2 87.59 2.56 Favored 'General case' 0 C--O 1.221 -0.397 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 179.416 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.489 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 8.0 t -109.47 134.98 49.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.92 0.39 . . . . 0.0 111.873 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 21.2 mt-30 -100.32 114.38 27.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.815 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.05 -58.6 0.61 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.672 -178.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 1.4 ttm -91.04 59.9 4.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.128 0.489 . . . . 0.0 110.359 179.358 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.6 pp -79.52 -33.37 15.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.985 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -39.1 -34.61 0.18 Allowed 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.876 -178.823 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.458 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 2.8 mm? -77.76 -44.45 27.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.87 0.366 . . . . 0.0 110.504 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -60.03 -34.84 73.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.851 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.52 42.92 2.38 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.324 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -165.42 171.14 13.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.803 0.335 . . . . 0.0 110.764 -179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 11.3 mt-30 -57.63 167.7 1.29 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.64 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -66.5 -166.68 0.11 Allowed 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.38 2.053 . . . . 0.0 112.005 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.442 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.0 OUTLIER -156.07 -175.84 5.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.575 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -99.71 148.08 24.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.771 0.319 . . . . 0.0 110.628 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.6 pp -119.76 172.84 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.528 0.68 . . . . 0.0 112.263 -179.466 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.609 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.3 mmtm -143.47 127.97 17.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 114.71 -1.132 . . . . 0.0 108.736 178.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 35.9 m -97.6 114.56 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.471 0.653 . . . . 0.0 111.503 -178.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 16.1 mt -92.5 -28.72 16.63 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.567 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.76 -163.66 18.38 Favored Glycine 0 N--CA 1.453 -0.202 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.593 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.08 -49.29 3.95 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.639 2.226 . . . . 0.0 111.992 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -114.82 11.58 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.101 179.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.95 148.54 42.84 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.856 0.36 . . . . 0.0 110.704 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.609 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.9 p90 -177.5 161.73 1.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 12.2 t -123.38 170.27 10.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.01 0.433 . . . . 0.0 111.218 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.6 pp -133.9 -179.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.844 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -56.42 -170.1 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.076 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -55.8 132.69 50.03 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.026 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.57 7.24 8.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.404 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -86.04 5.28 34.21 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.749 -0.205 . . . . 0.0 111.463 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -111.67 -23.48 10.63 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.684 0.278 . . . . 0.0 111.177 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.427 ' CZ ' HD12 ' A' ' 259' ' ' LEU . 29.5 m-85 -85.43 -170.41 3.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 64.1 m -88.56 -175.43 4.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.86 137.27 32.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.421 ' CG ' HG11 ' A' ' 224' ' ' VAL . 70.0 t80 -78.13 146.61 35.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.773 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 27.1 mt -125.02 -67.87 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.186 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.55 176.43 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.559 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.96 158.25 0.05 OUTLIER Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.287 -0.958 . . . . 0.0 112.068 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.13 108.83 0.9 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.98 178.66 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 14.8 mm -106.5 130.98 57.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.727 0.299 . . . . 0.0 110.479 179.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 13.5 p -99.72 109.75 25.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.916 0.389 . . . . 0.0 111.322 -179.59 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -111.77 156.34 22.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.654 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.032 -179.799 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.892 0.377 . . . . 0.0 111.203 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -95.85 -178.82 4.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -83.62 -27.91 37.32 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.481 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.59 168.41 1.65 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.8 0.333 . . . . 0.0 110.831 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 -152.83 29.14 0.52 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.039 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER 57.67 -175.72 0.07 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.023 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 11.9 m -158.12 34.31 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.112 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -81.45 -171.14 3.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.853 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 50.6 p -98.86 179.32 4.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -66.79 134.28 51.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.838 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.46 -67.6 0.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 15.5 p30 -66.72 165.68 14.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.881 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 135.39 131.97 3.1 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.496 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 60.35 179.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.784 0.326 . . . . 0.0 110.9 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 17.0 mt-30 60.01 160.12 0.1 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -52.51 174.11 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.531 2.154 . . . . 0.0 112.264 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.4 tp -98.53 154.2 18.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.889 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 90.1 p -151.56 167.05 29.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.04 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -157.15 164.7 37.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.962 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -109.89 154.55 22.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.013 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 90.3 t -99.92 123.2 52.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.794 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 31.2 t -100.14 -31.45 11.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.118 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -169.14 135.12 1.65 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 11.0 p -142.56 149.37 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.027 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 81.6 p -107.34 149.46 27.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.921 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -95.91 79.48 3.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.402 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -129.07 -161.43 1.11 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.789 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -152.49 87.51 4.15 Favored Pre-proline 0 C--N 1.331 -0.203 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.292 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.402 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 74.6 Cg_endo -82.7 169.6 59.52 Favored 'Cis proline' 0 C--N 1.348 0.513 0 C-N-CA 123.49 -1.462 . . . . 0.0 112.271 -0.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -111.9 153.01 17.57 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.24 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.87 121.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.83 0.348 . . . . 0.0 111.018 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.463 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 3.3 p -117.27 156.68 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.133 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.403 ' N ' ' CG2' ' A' ' 232' ' ' VAL . 87.8 m -122.2 160.6 24.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.564 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.6 m -99.9 170.04 8.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.816 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.67 140.93 36.88 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.848 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -53.6 -36.02 61.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.39 . . . . 0.0 110.823 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -94.09 44.85 1.13 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.074 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -159.85 159.59 32.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.218 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -127.47 146.59 50.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.007 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -101.28 149.42 24.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.776 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -143.83 43.74 0.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.688 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.41 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 1.6 m-85 -127.1 145.32 50.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.712 0.291 . . . . 0.0 110.651 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -108.65 173.29 6.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.974 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -59.58 94.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.62 -15.58 3.84 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.714 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -63.13 -178.36 0.23 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.738 0.304 . . . . 0.0 110.859 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 265' ' ' MET . 33.6 m-85 -131.79 146.46 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.985 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 19.5 m -144.85 150.43 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.282 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.0 p -120.86 164.28 16.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.414 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 4.2 m-30 -99.74 143.59 29.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.75 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 251' ' ' SER . . . . . 0.411 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 58.1 m -99.97 -90.77 0.31 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.408 -179.702 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.5 OUTLIER -116.3 88.75 2.96 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 120.505 0.193 . . . . 0.0 111.109 -179.851 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.411 HG21 ' HA3' ' A' ' 290' ' ' GLY . 2.4 t -100.24 155.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.977 0.418 . . . . 0.0 111.268 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -111.61 102.59 10.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.901 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.7 -53.71 0.81 Allowed Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.553 -178.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 39.2 ttm -93.04 49.35 1.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.982 0.42 . . . . 0.0 110.483 179.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -79.19 -34.01 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.78 -179.557 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.6 mm-40 -39.33 -34.74 0.22 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.936 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.414 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.8 mm? -59.7 -45.28 92.58 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.325 . . . . 0.0 110.792 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 47.3 t30 -64.02 -34.93 79.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.24 39.6 2.79 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.292 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.3 t -151.54 30.53 0.6 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.686 0.279 . . . . 0.0 110.945 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 61.31 156.16 0.11 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.545 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.1 168.06 6.57 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.37 2.046 . . . . 0.0 112.035 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.435 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.8 OUTLIER -132.67 -175.24 3.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.769 -179.859 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -99.67 134.85 41.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.543 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.41 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -103.8 172.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.627 0.727 . . . . 0.0 112.311 -179.239 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.591 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 10.0 ttpp -140.34 127.42 20.91 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.641 178.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 6.4 m -97.58 115.0 36.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 0.0 111.709 -178.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 51.1 mt -92.93 -28.83 16.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.385 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.23 -167.92 26.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.543 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.98 -49.6 9.38 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.534 2.156 . . . . 0.0 111.921 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -115.06 14.15 17.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.915 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.7 p -120.04 147.28 45.01 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.623 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.591 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.9 p90 -177.87 161.74 1.62 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.98 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.66 170.08 9.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.946 0.403 . . . . 0.0 111.113 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.7 pp -133.41 176.89 7.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.931 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 31.0 p -58.83 -177.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.922 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -66.63 110.12 3.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 10.2 t -108.03 31.71 5.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.6 m -87.12 -15.49 38.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.194 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.06 33.6 1.7 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.771 0.319 . . . . 0.0 111.021 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.405 ' CE2' HD12 ' A' ' 259' ' ' LEU . 26.1 m-85 -144.05 175.64 9.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.797 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.61 174.27 6.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.729 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -83.56 137.11 33.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -64.97 121.32 14.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.866 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 23.0 mt -105.99 -55.59 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 6.9 mtt180 -158.98 -171.33 3.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.378 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 53.34 177.62 0.08 OUTLIER Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.344 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 116.05 106.01 2.5 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.98 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.411 ' HB ' ' HB2' ' A' ' 251' ' ' SER . 7.6 mm -114.58 129.69 70.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 9.1 p -99.74 117.89 45.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.982 0.42 . . . . 0.0 111.484 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -120.45 175.72 5.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.629 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.64 99.6 9.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 14.8 m -59.41 162.03 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.191 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.8 68.68 1.31 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.81 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 31.1 m -59.65 152.26 57.92 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.206 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -47.53 134.09 21.08 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.774 2.316 . . . . 0.0 112.403 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 14.5 tttt -154.52 36.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.863 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 3.9 tttm -114.77 177.02 4.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.77 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.1 pt -78.6 76.99 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.095 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 1.4 m -95.16 125.36 39.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -135.74 160.12 39.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.988 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 61.3 mttm -132.28 142.18 49.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.83 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -139.06 97.51 3.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.025 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.449 ' N ' ' HD2' ' A' ' 307' ' ' PRO . 0.4 OUTLIER -77.04 -49.36 2.44 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.229 179.965 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.449 ' HD2' ' N ' ' A' ' 306' ' ' LEU . 87.5 Cg_endo -78.84 177.6 8.52 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.32 2.013 . . . . 0.0 112.352 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -111.12 135.28 51.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.197 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 72.4 m -154.13 103.03 2.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 4.0 mt -99.33 -65.64 0.95 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.897 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 5.7 m -128.2 124.49 62.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.834 -179.981 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.407 0 CA-C-O 120.815 0.341 . . . . 0.0 111.19 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -128.71 32.77 4.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.829 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -173.92 143.61 7.14 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.532 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -124.51 66.02 1.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.922 0.391 . . . . 0.0 110.869 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -84.99 173.55 10.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.917 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -128.99 147.05 50.83 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -121.09 -42.32 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.089 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -68.72 119.12 12.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.838 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 4.2 t -138.03 92.28 2.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -157.76 147.69 20.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.893 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 35.4 p -131.42 31.39 4.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.935 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -111.03 161.7 15.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 121.1 -130.88 8.4 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.394 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -81.58 111.14 17.61 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.81 0.338 . . . . 0.0 110.872 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . 0.468 ' N ' ' HD2' ' A' ' 216' ' ' PRO . 3.4 mt-30 -67.23 -49.48 44.16 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.236 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . 0.468 ' HD2' ' N ' ' A' ' 215' ' ' GLN . 71.6 Cg_endo -77.33 138.56 17.84 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.283 1.989 . . . . 0.0 112.39 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -147.01 167.76 23.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 2.2 m -157.6 134.42 9.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -136.71 159.6 41.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.038 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.2 mtt -105.09 155.36 19.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 45.2 t -100.67 137.02 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.002 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.2 t -112.18 -37.8 4.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.72 150.77 25.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.92 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 11.2 p -159.96 142.79 5.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.047 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 51.5 p -106.62 146.33 30.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.948 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 31.1 tttt -90.72 64.57 5.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.425 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -106.32 -156.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.811 -179.92 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -157.07 89.52 2.55 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.567 0.223 . . . . 0.0 111.389 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.425 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 91.2 Cg_endo -77.69 169.12 74.5 Favored 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 123.347 -1.522 . . . . 0.0 112.012 -0.273 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.72 148.67 16.54 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.429 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 30.7 t -99.92 120.48 49.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.907 0.384 . . . . 0.0 111.029 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.453 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.6 p -112.99 155.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.12 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.83 162.23 19.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.63 179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.9 m -99.95 166.58 10.99 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.954 0.407 . . . . 0.0 110.935 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 11.2 tp -59.28 153.66 18.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.701 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -51.68 -27.12 10.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.095 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -134.79 42.69 2.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.853 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -91.32 -176.65 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 1.3 tpm_? -130.62 135.46 47.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 38.5 p-80 -109.66 110.67 21.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -126.13 -0.48 7.53 Favored Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.991 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -80.45 139.67 36.33 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.866 0.365 . . . . 0.0 110.705 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.49 169.4 10.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.928 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 4.6 m -59.83 91.57 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.85 23.98 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.685 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -78.74 170.03 17.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 110.879 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 265' ' ' MET . 47.9 m-85 -104.36 122.39 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.903 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 30.2 m -128.07 143.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.345 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.2 p -119.82 165.85 14.04 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.739 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.492 ' CD2' HG22 ' A' ' 253' ' ' VAL . 4.0 m-30 -99.58 145.24 27.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.96 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -105.0 -88.29 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.988 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.606 ' O ' ' CG ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.63 90.99 3.45 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.233 0.54 . . . . 0.0 109.769 179.765 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.492 HG22 ' CD2' ' A' ' 250' ' ' PHE . 17.3 t -116.08 139.26 43.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.607 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 119.68 38.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.219 179.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.09 -65.67 0.5 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.778 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 6.4 ttm -85.75 59.73 5.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.089 0.471 . . . . 0.0 110.396 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 29.9 pt -80.14 -33.39 14.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.977 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.405 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.1 OUTLIER -38.94 -34.72 0.17 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.897 -178.87 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.474 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.1 mm? -75.15 -44.71 45.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.838 0.351 . . . . 0.0 110.614 179.587 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -57.45 -34.89 69.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.892 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.71 38.64 3.07 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.43 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -158.46 165.2 35.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.755 0.312 . . . . 0.0 110.759 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -56.55 167.66 0.94 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.669 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -67.98 169.37 16.58 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.335 2.023 . . . . 0.0 111.999 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.446 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.7 OUTLIER -129.39 -176.99 4.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.716 179.929 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.37 140.7 33.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.757 0.313 . . . . 0.0 110.649 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.2 pp -106.77 171.91 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.55 0.691 . . . . 0.0 112.212 -179.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.602 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -143.05 125.58 15.78 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.617 178.797 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.66 115.53 37.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.598 0.714 . . . . 0.0 111.43 -178.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 50.1 mt -94.27 -27.7 15.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.789 -1.096 . . . . 0.0 110.503 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -163.9 -170.67 29.14 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -62.96 -35.34 66.99 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.52 2.147 . . . . 0.0 112.056 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -123.93 2.44 8.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.169 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -112.24 149.94 31.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.798 0.333 . . . . 0.0 110.791 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.602 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.9 p90 -177.44 162.27 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.767 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 5.1 t -118.19 170.17 9.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.933 0.397 . . . . 0.0 111.332 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.2 pp -133.95 179.3 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.947 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.2 m -58.51 -173.41 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.9 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . 0.407 ' O ' ' CE2' ' A' ' 283' ' ' PHE . 1.7 m-20 -54.12 126.58 23.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.98 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -110.02 -30.15 7.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.968 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 2.9 m -59.44 -30.49 68.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.019 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -71.8 -31.01 66.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.998 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.427 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 50.7 m-85 -89.51 -172.92 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 75.4 m -78.63 -178.32 5.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.993 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -93.26 135.39 34.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.855 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.415 ' CE2' HG11 ' A' ' 253' ' ' VAL . 39.3 t80 -74.94 138.09 42.1 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.746 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.2 mt -117.05 -66.81 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.197 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 -152.65 170.68 19.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.664 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.77 149.72 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.143 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 142.81 116.64 1.18 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.801 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 3.9 mp -117.44 133.56 63.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.755 0.312 . . . . 0.0 110.711 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.8 p -99.88 122.08 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.219 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.7 m -131.48 158.19 41.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.94 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -90.5 118.81 30.25 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 3.5 m -57.75 122.32 7.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.27 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -98.29 -43.51 6.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.924 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 34.3 t 65.14 136.14 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.037 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -69.72 97.53 0.64 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 122.511 2.14 . . . . 0.0 112.274 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 8.7 tttt -99.13 -24.36 14.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.101 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 7.1 tmtm? 65.0 32.05 10.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.921 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 19.0 tt -96.41 128.58 47.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.097 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 6.9 p 62.26 117.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.947 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -154.07 33.05 0.43 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.921 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -142.88 -70.9 0.32 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.828 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 51.4 p -143.47 33.26 1.3 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.962 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.5 mp 61.02 56.11 3.44 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.939 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -78.55 -44.01 0.16 Allowed 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.684 2.256 . . . . 0.0 112.313 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -98.51 110.11 22.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.106 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.1 m -146.88 127.71 14.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER 61.67 174.48 0.12 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.838 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.2 p -64.67 138.29 23.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.07 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.233 -0.889 . . . . 0.0 110.869 179.995 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.486 1.364 0 CA-C-O 120.856 0.36 . . . . 0.0 111.187 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . 0.4 ' O ' ' CD1' ' A' ' 202' ' ' PHE . 15.0 p90 -161.37 117.66 2.17 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.909 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -177.2 36.05 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.457 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -63.27 -176.2 0.13 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.814 0.34 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -129.3 119.1 23.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.855 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -89.38 113.39 24.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.883 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 7.4 p -146.08 95.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.077 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 7.4 mt -139.58 86.71 2.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.84 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 60.18 179.66 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -113.23 -36.22 5.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.92 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 3.6 m 60.67 90.77 0.06 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -81.06 112.93 18.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.931 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -92.17 -66.81 1.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.471 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 62.1 mt-10 -96.88 174.27 6.88 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.81 0.338 . . . . 0.0 110.933 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . 0.402 ' CB ' ' CD ' ' A' ' 216' ' ' PRO . 0.4 OUTLIER -68.17 -60.82 4.63 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.931 179.943 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . 0.402 ' CD ' ' CB ' ' A' ' 215' ' ' GLN . 61.3 Cg_endo -73.12 -168.68 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.468 2.112 . . . . 0.0 112.341 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 29.7 tp -160.04 141.97 12.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.889 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 13.7 t -147.42 154.71 41.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.834 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.44 155.98 40.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.043 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -94.26 143.44 26.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 39.1 t -99.92 145.04 11.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.058 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 38.7 t -112.79 -32.96 6.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.073 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 14.7 ptm -169.5 159.05 8.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.427 HG13 ' CD1' ' A' ' 286' ' ' TYR . 8.5 p -158.87 149.21 7.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.062 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 63.3 p -99.46 147.56 25.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.948 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.04 81.44 3.7 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.428 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.6 t0 -127.76 -157.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.796 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 1.6 p30 -154.68 90.59 3.09 Favored Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 97.3 Cg_endo -77.13 169.39 74.38 Favored 'Cis proline' 0 C--N 1.347 0.477 0 C-N-CA 123.369 -1.513 . . . . 0.0 112.011 -0.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.76 151.3 17.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.45 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.6 t -99.87 140.25 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.843 0.354 . . . . 0.0 111.008 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.421 HG12 ' CE2' ' A' ' 275' ' ' PHE . 3.3 p -130.88 151.96 36.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.141 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 4.9 m -114.19 158.12 21.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.67 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.1 m -99.97 166.64 10.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 7.2 tp -59.11 152.25 20.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.789 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -50.95 -27.21 7.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.143 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -132.79 38.35 3.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -87.68 -169.0 2.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.158 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.2 ttm180 -145.35 106.84 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.924 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.492 ' CE1' ' CD2' ' A' ' 275' ' ' PHE . 27.5 t60 -107.61 143.64 35.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.82 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 177.04 68.79 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.678 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.452 ' CE2' ' CE1' ' A' ' 240' ' ' HIS . 15.3 m-85 -116.32 149.26 39.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.861 0.362 . . . . 0.0 110.762 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -69.28 151.33 46.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.5 m -57.86 97.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.78 15.35 9.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.721 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -64.9 -178.67 0.45 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.657 0.265 . . . . 0.0 110.743 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.482 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.8 m-85 -120.24 132.06 55.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.789 0.328 . . . . 0.0 110.982 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 17.8 m -137.32 154.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.421 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.4 p -125.59 165.0 19.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.556 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.463 ' CD2' HG22 ' A' ' 253' ' ' VAL . 4.6 m-30 -99.74 140.59 33.73 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.041 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 62.2 m -99.96 -94.09 0.26 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.033 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.54 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.2 OUTLIER -109.66 87.74 2.58 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 121.27 -0.172 . . . . 0.0 110.636 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.463 HG22 ' CD2' ' A' ' 250' ' ' PHE . 15.5 t -107.21 144.72 15.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.928 0.394 . . . . 0.0 111.726 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -107.92 114.94 29.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.912 179.161 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.6 -63.52 0.51 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.671 -0.776 . . . . 0.0 111.458 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 2.9 ttm -89.24 54.57 3.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.133 0.492 . . . . 0.0 110.152 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 14.2 pt -79.04 -33.35 15.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.045 -179.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -38.76 -34.71 0.16 Allowed 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.933 -178.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.45 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.2 mm? -71.08 -47.03 60.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.943 0.401 . . . . 0.0 110.49 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -55.86 -34.85 65.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.896 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.14 46.37 3.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -169.1 166.34 10.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.784 0.326 . . . . 0.0 110.663 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -55.91 164.19 1.83 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.9 168.54 13.43 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.242 1.961 . . . . 0.0 112.078 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.482 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.7 ptp -128.35 -172.29 2.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.516 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -99.37 151.43 21.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.758 0.313 . . . . 0.0 110.654 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 2.1 pp -123.1 174.0 8.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.593 0.711 . . . . 0.0 112.316 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.547 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.2 OUTLIER -147.43 127.77 13.95 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.738 178.919 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 34.9 m -97.88 112.75 30.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.434 0.635 . . . . 0.0 111.539 -178.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 17.6 mt -89.04 -28.0 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.449 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.63 -164.17 24.9 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.583 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 -44.25 9.06 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.586 2.191 . . . . 0.0 112.099 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -117.03 18.34 14.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.029 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.97 146.66 51.67 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.92 0.391 . . . . 0.0 110.794 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.547 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.2 p90 -178.62 154.12 0.74 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.639 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.7 t -105.58 170.06 8.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.014 0.435 . . . . 0.0 111.441 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.61 -178.02 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.84 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.31 175.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.987 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.38 133.2 50.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 62.9 p -118.07 28.57 8.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.06 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 80.3 p -82.21 -30.05 31.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.921 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . 0.405 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 77.5 m-20 -100.1 31.23 3.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.999 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.444 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 24.9 m-85 -138.12 -175.05 3.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.04 178.78 6.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.94 150.88 21.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.929 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.427 ' CD1' HG13 ' A' ' 224' ' ' VAL . 67.3 t80 -81.43 136.39 35.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.5 mt -120.0 -56.81 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.199 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.8 mmt85 -162.48 178.11 8.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.372 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.29 162.58 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.269 -0.967 . . . . 0.0 111.932 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 130.8 116.37 1.81 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.793 179.002 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.2 mt -120.51 133.59 66.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.747 0.308 . . . . 0.0 110.597 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 12.1 p -99.6 117.21 44.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.325 -179.448 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.31 142.54 50.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.812 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -80.7 101.59 9.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.927 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 27.1 m -57.05 132.76 21.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.135 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -169.73 77.95 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.874 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 297' ' ' VAL . 11.1 p 34.91 90.5 0.07 OUTLIER Pre-proline 0 N--CA 1.467 0.388 0 CA-C-N 115.977 -0.556 . . . . 0.0 112.032 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.8 128.92 31.55 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.618 2.212 . . . . 0.0 112.231 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.38 173.04 12.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -81.68 153.25 26.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.913 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 32.5 mm -70.65 148.66 10.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.044 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.2 154.02 17.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.962 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -159.86 118.49 2.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.849 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -99.88 -75.41 0.57 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.964 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.93 117.46 7.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.971 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 59.1 91.08 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.937 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -83.68 46.07 1.96 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.784 2.323 . . . . 0.0 112.73 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 50.55 97.0 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.85 0.357 . . . . 0.0 111.351 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 1.4 m -170.83 115.66 0.45 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.032 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 2.6 pp -83.11 121.17 26.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.82 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.2 p -59.19 130.83 23.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.885 -179.986 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 120.831 0.348 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 61.38 105.52 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.861 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -132.36 124.16 3.8 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.515 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -135.62 30.14 3.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.816 0.341 . . . . 0.0 110.883 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -158.52 166.02 33.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 64.15 -79.08 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -65.08 80.29 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.059 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -105.83 107.87 19.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.89 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 9.0 t -127.65 -176.11 3.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.829 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 1.7 t70 60.39 110.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.933 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.6 -32.23 7.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.893 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -176.64 -40.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.844 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 177.99 -92.53 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.496 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 59.39 94.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.832 0.349 . . . . 0.0 110.876 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . 0.413 ' N ' ' CD ' ' A' ' 216' ' ' PRO . 0.0 OUTLIER -69.07 -52.45 15.99 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.947 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . 0.413 ' CD ' ' N ' ' A' ' 215' ' ' GLN . 52.8 Cg_exo -54.63 134.28 61.42 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.447 2.098 . . . . 0.0 112.188 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 4.0 tp -129.74 139.73 51.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.87 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 63.8 m -134.02 160.22 38.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.991 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -148.0 153.25 38.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.57 155.97 17.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.055 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 41.0 t -105.19 135.31 43.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.021 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.6 t -111.52 -34.75 6.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -164.53 151.91 11.67 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.82 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.44 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 9.8 p -157.86 148.58 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.023 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 64.5 p -101.96 145.36 29.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.913 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -93.65 77.92 4.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.729 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.5 t70 -121.59 -153.68 0.56 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.773 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 37.1 t-20 -157.39 90.19 2.43 Favored Pre-proline 0 CA--C 1.531 0.232 0 CA-C-O 120.452 0.168 . . . . 0.0 111.256 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.401 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 97.4 Cg_endo -76.97 169.8 73.43 Favored 'Cis proline' 0 C--N 1.348 0.5 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.15 -0.253 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.4 149.58 16.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.458 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.2 t -99.88 138.72 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.832 0.348 . . . . 0.0 110.874 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.448 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 3.6 p -131.63 156.9 43.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.406 ' N ' ' CG2' ' A' ' 232' ' ' VAL . 94.3 m -120.92 161.68 21.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.368 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.4 m -99.9 169.86 8.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.908 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 3.2 tp -68.08 153.67 43.24 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.807 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -53.67 -28.3 32.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.97 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -121.68 30.64 6.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.891 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -92.14 -176.42 4.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.122 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -124.87 -175.89 3.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 6.2 t-80 -174.12 113.32 0.18 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -144.78 25.71 1.94 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.819 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.405 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 0.5 OUTLIER -99.04 138.64 35.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.861 0.362 . . . . 0.0 110.595 179.808 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -92.78 168.8 10.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 58.7 p -59.44 102.39 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 120.6 11.7 6.46 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.898 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -73.83 -176.14 2.34 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.732 0.301 . . . . 0.0 110.767 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -132.75 121.82 23.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.798 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 20.2 m -129.1 154.84 40.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 0.0 111.325 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.8 p -123.76 165.51 17.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.862 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.48 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.0 m-30 -99.61 144.27 28.89 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.96 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 28.7 t -102.88 -94.35 0.31 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.011 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -110.29 88.29 2.73 Favored 'General case' 0 C--O 1.225 -0.195 0 CA-C-O 120.511 0.196 . . . . 0.0 110.54 179.684 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.48 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 2.9 t -104.32 143.54 15.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.988 0.423 . . . . 0.0 111.745 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.06 110.81 23.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.924 179.152 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.73 -63.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.701 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 2.1 ttm -86.25 58.58 5.13 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 110.33 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 16.2 pt -79.32 -33.33 15.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.9 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.435 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 4.2 mp0 -38.99 -34.59 0.16 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.859 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.454 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.0 mm? -73.16 -46.82 48.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.938 0.399 . . . . 0.0 110.495 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -58.38 -34.94 71.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.788 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.62 45.35 2.74 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.346 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -165.92 163.96 18.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.775 0.321 . . . . 0.0 110.714 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -56.01 167.65 0.83 Allowed Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.599 179.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -68.68 154.39 71.47 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.302 2.002 . . . . 0.0 112.017 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.429 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.1 ptp -115.11 -177.03 3.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.574 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -99.7 138.67 36.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.773 0.321 . . . . 0.0 110.784 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.405 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -106.79 174.72 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.573 0.702 . . . . 0.0 112.2 -179.473 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -144.04 128.77 18.27 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.508 178.716 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 27.7 m -97.43 118.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.523 0.678 . . . . 0.0 111.495 -178.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 44.5 mt -92.42 -30.78 15.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.662 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.44 -158.99 32.17 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.312 -0.947 . . . . 0.0 113.097 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -63.89 112.13 1.74 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.71 2.273 . . . . 0.0 112.338 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 66.27 14.99 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.08 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -128.73 138.33 52.06 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.484 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.688 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.4 p90 -174.21 169.42 3.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.872 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.0 t -123.42 170.11 10.68 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.98 0.419 . . . . 0.0 111.415 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 11.6 pt -123.58 -177.53 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.802 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 m -57.5 -82.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.983 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -150.15 140.69 22.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.801 0.334 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 71.5 p -113.22 -26.92 8.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.146 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 t -54.53 -24.21 19.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.292 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . 0.401 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 3.3 m120 -94.47 20.91 7.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.23 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.453 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 35.7 m-85 -143.78 -179.61 6.57 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.774 0.321 . . . . 0.0 110.825 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.81 -171.79 0.74 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.893 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -98.87 125.86 44.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.44 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 26.9 t80 -69.98 120.67 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.797 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.2 mt -106.88 -68.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.185 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -138.48 -178.84 5.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.508 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.81 166.67 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.238 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 122.87 111.32 2.05 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.532 -0.842 . . . . 0.0 113.126 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.8 mp -118.69 128.35 75.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 12.6 p -99.55 113.1 33.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.017 0.437 . . . . 0.0 111.531 -179.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.4 m -115.28 -176.81 2.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.641 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -112.59 106.6 15.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.826 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 4.7 m -58.47 133.94 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.114 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -126.02 19.79 7.68 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.255 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.5 t 53.36 91.49 0.07 OUTLIER Pre-proline 0 C--N 1.331 -0.202 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.404 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.56 138.81 39.35 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.456 2.104 . . . . 0.0 112.278 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.37 175.02 5.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.952 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -71.89 124.5 24.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.918 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.9 pt -104.39 131.66 52.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.192 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 88.9 p -102.46 27.94 6.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.004 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 56.78 178.55 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.93 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -107.96 -36.06 6.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.8 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 1.4 m -154.27 158.44 40.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.905 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 60.39 82.74 0.22 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.92 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.95 -46.56 0.71 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.642 2.228 . . . . 0.0 112.357 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -142.14 -176.56 4.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.134 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 10.0 m -157.97 31.51 0.26 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -149.0 124.59 10.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.805 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.94 -30.12 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.23 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.207 -0.902 . . . . 0.0 110.857 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.768 0.318 . . . . 0.0 111.257 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -111.82 141.75 45.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.901 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 104.95 97.86 2.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.452 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -140.62 -66.16 0.44 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.794 0.33 . . . . 0.0 110.902 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -147.9 -46.55 0.16 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.962 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 1.4 ttp 62.61 29.44 16.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.981 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t 63.34 124.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.11 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 2.3 pp -158.37 103.77 1.81 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -138.13 -169.55 2.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.852 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -116.86 -171.72 2.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.966 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.7 t -92.1 150.7 20.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.984 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -109.93 -23.69 11.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.13 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -54.04 108.08 0.78 Allowed Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.631 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -142.72 -47.44 0.33 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.881 0.372 . . . . 0.0 110.94 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 2.4 pt20 -104.27 112.65 65.49 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.83 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -68.51 130.19 20.44 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.439 2.093 . . . . 0.0 112.296 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.94 -179.27 4.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.832 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.2 p -168.52 97.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.024 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -102.49 167.49 9.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.986 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 4.5 mmt -105.54 146.46 29.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.015 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.446 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 96.0 t -100.06 130.58 49.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 40.0 t -109.39 -34.88 6.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.066 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -157.0 148.29 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.043 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.433 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.0 p -155.93 113.09 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.005 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 68.8 p -70.81 135.69 48.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.05 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.54 82.96 6.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.726 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -129.85 -147.94 0.35 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.498 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -145.96 102.77 4.16 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 120.342 0.115 . . . . 0.0 110.881 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.414 ' HB2' ' O ' ' A' ' 277' ' ' ILE . 36.2 Cg_endo -68.24 -74.26 0.0 OUTLIER 'Cis proline' 0 C--N 1.349 0.555 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.656 0.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 154.42 139.73 2.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.18 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.3 t -99.83 127.85 52.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.895 0.378 . . . . 0.0 111.025 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.451 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.7 p -116.85 153.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.165 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 90.3 m -117.93 157.86 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.508 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -99.97 168.65 9.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 3.5 tp -68.95 150.81 47.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.781 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -48.5 -28.38 3.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.176 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -133.75 47.42 2.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.85 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -90.85 174.19 7.58 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.163 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -118.38 107.4 13.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.912 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 12.9 p80 -92.57 131.58 37.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.824 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -151.4 26.36 0.97 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.566 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.424 ' CD1' ' HG3' ' A' ' 294' ' ' GLN . 1.4 m-85 -112.3 140.86 46.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 110.719 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.66 175.48 5.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -61.18 88.67 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.773 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.18 -16.47 3.9 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.818 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.09 165.39 3.41 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.658 0.266 . . . . 0.0 110.708 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.498 ' HA ' ' O ' ' A' ' 265' ' ' MET . 5.0 m-85 -113.61 150.15 33.52 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.883 0.373 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.4 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 10.1 m -147.48 144.31 19.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.21 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 p -115.78 163.67 15.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.671 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.454 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 2.0 m-30 -99.44 142.78 30.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.77 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 65.3 m -99.82 -100.12 0.24 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.108 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 1.7 pt-20 -103.1 88.01 3.04 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.605 0.24 . . . . 0.0 110.641 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.45 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 9.8 t -100.9 136.71 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.853 0.358 . . . . 0.0 111.522 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -99.92 107.88 19.98 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.883 179.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.65 -66.02 0.46 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.79 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 32.1 ttm -84.04 59.65 5.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.164 0.506 . . . . 0.0 110.673 179.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 12.4 pt -80.23 -33.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.989 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -38.57 -34.5 0.14 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.454 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.4 mm? -61.64 -53.9 49.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.907 0.384 . . . . 0.0 110.613 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -57.39 -34.94 69.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.884 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.05 46.09 2.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 2.2 t -162.06 30.2 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.69 0.281 . . . . 0.0 110.981 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . 0.401 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 2.4 mt-30 58.33 167.66 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.773 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.401 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 30.1 Cg_endo -63.39 165.8 16.69 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.31 2.007 . . . . 0.0 112.067 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.498 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.7 ptp -134.52 -171.69 2.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.643 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -99.68 138.63 36.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.857 0.36 . . . . 0.0 110.568 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.6 pp -109.71 172.72 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.5 0.666 . . . . 0.0 112.181 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.538 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 8.5 tttm -143.54 125.51 15.29 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.788 -1.096 . . . . 0.0 108.833 178.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 27.4 m -97.61 108.9 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.459 0.647 . . . . 0.0 111.525 -178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.1 mt -86.02 -30.57 22.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.451 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.61 -168.53 27.91 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.615 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -60.1 -50.57 7.14 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.59 2.194 . . . . 0.0 111.816 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -112.91 21.87 15.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.723 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -130.33 145.93 51.85 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.736 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.538 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -179.18 155.68 0.73 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.4 t -104.3 170.08 8.11 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.162 0.506 . . . . 0.0 111.35 -179.249 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.414 ' O ' ' HB2' ' A' ' 229' ' ' PRO . 3.8 pt -124.67 -171.22 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.643 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -74.27 -168.46 0.65 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.623 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -69.77 105.6 2.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.412 ' HA ' ' CD1' ' A' ' 283' ' ' PHE . 4.4 t -132.89 74.25 1.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.932 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 10.1 p -125.76 -33.51 2.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.593 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 -95.14 25.4 4.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.647 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.412 ' CD1' ' HA ' ' A' ' 280' ' ' THR . 21.6 m-85 -117.36 -167.48 1.32 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.739 0.304 . . . . 0.0 110.739 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 31.0 t -74.56 175.95 7.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.842 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -99.4 131.71 45.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.433 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 24.7 t80 -69.01 117.56 10.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.029 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 6.0 mt -102.98 -60.06 3.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.47 -178.75 6.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.459 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . 0.401 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 57.87 158.31 0.02 OUTLIER Glycine 0 C--N 1.331 0.29 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.427 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 129.37 106.13 1.21 Allowed Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.513 -0.851 . . . . 0.0 112.865 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.7 mp -111.54 135.87 49.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.4 ' CG2' ' HB ' ' A' ' 248' ' ' VAL . 12.2 p -99.64 112.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.964 0.411 . . . . 0.0 111.549 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 49.8 m -107.2 171.91 7.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.701 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.424 ' HG3' ' CD1' ' A' ' 242' ' ' PHE . 2.2 tt0 -110.04 94.96 5.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.086 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 32.1 m -59.48 -171.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.013 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.88 90.24 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.861 0.362 . . . . 0.0 111.238 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 3.7 m -160.27 156.34 22.97 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.087 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.25 164.15 31.54 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.53 2.153 . . . . 0.0 112.265 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.03 -64.58 1.06 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 13.8 tttm -149.49 136.25 19.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.87 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 28.2 mm -81.58 137.75 20.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.18 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 10.1 m -113.77 162.68 16.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.89 179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -150.83 164.62 35.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.831 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 12.0 mttt 61.84 113.83 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.79 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 62.65 148.13 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -153.66 87.61 3.74 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -69.23 -35.38 14.32 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.586 2.191 . . . . 0.0 112.309 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 61.1 114.04 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.1 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 19.4 t -74.84 101.64 4.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.88 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -140.9 79.16 1.68 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.848 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.67 -36.01 4.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.063 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.274 -0.87 . . . . 0.0 110.931 179.956 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 . . . . . 0 N--CA 1.486 1.335 0 CA-C-O 120.859 0.361 . . . . 0.0 111.174 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -157.41 -47.57 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.937 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -84.35 -106.17 0.59 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.48 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -156.87 68.2 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.841 0.353 . . . . 0.0 110.912 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 61.99 117.59 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.914 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 61.27 112.03 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 10.8 p -153.02 -44.56 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.071 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 5.1 mp -101.44 -31.46 10.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.957 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 76.6 p -83.85 122.47 28.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.85 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -136.46 -51.83 0.7 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.992 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 9.0 t -98.69 122.51 42.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.95 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.95 151.46 45.43 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -148.44 -92.51 0.1 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.377 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -162.84 154.33 17.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.807 0.337 . . . . 0.0 110.853 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.86 132.93 21.73 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.71 -62.44 0.32 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.395 2.063 . . . . 0.0 112.242 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 8.1 tp -147.7 133.53 19.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.834 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 25.6 p -145.25 172.28 13.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -162.98 169.95 18.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.05 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.3 156.08 22.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.939 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 41.0 t -108.21 127.39 64.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.003 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 17.2 t -106.06 -34.68 7.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.974 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.76 137.33 10.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 11.1 p -142.8 122.08 8.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.064 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 31.0 p -81.7 138.67 35.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.112 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -90.56 78.32 6.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.77 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.415 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.9 t0 -123.07 -150.96 0.46 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.723 -179.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -159.44 90.49 1.93 Allowed Pre-proline 0 CA--C 1.532 0.255 0 CA-C-O 120.471 0.177 . . . . 0.0 111.202 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.415 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 81.2 Cg_endo -75.13 169.34 74.82 Favored 'Cis proline' 0 C--N 1.347 0.451 0 C-N-CA 123.322 -1.533 . . . . 0.0 111.937 -0.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -103.86 146.13 16.29 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.377 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.1 t -99.76 125.35 53.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.464 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.7 p -122.55 155.25 27.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.214 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 4.7 m -123.52 166.9 14.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.577 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -100.0 170.05 8.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.745 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.16 160.46 32.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.7 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -55.08 -29.81 58.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.992 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -119.13 34.64 5.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.829 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.94 159.6 15.22 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.019 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -124.65 140.02 53.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.977 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.4 t60 -118.76 144.19 46.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.82 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -159.57 26.39 0.34 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.739 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.407 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 1.6 m-85 -100.53 142.34 32.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.66 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -95.94 170.07 9.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.24 101.07 0.11 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.8 19.26 5.35 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.696 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -84.9 169.27 14.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.758 0.313 . . . . 0.0 110.702 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.441 ' HA ' ' O ' ' A' ' 265' ' ' MET . 62.5 m-85 -108.28 141.81 39.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.912 0.387 . . . . 0.0 111.033 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 32.5 m -146.21 143.5 21.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.1 179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.5 p -121.24 162.52 20.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.425 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 4.0 m-30 -99.76 149.61 23.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.1 m -108.5 -85.17 0.53 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.919 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.602 ' O ' ' CG ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.72 92.58 3.85 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.128 0.49 . . . . 0.0 109.828 179.678 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.422 HG23 ' CD2' ' A' ' 250' ' ' PHE . 3.3 t -112.46 140.63 31.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.479 -179.196 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 68.3 mt-30 -103.79 110.84 23.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.091 179.331 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.88 -57.75 0.64 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.591 -179.021 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -90.27 53.78 2.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.11 0.481 . . . . 0.0 110.353 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 18.8 pt -78.91 -33.79 16.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.843 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -39.24 -34.73 0.2 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.294 -0.412 . . . . 0.0 112.068 -178.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.425 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.5 mm? -66.47 -45.07 80.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 110.685 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -57.68 -38.86 75.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.994 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.7 50.22 1.14 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.511 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.2 t -161.67 30.12 0.13 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.711 0.291 . . . . 0.0 110.905 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 10.2 mt-30 58.82 166.22 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.762 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.34 166.01 13.94 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.441 2.094 . . . . 0.0 112.148 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.441 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.2 ptp -130.97 -174.84 3.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.713 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.52 136.53 39.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.801 0.334 . . . . 0.0 110.616 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.407 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.2 pp -103.15 175.77 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.662 0.744 . . . . 0.0 112.315 -179.317 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.626 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -148.89 128.84 13.46 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.621 178.805 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 26.1 m -97.73 122.89 49.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.528 0.68 . . . . 0.0 111.577 -178.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 48.4 mt -101.95 -29.1 12.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.504 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.49 -172.35 27.64 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.513 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.56 -33.98 65.79 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.556 2.171 . . . . 0.0 112.053 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -124.63 1.92 8.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.166 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -113.98 153.3 29.57 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.85 0.357 . . . . 0.0 110.805 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.626 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.53 169.05 2.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.831 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -124.1 170.08 11.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.993 0.425 . . . . 0.0 111.242 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.3 pt -125.73 -179.21 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.773 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.04 -173.37 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.865 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.67 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.827 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -99.85 33.47 2.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.979 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 31.2 t -109.21 30.78 6.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . 0.406 ' OD1' ' CZ ' ' A' ' 283' ' ' PHE . 28.2 p30 -150.09 30.71 0.7 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.851 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.406 ' CZ ' ' OD1' ' A' ' 282' ' ' ASN . 20.0 m-85 -138.04 -168.42 2.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -91.61 175.25 6.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.84 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -85.43 121.04 27.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -56.67 136.52 54.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.879 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . 0.449 HD11 HG22 ' A' ' 287' ' ' ILE . 30.9 mt -114.16 -59.83 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.301 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.01 173.3 11.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.734 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.36 150.51 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.31 112.53 0.95 Allowed Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.895 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.2 mp -109.22 128.87 64.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.806 0.336 . . . . 0.0 110.614 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.7 p -99.88 114.93 39.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.359 -179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 75.6 m -109.42 -178.03 3.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.638 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 31.9 tt0 -119.31 102.89 9.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.001 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 28.8 m -73.48 64.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.0 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 7.5 tttm -127.2 94.35 3.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 4.7 m -135.03 111.98 11.17 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.227 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . 0.408 ' O ' ' CG ' ' A' ' 299' ' ' LYS . 45.7 Cg_exo -56.22 -19.22 26.68 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.466 2.111 . . . . 0.0 112.505 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . 0.408 ' CG ' ' O ' ' A' ' 298' ' ' PRO . 5.7 ptmt 46.17 101.29 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.026 0.441 . . . . 0.0 111.659 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . 0.479 ' O ' ' CG2' ' A' ' 301' ' ' ILE . 10.8 mttt 66.78 179.62 0.22 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.936 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . 0.479 ' CG2' ' O ' ' A' ' 300' ' ' LYS . 7.4 tt 51.81 160.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.92 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 95.9 p -153.23 -46.52 0.1 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.015 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -142.06 151.22 42.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.891 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 23.6 mtmt 62.09 117.93 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.953 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 23.1 t -142.12 31.25 1.57 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.922 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 1.6 mp -97.59 150.37 36.71 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.46 -170.46 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.586 2.191 . . . . 0.0 112.193 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -118.17 137.19 53.15 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.135 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 55.9 p -118.3 148.0 42.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.942 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -105.62 -35.01 7.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.837 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 27.7 t -124.13 155.76 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.009 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.354 0 CA-C-O 120.839 0.352 . . . . 0.0 111.243 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -100.84 -31.07 11.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.93 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 145.97 138.26 3.19 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.463 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -79.82 -39.82 29.9 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.877 0.37 . . . . 0.0 110.94 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 60.34 94.29 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.937 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -176.72 123.41 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 9.9 p -124.52 69.33 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.998 0.428 . . . . 0.0 111.097 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 3.7 mm? 63.73 -79.81 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.073 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 21.8 p -99.52 -41.69 7.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.055 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 3.1 t70 64.35 95.91 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -157.97 143.2 16.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.849 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -155.55 112.18 3.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.959 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 73.89 -135.23 19.97 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.51 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -104.98 150.41 24.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.884 0.373 . . . . 0.0 110.895 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 -156.44 122.55 2.55 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.765 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -54.14 121.9 10.48 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.454 2.103 . . . . 0.0 112.257 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp -119.9 178.21 4.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.774 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.7 m -162.19 169.6 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.972 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -162.25 148.39 13.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.951 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.4 mtt -93.45 160.93 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.002 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.422 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 47.9 t -108.73 123.88 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.025 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 28.8 t -102.22 -30.68 10.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.52 143.21 5.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.955 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.401 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.2 p -149.2 137.33 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.087 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 43.8 p -90.22 145.51 24.95 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.83 78.28 4.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.813 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.71 -160.74 1.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.824 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 7.3 p-10 -154.4 90.04 3.22 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.277 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -80.1 169.72 68.61 Favored 'Cis proline' 0 C--N 1.348 0.503 0 C-N-CA 123.501 -1.458 . . . . 0.0 112.168 -0.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -113.76 157.13 15.16 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.334 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.0 t -99.79 125.45 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.858 0.361 . . . . 0.0 110.911 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.461 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.5 p -123.72 155.79 30.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.196 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.407 ' N ' ' CG2' ' A' ' 232' ' ' VAL . 89.1 m -124.16 159.11 30.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.615 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.0 m -99.97 165.9 11.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.86 0.362 . . . . 0.0 110.905 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 3.7 tp -59.92 150.12 29.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.741 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -52.24 -27.79 16.22 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.261 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -99.92 -26.74 13.9 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.04 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . 0.405 ' O ' ' CE2' ' A' ' 273' ' ' TYR . . . -74.4 140.81 44.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.243 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 27.5 ttt180 -120.59 145.31 47.5 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.902 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -86.24 131.53 34.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.935 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -119.52 -19.38 4.19 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.995 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.415 ' CE1' ' HB2' ' A' ' 294' ' ' GLN . 0.2 OUTLIER -78.9 145.93 33.85 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.777 0.322 . . . . 0.0 110.737 -179.879 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -101.92 179.66 4.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -63.72 105.44 0.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.997 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 128.24 -5.39 6.78 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.967 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -80.21 172.34 13.9 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.841 0.353 . . . . 0.0 110.98 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.437 ' HA ' ' O ' ' A' ' 265' ' ' MET . 4.4 m-85 -122.19 152.75 39.64 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.055 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.422 ' CG2' ' CG2' ' A' ' 292' ' ' VAL . 19.5 m -156.55 154.76 5.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.256 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 t -125.61 170.19 11.73 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.725 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.429 ' CD2' HG23 ' A' ' 253' ' ' VAL . 5.5 m-30 -99.6 159.45 15.03 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.13 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 29.3 t -113.37 -87.66 0.56 Allowed 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.065 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -114.66 88.57 2.89 Favored 'General case' 0 CA--C 1.521 -0.15 0 CA-C-O 120.54 0.209 . . . . 0.0 110.852 179.785 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.429 HG23 ' CD2' ' A' ' 250' ' ' PHE . 5.0 t -99.96 158.36 3.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.004 0.431 . . . . 0.0 111.462 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.2 mm-40 -119.04 106.11 12.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.941 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -56.55 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.482 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 2.2 ttm -96.59 51.53 1.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.153 0.502 . . . . 0.0 110.315 179.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.7 pp -75.74 -33.66 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.563 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.415 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 5.1 mm-40 -39.25 -34.64 0.2 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.695 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.425 HD12 ' CE2' ' A' ' 283' ' ' PHE . 3.4 mm? -59.22 -47.32 85.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 110.59 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -57.54 -46.41 83.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.871 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.82 47.56 2.98 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.538 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 5.1 t -152.14 34.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 59.74 168.49 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -67.55 151.34 79.77 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.349 2.033 . . . . 0.0 112.067 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.437 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 3.1 ptp -118.69 -178.01 3.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.711 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -99.75 157.25 16.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.504 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.8 pp -125.93 170.5 15.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.625 0.726 . . . . 0.0 112.312 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.612 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 14.4 mtpt -145.06 126.79 15.25 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.564 -1.198 . . . . 0.0 108.532 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 29.4 m -97.54 120.36 46.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.595 0.712 . . . . 0.0 111.587 -178.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.2 mt -99.11 -30.25 12.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.809 -1.087 . . . . 0.0 110.601 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -162.31 -173.81 31.44 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.565 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.82 -59.27 1.31 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.611 2.208 . . . . 0.0 112.243 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CE2' ' O ' ' A' ' 238' ' ' ALA . 10.0 m-85 -109.39 5.19 23.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.3 p -106.57 149.5 27.1 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.612 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -177.65 166.88 2.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.755 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.4 t -117.21 170.09 8.95 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.7 pt -131.11 179.89 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.16 -179.55 0.78 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.89 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.34 109.23 0.83 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.799 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.6 t -122.5 30.08 6.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.026 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 p -98.66 31.42 2.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.942 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.26 -45.95 1.0 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.425 ' CE2' HD12 ' A' ' 259' ' ' LEU . 30.5 m-85 -59.81 -168.21 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.878 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.2 176.77 9.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.913 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -83.79 125.99 32.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.976 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.401 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 20.7 t80 -61.12 135.04 57.64 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.81 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.7 mt -118.26 -64.71 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.008 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.85 -173.74 4.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.438 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.14 170.38 0.1 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.251 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 118.95 106.83 2.25 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.0 179.261 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 2.9 mp -116.94 125.3 73.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.739 0.304 . . . . 0.0 110.191 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.422 ' CG2' ' CG2' ' A' ' 248' ' ' VAL . 9.8 p -99.68 120.1 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.551 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.5 m -125.58 170.23 11.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.726 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.415 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 27.7 tt0 -86.3 118.33 25.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.896 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -78.63 164.45 3.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.086 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -161.23 30.21 0.14 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.985 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.509 ' N ' ' CD ' ' A' ' 298' ' ' PRO . 3.6 t -81.91 -45.82 1.04 Allowed Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.467 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . 0.509 ' CD ' ' N ' ' A' ' 297' ' ' VAL . 25.7 Cg_exo -62.58 -26.99 76.11 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.521 2.147 . . . . 0.0 112.234 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.22 154.02 14.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.044 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 59.52 30.01 19.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.045 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 3.7 mp 63.82 134.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 66.4 p -132.39 174.43 10.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.9 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -134.47 168.95 18.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.873 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -98.92 31.62 2.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 5.6 m -107.03 -178.51 3.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -132.63 87.22 42.22 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_exo -51.21 -25.67 18.02 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.535 2.157 . . . . 0.0 112.46 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 61.66 110.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.074 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 22.8 t -98.62 117.4 32.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -124.86 31.35 5.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 17.2 m -94.89 43.51 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.85 179.955 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 120.789 0.328 . . . . 0.0 111.234 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -105.48 134.34 48.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.908 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 73.95 -105.12 1.75 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.522 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 61.22 112.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.864 0.364 . . . . 0.0 110.881 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -95.63 -31.6 13.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.901 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.07 109.26 2.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.3 m -114.94 31.23 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.128 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -85.98 160.7 19.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.52 154.43 42.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.932 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.9 t0 62.73 146.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.966 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 59.94 30.39 19.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 41.7 t30 -68.98 -31.2 69.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.896 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -111.07 167.49 12.53 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.568 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -76.74 -30.0 56.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.745 0.307 . . . . 0.0 110.972 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . 0.409 ' CB ' ' CD ' ' A' ' 216' ' ' PRO . 7.9 mt-30 -58.69 -60.72 9.49 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.065 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . 0.409 ' CD ' ' CB ' ' A' ' 215' ' ' GLN . 45.8 Cg_endo -68.76 150.89 74.46 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.464 2.109 . . . . 0.0 112.328 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.7 tp -130.49 -173.88 3.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 36.3 p -152.53 146.39 25.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -141.8 145.24 34.5 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.026 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -82.8 151.27 26.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.983 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 83.7 t -104.25 143.85 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.065 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.2 t -117.32 -38.52 3.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.774 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.7 mtp -159.63 143.61 14.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.433 HG11 ' CD2' ' A' ' 286' ' ' TYR . 10.5 p -143.68 121.32 6.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.028 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 32.9 p -79.89 142.76 34.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.007 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.56 78.54 4.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.799 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.422 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 4.7 t0 -127.84 -158.91 0.91 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.749 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -153.53 90.8 3.37 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.543 0.211 . . . . 0.0 111.325 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.422 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 96.9 Cg_endo -77.23 169.17 74.85 Favored 'Cis proline' 0 C--N 1.348 0.512 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.949 -0.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.27 17.53 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.453 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 21.4 t -99.84 136.09 32.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.844 0.355 . . . . 0.0 111.19 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.452 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 6.3 p -127.67 138.12 55.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.014 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.46 162.33 13.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.65 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.99 165.88 11.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.887 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -58.76 158.0 8.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.701 179.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.76 -27.64 29.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.109 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.32 38.51 3.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.804 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -99.22 169.54 9.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.096 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 4.0 tpt180 -150.02 135.71 18.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.001 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.428 ' HB2' ' CE2' ' A' ' 242' ' ' PHE . 27.1 p-80 -137.78 135.96 36.82 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.766 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -122.15 65.07 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.669 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.428 ' CE2' ' HB2' ' A' ' 240' ' ' HIS . 0.9 OUTLIER -111.87 142.1 44.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.848 0.356 . . . . 0.0 110.656 179.856 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.55 172.26 9.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 27.0 m -64.17 99.54 0.28 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.003 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.26 17.89 6.97 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.902 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.01 -175.46 2.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.704 0.288 . . . . 0.0 110.687 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.0 m-85 -120.93 151.95 39.08 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.909 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 35.0 m -156.04 152.2 8.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.374 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.9 p -128.45 168.91 14.95 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.462 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.5 m-30 -99.79 140.94 33.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.135 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.8 m -104.09 -81.38 0.52 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.899 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.572 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -119.56 88.17 2.88 Favored 'General case' 0 C--O 1.216 -0.661 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.61 179.567 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.462 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 9.2 t -114.72 134.17 58.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 120.934 0.397 . . . . 0.0 111.882 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 64.2 mt-30 -99.65 119.82 38.7 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.028 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -62.91 0.51 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.366 -178.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 2.3 ttm -87.9 58.84 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.156 0.503 . . . . 0.0 110.162 179.032 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . 0.433 ' O ' ' N ' ' A' ' 260' ' ' ASN . 1.0 OUTLIER -77.46 -33.34 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.961 -179.437 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.422 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 37.9 mm-40 -39.14 -34.65 0.18 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.444 ' CD1' ' CE2' ' A' ' 283' ' ' PHE . 2.7 mm? -76.87 -39.89 49.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.873 0.368 . . . . 0.0 110.69 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.433 ' N ' ' O ' ' A' ' 257' ' ' ILE . 0.6 OUTLIER -57.09 -36.99 71.27 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.91 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.54 29.1 10.15 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.325 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -144.18 158.42 43.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.767 0.317 . . . . 0.0 110.762 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 12.7 mt-30 -54.42 165.75 0.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.754 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -64.05 174.63 3.8 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.427 2.085 . . . . 0.0 111.826 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.3 OUTLIER -133.86 -177.75 4.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.753 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -99.51 132.83 44.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.455 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.2 pp -102.61 172.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.8 0.81 . . . . 0.0 112.591 -179.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.577 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 43.8 mmtt -142.13 129.69 21.41 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.302 -1.317 . . . . 0.0 108.299 178.484 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 5.8 m -97.48 113.55 32.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.457 0.646 . . . . 0.0 111.567 -178.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.8 mt -93.77 -27.77 16.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.707 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.59 -170.93 34.68 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.811 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -66.99 -27.25 42.89 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.636 2.224 . . . . 0.0 112.309 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 44.5 m-85 -129.42 18.31 5.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.03 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.79 148.85 47.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.843 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.577 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 6.6 p90 -178.55 149.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.611 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 268' ' ' LYS . 1.6 t -107.49 170.14 8.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.275 -179.353 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.7 pp -123.7 -175.85 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.739 179.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 42.7 t -56.87 -77.36 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.038 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -150.06 133.39 16.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.06 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.2 -28.23 5.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.195 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 22.5 p -60.38 -18.61 51.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.373 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -94.49 29.72 2.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.213 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.444 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 58.4 m-85 -150.07 -174.89 4.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.944 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.5 m -70.74 175.32 5.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.967 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -90.98 136.91 32.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.961 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.433 ' CD2' HG11 ' A' ' 224' ' ' VAL . 11.9 t80 -64.73 142.88 58.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.77 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.7 -61.72 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 2.1 mmt-85 -165.35 171.45 13.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.405 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 62.53 153.04 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.095 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.28 132.96 2.86 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.299 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 3.2 mt -135.45 136.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.566 -0.317 . . . . 0.0 110.3 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 11.8 p -99.83 127.2 52.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.192 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.4 m -130.7 135.43 47.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -77.62 105.4 8.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.85 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 16.1 m -58.8 149.52 5.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.192 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -72.92 -67.32 0.57 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.987 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 7.7 p -130.64 99.59 18.59 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.07 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.9 -38.52 7.37 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.53 2.153 . . . . 0.0 112.413 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.17 131.7 6.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -148.5 28.36 0.88 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.922 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . 0.431 HG22 HD11 ' A' ' 301' ' ' ILE . 0.2 OUTLIER -51.77 177.47 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.434 -179.885 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 3.5 t 63.46 128.9 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.007 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 60.61 52.36 4.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.907 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.99 -169.16 0.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.78 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -104.64 -66.04 0.99 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.933 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.5 mt -148.77 112.71 3.65 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.77 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -68.19 -40.51 8.55 Favored 'Trans proline' 0 C--N 1.347 0.459 0 C-N-CA 122.446 2.097 . . . . 0.0 112.389 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -168.43 -67.45 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.11 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 91.5 p -166.08 125.67 1.64 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.845 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 14.1 mt -69.42 136.23 51.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.921 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 12.3 p -114.46 153.13 16.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.069 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.342 -0.837 . . . . 0.0 110.877 -179.975 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.738 0.304 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 63.33 109.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.828 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 129.66 -37.01 2.25 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.453 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -67.15 -49.98 62.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.784 0.326 . . . . 0.0 110.86 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -126.01 119.73 28.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.86 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 2.8 ptp -106.47 117.11 33.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.846 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -83.17 96.04 3.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.141 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -166.07 135.61 3.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.941 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 25.8 m -109.08 38.47 2.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.872 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -123.49 156.88 34.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.868 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -165.37 -45.13 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 17.2 m-80 -89.54 163.1 15.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.985 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -176.22 115.85 0.54 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.467 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -97.11 135.34 39.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.892 0.377 . . . . 0.0 110.856 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.17 89.74 6.34 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.807 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.51 146.87 63.09 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.493 2.128 . . . . 0.0 112.327 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.31 147.66 35.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.819 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.8 m -146.43 176.84 9.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.002 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -164.15 141.99 7.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.073 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 7.6 mtm -79.32 156.47 28.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.994 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 58.9 t -100.23 137.3 28.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.996 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.4 t -109.75 -31.21 7.53 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.824 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -171.9 131.66 0.67 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.425 HG11 ' CG ' ' A' ' 286' ' ' TYR . 11.9 p -133.91 115.88 22.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.118 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 34.0 p -75.43 141.77 43.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.079 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.77 87.39 6.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.869 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.411 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.8 OUTLIER -136.96 -160.41 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.765 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.402 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 37.4 t-20 -155.77 92.58 2.65 Favored Pre-proline 0 CA--C 1.531 0.228 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.263 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.411 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 87.1 Cg_endo -76.11 169.59 74.08 Favored 'Cis proline' 0 C--N 1.348 0.549 0 C-N-CA 123.389 -1.504 . . . . 0.0 112.098 -0.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.56 145.74 18.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.335 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 28.1 t -99.84 125.92 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.99 0.424 . . . . 0.0 111.067 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.452 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 4.1 p -115.82 157.29 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.4 ' N ' ' CG2' ' A' ' 232' ' ' VAL . 86.5 m -119.56 161.85 19.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.503 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.4 m -99.87 164.75 11.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 110.867 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 24.1 tp -57.44 157.88 6.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -53.88 -26.91 27.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.046 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -125.28 29.75 5.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.946 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -90.81 -178.13 5.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.193 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 3.6 tpt85 -150.09 139.42 21.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 10.5 t-160 -106.64 127.26 53.2 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.746 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -135.8 24.57 3.3 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.967 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.414 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 0.2 OUTLIER -106.9 138.66 42.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.575 179.774 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -90.81 172.45 8.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.977 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.2 p -63.54 101.62 0.35 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.802 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 119.66 7.14 9.92 Favored Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.851 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.58 -174.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.723 0.297 . . . . 0.0 110.769 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 265' ' ' MET . 90.1 m-85 -129.85 142.64 50.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.881 0.372 . . . . 0.0 111.167 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 18.6 m -151.32 154.71 7.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.63 170.5 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.879 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.477 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.3 m-30 -99.1 142.47 30.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.4 m -100.39 -82.49 0.45 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.944 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.6 ' O ' ' CG ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -123.75 91.17 3.41 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.299 0.571 . . . . 0.0 109.793 179.575 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.477 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 2.6 t -114.39 138.05 45.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.568 -178.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -101.57 118.1 36.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.094 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.54 -62.43 0.54 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.858 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.414 ' HG3' HD21 ' A' ' 259' ' ' LEU . 23.3 tpp -88.54 57.45 4.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.167 0.508 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . 0.472 HG22 HD11 ' A' ' 257' ' ' ILE . 0.2 OUTLIER -77.09 -33.3 20.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.977 -179.355 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.41 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.5 OUTLIER -39.03 -34.7 0.17 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.983 -178.756 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.433 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 2.8 mm? -74.76 -43.16 56.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.035 0.445 . . . . 0.0 110.385 179.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.417 ' N ' ' O ' ' A' ' 257' ' ' ILE . 0.6 OUTLIER -50.49 -40.01 49.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.112 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -106.79 46.5 1.16 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 12.9 t -144.07 26.38 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.313 . . . . 0.0 111.085 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 58.14 166.41 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.835 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -61.4 144.9 98.53 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.421 2.081 . . . . 0.0 112.102 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.442 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.3 ptp -115.36 -171.85 2.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.51 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -99.81 149.74 23.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.761 0.315 . . . . 0.0 110.572 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.2 pp -119.87 175.76 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.569 0.7 . . . . 0.0 112.441 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.679 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 2.2 tttp -146.18 131.27 18.32 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.6 -1.182 . . . . 0.0 108.475 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 27.5 m -97.55 119.77 46.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.369 0.604 . . . . 0.0 111.537 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.5 mt -95.48 -29.51 14.35 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.779 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 165.71 -159.81 33.1 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 113.108 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.84 112.66 1.88 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.81 2.34 . . . . 0.0 112.301 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 65.46 15.8 10.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.104 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -130.74 134.66 47.08 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.494 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.679 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.2 p90 -171.85 169.86 5.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.94 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.8 t -124.74 170.07 11.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.6 pp -135.28 -179.87 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.928 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 29.8 p -55.77 -172.47 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.005 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -62.14 119.68 9.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 10.0 t -135.33 30.74 3.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.956 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 35.3 t -97.37 -34.06 11.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.923 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -70.21 -25.39 63.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.055 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.41 ' CD1' ' HB3' ' A' ' 258' ' ' GLN . 20.7 m-85 -77.48 -170.66 1.86 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.918 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.27 -160.54 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.762 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -117.98 131.18 56.51 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.839 0.352 . . . . 0.0 110.715 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.425 ' CG ' HG11 ' A' ' 224' ' ' VAL . 17.3 t80 -57.82 131.05 49.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.983 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.0 mt -111.89 -64.85 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.031 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.06 164.84 36.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.724 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.81 151.73 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.199 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.06 122.29 1.84 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.721 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 26.8 mt -125.85 131.6 71.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.776 0.322 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 13.2 p -99.98 108.82 23.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.031 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 62.3 m -103.51 169.12 8.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -106.08 100.9 10.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.82 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 17.2 m -68.34 143.93 14.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.28 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 31.6 mttp -95.53 -55.23 3.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.895 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 4.5 m 41.24 80.72 0.27 Allowed Pre-proline 0 N--CA 1.464 0.237 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.779 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.24 -22.67 25.27 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.521 2.147 . . . . 0.0 112.401 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -172.28 -39.25 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.048 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 18.6 mtpt 66.74 173.32 0.25 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.798 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 31.5 mt -96.95 85.97 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 50.6 m -145.23 123.62 12.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.93 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -141.11 -48.95 0.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.946 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.22 93.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.913 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -98.09 119.38 36.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.936 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -104.36 105.38 49.35 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.837 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.73 120.14 7.15 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.384 2.056 . . . . 0.0 112.25 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -59.28 177.47 0.18 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.132 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -112.48 145.13 40.75 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.884 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 4.4 mt -107.17 124.39 49.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.856 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 5.9 m -99.88 86.33 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.099 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.947 179.915 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 . . . . . 0 N--CA 1.487 1.416 0 CA-C-O 120.843 0.354 . . . . 0.0 111.209 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 63.33 124.95 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.96 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -102.67 -89.98 2.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.404 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 60.44 86.35 0.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.783 0.325 . . . . 0.0 110.943 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -175.08 151.35 1.3 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.904 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 25.3 mtt -100.72 -55.3 2.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.914 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 10.8 p -176.21 51.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.081 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 2.4 mp 61.69 152.97 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 8.6 t -138.79 31.37 2.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.91 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.25 164.63 11.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.85 40.85 1.13 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.936 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -171.14 103.44 0.21 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.927 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 128.25 100.66 1.03 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.515 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -117.33 127.1 53.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.815 0.34 . . . . 0.0 110.912 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -99.48 131.85 24.21 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.854 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.87 152.38 23.3 Favored 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.471 2.114 . . . . 0.0 112.328 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -111.71 143.1 43.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.85 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.8 p -137.79 152.08 48.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.951 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -137.34 147.82 45.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.06 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -86.57 151.17 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.887 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 59.0 t -99.94 136.24 32.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.009 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.0 t -111.61 -34.27 6.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.974 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.4 mtp -163.99 153.75 14.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.992 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 11.0 p -157.14 135.61 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.05 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.3 140.75 29.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -86.75 74.06 9.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.861 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.422 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.4 t0 -122.09 -156.73 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.68 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -158.91 91.18 2.01 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-O 120.516 0.198 . . . . 0.0 111.307 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.422 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 80.2 Cg_endo -76.06 169.72 73.71 Favored 'Cis proline' 0 C--N 1.348 0.527 0 C-N-CA 123.451 -1.479 . . . . 0.0 112.074 -0.108 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.21 151.8 17.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.501 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.9 t -99.98 114.69 39.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 0.0 111.109 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.434 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 4.3 p -106.15 157.1 6.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.108 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 1.7 m -121.81 165.02 16.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.581 179.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.03 169.98 8.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.908 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -68.86 158.66 34.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.754 179.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -54.21 -33.53 58.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.044 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -122.38 29.98 6.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.892 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -82.24 -175.66 5.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -148.45 107.62 3.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.952 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.462 ' CE1' ' CD2' ' A' ' 242' ' ' PHE . 34.5 t-80 -97.29 136.64 37.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.767 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -164.48 62.94 0.24 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.697 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.462 ' CD2' ' CE1' ' A' ' 240' ' ' HIS . 3.8 m-85 -122.6 143.81 49.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.817 0.341 . . . . 0.0 110.759 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.26 156.7 36.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 5.7 m -58.48 97.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.96 10.37 12.34 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.826 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -60.04 174.11 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.747 0.274 . . . . 0.0 110.724 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.447 ' HA ' ' O ' ' A' ' 265' ' ' MET . 54.7 m-85 -115.99 130.93 57.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.813 0.34 . . . . 0.0 111.066 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 15.0 m -144.96 159.36 13.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.019 0.438 . . . . 0.0 111.399 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.21 170.71 14.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.453 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 3.6 m-30 -99.08 145.49 27.07 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.967 -179.581 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -100.37 -86.6 0.39 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.088 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -119.33 88.32 2.91 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-O 120.535 0.207 . . . . 0.0 110.664 179.627 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.453 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 2.8 t -102.16 149.9 6.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.55 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.59 30.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.811 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 100.1 -73.29 0.45 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.431 -178.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 3.3 tpp -83.71 60.28 5.65 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.2 0.524 . . . . 0.0 110.215 179.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 16.1 pt -78.63 -33.0 16.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.498 -0.774 . . . . 0.0 112.001 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -38.32 -34.39 0.13 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.897 -178.669 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -63.7 -50.25 69.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.979 0.419 . . . . 0.0 110.239 179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -53.32 -34.73 58.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.998 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -85.84 45.06 3.42 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.808 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 4.6 t -165.78 150.21 8.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.743 0.306 . . . . 0.0 110.767 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.64 159.95 0.5 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.849 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -53.35 149.13 30.62 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.449 2.099 . . . . 0.0 111.87 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.447 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 5.7 ptp -111.91 -173.04 2.16 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.476 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -99.75 155.32 17.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.762 0.315 . . . . 0.0 110.792 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.8 pp -123.47 169.64 14.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.5 0.667 . . . . 0.0 112.127 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.584 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -142.36 125.44 16.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.825 -1.079 . . . . 0.0 108.818 178.707 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.415 HG11 ' CE1' ' A' ' 240' ' ' HIS . 33.0 m -97.65 112.61 30.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.53 0.681 . . . . 0.0 111.499 -178.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.5 mt -90.77 -27.72 18.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.522 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -167.31 -166.24 26.06 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.582 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.55 -52.88 3.31 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.573 2.182 . . . . 0.0 111.857 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 20.8 m-85 -112.86 18.92 17.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.87 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.88 145.65 49.7 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.67 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.584 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.8 p90 -178.07 159.2 1.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -108.92 170.05 8.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.158 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.2 pt -131.2 -179.98 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.803 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.33 172.85 1.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.905 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.74 118.91 7.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.857 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.9 t -141.17 51.2 1.6 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.984 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 7.2 p -102.69 -22.08 14.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.171 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -96.51 31.4 2.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.748 0.309 . . . . 0.0 111.089 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -128.77 -175.47 3.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.777 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.04 125.76 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.717 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.56 149.17 0.19 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.553 -179.688 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -78.14 137.36 38.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.853 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.3 mt -119.11 -65.18 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.102 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -148.71 -174.48 4.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.44 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 55.76 169.02 0.07 OUTLIER Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.258 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 122.09 116.75 2.4 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.981 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 2.8 mp -128.79 127.31 66.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.729 0.3 . . . . 0.0 110.252 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.7 p -99.65 111.06 28.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.992 0.425 . . . . 0.0 111.369 -179.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -106.36 158.31 16.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.706 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -95.04 92.64 6.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.968 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 13.3 m -58.83 175.07 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.094 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.78 32.89 0.49 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.889 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.6 t 59.17 84.04 0.21 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.053 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.09 159.14 54.21 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.624 2.216 . . . . 0.0 112.324 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.86 162.65 13.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -136.91 156.82 47.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.826 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 22.6 mm -113.99 144.06 22.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.076 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 27.3 t 63.25 152.38 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.935 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 60.68 109.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.738 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.72 83.01 1.16 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.977 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 27.6 t -111.57 128.97 56.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.691 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.5 ' HB2' ' HD3' ' A' ' 307' ' ' PRO . 14.8 mt -88.28 -48.45 0.44 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.452 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.5 ' HD3' ' HB2' ' A' ' 306' ' ' LEU . 49.9 Cg_endo -91.37 -78.35 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 122.75 2.3 . . . . 0.0 112.674 -179.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -176.67 -165.96 0.14 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.827 0.346 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -118.92 -44.74 2.6 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.819 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -130.12 157.17 43.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.768 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.41 -61.09 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.141 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.95 179.97 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 120.873 0.368 . . . . 0.0 111.177 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -137.61 157.28 46.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.01 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 88.82 63.74 1.33 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.495 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -62.34 -66.08 0.59 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.816 0.341 . . . . 0.0 110.904 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -116.57 80.19 1.43 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 2.1 mtt -125.17 -44.27 1.9 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.868 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 31.0 m -65.96 -30.33 49.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.171 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 2.2 tt -86.65 61.18 6.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -118.35 130.01 55.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.814 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.5 t0 74.3 -58.73 0.58 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.025 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 75.65 -62.56 0.43 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.905 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -162.41 -69.5 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.96 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -139.21 175.61 21.51 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.557 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -83.61 130.02 34.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.88 0.371 . . . . 0.0 110.826 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -102.58 157.75 33.1 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.928 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.04 -61.72 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.548 2.165 . . . . 0.0 112.256 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.6 tp -149.45 157.66 43.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 55.9 p -158.0 160.51 37.57 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.025 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -159.11 170.08 22.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.079 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 6.6 mtm -105.88 157.04 17.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.8 t -109.51 130.6 62.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.836 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 22.9 t -109.94 -35.1 6.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.162 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.46 148.51 27.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.936 0.398 . . . . 0.0 111.067 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.447 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.3 p -158.31 137.04 3.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.969 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 144.63 29.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.01 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.2 ttmt -89.68 72.63 7.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.815 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -122.49 -160.77 0.9 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.858 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 8.0 p-10 -156.08 90.91 2.7 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.175 -179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -78.87 169.9 70.92 Favored 'Cis proline' 0 C--N 1.349 0.577 0 C-N-CA 123.495 -1.46 . . . . 0.0 112.179 -0.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.17 153.01 17.87 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.444 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.3 t -99.85 122.35 51.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.883 0.373 . . . . 0.0 111.0 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.434 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.8 p -114.34 153.81 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.165 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 1.7 m -123.33 155.73 36.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.486 179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.85 170.02 8.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.83 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -71.83 143.43 49.46 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.764 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -24.86 30.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.399 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -100.54 -18.07 16.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.364 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -79.57 168.01 19.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.824 0.345 . . . . 0.0 111.247 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.08 -167.83 1.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.864 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 9.3 p80 -171.96 155.33 3.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.847 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 179.26 54.33 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.872 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.404 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 1.1 m-85 -103.74 141.05 36.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.823 0.344 . . . . 0.0 110.575 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -71.69 153.44 42.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.7 m -57.08 97.44 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.12 9.44 15.67 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.746 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.17 -165.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.772 0.286 . . . . 0.0 110.545 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.548 ' HA ' ' O ' ' A' ' 265' ' ' MET . 86.9 m-85 -128.9 143.06 50.78 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.916 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.404 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 15.9 m -149.58 134.87 10.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.731 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.1 p -111.95 166.47 11.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.434 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.478 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.7 m-30 -99.85 143.93 29.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.02 -179.853 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 25.7 m -99.93 -86.28 0.39 Allowed 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.988 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.598 ' O ' ' CG ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -120.02 92.76 3.85 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.266 0.555 . . . . 0.0 110.006 179.896 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.478 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 4.6 t -111.43 139.02 37.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.383 -179.264 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -99.93 116.27 31.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.194 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.23 -65.53 0.5 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.629 -0.795 . . . . 0.0 111.897 -179.253 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 1.5 ttt -89.91 59.38 4.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.487 . . . . 0.0 110.534 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 15.0 pt -77.99 -33.94 18.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.67 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.7 mm100 -39.24 -34.64 0.2 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.81 -179.091 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.454 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.3 mm? -60.6 -49.54 77.12 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.884 0.373 . . . . 0.0 110.576 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -64.75 -34.82 79.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.835 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -93.1 39.38 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.496 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.5 t -159.26 34.25 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 0.0 110.716 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 61.88 168.41 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.597 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -61.46 -153.15 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 111.702 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.548 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.9 ptp -172.78 -175.89 1.36 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.805 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.58 147.37 25.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.656 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.404 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.2 pp -119.73 174.99 4.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.675 0.75 . . . . 0.0 112.482 -179.49 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.652 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.0 mttt -147.33 131.07 16.95 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.401 178.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 34.6 m -97.54 122.33 49.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.433 0.635 . . . . 0.0 111.63 -178.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 15.0 mt -96.77 -30.87 12.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.651 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.29 -171.81 42.09 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.245 -0.979 . . . . 0.0 113.214 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_exo -51.75 112.96 0.96 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.793 2.328 . . . . 0.0 112.475 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 64.71 19.41 11.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.054 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.5 p -133.0 139.35 47.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.459 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.652 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.3 p90 -176.97 166.48 2.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 -179.57 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -118.56 170.05 9.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.992 0.425 . . . . 0.0 111.161 -179.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -134.62 -178.63 2.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.848 179.814 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 29.9 p -57.35 -177.55 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -72.56 124.06 24.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.416 ' HA ' ' CD1' ' A' ' 283' ' ' PHE . 8.6 t -137.69 51.88 1.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.971 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 96.5 p -88.37 -54.8 4.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -67.4 -19.62 65.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.192 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.434 ' CE2' HD12 ' A' ' 259' ' ' LEU . 23.5 m-85 -59.49 -176.94 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.748 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 48.1 t -78.18 -175.81 4.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.895 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.79 127.25 48.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.907 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.447 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 65.4 t80 -72.21 140.97 48.99 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 26.1 mt -125.45 -63.51 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.09 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 5.7 mmt180 -153.94 175.56 13.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.655 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.48 149.65 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.424 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.06 115.47 1.19 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.768 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 18.4 mm -114.29 133.43 60.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 120.743 0.306 . . . . 0.0 110.821 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.404 ' CG2' ' HB ' ' A' ' 248' ' ' VAL . 14.1 p -99.89 114.65 38.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.035 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.3 m -119.56 154.44 33.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.051 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 12.9 tt0 -66.53 85.85 0.11 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.962 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER 51.17 -179.47 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.414 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.48 -65.19 0.18 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 16.3 m -141.08 130.94 13.02 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.041 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.66 -168.37 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.49 2.126 . . . . 0.0 112.372 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.92 154.35 25.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.72 33.03 5.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.882 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 2.5 tt -171.07 114.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.099 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.82 -66.9 0.19 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.874 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -138.85 -55.56 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 61.0 106.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 3.0 p -175.09 134.47 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.964 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.8 mp -131.93 68.95 80.89 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.835 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.79 -172.28 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.561 2.174 . . . . 0.0 112.242 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -131.16 161.45 32.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.118 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 93.3 p -70.16 88.31 0.61 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.88 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -115.6 110.39 19.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t 59.73 86.91 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.152 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.174 -0.917 . . . . 0.0 110.878 179.999 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.841 0.353 . . . . 0.0 111.169 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -79.48 95.2 5.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.872 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 179.03 -36.74 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -123.5 75.86 1.36 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.85 0.357 . . . . 0.0 110.949 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 22.0 mm-40 -151.88 137.27 17.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.945 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 5.3 mtp -108.11 127.66 54.0 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 8.1 p -133.49 69.43 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.002 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.12 114.73 28.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.787 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 2.3 m -128.88 168.3 16.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.896 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -63.58 -172.9 0.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.928 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 27.9 m -78.3 -35.89 47.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.824 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -106.69 143.55 34.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.826 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -103.08 -95.03 2.31 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.534 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 60.01 96.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.943 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -73.2 124.07 90.2 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.815 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -54.97 -171.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.407 2.071 . . . . 0.0 112.28 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.83 126.04 35.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.747 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 50.2 p -136.21 127.87 28.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -122.18 148.8 44.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.079 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -78.31 145.97 35.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.948 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.0 t -99.94 140.6 18.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 6.5 t -105.93 -29.66 9.83 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.016 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.81 158.69 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.027 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.453 ' CG1' ' CD2' ' A' ' 286' ' ' TYR . 11.6 p -160.93 122.08 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 65.0 p -84.31 143.25 29.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.037 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.42 56.34 3.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.461 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.6 t0 -91.61 -151.02 0.26 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.818 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -159.85 90.57 1.84 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-O 120.489 0.185 . . . . 0.0 111.372 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.461 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 71.8 Cg_endo -73.24 169.11 74.02 Favored 'Cis proline' 0 C--N 1.347 0.493 0 C-N-CA 123.244 -1.565 . . . . 0.0 111.836 -0.132 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -101.41 147.28 17.59 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.436 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.1 t -99.81 145.65 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.87 0.367 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.448 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 4.4 p -139.2 151.15 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.22 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 63.6 m -122.5 161.01 24.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.412 179.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.1 m -99.84 169.29 9.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.879 0.371 . . . . 0.0 110.86 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 2.9 tp -70.69 148.16 48.32 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.834 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -56.26 -30.83 62.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -106.36 50.76 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -178.35 152.79 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.25 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 20.7 ttm105 -135.89 155.41 50.34 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.857 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 23.4 p-80 -111.23 148.37 32.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.792 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -130.27 70.4 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.723 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.426 ' CE1' ' HB2' ' A' ' 294' ' ' GLN . 0.9 OUTLIER -126.55 141.54 51.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.766 0.317 . . . . 0.0 110.746 179.78 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.61 166.97 12.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.941 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 13.2 m -59.58 100.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.9 18.42 5.58 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.856 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.52 174.75 10.78 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.715 0.293 . . . . 0.0 110.767 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.431 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.4 m-85 -114.3 134.06 55.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 19.1 m -138.24 153.44 26.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.053 0.454 . . . . 0.0 111.359 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 11.1 p -124.2 165.11 18.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.577 179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.489 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 1.9 m-30 -99.8 141.3 32.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.045 -179.69 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 251' ' ' SER . . . . . 0.4 ' CB ' ' HB ' ' A' ' 291' ' ' ILE . 31.3 t -99.91 -101.65 0.23 Allowed 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.7 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' A' ' 290' ' ' GLY . 3.3 pt-20 -102.52 87.58 3.04 Favored 'General case' 0 C--O 1.223 -0.333 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.489 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 5.4 t -105.74 134.38 47.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.869 0.366 . . . . 0.0 111.786 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 18.8 mt-30 -99.9 116.02 30.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.777 178.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.35 -69.02 0.42 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.542 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 10.8 tpp -82.74 62.18 6.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.111 0.481 . . . . 0.0 110.235 179.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 37.2 pt -80.09 -33.34 14.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.274 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -38.64 -34.63 0.15 Allowed 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -178.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.466 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.2 mm? -72.8 -46.48 52.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.892 0.377 . . . . 0.0 110.703 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 24.2 t30 -57.57 -34.92 69.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.934 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.83 46.27 2.5 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.367 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.66 161.66 13.61 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.858 0.361 . . . . 0.0 110.898 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -54.99 156.83 6.44 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.682 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -57.38 157.11 23.17 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.508 2.138 . . . . 0.0 111.941 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.431 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.7 ptp -117.07 -171.19 1.98 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -99.48 153.17 19.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.755 0.312 . . . . 0.0 110.615 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.7 pp -121.84 173.62 7.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.643 0.735 . . . . 0.0 112.312 -179.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.588 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 6.1 tttt -144.43 127.14 16.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.749 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 15.5 m -97.75 115.18 37.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.436 0.636 . . . . 0.0 111.598 -178.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 15.7 mt -94.96 -28.14 15.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.49 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.53 -178.95 39.5 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.576 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -50.61 -48.5 20.21 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.635 2.223 . . . . 0.0 112.217 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 80.8 m-85 -115.95 15.09 16.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.112 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.92 147.72 45.66 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.692 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.588 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.5 p90 -178.35 159.59 1.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.725 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 9.4 t -114.3 170.13 8.53 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.975 0.417 . . . . 0.0 111.32 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.06 -179.17 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.929 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 179.96 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.934 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -60.92 134.49 57.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 1.1 p -116.25 -19.92 10.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.372 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 93.0 p -52.92 -27.63 19.69 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 111.332 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -77.76 -25.87 49.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.142 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.451 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 13.1 m-85 -91.09 -168.3 2.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.976 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 8.5 p -83.4 -147.09 0.08 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.568 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -119.07 147.11 44.5 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.831 0.348 . . . . 0.0 110.844 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.453 ' CD2' ' CG1' ' A' ' 224' ' ' VAL . 44.5 t80 -80.02 141.49 35.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 30.3 mt -120.45 -59.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.998 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 4.3 mmt85 -163.32 176.63 9.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.408 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.02 155.55 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.935 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.64 119.24 1.77 Allowed Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.867 178.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.4 ' HB ' ' CB ' ' A' ' 251' ' ' SER . 10.9 mt -122.25 134.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.812 0.339 . . . . 0.0 110.557 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 13.4 p -99.73 107.35 20.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.252 -179.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 71.0 m -115.12 123.22 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.771 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.426 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 0.0 OUTLIER -72.65 111.15 7.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.025 -179.865 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 12.5 m -54.52 157.78 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.312 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.25 79.77 6.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.064 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.457 ' N ' ' HD3' ' A' ' 298' ' ' PRO . 10.7 p -167.69 63.66 0.65 Allowed Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.208 179.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . 0.457 ' HD3' ' N ' ' A' ' 297' ' ' VAL . 5.7 Cg_exo -78.05 -51.62 0.07 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.922 2.415 . . . . 0.0 112.335 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.5 149.64 16.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.182 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 1.2 ttmt -144.61 88.53 1.93 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.749 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 4.7 mt 66.35 92.39 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.016 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 4.8 t -110.95 110.81 21.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.934 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 65.97 -75.37 0.05 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.966 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 14.9 pttt -178.16 -176.17 0.52 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.885 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.24 113.89 6.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 60.72 101.49 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.833 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -49.59 166.21 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.487 2.125 . . . . 0.0 112.339 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 61.54 45.0 8.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.033 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -136.65 104.78 5.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.968 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 2.7 tp -82.83 -53.83 5.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.836 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 15.0 t -111.12 24.7 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.207 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.216 -0.897 . . . . 0.0 110.964 179.936 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 120.789 0.328 . . . . 0.0 111.151 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 65.7 m-85 59.53 92.85 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.015 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -152.79 134.34 4.43 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.517 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -139.67 153.17 47.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.774 0.321 . . . . 0.0 110.937 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -108.73 -31.61 7.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.956 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 21.0 ptt? -94.53 172.65 8.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.009 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 27.6 t 64.67 83.37 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.095 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -142.09 178.89 7.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.819 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 12.7 t -176.46 -160.77 0.07 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.851 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 75.23 106.71 0.08 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.891 0.377 . . . . 0.0 110.821 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.98 148.46 45.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.987 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -118.72 -43.43 2.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 111.01 -119.14 5.11 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.512 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 60.74 23.91 13.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.75 0.309 . . . . 0.0 111.01 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 8.8 mm100 -143.5 86.2 9.0 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.959 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.12 -177.6 2.07 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.663 2.242 . . . . 0.0 112.272 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 3.9 tp -87.55 162.27 17.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.857 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.5 p -162.34 107.7 1.21 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -100.08 153.77 18.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.978 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 38.8 mtt -90.68 145.77 24.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.935 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.42 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 98.8 t -99.87 136.62 30.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.815 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.1 t -105.95 -35.75 7.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.024 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -163.21 143.6 9.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 12.8 p -146.5 130.58 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.053 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 11.4 p -92.29 146.18 23.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.043 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.8 tttm -92.17 86.61 5.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.732 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.413 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.5 OUTLIER -132.96 -158.07 0.86 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.787 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 9.5 p-10 -158.73 91.87 2.01 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-O 120.503 0.192 . . . . 0.0 111.203 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.413 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 86.9 Cg_endo -75.86 169.52 74.28 Favored 'Cis proline' 0 C--N 1.347 0.498 0 C-N-CA 123.327 -1.53 . . . . 0.0 112.083 -0.265 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.97 146.9 17.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.471 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.9 t -99.85 126.87 53.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.973 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.454 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 3.8 p -121.09 155.32 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.275 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 6.7 m -118.25 161.3 20.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.648 179.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.85 161.68 13.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.881 0.372 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 8.2 tp -60.26 154.35 20.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.825 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -52.62 -27.12 15.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.032 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -128.48 37.37 4.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -94.77 -167.41 1.64 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.151 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.62 176.57 8.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.011 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -155.08 114.0 3.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.711 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -133.28 26.38 3.54 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.817 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.446 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 0.1 OUTLIER -106.4 135.32 48.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 179.799 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -89.85 174.34 7.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.071 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.28 101.33 0.3 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 113.97 15.86 8.27 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.732 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -76.4 -175.75 3.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.728 0.299 . . . . 0.0 110.653 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.47 ' HA ' ' O ' ' A' ' 265' ' ' MET . 63.1 m-85 -121.95 141.45 51.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.983 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 22.5 m -137.4 155.28 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.504 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.2 p -129.29 161.42 30.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.693 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.508 ' CD2' HG22 ' A' ' 253' ' ' VAL . 2.6 m-30 -99.85 137.11 38.76 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.999 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 72.4 m -99.77 -104.85 0.22 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.671 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.3 OUTLIER -100.18 87.47 3.46 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.508 HG22 ' CD2' ' A' ' 250' ' ' PHE . 21.8 t -109.91 138.1 39.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.883 0.373 . . . . 0.0 111.707 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -100.73 118.66 37.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.935 179.145 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.45 -65.57 0.48 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.673 -179.049 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 6.3 ttm -85.11 58.95 5.32 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.053 0.454 . . . . 0.0 110.357 179.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 4.8 pt -79.99 -33.36 14.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.037 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -39.06 -34.75 0.18 Allowed 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.5 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 2.7 mm? -79.86 -42.09 24.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.872 0.368 . . . . 0.0 110.701 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 44.8 t30 -54.99 -34.88 63.78 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.063 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.88 28.22 13.41 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.293 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -142.24 165.08 28.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 110.753 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -58.04 166.26 2.14 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.595 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.48 158.39 53.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.363 2.042 . . . . 0.0 112.094 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.1 ptp -116.61 -174.17 2.52 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.517 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -99.56 151.26 21.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.719 0.295 . . . . 0.0 110.705 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.8 pp -122.22 174.96 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.612 0.72 . . . . 0.0 112.376 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.604 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.3 tptt -146.86 130.71 17.1 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.576 -1.193 . . . . 0.0 108.5 178.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 31.0 m -97.74 120.17 46.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.494 0.664 . . . . 0.0 111.585 -178.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.4 mt -98.2 -29.99 12.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.462 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.55 -175.3 36.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.524 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.85 -53.91 6.01 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.638 2.226 . . . . 0.0 112.387 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -112.77 23.22 13.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -133.23 148.45 52.0 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.751 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.604 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -175.33 167.3 3.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -117.58 170.15 8.98 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 14.3 pt -133.09 -179.38 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.843 179.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 32.0 p -63.6 171.0 2.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.83 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.9 p-10 -58.73 112.22 1.55 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.966 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 11.2 p -115.81 24.94 11.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.058 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 91.6 p -90.48 9.78 27.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.357 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 62.4 m-20 -111.38 -32.05 6.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.348 . . . . 0.0 110.801 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -78.17 -165.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.802 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.96 -179.78 6.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.868 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -94.1 130.86 40.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 54.4 t80 -60.12 136.33 57.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.838 179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 47.7 mt -115.73 -67.92 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.09 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -151.91 174.01 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.297 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.82 155.98 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.911 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 138.78 116.12 1.38 Allowed Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.901 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.1 mp -121.98 138.33 52.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.8 0.334 . . . . 0.0 110.573 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 13.4 p -99.7 124.95 53.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.517 -179.404 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -121.76 131.94 54.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.528 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.446 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER -86.06 97.82 10.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.317 -179.584 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 35.9 m -58.79 143.18 13.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.753 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -134.17 24.72 3.87 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.339 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.452 ' HB ' ' HD3' ' A' ' 298' ' ' PRO . 2.0 t -90.12 -50.21 0.36 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.406 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . 0.452 ' HD3' ' HB ' ' A' ' 297' ' ' VAL . 3.7 Cg_exo -80.83 -168.23 0.6 Allowed 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.998 2.465 . . . . 0.0 112.219 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 18.5 tttt -179.13 -50.99 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.766 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 3.6 tptt -140.97 -63.8 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.836 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 2.5 pp -71.56 -179.06 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.085 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 99.0 p -161.9 -49.72 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.948 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -68.23 172.8 5.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -133.44 154.52 50.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.909 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 59.5 p -157.38 94.66 1.4 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.7 mp -112.03 87.09 8.3 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.881 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.58 139.76 41.67 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.576 2.184 . . . . 0.0 112.406 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -147.81 -55.17 0.22 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.06 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.87 -76.52 0.6 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.89 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 13.6 mt 58.9 -178.94 0.08 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.907 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t -116.74 -39.28 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.094 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.888 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 . . . . . 0 N--CA 1.486 1.328 0 CA-C-O 120.86 0.362 . . . . 0.0 111.202 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -110.88 162.8 14.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.876 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 162.63 -145.92 11.24 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.539 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -157.16 102.71 1.97 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.847 0.356 . . . . 0.0 110.9 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -142.0 -53.64 0.43 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.877 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -78.47 161.25 27.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.908 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -151.97 -49.12 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.13 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 1.4 mp -112.79 142.88 44.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.924 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.65 -30.73 7.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.918 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 61.56 170.77 0.11 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 16.1 m 60.8 84.47 0.13 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.93 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -174.4 144.47 0.91 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.968 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -165.02 -52.16 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.49 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -94.43 -170.74 2.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.732 0.301 . . . . 0.0 110.815 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.61 75.64 0.39 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.88 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.04 -29.27 22.79 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.69 2.26 . . . . 0.0 112.254 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.1 mp -91.09 127.72 36.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.747 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.87 150.11 22.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.086 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -156.63 154.19 29.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.075 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 3.4 mtt -95.23 164.19 12.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.112 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 36.5 t -114.72 140.43 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 4.3 t -114.42 -26.33 8.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.255 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -166.73 162.63 16.33 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.851 0.358 . . . . 0.0 111.042 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.444 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.8 p -168.02 151.64 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.176 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 40.1 p -113.93 150.53 33.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 7.5 ttmt -92.53 84.82 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.859 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.405 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.3 t0 -134.67 -160.16 1.03 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.823 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 14.1 p-10 -156.28 89.7 2.74 Favored Pre-proline 0 CA--C 1.531 0.233 0 CA-C-O 120.506 0.193 . . . . 0.0 111.371 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.405 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 85.1 Cg_endo -79.36 169.45 71.28 Favored 'Cis proline' 0 C--N 1.349 0.591 0 C-N-CA 123.448 -1.48 . . . . 0.0 112.202 -0.078 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.65 155.24 16.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.391 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.5 t -99.87 111.09 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.9 0.381 . . . . 0.0 111.028 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.458 ' CG1' ' CZ ' ' A' ' 275' ' ' PHE . 2.0 p -102.9 151.95 5.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.059 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.12 139.73 52.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.312 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 61.3 m -99.91 170.07 8.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.023 0.44 . . . . 0.0 111.133 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.487 ' HB3' ' CB ' ' A' ' 238' ' ' ALA . 3.6 tt -49.68 161.27 0.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.923 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -42.05 -31.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.242 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -165.5 51.1 0.1 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.816 0.341 . . . . 0.0 111.239 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . 0.487 ' CB ' ' HB3' ' A' ' 235' ' ' LEU . . . -121.33 30.99 6.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.484 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -150.15 131.76 14.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.866 0.365 . . . . 0.0 111.121 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 170.04 90.16 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.852 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 179.79 -35.69 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.779 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -85.63 134.5 33.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.922 0.391 . . . . 0.0 110.719 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -105.61 171.39 7.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.83 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 62.8 m -53.06 102.03 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.37 25.36 4.7 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.593 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -93.89 166.61 12.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.777 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.447 ' HA ' ' O ' ' A' ' 265' ' ' MET . 94.6 m-85 -110.86 135.48 51.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.832 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 14.7 m -143.18 145.58 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.436 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 16.9 p -116.27 170.27 8.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.571 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.471 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.5 m-30 -99.46 139.61 34.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.938 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -104.73 -87.95 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.222 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -108.14 88.06 2.64 Favored 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 116.848 -0.16 . . . . 0.0 110.826 179.802 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.471 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 11.2 t -113.95 132.13 63.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.945 0.403 . . . . 0.0 111.803 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -99.77 115.89 30.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.925 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.94 -59.55 0.59 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.552 -178.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 2.5 ttm -92.14 54.63 2.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.107 0.479 . . . . 0.0 110.163 179.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 33.2 pt -77.21 -33.55 20.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.763 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -39.14 -34.66 0.18 Allowed 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.835 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.425 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.5 mm? -66.65 -47.11 73.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.915 0.388 . . . . 0.0 110.618 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -56.37 -34.78 66.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.909 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.54 46.24 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.318 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.7 t -167.61 163.83 14.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.749 0.309 . . . . 0.0 110.596 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.28 166.33 0.9 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.586 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -68.82 178.61 3.83 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.311 2.007 . . . . 0.0 112.013 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.447 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.0 OUTLIER -136.89 176.18 8.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.78 -179.957 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -99.49 125.07 45.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.4 pp -88.7 163.88 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.546 0.689 . . . . 0.0 112.229 -179.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.639 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.5 OUTLIER -137.88 125.52 22.25 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.744 -1.117 . . . . 0.0 108.586 178.445 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 30.3 m -97.29 114.77 35.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.547 0.689 . . . . 0.0 111.573 -178.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.0 mt -92.03 -28.45 17.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.494 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -161.59 -163.52 14.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.589 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.47 -48.67 4.15 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.572 2.182 . . . . 0.0 112.111 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -115.27 7.77 15.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.212 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.67 152.73 30.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.764 0.316 . . . . 0.0 110.676 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.639 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.1 p90 -179.78 162.44 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.821 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.7 t -118.64 169.99 9.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.07 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.3 pp -134.22 -177.51 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.911 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -54.88 -176.4 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 0.0 111.048 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -71.89 99.77 2.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 3.2 t -102.83 56.57 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 59.8 p -104.85 -26.38 12.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.988 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -96.54 31.53 2.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.98 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -126.08 -175.66 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.79 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.45 170.97 12.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.91 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -83.96 122.09 28.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.444 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 37.5 t80 -59.25 142.81 50.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.722 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . 0.438 HG23 HD11 ' A' ' 287' ' ' ILE . 33.7 mt -119.92 -69.21 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.237 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.2 173.82 14.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.729 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.41 153.81 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.216 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.0 124.38 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.904 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 30.8 mt -123.04 134.45 66.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.789 0.328 . . . . 0.0 110.797 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.4 ' O ' ' CG1' ' A' ' 292' ' ' VAL . 13.1 p -99.94 102.42 13.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.963 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.7 m -113.72 150.89 32.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.022 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 -79.62 121.63 25.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 2.0 m -57.38 163.01 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.27 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 1.4 pttt -139.0 30.05 2.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.93 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 29.8 m 41.67 53.24 7.26 Favored Pre-proline 0 CA--C 1.531 0.23 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.704 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.27 64.83 3.56 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.538 2.159 . . . . 0.0 112.289 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -113.72 40.71 2.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.929 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.43 33.92 4.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.952 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -68.76 -32.71 55.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.07 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 37.9 t -69.82 140.99 53.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.92 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.55 -46.35 7.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.939 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 3.9 tptm -137.12 -62.14 0.64 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.908 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 1.8 m -148.14 128.33 13.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.29 103.62 55.49 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.819 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -50.32 -62.78 0.35 Allowed 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.449 2.099 . . . . 0.0 112.424 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -179.54 -71.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -85.08 91.65 8.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.945 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 1.6 tp -111.17 -47.28 3.22 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.862 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.1 p -101.41 -29.09 3.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.087 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.937 -179.974 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.831 0.348 . . . . 0.0 111.184 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -94.04 -169.15 2.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.845 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 135.64 -111.6 0.91 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.491 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 62.79 -79.84 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.708 0.289 . . . . 0.0 111.02 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -102.26 -44.88 5.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.974 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 69.2 -64.39 0.33 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.977 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 9.8 t 73.5 91.2 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -127.7 -176.86 3.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.77 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 3.7 t -109.89 76.7 1.01 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.865 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -108.45 141.37 40.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.92 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 4.4 m -150.89 35.88 0.61 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.942 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 15.8 p-10 -164.78 -43.95 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.938 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -143.05 174.15 23.81 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.564 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 59.64 21.05 9.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.677 0.275 . . . . 0.0 111.218 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . 0.519 ' CB ' ' HD3' ' A' ' 216' ' ' PRO . 2.5 mm-40 -122.41 -60.4 0.03 OUTLIER Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.326 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . 0.519 ' HD3' ' CB ' ' A' ' 215' ' ' GLN . 32.5 Cg_exo -58.18 -161.83 0.02 OUTLIER 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.164 1.91 . . . . 0.0 112.215 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp -138.31 100.97 4.26 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.7 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 52.8 p -124.47 146.91 48.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.04 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -128.38 167.05 17.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.001 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 11.6 mtt -94.09 148.56 22.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.923 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 49.1 t -99.91 139.32 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.953 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.3 t -106.77 -32.94 7.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.053 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.4 mtp -168.89 144.28 3.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.973 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.446 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 10.8 p -142.78 140.87 27.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.047 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 15.6 p -95.91 144.31 26.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.028 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.6 tttt -94.1 83.01 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.445 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.2 t0 -128.67 -158.17 0.87 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.738 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 1.6 p30 -154.27 89.62 3.3 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-O 120.472 0.177 . . . . 0.0 111.336 -179.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.445 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 93.7 Cg_endo -77.71 169.16 74.37 Favored 'Cis proline' 0 C--N 1.347 0.491 0 C-N-CA 123.437 -1.485 . . . . 0.0 111.996 -0.162 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.76 149.77 17.01 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.598 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.8 141.81 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.72 0.295 . . . . 0.0 110.905 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.424 ' CG1' ' CZ ' ' A' ' 275' ' ' PHE . 5.3 p -134.43 157.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.246 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 91.8 m -122.11 156.79 32.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.582 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.94 166.14 11.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.919 0.39 . . . . 0.0 110.721 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 2.5 tp -66.98 148.15 52.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.785 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -55.38 -26.73 43.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -98.05 -26.28 14.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.016 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -68.85 172.68 6.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.21 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -145.97 145.25 30.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.967 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.4 ' NE2' ' CD2' ' A' ' 242' ' ' PHE . 17.2 t-80 -98.36 135.65 39.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -137.09 27.82 2.86 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.525 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.459 ' CE1' ' HB2' ' A' ' 294' ' ' GLN . 0.1 OUTLIER -116.34 146.34 42.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.584 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -102.55 173.26 6.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.141 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 80.6 p -59.87 103.17 0.19 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.84 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 127.87 -17.78 6.0 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.531 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.09 -178.8 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.739 0.304 . . . . 0.0 110.808 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.463 ' HA ' ' O ' ' A' ' 265' ' ' MET . 49.1 m-85 -122.99 162.08 23.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.07 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.41 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 28.8 m -151.74 155.06 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.5 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.8 p -129.66 159.31 36.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.501 179.627 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.483 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 2.3 m-30 -99.65 136.3 39.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.0 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 35.1 t -99.78 -92.49 0.28 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.543 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.73 87.77 2.61 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.468 179.499 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.474 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 3.9 t -106.3 137.59 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.939 0.4 . . . . 0.0 111.809 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -99.97 112.83 25.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.813 179.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.04 -60.28 0.56 Allowed Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.69 -178.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 3.0 ttm -87.88 59.15 5.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.144 0.497 . . . . 0.0 110.478 179.297 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 28.7 pt -79.95 -33.57 14.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.922 -179.432 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -38.89 -34.64 0.16 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.36 -0.382 . . . . 0.0 112.021 -178.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.483 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.1 mm? -73.01 -46.01 54.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.901 0.381 . . . . 0.0 110.634 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -56.23 -34.85 66.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.864 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.03 46.61 2.89 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.351 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -170.35 160.99 7.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -56.22 156.26 11.17 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.704 179.792 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.22 171.76 1.61 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.318 2.012 . . . . 0.0 112.062 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.463 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.6 OUTLIER -131.75 -174.36 3.39 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.628 -179.892 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -99.51 148.86 23.82 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.724 0.297 . . . . 0.0 110.698 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.4 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -118.64 177.36 2.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.637 0.732 . . . . 0.0 112.376 -179.2 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.638 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.44 130.27 19.27 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.473 -1.239 . . . . 0.0 108.27 178.585 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 31.9 m -97.49 117.61 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.588 0.708 . . . . 0.0 111.691 -178.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.3 mt -91.16 -28.31 17.95 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.846 -1.07 . . . . 0.0 110.545 -179.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 162.64 -166.57 36.75 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.224 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -52.83 112.66 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.785 2.323 . . . . 0.0 112.506 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 62.4 m-85 63.07 18.02 10.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.107 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -128.42 136.95 51.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.454 179.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.638 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.77 160.64 1.94 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.806 -179.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.1 t -112.61 170.11 8.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.998 0.428 . . . . 0.0 111.179 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -130.88 -179.5 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.919 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -55.5 -173.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.983 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -58.67 122.56 13.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.5 24.19 13.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.081 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 34.0 t -98.31 -26.6 14.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.031 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . 0.404 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 17.8 t30 -97.41 34.83 1.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.969 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.447 ' CE2' ' CD1' ' A' ' 259' ' ' LEU . 24.5 m-85 -137.75 -175.5 4.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.852 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 28.7 t -86.35 176.98 7.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -85.62 132.2 34.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.964 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.446 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 16.3 t80 -77.49 144.44 37.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.66 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 35.7 mt -126.24 -68.43 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -146.91 -179.87 7.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.602 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.5 161.57 0.05 OUTLIER Glycine 0 C--N 1.332 0.324 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.27 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 132.56 116.22 1.73 Allowed Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.919 178.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 20.6 mt -118.66 133.92 63.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.798 0.332 . . . . 0.0 110.592 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.41 ' CG2' ' HB ' ' A' ' 248' ' ' VAL . 12.5 p -99.77 120.9 49.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.567 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 20.8 m -119.64 136.69 54.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.67 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.459 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 7.4 tt0 -82.13 96.62 7.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.187 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 31.0 m -71.47 64.59 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.017 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 2.7 ttpp -148.75 -66.12 0.23 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.97 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.3 t 67.51 73.76 0.35 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_exo -56.18 95.72 0.06 OUTLIER 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.529 2.152 . . . . 0.0 112.237 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.99 137.67 53.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.992 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 43.48 82.28 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.552 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 3.5 mp -120.3 -41.21 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.13 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 9.8 p 61.65 32.78 18.4 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.958 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 59.53 -171.14 0.13 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.034 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -146.52 124.34 11.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.936 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 14.5 p -138.02 50.12 1.92 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.677 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.449 ' N ' ' CD ' ' A' ' 307' ' ' PRO . 2.8 mp -79.61 -49.14 1.39 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.312 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.449 ' CD ' ' N ' ' A' ' 306' ' ' LEU . 92.4 Cg_endo -83.13 11.59 3.22 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.602 2.202 . . . . 0.0 113.087 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -55.68 123.73 15.07 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.797 0.332 . . . . 0.0 111.227 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.06 -56.81 1.1 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.959 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 1.1 mt -87.0 55.78 3.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.916 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.4 t -78.69 156.21 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.185 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.794 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.486 1.372 0 CA-C-O 120.816 0.341 . . . . 0.0 111.16 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 13.5 t80 -103.48 -35.62 8.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.9 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 163.27 176.04 34.87 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.497 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -70.63 142.33 51.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.768 0.318 . . . . 0.0 110.962 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -165.26 137.91 4.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.89 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -148.5 -69.01 0.22 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.847 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 14.5 p -177.84 45.23 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.025 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -159.02 74.89 0.67 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.88 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -113.41 -51.18 2.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.863 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 60.16 -176.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.892 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.98 -177.75 4.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.895 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -86.2 133.07 33.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -102.89 45.33 1.35 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.48 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -151.97 172.25 16.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.829 0.347 . . . . 0.0 110.847 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.05 94.51 4.0 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -66.97 154.14 75.61 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.432 2.088 . . . . 0.0 112.084 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -150.44 -175.04 4.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.056 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.4 m -138.37 103.62 4.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.507 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -102.12 157.7 16.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.973 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 34.1 mtp -101.73 167.98 9.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.9 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.39 128.6 70.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.992 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.6 t -104.31 -29.42 10.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -167.5 152.66 7.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.001 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.444 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 12.0 p -158.72 145.37 7.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 7.1 p -106.52 146.38 30.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.853 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.31 80.57 3.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.838 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.427 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.6 OUTLIER -126.22 -157.9 0.82 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -154.02 91.0 3.22 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.355 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.427 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 80.2 Cg_endo -76.3 169.07 75.44 Favored 'Cis proline' 0 C--N 1.348 0.516 0 C-N-CA 123.345 -1.523 . . . . 0.0 112.044 -0.143 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.9 151.9 17.59 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.494 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.1 t -99.98 145.86 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 111.135 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.456 ' CG1' ' CZ ' ' A' ' 275' ' ' PHE . 2.7 p -142.7 150.2 18.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.097 -179.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 81.0 m -124.98 143.27 50.98 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.492 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 26.2 m -100.0 170.07 8.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.977 0.418 . . . . 0.0 111.054 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 1.2 tp -56.5 140.49 45.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.996 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -54.16 -26.7 29.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.984 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.6 mt-10 -114.84 34.49 4.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -166.41 76.44 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.204 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . 0.404 ' O ' ' CG ' ' A' ' 240' ' ' HIS . 38.3 tpt85 -150.06 87.07 1.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.828 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.404 ' CG ' ' O ' ' A' ' 239' ' ' ARG . 1.0 OUTLIER -178.8 106.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.107 179.986 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 162.11 -14.96 0.14 Allowed Glycine 0 CA--C 1.52 0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 113.562 179.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.432 ' CZ ' HG12 ' A' ' 292' ' ' VAL . 0.0 OUTLIER -131.75 132.19 43.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 117.17 0.485 . . . . 0.0 111.258 -179.41 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -124.09 -169.58 1.99 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.778 179.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.2 m -61.32 106.07 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.068 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 100.67 26.94 7.79 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.684 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.55 169.75 8.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.765 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 265' ' ' MET . 76.8 m-85 -108.17 148.96 29.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.803 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.424 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 34.3 m -149.71 144.26 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 111.578 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.7 p -123.67 156.88 35.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.462 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.447 ' CD2' HG22 ' A' ' 253' ' ' VAL . 4.8 m-30 -99.52 139.09 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -99.7 -91.86 0.29 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.11 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.06 87.74 2.59 Favored 'General case' 0 C--O 1.224 -0.278 0 C-N-CA 121.21 -0.196 . . . . 0.0 110.822 179.703 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.447 HG22 ' CD2' ' A' ' 250' ' ' PHE . 21.2 t -109.31 143.69 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.871 0.367 . . . . 0.0 111.491 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -105.72 114.93 29.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.087 179.326 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.36 -64.07 0.52 Allowed Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.596 -179.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 31.1 ttm -88.91 54.54 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.165 0.507 . . . . 0.0 110.283 179.271 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 2.2 pp -80.04 -33.76 14.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.928 -179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.442 ' HB3' ' CE2' ' A' ' 283' ' ' PHE . 5.7 mm-40 -39.07 -34.47 0.17 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 112.006 -178.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.45 HD23 ' CD2' ' A' ' 283' ' ' PHE . 2.9 mm? -64.02 -48.36 76.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.839 0.352 . . . . 0.0 110.682 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.0 t-20 -55.66 -35.06 65.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.94 49.38 1.02 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.71 28.96 0.13 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.104 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 60.86 156.67 0.11 Allowed Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.525 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -55.77 176.33 0.17 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.35 2.033 . . . . 0.0 111.991 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.5 ptp -142.76 -173.9 4.01 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.632 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -99.39 137.33 38.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.345 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.1 pt -106.07 176.45 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.727 0.775 . . . . 0.0 112.472 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.669 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.5 tttt -148.21 129.95 15.11 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.162 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 29.0 m -97.3 123.83 49.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.583 0.706 . . . . 0.0 111.423 -178.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 55.1 mt -96.41 -28.17 14.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.82 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 169.59 -160.78 34.06 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.417 -0.897 . . . . 0.0 113.14 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.7 111.49 1.92 Allowed 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.711 2.274 . . . . 0.0 112.294 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 71.1 9.37 6.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.23 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.6 p -124.52 145.0 49.81 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.754 0.312 . . . . 0.0 110.617 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.669 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -178.61 170.04 1.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.744 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.9 t -120.35 169.93 9.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.15 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.1 pp -138.54 -177.91 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.025 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -54.89 163.65 0.96 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.974 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -58.41 140.4 53.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.007 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 6.2 t -145.67 31.83 1.06 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 19.9 p -71.24 -46.8 60.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.89 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 12.1 t30 -76.98 -22.53 53.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.059 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.45 ' CD2' HD23 ' A' ' 259' ' ' LEU . 3.3 m-85 -67.83 -176.15 0.63 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.3 m -87.29 151.14 23.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.2 142.23 50.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.006 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.444 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 17.6 t80 -72.1 144.96 48.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.88 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.5 mt -124.49 -63.96 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.4 mmt180 -152.8 178.85 9.19 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.434 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.33 164.53 0.08 OUTLIER Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.283 -0.961 . . . . 0.0 112.085 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 127.89 114.97 1.86 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.038 178.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.409 ' CD1' ' N ' ' A' ' 291' ' ' ILE . 3.2 mp -121.56 131.06 73.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.79 0.329 . . . . 0.0 110.151 179.228 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.432 HG12 ' CZ ' ' A' ' 242' ' ' PHE . 12.9 p -99.83 118.13 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.389 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 58.0 m -121.32 146.95 46.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 6.6 tm0? -84.57 98.33 10.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.962 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 30.3 m -60.59 122.55 11.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.162 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.58 -48.17 1.81 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.6 t -110.53 96.52 27.91 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.052 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -49.31 -56.65 2.95 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.523 2.149 . . . . 0.0 112.467 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.38 130.77 6.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.982 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 13.2 tptt -175.28 74.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.833 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 2.4 pp -148.45 123.73 2.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.117 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 67.7 m -97.27 129.8 44.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.951 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -100.72 124.17 45.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.87 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.34 148.31 28.67 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.936 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 33.4 m -140.17 175.9 9.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.963 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 2.9 mp -99.42 126.77 36.45 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.835 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -73.46 166.08 30.8 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.466 2.11 . . . . 0.0 112.317 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 59.49 164.75 0.05 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.174 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 5.8 m -146.77 -56.66 0.26 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.858 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -123.78 74.01 1.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.897 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 7.8 m -120.21 171.19 8.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.126 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.21 -0.9 . . . . 0.0 110.899 -179.966 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 120.802 0.334 . . . . 0.0 111.19 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -95.89 -37.23 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.86 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 169.05 -165.51 38.98 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.485 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -147.08 40.54 1.05 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.841 0.353 . . . . 0.0 110.878 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 62.5 mt-10 -59.84 171.4 0.93 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.918 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 3.7 mtm -89.91 118.22 29.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.866 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 12.2 p -140.29 120.5 13.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.094 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 11.9 mt -131.32 52.21 2.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 2.9 m 61.85 114.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.823 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -73.86 164.95 25.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 16.8 p -154.39 113.49 3.68 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -125.76 103.05 7.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.874 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 124.09 -152.03 17.23 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.471 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -131.13 147.07 52.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.885 0.374 . . . . 0.0 110.928 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -164.79 142.44 5.23 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.849 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.93 -175.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.556 2.171 . . . . 0.0 112.243 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -83.24 111.6 19.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.816 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.3 m -125.22 159.95 30.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.038 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.96 162.0 37.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.031 179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.72 146.39 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.065 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.0 137.59 27.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.91 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.6 t -108.84 -42.07 4.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -151.03 153.74 35.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.109 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.442 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.5 p -161.87 140.28 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.989 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 1.5 p -95.32 148.13 22.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.08 55.86 2.42 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.435 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -102.79 -158.32 0.66 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.708 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -156.97 91.81 2.43 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 120.504 0.193 . . . . 0.0 111.307 -179.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.435 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 73.3 Cg_endo -75.54 169.6 74.08 Favored 'Cis proline' 0 C--N 1.348 0.529 0 C-N-CA 123.436 -1.485 . . . . 0.0 112.002 -0.182 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.54 17.47 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.558 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.98 124.69 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.885 0.374 . . . . 0.0 110.974 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.428 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.9 p -117.51 154.39 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.207 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 1.3 m -120.57 155.51 33.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.567 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.0 m -99.94 162.58 12.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.844 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 4.3 tp -60.11 147.69 38.64 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.794 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -64.94 -26.95 68.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.084 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -95.47 -15.12 23.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.054 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -97.15 171.07 8.69 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.865 0.364 . . . . 0.0 111.172 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -135.1 160.58 37.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.923 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.5 p-80 -96.81 146.81 24.57 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -138.12 25.05 2.93 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.69 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.404 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 0.4 OUTLIER -128.3 147.57 50.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.803 0.335 . . . . 0.0 110.732 179.875 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -105.13 174.78 5.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.972 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.6 t -62.49 97.23 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.82 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 137.44 -17.43 3.53 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.561 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.54 -171.24 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.753 0.311 . . . . 0.0 110.8 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.479 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -138.46 141.99 39.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.787 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.421 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 33.8 m -148.71 146.03 17.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.039 0.447 . . . . 0.0 111.545 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 21.3 p -112.73 170.08 8.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.33 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.415 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 4.2 m-30 -99.62 143.07 30.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.082 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -99.97 -86.64 0.38 Allowed 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.134 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.6 ' O ' ' CG ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.84 92.62 3.85 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-O 121.127 0.489 . . . . 0.0 110.008 179.997 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.417 HG11 ' CE2' ' A' ' 286' ' ' TYR . 5.0 t -109.15 149.03 12.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.349 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 288' ' ' ARG . 18.1 mm-40 -110.36 109.33 19.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.026 179.136 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.57 -53.47 0.83 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.6 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 11.0 ttm -95.63 54.03 1.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.988 0.423 . . . . 0.0 110.333 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 43.7 pt -80.03 -34.35 15.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.71 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.0 mp0 -39.63 -34.62 0.25 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.748 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.415 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 2.3 mm? -61.02 -46.44 90.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.38 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -61.55 -36.43 80.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.893 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.5 42.93 2.26 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.362 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.4 t -156.06 31.06 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.817 0.342 . . . . 0.0 110.934 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . 0.414 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 0.4 OUTLIER 59.67 168.03 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.622 -179.898 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.414 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 28.9 Cg_endo -62.78 -173.03 0.13 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.372 2.048 . . . . 0.0 112.04 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.479 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.4 OUTLIER -156.03 -177.95 6.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.635 -179.917 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -99.85 135.07 41.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.611 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.404 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -105.67 178.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 0.0 112.087 -179.604 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.66 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 29.7 mttt -149.01 131.02 15.3 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.659 178.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 10.5 m -97.33 121.8 48.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.473 0.654 . . . . 0.0 111.367 -178.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 15.3 mt -96.81 -30.29 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.868 -179.527 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 164.76 -166.79 38.21 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.074 -1.06 . . . . 0.0 113.404 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_exo -51.16 112.93 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.897 2.398 . . . . 0.0 112.696 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 60.37 20.59 10.17 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.036 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -130.86 139.47 50.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.586 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.66 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.6 p90 -177.17 166.13 2.35 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.734 -179.615 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.9 t -114.83 170.08 8.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.997 0.427 . . . . 0.0 111.133 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -138.56 -179.69 2.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.916 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.44 160.5 3.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.999 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 13.5 p30 -56.81 138.03 53.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.024 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.424 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.6 p -133.09 27.11 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.954 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -69.54 -30.31 68.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.95 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -84.94 -31.11 23.78 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.424 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 21.3 m-85 -70.1 -175.51 0.97 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.829 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.99 179.83 6.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -89.63 124.93 35.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.442 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 15.1 t80 -59.41 139.55 56.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.776 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.8 mt -117.33 -62.2 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.021 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.41 ' O ' ' HB2' ' A' ' 254' ' ' GLN . 2.8 mmt180 -158.2 175.8 13.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.581 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.52 151.44 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.443 -0.884 . . . . 0.0 112.408 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.23 115.66 1.31 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.642 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 3.4 mp -113.24 134.12 56.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.797 0.332 . . . . 0.0 110.954 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.421 ' CG2' ' HB ' ' A' ' 248' ' ' VAL . 13.5 p -99.81 115.04 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.124 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.0 m -119.05 143.49 47.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.15 -179.665 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -64.86 83.76 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.948 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER 39.88 92.83 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.844 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -80.18 -7.41 58.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.402 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.4 t 67.12 110.1 0.03 OUTLIER Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.578 0.228 . . . . 0.0 111.076 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_exo -51.45 179.43 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.486 2.124 . . . . 0.0 112.376 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -117.35 -39.55 3.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.972 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 5.5 ttmm -58.54 129.01 40.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.993 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 8.9 mt 59.7 100.51 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.064 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 37.1 p -135.57 143.6 45.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.816 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -98.87 32.88 2.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.915 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.59 141.45 47.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.842 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 1.1 m 59.83 172.47 0.08 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.925 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.425 ' CD1' ' N ' ' A' ' 306' ' ' LEU . 0.0 OUTLIER -51.77 139.06 31.78 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.271 -179.865 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -78.66 115.73 3.67 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.535 2.157 . . . . 0.0 112.347 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -89.72 76.53 7.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.001 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.0 m -131.81 151.19 51.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.002 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 4.9 tp -140.93 112.06 7.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.884 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.17 -48.68 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.07 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.258 -0.877 . . . . 0.0 110.878 179.979 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.484 1.275 0 CA-C-O 120.877 0.37 . . . . 0.0 111.172 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 57.7 m-85 -119.11 132.04 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.818 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 60.15 -178.97 2.6 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.529 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -87.96 89.62 8.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.886 0.374 . . . . 0.0 110.892 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -79.89 -67.64 0.74 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.872 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.96 -178.27 5.26 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t 64.14 112.16 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.057 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -157.63 162.57 38.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.947 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 59.5 p -141.42 30.21 1.75 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.897 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -177.92 171.82 1.73 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -148.93 27.64 0.86 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.983 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -177.53 161.7 1.75 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 66.89 -155.79 52.12 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.62 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 61.39 152.89 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.913 0.387 . . . . 0.0 110.971 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . 0.428 ' CB ' ' HD3' ' A' ' 216' ' ' PRO . 0.0 OUTLIER -179.02 -52.21 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.959 179.809 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . 0.428 ' HD3' ' CB ' ' A' ' 215' ' ' GLN . 15.7 Cg_exo -67.88 84.33 0.42 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.537 2.158 . . . . 0.0 112.201 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -68.01 163.29 22.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.837 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.5 p -149.52 124.21 9.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -115.7 170.06 8.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.56 165.76 11.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.895 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.403 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 88.0 t -115.4 125.96 72.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 27.9 t -108.13 -31.15 8.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.27 135.1 7.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 11.5 p -142.86 150.26 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 66.3 p -107.42 148.16 29.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.1 tmtt? -99.28 70.18 1.73 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -120.52 -159.64 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 20.4 p30 -153.6 91.03 3.32 Favored Pre-proline 0 CA--C 1.531 0.234 0 CA-C-N 116.717 -0.22 . . . . 0.0 111.328 -179.645 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -78.21 169.75 72.14 Favored 'Cis proline' 0 C--N 1.348 0.535 0 C-N-CA 123.422 -1.491 . . . . 0.0 112.112 -0.142 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.8 149.84 18.78 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.74 140.13 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.878 0.371 . . . . 0.0 110.999 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.443 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 5.3 p -134.6 158.04 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.264 -179.691 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.401 ' N ' ' CG2' ' A' ' 232' ' ' VAL . 0.6 OUTLIER -125.01 160.26 29.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.516 179.697 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.83 167.31 10.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.874 0.369 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.01 159.83 10.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.731 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -55.36 -29.87 59.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.014 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -117.48 32.35 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -78.19 -176.94 4.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.111 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 -144.16 148.02 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.943 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -96.99 141.84 29.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.822 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -163.07 29.94 0.26 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.595 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.402 ' HB2' ' CD1' ' A' ' 267' ' ' ILE . 0.1 OUTLIER -147.74 130.56 16.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.752 0.31 . . . . 0.0 110.755 179.991 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.67 179.17 4.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.998 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.67 104.7 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.891 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 123.81 -13.64 8.11 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.757 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -67.67 172.98 4.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.809 0.338 . . . . 0.0 110.777 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -123.31 158.24 31.44 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 19.8 m -155.11 142.66 12.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.198 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 p -109.99 166.13 11.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.303 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.434 ' CD2' HG23 ' A' ' 253' ' ' VAL . 2.4 m-30 -99.66 152.24 20.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.863 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 61.3 m -108.5 -98.77 0.38 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.072 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.498 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.6 OUTLIER -107.09 88.25 2.69 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.592 0.234 . . . . 0.0 110.666 179.892 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.434 HG23 ' CD2' ' A' ' 250' ' ' PHE . 4.1 t -100.93 148.28 7.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.042 0.449 . . . . 0.0 111.625 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.41 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.0 OUTLIER -111.1 108.59 18.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.576 178.955 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.35 -59.92 0.55 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.276 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 21.2 ttm -92.19 54.88 2.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.177 0.513 . . . . 0.0 110.061 179.08 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 9.0 pt -79.25 -33.23 15.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.598 -0.728 . . . . 0.0 112.22 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.409 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 2.5 mm100 -38.64 -34.54 0.15 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.86 -178.677 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.432 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.3 mm? -67.69 -49.68 61.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.979 0.418 . . . . 0.0 110.474 179.403 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -58.65 -34.83 71.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.78 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.43 44.38 2.92 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.468 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.9 t -164.99 162.97 20.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.6 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -54.5 156.73 5.77 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.553 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -63.05 169.53 8.96 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.272 1.982 . . . . 0.0 111.821 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 265' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -134.55 -175.59 3.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.856 -179.69 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -99.66 154.66 18.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.417 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.402 ' CD1' ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -123.02 174.94 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.66 0.743 . . . . 0.0 112.194 -179.271 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.569 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 32.1 mmtm -143.27 129.07 19.39 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.705 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 22.3 m -97.54 112.91 30.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.473 0.654 . . . . 0.0 111.48 -178.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 13.3 mt -91.02 -27.06 18.88 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.569 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.45 -164.01 21.21 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.627 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -63.34 -50.62 3.35 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.585 2.19 . . . . 0.0 112.027 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -114.1 12.47 17.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.047 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -118.83 147.32 44.06 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.636 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.569 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 10.4 p90 -177.95 158.54 1.26 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.959 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.0 t -112.84 170.12 8.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.5 pp -135.93 -179.01 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.986 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -55.56 -178.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.891 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -68.13 110.32 3.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.43 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.9 t -110.33 32.97 4.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.4 m -87.78 -22.6 24.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -95.43 38.0 1.17 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.984 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.43 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 25.0 m-85 -137.76 -171.48 3.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.728 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -88.85 -166.93 1.72 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.83 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -96.75 145.23 26.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -85.89 139.58 31.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.733 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 68.4 mt -124.27 -71.16 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.41 ' O ' ' N ' ' A' ' 254' ' ' GLN . 3.4 mpt_? -138.93 -178.22 5.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.421 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 57.16 160.59 0.02 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.389 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 128.99 102.11 1.04 Allowed Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.923 179.109 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.5 mp -109.25 129.04 64.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.738 0.304 . . . . 0.0 110.193 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.3 p -99.61 108.83 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.051 0.453 . . . . 0.0 111.474 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -109.11 173.15 6.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.585 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -99.42 101.98 13.41 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.998 0.428 . . . . 0.0 111.032 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.425 ' CG1' ' CG1' ' A' ' 297' ' ' VAL . 0.5 OUTLIER -61.75 -39.31 82.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.989 179.99 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 4.0 tmtt? 62.79 48.6 4.05 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.368 179.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.425 ' CG1' ' CG1' ' A' ' 295' ' ' VAL . 11.8 p -106.62 88.34 3.36 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.96 0.409 . . . . 0.0 111.108 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.28 -47.46 1.61 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.509 2.139 . . . . 0.0 112.248 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 2.7 mttp -164.74 69.97 0.17 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.88 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.33 176.92 8.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.858 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.1 tp -178.98 -37.71 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.154 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -54.24 171.31 0.11 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.077 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -97.62 84.58 3.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 7.9 mmtt -101.98 102.09 12.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.97 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.26 -166.67 2.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.91 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 24.6 tp 63.47 64.87 1.34 Allowed Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.965 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.55 -48.45 21.83 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.551 2.168 . . . . 0.0 112.242 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -132.14 -178.85 5.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.051 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 17.7 m -155.0 121.02 5.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.899 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 3.8 mt -82.41 148.37 28.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.986 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 31.4 m -116.19 31.19 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.158 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 22.8 tp10 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.165 -0.921 . . . . 0.0 110.938 179.975 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 120.772 0.32 . . . . 0.0 111.22 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -98.59 30.67 3.17 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.965 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -157.81 125.77 1.61 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.494 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.8 mp0 -102.68 30.53 4.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.83 0.347 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -125.85 -80.38 0.61 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.91 179.877 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 171.83 41.01 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.937 0.399 . . . . 0.0 110.819 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.01 109.63 21.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.06 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 5.9 tt -172.01 -60.36 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 9.0 t -106.14 106.32 16.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.873 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -131.83 114.49 14.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.962 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 2.2 t -71.07 -38.56 72.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.813 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 6.9 t30 60.78 -174.71 0.12 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.045 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 169.06 83.44 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.384 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 61.12 98.72 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.887 0.375 . . . . 0.0 110.881 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -176.9 93.81 0.24 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.896 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -49.66 -61.66 0.54 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.596 2.198 . . . . 0.0 112.382 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -172.46 -176.83 1.63 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.947 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 p -162.57 141.74 9.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.948 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -137.4 154.66 49.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.101 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.7 mmm -101.23 156.61 17.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 44.6 t -100.67 138.94 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.973 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 15.0 t -110.24 -39.99 4.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.898 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.3 mmm -169.37 138.96 2.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 8.2 p -139.26 151.17 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.08 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.8 p -102.06 148.08 25.82 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.005 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? -92.19 85.55 5.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.747 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.438 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.8 t0 -132.31 -154.79 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.758 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 31.4 p30 -159.04 90.77 2.0 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-O 120.445 0.164 . . . . 0.0 111.234 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.438 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 72.8 Cg_endo -74.96 169.03 75.65 Favored 'Cis proline' 0 C--N 1.348 0.543 0 C-N-CA 123.387 -1.505 . . . . 0.0 112.081 -0.282 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.42 151.31 17.14 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 16.9 t -99.9 131.86 46.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 111.074 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.456 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 6.3 p -128.87 158.02 41.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.253 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.77 164.59 18.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.686 179.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.3 m -99.94 168.81 9.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.871 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 5.8 tp -64.88 151.25 46.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -58.71 -26.23 63.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.197 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -114.91 32.23 6.16 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -133.07 155.91 48.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.256 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.29 158.6 33.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.883 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -92.31 145.16 24.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -136.97 42.45 1.31 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.579 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -137.99 138.92 39.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.779 0.323 . . . . 0.0 110.775 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -88.68 171.9 9.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.924 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.5 m -62.72 101.88 0.29 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.868 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 117.24 0.32 18.9 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.85 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.6 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.658 0.266 . . . . 0.0 110.777 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.545 ' HA ' ' O ' ' A' ' 265' ' ' MET . 38.2 m-85 -134.41 143.37 47.55 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.896 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.414 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 3.4 m -149.99 142.33 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.609 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 25.1 p -115.79 165.91 12.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.452 179.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.45 ' CD2' ' HB2' ' A' ' 259' ' ' LEU . 3.9 m-30 -99.71 148.67 24.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.992 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.7 m -99.89 -90.32 0.31 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.09 -179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.496 ' O ' ' N ' ' A' ' 290' ' ' GLY . 5.1 pt-20 -113.22 88.03 2.74 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 120.519 0.199 . . . . 0.0 110.768 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.444 HG23 ' CD2' ' A' ' 250' ' ' PHE . 12.1 t -100.02 148.09 6.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 111.6 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.406 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.9 OUTLIER -116.24 110.45 18.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.77 -62.21 0.53 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.627 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 25.9 ttm -91.79 61.78 4.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.227 0.537 . . . . 0.0 110.225 179.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 23.8 pt -80.03 -32.3 13.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.336 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.438 ' HB2' ' CZ ' ' A' ' 283' ' ' PHE . 3.8 tp-100 -37.61 -34.44 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -178.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.45 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.1 mm? -67.65 -52.08 42.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.973 0.416 . . . . 0.0 110.414 179.457 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -64.61 -34.95 79.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.119 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.27 38.56 3.16 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.836 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 3.2 t -157.99 36.39 0.25 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.766 0.317 . . . . 0.0 111.08 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . 0.442 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 11.8 mt-30 59.05 169.16 0.07 OUTLIER Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.488 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.442 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 14.2 Cg_endo -56.97 -164.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.253 1.969 . . . . 0.0 111.593 179.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.545 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.0 OUTLIER -169.44 -173.2 1.63 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.791 -179.713 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.55 143.23 30.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.407 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.1 pp -118.59 176.81 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.665 0.745 . . . . 0.0 112.388 -179.225 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.501 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -149.87 129.64 13.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.374 178.596 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 29.3 m -97.59 112.11 28.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.507 0.67 . . . . 0.0 111.546 -178.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 40.4 mt -86.14 -29.78 23.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.476 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.9 -167.23 21.09 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -61.61 -43.52 26.54 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.508 2.139 . . . . 0.0 111.826 179.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -117.5 -5.1 11.23 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.049 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.3 p -100.2 148.26 24.81 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.841 0.353 . . . . 0.0 111.006 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.501 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 6.7 p90 -178.58 162.62 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.566 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.7 t -112.39 167.37 10.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.993 0.425 . . . . 0.0 111.354 -179.395 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.2 pp -137.9 -173.42 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.751 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -52.0 179.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.932 0.396 . . . . 0.0 111.159 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -94.69 140.59 29.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.998 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 11.7 t -151.21 39.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.78 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 28.9 t -73.93 -7.57 52.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.574 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -108.33 5.94 25.99 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.522 0.201 . . . . 0.0 111.53 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.438 ' CZ ' ' HB2' ' A' ' 258' ' ' GLN . 0.2 OUTLIER -110.73 -158.44 0.65 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.594 0.235 . . . . 0.0 110.883 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 2.2 m -96.49 156.62 16.26 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.856 0.36 . . . . 0.0 111.077 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -74.29 151.9 39.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.406 ' CE2' ' O ' ' A' ' 289' ' ' GLY . 32.1 t80 -58.86 124.48 19.99 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.927 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 29.5 mt -102.77 -47.79 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.005 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.406 ' O ' ' N ' ' A' ' 254' ' ' GLN . 1.1 mmt-85 -176.97 175.37 1.59 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.167 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . 0.406 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 60.39 158.42 0.06 OUTLIER Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.178 -1.01 . . . . 0.0 111.966 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 131.76 115.84 1.73 Allowed Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.723 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.7 mp -125.26 128.38 72.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.775 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.414 ' CG2' ' HB ' ' A' ' 248' ' ' VAL . 14.5 p -100.0 118.79 47.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.175 -179.685 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.9 m -129.58 168.19 16.79 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.121 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -67.44 84.68 0.17 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.104 0.478 . . . . 0.0 111.034 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.415 ' CG1' ' HG3' ' A' ' 264' ' ' PRO . 0.2 OUTLIER 55.03 167.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.553 -0.748 . . . . 0.0 111.474 179.387 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 27.5 tttt -82.99 -34.58 26.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.926 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.6 t 64.21 131.62 0.03 OUTLIER Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.961 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -72.37 -168.42 0.39 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.485 2.123 . . . . 0.0 112.361 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.64 84.76 0.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.974 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -166.12 155.86 12.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.891 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 2.0 pp -117.48 152.81 19.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.119 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 66.8 m -120.0 37.66 4.16 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.878 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 61.21 166.73 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.863 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 2.0 mmtp -60.47 154.82 19.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.962 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -149.99 94.7 2.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.95 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 11.8 mt -137.85 106.74 8.21 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.84 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -68.43 -44.1 3.64 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.422 2.081 . . . . 0.0 112.251 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -108.32 160.07 16.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.094 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.32 79.05 1.34 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.895 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 65.4 mt -88.12 -39.37 14.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.939 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.2 p -176.1 149.42 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.077 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.237 -0.887 . . . . 0.0 110.971 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 . . . . . 0 N--CA 1.485 1.321 0 CA-C-O 120.789 0.328 . . . . 0.0 111.239 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -92.2 96.33 10.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.965 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -157.72 129.53 2.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.522 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -103.7 -27.14 12.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.8 0.334 . . . . 0.0 111.065 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -64.87 81.16 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.031 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -161.93 -53.2 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.882 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 6.0 m -105.71 -30.6 2.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.074 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -107.78 29.87 6.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.85 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 2.7 t -93.59 -39.32 10.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.911 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -142.72 -74.56 0.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.944 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 16.5 m 60.05 162.19 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.935 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -175.66 38.89 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -100.64 -140.62 11.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.477 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -167.48 -169.82 1.3 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.756 0.312 . . . . 0.0 110.881 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 60.69 98.64 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.83 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -49.39 176.14 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.493 2.129 . . . . 0.0 112.48 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -97.92 -171.09 2.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.926 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 11.2 t -166.53 155.67 11.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.796 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -149.1 166.8 27.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.019 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 10.9 mtp -107.63 147.48 30.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 40.5 t -105.93 139.56 26.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.995 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 8.3 t -106.61 -31.9 8.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.976 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.1 ptm -168.16 163.94 13.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.968 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.421 HG11 ' CG ' ' A' ' 286' ' ' TYR . 12.6 p -162.36 118.62 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.037 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 76.9 p -76.48 140.59 41.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.828 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -90.17 68.15 7.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.795 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -106.69 -148.0 0.41 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.781 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -160.26 88.88 1.82 Allowed Pre-proline 0 CA--C 1.531 0.227 0 CA-C-O 120.536 0.208 . . . . 0.0 111.305 -179.67 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -76.4 169.52 74.23 Favored 'Cis proline' 0 C--N 1.347 0.488 0 C-N-CA 123.27 -1.554 . . . . 0.0 111.945 -0.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -100.43 147.63 18.08 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.501 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.2 t -99.81 118.89 47.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.847 0.356 . . . . 0.0 111.058 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.457 ' CG1' ' CE2' ' A' ' 275' ' ' PHE . 2.8 p -110.37 154.24 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.058 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.32 161.8 28.56 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.691 179.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -100.04 169.63 9.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.92 0.39 . . . . 0.0 110.845 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.26 161.6 6.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.794 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -54.63 -32.86 59.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.074 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -119.16 32.19 6.24 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.824 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -82.81 -175.74 5.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.082 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.41 136.12 23.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.933 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 2.8 t60 -105.9 137.24 44.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -149.83 26.73 1.17 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.674 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -114.52 138.39 50.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.813 0.339 . . . . 0.0 110.679 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 165.0 14.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.03 87.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 138.51 -12.72 3.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.718 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -57.46 -179.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.771 0.32 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 265' ' ' MET . 51.1 m-85 -125.07 146.77 49.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.057 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 19.5 m -148.47 147.86 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.173 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.5 p -115.95 167.88 10.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.623 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.489 ' CD2' ' CG2' ' A' ' 253' ' ' VAL . 2.6 m-30 -99.64 146.65 26.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.077 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 53.8 m -109.46 -89.94 0.47 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.77 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.2 87.59 2.56 Favored 'General case' 0 C--O 1.221 -0.397 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 179.416 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.489 ' CG2' ' CD2' ' A' ' 250' ' ' PHE . 8.0 t -109.47 134.98 49.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.92 0.39 . . . . 0.0 111.873 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 21.2 mt-30 -100.32 114.38 27.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.815 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.05 -58.6 0.61 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.672 -178.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 1.4 ttm -91.04 59.9 4.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.128 0.489 . . . . 0.0 110.359 179.358 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.6 pp -79.52 -33.37 15.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.985 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -39.1 -34.61 0.18 Allowed 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.876 -178.823 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.458 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 2.8 mm? -77.76 -44.45 27.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.87 0.366 . . . . 0.0 110.504 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -60.03 -34.84 73.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.851 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.52 42.92 2.38 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.324 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -165.42 171.14 13.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.803 0.335 . . . . 0.0 110.764 -179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 11.3 mt-30 -57.63 167.7 1.29 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.64 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -66.5 -166.68 0.11 Allowed 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.38 2.053 . . . . 0.0 112.005 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.442 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 1.0 OUTLIER -156.07 -175.84 5.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.575 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -99.71 148.08 24.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.771 0.319 . . . . 0.0 110.628 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.6 pp -119.76 172.84 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.528 0.68 . . . . 0.0 112.263 -179.466 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.609 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.3 mmtm -143.47 127.97 17.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 114.71 -1.132 . . . . 0.0 108.736 178.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 35.9 m -97.6 114.56 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.471 0.653 . . . . 0.0 111.503 -178.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 16.1 mt -92.5 -28.72 16.63 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.567 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.76 -163.66 18.38 Favored Glycine 0 N--CA 1.453 -0.202 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.593 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.08 -49.29 3.95 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.639 2.226 . . . . 0.0 111.992 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -114.82 11.58 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.101 179.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.95 148.54 42.84 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.856 0.36 . . . . 0.0 110.704 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.609 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.9 p90 -177.5 161.73 1.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 12.2 t -123.38 170.27 10.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.01 0.433 . . . . 0.0 111.218 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.6 pp -133.9 -179.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.844 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -56.42 -170.1 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.076 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -55.8 132.69 50.03 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.026 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.57 7.24 8.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.404 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -86.04 5.28 34.21 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.749 -0.205 . . . . 0.0 111.463 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -111.67 -23.48 10.63 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.684 0.278 . . . . 0.0 111.177 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.427 ' CZ ' HD12 ' A' ' 259' ' ' LEU . 29.5 m-85 -85.43 -170.41 3.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 64.1 m -88.56 -175.43 4.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.86 137.27 32.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.421 ' CG ' HG11 ' A' ' 224' ' ' VAL . 70.0 t80 -78.13 146.61 35.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.773 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 27.1 mt -125.02 -67.87 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.186 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.55 176.43 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.559 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.96 158.25 0.05 OUTLIER Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.287 -0.958 . . . . 0.0 112.068 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.13 108.83 0.9 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.98 178.66 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 14.8 mm -106.5 130.98 57.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.727 0.299 . . . . 0.0 110.479 179.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 13.5 p -99.72 109.75 25.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.916 0.389 . . . . 0.0 111.322 -179.59 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -111.77 156.34 22.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.654 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 -90.39 108.44 19.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.032 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -58.62 167.08 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.876 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 3.9 tttp -151.09 -71.54 0.17 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.026 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.5 96.44 6.96 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.115 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.39 115.73 4.18 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.43 2.087 . . . . 0.0 112.269 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 35.6 tptt -151.47 31.69 0.58 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.861 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 3.4 ptmt -122.66 109.1 13.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 33.5 mt -85.72 -67.98 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.168 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 50.4 p 179.77 163.05 0.99 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.889 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 63.37 -79.02 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.021 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -115.93 89.2 3.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.008 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 2.5 p -97.17 -35.77 10.67 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.818 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.525 ' H ' ' HD2' ' A' ' 307' ' ' PRO . 0.6 OUTLIER -147.18 -60.13 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.217 179.69 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.525 ' HD2' ' H ' ' A' ' 306' ' ' LEU . 34.6 Cg_endo -63.62 77.32 0.14 Allowed 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 122.069 1.846 . . . . 0.0 112.236 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -176.23 -73.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.142 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 3.3 p 50.22 86.33 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.234 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 15.5 tp -164.86 91.4 0.55 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.886 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t 62.52 158.85 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.136 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.858 -179.949 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.4 tp . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.803 0.335 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 90.1 p -151.56 167.05 29.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.04 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.703 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -157.15 164.7 37.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.962 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -109.89 154.55 22.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.013 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 90.3 t -99.92 123.2 52.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.794 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 31.2 t -100.14 -31.45 11.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.118 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -169.14 135.12 1.65 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.675 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.0 p -142.56 149.37 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.027 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 81.6 p -107.34 149.46 27.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.921 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -95.91 79.48 3.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.412 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -129.07 -161.43 1.11 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.789 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.442 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 5.4 p-10 -152.49 87.51 4.15 Favored Pre-proline 0 C--N 1.331 -0.203 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.292 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 74.6 Cg_endo -82.7 169.6 59.52 Favored 'Cis proline' 0 C--N 1.348 0.513 0 C-N-CA 123.49 -1.462 . . . . 0.0 112.271 -0.196 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -111.9 153.01 17.57 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.24 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.87 121.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.83 0.348 . . . . 0.0 111.018 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 224' ' ' VAL . 3.3 p -117.27 156.68 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.133 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.453 ' N ' HG22 ' A' ' 232' ' ' VAL . 87.8 m -122.2 160.6 24.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.564 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 234' ' ' CYS . . . . . 0.407 ' N ' HG22 ' A' ' 233' ' ' THR . 1.6 m -99.9 170.04 8.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.816 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.67 140.93 36.88 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.848 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -53.6 -36.02 61.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.39 . . . . 0.0 110.823 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -94.09 44.85 1.13 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.074 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -159.85 159.59 32.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.218 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -127.47 146.59 50.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.007 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -101.28 149.42 24.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.776 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -143.83 43.74 0.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.688 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.696 ' O ' HG11 ' A' ' 269' ' ' VAL . 1.6 m-85 -127.1 145.32 50.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.712 0.291 . . . . 0.0 110.651 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -108.65 173.29 6.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.974 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.526 HG22 ' HG3' ' A' ' 268' ' ' LYS . 0.7 OUTLIER -59.58 94.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 -179.967 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.62 -15.58 3.84 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.714 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -63.13 -178.36 0.23 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.738 0.304 . . . . 0.0 110.859 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 265' ' ' MET . 33.6 m-85 -131.79 146.46 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.985 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.525 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -144.85 150.43 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.282 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.0 p -120.86 164.28 16.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.74 ' HD2' HG21 ' A' ' 253' ' ' VAL . 4.2 m-30 -99.74 143.59 29.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.75 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.418 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 58.1 m -99.97 -90.77 0.31 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.408 -179.702 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.5 OUTLIER -116.3 88.75 2.96 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 120.505 0.193 . . . . 0.0 111.109 -179.851 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.744 HG22 ' HA2' ' A' ' 290' ' ' GLY . 2.4 t -100.24 155.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.977 0.418 . . . . 0.0 111.268 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -111.61 102.59 10.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.901 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.7 -53.71 0.81 Allowed Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.553 -178.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.638 ' HG2' HD23 ' A' ' 259' ' ' LEU . 39.2 ttm -93.04 49.35 1.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.982 0.42 . . . . 0.0 110.483 179.367 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -79.19 -34.01 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.78 -179.557 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.6 mm-40 -39.33 -34.74 0.22 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.936 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.678 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.8 mm? -59.7 -45.28 92.58 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.325 . . . . 0.0 110.792 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 47.3 t30 -64.02 -34.93 79.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.24 39.6 2.79 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.292 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.3 t -151.54 30.53 0.6 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.686 0.279 . . . . 0.0 110.945 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 61.31 156.16 0.11 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.545 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.1 168.06 6.57 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.37 2.046 . . . . 0.0 112.035 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.678 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.8 OUTLIER -132.67 -175.24 3.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.769 -179.859 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -99.67 134.85 41.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.543 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.525 HG23 HG22 ' A' ' 248' ' ' VAL . 1.0 OUTLIER -103.8 172.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.627 0.727 . . . . 0.0 112.311 -179.239 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.606 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 10.0 ttpp -140.34 127.42 20.91 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.641 178.609 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.696 HG11 ' O ' ' A' ' 242' ' ' PHE . 6.4 m -97.58 115.0 36.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 0.0 111.709 -178.297 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 51.1 mt -92.93 -28.83 16.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.385 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.23 -167.92 26.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.543 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.98 -49.6 9.38 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.534 2.156 . . . . 0.0 111.921 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -115.06 14.15 17.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.915 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.7 p -120.04 147.28 45.01 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.623 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.606 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.9 p90 -177.87 161.74 1.62 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.98 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.66 170.08 9.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.946 0.403 . . . . 0.0 111.113 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.725 HD12 ' O ' ' A' ' 278' ' ' CYS . 1.7 pp -133.41 176.89 7.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.931 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.725 ' O ' HD12 ' A' ' 277' ' ' ILE . 31.0 p -58.83 -177.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.922 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -66.63 110.12 3.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 10.2 t -108.03 31.71 5.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.6 m -87.12 -15.49 38.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.194 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.06 33.6 1.7 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.771 0.319 . . . . 0.0 111.021 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -144.05 175.64 9.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.797 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.61 174.27 6.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.729 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -83.56 137.11 33.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -64.97 121.32 14.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.866 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 23.0 mt -105.99 -55.59 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 6.9 mtt180 -158.98 -171.33 3.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.378 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 53.34 177.62 0.08 OUTLIER Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.344 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.744 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 116.05 106.01 2.5 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.98 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' A' ' 251' ' ' SER . 7.6 mm -114.58 129.69 70.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.703 HG13 ' HB3' ' A' ' 219' ' ' ALA . 9.1 p -99.74 117.89 45.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.982 0.42 . . . . 0.0 111.484 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -120.45 175.72 5.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.629 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.747 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.054 0 CA-C-O 120.828 0.347 . . . . 0.0 110.875 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 2.2 m -157.6 134.42 9.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.428 ' HB2' ' O ' ' A' ' 239' ' ' ARG . . . -136.71 159.6 41.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.038 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.2 mtt -105.09 155.36 19.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 45.2 t -100.67 137.02 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.002 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.2 t -112.18 -37.8 4.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.72 150.77 25.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.92 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.438 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.2 p -159.96 142.79 5.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.047 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 51.5 p -106.62 146.33 30.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.948 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 31.1 tttt -90.72 64.57 5.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.437 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -106.32 -156.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.811 -179.92 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.458 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 9.3 t-20 -157.07 89.52 2.55 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.567 0.223 . . . . 0.0 111.389 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 91.2 Cg_endo -77.69 169.12 74.5 Favored 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 123.347 -1.522 . . . . 0.0 112.012 -0.273 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.72 148.67 16.54 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.429 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 30.7 t -99.92 120.48 49.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.907 0.384 . . . . 0.0 111.029 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.523 HG13 ' CE2' ' A' ' 275' ' ' PHE . 2.6 p -112.99 155.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.12 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.439 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -119.83 162.23 19.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.63 179.817 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.9 m -99.95 166.58 10.99 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.954 0.407 . . . . 0.0 110.935 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.812 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 11.2 tp -59.28 153.66 18.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.701 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -51.68 -27.12 10.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.095 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.481 ' HG3' HD23 ' A' ' 235' ' ' LEU . 2.5 pt-20 -134.79 42.69 2.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.853 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.812 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -91.32 -176.65 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.428 ' O ' ' HB2' ' A' ' 219' ' ' ALA . 1.3 tpm_? -130.62 135.46 47.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 38.5 p-80 -109.66 110.67 21.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 241' ' ' GLY . . . . . 0.747 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -126.13 -0.48 7.53 Favored Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.991 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.401 ' HB3' ' HB3' ' A' ' 246' ' ' ASP . 1.5 m-85 -80.45 139.67 36.33 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.866 0.365 . . . . 0.0 110.705 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 243' ' ' GLU . . . . . 0.449 ' O ' HD11 ' A' ' 267' ' ' ILE . 0.8 OUTLIER -92.49 169.4 10.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.928 -179.919 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 4.6 m -59.83 91.57 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.85 23.98 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.685 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.401 ' HB3' ' HB3' ' A' ' 242' ' ' PHE . 1.5 t70 -78.74 170.03 17.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 110.879 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 47.9 m-85 -104.36 122.39 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.903 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 267' ' ' ILE . 30.2 m -128.07 143.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.345 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.2 p -119.82 165.85 14.04 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.739 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.509 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.0 m-30 -99.58 145.24 27.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.96 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.402 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 0.5 OUTLIER -105.0 -88.29 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.988 -179.93 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.606 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.63 90.99 3.45 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.233 0.54 . . . . 0.0 109.769 179.765 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.754 HG22 ' CA ' ' A' ' 290' ' ' GLY . 17.3 t -116.08 139.26 43.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.607 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 119.68 38.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.219 179.333 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.09 -65.67 0.5 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.778 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.67 ' HG2' HD23 ' A' ' 259' ' ' LEU . 6.4 ttm -85.75 59.73 5.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.089 0.471 . . . . 0.0 110.396 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.41 HG13 ' N ' ' A' ' 258' ' ' GLN . 29.9 pt -80.14 -33.39 14.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.977 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.416 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.1 OUTLIER -38.94 -34.72 0.17 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.897 -178.87 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.838 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.1 mm? -75.15 -44.71 45.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.838 0.351 . . . . 0.0 110.614 179.587 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -57.45 -34.89 69.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.892 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.71 38.64 3.07 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.43 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -158.46 165.2 35.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.755 0.312 . . . . 0.0 110.759 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -56.55 167.66 0.94 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.669 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -67.98 169.37 16.58 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.335 2.023 . . . . 0.0 111.999 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.638 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.7 OUTLIER -129.39 -176.99 4.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.716 179.929 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.37 140.7 33.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.757 0.313 . . . . 0.0 110.649 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.449 HD11 ' O ' ' A' ' 243' ' ' GLU . 1.2 pp -106.77 171.91 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.55 0.691 . . . . 0.0 112.212 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.622 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -143.05 125.58 15.78 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.617 178.797 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.66 115.53 37.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.598 0.714 . . . . 0.0 111.43 -178.386 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 50.1 mt -94.27 -27.7 15.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.789 -1.096 . . . . 0.0 110.503 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -163.9 -170.67 29.14 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -62.96 -35.34 66.99 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.52 2.147 . . . . 0.0 112.056 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -123.93 2.44 8.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.169 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -112.24 149.94 31.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.798 0.333 . . . . 0.0 110.791 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.622 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.9 p90 -177.44 162.27 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.767 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 5.1 t -118.19 170.17 9.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.933 0.397 . . . . 0.0 111.332 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.456 HD12 ' O ' ' A' ' 278' ' ' CYS . 1.2 pp -133.95 179.3 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.947 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.456 ' O ' HD12 ' A' ' 277' ' ' ILE . 1.2 m -58.51 -173.41 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.9 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.407 ' O ' ' CE2' ' A' ' 283' ' ' PHE . 1.7 m-20 -54.12 126.58 23.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.98 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.541 HG22 ' CE ' ' A' ' 256' ' ' MET . 0.3 OUTLIER -110.02 -30.15 7.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.968 -179.898 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 2.9 m -59.44 -30.49 68.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.019 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -71.8 -31.01 66.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.998 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.838 ' CE2' HD11 ' A' ' 259' ' ' LEU . 50.7 m-85 -89.51 -172.92 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 75.4 m -78.63 -178.32 5.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.993 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -93.26 135.39 34.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.855 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.722 ' CE2' HG13 ' A' ' 253' ' ' VAL . 39.3 t80 -74.94 138.09 42.1 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.746 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.2 mt -117.05 -66.81 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.197 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 -152.65 170.68 19.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.664 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.77 149.72 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.143 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.754 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 142.81 116.64 1.18 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.801 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.437 HD12 ' N ' ' A' ' 291' ' ' ILE . 3.9 mp -117.44 133.56 63.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.755 0.312 . . . . 0.0 110.711 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.481 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.8 p -99.88 122.08 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.219 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.7 m -131.48 158.19 41.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.94 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.745 HD23 ' CE1' ' A' ' 242' ' ' PHE . 29.7 tp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.844 0.355 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 13.7 t -147.42 154.71 41.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.834 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.44 155.98 40.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.043 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -94.26 143.44 26.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 39.1 t -99.92 145.04 11.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.058 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 38.7 t -112.79 -32.96 6.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.073 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 14.7 ptm -169.5 159.05 8.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.559 HG12 ' CG ' ' A' ' 286' ' ' TYR . 8.5 p -158.87 149.21 7.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.062 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 63.3 p -99.46 147.56 25.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.948 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.04 81.44 3.7 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.435 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.6 t0 -127.76 -157.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.796 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.464 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 1.6 p30 -154.68 90.59 3.09 Favored Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 -179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 97.3 Cg_endo -77.13 169.39 74.38 Favored 'Cis proline' 0 C--N 1.347 0.477 0 C-N-CA 123.369 -1.513 . . . . 0.0 112.011 -0.272 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.76 151.3 17.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.45 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.6 t -99.87 140.25 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.843 0.354 . . . . 0.0 111.008 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.574 HG13 ' CE1' ' A' ' 275' ' ' PHE . 3.3 p -130.88 151.96 36.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.141 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 4.9 m -114.19 158.12 21.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.67 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.1 m -99.97 166.64 10.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.819 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 7.2 tp -59.11 152.25 20.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.789 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -50.95 -27.21 7.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.143 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -132.79 38.35 3.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.819 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -87.68 -169.0 2.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.158 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.2 ttm180 -145.35 106.84 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.924 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.422 ' CE1' HG12 ' A' ' 269' ' ' VAL . 15.6 t-80 -107.61 143.64 35.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.82 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 177.04 68.79 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.678 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.745 ' CE1' HD23 ' A' ' 217' ' ' LEU . 15.3 m-85 -116.32 149.26 39.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.861 0.362 . . . . 0.0 110.762 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -69.28 151.33 46.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.5 m -57.86 97.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.78 15.35 9.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.721 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -64.9 -178.67 0.45 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.657 0.265 . . . . 0.0 110.743 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.495 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.8 m-85 -120.24 132.06 55.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.789 0.328 . . . . 0.0 110.982 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.419 HG22 HG23 ' A' ' 267' ' ' ILE . 17.8 m -137.32 154.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.421 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.4 p -125.59 165.0 19.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.556 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.665 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.6 m-30 -99.74 140.59 33.73 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.041 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 62.2 m -99.96 -94.09 0.26 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.033 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.54 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.2 OUTLIER -109.66 87.74 2.58 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 121.27 -0.172 . . . . 0.0 110.636 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.665 HG21 ' CD2' ' A' ' 250' ' ' PHE . 15.5 t -107.21 144.72 15.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.928 0.394 . . . . 0.0 111.726 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -107.92 114.94 29.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.912 179.161 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.6 -63.52 0.51 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.671 -0.776 . . . . 0.0 111.458 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.64 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.9 ttm -89.24 54.57 3.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.133 0.492 . . . . 0.0 110.152 179.035 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.415 HG22 ' O ' ' A' ' 253' ' ' VAL . 14.2 pt -79.04 -33.35 15.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.045 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -38.76 -34.71 0.16 Allowed 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.933 -178.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.64 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.2 mm? -71.08 -47.03 60.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.943 0.401 . . . . 0.0 110.49 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -55.86 -34.85 65.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.896 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.14 46.37 3.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -169.1 166.34 10.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.784 0.326 . . . . 0.0 110.663 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -55.91 164.19 1.83 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.9 168.54 13.43 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.242 1.961 . . . . 0.0 112.078 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.497 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -128.35 -172.29 2.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.516 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -99.37 151.43 21.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.758 0.313 . . . . 0.0 110.654 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.419 HG23 HG22 ' A' ' 248' ' ' VAL . 2.1 pp -123.1 174.0 8.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.593 0.711 . . . . 0.0 112.316 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.569 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.2 OUTLIER -147.43 127.77 13.95 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.738 178.919 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 269' ' ' VAL . 34.9 m -97.88 112.75 30.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.434 0.635 . . . . 0.0 111.539 -178.535 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 270' ' ' LEU . 17.6 mt -89.04 -28.0 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.449 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.63 -164.17 24.9 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.583 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 -44.25 9.06 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.586 2.191 . . . . 0.0 112.099 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -117.03 18.34 14.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.029 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.97 146.66 51.67 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.92 0.391 . . . . 0.0 110.794 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.574 ' CE1' HG13 ' A' ' 232' ' ' VAL . 2.2 p90 -178.62 154.12 0.74 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.639 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.7 t -105.58 170.06 8.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.014 0.435 . . . . 0.0 111.441 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.61 -178.02 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.84 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.31 175.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.987 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.38 133.2 50.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 62.9 p -118.07 28.57 8.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.06 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 80.3 p -82.21 -30.05 31.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.921 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.405 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 77.5 m-20 -100.1 31.23 3.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.999 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 259' ' ' LEU . 24.9 m-85 -138.12 -175.05 3.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.04 178.78 6.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.94 150.88 21.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.929 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.559 ' CG ' HG12 ' A' ' 224' ' ' VAL . 67.3 t80 -81.43 136.39 35.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.5 mt -120.0 -56.81 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.199 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.8 mmt85 -162.48 178.11 8.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.372 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.29 162.58 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.269 -0.967 . . . . 0.0 111.932 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.636 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 130.8 116.37 1.81 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.793 179.002 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.2 mt -120.51 133.59 66.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.747 0.308 . . . . 0.0 110.597 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.549 ' O ' HG13 ' A' ' 292' ' ' VAL . 12.1 p -99.6 117.21 44.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.325 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.31 142.54 50.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.812 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.927 -179.938 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 4.0 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.89 0.376 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 63.8 m -134.02 160.22 38.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.991 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.62 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -148.0 153.25 38.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.57 155.97 17.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.055 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.401 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 41.0 t -105.19 135.31 43.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.021 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.6 t -111.52 -34.75 6.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -164.53 151.91 11.67 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.82 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.536 HG12 ' CD1' ' A' ' 286' ' ' TYR . 9.8 p -157.86 148.58 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.023 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 64.5 p -101.96 145.36 29.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.913 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -93.65 77.92 4.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.729 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.411 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.5 t70 -121.59 -153.68 0.56 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.773 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.431 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 37.1 t-20 -157.39 90.19 2.43 Favored Pre-proline 0 CA--C 1.531 0.232 0 CA-C-O 120.452 0.168 . . . . 0.0 111.256 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 97.4 Cg_endo -76.97 169.8 73.43 Favored 'Cis proline' 0 C--N 1.348 0.5 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.15 -0.253 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.4 149.58 16.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.458 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.2 t -99.88 138.72 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.832 0.348 . . . . 0.0 110.874 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.632 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 3.6 p -131.63 156.9 43.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.463 ' N ' HG22 ' A' ' 232' ' ' VAL . 94.3 m -120.92 161.68 21.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.368 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 234' ' ' CYS . . . . . 0.415 ' N ' HG22 ' A' ' 233' ' ' THR . 2.4 m -99.9 169.86 8.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.908 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.61 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 3.2 tp -68.08 153.67 43.24 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.807 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -53.67 -28.3 32.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.97 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.544 ' CG ' HD23 ' A' ' 235' ' ' LEU . 9.6 pt-20 -121.68 30.64 6.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.891 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.61 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -92.14 -176.42 4.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.122 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -124.87 -175.89 3.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 32.0 t60 -174.12 113.32 0.18 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -144.78 25.71 1.94 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.819 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.502 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.5 OUTLIER -99.04 138.64 35.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.861 0.362 . . . . 0.0 110.595 179.808 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -92.78 168.8 10.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 58.7 p -59.44 102.39 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 120.6 11.7 6.46 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.898 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -73.83 -176.14 2.34 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.732 0.301 . . . . 0.0 110.767 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.441 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -132.75 121.82 23.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.798 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.49 HG22 HG23 ' A' ' 267' ' ' ILE . 20.2 m -129.1 154.84 40.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 0.0 111.325 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.8 p -123.76 165.51 17.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.862 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 1.012 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.0 m-30 -99.61 144.27 28.89 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.96 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 28.7 t -102.88 -94.35 0.31 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.011 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -110.29 88.29 2.73 Favored 'General case' 0 C--O 1.225 -0.195 0 CA-C-O 120.511 0.196 . . . . 0.0 110.54 179.684 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 1.012 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.9 t -104.32 143.54 15.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.988 0.423 . . . . 0.0 111.745 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -104.06 110.81 23.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.924 179.152 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.73 -63.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.701 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.472 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.1 ttm -86.25 58.58 5.13 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 110.33 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.401 HG13 ' N ' ' A' ' 258' ' ' GLN . 16.2 pt -79.32 -33.33 15.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.9 -179.362 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.449 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 4.2 mp0 -38.99 -34.59 0.16 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.859 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.764 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.0 mm? -73.16 -46.82 48.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.938 0.399 . . . . 0.0 110.495 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -58.38 -34.94 71.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.788 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.62 45.35 2.74 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.346 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -165.92 163.96 18.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.775 0.321 . . . . 0.0 110.714 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -56.01 167.65 0.83 Allowed Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.599 179.812 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -68.68 154.39 71.47 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.302 2.002 . . . . 0.0 112.017 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.463 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.1 ptp -115.11 -177.03 3.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.574 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -99.7 138.67 36.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.773 0.321 . . . . 0.0 110.784 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.502 HD11 ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -106.79 174.72 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.573 0.702 . . . . 0.0 112.2 -179.473 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.713 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -144.04 128.77 18.27 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.508 178.716 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.492 HG11 ' O ' ' A' ' 242' ' ' PHE . 27.7 m -97.43 118.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.523 0.678 . . . . 0.0 111.495 -178.343 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 44.5 mt -92.42 -30.78 15.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.662 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.44 -158.99 32.17 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.312 -0.947 . . . . 0.0 113.097 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -63.89 112.13 1.74 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.71 2.273 . . . . 0.0 112.338 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 66.27 14.99 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.08 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -128.73 138.33 52.06 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.484 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.713 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.4 p90 -174.21 169.42 3.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.872 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.0 t -123.42 170.11 10.68 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.98 0.419 . . . . 0.0 111.415 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.67 HD11 ' CG2' ' A' ' 280' ' ' THR . 11.6 pt -123.58 -177.53 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.802 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 m -57.5 -82.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.983 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -150.15 140.69 22.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.801 0.334 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.67 ' CG2' HD11 ' A' ' 277' ' ' ILE . 71.5 p -113.22 -26.92 8.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 t -54.53 -24.21 19.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.292 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.401 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 3.3 m120 -94.47 20.91 7.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.23 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.764 ' CE2' HD11 ' A' ' 259' ' ' LEU . 35.7 m-85 -143.78 -179.61 6.57 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.774 0.321 . . . . 0.0 110.825 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.81 -171.79 0.74 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.893 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -98.87 125.86 44.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.536 ' CD1' HG12 ' A' ' 224' ' ' VAL . 26.9 t80 -69.98 120.67 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.797 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.2 mt -106.88 -68.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.185 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -138.48 -178.84 5.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.508 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.81 166.67 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.238 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.665 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 122.87 111.32 2.05 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.532 -0.842 . . . . 0.0 113.126 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.455 HD12 ' N ' ' A' ' 291' ' ' ILE . 4.8 mp -118.69 128.35 75.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.62 HG13 ' HB3' ' A' ' 219' ' ' ALA . 12.6 p -99.55 113.1 33.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.017 0.437 . . . . 0.0 111.531 -179.329 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.4 m -115.28 -176.81 2.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.641 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.826 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.806 0.336 . . . . 0.0 110.832 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.2 p -168.52 97.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.024 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.743 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -102.49 167.49 9.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.986 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 4.5 mmt -105.54 146.46 29.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.015 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.446 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 96.0 t -100.06 130.58 49.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 40.0 t -109.39 -34.88 6.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.066 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -157.0 148.29 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.043 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 224' ' ' VAL . 11.0 p -155.93 113.09 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.005 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 68.8 p -70.81 135.69 48.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.05 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.54 82.96 6.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.726 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -129.85 -147.94 0.35 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.498 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -145.96 102.77 4.16 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 120.342 0.115 . . . . 0.0 110.881 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.449 ' HB2' ' O ' ' A' ' 277' ' ' ILE . 36.2 Cg_endo -68.24 -74.26 0.0 OUTLIER 'Cis proline' 0 C--N 1.349 0.555 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.656 0.171 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 154.42 139.73 2.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.18 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.3 t -99.83 127.85 52.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.895 0.378 . . . . 0.0 111.025 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.543 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.7 p -116.85 153.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.165 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 90.3 m -117.93 157.86 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.508 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -99.97 168.65 9.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.664 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 3.5 tp -68.95 150.81 47.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.781 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -48.5 -28.38 3.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.176 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -133.75 47.42 2.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.85 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.664 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -90.85 174.19 7.58 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.163 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -118.38 107.4 13.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.912 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 53.7 p-80 -92.57 131.58 37.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.824 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -151.4 26.36 0.97 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.566 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.711 ' O ' HG11 ' A' ' 269' ' ' VAL . 1.4 m-85 -112.3 140.86 46.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 110.719 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.66 175.48 5.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -61.18 88.67 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.773 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.18 -16.47 3.9 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.818 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.09 165.39 3.41 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.658 0.266 . . . . 0.0 110.708 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 265' ' ' MET . 5.0 m-85 -113.61 150.15 33.52 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.883 0.373 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 267' ' ' ILE . 10.1 m -147.48 144.31 19.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.21 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 p -115.78 163.67 15.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.671 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.955 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.0 m-30 -99.44 142.78 30.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.77 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.411 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 65.3 m -99.82 -100.12 0.24 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.108 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 1.7 pt-20 -103.1 88.01 3.04 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.605 0.24 . . . . 0.0 110.641 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.955 HG21 ' CD2' ' A' ' 250' ' ' PHE . 9.8 t -100.9 136.71 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.853 0.358 . . . . 0.0 111.522 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -99.92 107.88 19.98 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.883 179.188 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.65 -66.02 0.46 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.79 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.596 ' HG2' HD23 ' A' ' 259' ' ' LEU . 32.1 ttm -84.04 59.65 5.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.164 0.506 . . . . 0.0 110.673 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 12.4 pt -80.23 -33.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.989 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -38.57 -34.5 0.14 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.513 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.647 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.4 mm? -61.64 -53.9 49.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.907 0.384 . . . . 0.0 110.613 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 33.1 t30 -57.39 -34.94 69.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.884 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.05 46.09 2.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 2.2 t -162.06 30.2 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.69 0.281 . . . . 0.0 110.981 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 263' ' ' GLN . . . . . 0.41 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 2.4 mt-30 58.33 167.66 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.773 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.41 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 30.1 Cg_endo -63.39 165.8 16.69 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.31 2.007 . . . . 0.0 112.067 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.647 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -134.52 -171.69 2.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.643 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -99.68 138.63 36.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.857 0.36 . . . . 0.0 110.568 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.442 HD13 ' HB2' ' A' ' 242' ' ' PHE . 1.6 pp -109.71 172.72 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.5 0.666 . . . . 0.0 112.181 -179.433 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 8.5 tttm -143.54 125.51 15.29 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.788 -1.096 . . . . 0.0 108.833 178.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.711 HG11 ' O ' ' A' ' 242' ' ' PHE . 27.4 m -97.61 108.9 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.459 0.647 . . . . 0.0 111.525 -178.476 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.1 mt -86.02 -30.57 22.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.451 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.61 -168.53 27.91 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.615 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -60.1 -50.57 7.14 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.59 2.194 . . . . 0.0 111.816 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -112.91 21.87 15.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.723 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -130.33 145.93 51.85 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.736 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.554 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -179.18 155.68 0.73 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.4 t -104.3 170.08 8.11 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.162 0.506 . . . . 0.0 111.35 -179.249 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.547 ' CD1' HG21 ' A' ' 280' ' ' THR . 3.8 pt -124.67 -171.22 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.643 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -74.27 -168.46 0.65 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.623 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -69.77 105.6 2.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.547 HG21 ' CD1' ' A' ' 277' ' ' ILE . 4.4 t -132.89 74.25 1.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.932 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 10.1 p -125.76 -33.51 2.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.593 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 -95.14 25.4 4.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.647 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.426 ' CD1' ' HA ' ' A' ' 280' ' ' THR . 21.6 m-85 -117.36 -167.48 1.32 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.739 0.304 . . . . 0.0 110.739 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 31.0 t -74.56 175.95 7.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.842 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -99.4 131.71 45.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.433 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 24.7 t80 -69.01 117.56 10.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.029 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 6.0 mt -102.98 -60.06 3.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.47 -178.75 6.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.459 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 289' ' ' GLY . . . . . 0.401 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 57.87 158.31 0.02 OUTLIER Glycine 0 C--N 1.331 0.29 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.427 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.534 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 129.37 106.13 1.21 Allowed Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.513 -0.851 . . . . 0.0 112.865 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.481 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.7 mp -111.54 135.87 49.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.412 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.743 ' CG1' ' HB3' ' A' ' 219' ' ' ALA . 12.2 p -99.64 112.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.964 0.411 . . . . 0.0 111.549 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 49.8 m -107.2 171.91 7.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.701 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.42 ' HG3' ' CD1' ' A' ' 242' ' ' PHE . 4.7 tt0 . . . . . 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.086 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.579 HD23 ' CE1' ' A' ' 242' ' ' PHE . 8.1 tp . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.793 0.33 . . . . 0.0 110.834 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 25.6 p -145.25 172.28 13.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.511 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -162.98 169.95 18.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.05 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.3 156.08 22.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.939 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 41.0 t -108.21 127.39 64.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.003 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 17.2 t -106.06 -34.68 7.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.974 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.76 137.33 10.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.74 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.1 p -142.8 122.08 8.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.064 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 31.0 p -81.7 138.67 35.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.112 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -90.56 78.32 6.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.77 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.428 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.9 t0 -123.07 -150.96 0.46 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.723 -179.741 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.422 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 17.2 p30 -159.44 90.49 1.93 Allowed Pre-proline 0 CA--C 1.532 0.255 0 CA-C-O 120.471 0.177 . . . . 0.0 111.202 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 81.2 Cg_endo -75.13 169.34 74.82 Favored 'Cis proline' 0 C--N 1.347 0.451 0 C-N-CA 123.322 -1.533 . . . . 0.0 111.937 -0.273 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -103.86 146.13 16.29 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.377 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.1 t -99.76 125.35 53.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.74 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.7 p -122.55 155.25 27.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.214 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.426 ' N ' HG22 ' A' ' 232' ' ' VAL . 4.7 m -123.52 166.9 14.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.577 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -100.0 170.05 8.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.745 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.564 HD23 ' HG2' ' A' ' 237' ' ' GLU . 0.4 OUTLIER -72.16 160.46 32.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.7 179.867 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -55.08 -29.81 58.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.992 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.564 ' HG2' HD23 ' A' ' 235' ' ' LEU . 9.3 pt-20 -119.13 34.64 5.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.829 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.94 159.6 15.22 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.019 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -124.65 140.02 53.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.977 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.4 t60 -118.76 144.19 46.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.82 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 241' ' ' GLY . . . . . 0.496 ' HA3' HD21 ' A' ' 217' ' ' LEU . . . -159.57 26.39 0.34 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.739 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.579 ' CE1' HD23 ' A' ' 217' ' ' LEU . 1.6 m-85 -100.53 142.34 32.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.66 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -95.94 170.07 9.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.24 101.07 0.11 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.8 19.26 5.35 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.696 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -84.9 169.27 14.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.758 0.313 . . . . 0.0 110.702 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.454 ' HA ' ' O ' ' A' ' 265' ' ' MET . 62.5 m-85 -108.28 141.81 39.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.912 0.387 . . . . 0.0 111.033 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.451 HG22 HG23 ' A' ' 267' ' ' ILE . 32.5 m -146.21 143.5 21.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.1 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.5 p -121.24 162.52 20.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.93 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.0 m-30 -99.76 149.61 23.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.1 m -108.5 -85.17 0.53 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.919 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.602 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.72 92.58 3.85 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.128 0.49 . . . . 0.0 109.828 179.678 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.93 HG21 ' CD2' ' A' ' 250' ' ' PHE . 3.3 t -112.46 140.63 31.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.479 -179.196 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 68.3 mt-30 -103.79 110.84 23.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.091 179.331 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.88 -57.75 0.64 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.591 -179.021 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.676 ' HG2' HD23 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -90.27 53.78 2.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.11 0.481 . . . . 0.0 110.353 179.334 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 18.8 pt -78.91 -33.79 16.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.843 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -39.24 -34.73 0.2 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.294 -0.412 . . . . 0.0 112.068 -178.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.807 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.5 mm? -66.47 -45.07 80.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 110.685 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -57.68 -38.86 75.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.994 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.7 50.22 1.14 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.511 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.2 t -161.67 30.12 0.13 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.711 0.291 . . . . 0.0 110.905 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 10.2 mt-30 58.82 166.22 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.762 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.34 166.01 13.94 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.441 2.094 . . . . 0.0 112.148 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.807 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.2 ptp -130.97 -174.84 3.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.713 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.52 136.53 39.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.801 0.334 . . . . 0.0 110.616 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.451 HG23 HG22 ' A' ' 248' ' ' VAL . 1.2 pp -103.15 175.77 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.662 0.744 . . . . 0.0 112.315 -179.317 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.649 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -148.89 128.84 13.46 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.621 178.805 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.504 HG11 ' O ' ' A' ' 242' ' ' PHE . 26.1 m -97.73 122.89 49.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.528 0.68 . . . . 0.0 111.577 -178.424 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 48.4 mt -101.95 -29.1 12.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.504 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.49 -172.35 27.64 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.513 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.56 -33.98 65.79 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.556 2.171 . . . . 0.0 112.053 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -124.63 1.92 8.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.166 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -113.98 153.3 29.57 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.85 0.357 . . . . 0.0 110.805 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.649 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.53 169.05 2.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.831 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -124.1 170.08 11.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.993 0.425 . . . . 0.0 111.242 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.3 pt -125.73 -179.21 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.773 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.04 -173.37 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.865 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.67 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.827 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -99.85 33.47 2.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.979 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 31.2 t -109.21 30.78 6.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.406 ' OD1' ' CZ ' ' A' ' 283' ' ' PHE . 28.2 p30 -150.09 30.71 0.7 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.851 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.406 ' CZ ' ' OD1' ' A' ' 282' ' ' ASN . 20.0 m-85 -138.04 -168.42 2.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.462 ' O ' ' HE3' ' A' ' 256' ' ' MET . 0.1 OUTLIER -91.61 175.25 6.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.84 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -85.43 121.04 27.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.426 ' HE1' HG13 ' A' ' 253' ' ' VAL . 64.8 t80 -56.67 136.52 54.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.879 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 30.9 mt -114.16 -59.83 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.301 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.01 173.3 11.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.734 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.36 150.51 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.31 112.53 0.95 Allowed Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.895 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.2 mp -109.22 128.87 64.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.806 0.336 . . . . 0.0 110.614 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.7 p -99.88 114.93 39.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.359 -179.681 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 75.6 m -109.42 -178.03 3.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.638 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 31.9 tt0 . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.001 -179.905 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.745 0.307 . . . . 0.0 110.774 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.7 m -162.19 169.6 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.972 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -162.25 148.39 13.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.951 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.4 mtt -93.45 160.93 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.002 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.425 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 47.9 t -108.73 123.88 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.025 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 28.8 t -102.22 -30.68 10.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.52 143.21 5.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.955 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.651 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.2 p -149.2 137.33 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.087 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 43.8 p -90.22 145.51 24.95 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.83 78.28 4.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.813 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.71 -160.74 1.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.824 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.424 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 7.3 p-10 -154.4 90.04 3.22 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.277 -179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 92.5 Cg_endo -80.1 169.72 68.61 Favored 'Cis proline' 0 C--N 1.348 0.503 0 C-N-CA 123.501 -1.458 . . . . 0.0 112.168 -0.185 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -113.76 157.13 15.16 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.334 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.0 t -99.79 125.45 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.858 0.361 . . . . 0.0 110.911 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.651 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.5 p -123.72 155.79 30.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.196 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 232' ' ' VAL . 89.1 m -124.16 159.11 30.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.615 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.0 m -99.97 165.9 11.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.86 0.362 . . . . 0.0 110.905 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 3.7 tp -59.92 150.12 29.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.741 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -52.24 -27.79 16.22 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.261 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -99.92 -26.74 13.9 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.04 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.405 ' O ' ' CE2' ' A' ' 273' ' ' TYR . . . -74.4 140.81 44.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.243 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 27.5 ttt180 -120.59 145.31 47.5 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.902 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -86.24 131.53 34.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.935 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -119.52 -19.38 4.19 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.995 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.485 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -78.9 145.93 33.85 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.777 0.322 . . . . 0.0 110.737 -179.879 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -101.92 179.66 4.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.538 HG23 HG22 ' A' ' 269' ' ' VAL . 0.7 OUTLIER -63.72 105.44 0.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.997 -179.995 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 128.24 -5.39 6.78 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.967 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.418 ' CB ' ' HB3' ' A' ' 242' ' ' PHE . 2.3 t70 -80.21 172.34 13.9 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.841 0.353 . . . . 0.0 110.98 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.444 ' HA ' ' O ' ' A' ' 265' ' ' MET . 4.4 m-85 -122.19 152.75 39.64 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.055 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.537 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -156.55 154.76 5.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.256 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 t -125.61 170.19 11.73 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.725 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.809 ' CD2' HG21 ' A' ' 253' ' ' VAL . 5.5 m-30 -99.6 159.45 15.03 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.13 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 29.3 t -113.37 -87.66 0.56 Allowed 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.065 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -114.66 88.57 2.89 Favored 'General case' 0 CA--C 1.521 -0.15 0 CA-C-O 120.54 0.209 . . . . 0.0 110.852 179.785 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.809 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.0 t -99.96 158.36 3.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.004 0.431 . . . . 0.0 111.462 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.431 ' N ' HG12 ' A' ' 253' ' ' VAL . 2.2 mm-40 -119.04 106.11 12.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.941 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -56.55 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.482 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.457 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.2 ttm -96.59 51.53 1.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.153 0.502 . . . . 0.0 110.315 179.166 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.7 pp -75.74 -33.66 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.563 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.433 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 5.1 mm-40 -39.25 -34.64 0.2 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.695 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.53 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.4 mm? -59.22 -47.32 85.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 110.59 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -57.54 -46.41 83.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.871 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.82 47.56 2.98 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.538 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 5.1 t -152.14 34.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 263' ' ' GLN . . . . . 0.404 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 4.3 mt-30 59.74 168.49 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.404 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 43.8 Cg_endo -67.55 151.34 79.77 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.349 2.033 . . . . 0.0 112.067 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.53 ' SD ' HD12 ' A' ' 259' ' ' LEU . 3.1 ptp -118.69 -178.01 3.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.711 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -99.75 157.25 16.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.504 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.537 HG23 HG22 ' A' ' 248' ' ' VAL . 1.8 pp -125.93 170.5 15.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.625 0.726 . . . . 0.0 112.312 -179.539 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.628 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 14.4 mtpt -145.06 126.79 15.25 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.564 -1.198 . . . . 0.0 108.532 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.538 HG22 HG23 ' A' ' 244' ' ' THR . 29.4 m -97.54 120.36 46.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.595 0.712 . . . . 0.0 111.587 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.2 mt -99.11 -30.25 12.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.809 -1.087 . . . . 0.0 110.601 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -162.31 -173.81 31.44 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.565 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.82 -59.27 1.31 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.611 2.208 . . . . 0.0 112.243 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CE2' ' O ' ' A' ' 238' ' ' ALA . 10.0 m-85 -109.39 5.19 23.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.3 p -106.57 149.5 27.1 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.628 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -177.65 166.88 2.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.755 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.4 t -117.21 170.09 8.95 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.7 pt -131.11 179.89 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.16 -179.55 0.78 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.89 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.34 109.23 0.83 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.799 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.6 t -122.5 30.08 6.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.026 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 p -98.66 31.42 2.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.942 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.26 -45.95 1.0 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.453 ' CD2' HD21 ' A' ' 259' ' ' LEU . 30.5 m-85 -59.81 -168.21 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.878 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.2 176.77 9.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.913 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -83.79 125.99 32.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.976 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.401 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 20.7 t80 -61.12 135.04 57.64 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.81 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.7 mt -118.26 -64.71 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.008 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.85 -173.74 4.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.438 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.14 170.38 0.1 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.251 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.62 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 118.95 106.83 2.25 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.0 179.261 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.411 ' CD1' ' HG3' ' A' ' 252' ' ' GLU . 2.9 mp -116.94 125.3 73.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.739 0.304 . . . . 0.0 110.191 179.357 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.505 ' O ' HG13 ' A' ' 292' ' ' VAL . 9.8 p -99.68 120.1 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.551 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.5 m -125.58 170.23 11.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.726 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.421 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 27.7 tt0 . . . . . 0 C--N 1.329 -0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.896 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.7 tp . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.872 0.368 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 36.3 p -152.53 146.39 25.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -141.8 145.24 34.5 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.026 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.606 ' HB3' HD13 ' A' ' 235' ' ' LEU . 1.0 OUTLIER -82.8 151.27 26.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.983 -179.942 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 83.7 t -104.25 143.85 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.065 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.2 t -117.32 -38.52 3.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.774 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.7 mtp -159.63 143.61 14.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 224' ' ' VAL . 10.5 p -143.68 121.32 6.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.028 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 32.9 p -79.89 142.76 34.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.007 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.56 78.54 4.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.799 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.43 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 4.7 t0 -127.84 -158.91 0.91 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.749 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.428 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 46.4 t30 -153.53 90.8 3.37 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.543 0.211 . . . . 0.0 111.325 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.43 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 96.9 Cg_endo -77.23 169.17 74.85 Favored 'Cis proline' 0 C--N 1.348 0.512 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.949 -0.245 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.27 17.53 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.453 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 21.4 t -99.84 136.09 32.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.844 0.355 . . . . 0.0 111.19 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.566 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 6.3 p -127.67 138.12 55.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.014 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.46 162.33 13.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.65 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.99 165.88 11.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.887 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.712 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 0.5 OUTLIER -58.76 158.0 8.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.701 179.768 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.76 -27.64 29.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.109 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.32 38.51 3.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.804 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.712 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -99.22 169.54 9.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.096 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 4.0 tpt180 -150.02 135.71 18.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.001 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.441 ' HB2' ' CE2' ' A' ' 242' ' ' PHE . 27.1 p-80 -137.78 135.96 36.82 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.766 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -122.15 65.07 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.669 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 240' ' ' HIS . 0.9 OUTLIER -111.87 142.1 44.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.848 0.356 . . . . 0.0 110.656 179.856 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.55 172.26 9.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 27.0 m -64.17 99.54 0.28 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.003 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.26 17.89 6.97 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.902 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.01 -175.46 2.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.704 0.288 . . . . 0.0 110.687 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.47 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.0 m-85 -120.93 151.95 39.08 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.909 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.478 ' HB ' HG23 ' A' ' 292' ' ' VAL . 35.0 m -156.04 152.2 8.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.374 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.9 p -128.45 168.91 14.95 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.952 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.5 m-30 -99.79 140.94 33.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.135 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.452 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 1.8 m -104.09 -81.38 0.52 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.899 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.761 ' HG3' HD12 ' A' ' 291' ' ' ILE . 0.4 OUTLIER -119.56 88.17 2.88 Favored 'General case' 0 C--O 1.216 -0.661 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.61 179.567 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.952 HG21 ' CD2' ' A' ' 250' ' ' PHE . 9.2 t -114.72 134.17 58.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 120.934 0.397 . . . . 0.0 111.882 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 64.2 mt-30 -99.65 119.82 38.7 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.028 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -62.91 0.51 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.366 -178.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.638 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.3 ttm -87.9 58.84 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.156 0.503 . . . . 0.0 110.162 179.032 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.433 ' O ' ' N ' ' A' ' 260' ' ' ASN . 1.0 OUTLIER -77.46 -33.34 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.961 -179.437 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.438 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 37.9 mm-40 -39.14 -34.65 0.18 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.788 HD11 ' CE2' ' A' ' 283' ' ' PHE . 2.7 mm? -76.87 -39.89 49.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.873 0.368 . . . . 0.0 110.69 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.452 ' ND2' ' O ' ' A' ' 251' ' ' SER . 0.1 OUTLIER -57.09 -36.99 71.27 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.91 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.54 29.1 10.15 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.325 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -144.18 158.42 43.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.767 0.317 . . . . 0.0 110.762 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 12.7 mt-30 -54.42 165.75 0.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.754 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -64.05 174.63 3.8 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.427 2.085 . . . . 0.0 111.826 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.3 OUTLIER -133.86 -177.75 4.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.753 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -99.51 132.83 44.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.455 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.467 HG23 HG22 ' A' ' 248' ' ' VAL . 1.2 pp -102.61 172.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.8 0.81 . . . . 0.0 112.591 -179.08 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.598 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 43.8 mmtt -142.13 129.69 21.41 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.302 -1.317 . . . . 0.0 108.299 178.484 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 5.8 m -97.48 113.55 32.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.457 0.646 . . . . 0.0 111.567 -178.362 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.8 mt -93.77 -27.77 16.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.707 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.59 -170.93 34.68 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.811 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -66.99 -27.25 42.89 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.636 2.224 . . . . 0.0 112.309 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 44.5 m-85 -129.42 18.31 5.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.03 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.79 148.85 47.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.843 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.598 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 6.6 p90 -178.55 149.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.611 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 268' ' ' LYS . 1.6 t -107.49 170.14 8.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.275 -179.353 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.553 HD11 HG23 ' A' ' 280' ' ' THR . 2.7 pp -123.7 -175.85 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.739 179.75 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.401 ' C ' HD12 ' A' ' 277' ' ' ILE . 42.7 t -56.87 -77.36 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.038 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.458 ' N ' HD12 ' A' ' 277' ' ' ILE . 21.1 p-10 -150.06 133.39 16.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.06 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.553 HG23 HD11 ' A' ' 277' ' ' ILE . 0.7 OUTLIER -118.2 -28.23 5.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.195 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 22.5 p -60.38 -18.61 51.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.373 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -94.49 29.72 2.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.213 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.788 ' CE2' HD11 ' A' ' 259' ' ' LEU . 58.4 m-85 -150.07 -174.89 4.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.944 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.5 m -70.74 175.32 5.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.967 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -90.98 136.91 32.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.961 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 11.9 t80 -64.73 142.88 58.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.77 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.7 -61.72 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 2.1 mmt-85 -165.35 171.45 13.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.405 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 62.53 153.04 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.095 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.28 132.96 2.86 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.299 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.761 HD12 ' HG3' ' A' ' 252' ' ' GLU . 3.2 mt -135.45 136.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.566 -0.317 . . . . 0.0 110.3 179.641 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.478 HG23 ' HB ' ' A' ' 248' ' ' VAL . 11.8 p -99.83 127.2 52.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.192 -179.762 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.4 m -130.7 135.43 47.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.85 -179.987 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.826 0.346 . . . . 0.0 110.819 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.8 m -146.43 176.84 9.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.002 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -164.15 141.99 7.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.073 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 7.6 mtm -79.32 156.47 28.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.994 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 58.9 t -100.23 137.3 28.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.996 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.4 t -109.75 -31.21 7.53 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.824 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -171.9 131.66 0.67 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.57 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.9 p -133.91 115.88 22.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.118 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 34.0 p -75.43 141.77 43.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.079 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.77 87.39 6.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.869 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.419 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.8 OUTLIER -136.96 -160.41 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.765 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 37.4 t-20 -155.77 92.58 2.65 Favored Pre-proline 0 CA--C 1.531 0.228 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.263 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.419 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 87.1 Cg_endo -76.11 169.59 74.08 Favored 'Cis proline' 0 C--N 1.348 0.549 0 C-N-CA 123.389 -1.504 . . . . 0.0 112.098 -0.164 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.56 145.74 18.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.335 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 28.1 t -99.84 125.92 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.99 0.424 . . . . 0.0 111.067 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.667 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.1 p -115.82 157.29 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.483 ' N ' HG22 ' A' ' 232' ' ' VAL . 86.5 m -119.56 161.85 19.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.503 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 234' ' ' CYS . . . . . 0.423 ' N ' HG22 ' A' ' 233' ' ' THR . 4.4 m -99.87 164.75 11.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 110.867 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.674 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 24.1 tp -57.44 157.88 6.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 236' ' ' ASP . . . . . 0.401 ' N ' ' HG ' ' A' ' 235' ' ' LEU . 0.4 OUTLIER -53.88 -26.91 27.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.046 179.953 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.474 ' HG2' HD23 ' A' ' 235' ' ' LEU . 0.0 OUTLIER -125.28 29.75 5.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.946 179.976 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.674 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -90.81 -178.13 5.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.193 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 3.6 tpt85 -150.09 139.42 21.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.591 ' NE2' HG12 ' A' ' 269' ' ' VAL . 0.8 OUTLIER -106.64 127.26 53.2 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.746 179.812 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -135.8 24.57 3.3 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.967 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.538 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -106.9 138.66 42.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.575 179.774 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -90.81 172.45 8.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.977 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.614 HG23 HG22 ' A' ' 269' ' ' VAL . 3.2 p -63.54 101.62 0.35 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.802 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 119.66 7.14 9.92 Favored Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.851 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.58 -174.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.723 0.297 . . . . 0.0 110.769 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.456 ' HA ' ' O ' ' A' ' 265' ' ' MET . 90.1 m-85 -129.85 142.64 50.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.881 0.372 . . . . 0.0 111.167 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.496 HG22 HG23 ' A' ' 267' ' ' ILE . 18.6 m -151.32 154.71 7.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.63 170.5 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.879 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.989 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.3 m-30 -99.1 142.47 30.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.464 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 1.4 m -100.39 -82.49 0.45 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.944 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.6 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -123.75 91.17 3.41 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.299 0.571 . . . . 0.0 109.793 179.575 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.989 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.6 t -114.39 138.05 45.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.568 -178.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -101.57 118.1 36.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.094 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.54 -62.43 0.54 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.858 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.622 ' HG3' HD23 ' A' ' 259' ' ' LEU . 23.3 tpp -88.54 57.45 4.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.167 0.508 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.593 HD13 ' H ' ' A' ' 257' ' ' ILE . 0.2 OUTLIER -77.09 -33.3 20.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.977 -179.355 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.417 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.5 OUTLIER -39.03 -34.7 0.17 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.983 -178.756 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.813 HD12 ' SD ' ' A' ' 265' ' ' MET . 2.8 mm? -74.76 -43.16 56.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.035 0.445 . . . . 0.0 110.385 179.61 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.471 ' ND2' ' O ' ' A' ' 250' ' ' PHE . 0.1 OUTLIER -50.49 -40.01 49.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.112 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -106.79 46.5 1.16 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 12.9 t -144.07 26.38 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.313 . . . . 0.0 111.085 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 58.14 166.41 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.835 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -61.4 144.9 98.53 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.421 2.081 . . . . 0.0 112.102 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.813 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.3 ptp -115.36 -171.85 2.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.51 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -99.81 149.74 23.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.761 0.315 . . . . 0.0 110.572 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 277' ' ' ILE . 1.2 pp -119.87 175.76 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.569 0.7 . . . . 0.0 112.441 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.703 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 2.2 tttp -146.18 131.27 18.32 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.6 -1.182 . . . . 0.0 108.475 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.614 HG22 HG23 ' A' ' 244' ' ' THR . 27.5 m -97.55 119.77 46.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.369 0.604 . . . . 0.0 111.537 -178.415 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.463 ' HA ' HD23 ' A' ' 270' ' ' LEU . 14.5 mt -95.48 -29.51 14.35 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.779 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 165.71 -159.81 33.1 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 113.108 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.84 112.66 1.88 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.81 2.34 . . . . 0.0 112.301 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 65.46 15.8 10.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.104 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -130.74 134.66 47.08 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.494 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.703 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.2 p90 -171.85 169.86 5.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.94 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.8 t -124.74 170.07 11.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 267' ' ' ILE . 2.6 pp -135.28 -179.87 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.928 179.725 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.712 ' O ' HD12 ' A' ' 277' ' ' ILE . 29.8 p -55.77 -172.47 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.005 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -62.14 119.68 9.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.647 HG21 HD11 ' A' ' 277' ' ' ILE . 10.0 t -135.33 30.74 3.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.956 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 35.3 t -97.37 -34.06 11.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.923 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -70.21 -25.39 63.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.055 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.604 ' CD2' HD21 ' A' ' 259' ' ' LEU . 20.7 m-85 -77.48 -170.66 1.86 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.918 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.27 -160.54 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.762 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -117.98 131.18 56.51 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.839 0.352 . . . . 0.0 110.715 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.47 ' CG ' HG12 ' A' ' 224' ' ' VAL . 17.3 t80 -57.82 131.05 49.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.983 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.0 mt -111.89 -64.85 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.031 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.06 164.84 36.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.724 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.81 151.73 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.199 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.549 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 141.06 122.29 1.84 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.721 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 26.8 mt -125.85 131.6 71.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.776 0.322 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.2 p -99.98 108.82 23.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.031 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 62.3 m -103.51 169.12 8.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.82 179.97 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.781 0.324 . . . . 0.0 110.85 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.8 p -137.79 152.08 48.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.951 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -137.34 147.82 45.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.06 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.733 ' HB3' HD13 ' A' ' 235' ' ' LEU . 0.0 OUTLIER -86.57 151.17 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.887 -179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 59.0 t -99.94 136.24 32.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.009 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.0 t -111.61 -34.27 6.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.974 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.4 mtp -163.99 153.75 14.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.992 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.41 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.0 p -157.14 135.61 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.05 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.3 140.75 29.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -86.75 74.06 9.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.861 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.4 t0 -122.09 -156.73 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.68 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 9.5 p-10 -158.91 91.18 2.01 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-O 120.516 0.198 . . . . 0.0 111.307 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 80.2 Cg_endo -76.06 169.72 73.71 Favored 'Cis proline' 0 C--N 1.348 0.527 0 C-N-CA 123.451 -1.479 . . . . 0.0 112.074 -0.108 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.21 151.8 17.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.501 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.9 t -99.98 114.69 39.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 0.0 111.109 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.509 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.3 p -106.15 157.1 6.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.108 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.471 ' N ' HG22 ' A' ' 232' ' ' VAL . 1.7 m -121.81 165.02 16.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.581 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.03 169.98 8.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.908 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.733 HD13 ' HB3' ' A' ' 220' ' ' MET . 0.6 OUTLIER -68.86 158.66 34.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.754 179.829 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -54.21 -33.53 58.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.044 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.544 ' HG3' HD23 ' A' ' 235' ' ' LEU . 0.1 OUTLIER -122.38 29.98 6.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.892 179.88 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.605 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -82.24 -175.66 5.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -148.45 107.62 3.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.952 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.563 ' CE1' HG12 ' A' ' 269' ' ' VAL . 34.5 t-80 -97.29 136.64 37.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.767 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -164.48 62.94 0.24 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.697 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.462 ' CD2' ' CE1' ' A' ' 240' ' ' HIS . 3.8 m-85 -122.6 143.81 49.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.817 0.341 . . . . 0.0 110.759 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.26 156.7 36.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 5.7 m -58.48 97.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.96 10.37 12.34 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.826 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -60.04 174.11 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.747 0.274 . . . . 0.0 110.724 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 265' ' ' MET . 54.7 m-85 -115.99 130.93 57.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.813 0.34 . . . . 0.0 111.066 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.507 HG21 ' CG2' ' A' ' 292' ' ' VAL . 15.0 m -144.96 159.36 13.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.019 0.438 . . . . 0.0 111.399 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.21 170.71 14.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.983 ' CD2' HG21 ' A' ' 253' ' ' VAL . 3.6 m-30 -99.08 145.49 27.07 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.967 -179.581 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -100.37 -86.6 0.39 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.088 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -119.33 88.32 2.91 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-O 120.535 0.207 . . . . 0.0 110.664 179.627 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.983 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.8 t -102.16 149.9 6.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.55 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.59 30.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.811 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 100.1 -73.29 0.45 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.431 -178.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.436 ' HE1' ' HA ' ' A' ' 285' ' ' ASP . 3.3 tpp -83.71 60.28 5.65 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.2 0.524 . . . . 0.0 110.215 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 16.1 pt -78.63 -33.0 16.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.498 -0.774 . . . . 0.0 112.001 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -38.32 -34.39 0.13 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.897 -178.669 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.493 HD22 ' N ' ' A' ' 259' ' ' LEU . 3.1 mm? -63.7 -50.25 69.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.979 0.419 . . . . 0.0 110.239 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.466 ' ND2' ' O ' ' A' ' 250' ' ' PHE . 9.9 t-20 -53.32 -34.73 58.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.998 179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -85.84 45.06 3.42 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.808 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 4.6 t -165.78 150.21 8.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.743 0.306 . . . . 0.0 110.767 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.64 159.95 0.5 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.849 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -53.35 149.13 30.62 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.449 2.099 . . . . 0.0 111.87 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 5.7 ptp -111.91 -173.04 2.16 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.476 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -99.75 155.32 17.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.762 0.315 . . . . 0.0 110.792 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.48 HG23 HG22 ' A' ' 248' ' ' VAL . 1.8 pp -123.47 169.64 14.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.5 0.667 . . . . 0.0 112.127 -179.625 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.607 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -142.36 125.44 16.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.825 -1.079 . . . . 0.0 108.818 178.707 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 269' ' ' VAL . 33.0 m -97.65 112.61 30.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.53 0.681 . . . . 0.0 111.499 -178.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.5 mt -90.77 -27.72 18.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.522 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -167.31 -166.24 26.06 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.582 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.55 -52.88 3.31 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.573 2.182 . . . . 0.0 111.857 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 20.8 m-85 -112.86 18.92 17.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.87 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.88 145.65 49.7 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.67 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.607 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.8 p90 -178.07 159.2 1.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -108.92 170.05 8.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.158 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.2 pt -131.2 -179.98 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.803 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.33 172.85 1.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.905 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.74 118.91 7.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.857 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.9 t -141.17 51.2 1.6 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.984 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 7.2 p -102.69 -22.08 14.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.171 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -96.51 31.4 2.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.748 0.309 . . . . 0.0 111.089 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -128.77 -175.47 3.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.777 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.04 125.76 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.717 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.436 ' HA ' ' HE1' ' A' ' 256' ' ' MET . 0.2 OUTLIER -42.56 149.17 0.19 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.553 -179.688 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -78.14 137.36 38.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.853 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.3 mt -119.11 -65.18 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.102 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -148.71 -174.48 4.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.44 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 55.76 169.02 0.07 OUTLIER Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.258 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.653 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 122.09 116.75 2.4 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.981 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 2.8 mp -128.79 127.31 66.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.729 0.3 . . . . 0.0 110.252 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.59 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.7 p -99.65 111.06 28.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.992 0.425 . . . . 0.0 111.369 -179.405 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -106.36 158.31 16.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.706 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.968 -179.828 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.6 tp . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.819 0.342 . . . . 0.0 110.828 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 55.9 p -158.0 160.51 37.57 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.025 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.422 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -159.11 170.08 22.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.079 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 6.6 mtm -105.88 157.04 17.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.8 t -109.51 130.6 62.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.836 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 22.9 t -109.94 -35.1 6.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.162 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.46 148.51 27.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.936 0.398 . . . . 0.0 111.067 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.447 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.3 p -158.31 137.04 3.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.969 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 144.63 29.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.01 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.2 ttmt -89.68 72.63 7.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.815 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.1 t70 -122.49 -160.77 0.9 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.858 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.404 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 8.0 p-10 -156.08 90.91 2.7 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.175 -179.687 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.406 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 83.6 Cg_endo -78.87 169.9 70.92 Favored 'Cis proline' 0 C--N 1.349 0.577 0 C-N-CA 123.495 -1.46 . . . . 0.0 112.179 -0.102 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.17 153.01 17.87 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.444 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.3 t -99.85 122.35 51.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.883 0.373 . . . . 0.0 111.0 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.587 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.8 p -114.34 153.81 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.165 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 273' ' ' TYR . 1.7 m -123.33 155.73 36.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.486 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.85 170.02 8.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.83 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.764 HD23 ' H ' ' A' ' 237' ' ' GLU . 0.3 OUTLIER -71.83 143.43 49.46 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.764 179.883 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -24.86 30.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.399 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.764 ' H ' HD23 ' A' ' 235' ' ' LEU . 6.5 mt-10 -100.54 -18.07 16.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.364 -179.856 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -79.57 168.01 19.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.824 0.345 . . . . 0.0 111.247 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.08 -167.83 1.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.864 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 9.3 p80 -171.96 155.33 3.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.847 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 179.26 54.33 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.872 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.435 ' HB2' HD11 ' A' ' 267' ' ' ILE . 1.1 m-85 -103.74 141.05 36.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.823 0.344 . . . . 0.0 110.575 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -71.69 153.44 42.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.7 m -57.08 97.44 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.12 9.44 15.67 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.746 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.17 -165.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.772 0.286 . . . . 0.0 110.545 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.563 ' HA ' ' O ' ' A' ' 265' ' ' MET . 86.9 m-85 -128.9 143.06 50.78 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.916 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.5 HG22 HG23 ' A' ' 267' ' ' ILE . 15.9 m -149.58 134.87 10.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.731 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.1 p -111.95 166.47 11.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.434 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 1.003 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.7 m-30 -99.85 143.93 29.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.02 -179.853 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 25.7 m -99.93 -86.28 0.39 Allowed 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.988 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.598 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -120.02 92.76 3.85 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.266 0.555 . . . . 0.0 110.006 179.896 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 1.003 HG21 ' CD2' ' A' ' 250' ' ' PHE . 4.6 t -111.43 139.02 37.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.383 -179.264 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -99.93 116.27 31.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.194 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.23 -65.53 0.5 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.629 -0.795 . . . . 0.0 111.897 -179.253 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 1.5 ttt -89.91 59.38 4.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.487 . . . . 0.0 110.534 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 15.0 pt -77.99 -33.94 18.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.67 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.7 mm100 -39.24 -34.64 0.2 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.81 -179.091 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.468 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.3 mm? -60.6 -49.54 77.12 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.884 0.373 . . . . 0.0 110.576 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -64.75 -34.82 79.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.835 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -93.1 39.38 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.496 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.5 t -159.26 34.25 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 0.0 110.716 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 61.88 168.41 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.597 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -61.46 -153.15 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 111.702 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.563 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.9 ptp -172.78 -175.89 1.36 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.805 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.58 147.37 25.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.656 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.644 HG22 HG22 ' A' ' 277' ' ' ILE . 1.2 pp -119.73 174.99 4.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.675 0.75 . . . . 0.0 112.482 -179.49 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.674 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.0 mttt -147.33 131.07 16.95 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.401 178.67 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.443 HG23 ' O ' ' A' ' 269' ' ' VAL . 34.6 m -97.54 122.33 49.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.433 0.635 . . . . 0.0 111.63 -178.279 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 270' ' ' LEU . 15.0 mt -96.77 -30.87 12.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.651 -179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.29 -171.81 42.09 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.245 -0.979 . . . . 0.0 113.214 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_exo -51.75 112.96 0.96 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.793 2.328 . . . . 0.0 112.475 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.532 ' O ' HG23 ' A' ' 233' ' ' THR . 67.9 m-85 64.71 19.41 11.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.054 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.5 p -133.0 139.35 47.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.459 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.674 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.3 p90 -176.97 166.48 2.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 -179.57 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -118.56 170.05 9.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.992 0.425 . . . . 0.0 111.161 -179.489 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.644 HG22 HG22 ' A' ' 267' ' ' ILE . 1.0 OUTLIER -134.62 -178.63 2.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.848 179.814 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 29.9 p -57.35 -177.55 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -72.56 124.06 24.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.428 ' HA ' ' CD1' ' A' ' 283' ' ' PHE . 8.6 t -137.69 51.88 1.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.971 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 96.5 p -88.37 -54.8 4.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -67.4 -19.62 65.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.192 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.428 ' CD1' ' HA ' ' A' ' 280' ' ' THR . 23.5 m-85 -59.49 -176.94 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.748 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 48.1 t -78.18 -175.81 4.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.895 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.79 127.25 48.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.907 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.495 ' CE1' HG13 ' A' ' 253' ' ' VAL . 65.4 t80 -72.21 140.97 48.99 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 26.1 mt -125.45 -63.51 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.09 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 5.7 mmt180 -153.94 175.56 13.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.655 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.48 149.65 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.424 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.06 115.47 1.19 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.768 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 18.4 mm -114.29 133.43 60.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 120.743 0.306 . . . . 0.0 110.821 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.55 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.1 p -99.89 114.65 38.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.035 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.3 m -119.56 154.44 33.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.051 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 12.9 tt0 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.962 179.898 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.851 0.357 . . . . 0.0 110.747 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 50.2 p -136.21 127.87 28.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -122.18 148.8 44.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.079 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -78.31 145.97 35.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.948 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.0 t -99.94 140.6 18.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 6.5 t -105.93 -29.66 9.83 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.016 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.81 158.69 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.027 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.481 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.6 p -160.93 122.08 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 65.0 p -84.31 143.25 29.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.037 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.42 56.34 3.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.473 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.6 t0 -91.61 -151.02 0.26 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.818 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.45 ' ND2' ' OD1' ' A' ' 279' ' ' ASP . 1.6 t30 -159.85 90.57 1.84 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-O 120.489 0.185 . . . . 0.0 111.372 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.473 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 71.8 Cg_endo -73.24 169.11 74.02 Favored 'Cis proline' 0 C--N 1.347 0.493 0 C-N-CA 123.244 -1.565 . . . . 0.0 111.836 -0.132 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -101.41 147.28 17.59 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.436 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.1 t -99.81 145.65 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.87 0.367 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.539 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.4 p -139.2 151.15 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.22 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.412 HG22 ' N ' ' A' ' 234' ' ' CYS . 63.6 m -122.5 161.01 24.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.412 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 234' ' ' CYS . . . . . 0.412 ' N ' HG22 ' A' ' 233' ' ' THR . 3.1 m -99.84 169.29 9.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.879 0.371 . . . . 0.0 110.86 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 2.9 tp -70.69 148.16 48.32 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.834 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -56.26 -30.83 62.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -106.36 50.76 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -178.35 152.79 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.25 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 20.7 ttm105 -135.89 155.41 50.34 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.857 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 23.4 p-80 -111.23 148.37 32.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.792 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -130.27 70.4 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.723 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.61 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.9 OUTLIER -126.55 141.54 51.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.766 0.317 . . . . 0.0 110.746 179.78 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.61 166.97 12.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.941 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 13.2 m -59.58 100.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.9 18.42 5.58 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.856 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.52 174.75 10.78 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.715 0.293 . . . . 0.0 110.767 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.4 m-85 -114.3 134.06 55.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 267' ' ' ILE . 19.1 m -138.24 153.44 26.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.053 0.454 . . . . 0.0 111.359 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 11.1 p -124.2 165.11 18.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.577 179.729 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 1.055 ' CD2' HG21 ' A' ' 253' ' ' VAL . 1.9 m-30 -99.8 141.3 32.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.045 -179.69 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.415 ' CB ' ' HB ' ' A' ' 291' ' ' ILE . 31.3 t -99.91 -101.65 0.23 Allowed 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.7 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' A' ' 290' ' ' GLY . 3.3 pt-20 -102.52 87.58 3.04 Favored 'General case' 0 C--O 1.223 -0.333 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 1.055 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.4 t -105.74 134.38 47.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.869 0.366 . . . . 0.0 111.786 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 18.8 mt-30 -99.9 116.02 30.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.777 178.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.35 -69.02 0.42 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.542 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.608 ' HG3' HD23 ' A' ' 259' ' ' LEU . 10.8 tpp -82.74 62.18 6.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.111 0.481 . . . . 0.0 110.235 179.193 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 37.2 pt -80.09 -33.34 14.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.274 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -38.64 -34.63 0.15 Allowed 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -178.556 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.792 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.2 mm? -72.8 -46.48 52.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.892 0.377 . . . . 0.0 110.703 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 24.2 t30 -57.57 -34.92 69.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.934 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.83 46.27 2.5 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.367 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.66 161.66 13.61 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.858 0.361 . . . . 0.0 110.898 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -54.99 156.83 6.44 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.682 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -57.38 157.11 23.17 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.508 2.138 . . . . 0.0 111.941 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.635 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -117.07 -171.19 1.98 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -99.48 153.17 19.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.755 0.312 . . . . 0.0 110.615 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 248' ' ' VAL . 1.7 pp -121.84 173.62 7.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.643 0.735 . . . . 0.0 112.312 -179.315 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 6.1 tttt -144.43 127.14 16.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.749 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.61 HG11 ' O ' ' A' ' 242' ' ' PHE . 15.5 m -97.75 115.18 37.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.436 0.636 . . . . 0.0 111.598 -178.484 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.418 HD23 ' HA ' ' A' ' 270' ' ' LEU . 15.7 mt -94.96 -28.14 15.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.49 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.53 -178.95 39.5 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.576 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -50.61 -48.5 20.21 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.635 2.223 . . . . 0.0 112.217 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 80.8 m-85 -115.95 15.09 16.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.112 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.92 147.72 45.66 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.692 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.611 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.5 p90 -178.35 159.59 1.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.725 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 9.4 t -114.3 170.13 8.53 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.975 0.417 . . . . 0.0 111.32 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.06 -179.17 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.929 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 179.96 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.934 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.45 ' OD1' ' ND2' ' A' ' 228' ' ' ASN . 68.2 m-20 -60.92 134.49 57.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 1.1 p -116.25 -19.92 10.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.372 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 93.0 p -52.92 -27.63 19.69 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 111.332 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -77.76 -25.87 49.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.142 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.792 ' CE2' HD11 ' A' ' 259' ' ' LEU . 13.1 m-85 -91.09 -168.3 2.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.976 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 8.5 p -83.4 -147.09 0.08 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.568 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -119.07 147.11 44.5 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.831 0.348 . . . . 0.0 110.844 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.453 ' CD2' ' CG1' ' A' ' 224' ' ' VAL . 44.5 t80 -80.02 141.49 35.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 30.3 mt -120.45 -59.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.998 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 4.3 mmt85 -163.32 176.63 9.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.408 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.02 155.55 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.935 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.64 119.24 1.77 Allowed Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.867 178.897 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.415 ' HB ' ' CB ' ' A' ' 251' ' ' SER . 10.9 mt -122.25 134.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.812 0.339 . . . . 0.0 110.557 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.608 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.4 p -99.73 107.35 20.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.252 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 71.0 m -115.12 123.22 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.771 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.445 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 4.5 tt0 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.025 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 3.9 tp . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.806 0.336 . . . . 0.0 110.857 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.5 p -162.34 107.7 1.21 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.48 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -100.08 153.77 18.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.978 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.686 ' SD ' HD22 ' A' ' 235' ' ' LEU . 38.8 mtt -90.68 145.77 24.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.935 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.424 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 98.8 t -99.87 136.62 30.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.815 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.1 t -105.95 -35.75 7.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.024 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -163.21 143.6 9.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.444 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.8 p -146.5 130.58 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.053 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 11.4 p -92.29 146.18 23.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.043 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.8 tttm -92.17 86.61 5.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.732 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.423 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.5 OUTLIER -132.96 -158.07 0.86 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.787 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 9.5 p-10 -158.73 91.87 2.01 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-O 120.503 0.192 . . . . 0.0 111.203 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.423 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 86.9 Cg_endo -75.86 169.52 74.28 Favored 'Cis proline' 0 C--N 1.347 0.498 0 C-N-CA 123.327 -1.53 . . . . 0.0 112.083 -0.265 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.97 146.9 17.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.471 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.9 t -99.85 126.87 53.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.973 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.566 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 3.8 p -121.09 155.32 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.275 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.438 ' N ' HG22 ' A' ' 232' ' ' VAL . 6.7 m -118.25 161.3 20.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.648 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.85 161.68 13.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.881 0.372 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.686 HD22 ' SD ' ' A' ' 220' ' ' MET . 8.2 tp -60.26 154.35 20.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.825 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -52.62 -27.12 15.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.032 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.497 ' HG3' HD23 ' A' ' 235' ' ' LEU . 3.2 pt-20 -128.48 37.37 4.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -94.77 -167.41 1.64 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.151 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.62 176.57 8.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.011 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -155.08 114.0 3.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.711 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -133.28 26.38 3.54 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.817 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 0.1 OUTLIER -106.4 135.32 48.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 179.799 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -89.85 174.34 7.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.071 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.28 101.33 0.3 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 113.97 15.86 8.27 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.732 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -76.4 -175.75 3.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.728 0.299 . . . . 0.0 110.653 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.483 ' HA ' ' O ' ' A' ' 265' ' ' MET . 63.1 m-85 -121.95 141.45 51.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.983 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.652 ' HB ' HG23 ' A' ' 292' ' ' VAL . 22.5 m -137.4 155.28 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.504 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.2 p -129.29 161.42 30.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.693 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.521 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.6 m-30 -99.85 137.11 38.76 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.999 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.408 ' CB ' ' HB ' ' A' ' 291' ' ' ILE . 72.4 m -99.77 -104.85 0.22 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.671 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.3 OUTLIER -100.18 87.47 3.46 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.687 HG22 ' CA ' ' A' ' 290' ' ' GLY . 21.8 t -109.91 138.1 39.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.883 0.373 . . . . 0.0 111.707 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -100.73 118.66 37.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.935 179.145 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.45 -65.57 0.48 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.673 -179.049 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.653 ' HG2' HD23 ' A' ' 259' ' ' LEU . 6.3 ttm -85.11 58.95 5.32 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.053 0.454 . . . . 0.0 110.357 179.209 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 4.8 pt -79.99 -33.36 14.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.037 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -39.06 -34.75 0.18 Allowed 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.653 HD23 ' HG2' ' A' ' 256' ' ' MET . 2.7 mm? -79.86 -42.09 24.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.872 0.368 . . . . 0.0 110.701 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 44.8 t30 -54.99 -34.88 63.78 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.063 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.88 28.22 13.41 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.293 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -142.24 165.08 28.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 110.753 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -58.04 166.26 2.14 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.595 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.48 158.39 53.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.363 2.042 . . . . 0.0 112.094 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.483 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.1 ptp -116.61 -174.17 2.52 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.517 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -99.56 151.26 21.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.719 0.295 . . . . 0.0 110.705 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.482 HG21 HG11 ' A' ' 248' ' ' VAL . 1.8 pp -122.22 174.96 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.612 0.72 . . . . 0.0 112.376 -179.542 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.625 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.3 tptt -146.86 130.71 17.1 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.576 -1.193 . . . . 0.0 108.5 178.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 269' ' ' VAL . 31.0 m -97.74 120.17 46.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.494 0.664 . . . . 0.0 111.585 -178.57 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.432 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.4 mt -98.2 -29.99 12.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.462 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.55 -175.3 36.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.524 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.85 -53.91 6.01 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.638 2.226 . . . . 0.0 112.387 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -112.77 23.22 13.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -133.23 148.45 52.0 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.751 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.625 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -175.33 167.3 3.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -117.58 170.15 8.98 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.473 HD12 HG21 ' A' ' 280' ' ' THR . 14.3 pt -133.09 -179.38 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.843 179.753 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.622 ' O ' HG23 ' A' ' 280' ' ' THR . 32.0 p -63.6 171.0 2.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.83 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.9 p-10 -58.73 112.22 1.55 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.966 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.622 HG23 ' O ' ' A' ' 278' ' ' CYS . 11.2 p -115.81 24.94 11.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.058 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 91.6 p -90.48 9.78 27.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.357 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 62.4 m-20 -111.38 -32.05 6.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.348 . . . . 0.0 110.801 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.552 ' CE2' HD11 ' A' ' 259' ' ' LEU . 12.3 m-85 -78.17 -165.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.802 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.96 -179.78 6.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.868 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -94.1 130.86 40.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.449 ' CE2' HG13 ' A' ' 253' ' ' VAL . 54.4 t80 -60.12 136.33 57.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.838 179.899 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 47.7 mt -115.73 -67.92 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.09 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -151.91 174.01 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.297 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.82 155.98 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.911 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.687 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 138.78 116.12 1.38 Allowed Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.901 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.469 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.1 mp -121.98 138.33 52.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.8 0.334 . . . . 0.0 110.573 179.599 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.652 HG23 ' HB ' ' A' ' 248' ' ' VAL . 13.4 p -99.7 124.95 53.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.517 -179.404 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -121.76 131.94 54.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.528 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.449 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.317 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.754 HD21 ' O ' ' A' ' 241' ' ' GLY . 1.1 mp . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.8 0.333 . . . . 0.0 110.747 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.87 150.11 22.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.086 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.45 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -156.63 154.19 29.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 3.4 mtt -95.23 164.19 12.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.112 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 36.5 t -114.72 140.43 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 4.3 t -114.42 -26.33 8.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.255 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -166.73 162.63 16.33 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.851 0.358 . . . . 0.0 111.042 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.444 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.8 p -168.02 151.64 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.176 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 40.1 p -113.93 150.53 33.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 7.5 ttmt -92.53 84.82 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.859 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.414 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.3 t0 -134.67 -160.16 1.03 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.823 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.403 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 14.1 p-10 -156.28 89.7 2.74 Favored Pre-proline 0 CA--C 1.531 0.233 0 CA-C-O 120.506 0.193 . . . . 0.0 111.371 -179.808 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.414 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 85.1 Cg_endo -79.36 169.45 71.28 Favored 'Cis proline' 0 C--N 1.349 0.591 0 C-N-CA 123.448 -1.48 . . . . 0.0 112.202 -0.078 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.65 155.24 16.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.391 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.5 t -99.87 111.09 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.9 0.381 . . . . 0.0 111.028 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.619 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.0 p -102.9 151.95 5.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.059 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.12 139.73 52.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.312 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 61.3 m -99.91 170.07 8.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.023 0.44 . . . . 0.0 111.133 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.638 HD23 ' H ' ' A' ' 237' ' ' GLU . 3.6 tt -49.68 161.27 0.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.923 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -42.05 -31.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.242 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.638 ' H ' HD23 ' A' ' 235' ' ' LEU . 7.3 pt-20 -165.5 51.1 0.1 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.816 0.341 . . . . 0.0 111.239 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -121.33 30.99 6.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.484 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -150.15 131.76 14.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.866 0.365 . . . . 0.0 111.121 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 170.04 90.16 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.852 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 241' ' ' GLY . . . . . 0.754 ' O ' HD21 ' A' ' 217' ' ' LEU . . . 179.79 -35.69 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.779 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.45 ' CD1' HD23 ' A' ' 217' ' ' LEU . 0.1 OUTLIER -85.63 134.5 33.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.922 0.391 . . . . 0.0 110.719 -179.86 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -105.61 171.39 7.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.83 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 62.8 m -53.06 102.03 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.37 25.36 4.7 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.593 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -93.89 166.61 12.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.777 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 265' ' ' MET . 94.6 m-85 -110.86 135.48 51.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.832 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.477 HG22 HG23 ' A' ' 267' ' ' ILE . 14.7 m -143.18 145.58 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.436 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 16.9 p -116.27 170.27 8.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.571 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 1.024 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.5 m-30 -99.46 139.61 34.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.938 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -104.73 -87.95 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.222 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -108.14 88.06 2.64 Favored 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 116.848 -0.16 . . . . 0.0 110.826 179.802 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 1.024 HG21 ' CD2' ' A' ' 250' ' ' PHE . 11.2 t -113.95 132.13 63.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.945 0.403 . . . . 0.0 111.803 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -99.77 115.89 30.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.925 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.94 -59.55 0.59 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.552 -178.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.538 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.5 ttm -92.14 54.63 2.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.107 0.479 . . . . 0.0 110.163 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.438 HG22 ' O ' ' A' ' 253' ' ' VAL . 33.2 pt -77.21 -33.55 20.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.763 -179.47 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -39.14 -34.66 0.18 Allowed 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.835 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.538 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.5 mm? -66.65 -47.11 73.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.915 0.388 . . . . 0.0 110.618 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -56.37 -34.78 66.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.909 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.54 46.24 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.318 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.7 t -167.61 163.83 14.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.749 0.309 . . . . 0.0 110.596 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.28 166.33 0.9 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.586 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -68.82 178.61 3.83 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.311 2.007 . . . . 0.0 112.013 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.532 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.0 OUTLIER -136.89 176.18 8.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.78 -179.957 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -99.49 125.07 45.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.477 HG23 HG22 ' A' ' 248' ' ' VAL . 1.4 pp -88.7 163.88 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.546 0.689 . . . . 0.0 112.229 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.655 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.5 OUTLIER -137.88 125.52 22.25 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.744 -1.117 . . . . 0.0 108.586 178.445 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.53 HG23 ' O ' ' A' ' 269' ' ' VAL . 30.3 m -97.29 114.77 35.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.547 0.689 . . . . 0.0 111.573 -178.287 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.0 mt -92.03 -28.45 17.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.494 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -161.59 -163.52 14.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.589 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.47 -48.67 4.15 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.572 2.182 . . . . 0.0 112.111 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -115.27 7.77 15.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.212 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.67 152.73 30.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.764 0.316 . . . . 0.0 110.676 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.655 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.1 p90 -179.78 162.44 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.821 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.7 t -118.64 169.99 9.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.07 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.517 HD11 ' CG2' ' A' ' 280' ' ' THR . 1.3 pp -134.22 -177.51 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.911 179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.406 ' HB2' ' HB2' ' A' ' 265' ' ' MET . 0.1 OUTLIER -54.88 -176.4 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 0.0 111.048 -179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -71.89 99.77 2.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.517 ' CG2' HD11 ' A' ' 277' ' ' ILE . 3.2 t -102.83 56.57 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 59.8 p -104.85 -26.38 12.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.988 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -96.54 31.53 2.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.98 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -126.08 -175.66 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.79 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.45 170.97 12.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.91 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -83.96 122.09 28.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.521 ' CE2' HG13 ' A' ' 253' ' ' VAL . 37.5 t80 -59.25 142.81 50.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.722 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 33.7 mt -119.92 -69.21 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.237 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.2 173.82 14.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.729 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.41 153.81 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.216 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.0 124.38 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.904 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 30.8 mt -123.04 134.45 66.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.789 0.328 . . . . 0.0 110.797 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.645 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.1 p -99.94 102.42 13.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.963 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.7 m -113.72 150.89 32.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.022 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.916 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.808 0.337 . . . . 0.0 110.7 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 52.8 p -124.47 146.91 48.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.04 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.658 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -128.38 167.05 17.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.001 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.423 ' SD ' HD22 ' A' ' 235' ' ' LEU . 11.6 mtt -94.09 148.56 22.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.923 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 49.1 t -99.91 139.32 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.953 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.3 t -106.77 -32.94 7.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.053 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.4 mtp -168.89 144.28 3.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.973 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.595 HG23 ' HB ' ' A' ' 232' ' ' VAL . 10.8 p -142.78 140.87 27.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.047 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 15.6 p -95.91 144.31 26.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.028 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.6 tttt -94.1 83.01 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.456 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.2 t0 -128.67 -158.17 0.87 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.738 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 10.4 p-10 -154.27 89.62 3.3 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-O 120.472 0.177 . . . . 0.0 111.336 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.456 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 93.7 Cg_endo -77.71 169.16 74.37 Favored 'Cis proline' 0 C--N 1.347 0.491 0 C-N-CA 123.437 -1.485 . . . . 0.0 111.996 -0.162 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.76 149.77 17.01 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.598 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.8 141.81 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.72 0.295 . . . . 0.0 110.905 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.61 HG13 ' CE1' ' A' ' 275' ' ' PHE . 5.3 p -134.43 157.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.246 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.482 ' N ' HG22 ' A' ' 232' ' ' VAL . 91.8 m -122.11 156.79 32.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.582 179.757 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.94 166.14 11.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.919 0.39 . . . . 0.0 110.721 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.556 HD23 ' HB2' ' A' ' 237' ' ' GLU . 2.5 tp -66.98 148.15 52.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.785 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -55.38 -26.73 43.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.556 ' HB2' HD23 ' A' ' 235' ' ' LEU . 3.2 mm-40 -98.05 -26.28 14.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.016 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.658 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -68.85 172.68 6.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.21 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -145.97 145.25 30.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.967 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.417 ' CE1' HG12 ' A' ' 269' ' ' VAL . 17.2 t-80 -98.36 135.65 39.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -137.09 27.82 2.86 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.525 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.576 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.1 OUTLIER -116.34 146.34 42.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.584 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -102.55 173.26 6.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.141 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.522 ' CG2' HG22 ' A' ' 269' ' ' VAL . 80.6 p -59.87 103.17 0.19 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.84 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 127.87 -17.78 6.0 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.531 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.09 -178.8 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.739 0.304 . . . . 0.0 110.808 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' A' ' 265' ' ' MET . 49.1 m-85 -122.99 162.08 23.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.07 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.622 ' HB ' HG23 ' A' ' 292' ' ' VAL . 28.8 m -151.74 155.06 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.5 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.8 p -129.66 159.31 36.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.501 179.627 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 1.028 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.3 m-30 -99.65 136.3 39.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.0 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 35.1 t -99.78 -92.49 0.28 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.543 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.73 87.77 2.61 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.468 179.499 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 1.028 HG21 ' CD2' ' A' ' 250' ' ' PHE . 3.9 t -106.3 137.59 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.939 0.4 . . . . 0.0 111.809 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -99.97 112.83 25.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.813 179.061 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.04 -60.28 0.56 Allowed Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.69 -178.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.646 ' HG2' HD23 ' A' ' 259' ' ' LEU . 3.0 ttm -87.88 59.15 5.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.144 0.497 . . . . 0.0 110.478 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.409 HG13 ' N ' ' A' ' 258' ' ' GLN . 28.7 pt -79.95 -33.57 14.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.922 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.409 ' N ' HG13 ' A' ' 257' ' ' ILE . 1.8 mp0 -38.89 -34.64 0.16 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.36 -0.382 . . . . 0.0 112.021 -178.86 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.849 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.1 mm? -73.01 -46.01 54.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.901 0.381 . . . . 0.0 110.634 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -56.23 -34.85 66.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.864 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.03 46.61 2.89 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.351 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -170.35 160.99 7.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -56.22 156.26 11.17 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.704 179.792 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.22 171.76 1.61 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.318 2.012 . . . . 0.0 112.062 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.674 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.6 OUTLIER -131.75 -174.36 3.39 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.628 -179.892 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -99.51 148.86 23.82 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.724 0.297 . . . . 0.0 110.698 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.561 HD11 ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -118.64 177.36 2.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.637 0.732 . . . . 0.0 112.376 -179.2 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.658 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.44 130.27 19.27 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.473 -1.239 . . . . 0.0 108.27 178.585 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.576 HG11 ' O ' ' A' ' 242' ' ' PHE . 31.9 m -97.49 117.61 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.588 0.708 . . . . 0.0 111.691 -178.243 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.464 ' HA ' HD23 ' A' ' 270' ' ' LEU . 14.3 mt -91.16 -28.31 17.95 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.846 -1.07 . . . . 0.0 110.545 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 162.64 -166.57 36.75 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.224 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -52.83 112.66 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.785 2.323 . . . . 0.0 112.506 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 62.4 m-85 63.07 18.02 10.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.107 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -128.42 136.95 51.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.454 179.668 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.658 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.77 160.64 1.94 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.806 -179.669 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.1 t -112.61 170.11 8.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.998 0.428 . . . . 0.0 111.179 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.558 HG22 HG22 ' A' ' 267' ' ' ILE . 0.9 OUTLIER -130.88 -179.5 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.919 179.83 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -55.5 -173.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.983 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -58.67 122.56 13.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.5 24.19 13.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.081 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 34.0 t -98.31 -26.6 14.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.031 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.404 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 17.8 t30 -97.41 34.83 1.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.969 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.849 ' CE2' HD11 ' A' ' 259' ' ' LEU . 24.5 m-85 -137.75 -175.5 4.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.852 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 28.7 t -86.35 176.98 7.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -85.62 132.2 34.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.964 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.467 ' CE2' HG13 ' A' ' 253' ' ' VAL . 16.3 t80 -77.49 144.44 37.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.66 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 35.7 mt -126.24 -68.43 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -146.91 -179.87 7.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.602 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.5 161.57 0.05 OUTLIER Glycine 0 C--N 1.332 0.324 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.27 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 132.56 116.22 1.73 Allowed Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.919 178.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 20.6 mt -118.66 133.92 63.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.798 0.332 . . . . 0.0 110.592 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.622 HG23 ' HB ' ' A' ' 248' ' ' VAL . 12.5 p -99.77 120.9 49.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.567 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 20.8 m -119.64 136.69 54.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.67 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.475 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 7.4 tt0 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.187 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.481 HD22 ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.938 0.399 . . . . 0.0 111.056 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.4 m -138.37 103.62 4.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.507 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.407 ' HB3' ' CZ ' ' A' ' 242' ' ' PHE . . . -102.12 157.7 16.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.973 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 34.1 mtp -101.73 167.98 9.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.9 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.39 128.6 70.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.992 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.6 t -104.31 -29.42 10.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -167.5 152.66 7.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.001 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.675 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.0 p -158.72 145.37 7.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 7.1 p -106.52 146.38 30.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.853 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.31 80.57 3.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.838 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.439 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.6 OUTLIER -126.22 -157.9 0.82 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -154.02 91.0 3.22 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.355 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.439 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 80.2 Cg_endo -76.3 169.07 75.44 Favored 'Cis proline' 0 C--N 1.348 0.516 0 C-N-CA 123.345 -1.523 . . . . 0.0 112.044 -0.143 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.9 151.9 17.59 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.494 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.1 t -99.98 145.86 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 111.135 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.7 p -142.7 150.2 18.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.097 -179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 273' ' ' TYR . 81.0 m -124.98 143.27 50.98 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.492 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 26.2 m -100.0 170.07 8.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.977 0.418 . . . . 0.0 111.054 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.736 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 1.2 tp -56.5 140.49 45.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.996 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -54.16 -26.7 29.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.984 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.6 mt-10 -114.84 34.49 4.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.736 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -166.41 76.44 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.204 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.48 HH22 HG12 ' A' ' 269' ' ' VAL . 38.3 tpt85 -150.06 87.07 1.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.828 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.481 ' O ' HD22 ' A' ' 217' ' ' LEU . 1.0 OUTLIER -178.8 106.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.107 179.986 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 162.11 -14.96 0.14 Allowed Glycine 0 CA--C 1.52 0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 113.562 179.615 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.568 ' HB2' HD13 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -131.75 132.19 43.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 117.17 0.485 . . . . 0.0 111.258 -179.41 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 243' ' ' GLU . . . . . 0.439 ' O ' HD11 ' A' ' 267' ' ' ILE . 0.7 OUTLIER -124.09 -169.58 1.99 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.778 179.863 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.2 m -61.32 106.07 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.068 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 100.67 26.94 7.79 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.684 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.55 169.75 8.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.765 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.481 ' HA ' ' O ' ' A' ' 265' ' ' MET . 76.8 m-85 -108.17 148.96 29.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.803 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.577 ' HB ' HG23 ' A' ' 292' ' ' VAL . 34.3 m -149.71 144.26 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 111.578 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.7 p -123.67 156.88 35.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.462 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.552 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.8 m-30 -99.52 139.09 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -99.7 -91.86 0.29 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.11 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.06 87.74 2.59 Favored 'General case' 0 C--O 1.224 -0.278 0 C-N-CA 121.21 -0.196 . . . . 0.0 110.822 179.703 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.704 HG22 ' CA ' ' A' ' 290' ' ' GLY . 21.2 t -109.31 143.69 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.871 0.367 . . . . 0.0 111.491 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -105.72 114.93 29.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.087 179.326 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.36 -64.07 0.52 Allowed Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.596 -179.049 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.903 ' HG2' HD23 ' A' ' 259' ' ' LEU . 31.1 ttm -88.91 54.54 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.165 0.507 . . . . 0.0 110.283 179.271 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.58 HG22 ' O ' ' A' ' 253' ' ' VAL . 2.2 pp -80.04 -33.76 14.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.928 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.463 ' HB3' ' CE2' ' A' ' 283' ' ' PHE . 5.7 mm-40 -39.07 -34.47 0.17 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 112.006 -178.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.903 HD23 ' HG2' ' A' ' 256' ' ' MET . 2.9 mm? -64.02 -48.36 76.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.839 0.352 . . . . 0.0 110.682 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.0 t-20 -55.66 -35.06 65.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.94 49.38 1.02 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.71 28.96 0.13 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.104 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 263' ' ' GLN . . . . . 0.402 ' HB3' ' HD2' ' A' ' 264' ' ' PRO . 6.7 mt-30 60.86 156.67 0.11 Allowed Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.525 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 263' ' ' GLN . 13.3 Cg_endo -55.77 176.33 0.17 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.35 2.033 . . . . 0.0 111.991 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.727 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.5 ptp -142.76 -173.9 4.01 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.632 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -99.39 137.33 38.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.345 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.568 HD13 ' HB2' ' A' ' 242' ' ' PHE . 1.1 pt -106.07 176.45 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.727 0.775 . . . . 0.0 112.472 -179.063 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.5 tttt -148.21 129.95 15.11 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.162 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.48 HG12 HH22 ' A' ' 239' ' ' ARG . 29.0 m -97.3 123.83 49.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.583 0.706 . . . . 0.0 111.423 -178.251 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 55.1 mt -96.41 -28.17 14.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.82 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 169.59 -160.78 34.06 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.417 -0.897 . . . . 0.0 113.14 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.7 111.49 1.92 Allowed 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.711 2.274 . . . . 0.0 112.294 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.824 ' O ' HG23 ' A' ' 233' ' ' THR . 16.2 m-85 71.1 9.37 6.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.23 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.6 p -124.52 145.0 49.81 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.754 0.312 . . . . 0.0 110.617 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.688 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -178.61 170.04 1.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.744 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.9 t -120.35 169.93 9.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.15 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.861 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.1 pp -138.54 -177.91 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.025 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.861 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -54.89 163.65 0.96 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.974 179.962 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -58.41 140.4 53.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.007 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 6.2 t -145.67 31.83 1.06 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 19.9 p -71.24 -46.8 60.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.89 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 12.1 t30 -76.98 -22.53 53.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.059 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.463 ' CE2' ' HB3' ' A' ' 258' ' ' GLN . 3.3 m-85 -67.83 -176.15 0.63 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.3 m -87.29 151.14 23.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.2 142.23 50.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.006 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.444 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 17.6 t80 -72.1 144.96 48.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.88 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.5 mt -124.49 -63.96 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.4 mmt180 -152.8 178.85 9.19 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.434 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.33 164.53 0.08 OUTLIER Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.283 -0.961 . . . . 0.0 112.085 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.704 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 127.89 114.97 1.86 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.038 178.815 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.651 HD12 ' N ' ' A' ' 291' ' ' ILE . 3.2 mp -121.56 131.06 73.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.79 0.329 . . . . 0.0 110.151 179.228 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.577 HG23 ' HB ' ' A' ' 248' ' ' VAL . 12.9 p -99.83 118.13 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.389 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 58.0 m -121.32 146.95 46.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 6.6 tm0? . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.962 -179.928 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.462 HD23 ' HA3' ' A' ' 241' ' ' GLY . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.352 . . . . 0.0 110.816 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.3 m -125.22 159.95 30.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.038 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.478 ' O ' HG23 ' A' ' 291' ' ' ILE . . . -143.96 162.0 37.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.031 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.72 146.39 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.065 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.0 137.59 27.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.91 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.6 t -108.84 -42.07 4.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -151.03 153.74 35.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.109 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.527 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.5 p -161.87 140.28 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.989 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 1.5 p -95.32 148.13 22.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.08 55.86 2.42 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.445 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -102.79 -158.32 0.66 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.708 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 7.0 p-10 -156.97 91.81 2.43 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 120.504 0.193 . . . . 0.0 111.307 -179.693 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.445 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 73.3 Cg_endo -75.54 169.6 74.08 Favored 'Cis proline' 0 C--N 1.348 0.529 0 C-N-CA 123.436 -1.485 . . . . 0.0 112.002 -0.182 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.54 17.47 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.558 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.98 124.69 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.885 0.374 . . . . 0.0 110.974 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.634 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.9 p -117.51 154.39 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.207 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.593 HG23 ' O ' ' A' ' 273' ' ' TYR . 1.3 m -120.57 155.51 33.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.567 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.0 m -99.94 162.58 12.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.844 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.498 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 4.3 tp -60.11 147.69 38.64 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.794 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -64.94 -26.95 68.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.084 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -95.47 -15.12 23.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.054 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.498 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -97.15 171.07 8.69 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.865 0.364 . . . . 0.0 111.172 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -135.1 160.58 37.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.923 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.5 p-80 -96.81 146.81 24.57 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 241' ' ' GLY . . . . . 0.462 ' HA3' HD23 ' A' ' 217' ' ' LEU . . . -138.12 25.05 2.93 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.69 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.452 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.4 OUTLIER -128.3 147.57 50.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.803 0.335 . . . . 0.0 110.732 179.875 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -105.13 174.78 5.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.972 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.6 t -62.49 97.23 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.82 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 137.44 -17.43 3.53 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.561 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.54 -171.24 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.753 0.311 . . . . 0.0 110.8 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -138.46 141.99 39.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.787 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.43 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 33.8 m -148.71 146.03 17.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.039 0.447 . . . . 0.0 111.545 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 21.3 p -112.73 170.08 8.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.33 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.863 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.2 m-30 -99.62 143.07 30.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.082 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -99.97 -86.64 0.38 Allowed 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.134 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.6 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.84 92.62 3.85 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-O 121.127 0.489 . . . . 0.0 110.008 179.997 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.863 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.0 t -109.15 149.03 12.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.349 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 288' ' ' ARG . 18.1 mm-40 -110.36 109.33 19.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.026 179.136 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.57 -53.47 0.83 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.6 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.496 ' HG2' HD23 ' A' ' 259' ' ' LEU . 11.0 ttm -95.63 54.03 1.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.988 0.423 . . . . 0.0 110.333 179.456 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 43.7 pt -80.03 -34.35 15.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.71 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.0 mp0 -39.63 -34.62 0.25 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.748 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.724 HD12 ' SD ' ' A' ' 265' ' ' MET . 2.3 mm? -61.02 -46.44 90.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.38 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 33.5 t30 -61.55 -36.43 80.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.893 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.5 42.93 2.26 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.362 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.4 t -156.06 31.06 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.817 0.342 . . . . 0.0 110.934 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 263' ' ' GLN . . . . . 0.421 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 0.4 OUTLIER 59.67 168.03 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.622 -179.898 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.421 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 28.9 Cg_endo -62.78 -173.03 0.13 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.372 2.048 . . . . 0.0 112.04 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.724 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.4 OUTLIER -156.03 -177.95 6.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.635 -179.917 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -99.85 135.07 41.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.611 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.74 HG22 HG22 ' A' ' 277' ' ' ILE . 1.0 OUTLIER -105.67 178.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 0.0 112.087 -179.604 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.679 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 29.7 mttt -149.01 131.02 15.3 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.659 178.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 10.5 m -97.33 121.8 48.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.473 0.654 . . . . 0.0 111.367 -178.494 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.435 ' HA ' HD23 ' A' ' 270' ' ' LEU . 15.3 mt -96.81 -30.29 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.868 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 164.76 -166.79 38.21 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.074 -1.06 . . . . 0.0 113.404 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_exo -51.16 112.93 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.897 2.398 . . . . 0.0 112.696 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.593 ' O ' HG23 ' A' ' 233' ' ' THR . 31.9 m-85 60.37 20.59 10.17 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.036 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -130.86 139.47 50.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.586 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.679 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.6 p90 -177.17 166.13 2.35 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.734 -179.615 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.9 t -114.83 170.08 8.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.997 0.427 . . . . 0.0 111.133 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.74 HG22 HG22 ' A' ' 267' ' ' ILE . 0.8 OUTLIER -138.56 -179.69 2.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.916 179.923 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.44 160.5 3.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.999 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 13.5 p30 -56.81 138.03 53.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.024 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.432 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.6 p -133.09 27.11 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.954 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -69.54 -30.31 68.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.95 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -84.94 -31.11 23.78 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.432 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 21.3 m-85 -70.1 -175.51 0.97 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.829 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.99 179.83 6.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -89.63 124.93 35.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.47 ' CE2' HG13 ' A' ' 253' ' ' VAL . 15.1 t80 -59.41 139.55 56.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.776 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.8 mt -117.33 -62.2 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.021 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.414 ' O ' ' HB2' ' A' ' 254' ' ' GLN . 2.8 mmt180 -158.2 175.8 13.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.581 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.52 151.44 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.443 -0.884 . . . . 0.0 112.408 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.23 115.66 1.31 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.642 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 219' ' ' ALA . 3.4 mp -113.24 134.12 56.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.797 0.332 . . . . 0.0 110.954 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.559 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.5 p -99.81 115.04 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.124 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.0 m -119.05 143.49 47.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.15 -179.665 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 . . . . . 0 C--N 1.331 -0.205 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.948 179.871 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.573 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.052 0 CA-C-O 120.785 0.326 . . . . 0.0 110.837 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.5 p -149.52 124.21 9.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.618 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -115.7 170.06 8.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.56 165.76 11.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.895 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.405 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 88.0 t -115.4 125.96 72.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 27.9 t -108.13 -31.15 8.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.27 135.1 7.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.624 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.5 p -142.86 150.26 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 66.3 p -107.42 148.16 29.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.1 tmtt? -99.28 70.18 1.73 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.2 t0 -120.52 -159.64 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 20.4 p30 -153.6 91.03 3.32 Favored Pre-proline 0 CA--C 1.531 0.234 0 CA-C-N 116.717 -0.22 . . . . 0.0 111.328 -179.645 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.401 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 88.1 Cg_endo -78.21 169.75 72.14 Favored 'Cis proline' 0 C--N 1.348 0.535 0 C-N-CA 123.422 -1.491 . . . . 0.0 112.112 -0.142 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.8 149.84 18.78 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.74 140.13 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.878 0.371 . . . . 0.0 110.999 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.624 ' HB ' HG23 ' A' ' 224' ' ' VAL . 5.3 p -134.6 158.04 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.264 -179.691 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.481 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.6 OUTLIER -125.01 160.26 29.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.516 179.697 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.83 167.31 10.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.874 0.369 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.748 HD23 ' HG2' ' A' ' 237' ' ' GLU . 1.0 OUTLIER -61.01 159.83 10.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.731 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -55.36 -29.87 59.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.014 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.748 ' HG2' HD23 ' A' ' 235' ' ' LEU . 1.8 pt-20 -117.48 32.35 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -78.19 -176.94 4.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.111 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 -144.16 148.02 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.943 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -96.99 141.84 29.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.822 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 241' ' ' GLY . . . . . 0.573 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -163.07 29.94 0.26 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.595 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.494 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.1 OUTLIER -147.74 130.56 16.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.752 0.31 . . . . 0.0 110.755 179.991 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.67 179.17 4.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.998 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.67 104.7 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.891 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 123.81 -13.64 8.11 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.757 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -67.67 172.98 4.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.809 0.338 . . . . 0.0 110.777 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -123.31 158.24 31.44 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.45 HG22 HG23 ' A' ' 267' ' ' ILE . 19.8 m -155.11 142.66 12.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.198 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 p -109.99 166.13 11.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.303 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.922 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.4 m-30 -99.66 152.24 20.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.863 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.414 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 61.3 m -108.5 -98.77 0.38 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.072 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.498 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.6 OUTLIER -107.09 88.25 2.69 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.592 0.234 . . . . 0.0 110.666 179.892 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.922 HG21 ' CD2' ' A' ' 250' ' ' PHE . 4.1 t -100.93 148.28 7.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.042 0.449 . . . . 0.0 111.625 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.41 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.0 OUTLIER -111.1 108.59 18.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.576 178.955 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.35 -59.92 0.55 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.276 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.804 ' HG2' HD23 ' A' ' 259' ' ' LEU . 21.2 ttm -92.19 54.88 2.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.177 0.513 . . . . 0.0 110.061 179.08 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 9.0 pt -79.25 -33.23 15.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.598 -0.728 . . . . 0.0 112.22 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.42 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 2.5 mm100 -38.64 -34.54 0.15 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.86 -178.677 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.804 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.3 mm? -67.69 -49.68 61.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.979 0.418 . . . . 0.0 110.474 179.403 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -58.65 -34.83 71.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.78 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.43 44.38 2.92 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.468 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.9 t -164.99 162.97 20.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.6 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -54.5 156.73 5.77 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.553 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -63.05 169.53 8.96 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.272 1.982 . . . . 0.0 111.821 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.508 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.0 OUTLIER -134.55 -175.59 3.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.856 -179.69 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -99.66 154.66 18.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.417 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.76 HG22 HG22 ' A' ' 277' ' ' ILE . 1.0 OUTLIER -123.02 174.94 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.66 0.743 . . . . 0.0 112.194 -179.271 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.589 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 32.1 mmtm -143.27 129.07 19.39 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.705 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 269' ' ' VAL . 22.3 m -97.54 112.91 30.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.473 0.654 . . . . 0.0 111.48 -178.455 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 270' ' ' LEU . 13.3 mt -91.02 -27.06 18.88 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.569 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.45 -164.01 21.21 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.627 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -63.34 -50.62 3.35 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.585 2.19 . . . . 0.0 112.027 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.408 ' O ' HG23 ' A' ' 233' ' ' THR . 57.5 m-85 -114.1 12.47 17.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.047 179.665 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -118.83 147.32 44.06 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.636 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.613 ' CZ ' HG13 ' A' ' 232' ' ' VAL . 10.4 p90 -177.95 158.54 1.26 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.959 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.0 t -112.84 170.12 8.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.647 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.865 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.5 pp -135.93 -179.01 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.986 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.865 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.1 OUTLIER -55.56 -178.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.891 -179.982 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -68.13 110.32 3.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.44 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.9 t -110.33 32.97 4.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.4 m -87.78 -22.6 24.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -95.43 38.0 1.17 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.984 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.457 ' CE2' HD11 ' A' ' 259' ' ' LEU . 25.0 m-85 -137.76 -171.48 3.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.728 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -88.85 -166.93 1.72 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.83 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -96.75 145.23 26.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -85.89 139.58 31.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.733 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.87 HG22 ' HD3' ' A' ' 288' ' ' ARG . 68.4 mt -124.27 -71.16 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.87 ' HD3' HG22 ' A' ' 287' ' ' ILE . 3.4 mpt_? -138.93 -178.22 5.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.421 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 57.16 160.59 0.02 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.389 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.585 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 128.99 102.11 1.04 Allowed Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.923 179.109 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.414 ' CD1' ' HB2' ' A' ' 251' ' ' SER . 4.5 mp -109.25 129.04 64.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.738 0.304 . . . . 0.0 110.193 179.363 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.618 HG13 ' HB3' ' A' ' 219' ' ' ALA . 14.3 p -99.61 108.83 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.051 0.453 . . . . 0.0 111.474 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -109.11 173.15 6.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.585 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 . . . . . 0 C--N 1.328 -0.368 0 CA-C-O 120.998 0.428 . . . . 0.0 111.032 -179.937 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.409 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.1 OUTLIER . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.748 0.308 . . . . 0.0 110.947 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 p -162.57 141.74 9.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.948 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.506 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -137.4 154.66 49.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.101 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.7 mmm -101.23 156.61 17.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 44.6 t -100.67 138.94 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.973 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 15.0 t -110.24 -39.99 4.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.898 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.3 mmm -169.37 138.96 2.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.496 HG23 ' HB ' ' A' ' 232' ' ' VAL . 8.2 p -139.26 151.17 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.08 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.8 p -102.06 148.08 25.82 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.005 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? -92.19 85.55 5.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.747 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.45 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.8 t0 -132.31 -154.79 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.758 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.423 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 31.4 p30 -159.04 90.77 2.0 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-O 120.445 0.164 . . . . 0.0 111.234 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.45 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 72.8 Cg_endo -74.96 169.03 75.65 Favored 'Cis proline' 0 C--N 1.348 0.543 0 C-N-CA 123.387 -1.505 . . . . 0.0 112.081 -0.282 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.42 151.31 17.14 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 16.9 t -99.9 131.86 46.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 111.074 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.584 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 6.3 p -128.87 158.02 41.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.253 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.489 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -123.77 164.59 18.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.686 179.703 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.3 m -99.94 168.81 9.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.871 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 5.8 tp -64.88 151.25 46.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -58.71 -26.23 63.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.197 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -114.91 32.23 6.16 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -133.07 155.91 48.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.256 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.29 158.6 33.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.883 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -92.31 145.16 24.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 241' ' ' GLY . . . . . 0.409 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -136.97 42.45 1.31 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.579 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.46 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.4 OUTLIER -137.99 138.92 39.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.779 0.323 . . . . 0.0 110.775 179.889 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -88.68 171.9 9.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.924 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.5 m -62.72 101.88 0.29 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.868 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 117.24 0.32 18.9 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.85 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.407 ' CB ' ' HB3' ' A' ' 242' ' ' PHE . 0.4 OUTLIER -65.6 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.658 0.266 . . . . 0.0 110.777 179.923 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.56 ' HA ' ' O ' ' A' ' 265' ' ' MET . 38.2 m-85 -134.41 143.37 47.55 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.896 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.471 HG22 ' CG2' ' A' ' 267' ' ' ILE . 3.4 m -149.99 142.33 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.609 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 25.1 p -115.79 165.91 12.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.452 179.469 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.925 ' CD2' HG21 ' A' ' 253' ' ' VAL . 3.9 m-30 -99.71 148.67 24.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.992 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.42 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 58.7 m -99.89 -90.32 0.31 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.09 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.496 ' O ' ' N ' ' A' ' 290' ' ' GLY . 5.1 pt-20 -113.22 88.03 2.74 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 120.519 0.199 . . . . 0.0 110.768 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.925 HG21 ' CD2' ' A' ' 250' ' ' PHE . 12.1 t -100.02 148.09 6.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 111.6 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.406 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.9 OUTLIER -116.24 110.45 18.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.77 -62.21 0.53 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.627 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.726 ' SD ' HG21 ' A' ' 280' ' ' THR . 25.9 ttm -91.79 61.78 4.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.227 0.537 . . . . 0.0 110.225 179.237 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 23.8 pt -80.03 -32.3 13.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.336 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.445 ' HB2' ' CE2' ' A' ' 283' ' ' PHE . 3.8 tp-100 -37.61 -34.44 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -178.124 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.767 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.1 mm? -67.65 -52.08 42.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.973 0.416 . . . . 0.0 110.414 179.457 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -64.61 -34.95 79.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.119 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.27 38.56 3.16 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.836 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 3.2 t -157.99 36.39 0.25 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.766 0.317 . . . . 0.0 111.08 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 263' ' ' GLN . . . . . 0.449 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 11.8 mt-30 59.05 169.16 0.07 OUTLIER Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.488 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.449 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 14.2 Cg_endo -56.97 -164.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.253 1.969 . . . . 0.0 111.593 179.812 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.767 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -169.44 -173.2 1.63 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.791 -179.713 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.55 143.23 30.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.407 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.471 ' CG2' HG22 ' A' ' 248' ' ' VAL . 1.1 pp -118.59 176.81 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.665 0.745 . . . . 0.0 112.388 -179.225 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.522 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -149.87 129.64 13.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.374 178.596 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 269' ' ' VAL . 29.3 m -97.59 112.11 28.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.507 0.67 . . . . 0.0 111.546 -178.255 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 40.4 mt -86.14 -29.78 23.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.476 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.9 -167.23 21.09 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -61.61 -43.52 26.54 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.508 2.139 . . . . 0.0 111.826 179.799 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -117.5 -5.1 11.23 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.049 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.3 p -100.2 148.26 24.81 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.841 0.353 . . . . 0.0 111.006 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.584 ' CZ ' HG13 ' A' ' 232' ' ' VAL . 6.7 p90 -178.58 162.62 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.566 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.409 ' HB3' ' HG3' ' A' ' 268' ' ' LYS . 3.7 t -112.39 167.37 10.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.993 0.425 . . . . 0.0 111.354 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.592 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.2 pp -137.9 -173.42 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.751 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.592 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -52.0 179.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.932 0.396 . . . . 0.0 111.159 -179.939 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -94.69 140.59 29.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.998 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.726 HG21 ' SD ' ' A' ' 256' ' ' MET . 11.7 t -151.21 39.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.78 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 28.9 t -73.93 -7.57 52.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.574 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -108.33 5.94 25.99 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.522 0.201 . . . . 0.0 111.53 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.445 ' CE2' ' HB2' ' A' ' 258' ' ' GLN . 0.2 OUTLIER -110.73 -158.44 0.65 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.594 0.235 . . . . 0.0 110.883 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 2.2 m -96.49 156.62 16.26 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.856 0.36 . . . . 0.0 111.077 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -74.29 151.9 39.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.416 ' HB2' HG13 ' A' ' 224' ' ' VAL . 32.1 t80 -58.86 124.48 19.99 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.927 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 29.5 mt -102.77 -47.79 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.005 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.406 ' O ' ' N ' ' A' ' 254' ' ' GLN . 1.1 mmt-85 -176.97 175.37 1.59 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.167 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 289' ' ' GLY . . . . . 0.406 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 60.39 158.42 0.06 OUTLIER Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.178 -1.01 . . . . 0.0 111.966 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 131.76 115.84 1.73 Allowed Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.723 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.7 mp -125.26 128.38 72.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.775 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.53 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.5 p -100.0 118.79 47.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.175 -179.685 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.9 m -129.58 168.19 16.79 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.121 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 . . . . . 0 C--N 1.33 -0.265 0 CA-C-O 121.104 0.478 . . . . 0.0 111.034 -179.993 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.806 0.336 . . . . 0.0 110.926 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 11.2 t -166.53 155.67 11.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.796 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.585 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -149.1 166.8 27.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.019 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.557 ' HE1' HD22 ' A' ' 235' ' ' LEU . 10.9 mtp -107.63 147.48 30.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 40.5 t -105.93 139.56 26.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.995 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 8.3 t -106.61 -31.9 8.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.976 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.1 ptm -168.16 163.94 13.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.968 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.644 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.6 p -162.36 118.62 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.037 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 76.9 p -76.48 140.59 41.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.828 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -90.17 68.15 7.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.795 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.408 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 5.0 t0 -106.69 -148.0 0.41 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.781 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -160.26 88.88 1.82 Allowed Pre-proline 0 CA--C 1.531 0.227 0 CA-C-O 120.536 0.208 . . . . 0.0 111.305 -179.67 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.408 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 97.2 Cg_endo -76.4 169.52 74.23 Favored 'Cis proline' 0 C--N 1.347 0.488 0 C-N-CA 123.27 -1.554 . . . . 0.0 111.945 -0.148 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -100.43 147.63 18.08 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.501 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.2 t -99.81 118.89 47.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.847 0.356 . . . . 0.0 111.058 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.644 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.8 p -110.37 154.24 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.058 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.403 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -128.32 161.8 28.56 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.691 179.731 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -100.04 169.63 9.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.92 0.39 . . . . 0.0 110.845 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.655 HD23 ' HG2' ' A' ' 237' ' ' GLU . 0.4 OUTLIER -60.26 161.6 6.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.794 179.891 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -54.63 -32.86 59.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.074 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.655 ' HG2' HD23 ' A' ' 235' ' ' LEU . 9.3 pt-20 -119.16 32.19 6.24 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.824 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -82.81 -175.74 5.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.082 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.41 136.12 23.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.933 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 2.8 t60 -105.9 137.24 44.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -149.83 26.73 1.17 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.674 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.618 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -114.52 138.39 50.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.813 0.339 . . . . 0.0 110.679 179.899 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 165.0 14.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.03 87.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 138.51 -12.72 3.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.718 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -57.46 -179.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.771 0.32 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.451 ' HA ' ' O ' ' A' ' 265' ' ' MET . 51.1 m-85 -125.07 146.77 49.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.057 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.436 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -148.47 147.86 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.173 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.5 p -115.95 167.88 10.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.623 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 1.038 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.6 m-30 -99.64 146.65 26.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.077 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.412 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 53.8 m -109.46 -89.94 0.47 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.77 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.2 87.59 2.56 Favored 'General case' 0 C--O 1.221 -0.397 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 179.416 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 1.038 HG21 ' CD2' ' A' ' 250' ' ' PHE . 8.0 t -109.47 134.98 49.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.92 0.39 . . . . 0.0 111.873 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 21.2 mt-30 -100.32 114.38 27.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.815 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.05 -58.6 0.61 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.672 -178.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.681 ' HG2' HD23 ' A' ' 259' ' ' LEU . 1.4 ttm -91.04 59.9 4.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.128 0.489 . . . . 0.0 110.359 179.358 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.6 pp -79.52 -33.37 15.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.985 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -39.1 -34.61 0.18 Allowed 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.876 -178.823 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.857 HD11 ' CE2' ' A' ' 283' ' ' PHE . 2.8 mm? -77.76 -44.45 27.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.87 0.366 . . . . 0.0 110.504 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -60.03 -34.84 73.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.851 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.52 42.92 2.38 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.324 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -165.42 171.14 13.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.803 0.335 . . . . 0.0 110.764 -179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 11.3 mt-30 -57.63 167.7 1.29 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.64 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -66.5 -166.68 0.11 Allowed 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.38 2.053 . . . . 0.0 112.005 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.59 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -156.07 -175.84 5.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.575 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -99.71 148.08 24.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.771 0.319 . . . . 0.0 110.628 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.707 HG22 HG22 ' A' ' 277' ' ' ILE . 1.6 pp -119.76 172.84 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.528 0.68 . . . . 0.0 112.263 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.627 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.3 mmtm -143.47 127.97 17.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 114.71 -1.132 . . . . 0.0 108.736 178.864 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.618 HG11 ' O ' ' A' ' 242' ' ' PHE . 35.9 m -97.6 114.56 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.471 0.653 . . . . 0.0 111.503 -178.556 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.402 HD23 ' HA ' ' A' ' 270' ' ' LEU . 16.1 mt -92.5 -28.72 16.63 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.567 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.76 -163.66 18.38 Favored Glycine 0 N--CA 1.453 -0.202 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.593 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.08 -49.29 3.95 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.639 2.226 . . . . 0.0 111.992 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -114.82 11.58 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.101 179.773 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.95 148.54 42.84 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.856 0.36 . . . . 0.0 110.704 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.627 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.9 p90 -177.5 161.73 1.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 12.2 t -123.38 170.27 10.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.01 0.433 . . . . 0.0 111.218 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.707 HG22 HG22 ' A' ' 267' ' ' ILE . 1.6 pp -133.9 -179.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.844 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.484 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.4 OUTLIER -56.42 -170.1 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.076 -179.915 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -55.8 132.69 50.03 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.026 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.57 7.24 8.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.404 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -86.04 5.28 34.21 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.749 -0.205 . . . . 0.0 111.463 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -111.67 -23.48 10.63 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.684 0.278 . . . . 0.0 111.177 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.857 ' CE2' HD11 ' A' ' 259' ' ' LEU . 29.5 m-85 -85.43 -170.41 3.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 64.1 m -88.56 -175.43 4.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.86 137.27 32.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.582 ' CE1' HG13 ' A' ' 253' ' ' VAL . 70.0 t80 -78.13 146.61 35.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.773 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 27.1 mt -125.02 -67.87 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.186 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.55 176.43 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.559 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.96 158.25 0.05 OUTLIER Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.287 -0.958 . . . . 0.0 112.068 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.13 108.83 0.9 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.98 178.66 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.412 ' HB ' ' HB2' ' A' ' 251' ' ' SER . 14.8 mm -106.5 130.98 57.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.727 0.299 . . . . 0.0 110.479 179.505 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.597 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.5 p -99.72 109.75 25.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.916 0.389 . . . . 0.0 111.322 -179.59 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -111.77 156.34 22.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.654 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.032 -179.799 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.892 0.377 . . . . 0.0 111.203 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -95.85 -178.82 4.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -83.62 -27.91 37.32 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.481 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.59 168.41 1.65 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.8 0.333 . . . . 0.0 110.831 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 -152.83 29.14 0.52 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.039 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 206' ' ' MET . . . . . 0.495 ' O ' HG13 ' A' ' 207' ' ' VAL . 0.4 OUTLIER 57.67 -175.72 0.07 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.023 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.495 HG13 ' O ' ' A' ' 206' ' ' MET . 11.9 m -158.12 34.31 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.112 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -81.45 -171.14 3.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.853 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 50.6 p -98.86 179.32 4.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -66.79 134.28 51.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.838 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.46 -67.6 0.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 15.5 p30 -66.72 165.68 14.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.881 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 135.39 131.97 3.1 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.496 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 60.35 179.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.784 0.326 . . . . 0.0 110.9 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 17.0 mt-30 60.01 160.12 0.1 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -52.51 174.11 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.531 2.154 . . . . 0.0 112.264 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.4 tp -98.53 154.2 18.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.889 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 90.1 p -151.56 167.05 29.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.04 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.703 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -157.15 164.7 37.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.962 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -109.89 154.55 22.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.013 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 90.3 t -99.92 123.2 52.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.794 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 31.2 t -100.14 -31.45 11.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.118 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -169.14 135.12 1.65 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.675 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.0 p -142.56 149.37 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.027 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 81.6 p -107.34 149.46 27.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.921 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -95.91 79.48 3.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.412 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -129.07 -161.43 1.11 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.789 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.442 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 5.4 p-10 -152.49 87.51 4.15 Favored Pre-proline 0 C--N 1.331 -0.203 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.292 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 74.6 Cg_endo -82.7 169.6 59.52 Favored 'Cis proline' 0 C--N 1.348 0.513 0 C-N-CA 123.49 -1.462 . . . . 0.0 112.271 -0.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -111.9 153.01 17.57 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.24 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.87 121.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.83 0.348 . . . . 0.0 111.018 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 224' ' ' VAL . 3.3 p -117.27 156.68 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.133 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.453 ' N ' HG22 ' A' ' 232' ' ' VAL . 87.8 m -122.2 160.6 24.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.564 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 234' ' ' CYS . . . . . 0.407 ' N ' HG22 ' A' ' 233' ' ' THR . 1.6 m -99.9 170.04 8.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.816 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.67 140.93 36.88 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.848 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -53.6 -36.02 61.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.39 . . . . 0.0 110.823 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -94.09 44.85 1.13 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.074 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -159.85 159.59 32.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.218 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -127.47 146.59 50.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.007 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -101.28 149.42 24.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.776 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -143.83 43.74 0.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.688 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.696 ' O ' HG11 ' A' ' 269' ' ' VAL . 1.6 m-85 -127.1 145.32 50.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.712 0.291 . . . . 0.0 110.651 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -108.65 173.29 6.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.974 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.526 HG22 ' HG3' ' A' ' 268' ' ' LYS . 0.7 OUTLIER -59.58 94.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 -179.967 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.62 -15.58 3.84 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.714 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -63.13 -178.36 0.23 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.738 0.304 . . . . 0.0 110.859 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 265' ' ' MET . 33.6 m-85 -131.79 146.46 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.985 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.525 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -144.85 150.43 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.282 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.0 p -120.86 164.28 16.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.74 ' HD2' HG21 ' A' ' 253' ' ' VAL . 4.2 m-30 -99.74 143.59 29.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.75 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.418 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 58.1 m -99.97 -90.77 0.31 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.408 -179.702 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.5 OUTLIER -116.3 88.75 2.96 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 120.505 0.193 . . . . 0.0 111.109 -179.851 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.744 HG22 ' HA2' ' A' ' 290' ' ' GLY . 2.4 t -100.24 155.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.977 0.418 . . . . 0.0 111.268 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -111.61 102.59 10.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.901 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.7 -53.71 0.81 Allowed Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.553 -178.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.638 ' HG2' HD23 ' A' ' 259' ' ' LEU . 39.2 ttm -93.04 49.35 1.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.982 0.42 . . . . 0.0 110.483 179.367 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -79.19 -34.01 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.78 -179.557 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.6 mm-40 -39.33 -34.74 0.22 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.936 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.678 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.8 mm? -59.7 -45.28 92.58 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.325 . . . . 0.0 110.792 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 47.3 t30 -64.02 -34.93 79.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.24 39.6 2.79 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.292 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.3 t -151.54 30.53 0.6 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.686 0.279 . . . . 0.0 110.945 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 61.31 156.16 0.11 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.545 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.527 ' HG3' HG11 ' A' ' 295' ' ' VAL . 20.7 Cg_endo -60.1 168.06 6.57 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.37 2.046 . . . . 0.0 112.035 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.678 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.8 OUTLIER -132.67 -175.24 3.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.769 -179.859 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -99.67 134.85 41.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.543 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.525 HG23 HG22 ' A' ' 248' ' ' VAL . 1.0 OUTLIER -103.8 172.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.627 0.727 . . . . 0.0 112.311 -179.239 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.606 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 10.0 ttpp -140.34 127.42 20.91 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.641 178.609 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.696 HG11 ' O ' ' A' ' 242' ' ' PHE . 6.4 m -97.58 115.0 36.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 0.0 111.709 -178.297 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 51.1 mt -92.93 -28.83 16.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.385 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.23 -167.92 26.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.543 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.98 -49.6 9.38 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.534 2.156 . . . . 0.0 111.921 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -115.06 14.15 17.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.915 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.7 p -120.04 147.28 45.01 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.623 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.606 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.9 p90 -177.87 161.74 1.62 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.98 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.66 170.08 9.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.946 0.403 . . . . 0.0 111.113 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.725 HD12 ' O ' ' A' ' 278' ' ' CYS . 1.7 pp -133.41 176.89 7.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.931 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.725 ' O ' HD12 ' A' ' 277' ' ' ILE . 31.0 p -58.83 -177.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.922 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -66.63 110.12 3.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 10.2 t -108.03 31.71 5.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.6 m -87.12 -15.49 38.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.194 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.06 33.6 1.7 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.771 0.319 . . . . 0.0 111.021 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -144.05 175.64 9.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.797 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.61 174.27 6.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.729 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -83.56 137.11 33.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -64.97 121.32 14.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.866 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 23.0 mt -105.99 -55.59 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 6.9 mtt180 -158.98 -171.33 3.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.378 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 53.34 177.62 0.08 OUTLIER Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.344 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.744 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 116.05 106.01 2.5 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.98 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' A' ' 251' ' ' SER . 7.6 mm -114.58 129.69 70.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.703 HG13 ' HB3' ' A' ' 219' ' ' ALA . 9.1 p -99.74 117.89 45.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.982 0.42 . . . . 0.0 111.484 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -120.45 175.72 5.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.629 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.64 99.6 9.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.527 HG11 ' HG3' ' A' ' 264' ' ' PRO . 14.8 m -59.41 162.03 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.191 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.8 68.68 1.31 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.81 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.487 HG13 HG23 ' A' ' 295' ' ' VAL . 31.1 m -59.65 152.26 57.92 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.206 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -47.53 134.09 21.08 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.774 2.316 . . . . 0.0 112.403 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 14.5 tttt -154.52 36.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.863 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 3.9 tttm -114.77 177.02 4.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.77 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.1 pt -78.6 76.99 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.095 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 1.4 m -95.16 125.36 39.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -135.74 160.12 39.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.988 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 61.3 mttm -132.28 142.18 49.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.83 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -139.06 97.51 3.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.025 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.472 ' N ' ' HD2' ' A' ' 307' ' ' PRO . 0.4 OUTLIER -77.04 -49.36 2.44 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.229 179.965 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.472 ' HD2' ' N ' ' A' ' 306' ' ' LEU . 87.5 Cg_endo -78.84 177.6 8.52 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.32 2.013 . . . . 0.0 112.352 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -111.12 135.28 51.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.197 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 72.4 m -154.13 103.03 2.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 4.0 mt -99.33 -65.64 0.95 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.897 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 5.7 m -128.2 124.49 62.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.834 -179.981 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.407 0 CA-C-O 120.815 0.341 . . . . 0.0 111.19 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -128.71 32.77 4.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.829 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -173.92 143.61 7.14 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.532 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -124.51 66.02 1.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.922 0.391 . . . . 0.0 110.869 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -84.99 173.55 10.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.917 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -128.99 147.05 50.83 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -121.09 -42.32 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.089 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -68.72 119.12 12.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.838 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 209' ' ' THR . 4.2 t -138.03 92.28 2.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.891 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -157.76 147.69 20.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.893 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 35.4 p -131.42 31.39 4.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.935 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -111.03 161.7 15.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 121.1 -130.88 8.4 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.394 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -81.58 111.14 17.61 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.81 0.338 . . . . 0.0 110.872 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.49 ' N ' ' HD2' ' A' ' 216' ' ' PRO . 3.4 mt-30 -67.23 -49.48 44.16 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.236 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.49 ' HD2' ' N ' ' A' ' 215' ' ' GLN . 71.6 Cg_endo -77.33 138.56 17.84 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.283 1.989 . . . . 0.0 112.39 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.747 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.3 OUTLIER -147.01 167.76 23.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 2.2 m -157.6 134.42 9.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.428 ' HB2' ' O ' ' A' ' 239' ' ' ARG . . . -136.71 159.6 41.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.038 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.2 mtt -105.09 155.36 19.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 45.2 t -100.67 137.02 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.002 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.2 t -112.18 -37.8 4.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.72 150.77 25.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.92 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.438 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.2 p -159.96 142.79 5.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.047 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 51.5 p -106.62 146.33 30.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.948 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 31.1 tttt -90.72 64.57 5.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.437 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -106.32 -156.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.811 -179.92 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.458 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 9.3 t-20 -157.07 89.52 2.55 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.567 0.223 . . . . 0.0 111.389 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 91.2 Cg_endo -77.69 169.12 74.5 Favored 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 123.347 -1.522 . . . . 0.0 112.012 -0.273 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.72 148.67 16.54 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.429 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 30.7 t -99.92 120.48 49.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.907 0.384 . . . . 0.0 111.029 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.523 HG13 ' CE2' ' A' ' 275' ' ' PHE . 2.6 p -112.99 155.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.12 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.439 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -119.83 162.23 19.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.63 179.817 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.9 m -99.95 166.58 10.99 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.954 0.407 . . . . 0.0 110.935 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.812 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 11.2 tp -59.28 153.66 18.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.701 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -51.68 -27.12 10.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.095 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.481 ' HG3' HD23 ' A' ' 235' ' ' LEU . 2.5 pt-20 -134.79 42.69 2.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.853 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.812 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -91.32 -176.65 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.428 ' O ' ' HB2' ' A' ' 219' ' ' ALA . 1.3 tpm_? -130.62 135.46 47.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 38.5 p-80 -109.66 110.67 21.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 241' ' ' GLY . . . . . 0.747 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -126.13 -0.48 7.53 Favored Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.991 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.401 ' HB3' ' HB3' ' A' ' 246' ' ' ASP . 1.5 m-85 -80.45 139.67 36.33 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.866 0.365 . . . . 0.0 110.705 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 243' ' ' GLU . . . . . 0.449 ' O ' HD11 ' A' ' 267' ' ' ILE . 0.8 OUTLIER -92.49 169.4 10.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.928 -179.919 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 4.6 m -59.83 91.57 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.85 23.98 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.685 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.401 ' HB3' ' HB3' ' A' ' 242' ' ' PHE . 1.5 t70 -78.74 170.03 17.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 110.879 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 47.9 m-85 -104.36 122.39 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.903 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 267' ' ' ILE . 30.2 m -128.07 143.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.345 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.2 p -119.82 165.85 14.04 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.739 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.509 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.0 m-30 -99.58 145.24 27.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.96 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.402 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 0.5 OUTLIER -105.0 -88.29 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.988 -179.93 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.606 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.63 90.99 3.45 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.233 0.54 . . . . 0.0 109.769 179.765 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.754 HG22 ' CA ' ' A' ' 290' ' ' GLY . 17.3 t -116.08 139.26 43.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.607 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 119.68 38.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.219 179.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.09 -65.67 0.5 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.778 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.67 ' HG2' HD23 ' A' ' 259' ' ' LEU . 6.4 ttm -85.75 59.73 5.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.089 0.471 . . . . 0.0 110.396 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.41 HG13 ' N ' ' A' ' 258' ' ' GLN . 29.9 pt -80.14 -33.39 14.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.977 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.416 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.1 OUTLIER -38.94 -34.72 0.17 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.897 -178.87 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.838 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.1 mm? -75.15 -44.71 45.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.838 0.351 . . . . 0.0 110.614 179.587 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -57.45 -34.89 69.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.892 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.71 38.64 3.07 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.43 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -158.46 165.2 35.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.755 0.312 . . . . 0.0 110.759 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -56.55 167.66 0.94 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.669 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.55 ' HG3' HG11 ' A' ' 295' ' ' VAL . 48.7 Cg_endo -67.98 169.37 16.58 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.335 2.023 . . . . 0.0 111.999 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.638 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.7 OUTLIER -129.39 -176.99 4.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.716 179.929 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.37 140.7 33.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.757 0.313 . . . . 0.0 110.649 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.449 HD11 ' O ' ' A' ' 243' ' ' GLU . 1.2 pp -106.77 171.91 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.55 0.691 . . . . 0.0 112.212 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.622 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -143.05 125.58 15.78 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.617 178.797 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.66 115.53 37.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.598 0.714 . . . . 0.0 111.43 -178.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 50.1 mt -94.27 -27.7 15.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.789 -1.096 . . . . 0.0 110.503 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -163.9 -170.67 29.14 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -62.96 -35.34 66.99 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.52 2.147 . . . . 0.0 112.056 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -123.93 2.44 8.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.169 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -112.24 149.94 31.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.798 0.333 . . . . 0.0 110.791 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.622 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.9 p90 -177.44 162.27 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.767 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 5.1 t -118.19 170.17 9.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.933 0.397 . . . . 0.0 111.332 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.456 HD12 ' O ' ' A' ' 278' ' ' CYS . 1.2 pp -133.95 179.3 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.947 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.456 ' O ' HD12 ' A' ' 277' ' ' ILE . 1.2 m -58.51 -173.41 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.9 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.407 ' O ' ' CE2' ' A' ' 283' ' ' PHE . 1.7 m-20 -54.12 126.58 23.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.98 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.541 HG22 ' CE ' ' A' ' 256' ' ' MET . 0.3 OUTLIER -110.02 -30.15 7.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.968 -179.898 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 2.9 m -59.44 -30.49 68.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.019 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -71.8 -31.01 66.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.998 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.838 ' CE2' HD11 ' A' ' 259' ' ' LEU . 50.7 m-85 -89.51 -172.92 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 75.4 m -78.63 -178.32 5.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.993 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -93.26 135.39 34.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.855 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.722 ' CE2' HG13 ' A' ' 253' ' ' VAL . 39.3 t80 -74.94 138.09 42.1 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.746 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.2 mt -117.05 -66.81 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.197 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 -152.65 170.68 19.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.664 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.77 149.72 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.143 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.754 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 142.81 116.64 1.18 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.801 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.437 HD12 ' N ' ' A' ' 291' ' ' ILE . 3.9 mp -117.44 133.56 63.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.755 0.312 . . . . 0.0 110.711 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.481 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.8 p -99.88 122.08 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.219 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.7 m -131.48 158.19 41.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.94 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -90.5 118.81 30.25 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.55 HG11 ' HG3' ' A' ' 264' ' ' PRO . 3.5 m -57.75 122.32 7.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.27 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -98.29 -43.51 6.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.924 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.431 HG13 ' HD2' ' A' ' 298' ' ' PRO . 34.3 t 65.14 136.14 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.037 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.431 ' HD2' HG13 ' A' ' 297' ' ' VAL . 55.5 Cg_endo -69.72 97.53 0.64 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 122.511 2.14 . . . . 0.0 112.274 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 8.7 tttt -99.13 -24.36 14.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.101 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 7.1 tmtm? 65.0 32.05 10.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.921 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 19.0 tt -96.41 128.58 47.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.097 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 6.9 p 62.26 117.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.947 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -154.07 33.05 0.43 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.921 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -142.88 -70.9 0.32 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.828 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 51.4 p -143.47 33.26 1.3 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.962 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.5 mp 61.02 56.11 3.44 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.939 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -78.55 -44.01 0.16 Allowed 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.684 2.256 . . . . 0.0 112.313 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -98.51 110.11 22.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.106 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.1 m -146.88 127.71 14.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER 61.67 174.48 0.12 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.838 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.2 p -64.67 138.29 23.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.07 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.233 -0.889 . . . . 0.0 110.869 179.995 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.486 1.364 0 CA-C-O 120.856 0.36 . . . . 0.0 111.187 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 202' ' ' PHE . . . . . 0.4 ' O ' ' CD1' ' A' ' 202' ' ' PHE . 15.0 p90 -161.37 117.66 2.17 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.909 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -177.2 36.05 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.457 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -63.27 -176.2 0.13 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.814 0.34 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -129.3 119.1 23.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.855 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -89.38 113.39 24.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.883 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 207' ' ' VAL . 7.4 p -146.08 95.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.077 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 7.4 mt -139.58 86.71 2.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.84 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.438 HG22 ' H ' ' A' ' 210' ' ' ASP . 0.2 OUTLIER 60.18 179.66 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 180.0 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.438 ' H ' HG22 ' A' ' 209' ' ' THR . 5.3 t0 -113.23 -36.22 5.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.92 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 3.6 m 60.67 90.77 0.06 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -81.06 112.93 18.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.931 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -92.17 -66.81 1.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.471 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 62.1 mt-10 -96.88 174.27 6.88 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.81 0.338 . . . . 0.0 110.933 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.402 ' CB ' ' CD ' ' A' ' 216' ' ' PRO . 0.4 OUTLIER -68.17 -60.82 4.63 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.931 179.943 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.402 ' CD ' ' CB ' ' A' ' 215' ' ' GLN . 61.3 Cg_endo -73.12 -168.68 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.468 2.112 . . . . 0.0 112.341 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.745 HD23 ' CE1' ' A' ' 242' ' ' PHE . 29.7 tp -160.04 141.97 12.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.889 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 13.7 t -147.42 154.71 41.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.834 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.44 155.98 40.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.043 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -94.26 143.44 26.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 39.1 t -99.92 145.04 11.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.058 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 38.7 t -112.79 -32.96 6.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.073 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 14.7 ptm -169.5 159.05 8.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.559 HG12 ' CG ' ' A' ' 286' ' ' TYR . 8.5 p -158.87 149.21 7.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.062 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 63.3 p -99.46 147.56 25.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.948 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.04 81.44 3.7 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.435 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.6 t0 -127.76 -157.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.796 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.464 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 1.6 p30 -154.68 90.59 3.09 Favored Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 -179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 97.3 Cg_endo -77.13 169.39 74.38 Favored 'Cis proline' 0 C--N 1.347 0.477 0 C-N-CA 123.369 -1.513 . . . . 0.0 112.011 -0.272 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.76 151.3 17.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.45 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.6 t -99.87 140.25 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.843 0.354 . . . . 0.0 111.008 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.574 HG13 ' CE1' ' A' ' 275' ' ' PHE . 3.3 p -130.88 151.96 36.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.141 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 4.9 m -114.19 158.12 21.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.67 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.1 m -99.97 166.64 10.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.819 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 7.2 tp -59.11 152.25 20.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.789 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -50.95 -27.21 7.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.143 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -132.79 38.35 3.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.819 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -87.68 -169.0 2.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.158 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.2 ttm180 -145.35 106.84 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.924 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.422 ' CE1' HG12 ' A' ' 269' ' ' VAL . 15.6 t-80 -107.61 143.64 35.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.82 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 177.04 68.79 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.678 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.745 ' CE1' HD23 ' A' ' 217' ' ' LEU . 15.3 m-85 -116.32 149.26 39.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.861 0.362 . . . . 0.0 110.762 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -69.28 151.33 46.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.5 m -57.86 97.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.78 15.35 9.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.721 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -64.9 -178.67 0.45 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.657 0.265 . . . . 0.0 110.743 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.495 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.8 m-85 -120.24 132.06 55.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.789 0.328 . . . . 0.0 110.982 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.419 HG22 HG23 ' A' ' 267' ' ' ILE . 17.8 m -137.32 154.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.421 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.4 p -125.59 165.0 19.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.556 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.665 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.6 m-30 -99.74 140.59 33.73 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.041 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 62.2 m -99.96 -94.09 0.26 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.033 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.54 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.2 OUTLIER -109.66 87.74 2.58 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 121.27 -0.172 . . . . 0.0 110.636 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.665 HG21 ' CD2' ' A' ' 250' ' ' PHE . 15.5 t -107.21 144.72 15.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.928 0.394 . . . . 0.0 111.726 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -107.92 114.94 29.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.912 179.161 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.6 -63.52 0.51 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.671 -0.776 . . . . 0.0 111.458 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.64 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.9 ttm -89.24 54.57 3.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.133 0.492 . . . . 0.0 110.152 179.035 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.415 HG22 ' O ' ' A' ' 253' ' ' VAL . 14.2 pt -79.04 -33.35 15.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.045 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -38.76 -34.71 0.16 Allowed 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.933 -178.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.64 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.2 mm? -71.08 -47.03 60.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.943 0.401 . . . . 0.0 110.49 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -55.86 -34.85 65.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.896 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.14 46.37 3.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -169.1 166.34 10.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.784 0.326 . . . . 0.0 110.663 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -55.91 164.19 1.83 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.644 ' HG3' HG21 ' A' ' 295' ' ' VAL . 36.6 Cg_endo -64.9 168.54 13.43 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.242 1.961 . . . . 0.0 112.078 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.497 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -128.35 -172.29 2.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.516 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -99.37 151.43 21.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.758 0.313 . . . . 0.0 110.654 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.419 HG23 HG22 ' A' ' 248' ' ' VAL . 2.1 pp -123.1 174.0 8.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.593 0.711 . . . . 0.0 112.316 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.569 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.2 OUTLIER -147.43 127.77 13.95 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.738 178.919 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 269' ' ' VAL . 34.9 m -97.88 112.75 30.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.434 0.635 . . . . 0.0 111.539 -178.535 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 270' ' ' LEU . 17.6 mt -89.04 -28.0 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.449 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.63 -164.17 24.9 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.583 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 -44.25 9.06 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.586 2.191 . . . . 0.0 112.099 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -117.03 18.34 14.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.029 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.97 146.66 51.67 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.92 0.391 . . . . 0.0 110.794 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.574 ' CE1' HG13 ' A' ' 232' ' ' VAL . 2.2 p90 -178.62 154.12 0.74 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.639 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.7 t -105.58 170.06 8.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.014 0.435 . . . . 0.0 111.441 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.61 -178.02 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.84 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.31 175.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.987 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.38 133.2 50.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 62.9 p -118.07 28.57 8.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.06 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 80.3 p -82.21 -30.05 31.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.921 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.405 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 77.5 m-20 -100.1 31.23 3.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.999 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 259' ' ' LEU . 24.9 m-85 -138.12 -175.05 3.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.04 178.78 6.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.94 150.88 21.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.929 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.559 ' CG ' HG12 ' A' ' 224' ' ' VAL . 67.3 t80 -81.43 136.39 35.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.5 mt -120.0 -56.81 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.199 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.8 mmt85 -162.48 178.11 8.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.372 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.29 162.58 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.269 -0.967 . . . . 0.0 111.932 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.636 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 130.8 116.37 1.81 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.793 179.002 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.2 mt -120.51 133.59 66.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.747 0.308 . . . . 0.0 110.597 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.549 ' O ' HG13 ' A' ' 292' ' ' VAL . 12.1 p -99.6 117.21 44.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.325 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.31 142.54 50.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.812 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -80.7 101.59 9.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.927 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.644 HG21 ' HG3' ' A' ' 264' ' ' PRO . 27.1 m -57.05 132.76 21.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.135 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -169.73 77.95 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.874 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.614 HG13 ' O ' ' A' ' 297' ' ' VAL . 11.1 p 34.91 90.5 0.07 OUTLIER Pre-proline 0 N--CA 1.467 0.388 0 CA-C-N 115.977 -0.556 . . . . 0.0 112.032 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.8 128.92 31.55 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.618 2.212 . . . . 0.0 112.231 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.38 173.04 12.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -81.68 153.25 26.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.913 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 32.5 mm -70.65 148.66 10.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.044 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.2 154.02 17.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.962 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -159.86 118.49 2.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.849 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -99.88 -75.41 0.57 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.964 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.93 117.46 7.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.971 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 59.1 91.08 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.937 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -83.68 46.07 1.96 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.784 2.323 . . . . 0.0 112.73 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 50.55 97.0 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.85 0.357 . . . . 0.0 111.351 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 1.4 m -170.83 115.66 0.45 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.032 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 2.6 pp -83.11 121.17 26.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.82 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.2 p -59.19 130.83 23.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.885 -179.986 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 120.831 0.348 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 61.38 105.52 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.861 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -132.36 124.16 3.8 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.515 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -135.62 30.14 3.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.816 0.341 . . . . 0.0 110.883 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -158.52 166.02 33.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 64.15 -79.08 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -65.08 80.29 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.059 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -105.83 107.87 19.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.89 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 9.0 t -127.65 -176.11 3.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.829 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 1.7 t70 60.39 110.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.933 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.6 -32.23 7.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.893 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -176.64 -40.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.844 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 177.99 -92.53 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.496 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 59.39 94.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.832 0.349 . . . . 0.0 110.876 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.413 ' N ' ' CD ' ' A' ' 216' ' ' PRO . 0.0 OUTLIER -69.07 -52.45 15.99 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.947 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.413 ' CD ' ' N ' ' A' ' 215' ' ' GLN . 52.8 Cg_exo -54.63 134.28 61.42 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.447 2.098 . . . . 0.0 112.188 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 4.0 tp -129.74 139.73 51.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.87 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 63.8 m -134.02 160.22 38.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.991 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.62 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -148.0 153.25 38.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.57 155.97 17.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.055 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.401 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 41.0 t -105.19 135.31 43.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.021 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.6 t -111.52 -34.75 6.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -164.53 151.91 11.67 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.82 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.536 HG12 ' CD1' ' A' ' 286' ' ' TYR . 9.8 p -157.86 148.58 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.023 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 64.5 p -101.96 145.36 29.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.913 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -93.65 77.92 4.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.729 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.411 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.5 t70 -121.59 -153.68 0.56 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.773 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.431 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 37.1 t-20 -157.39 90.19 2.43 Favored Pre-proline 0 CA--C 1.531 0.232 0 CA-C-O 120.452 0.168 . . . . 0.0 111.256 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 97.4 Cg_endo -76.97 169.8 73.43 Favored 'Cis proline' 0 C--N 1.348 0.5 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.15 -0.253 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.4 149.58 16.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.458 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.2 t -99.88 138.72 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.832 0.348 . . . . 0.0 110.874 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.632 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 3.6 p -131.63 156.9 43.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.463 ' N ' HG22 ' A' ' 232' ' ' VAL . 94.3 m -120.92 161.68 21.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.368 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 234' ' ' CYS . . . . . 0.415 ' N ' HG22 ' A' ' 233' ' ' THR . 2.4 m -99.9 169.86 8.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.908 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.61 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 3.2 tp -68.08 153.67 43.24 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.807 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -53.67 -28.3 32.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.97 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.544 ' CG ' HD23 ' A' ' 235' ' ' LEU . 9.6 pt-20 -121.68 30.64 6.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.891 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.61 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -92.14 -176.42 4.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.122 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -124.87 -175.89 3.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 32.0 t60 -174.12 113.32 0.18 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -144.78 25.71 1.94 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.819 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.502 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.5 OUTLIER -99.04 138.64 35.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.861 0.362 . . . . 0.0 110.595 179.808 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -92.78 168.8 10.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 58.7 p -59.44 102.39 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 120.6 11.7 6.46 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.898 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -73.83 -176.14 2.34 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.732 0.301 . . . . 0.0 110.767 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.441 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -132.75 121.82 23.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.798 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.49 HG22 HG23 ' A' ' 267' ' ' ILE . 20.2 m -129.1 154.84 40.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 0.0 111.325 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.8 p -123.76 165.51 17.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.862 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 1.012 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.0 m-30 -99.61 144.27 28.89 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.96 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 28.7 t -102.88 -94.35 0.31 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.011 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -110.29 88.29 2.73 Favored 'General case' 0 C--O 1.225 -0.195 0 CA-C-O 120.511 0.196 . . . . 0.0 110.54 179.684 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 1.012 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.9 t -104.32 143.54 15.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.988 0.423 . . . . 0.0 111.745 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -104.06 110.81 23.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.924 179.152 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.73 -63.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.701 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.472 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.1 ttm -86.25 58.58 5.13 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 110.33 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.401 HG13 ' N ' ' A' ' 258' ' ' GLN . 16.2 pt -79.32 -33.33 15.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.9 -179.362 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.449 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 4.2 mp0 -38.99 -34.59 0.16 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.859 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.764 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.0 mm? -73.16 -46.82 48.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.938 0.399 . . . . 0.0 110.495 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -58.38 -34.94 71.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.788 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.62 45.35 2.74 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.346 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -165.92 163.96 18.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.775 0.321 . . . . 0.0 110.714 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -56.01 167.65 0.83 Allowed Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.599 179.812 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.599 ' HG3' HG21 ' A' ' 295' ' ' VAL . 54.0 Cg_endo -68.68 154.39 71.47 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.302 2.002 . . . . 0.0 112.017 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.463 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.1 ptp -115.11 -177.03 3.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.574 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -99.7 138.67 36.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.773 0.321 . . . . 0.0 110.784 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.502 HD11 ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -106.79 174.72 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.573 0.702 . . . . 0.0 112.2 -179.473 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.713 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -144.04 128.77 18.27 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.508 178.716 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.492 HG11 ' O ' ' A' ' 242' ' ' PHE . 27.7 m -97.43 118.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.523 0.678 . . . . 0.0 111.495 -178.343 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 44.5 mt -92.42 -30.78 15.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.662 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.44 -158.99 32.17 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.312 -0.947 . . . . 0.0 113.097 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -63.89 112.13 1.74 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.71 2.273 . . . . 0.0 112.338 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 66.27 14.99 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.08 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -128.73 138.33 52.06 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.484 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.713 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.4 p90 -174.21 169.42 3.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.872 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.0 t -123.42 170.11 10.68 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.98 0.419 . . . . 0.0 111.415 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.67 HD11 ' CG2' ' A' ' 280' ' ' THR . 11.6 pt -123.58 -177.53 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.802 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 m -57.5 -82.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.983 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -150.15 140.69 22.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.801 0.334 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.67 ' CG2' HD11 ' A' ' 277' ' ' ILE . 71.5 p -113.22 -26.92 8.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 t -54.53 -24.21 19.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.292 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.401 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 3.3 m120 -94.47 20.91 7.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.23 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.764 ' CE2' HD11 ' A' ' 259' ' ' LEU . 35.7 m-85 -143.78 -179.61 6.57 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.774 0.321 . . . . 0.0 110.825 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.81 -171.79 0.74 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.893 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -98.87 125.86 44.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.536 ' CD1' HG12 ' A' ' 224' ' ' VAL . 26.9 t80 -69.98 120.67 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.797 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.2 mt -106.88 -68.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.185 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -138.48 -178.84 5.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.508 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.81 166.67 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.238 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.665 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 122.87 111.32 2.05 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.532 -0.842 . . . . 0.0 113.126 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.455 HD12 ' N ' ' A' ' 291' ' ' ILE . 4.8 mp -118.69 128.35 75.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.62 HG13 ' HB3' ' A' ' 219' ' ' ALA . 12.6 p -99.55 113.1 33.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.017 0.437 . . . . 0.0 111.531 -179.329 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.4 m -115.28 -176.81 2.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.641 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -112.59 106.6 15.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.826 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.599 HG21 ' HG3' ' A' ' 264' ' ' PRO . 4.7 m -58.47 133.94 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.114 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -126.02 19.79 7.68 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.255 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.5 t 53.36 91.49 0.07 OUTLIER Pre-proline 0 C--N 1.331 -0.202 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.404 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.56 138.81 39.35 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.456 2.104 . . . . 0.0 112.278 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.37 175.02 5.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.952 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -71.89 124.5 24.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.918 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.9 pt -104.39 131.66 52.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.192 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 88.9 p -102.46 27.94 6.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.004 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 56.78 178.55 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.93 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -107.96 -36.06 6.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.8 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 1.4 m -154.27 158.44 40.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.905 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 60.39 82.74 0.22 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.92 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.95 -46.56 0.71 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.642 2.228 . . . . 0.0 112.357 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -142.14 -176.56 4.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.134 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 10.0 m -157.97 31.51 0.26 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -149.0 124.59 10.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.805 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.94 -30.12 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.23 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.207 -0.902 . . . . 0.0 110.857 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.768 0.318 . . . . 0.0 111.257 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -111.82 141.75 45.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.901 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 104.95 97.86 2.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.452 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -140.62 -66.16 0.44 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.794 0.33 . . . . 0.0 110.902 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -147.9 -46.55 0.16 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.962 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 1.4 ttp 62.61 29.44 16.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.981 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.461 HG13 ' HE1' ' A' ' 303' ' ' PHE . 21.5 t 63.34 124.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.11 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.604 HD12 ' O ' ' A' ' 208' ' ' LEU . 2.3 pp -158.37 103.77 1.81 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.469 HG22 ' CD1' ' A' ' 306' ' ' LEU . 0.0 OUTLIER -138.13 -169.55 2.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.852 -179.991 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -116.86 -171.72 2.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.966 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.7 t -92.1 150.7 20.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.984 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -109.93 -23.69 11.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.13 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -54.04 108.08 0.78 Allowed Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.631 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -142.72 -47.44 0.33 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.881 0.372 . . . . 0.0 110.94 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 2.4 pt20 -104.27 112.65 65.49 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.83 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -68.51 130.19 20.44 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.439 2.093 . . . . 0.0 112.296 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.94 -179.27 4.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.832 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.2 p -168.52 97.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.024 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.743 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -102.49 167.49 9.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.986 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 4.5 mmt -105.54 146.46 29.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.015 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.446 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 96.0 t -100.06 130.58 49.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 40.0 t -109.39 -34.88 6.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.066 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -157.0 148.29 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.043 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 224' ' ' VAL . 11.0 p -155.93 113.09 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.005 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 68.8 p -70.81 135.69 48.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.05 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.54 82.96 6.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.726 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -129.85 -147.94 0.35 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.498 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -145.96 102.77 4.16 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 120.342 0.115 . . . . 0.0 110.881 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.449 ' HB2' ' O ' ' A' ' 277' ' ' ILE . 36.2 Cg_endo -68.24 -74.26 0.0 OUTLIER 'Cis proline' 0 C--N 1.349 0.555 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.656 0.171 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 154.42 139.73 2.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.18 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.3 t -99.83 127.85 52.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.895 0.378 . . . . 0.0 111.025 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.543 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.7 p -116.85 153.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.165 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 90.3 m -117.93 157.86 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.508 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -99.97 168.65 9.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.664 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 3.5 tp -68.95 150.81 47.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.781 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -48.5 -28.38 3.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.176 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -133.75 47.42 2.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.85 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.664 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -90.85 174.19 7.58 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.163 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -118.38 107.4 13.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.912 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 53.7 p-80 -92.57 131.58 37.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.824 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -151.4 26.36 0.97 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.566 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.711 ' O ' HG11 ' A' ' 269' ' ' VAL . 1.4 m-85 -112.3 140.86 46.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 110.719 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.66 175.48 5.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -61.18 88.67 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.773 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.18 -16.47 3.9 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.818 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.09 165.39 3.41 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.658 0.266 . . . . 0.0 110.708 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 265' ' ' MET . 5.0 m-85 -113.61 150.15 33.52 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.883 0.373 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 267' ' ' ILE . 10.1 m -147.48 144.31 19.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.21 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 p -115.78 163.67 15.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.671 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.955 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.0 m-30 -99.44 142.78 30.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.77 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.411 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 65.3 m -99.82 -100.12 0.24 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.108 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 1.7 pt-20 -103.1 88.01 3.04 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.605 0.24 . . . . 0.0 110.641 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.955 HG21 ' CD2' ' A' ' 250' ' ' PHE . 9.8 t -100.9 136.71 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.853 0.358 . . . . 0.0 111.522 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -99.92 107.88 19.98 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.883 179.188 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.65 -66.02 0.46 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.79 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.596 ' HG2' HD23 ' A' ' 259' ' ' LEU . 32.1 ttm -84.04 59.65 5.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.164 0.506 . . . . 0.0 110.673 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 12.4 pt -80.23 -33.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.989 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -38.57 -34.5 0.14 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.513 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.647 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.4 mm? -61.64 -53.9 49.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.907 0.384 . . . . 0.0 110.613 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 33.1 t30 -57.39 -34.94 69.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.884 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.05 46.09 2.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 2.2 t -162.06 30.2 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.69 0.281 . . . . 0.0 110.981 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 263' ' ' GLN . . . . . 0.41 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 2.4 mt-30 58.33 167.66 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.773 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.651 ' HB3' HG11 ' A' ' 295' ' ' VAL . 30.1 Cg_endo -63.39 165.8 16.69 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.31 2.007 . . . . 0.0 112.067 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.647 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -134.52 -171.69 2.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.643 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -99.68 138.63 36.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.857 0.36 . . . . 0.0 110.568 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.442 HD13 ' HB2' ' A' ' 242' ' ' PHE . 1.6 pp -109.71 172.72 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.5 0.666 . . . . 0.0 112.181 -179.433 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 8.5 tttm -143.54 125.51 15.29 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.788 -1.096 . . . . 0.0 108.833 178.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.711 HG11 ' O ' ' A' ' 242' ' ' PHE . 27.4 m -97.61 108.9 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.459 0.647 . . . . 0.0 111.525 -178.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.1 mt -86.02 -30.57 22.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.451 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.61 -168.53 27.91 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.615 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -60.1 -50.57 7.14 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.59 2.194 . . . . 0.0 111.816 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -112.91 21.87 15.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.723 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -130.33 145.93 51.85 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.736 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.554 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -179.18 155.68 0.73 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.4 t -104.3 170.08 8.11 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.162 0.506 . . . . 0.0 111.35 -179.249 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.547 ' CD1' HG21 ' A' ' 280' ' ' THR . 3.8 pt -124.67 -171.22 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.643 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -74.27 -168.46 0.65 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.623 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -69.77 105.6 2.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.547 HG21 ' CD1' ' A' ' 277' ' ' ILE . 4.4 t -132.89 74.25 1.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.932 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 10.1 p -125.76 -33.51 2.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.593 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 -95.14 25.4 4.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.647 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.426 ' CD1' ' HA ' ' A' ' 280' ' ' THR . 21.6 m-85 -117.36 -167.48 1.32 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.739 0.304 . . . . 0.0 110.739 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 31.0 t -74.56 175.95 7.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.842 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -99.4 131.71 45.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.433 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 24.7 t80 -69.01 117.56 10.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.029 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 6.0 mt -102.98 -60.06 3.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.47 -178.75 6.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.459 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 289' ' ' GLY . . . . . 0.401 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 57.87 158.31 0.02 OUTLIER Glycine 0 C--N 1.331 0.29 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.427 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.534 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 129.37 106.13 1.21 Allowed Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.513 -0.851 . . . . 0.0 112.865 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.481 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.7 mp -111.54 135.87 49.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.412 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.743 ' CG1' ' HB3' ' A' ' 219' ' ' ALA . 12.2 p -99.64 112.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.964 0.411 . . . . 0.0 111.549 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 49.8 m -107.2 171.91 7.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.701 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.42 ' HG3' ' CD1' ' A' ' 242' ' ' PHE . 4.7 tt0 -110.04 94.96 5.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.086 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.815 ' O ' HG22 ' A' ' 297' ' ' VAL . 32.1 m -59.48 -171.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.013 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.575 ' O ' HG13 ' A' ' 297' ' ' VAL . 0.0 OUTLIER -52.88 90.24 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.861 0.362 . . . . 0.0 111.238 -179.833 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.815 HG22 ' O ' ' A' ' 295' ' ' VAL . 3.7 m -160.27 156.34 22.97 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.087 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.25 164.15 31.54 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.53 2.153 . . . . 0.0 112.265 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.03 -64.58 1.06 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 13.8 tttm -149.49 136.25 19.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.87 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 28.2 mm -81.58 137.75 20.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.18 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 10.1 m -113.77 162.68 16.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.89 179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 303' ' ' PHE . . . . . 0.461 ' HE1' HG13 ' A' ' 207' ' ' VAL . 23.7 t80 -150.83 164.62 35.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.831 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 12.0 mttt 61.84 113.83 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.79 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 62.65 148.13 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.469 ' CD1' HG22 ' A' ' 209' ' ' THR . 0.6 OUTLIER -153.66 87.61 3.74 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 179.993 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -69.23 -35.38 14.32 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.586 2.191 . . . . 0.0 112.309 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 61.1 114.04 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.1 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 19.4 t -74.84 101.64 4.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.88 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 310' ' ' LEU . . . . . 0.642 ' O ' HD12 ' A' ' 310' ' ' LEU . 0.5 OUTLIER -140.9 79.16 1.68 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.848 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.67 -36.01 4.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.063 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.274 -0.87 . . . . 0.0 110.931 179.956 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 . . . . . 0 N--CA 1.486 1.335 0 CA-C-O 120.859 0.361 . . . . 0.0 111.174 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -157.41 -47.57 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.937 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -84.35 -106.17 0.59 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.48 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -156.87 68.2 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.841 0.353 . . . . 0.0 110.912 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 61.99 117.59 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.914 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 61.27 112.03 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.476 HG13 ' N ' ' A' ' 208' ' ' LEU . 10.8 p -153.02 -44.56 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.071 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.476 ' N ' HG13 ' A' ' 207' ' ' VAL . 5.1 mp -101.44 -31.46 10.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.957 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 76.6 p -83.85 122.47 28.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.85 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -136.46 -51.83 0.7 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.992 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 9.0 t -98.69 122.51 42.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.95 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -124.95 151.46 45.43 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -148.44 -92.51 0.1 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.377 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -162.84 154.33 17.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.807 0.337 . . . . 0.0 110.853 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.86 132.93 21.73 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.71 -62.44 0.32 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.395 2.063 . . . . 0.0 112.242 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.579 HD23 ' CE1' ' A' ' 242' ' ' PHE . 8.1 tp -147.7 133.53 19.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.834 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 25.6 p -145.25 172.28 13.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.511 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -162.98 169.95 18.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.05 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.3 156.08 22.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.939 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 41.0 t -108.21 127.39 64.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.003 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 17.2 t -106.06 -34.68 7.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.974 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.76 137.33 10.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.74 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.1 p -142.8 122.08 8.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.064 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 31.0 p -81.7 138.67 35.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.112 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -90.56 78.32 6.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.77 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.428 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.9 t0 -123.07 -150.96 0.46 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.723 -179.741 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.422 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 17.2 p30 -159.44 90.49 1.93 Allowed Pre-proline 0 CA--C 1.532 0.255 0 CA-C-O 120.471 0.177 . . . . 0.0 111.202 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 81.2 Cg_endo -75.13 169.34 74.82 Favored 'Cis proline' 0 C--N 1.347 0.451 0 C-N-CA 123.322 -1.533 . . . . 0.0 111.937 -0.273 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -103.86 146.13 16.29 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.377 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.1 t -99.76 125.35 53.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.74 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.7 p -122.55 155.25 27.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.214 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.426 ' N ' HG22 ' A' ' 232' ' ' VAL . 4.7 m -123.52 166.9 14.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.577 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -100.0 170.05 8.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.745 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.564 HD23 ' HG2' ' A' ' 237' ' ' GLU . 0.4 OUTLIER -72.16 160.46 32.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.7 179.867 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -55.08 -29.81 58.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.992 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.564 ' HG2' HD23 ' A' ' 235' ' ' LEU . 9.3 pt-20 -119.13 34.64 5.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.829 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.94 159.6 15.22 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.019 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -124.65 140.02 53.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.977 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.4 t60 -118.76 144.19 46.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.82 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 241' ' ' GLY . . . . . 0.496 ' HA3' HD21 ' A' ' 217' ' ' LEU . . . -159.57 26.39 0.34 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.739 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.579 ' CE1' HD23 ' A' ' 217' ' ' LEU . 1.6 m-85 -100.53 142.34 32.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.66 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -95.94 170.07 9.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.24 101.07 0.11 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.8 19.26 5.35 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.696 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -84.9 169.27 14.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.758 0.313 . . . . 0.0 110.702 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.454 ' HA ' ' O ' ' A' ' 265' ' ' MET . 62.5 m-85 -108.28 141.81 39.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.912 0.387 . . . . 0.0 111.033 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.451 HG22 HG23 ' A' ' 267' ' ' ILE . 32.5 m -146.21 143.5 21.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.1 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.5 p -121.24 162.52 20.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.93 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.0 m-30 -99.76 149.61 23.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.1 m -108.5 -85.17 0.53 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.919 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.602 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.72 92.58 3.85 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.128 0.49 . . . . 0.0 109.828 179.678 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.93 HG21 ' CD2' ' A' ' 250' ' ' PHE . 3.3 t -112.46 140.63 31.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.479 -179.196 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 68.3 mt-30 -103.79 110.84 23.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.091 179.331 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.88 -57.75 0.64 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.591 -179.021 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.676 ' HG2' HD23 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -90.27 53.78 2.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.11 0.481 . . . . 0.0 110.353 179.334 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 18.8 pt -78.91 -33.79 16.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.843 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -39.24 -34.73 0.2 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.294 -0.412 . . . . 0.0 112.068 -178.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.807 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.5 mm? -66.47 -45.07 80.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 110.685 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -57.68 -38.86 75.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.994 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.7 50.22 1.14 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.511 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.2 t -161.67 30.12 0.13 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.711 0.291 . . . . 0.0 110.905 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 10.2 mt-30 58.82 166.22 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.762 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.71 ' HG3' HG21 ' A' ' 295' ' ' VAL . 27.6 Cg_endo -62.34 166.01 13.94 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.441 2.094 . . . . 0.0 112.148 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.807 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.2 ptp -130.97 -174.84 3.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.713 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.52 136.53 39.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.801 0.334 . . . . 0.0 110.616 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.451 HG23 HG22 ' A' ' 248' ' ' VAL . 1.2 pp -103.15 175.77 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.662 0.744 . . . . 0.0 112.315 -179.317 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.649 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -148.89 128.84 13.46 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.621 178.805 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.504 HG11 ' O ' ' A' ' 242' ' ' PHE . 26.1 m -97.73 122.89 49.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.528 0.68 . . . . 0.0 111.577 -178.424 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 48.4 mt -101.95 -29.1 12.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.504 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.49 -172.35 27.64 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.513 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.56 -33.98 65.79 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.556 2.171 . . . . 0.0 112.053 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -124.63 1.92 8.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.166 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -113.98 153.3 29.57 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.85 0.357 . . . . 0.0 110.805 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.649 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.53 169.05 2.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.831 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -124.1 170.08 11.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.993 0.425 . . . . 0.0 111.242 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.3 pt -125.73 -179.21 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.773 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.04 -173.37 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.865 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.67 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.827 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -99.85 33.47 2.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.979 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 31.2 t -109.21 30.78 6.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.406 ' OD1' ' CZ ' ' A' ' 283' ' ' PHE . 28.2 p30 -150.09 30.71 0.7 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.851 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.406 ' CZ ' ' OD1' ' A' ' 282' ' ' ASN . 20.0 m-85 -138.04 -168.42 2.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.462 ' O ' ' HE3' ' A' ' 256' ' ' MET . 0.1 OUTLIER -91.61 175.25 6.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.84 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -85.43 121.04 27.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.426 ' HE1' HG13 ' A' ' 253' ' ' VAL . 64.8 t80 -56.67 136.52 54.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.879 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 30.9 mt -114.16 -59.83 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.301 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.01 173.3 11.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.734 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.36 150.51 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.31 112.53 0.95 Allowed Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.895 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.2 mp -109.22 128.87 64.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.806 0.336 . . . . 0.0 110.614 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.7 p -99.88 114.93 39.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.359 -179.681 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 75.6 m -109.42 -178.03 3.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.638 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 31.9 tt0 -119.31 102.89 9.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.001 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.71 HG21 ' HG3' ' A' ' 264' ' ' PRO . 28.8 m -73.48 64.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.0 179.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 7.5 tttm -127.2 94.35 3.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 4.7 m -135.03 111.98 11.17 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.227 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.408 ' O ' ' CG ' ' A' ' 299' ' ' LYS . 45.7 Cg_exo -56.22 -19.22 26.68 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.466 2.111 . . . . 0.0 112.505 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.408 ' CG ' ' O ' ' A' ' 298' ' ' PRO . 5.7 ptmt 46.17 101.29 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.026 0.441 . . . . 0.0 111.659 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.691 ' O ' HG22 ' A' ' 301' ' ' ILE . 10.8 mttt 66.78 179.62 0.22 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.936 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.691 HG22 ' O ' ' A' ' 300' ' ' LYS . 7.4 tt 51.81 160.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.92 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 95.9 p -153.23 -46.52 0.1 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.015 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -142.06 151.22 42.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.891 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 23.6 mtmt 62.09 117.93 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.953 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 23.1 t -142.12 31.25 1.57 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.922 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 1.6 mp -97.59 150.37 36.71 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.46 -170.46 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.586 2.191 . . . . 0.0 112.193 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -118.17 137.19 53.15 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.135 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 55.9 p -118.3 148.0 42.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.942 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -105.62 -35.01 7.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.837 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 311' ' ' VAL . . . . . 0.434 HG12 ' N ' ' A' ' 312' ' ' GLU . 27.7 t -124.13 155.76 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.009 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 312' ' ' GLU . . . . . 0.434 ' N ' HG12 ' A' ' 311' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.849 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.354 0 CA-C-O 120.839 0.352 . . . . 0.0 111.243 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -100.84 -31.07 11.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.93 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 145.97 138.26 3.19 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.463 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -79.82 -39.82 29.9 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.877 0.37 . . . . 0.0 110.94 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 60.34 94.29 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.937 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -176.72 123.41 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.607 ' O ' HG13 ' A' ' 207' ' ' VAL . 9.9 p -124.52 69.33 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.998 0.428 . . . . 0.0 111.097 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.4 HD13 ' HA ' ' A' ' 208' ' ' LEU . 3.7 mm? 63.73 -79.81 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.073 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 21.8 p -99.52 -41.69 7.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.055 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 3.1 t70 64.35 95.91 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -157.97 143.2 16.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.849 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -155.55 112.18 3.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.959 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 73.89 -135.23 19.97 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.51 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -104.98 150.41 24.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.884 0.373 . . . . 0.0 110.895 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 -156.44 122.55 2.55 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.765 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -54.14 121.9 10.48 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.454 2.103 . . . . 0.0 112.257 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp -119.9 178.21 4.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.774 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.7 m -162.19 169.6 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.972 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -162.25 148.39 13.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.951 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.4 mtt -93.45 160.93 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.002 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.425 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 47.9 t -108.73 123.88 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.025 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 28.8 t -102.22 -30.68 10.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.52 143.21 5.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.955 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.651 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.2 p -149.2 137.33 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.087 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 43.8 p -90.22 145.51 24.95 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.83 78.28 4.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.813 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.71 -160.74 1.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.824 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.424 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 7.3 p-10 -154.4 90.04 3.22 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.277 -179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 92.5 Cg_endo -80.1 169.72 68.61 Favored 'Cis proline' 0 C--N 1.348 0.503 0 C-N-CA 123.501 -1.458 . . . . 0.0 112.168 -0.185 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -113.76 157.13 15.16 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.334 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.0 t -99.79 125.45 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.858 0.361 . . . . 0.0 110.911 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.651 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.5 p -123.72 155.79 30.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.196 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 232' ' ' VAL . 89.1 m -124.16 159.11 30.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.615 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.0 m -99.97 165.9 11.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.86 0.362 . . . . 0.0 110.905 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 3.7 tp -59.92 150.12 29.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.741 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -52.24 -27.79 16.22 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.261 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -99.92 -26.74 13.9 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.04 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.405 ' O ' ' CE2' ' A' ' 273' ' ' TYR . . . -74.4 140.81 44.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.243 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 27.5 ttt180 -120.59 145.31 47.5 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.902 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -86.24 131.53 34.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.935 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -119.52 -19.38 4.19 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.995 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.485 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -78.9 145.93 33.85 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.777 0.322 . . . . 0.0 110.737 -179.879 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -101.92 179.66 4.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.538 HG23 HG22 ' A' ' 269' ' ' VAL . 0.7 OUTLIER -63.72 105.44 0.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.997 -179.995 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 128.24 -5.39 6.78 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.967 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.418 ' CB ' ' HB3' ' A' ' 242' ' ' PHE . 2.3 t70 -80.21 172.34 13.9 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.841 0.353 . . . . 0.0 110.98 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.444 ' HA ' ' O ' ' A' ' 265' ' ' MET . 4.4 m-85 -122.19 152.75 39.64 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.055 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.537 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -156.55 154.76 5.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.256 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 t -125.61 170.19 11.73 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.725 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.809 ' CD2' HG21 ' A' ' 253' ' ' VAL . 5.5 m-30 -99.6 159.45 15.03 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.13 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 29.3 t -113.37 -87.66 0.56 Allowed 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.065 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -114.66 88.57 2.89 Favored 'General case' 0 CA--C 1.521 -0.15 0 CA-C-O 120.54 0.209 . . . . 0.0 110.852 179.785 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.809 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.0 t -99.96 158.36 3.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.004 0.431 . . . . 0.0 111.462 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.431 ' N ' HG12 ' A' ' 253' ' ' VAL . 2.2 mm-40 -119.04 106.11 12.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.941 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -56.55 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.482 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.457 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.2 ttm -96.59 51.53 1.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.153 0.502 . . . . 0.0 110.315 179.166 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.7 pp -75.74 -33.66 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.563 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.433 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 5.1 mm-40 -39.25 -34.64 0.2 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.695 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.53 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.4 mm? -59.22 -47.32 85.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 110.59 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -57.54 -46.41 83.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.871 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.82 47.56 2.98 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.538 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 5.1 t -152.14 34.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 263' ' ' GLN . . . . . 0.404 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 4.3 mt-30 59.74 168.49 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.583 ' HB3' HG21 ' A' ' 295' ' ' VAL . 43.8 Cg_endo -67.55 151.34 79.77 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.349 2.033 . . . . 0.0 112.067 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.53 ' SD ' HD12 ' A' ' 259' ' ' LEU . 3.1 ptp -118.69 -178.01 3.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.711 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -99.75 157.25 16.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.504 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.537 HG23 HG22 ' A' ' 248' ' ' VAL . 1.8 pp -125.93 170.5 15.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.625 0.726 . . . . 0.0 112.312 -179.539 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.628 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 14.4 mtpt -145.06 126.79 15.25 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.564 -1.198 . . . . 0.0 108.532 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.538 HG22 HG23 ' A' ' 244' ' ' THR . 29.4 m -97.54 120.36 46.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.595 0.712 . . . . 0.0 111.587 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.2 mt -99.11 -30.25 12.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.809 -1.087 . . . . 0.0 110.601 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -162.31 -173.81 31.44 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.565 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.82 -59.27 1.31 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.611 2.208 . . . . 0.0 112.243 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CE2' ' O ' ' A' ' 238' ' ' ALA . 10.0 m-85 -109.39 5.19 23.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.3 p -106.57 149.5 27.1 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.628 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -177.65 166.88 2.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.755 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.4 t -117.21 170.09 8.95 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.7 pt -131.11 179.89 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.16 -179.55 0.78 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.89 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.34 109.23 0.83 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.799 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.6 t -122.5 30.08 6.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.026 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 p -98.66 31.42 2.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.942 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.26 -45.95 1.0 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.453 ' CD2' HD21 ' A' ' 259' ' ' LEU . 30.5 m-85 -59.81 -168.21 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.878 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.2 176.77 9.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.913 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -83.79 125.99 32.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.976 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.401 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 20.7 t80 -61.12 135.04 57.64 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.81 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.7 mt -118.26 -64.71 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.008 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.85 -173.74 4.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.438 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.14 170.38 0.1 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.251 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.62 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 118.95 106.83 2.25 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.0 179.261 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.411 ' CD1' ' HG3' ' A' ' 252' ' ' GLU . 2.9 mp -116.94 125.3 73.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.739 0.304 . . . . 0.0 110.191 179.357 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.505 ' O ' HG13 ' A' ' 292' ' ' VAL . 9.8 p -99.68 120.1 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.551 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.5 m -125.58 170.23 11.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.726 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.421 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 27.7 tt0 -86.3 118.33 25.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.896 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.583 HG21 ' HB3' ' A' ' 264' ' ' PRO . 0.4 OUTLIER -78.63 164.45 3.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.086 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -161.23 30.21 0.14 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.985 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.509 ' N ' ' CD ' ' A' ' 298' ' ' PRO . 3.6 t -81.91 -45.82 1.04 Allowed Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.467 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.509 ' CD ' ' N ' ' A' ' 297' ' ' VAL . 25.7 Cg_exo -62.58 -26.99 76.11 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.521 2.147 . . . . 0.0 112.234 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.22 154.02 14.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.044 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.605 ' C ' HD12 ' A' ' 301' ' ' ILE . 0.0 OUTLIER 59.52 30.01 19.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.045 -179.958 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.605 HD12 ' C ' ' A' ' 300' ' ' LYS . 3.7 mp 63.82 134.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 66.4 p -132.39 174.43 10.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.9 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -134.47 168.95 18.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.873 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -98.92 31.62 2.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 5.6 m -107.03 -178.51 3.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -132.63 87.22 42.22 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_exo -51.21 -25.67 18.02 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.535 2.157 . . . . 0.0 112.46 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 61.66 110.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.074 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.453 ' O ' HD22 ' A' ' 310' ' ' LEU . 22.8 t -98.62 117.4 32.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 310' ' ' LEU . . . . . 0.453 HD22 ' O ' ' A' ' 309' ' ' SER . 2.2 mm? -124.86 31.35 5.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 17.2 m -94.89 43.51 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.85 179.955 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 120.789 0.328 . . . . 0.0 111.234 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -105.48 134.34 48.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.908 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 73.95 -105.12 1.75 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.522 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 61.22 112.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.864 0.364 . . . . 0.0 110.881 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -95.63 -31.6 13.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.901 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.07 109.26 2.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.3 m -114.94 31.23 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.128 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.504 HD12 ' H ' ' A' ' 208' ' ' LEU . 0.9 OUTLIER -85.98 160.7 19.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.52 154.43 42.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.932 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.9 t0 62.73 146.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.966 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 59.94 30.39 19.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 41.7 t30 -68.98 -31.2 69.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.896 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -111.07 167.49 12.53 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.568 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -76.74 -30.0 56.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.745 0.307 . . . . 0.0 110.972 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.423 ' N ' ' HD2' ' A' ' 216' ' ' PRO . 7.9 mt-30 -58.69 -60.72 9.49 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.065 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.423 ' HD2' ' N ' ' A' ' 215' ' ' GLN . 45.8 Cg_endo -68.76 150.89 74.46 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.464 2.109 . . . . 0.0 112.328 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.7 tp -130.49 -173.88 3.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 36.3 p -152.53 146.39 25.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -141.8 145.24 34.5 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.026 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.606 ' HB3' HD13 ' A' ' 235' ' ' LEU . 1.0 OUTLIER -82.8 151.27 26.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.983 -179.942 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 83.7 t -104.25 143.85 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.065 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.2 t -117.32 -38.52 3.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.774 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.7 mtp -159.63 143.61 14.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 224' ' ' VAL . 10.5 p -143.68 121.32 6.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.028 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 32.9 p -79.89 142.76 34.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.007 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.56 78.54 4.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.799 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.43 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 4.7 t0 -127.84 -158.91 0.91 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.749 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.428 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 46.4 t30 -153.53 90.8 3.37 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.543 0.211 . . . . 0.0 111.325 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.43 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 96.9 Cg_endo -77.23 169.17 74.85 Favored 'Cis proline' 0 C--N 1.348 0.512 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.949 -0.245 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.27 17.53 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.453 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 21.4 t -99.84 136.09 32.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.844 0.355 . . . . 0.0 111.19 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.566 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 6.3 p -127.67 138.12 55.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.014 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.46 162.33 13.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.65 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.99 165.88 11.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.887 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.712 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 0.5 OUTLIER -58.76 158.0 8.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.701 179.768 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.76 -27.64 29.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.109 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.32 38.51 3.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.804 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.712 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -99.22 169.54 9.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.096 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 4.0 tpt180 -150.02 135.71 18.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.001 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.441 ' HB2' ' CE2' ' A' ' 242' ' ' PHE . 27.1 p-80 -137.78 135.96 36.82 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.766 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -122.15 65.07 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.669 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 240' ' ' HIS . 0.9 OUTLIER -111.87 142.1 44.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.848 0.356 . . . . 0.0 110.656 179.856 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.55 172.26 9.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 27.0 m -64.17 99.54 0.28 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.003 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.26 17.89 6.97 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.902 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.01 -175.46 2.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.704 0.288 . . . . 0.0 110.687 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.47 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.0 m-85 -120.93 151.95 39.08 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.909 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.478 ' HB ' HG23 ' A' ' 292' ' ' VAL . 35.0 m -156.04 152.2 8.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.374 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.9 p -128.45 168.91 14.95 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.952 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.5 m-30 -99.79 140.94 33.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.135 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.452 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 1.8 m -104.09 -81.38 0.52 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.899 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.761 ' HG3' HD12 ' A' ' 291' ' ' ILE . 0.4 OUTLIER -119.56 88.17 2.88 Favored 'General case' 0 C--O 1.216 -0.661 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.61 179.567 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.952 HG21 ' CD2' ' A' ' 250' ' ' PHE . 9.2 t -114.72 134.17 58.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 120.934 0.397 . . . . 0.0 111.882 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 64.2 mt-30 -99.65 119.82 38.7 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.028 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -62.91 0.51 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.366 -178.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.638 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.3 ttm -87.9 58.84 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.156 0.503 . . . . 0.0 110.162 179.032 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.433 ' O ' ' N ' ' A' ' 260' ' ' ASN . 1.0 OUTLIER -77.46 -33.34 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.961 -179.437 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.438 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 37.9 mm-40 -39.14 -34.65 0.18 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.788 HD11 ' CE2' ' A' ' 283' ' ' PHE . 2.7 mm? -76.87 -39.89 49.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.873 0.368 . . . . 0.0 110.69 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.452 ' ND2' ' O ' ' A' ' 251' ' ' SER . 0.1 OUTLIER -57.09 -36.99 71.27 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.91 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.54 29.1 10.15 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.325 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -144.18 158.42 43.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.767 0.317 . . . . 0.0 110.762 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 12.7 mt-30 -54.42 165.75 0.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.754 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.774 ' HG3' HG21 ' A' ' 295' ' ' VAL . 35.6 Cg_endo -64.05 174.63 3.8 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.427 2.085 . . . . 0.0 111.826 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.3 OUTLIER -133.86 -177.75 4.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.753 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -99.51 132.83 44.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.455 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.467 HG23 HG22 ' A' ' 248' ' ' VAL . 1.2 pp -102.61 172.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.8 0.81 . . . . 0.0 112.591 -179.08 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.598 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 43.8 mmtt -142.13 129.69 21.41 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.302 -1.317 . . . . 0.0 108.299 178.484 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 5.8 m -97.48 113.55 32.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.457 0.646 . . . . 0.0 111.567 -178.362 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.8 mt -93.77 -27.77 16.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.707 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.59 -170.93 34.68 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.811 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -66.99 -27.25 42.89 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.636 2.224 . . . . 0.0 112.309 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 44.5 m-85 -129.42 18.31 5.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.03 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.79 148.85 47.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.843 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.598 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 6.6 p90 -178.55 149.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.611 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 268' ' ' LYS . 1.6 t -107.49 170.14 8.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.275 -179.353 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.553 HD11 HG23 ' A' ' 280' ' ' THR . 2.7 pp -123.7 -175.85 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.739 179.75 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.401 ' C ' HD12 ' A' ' 277' ' ' ILE . 42.7 t -56.87 -77.36 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.038 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.458 ' N ' HD12 ' A' ' 277' ' ' ILE . 21.1 p-10 -150.06 133.39 16.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.06 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.553 HG23 HD11 ' A' ' 277' ' ' ILE . 0.7 OUTLIER -118.2 -28.23 5.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.195 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 22.5 p -60.38 -18.61 51.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.373 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -94.49 29.72 2.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.213 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.788 ' CE2' HD11 ' A' ' 259' ' ' LEU . 58.4 m-85 -150.07 -174.89 4.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.944 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.5 m -70.74 175.32 5.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.967 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -90.98 136.91 32.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.961 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 11.9 t80 -64.73 142.88 58.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.77 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.7 -61.72 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 2.1 mmt-85 -165.35 171.45 13.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.405 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 62.53 153.04 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.095 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.28 132.96 2.86 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.299 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.761 HD12 ' HG3' ' A' ' 252' ' ' GLU . 3.2 mt -135.45 136.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.566 -0.317 . . . . 0.0 110.3 179.641 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.478 HG23 ' HB ' ' A' ' 248' ' ' VAL . 11.8 p -99.83 127.2 52.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.192 -179.762 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.4 m -130.7 135.43 47.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -77.62 105.4 8.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.85 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.774 HG21 ' HG3' ' A' ' 264' ' ' PRO . 16.1 m -58.8 149.52 5.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.192 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -72.92 -67.32 0.57 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.987 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.637 HG13 ' O ' ' A' ' 297' ' ' VAL . 7.7 p -130.64 99.59 18.59 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.07 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.415 ' HB3' ' HG2' ' A' ' 264' ' ' PRO . 55.8 Cg_endo -69.9 -38.52 7.37 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.53 2.153 . . . . 0.0 112.413 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.17 131.7 6.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -148.5 28.36 0.88 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.922 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.52 ' N ' HD13 ' A' ' 301' ' ' ILE . 0.2 OUTLIER -51.77 177.47 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.434 -179.885 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 3.5 t 63.46 128.9 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.007 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 60.61 52.36 4.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.907 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.99 -169.16 0.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.78 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -104.64 -66.04 0.99 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.933 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.5 mt -148.77 112.71 3.65 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.77 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -68.19 -40.51 8.55 Favored 'Trans proline' 0 C--N 1.347 0.459 0 C-N-CA 122.446 2.097 . . . . 0.0 112.389 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -168.43 -67.45 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.11 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 91.5 p -166.08 125.67 1.64 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.845 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 14.1 mt -69.42 136.23 51.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.921 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 12.3 p -114.46 153.13 16.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.069 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.342 -0.837 . . . . 0.0 110.877 -179.975 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.738 0.304 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 63.33 109.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.828 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 129.66 -37.01 2.25 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.453 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -67.15 -49.98 62.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.784 0.326 . . . . 0.0 110.86 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -126.01 119.73 28.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.86 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 2.8 ptp -106.47 117.11 33.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.846 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -83.17 96.04 3.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.141 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.569 HD22 ' HB2' ' A' ' 210' ' ' ASP . 0.6 OUTLIER -166.07 135.61 3.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.941 179.905 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.53 ' O ' HG22 ' A' ' 209' ' ' THR . 25.8 m -109.08 38.47 2.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.872 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.569 ' HB2' HD22 ' A' ' 208' ' ' LEU . 1.3 m-20 -123.49 156.88 34.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.868 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -165.37 -45.13 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 17.2 m-80 -89.54 163.1 15.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.985 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -176.22 115.85 0.54 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.467 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -97.11 135.34 39.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.892 0.377 . . . . 0.0 110.856 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.17 89.74 6.34 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.807 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.51 146.87 63.09 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.493 2.128 . . . . 0.0 112.327 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.31 147.66 35.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.819 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.8 m -146.43 176.84 9.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.002 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -164.15 141.99 7.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.073 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 7.6 mtm -79.32 156.47 28.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.994 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 58.9 t -100.23 137.3 28.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.996 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.4 t -109.75 -31.21 7.53 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.824 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -171.9 131.66 0.67 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.57 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.9 p -133.91 115.88 22.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.118 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 34.0 p -75.43 141.77 43.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.079 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.77 87.39 6.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.869 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.419 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.8 OUTLIER -136.96 -160.41 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.765 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 37.4 t-20 -155.77 92.58 2.65 Favored Pre-proline 0 CA--C 1.531 0.228 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.263 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.419 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 87.1 Cg_endo -76.11 169.59 74.08 Favored 'Cis proline' 0 C--N 1.348 0.549 0 C-N-CA 123.389 -1.504 . . . . 0.0 112.098 -0.164 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.56 145.74 18.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.335 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 28.1 t -99.84 125.92 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.99 0.424 . . . . 0.0 111.067 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.667 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.1 p -115.82 157.29 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.483 ' N ' HG22 ' A' ' 232' ' ' VAL . 86.5 m -119.56 161.85 19.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.503 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 234' ' ' CYS . . . . . 0.423 ' N ' HG22 ' A' ' 233' ' ' THR . 4.4 m -99.87 164.75 11.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 110.867 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.674 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 24.1 tp -57.44 157.88 6.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 236' ' ' ASP . . . . . 0.401 ' N ' ' HG ' ' A' ' 235' ' ' LEU . 0.4 OUTLIER -53.88 -26.91 27.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.046 179.953 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.474 ' HG2' HD23 ' A' ' 235' ' ' LEU . 0.0 OUTLIER -125.28 29.75 5.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.946 179.976 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.674 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -90.81 -178.13 5.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.193 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 3.6 tpt85 -150.09 139.42 21.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.591 ' NE2' HG12 ' A' ' 269' ' ' VAL . 0.8 OUTLIER -106.64 127.26 53.2 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.746 179.812 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -135.8 24.57 3.3 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.967 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.538 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -106.9 138.66 42.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.575 179.774 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -90.81 172.45 8.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.977 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.614 HG23 HG22 ' A' ' 269' ' ' VAL . 3.2 p -63.54 101.62 0.35 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.802 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 119.66 7.14 9.92 Favored Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.851 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.58 -174.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.723 0.297 . . . . 0.0 110.769 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.456 ' HA ' ' O ' ' A' ' 265' ' ' MET . 90.1 m-85 -129.85 142.64 50.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.881 0.372 . . . . 0.0 111.167 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.496 HG22 HG23 ' A' ' 267' ' ' ILE . 18.6 m -151.32 154.71 7.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.63 170.5 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.879 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.989 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.3 m-30 -99.1 142.47 30.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.464 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 1.4 m -100.39 -82.49 0.45 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.944 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.6 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -123.75 91.17 3.41 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.299 0.571 . . . . 0.0 109.793 179.575 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.989 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.6 t -114.39 138.05 45.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.568 -178.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -101.57 118.1 36.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.094 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.54 -62.43 0.54 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.858 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.622 ' HG3' HD23 ' A' ' 259' ' ' LEU . 23.3 tpp -88.54 57.45 4.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.167 0.508 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.593 HD13 ' H ' ' A' ' 257' ' ' ILE . 0.2 OUTLIER -77.09 -33.3 20.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.977 -179.355 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.417 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.5 OUTLIER -39.03 -34.7 0.17 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.983 -178.756 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.813 HD12 ' SD ' ' A' ' 265' ' ' MET . 2.8 mm? -74.76 -43.16 56.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.035 0.445 . . . . 0.0 110.385 179.61 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.471 ' ND2' ' O ' ' A' ' 250' ' ' PHE . 0.1 OUTLIER -50.49 -40.01 49.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.112 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -106.79 46.5 1.16 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 12.9 t -144.07 26.38 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.313 . . . . 0.0 111.085 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 58.14 166.41 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.835 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.704 ' CB ' HG21 ' A' ' 295' ' ' VAL . 22.1 Cg_endo -61.4 144.9 98.53 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.421 2.081 . . . . 0.0 112.102 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.813 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.3 ptp -115.36 -171.85 2.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.51 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -99.81 149.74 23.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.761 0.315 . . . . 0.0 110.572 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 277' ' ' ILE . 1.2 pp -119.87 175.76 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.569 0.7 . . . . 0.0 112.441 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.703 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 2.2 tttp -146.18 131.27 18.32 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.6 -1.182 . . . . 0.0 108.475 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.614 HG22 HG23 ' A' ' 244' ' ' THR . 27.5 m -97.55 119.77 46.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.369 0.604 . . . . 0.0 111.537 -178.415 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.463 ' HA ' HD23 ' A' ' 270' ' ' LEU . 14.5 mt -95.48 -29.51 14.35 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.779 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 165.71 -159.81 33.1 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 113.108 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.84 112.66 1.88 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.81 2.34 . . . . 0.0 112.301 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 65.46 15.8 10.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.104 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -130.74 134.66 47.08 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.494 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.703 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.2 p90 -171.85 169.86 5.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.94 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.8 t -124.74 170.07 11.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 267' ' ' ILE . 2.6 pp -135.28 -179.87 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.928 179.725 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.712 ' O ' HD12 ' A' ' 277' ' ' ILE . 29.8 p -55.77 -172.47 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.005 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -62.14 119.68 9.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.647 HG21 HD11 ' A' ' 277' ' ' ILE . 10.0 t -135.33 30.74 3.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.956 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 35.3 t -97.37 -34.06 11.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.923 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -70.21 -25.39 63.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.055 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.604 ' CD2' HD21 ' A' ' 259' ' ' LEU . 20.7 m-85 -77.48 -170.66 1.86 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.918 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.27 -160.54 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.762 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -117.98 131.18 56.51 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.839 0.352 . . . . 0.0 110.715 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.47 ' CG ' HG12 ' A' ' 224' ' ' VAL . 17.3 t80 -57.82 131.05 49.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.983 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.0 mt -111.89 -64.85 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.031 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.06 164.84 36.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.724 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.81 151.73 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.199 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.549 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 141.06 122.29 1.84 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.721 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 26.8 mt -125.85 131.6 71.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.776 0.322 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.2 p -99.98 108.82 23.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.031 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 62.3 m -103.51 169.12 8.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -106.08 100.9 10.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.82 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.704 HG21 ' CB ' ' A' ' 264' ' ' PRO . 17.2 m -68.34 143.93 14.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.28 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 31.6 mttp -95.53 -55.23 3.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.895 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 4.5 m 41.24 80.72 0.27 Allowed Pre-proline 0 N--CA 1.464 0.237 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.779 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.24 -22.67 25.27 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.521 2.147 . . . . 0.0 112.401 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -172.28 -39.25 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.048 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 18.6 mtpt 66.74 173.32 0.25 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.798 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 31.5 mt -96.95 85.97 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 50.6 m -145.23 123.62 12.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.93 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -141.11 -48.95 0.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.946 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.22 93.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.913 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -98.09 119.38 36.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.936 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -104.36 105.38 49.35 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.837 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.73 120.14 7.15 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.384 2.056 . . . . 0.0 112.25 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -59.28 177.47 0.18 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.132 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -112.48 145.13 40.75 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.884 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 4.4 mt -107.17 124.39 49.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.856 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 311' ' ' VAL . . . . . 0.434 ' O ' HG23 ' A' ' 311' ' ' VAL . 5.9 m -99.88 86.33 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.099 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.947 179.915 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 . . . . . 0 N--CA 1.487 1.416 0 CA-C-O 120.843 0.354 . . . . 0.0 111.209 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 63.33 124.95 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.96 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -102.67 -89.98 2.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.404 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 60.44 86.35 0.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.783 0.325 . . . . 0.0 110.943 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -175.08 151.35 1.3 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.904 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 25.3 mtt -100.72 -55.3 2.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.914 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.562 HG22 ' O ' ' A' ' 207' ' ' VAL . 10.8 p -176.21 51.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.081 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 2.4 mp 61.69 152.97 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 8.6 t -138.79 31.37 2.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.91 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.25 164.63 11.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.85 40.85 1.13 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.936 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -171.14 103.44 0.21 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.927 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 128.25 100.66 1.03 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.515 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -117.33 127.1 53.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.815 0.34 . . . . 0.0 110.912 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -99.48 131.85 24.21 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.854 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.87 152.38 23.3 Favored 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.471 2.114 . . . . 0.0 112.328 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -111.71 143.1 43.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.85 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.8 p -137.79 152.08 48.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.951 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -137.34 147.82 45.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.06 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.733 ' HB3' HD13 ' A' ' 235' ' ' LEU . 0.0 OUTLIER -86.57 151.17 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.887 -179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 59.0 t -99.94 136.24 32.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.009 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.0 t -111.61 -34.27 6.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.974 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.4 mtp -163.99 153.75 14.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.992 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.41 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.0 p -157.14 135.61 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.05 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.3 140.75 29.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -86.75 74.06 9.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.861 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.4 t0 -122.09 -156.73 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.68 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 9.5 p-10 -158.91 91.18 2.01 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-O 120.516 0.198 . . . . 0.0 111.307 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 80.2 Cg_endo -76.06 169.72 73.71 Favored 'Cis proline' 0 C--N 1.348 0.527 0 C-N-CA 123.451 -1.479 . . . . 0.0 112.074 -0.108 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.21 151.8 17.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.501 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.9 t -99.98 114.69 39.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 0.0 111.109 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.509 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.3 p -106.15 157.1 6.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.108 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.471 ' N ' HG22 ' A' ' 232' ' ' VAL . 1.7 m -121.81 165.02 16.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.581 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.03 169.98 8.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.908 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.733 HD13 ' HB3' ' A' ' 220' ' ' MET . 0.6 OUTLIER -68.86 158.66 34.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.754 179.829 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -54.21 -33.53 58.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.044 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.544 ' HG3' HD23 ' A' ' 235' ' ' LEU . 0.1 OUTLIER -122.38 29.98 6.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.892 179.88 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.605 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -82.24 -175.66 5.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -148.45 107.62 3.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.952 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.563 ' CE1' HG12 ' A' ' 269' ' ' VAL . 34.5 t-80 -97.29 136.64 37.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.767 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -164.48 62.94 0.24 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.697 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.462 ' CD2' ' CE1' ' A' ' 240' ' ' HIS . 3.8 m-85 -122.6 143.81 49.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.817 0.341 . . . . 0.0 110.759 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.26 156.7 36.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 5.7 m -58.48 97.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.96 10.37 12.34 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.826 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -60.04 174.11 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.747 0.274 . . . . 0.0 110.724 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 265' ' ' MET . 54.7 m-85 -115.99 130.93 57.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.813 0.34 . . . . 0.0 111.066 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.507 HG21 ' CG2' ' A' ' 292' ' ' VAL . 15.0 m -144.96 159.36 13.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.019 0.438 . . . . 0.0 111.399 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.21 170.71 14.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.983 ' CD2' HG21 ' A' ' 253' ' ' VAL . 3.6 m-30 -99.08 145.49 27.07 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.967 -179.581 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -100.37 -86.6 0.39 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.088 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -119.33 88.32 2.91 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-O 120.535 0.207 . . . . 0.0 110.664 179.627 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.983 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.8 t -102.16 149.9 6.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.55 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.59 30.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.811 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 100.1 -73.29 0.45 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.431 -178.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.436 ' HE1' ' HA ' ' A' ' 285' ' ' ASP . 3.3 tpp -83.71 60.28 5.65 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.2 0.524 . . . . 0.0 110.215 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 16.1 pt -78.63 -33.0 16.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.498 -0.774 . . . . 0.0 112.001 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -38.32 -34.39 0.13 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.897 -178.669 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.493 HD22 ' N ' ' A' ' 259' ' ' LEU . 3.1 mm? -63.7 -50.25 69.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.979 0.419 . . . . 0.0 110.239 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.466 ' ND2' ' O ' ' A' ' 250' ' ' PHE . 9.9 t-20 -53.32 -34.73 58.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.998 179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -85.84 45.06 3.42 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.808 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 4.6 t -165.78 150.21 8.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.743 0.306 . . . . 0.0 110.767 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.64 159.95 0.5 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.849 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.608 ' CB ' HG21 ' A' ' 295' ' ' VAL . 10.4 Cg_endo -53.35 149.13 30.62 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.449 2.099 . . . . 0.0 111.87 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 5.7 ptp -111.91 -173.04 2.16 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.476 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -99.75 155.32 17.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.762 0.315 . . . . 0.0 110.792 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.48 HG23 HG22 ' A' ' 248' ' ' VAL . 1.8 pp -123.47 169.64 14.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.5 0.667 . . . . 0.0 112.127 -179.625 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.607 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -142.36 125.44 16.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.825 -1.079 . . . . 0.0 108.818 178.707 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 269' ' ' VAL . 33.0 m -97.65 112.61 30.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.53 0.681 . . . . 0.0 111.499 -178.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.5 mt -90.77 -27.72 18.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.522 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -167.31 -166.24 26.06 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.582 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.55 -52.88 3.31 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.573 2.182 . . . . 0.0 111.857 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 20.8 m-85 -112.86 18.92 17.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.87 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.88 145.65 49.7 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.67 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.607 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.8 p90 -178.07 159.2 1.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -108.92 170.05 8.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.158 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.2 pt -131.2 -179.98 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.803 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.33 172.85 1.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.905 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.74 118.91 7.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.857 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.9 t -141.17 51.2 1.6 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.984 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 7.2 p -102.69 -22.08 14.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.171 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -96.51 31.4 2.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.748 0.309 . . . . 0.0 111.089 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -128.77 -175.47 3.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.777 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.04 125.76 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.717 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.436 ' HA ' ' HE1' ' A' ' 256' ' ' MET . 0.2 OUTLIER -42.56 149.17 0.19 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.553 -179.688 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -78.14 137.36 38.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.853 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.3 mt -119.11 -65.18 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.102 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -148.71 -174.48 4.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.44 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 55.76 169.02 0.07 OUTLIER Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.258 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.653 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 122.09 116.75 2.4 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.981 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 2.8 mp -128.79 127.31 66.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.729 0.3 . . . . 0.0 110.252 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.59 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.7 p -99.65 111.06 28.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.992 0.425 . . . . 0.0 111.369 -179.405 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -106.36 158.31 16.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.706 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -95.04 92.64 6.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.968 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.608 HG21 ' CB ' ' A' ' 264' ' ' PRO . 13.3 m -58.83 175.07 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.094 179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.78 32.89 0.49 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.889 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.6 t 59.17 84.04 0.21 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.053 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.09 159.14 54.21 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.624 2.216 . . . . 0.0 112.324 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.86 162.65 13.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -136.91 156.82 47.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.826 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 22.6 mm -113.99 144.06 22.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.076 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 27.3 t 63.25 152.38 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.935 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 60.68 109.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.738 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.72 83.01 1.16 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.977 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 27.6 t -111.57 128.97 56.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.691 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.512 ' HB2' ' HD3' ' A' ' 307' ' ' PRO . 14.8 mt -88.28 -48.45 0.44 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.452 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.512 ' HD3' ' HB2' ' A' ' 306' ' ' LEU . 49.9 Cg_endo -91.37 -78.35 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 122.75 2.3 . . . . 0.0 112.674 -179.759 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -176.67 -165.96 0.14 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.827 0.346 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -118.92 -44.74 2.6 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.819 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -130.12 157.17 43.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.768 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.41 -61.09 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.141 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.95 179.97 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 120.873 0.368 . . . . 0.0 111.177 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -137.61 157.28 46.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.01 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 88.82 63.74 1.33 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.495 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -62.34 -66.08 0.59 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.816 0.341 . . . . 0.0 110.904 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -116.57 80.19 1.43 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 2.1 mtt -125.17 -44.27 1.9 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.868 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 31.0 m -65.96 -30.33 49.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.171 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 2.2 tt -86.65 61.18 6.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -118.35 130.01 55.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.814 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.5 t0 74.3 -58.73 0.58 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.025 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 75.65 -62.56 0.43 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.905 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -162.41 -69.5 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.96 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -139.21 175.61 21.51 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.557 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -83.61 130.02 34.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.88 0.371 . . . . 0.0 110.826 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -102.58 157.75 33.1 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.928 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.04 -61.72 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.548 2.165 . . . . 0.0 112.256 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.6 tp -149.45 157.66 43.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 55.9 p -158.0 160.51 37.57 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.025 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.422 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -159.11 170.08 22.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.079 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 6.6 mtm -105.88 157.04 17.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.8 t -109.51 130.6 62.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.836 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 22.9 t -109.94 -35.1 6.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.162 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.46 148.51 27.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.936 0.398 . . . . 0.0 111.067 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.447 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.3 p -158.31 137.04 3.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.969 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 144.63 29.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.01 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.2 ttmt -89.68 72.63 7.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.815 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.1 t70 -122.49 -160.77 0.9 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.858 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.404 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 8.0 p-10 -156.08 90.91 2.7 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.175 -179.687 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.406 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 83.6 Cg_endo -78.87 169.9 70.92 Favored 'Cis proline' 0 C--N 1.349 0.577 0 C-N-CA 123.495 -1.46 . . . . 0.0 112.179 -0.102 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.17 153.01 17.87 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.444 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.3 t -99.85 122.35 51.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.883 0.373 . . . . 0.0 111.0 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.587 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.8 p -114.34 153.81 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.165 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 273' ' ' TYR . 1.7 m -123.33 155.73 36.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.486 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.85 170.02 8.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.83 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.764 HD23 ' H ' ' A' ' 237' ' ' GLU . 0.3 OUTLIER -71.83 143.43 49.46 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.764 179.883 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -24.86 30.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.399 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.764 ' H ' HD23 ' A' ' 235' ' ' LEU . 6.5 mt-10 -100.54 -18.07 16.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.364 -179.856 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -79.57 168.01 19.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.824 0.345 . . . . 0.0 111.247 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.08 -167.83 1.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.864 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 9.3 p80 -171.96 155.33 3.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.847 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 179.26 54.33 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.872 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.435 ' HB2' HD11 ' A' ' 267' ' ' ILE . 1.1 m-85 -103.74 141.05 36.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.823 0.344 . . . . 0.0 110.575 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -71.69 153.44 42.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.7 m -57.08 97.44 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.12 9.44 15.67 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.746 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.17 -165.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.772 0.286 . . . . 0.0 110.545 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.581 ' HB2' HG22 ' A' ' 295' ' ' VAL . 86.9 m-85 -128.9 143.06 50.78 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.916 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.5 HG22 HG23 ' A' ' 267' ' ' ILE . 15.9 m -149.58 134.87 10.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.731 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.1 p -111.95 166.47 11.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.434 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 1.003 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.7 m-30 -99.85 143.93 29.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.02 -179.853 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 25.7 m -99.93 -86.28 0.39 Allowed 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.988 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.598 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -120.02 92.76 3.85 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.266 0.555 . . . . 0.0 110.006 179.896 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 1.003 HG21 ' CD2' ' A' ' 250' ' ' PHE . 4.6 t -111.43 139.02 37.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.383 -179.264 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -99.93 116.27 31.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.194 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.23 -65.53 0.5 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.629 -0.795 . . . . 0.0 111.897 -179.253 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 1.5 ttt -89.91 59.38 4.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.487 . . . . 0.0 110.534 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 15.0 pt -77.99 -33.94 18.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.67 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.7 mm100 -39.24 -34.64 0.2 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.81 -179.091 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.468 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.3 mm? -60.6 -49.54 77.12 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.884 0.373 . . . . 0.0 110.576 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -64.75 -34.82 79.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.835 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -93.1 39.38 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.496 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.5 t -159.26 34.25 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 0.0 110.716 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 61.88 168.41 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.597 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.546 ' HG2' HG12 ' A' ' 295' ' ' VAL . 24.1 Cg_exo -61.46 -153.15 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 111.702 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.563 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.9 ptp -172.78 -175.89 1.36 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.805 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.58 147.37 25.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.656 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.644 HG22 HG22 ' A' ' 277' ' ' ILE . 1.2 pp -119.73 174.99 4.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.675 0.75 . . . . 0.0 112.482 -179.49 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.674 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.0 mttt -147.33 131.07 16.95 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.401 178.67 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.443 HG23 ' O ' ' A' ' 269' ' ' VAL . 34.6 m -97.54 122.33 49.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.433 0.635 . . . . 0.0 111.63 -178.279 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 270' ' ' LEU . 15.0 mt -96.77 -30.87 12.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.651 -179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.29 -171.81 42.09 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.245 -0.979 . . . . 0.0 113.214 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_exo -51.75 112.96 0.96 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.793 2.328 . . . . 0.0 112.475 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.532 ' O ' HG23 ' A' ' 233' ' ' THR . 67.9 m-85 64.71 19.41 11.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.054 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.5 p -133.0 139.35 47.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.459 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.674 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.3 p90 -176.97 166.48 2.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 -179.57 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -118.56 170.05 9.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.992 0.425 . . . . 0.0 111.161 -179.489 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.644 HG22 HG22 ' A' ' 267' ' ' ILE . 1.0 OUTLIER -134.62 -178.63 2.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.848 179.814 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 29.9 p -57.35 -177.55 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -72.56 124.06 24.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.428 ' HA ' ' CD1' ' A' ' 283' ' ' PHE . 8.6 t -137.69 51.88 1.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.971 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 96.5 p -88.37 -54.8 4.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -67.4 -19.62 65.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.192 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.428 ' CD1' ' HA ' ' A' ' 280' ' ' THR . 23.5 m-85 -59.49 -176.94 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.748 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 48.1 t -78.18 -175.81 4.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.895 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.79 127.25 48.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.907 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.495 ' CE1' HG13 ' A' ' 253' ' ' VAL . 65.4 t80 -72.21 140.97 48.99 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 26.1 mt -125.45 -63.51 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.09 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 5.7 mmt180 -153.94 175.56 13.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.655 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.48 149.65 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.424 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.06 115.47 1.19 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.768 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 18.4 mm -114.29 133.43 60.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 120.743 0.306 . . . . 0.0 110.821 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.55 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.1 p -99.89 114.65 38.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.035 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.3 m -119.56 154.44 33.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.051 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.481 ' C ' HG23 ' A' ' 295' ' ' VAL . 12.9 tt0 -66.53 85.85 0.11 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.962 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.581 HG22 ' HB2' ' A' ' 247' ' ' PHE . 0.0 OUTLIER 51.17 -179.47 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.414 179.746 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.48 -65.19 0.18 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 16.3 m -141.08 130.94 13.02 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.041 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.66 -168.37 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.49 2.126 . . . . 0.0 112.372 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.92 154.35 25.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.72 33.03 5.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.882 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.555 ' O ' HG23 ' A' ' 301' ' ' ILE . 2.5 tt -171.07 114.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.099 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.82 -66.9 0.19 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.874 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -138.85 -55.56 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 61.0 106.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 3.0 p -175.09 134.47 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.964 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.8 mp -131.93 68.95 80.89 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.835 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.79 -172.28 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.561 2.174 . . . . 0.0 112.242 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -131.16 161.45 32.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.118 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 93.3 p -70.16 88.31 0.61 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.88 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -115.6 110.39 19.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t 59.73 86.91 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.152 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.174 -0.917 . . . . 0.0 110.878 179.999 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.841 0.353 . . . . 0.0 111.169 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -79.48 95.2 5.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.872 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 179.03 -36.74 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -123.5 75.86 1.36 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.85 0.357 . . . . 0.0 110.949 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 22.0 mm-40 -151.88 137.27 17.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.945 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 5.3 mtp -108.11 127.66 54.0 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.583 ' O ' HG13 ' A' ' 207' ' ' VAL . 8.1 p -133.49 69.43 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.002 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.12 114.73 28.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.787 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.42 HG22 ' H ' ' A' ' 210' ' ' ASP . 2.3 m -128.88 168.3 16.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.896 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.42 ' H ' HG22 ' A' ' 209' ' ' THR . 1.8 t0 -63.58 -172.9 0.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.928 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 27.9 m -78.3 -35.89 47.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.824 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -106.69 143.55 34.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.826 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -103.08 -95.03 2.31 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.534 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 60.01 96.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.943 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -73.2 124.07 90.2 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.815 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -54.97 -171.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.407 2.071 . . . . 0.0 112.28 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.83 126.04 35.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.747 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 50.2 p -136.21 127.87 28.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -122.18 148.8 44.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.079 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -78.31 145.97 35.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.948 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.0 t -99.94 140.6 18.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 6.5 t -105.93 -29.66 9.83 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.016 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.81 158.69 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.027 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.481 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.6 p -160.93 122.08 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 65.0 p -84.31 143.25 29.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.037 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.42 56.34 3.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.473 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.6 t0 -91.61 -151.02 0.26 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.818 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.45 ' ND2' ' OD1' ' A' ' 279' ' ' ASP . 1.6 t30 -159.85 90.57 1.84 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-O 120.489 0.185 . . . . 0.0 111.372 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.473 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 71.8 Cg_endo -73.24 169.11 74.02 Favored 'Cis proline' 0 C--N 1.347 0.493 0 C-N-CA 123.244 -1.565 . . . . 0.0 111.836 -0.132 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -101.41 147.28 17.59 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.436 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.1 t -99.81 145.65 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.87 0.367 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.539 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.4 p -139.2 151.15 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.22 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.412 HG22 ' N ' ' A' ' 234' ' ' CYS . 63.6 m -122.5 161.01 24.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.412 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 234' ' ' CYS . . . . . 0.412 ' N ' HG22 ' A' ' 233' ' ' THR . 3.1 m -99.84 169.29 9.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.879 0.371 . . . . 0.0 110.86 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 2.9 tp -70.69 148.16 48.32 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.834 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -56.26 -30.83 62.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -106.36 50.76 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -178.35 152.79 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.25 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 20.7 ttm105 -135.89 155.41 50.34 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.857 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 23.4 p-80 -111.23 148.37 32.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.792 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -130.27 70.4 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.723 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.61 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.9 OUTLIER -126.55 141.54 51.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.766 0.317 . . . . 0.0 110.746 179.78 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.61 166.97 12.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.941 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 13.2 m -59.58 100.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.9 18.42 5.58 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.856 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.52 174.75 10.78 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.715 0.293 . . . . 0.0 110.767 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.4 m-85 -114.3 134.06 55.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 267' ' ' ILE . 19.1 m -138.24 153.44 26.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.053 0.454 . . . . 0.0 111.359 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 11.1 p -124.2 165.11 18.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.577 179.729 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 1.055 ' CD2' HG21 ' A' ' 253' ' ' VAL . 1.9 m-30 -99.8 141.3 32.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.045 -179.69 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.415 ' CB ' ' HB ' ' A' ' 291' ' ' ILE . 31.3 t -99.91 -101.65 0.23 Allowed 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.7 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' A' ' 290' ' ' GLY . 3.3 pt-20 -102.52 87.58 3.04 Favored 'General case' 0 C--O 1.223 -0.333 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 1.055 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.4 t -105.74 134.38 47.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.869 0.366 . . . . 0.0 111.786 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 18.8 mt-30 -99.9 116.02 30.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.777 178.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.35 -69.02 0.42 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.542 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.608 ' HG3' HD23 ' A' ' 259' ' ' LEU . 10.8 tpp -82.74 62.18 6.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.111 0.481 . . . . 0.0 110.235 179.193 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 37.2 pt -80.09 -33.34 14.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.274 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -38.64 -34.63 0.15 Allowed 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -178.556 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.792 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.2 mm? -72.8 -46.48 52.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.892 0.377 . . . . 0.0 110.703 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 24.2 t30 -57.57 -34.92 69.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.934 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.83 46.27 2.5 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.367 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.66 161.66 13.61 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.858 0.361 . . . . 0.0 110.898 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -54.99 156.83 6.44 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.682 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.794 ' HG3' HG11 ' A' ' 295' ' ' VAL . 19.6 Cg_endo -57.38 157.11 23.17 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.508 2.138 . . . . 0.0 111.941 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.635 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -117.07 -171.19 1.98 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -99.48 153.17 19.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.755 0.312 . . . . 0.0 110.615 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 248' ' ' VAL . 1.7 pp -121.84 173.62 7.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.643 0.735 . . . . 0.0 112.312 -179.315 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 6.1 tttt -144.43 127.14 16.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.749 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.61 HG11 ' O ' ' A' ' 242' ' ' PHE . 15.5 m -97.75 115.18 37.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.436 0.636 . . . . 0.0 111.598 -178.484 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.418 HD23 ' HA ' ' A' ' 270' ' ' LEU . 15.7 mt -94.96 -28.14 15.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.49 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.53 -178.95 39.5 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.576 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -50.61 -48.5 20.21 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.635 2.223 . . . . 0.0 112.217 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 80.8 m-85 -115.95 15.09 16.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.112 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.92 147.72 45.66 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.692 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.611 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.5 p90 -178.35 159.59 1.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.725 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 9.4 t -114.3 170.13 8.53 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.975 0.417 . . . . 0.0 111.32 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.06 -179.17 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.929 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 179.96 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.934 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.45 ' OD1' ' ND2' ' A' ' 228' ' ' ASN . 68.2 m-20 -60.92 134.49 57.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 1.1 p -116.25 -19.92 10.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.372 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 93.0 p -52.92 -27.63 19.69 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 111.332 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -77.76 -25.87 49.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.142 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.792 ' CE2' HD11 ' A' ' 259' ' ' LEU . 13.1 m-85 -91.09 -168.3 2.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.976 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 8.5 p -83.4 -147.09 0.08 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.568 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -119.07 147.11 44.5 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.831 0.348 . . . . 0.0 110.844 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.453 ' CD2' ' CG1' ' A' ' 224' ' ' VAL . 44.5 t80 -80.02 141.49 35.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 30.3 mt -120.45 -59.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.998 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 4.3 mmt85 -163.32 176.63 9.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.408 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.02 155.55 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.935 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.64 119.24 1.77 Allowed Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.867 178.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.415 ' HB ' ' CB ' ' A' ' 251' ' ' SER . 10.9 mt -122.25 134.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.812 0.339 . . . . 0.0 110.557 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.608 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.4 p -99.73 107.35 20.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.252 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 71.0 m -115.12 123.22 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.771 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.445 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 4.5 tt0 -72.65 111.15 7.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.025 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.794 HG11 ' HG3' ' A' ' 264' ' ' PRO . 12.5 m -54.52 157.78 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.312 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.25 79.77 6.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.064 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.756 HG12 HG23 ' A' ' 295' ' ' VAL . 10.7 p -167.69 63.66 0.65 Allowed Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.208 179.742 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.455 ' HD3' ' N ' ' A' ' 297' ' ' VAL . 5.7 Cg_exo -78.05 -51.62 0.07 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.922 2.415 . . . . 0.0 112.335 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.5 149.64 16.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.182 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 1.2 ttmt -144.61 88.53 1.93 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.749 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 4.7 mt 66.35 92.39 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.016 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 4.8 t -110.95 110.81 21.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.934 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 65.97 -75.37 0.05 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.966 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 14.9 pttt -178.16 -176.17 0.52 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.885 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.24 113.89 6.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 60.72 101.49 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.833 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -49.59 166.21 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.487 2.125 . . . . 0.0 112.339 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 61.54 45.0 8.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.033 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -136.65 104.78 5.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.968 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 2.7 tp -82.83 -53.83 5.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.836 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 311' ' ' VAL . . . . . 0.59 HG12 ' O ' ' A' ' 311' ' ' VAL . 15.0 t -111.12 24.7 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.207 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.216 -0.897 . . . . 0.0 110.964 179.936 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 120.789 0.328 . . . . 0.0 111.151 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 65.7 m-85 59.53 92.85 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.015 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -152.79 134.34 4.43 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.517 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -139.67 153.17 47.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.774 0.321 . . . . 0.0 110.937 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -108.73 -31.61 7.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.956 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 206' ' ' MET . . . . . 0.631 ' HG3' HG23 ' A' ' 207' ' ' VAL . 21.0 ptt? -94.53 172.65 8.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.009 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.631 HG23 ' HG3' ' A' ' 206' ' ' MET . 27.6 t 64.67 83.37 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.095 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -142.09 178.89 7.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.819 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 12.7 t -176.46 -160.77 0.07 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.851 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 75.23 106.71 0.08 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.891 0.377 . . . . 0.0 110.821 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.98 148.46 45.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.987 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -118.72 -43.43 2.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 111.01 -119.14 5.11 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.512 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 60.74 23.91 13.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.75 0.309 . . . . 0.0 111.01 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 8.8 mm100 -143.5 86.2 9.0 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.959 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.12 -177.6 2.07 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.663 2.242 . . . . 0.0 112.272 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 3.9 tp -87.55 162.27 17.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.857 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.5 p -162.34 107.7 1.21 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.48 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -100.08 153.77 18.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.978 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.686 ' SD ' HD22 ' A' ' 235' ' ' LEU . 38.8 mtt -90.68 145.77 24.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.935 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.424 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 98.8 t -99.87 136.62 30.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.815 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.1 t -105.95 -35.75 7.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.024 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -163.21 143.6 9.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.444 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.8 p -146.5 130.58 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.053 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 11.4 p -92.29 146.18 23.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.043 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.8 tttm -92.17 86.61 5.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.732 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.423 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.5 OUTLIER -132.96 -158.07 0.86 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.787 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 9.5 p-10 -158.73 91.87 2.01 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-O 120.503 0.192 . . . . 0.0 111.203 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.423 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 86.9 Cg_endo -75.86 169.52 74.28 Favored 'Cis proline' 0 C--N 1.347 0.498 0 C-N-CA 123.327 -1.53 . . . . 0.0 112.083 -0.265 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.97 146.9 17.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.471 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.9 t -99.85 126.87 53.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.973 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.566 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 3.8 p -121.09 155.32 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.275 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.438 ' N ' HG22 ' A' ' 232' ' ' VAL . 6.7 m -118.25 161.3 20.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.648 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.85 161.68 13.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.881 0.372 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.686 HD22 ' SD ' ' A' ' 220' ' ' MET . 8.2 tp -60.26 154.35 20.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.825 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -52.62 -27.12 15.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.032 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.497 ' HG3' HD23 ' A' ' 235' ' ' LEU . 3.2 pt-20 -128.48 37.37 4.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -94.77 -167.41 1.64 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.151 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.62 176.57 8.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.011 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -155.08 114.0 3.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.711 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -133.28 26.38 3.54 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.817 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 0.1 OUTLIER -106.4 135.32 48.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 179.799 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -89.85 174.34 7.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.071 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.28 101.33 0.3 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 113.97 15.86 8.27 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.732 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -76.4 -175.75 3.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.728 0.299 . . . . 0.0 110.653 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.483 ' HA ' ' O ' ' A' ' 265' ' ' MET . 63.1 m-85 -121.95 141.45 51.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.983 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.652 ' HB ' HG23 ' A' ' 292' ' ' VAL . 22.5 m -137.4 155.28 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.504 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.2 p -129.29 161.42 30.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.693 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.521 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.6 m-30 -99.85 137.11 38.76 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.999 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.408 ' CB ' ' HB ' ' A' ' 291' ' ' ILE . 72.4 m -99.77 -104.85 0.22 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.671 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.3 OUTLIER -100.18 87.47 3.46 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.687 HG22 ' CA ' ' A' ' 290' ' ' GLY . 21.8 t -109.91 138.1 39.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.883 0.373 . . . . 0.0 111.707 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -100.73 118.66 37.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.935 179.145 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.45 -65.57 0.48 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.673 -179.049 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.653 ' HG2' HD23 ' A' ' 259' ' ' LEU . 6.3 ttm -85.11 58.95 5.32 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.053 0.454 . . . . 0.0 110.357 179.209 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 4.8 pt -79.99 -33.36 14.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.037 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -39.06 -34.75 0.18 Allowed 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.653 HD23 ' HG2' ' A' ' 256' ' ' MET . 2.7 mm? -79.86 -42.09 24.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.872 0.368 . . . . 0.0 110.701 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 44.8 t30 -54.99 -34.88 63.78 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.063 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.88 28.22 13.41 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.293 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -142.24 165.08 28.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 110.753 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -58.04 166.26 2.14 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.595 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.507 ' HG3' HG21 ' A' ' 295' ' ' VAL . 37.2 Cg_endo -65.48 158.39 53.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.363 2.042 . . . . 0.0 112.094 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.483 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.1 ptp -116.61 -174.17 2.52 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.517 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -99.56 151.26 21.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.719 0.295 . . . . 0.0 110.705 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.482 HG21 HG11 ' A' ' 248' ' ' VAL . 1.8 pp -122.22 174.96 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.612 0.72 . . . . 0.0 112.376 -179.542 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.625 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.3 tptt -146.86 130.71 17.1 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.576 -1.193 . . . . 0.0 108.5 178.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 269' ' ' VAL . 31.0 m -97.74 120.17 46.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.494 0.664 . . . . 0.0 111.585 -178.57 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.432 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.4 mt -98.2 -29.99 12.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.462 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.55 -175.3 36.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.524 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.85 -53.91 6.01 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.638 2.226 . . . . 0.0 112.387 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -112.77 23.22 13.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -133.23 148.45 52.0 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.751 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.625 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -175.33 167.3 3.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -117.58 170.15 8.98 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.473 HD12 HG21 ' A' ' 280' ' ' THR . 14.3 pt -133.09 -179.38 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.843 179.753 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.622 ' O ' HG23 ' A' ' 280' ' ' THR . 32.0 p -63.6 171.0 2.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.83 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.9 p-10 -58.73 112.22 1.55 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.966 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.622 HG23 ' O ' ' A' ' 278' ' ' CYS . 11.2 p -115.81 24.94 11.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.058 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 91.6 p -90.48 9.78 27.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.357 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 62.4 m-20 -111.38 -32.05 6.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.348 . . . . 0.0 110.801 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.552 ' CE2' HD11 ' A' ' 259' ' ' LEU . 12.3 m-85 -78.17 -165.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.802 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.96 -179.78 6.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.868 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -94.1 130.86 40.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.449 ' CE2' HG13 ' A' ' 253' ' ' VAL . 54.4 t80 -60.12 136.33 57.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.838 179.899 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 47.7 mt -115.73 -67.92 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.09 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -151.91 174.01 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.297 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.82 155.98 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.911 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.687 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 138.78 116.12 1.38 Allowed Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.901 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.469 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.1 mp -121.98 138.33 52.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.8 0.334 . . . . 0.0 110.573 179.599 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.652 HG23 ' HB ' ' A' ' 248' ' ' VAL . 13.4 p -99.7 124.95 53.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.517 -179.404 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -121.76 131.94 54.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.528 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.449 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER -86.06 97.82 10.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.317 -179.584 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.507 HG21 ' HG3' ' A' ' 264' ' ' PRO . 35.9 m -58.79 143.18 13.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.753 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -134.17 24.72 3.87 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.339 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.445 ' HB ' ' HD3' ' A' ' 298' ' ' PRO . 2.0 t -90.12 -50.21 0.36 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.406 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.445 ' HD3' ' HB ' ' A' ' 297' ' ' VAL . 3.7 Cg_exo -80.83 -168.23 0.6 Allowed 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.998 2.465 . . . . 0.0 112.219 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 18.5 tttt -179.13 -50.99 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.766 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 3.6 tptt -140.97 -63.8 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.836 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 2.5 pp -71.56 -179.06 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.085 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 99.0 p -161.9 -49.72 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.948 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -68.23 172.8 5.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -133.44 154.52 50.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.909 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 59.5 p -157.38 94.66 1.4 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.7 mp -112.03 87.09 8.3 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.881 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.58 139.76 41.67 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.576 2.184 . . . . 0.0 112.406 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -147.81 -55.17 0.22 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.06 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.87 -76.52 0.6 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.89 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 13.6 mt 58.9 -178.94 0.08 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.907 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t -116.74 -39.28 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.094 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.888 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 . . . . . 0 N--CA 1.486 1.328 0 CA-C-O 120.86 0.362 . . . . 0.0 111.202 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -110.88 162.8 14.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.876 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 162.63 -145.92 11.24 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.539 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -157.16 102.71 1.97 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.847 0.356 . . . . 0.0 110.9 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -142.0 -53.64 0.43 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.877 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -78.47 161.25 27.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.908 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -151.97 -49.12 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.13 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 1.4 mp -112.79 142.88 44.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.924 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.65 -30.73 7.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.918 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 61.56 170.77 0.11 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 16.1 m 60.8 84.47 0.13 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.93 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -174.4 144.47 0.91 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.968 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -165.02 -52.16 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.49 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -94.43 -170.74 2.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.732 0.301 . . . . 0.0 110.815 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.61 75.64 0.39 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.88 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.04 -29.27 22.79 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.69 2.26 . . . . 0.0 112.254 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.754 HD21 ' O ' ' A' ' 241' ' ' GLY . 1.1 mp -91.09 127.72 36.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.747 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.87 150.11 22.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.086 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.45 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -156.63 154.19 29.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 3.4 mtt -95.23 164.19 12.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.112 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 36.5 t -114.72 140.43 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 4.3 t -114.42 -26.33 8.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.255 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -166.73 162.63 16.33 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.851 0.358 . . . . 0.0 111.042 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.444 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.8 p -168.02 151.64 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.176 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 40.1 p -113.93 150.53 33.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 7.5 ttmt -92.53 84.82 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.859 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.414 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.3 t0 -134.67 -160.16 1.03 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.823 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.403 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 14.1 p-10 -156.28 89.7 2.74 Favored Pre-proline 0 CA--C 1.531 0.233 0 CA-C-O 120.506 0.193 . . . . 0.0 111.371 -179.808 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.414 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 85.1 Cg_endo -79.36 169.45 71.28 Favored 'Cis proline' 0 C--N 1.349 0.591 0 C-N-CA 123.448 -1.48 . . . . 0.0 112.202 -0.078 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.65 155.24 16.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.391 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.5 t -99.87 111.09 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.9 0.381 . . . . 0.0 111.028 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.619 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.0 p -102.9 151.95 5.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.059 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.12 139.73 52.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.312 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 61.3 m -99.91 170.07 8.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.023 0.44 . . . . 0.0 111.133 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.638 HD23 ' H ' ' A' ' 237' ' ' GLU . 3.6 tt -49.68 161.27 0.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.923 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -42.05 -31.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.242 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.638 ' H ' HD23 ' A' ' 235' ' ' LEU . 7.3 pt-20 -165.5 51.1 0.1 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.816 0.341 . . . . 0.0 111.239 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -121.33 30.99 6.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.484 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -150.15 131.76 14.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.866 0.365 . . . . 0.0 111.121 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 170.04 90.16 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.852 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 241' ' ' GLY . . . . . 0.754 ' O ' HD21 ' A' ' 217' ' ' LEU . . . 179.79 -35.69 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.779 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.45 ' CD1' HD23 ' A' ' 217' ' ' LEU . 0.1 OUTLIER -85.63 134.5 33.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.922 0.391 . . . . 0.0 110.719 -179.86 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -105.61 171.39 7.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.83 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 62.8 m -53.06 102.03 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.37 25.36 4.7 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.593 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -93.89 166.61 12.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.777 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 265' ' ' MET . 94.6 m-85 -110.86 135.48 51.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.832 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.477 HG22 HG23 ' A' ' 267' ' ' ILE . 14.7 m -143.18 145.58 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.436 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 16.9 p -116.27 170.27 8.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.571 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 1.024 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.5 m-30 -99.46 139.61 34.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.938 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -104.73 -87.95 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.222 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -108.14 88.06 2.64 Favored 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 116.848 -0.16 . . . . 0.0 110.826 179.802 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 1.024 HG21 ' CD2' ' A' ' 250' ' ' PHE . 11.2 t -113.95 132.13 63.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.945 0.403 . . . . 0.0 111.803 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -99.77 115.89 30.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.925 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.94 -59.55 0.59 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.552 -178.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.538 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.5 ttm -92.14 54.63 2.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.107 0.479 . . . . 0.0 110.163 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.438 HG22 ' O ' ' A' ' 253' ' ' VAL . 33.2 pt -77.21 -33.55 20.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.763 -179.47 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -39.14 -34.66 0.18 Allowed 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.835 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.538 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.5 mm? -66.65 -47.11 73.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.915 0.388 . . . . 0.0 110.618 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -56.37 -34.78 66.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.909 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.54 46.24 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.318 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.7 t -167.61 163.83 14.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.749 0.309 . . . . 0.0 110.596 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.28 166.33 0.9 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.586 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.441 ' HG3' HG21 ' A' ' 295' ' ' VAL . 51.5 Cg_endo -68.82 178.61 3.83 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.311 2.007 . . . . 0.0 112.013 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.532 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.0 OUTLIER -136.89 176.18 8.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.78 -179.957 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -99.49 125.07 45.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.477 HG23 HG22 ' A' ' 248' ' ' VAL . 1.4 pp -88.7 163.88 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.546 0.689 . . . . 0.0 112.229 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.655 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.5 OUTLIER -137.88 125.52 22.25 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.744 -1.117 . . . . 0.0 108.586 178.445 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.53 HG23 ' O ' ' A' ' 269' ' ' VAL . 30.3 m -97.29 114.77 35.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.547 0.689 . . . . 0.0 111.573 -178.287 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.0 mt -92.03 -28.45 17.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.494 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -161.59 -163.52 14.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.589 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.47 -48.67 4.15 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.572 2.182 . . . . 0.0 112.111 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -115.27 7.77 15.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.212 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.67 152.73 30.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.764 0.316 . . . . 0.0 110.676 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.655 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.1 p90 -179.78 162.44 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.821 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.7 t -118.64 169.99 9.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.07 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.517 HD11 ' CG2' ' A' ' 280' ' ' THR . 1.3 pp -134.22 -177.51 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.911 179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.406 ' HB2' ' HB2' ' A' ' 265' ' ' MET . 0.1 OUTLIER -54.88 -176.4 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 0.0 111.048 -179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -71.89 99.77 2.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.517 ' CG2' HD11 ' A' ' 277' ' ' ILE . 3.2 t -102.83 56.57 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 59.8 p -104.85 -26.38 12.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.988 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -96.54 31.53 2.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.98 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -126.08 -175.66 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.79 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.45 170.97 12.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.91 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -83.96 122.09 28.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.521 ' CE2' HG13 ' A' ' 253' ' ' VAL . 37.5 t80 -59.25 142.81 50.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.722 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 33.7 mt -119.92 -69.21 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.237 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.2 173.82 14.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.729 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.41 153.81 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.216 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.0 124.38 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.904 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 30.8 mt -123.04 134.45 66.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.789 0.328 . . . . 0.0 110.797 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.645 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.1 p -99.94 102.42 13.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.963 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.7 m -113.72 150.89 32.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.022 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 -79.62 121.63 25.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.441 HG21 ' HG3' ' A' ' 264' ' ' PRO . 2.0 m -57.38 163.01 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.27 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 1.4 pttt -139.0 30.05 2.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.93 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 29.8 m 41.67 53.24 7.26 Favored Pre-proline 0 CA--C 1.531 0.23 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.704 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.27 64.83 3.56 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.538 2.159 . . . . 0.0 112.289 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -113.72 40.71 2.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.929 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.43 33.92 4.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.952 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -68.76 -32.71 55.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.07 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 37.9 t -69.82 140.99 53.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.92 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.55 -46.35 7.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.939 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 3.9 tptm -137.12 -62.14 0.64 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.908 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 1.8 m -148.14 128.33 13.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.623 HD11 HD22 ' A' ' 310' ' ' LEU . 0.2 OUTLIER -112.29 103.62 55.49 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.819 179.951 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -50.32 -62.78 0.35 Allowed 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.449 2.099 . . . . 0.0 112.424 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -179.54 -71.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -85.08 91.65 8.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.945 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 310' ' ' LEU . . . . . 0.623 HD22 HD11 ' A' ' 306' ' ' LEU . 1.6 tp -111.17 -47.28 3.22 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.862 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.1 p -101.41 -29.09 3.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.087 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.937 -179.974 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.831 0.348 . . . . 0.0 111.184 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -94.04 -169.15 2.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.845 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 135.64 -111.6 0.91 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.491 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 62.79 -79.84 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.708 0.289 . . . . 0.0 111.02 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -102.26 -44.88 5.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.974 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 69.2 -64.39 0.33 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.977 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 9.8 t 73.5 91.2 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -127.7 -176.86 3.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.77 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.406 HG23 ' O ' ' A' ' 209' ' ' THR . 3.7 t -109.89 76.7 1.01 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.865 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -108.45 141.37 40.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.92 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 4.4 m -150.89 35.88 0.61 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.942 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 15.8 p-10 -164.78 -43.95 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.938 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -143.05 174.15 23.81 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.564 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 59.64 21.05 9.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.677 0.275 . . . . 0.0 111.218 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.529 ' CB ' ' HD3' ' A' ' 216' ' ' PRO . 2.5 mm-40 -122.41 -60.4 0.03 OUTLIER Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.326 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.529 ' HD3' ' CB ' ' A' ' 215' ' ' GLN . 32.5 Cg_exo -58.18 -161.83 0.02 OUTLIER 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.164 1.91 . . . . 0.0 112.215 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp -138.31 100.97 4.26 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.7 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 52.8 p -124.47 146.91 48.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.04 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.658 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -128.38 167.05 17.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.001 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.423 ' SD ' HD22 ' A' ' 235' ' ' LEU . 11.6 mtt -94.09 148.56 22.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.923 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 49.1 t -99.91 139.32 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.953 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.3 t -106.77 -32.94 7.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.053 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.4 mtp -168.89 144.28 3.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.973 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.595 HG23 ' HB ' ' A' ' 232' ' ' VAL . 10.8 p -142.78 140.87 27.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.047 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 15.6 p -95.91 144.31 26.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.028 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.6 tttt -94.1 83.01 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.456 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.2 t0 -128.67 -158.17 0.87 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.738 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 10.4 p-10 -154.27 89.62 3.3 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-O 120.472 0.177 . . . . 0.0 111.336 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.456 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 93.7 Cg_endo -77.71 169.16 74.37 Favored 'Cis proline' 0 C--N 1.347 0.491 0 C-N-CA 123.437 -1.485 . . . . 0.0 111.996 -0.162 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.76 149.77 17.01 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.598 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.8 141.81 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.72 0.295 . . . . 0.0 110.905 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.61 HG13 ' CE1' ' A' ' 275' ' ' PHE . 5.3 p -134.43 157.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.246 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.482 ' N ' HG22 ' A' ' 232' ' ' VAL . 91.8 m -122.11 156.79 32.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.582 179.757 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.94 166.14 11.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.919 0.39 . . . . 0.0 110.721 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.556 HD23 ' HB2' ' A' ' 237' ' ' GLU . 2.5 tp -66.98 148.15 52.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.785 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -55.38 -26.73 43.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.556 ' HB2' HD23 ' A' ' 235' ' ' LEU . 3.2 mm-40 -98.05 -26.28 14.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.016 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.658 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -68.85 172.68 6.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.21 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -145.97 145.25 30.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.967 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.417 ' CE1' HG12 ' A' ' 269' ' ' VAL . 17.2 t-80 -98.36 135.65 39.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -137.09 27.82 2.86 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.525 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.576 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.1 OUTLIER -116.34 146.34 42.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.584 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -102.55 173.26 6.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.141 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.522 ' CG2' HG22 ' A' ' 269' ' ' VAL . 80.6 p -59.87 103.17 0.19 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.84 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 127.87 -17.78 6.0 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.531 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.09 -178.8 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.739 0.304 . . . . 0.0 110.808 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' A' ' 265' ' ' MET . 49.1 m-85 -122.99 162.08 23.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.07 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.622 ' HB ' HG23 ' A' ' 292' ' ' VAL . 28.8 m -151.74 155.06 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.5 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.8 p -129.66 159.31 36.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.501 179.627 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 1.028 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.3 m-30 -99.65 136.3 39.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.0 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 35.1 t -99.78 -92.49 0.28 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.543 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.73 87.77 2.61 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.468 179.499 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 1.028 HG21 ' CD2' ' A' ' 250' ' ' PHE . 3.9 t -106.3 137.59 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.939 0.4 . . . . 0.0 111.809 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -99.97 112.83 25.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.813 179.061 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.04 -60.28 0.56 Allowed Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.69 -178.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.646 ' HG2' HD23 ' A' ' 259' ' ' LEU . 3.0 ttm -87.88 59.15 5.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.144 0.497 . . . . 0.0 110.478 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.409 HG13 ' N ' ' A' ' 258' ' ' GLN . 28.7 pt -79.95 -33.57 14.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.922 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.409 ' N ' HG13 ' A' ' 257' ' ' ILE . 1.8 mp0 -38.89 -34.64 0.16 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.36 -0.382 . . . . 0.0 112.021 -178.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.849 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.1 mm? -73.01 -46.01 54.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.901 0.381 . . . . 0.0 110.634 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -56.23 -34.85 66.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.864 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.03 46.61 2.89 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.351 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -170.35 160.99 7.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -56.22 156.26 11.17 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.704 179.792 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.796 ' CG ' HG21 ' A' ' 295' ' ' VAL . 19.3 Cg_endo -58.22 171.76 1.61 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.318 2.012 . . . . 0.0 112.062 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.674 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.6 OUTLIER -131.75 -174.36 3.39 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.628 -179.892 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -99.51 148.86 23.82 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.724 0.297 . . . . 0.0 110.698 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.561 HD11 ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -118.64 177.36 2.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.637 0.732 . . . . 0.0 112.376 -179.2 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.658 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.44 130.27 19.27 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.473 -1.239 . . . . 0.0 108.27 178.585 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.576 HG11 ' O ' ' A' ' 242' ' ' PHE . 31.9 m -97.49 117.61 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.588 0.708 . . . . 0.0 111.691 -178.243 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.464 ' HA ' HD23 ' A' ' 270' ' ' LEU . 14.3 mt -91.16 -28.31 17.95 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.846 -1.07 . . . . 0.0 110.545 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 162.64 -166.57 36.75 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.224 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -52.83 112.66 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.785 2.323 . . . . 0.0 112.506 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 62.4 m-85 63.07 18.02 10.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.107 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -128.42 136.95 51.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.454 179.668 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.658 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.77 160.64 1.94 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.806 -179.669 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.1 t -112.61 170.11 8.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.998 0.428 . . . . 0.0 111.179 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.558 HG22 HG22 ' A' ' 267' ' ' ILE . 0.9 OUTLIER -130.88 -179.5 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.919 179.83 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -55.5 -173.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.983 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -58.67 122.56 13.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.5 24.19 13.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.081 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 34.0 t -98.31 -26.6 14.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.031 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.404 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 17.8 t30 -97.41 34.83 1.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.969 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.849 ' CE2' HD11 ' A' ' 259' ' ' LEU . 24.5 m-85 -137.75 -175.5 4.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.852 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 28.7 t -86.35 176.98 7.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -85.62 132.2 34.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.964 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.467 ' CE2' HG13 ' A' ' 253' ' ' VAL . 16.3 t80 -77.49 144.44 37.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.66 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 35.7 mt -126.24 -68.43 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -146.91 -179.87 7.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.602 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.5 161.57 0.05 OUTLIER Glycine 0 C--N 1.332 0.324 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.27 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 132.56 116.22 1.73 Allowed Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.919 178.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 20.6 mt -118.66 133.92 63.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.798 0.332 . . . . 0.0 110.592 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.622 HG23 ' HB ' ' A' ' 248' ' ' VAL . 12.5 p -99.77 120.9 49.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.567 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 20.8 m -119.64 136.69 54.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.67 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.475 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 7.4 tt0 -82.13 96.62 7.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.187 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.796 HG21 ' CG ' ' A' ' 264' ' ' PRO . 31.0 m -71.47 64.59 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.017 179.707 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 2.7 ttpp -148.75 -66.12 0.23 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.97 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.3 t 67.51 73.76 0.35 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.429 ' C ' HD11 ' A' ' 301' ' ' ILE . 45.3 Cg_exo -56.18 95.72 0.06 OUTLIER 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.529 2.152 . . . . 0.0 112.237 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.99 137.67 53.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.992 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 43.48 82.28 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.552 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.429 HD11 ' C ' ' A' ' 298' ' ' PRO . 3.5 mp -120.3 -41.21 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.13 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 9.8 p 61.65 32.78 18.4 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.958 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 59.53 -171.14 0.13 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.034 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -146.52 124.34 11.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.936 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 14.5 p -138.02 50.12 1.92 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.677 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.449 ' N ' ' CD ' ' A' ' 307' ' ' PRO . 2.8 mp -79.61 -49.14 1.39 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.312 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.449 ' CD ' ' N ' ' A' ' 306' ' ' LEU . 92.4 Cg_endo -83.13 11.59 3.22 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.602 2.202 . . . . 0.0 113.087 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -55.68 123.73 15.07 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.797 0.332 . . . . 0.0 111.227 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.06 -56.81 1.1 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.959 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 1.1 mt -87.0 55.78 3.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.916 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 311' ' ' VAL . . . . . 0.426 HG12 ' N ' ' A' ' 312' ' ' GLU . 21.4 t -78.69 156.21 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.185 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 312' ' ' GLU . . . . . 0.426 ' N ' HG12 ' A' ' 311' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.794 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.486 1.372 0 CA-C-O 120.816 0.341 . . . . 0.0 111.16 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 13.5 t80 -103.48 -35.62 8.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.9 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 163.27 176.04 34.87 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.497 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -70.63 142.33 51.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.768 0.318 . . . . 0.0 110.962 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -165.26 137.91 4.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.89 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -148.5 -69.01 0.22 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.847 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.578 HG22 ' O ' ' A' ' 207' ' ' VAL . 14.5 p -177.84 45.23 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.025 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -159.02 74.89 0.67 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.88 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -113.41 -51.18 2.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.863 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 60.16 -176.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.892 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.98 -177.75 4.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.895 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -86.2 133.07 33.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -102.89 45.33 1.35 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.48 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -151.97 172.25 16.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.829 0.347 . . . . 0.0 110.847 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.05 94.51 4.0 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -66.97 154.14 75.61 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.432 2.088 . . . . 0.0 112.084 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.481 HD22 ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -150.44 -175.04 4.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.056 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.4 m -138.37 103.62 4.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.507 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.407 ' HB3' ' CZ ' ' A' ' 242' ' ' PHE . . . -102.12 157.7 16.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.973 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 34.1 mtp -101.73 167.98 9.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.9 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.39 128.6 70.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.992 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.6 t -104.31 -29.42 10.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -167.5 152.66 7.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.001 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.675 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.0 p -158.72 145.37 7.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 7.1 p -106.52 146.38 30.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.853 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.31 80.57 3.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.838 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.439 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.6 OUTLIER -126.22 -157.9 0.82 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -154.02 91.0 3.22 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.355 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.439 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 80.2 Cg_endo -76.3 169.07 75.44 Favored 'Cis proline' 0 C--N 1.348 0.516 0 C-N-CA 123.345 -1.523 . . . . 0.0 112.044 -0.143 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.9 151.9 17.59 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.494 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.1 t -99.98 145.86 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 111.135 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.7 p -142.7 150.2 18.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.097 -179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 273' ' ' TYR . 81.0 m -124.98 143.27 50.98 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.492 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 26.2 m -100.0 170.07 8.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.977 0.418 . . . . 0.0 111.054 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.736 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 1.2 tp -56.5 140.49 45.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.996 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -54.16 -26.7 29.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.984 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.6 mt-10 -114.84 34.49 4.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.736 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -166.41 76.44 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.204 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.48 HH22 HG12 ' A' ' 269' ' ' VAL . 38.3 tpt85 -150.06 87.07 1.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.828 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.481 ' O ' HD22 ' A' ' 217' ' ' LEU . 1.0 OUTLIER -178.8 106.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.107 179.986 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 162.11 -14.96 0.14 Allowed Glycine 0 CA--C 1.52 0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 113.562 179.615 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.568 ' HB2' HD13 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -131.75 132.19 43.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 117.17 0.485 . . . . 0.0 111.258 -179.41 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 243' ' ' GLU . . . . . 0.439 ' O ' HD11 ' A' ' 267' ' ' ILE . 0.7 OUTLIER -124.09 -169.58 1.99 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.778 179.863 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.2 m -61.32 106.07 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.068 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 100.67 26.94 7.79 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.684 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.55 169.75 8.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.765 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.481 ' HA ' ' O ' ' A' ' 265' ' ' MET . 76.8 m-85 -108.17 148.96 29.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.803 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.577 ' HB ' HG23 ' A' ' 292' ' ' VAL . 34.3 m -149.71 144.26 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 111.578 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.7 p -123.67 156.88 35.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.462 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.552 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.8 m-30 -99.52 139.09 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -99.7 -91.86 0.29 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.11 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.06 87.74 2.59 Favored 'General case' 0 C--O 1.224 -0.278 0 C-N-CA 121.21 -0.196 . . . . 0.0 110.822 179.703 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.704 HG22 ' CA ' ' A' ' 290' ' ' GLY . 21.2 t -109.31 143.69 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.871 0.367 . . . . 0.0 111.491 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -105.72 114.93 29.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.087 179.326 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.36 -64.07 0.52 Allowed Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.596 -179.049 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.903 ' HG2' HD23 ' A' ' 259' ' ' LEU . 31.1 ttm -88.91 54.54 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.165 0.507 . . . . 0.0 110.283 179.271 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.58 HG22 ' O ' ' A' ' 253' ' ' VAL . 2.2 pp -80.04 -33.76 14.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.928 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.463 ' HB3' ' CE2' ' A' ' 283' ' ' PHE . 5.7 mm-40 -39.07 -34.47 0.17 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 112.006 -178.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.903 HD23 ' HG2' ' A' ' 256' ' ' MET . 2.9 mm? -64.02 -48.36 76.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.839 0.352 . . . . 0.0 110.682 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.0 t-20 -55.66 -35.06 65.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.94 49.38 1.02 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.71 28.96 0.13 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.104 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 263' ' ' GLN . . . . . 0.402 ' HB3' ' HD2' ' A' ' 264' ' ' PRO . 6.7 mt-30 60.86 156.67 0.11 Allowed Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.525 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.475 ' HG3' HG21 ' A' ' 295' ' ' VAL . 13.3 Cg_endo -55.77 176.33 0.17 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.35 2.033 . . . . 0.0 111.991 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.727 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.5 ptp -142.76 -173.9 4.01 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.632 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -99.39 137.33 38.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.345 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.568 HD13 ' HB2' ' A' ' 242' ' ' PHE . 1.1 pt -106.07 176.45 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.727 0.775 . . . . 0.0 112.472 -179.063 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.5 tttt -148.21 129.95 15.11 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.162 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.48 HG12 HH22 ' A' ' 239' ' ' ARG . 29.0 m -97.3 123.83 49.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.583 0.706 . . . . 0.0 111.423 -178.251 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 55.1 mt -96.41 -28.17 14.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.82 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 169.59 -160.78 34.06 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.417 -0.897 . . . . 0.0 113.14 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.7 111.49 1.92 Allowed 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.711 2.274 . . . . 0.0 112.294 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.824 ' O ' HG23 ' A' ' 233' ' ' THR . 16.2 m-85 71.1 9.37 6.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.23 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.6 p -124.52 145.0 49.81 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.754 0.312 . . . . 0.0 110.617 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.688 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -178.61 170.04 1.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.744 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.9 t -120.35 169.93 9.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.15 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.861 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.1 pp -138.54 -177.91 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.025 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.861 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -54.89 163.65 0.96 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.974 179.962 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -58.41 140.4 53.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.007 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 6.2 t -145.67 31.83 1.06 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 19.9 p -71.24 -46.8 60.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.89 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 12.1 t30 -76.98 -22.53 53.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.059 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.463 ' CE2' ' HB3' ' A' ' 258' ' ' GLN . 3.3 m-85 -67.83 -176.15 0.63 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.3 m -87.29 151.14 23.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.2 142.23 50.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.006 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.444 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 17.6 t80 -72.1 144.96 48.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.88 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.5 mt -124.49 -63.96 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.4 mmt180 -152.8 178.85 9.19 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.434 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.33 164.53 0.08 OUTLIER Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.283 -0.961 . . . . 0.0 112.085 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.704 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 127.89 114.97 1.86 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.038 178.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.651 HD12 ' N ' ' A' ' 291' ' ' ILE . 3.2 mp -121.56 131.06 73.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.79 0.329 . . . . 0.0 110.151 179.228 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.577 HG23 ' HB ' ' A' ' 248' ' ' VAL . 12.9 p -99.83 118.13 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.389 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 58.0 m -121.32 146.95 46.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 6.6 tm0? -84.57 98.33 10.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.962 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.475 HG21 ' HG3' ' A' ' 264' ' ' PRO . 30.3 m -60.59 122.55 11.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.162 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.58 -48.17 1.81 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.6 t -110.53 96.52 27.91 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.052 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -49.31 -56.65 2.95 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.523 2.149 . . . . 0.0 112.467 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.38 130.77 6.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.982 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 13.2 tptt -175.28 74.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.833 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.641 HD12 ' O ' ' A' ' 301' ' ' ILE . 2.4 pp -148.45 123.73 2.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.117 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 67.7 m -97.27 129.8 44.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.951 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -100.72 124.17 45.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.87 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.34 148.31 28.67 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.936 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 33.4 m -140.17 175.9 9.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.963 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 2.9 mp -99.42 126.77 36.45 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.835 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -73.46 166.08 30.8 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.466 2.11 . . . . 0.0 112.317 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 59.49 164.75 0.05 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.174 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 5.8 m -146.77 -56.66 0.26 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.858 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -123.78 74.01 1.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.897 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 7.8 m -120.21 171.19 8.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.126 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.21 -0.9 . . . . 0.0 110.899 -179.966 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 120.802 0.334 . . . . 0.0 111.19 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -95.89 -37.23 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.86 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 169.05 -165.51 38.98 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.485 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -147.08 40.54 1.05 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.841 0.353 . . . . 0.0 110.878 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 62.5 mt-10 -59.84 171.4 0.93 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.918 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 3.7 mtm -89.91 118.22 29.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.866 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.486 ' O ' HG13 ' A' ' 207' ' ' VAL . 12.2 p -140.29 120.5 13.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.094 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 11.9 mt -131.32 52.21 2.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 2.9 m 61.85 114.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.823 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -73.86 164.95 25.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 16.8 p -154.39 113.49 3.68 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -125.76 103.05 7.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.874 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 124.09 -152.03 17.23 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.471 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -131.13 147.07 52.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.885 0.374 . . . . 0.0 110.928 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -164.79 142.44 5.23 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.849 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.93 -175.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.556 2.171 . . . . 0.0 112.243 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.462 HD23 ' HA3' ' A' ' 241' ' ' GLY . 0.2 OUTLIER -83.24 111.6 19.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.816 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.3 m -125.22 159.95 30.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.038 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.478 ' O ' HG23 ' A' ' 291' ' ' ILE . . . -143.96 162.0 37.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.031 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.72 146.39 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.065 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.0 137.59 27.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.91 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.6 t -108.84 -42.07 4.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -151.03 153.74 35.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.109 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.527 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.5 p -161.87 140.28 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.989 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 1.5 p -95.32 148.13 22.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.08 55.86 2.42 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.445 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -102.79 -158.32 0.66 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.708 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 7.0 p-10 -156.97 91.81 2.43 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 120.504 0.193 . . . . 0.0 111.307 -179.693 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.445 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 73.3 Cg_endo -75.54 169.6 74.08 Favored 'Cis proline' 0 C--N 1.348 0.529 0 C-N-CA 123.436 -1.485 . . . . 0.0 112.002 -0.182 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.54 17.47 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.558 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.98 124.69 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.885 0.374 . . . . 0.0 110.974 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.634 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.9 p -117.51 154.39 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.207 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.593 HG23 ' O ' ' A' ' 273' ' ' TYR . 1.3 m -120.57 155.51 33.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.567 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.0 m -99.94 162.58 12.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.844 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.498 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 4.3 tp -60.11 147.69 38.64 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.794 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -64.94 -26.95 68.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.084 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -95.47 -15.12 23.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.054 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.498 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -97.15 171.07 8.69 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.865 0.364 . . . . 0.0 111.172 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -135.1 160.58 37.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.923 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.5 p-80 -96.81 146.81 24.57 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 241' ' ' GLY . . . . . 0.462 ' HA3' HD23 ' A' ' 217' ' ' LEU . . . -138.12 25.05 2.93 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.69 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.452 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.4 OUTLIER -128.3 147.57 50.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.803 0.335 . . . . 0.0 110.732 179.875 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -105.13 174.78 5.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.972 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.6 t -62.49 97.23 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.82 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 137.44 -17.43 3.53 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.561 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.54 -171.24 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.753 0.311 . . . . 0.0 110.8 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -138.46 141.99 39.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.787 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.43 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 33.8 m -148.71 146.03 17.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.039 0.447 . . . . 0.0 111.545 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 21.3 p -112.73 170.08 8.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.33 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.863 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.2 m-30 -99.62 143.07 30.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.082 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -99.97 -86.64 0.38 Allowed 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.134 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.6 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.84 92.62 3.85 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-O 121.127 0.489 . . . . 0.0 110.008 179.997 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.863 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.0 t -109.15 149.03 12.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.349 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 288' ' ' ARG . 18.1 mm-40 -110.36 109.33 19.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.026 179.136 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.57 -53.47 0.83 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.6 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.496 ' HG2' HD23 ' A' ' 259' ' ' LEU . 11.0 ttm -95.63 54.03 1.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.988 0.423 . . . . 0.0 110.333 179.456 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 43.7 pt -80.03 -34.35 15.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.71 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.0 mp0 -39.63 -34.62 0.25 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.748 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.724 HD12 ' SD ' ' A' ' 265' ' ' MET . 2.3 mm? -61.02 -46.44 90.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.38 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 33.5 t30 -61.55 -36.43 80.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.893 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.5 42.93 2.26 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.362 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.4 t -156.06 31.06 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.817 0.342 . . . . 0.0 110.934 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 263' ' ' GLN . . . . . 0.421 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 0.4 OUTLIER 59.67 168.03 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.622 -179.898 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.421 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 28.9 Cg_endo -62.78 -173.03 0.13 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.372 2.048 . . . . 0.0 112.04 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.724 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.4 OUTLIER -156.03 -177.95 6.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.635 -179.917 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -99.85 135.07 41.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.611 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.74 HG22 HG22 ' A' ' 277' ' ' ILE . 1.0 OUTLIER -105.67 178.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 0.0 112.087 -179.604 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.679 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 29.7 mttt -149.01 131.02 15.3 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.659 178.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 10.5 m -97.33 121.8 48.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.473 0.654 . . . . 0.0 111.367 -178.494 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.435 ' HA ' HD23 ' A' ' 270' ' ' LEU . 15.3 mt -96.81 -30.29 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.868 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 164.76 -166.79 38.21 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.074 -1.06 . . . . 0.0 113.404 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_exo -51.16 112.93 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.897 2.398 . . . . 0.0 112.696 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.593 ' O ' HG23 ' A' ' 233' ' ' THR . 31.9 m-85 60.37 20.59 10.17 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.036 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -130.86 139.47 50.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.586 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.679 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.6 p90 -177.17 166.13 2.35 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.734 -179.615 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.9 t -114.83 170.08 8.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.997 0.427 . . . . 0.0 111.133 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.74 HG22 HG22 ' A' ' 267' ' ' ILE . 0.8 OUTLIER -138.56 -179.69 2.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.916 179.923 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.44 160.5 3.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.999 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 13.5 p30 -56.81 138.03 53.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.024 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.432 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.6 p -133.09 27.11 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.954 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -69.54 -30.31 68.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.95 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -84.94 -31.11 23.78 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.432 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 21.3 m-85 -70.1 -175.51 0.97 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.829 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.99 179.83 6.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -89.63 124.93 35.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.47 ' CE2' HG13 ' A' ' 253' ' ' VAL . 15.1 t80 -59.41 139.55 56.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.776 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.8 mt -117.33 -62.2 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.021 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.414 ' O ' ' HB2' ' A' ' 254' ' ' GLN . 2.8 mmt180 -158.2 175.8 13.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.581 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.52 151.44 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.443 -0.884 . . . . 0.0 112.408 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.23 115.66 1.31 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.642 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 219' ' ' ALA . 3.4 mp -113.24 134.12 56.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.797 0.332 . . . . 0.0 110.954 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.559 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.5 p -99.81 115.04 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.124 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.0 m -119.05 143.49 47.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.15 -179.665 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -64.86 83.76 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.948 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER 39.88 92.83 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.844 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -80.18 -7.41 58.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.402 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.4 t 67.12 110.1 0.03 OUTLIER Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.578 0.228 . . . . 0.0 111.076 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_exo -51.45 179.43 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.486 2.124 . . . . 0.0 112.376 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -117.35 -39.55 3.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.972 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 5.5 ttmm -58.54 129.01 40.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.993 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 8.9 mt 59.7 100.51 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.064 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 37.1 p -135.57 143.6 45.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.816 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -98.87 32.88 2.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.915 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.59 141.45 47.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.842 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 1.1 m 59.83 172.47 0.08 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.925 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.728 ' O ' HD22 ' A' ' 306' ' ' LEU . 0.0 OUTLIER -51.77 139.06 31.78 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.271 -179.865 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -78.66 115.73 3.67 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.535 2.157 . . . . 0.0 112.347 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -89.72 76.53 7.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.001 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.0 m -131.81 151.19 51.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.002 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 4.9 tp -140.93 112.06 7.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.884 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.17 -48.68 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.07 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.258 -0.877 . . . . 0.0 110.878 179.979 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.484 1.275 0 CA-C-O 120.877 0.37 . . . . 0.0 111.172 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 57.7 m-85 -119.11 132.04 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.818 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 60.15 -178.97 2.6 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.529 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -87.96 89.62 8.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.886 0.374 . . . . 0.0 110.892 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -79.89 -67.64 0.74 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.872 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.96 -178.27 5.26 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t 64.14 112.16 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.057 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -157.63 162.57 38.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.947 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 59.5 p -141.42 30.21 1.75 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.897 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -177.92 171.82 1.73 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -148.93 27.64 0.86 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.983 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -177.53 161.7 1.75 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 66.89 -155.79 52.12 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.62 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 61.39 152.89 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.913 0.387 . . . . 0.0 110.971 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.43 ' CB ' ' HD3' ' A' ' 216' ' ' PRO . 0.0 OUTLIER -179.02 -52.21 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.959 179.809 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.43 ' HD3' ' CB ' ' A' ' 215' ' ' GLN . 15.7 Cg_exo -67.88 84.33 0.42 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.537 2.158 . . . . 0.0 112.201 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.573 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.2 OUTLIER -68.01 163.29 22.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.837 -179.924 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.5 p -149.52 124.21 9.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.618 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -115.7 170.06 8.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.56 165.76 11.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.895 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.405 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 88.0 t -115.4 125.96 72.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 27.9 t -108.13 -31.15 8.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.27 135.1 7.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.624 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.5 p -142.86 150.26 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 66.3 p -107.42 148.16 29.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.1 tmtt? -99.28 70.18 1.73 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.2 t0 -120.52 -159.64 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 20.4 p30 -153.6 91.03 3.32 Favored Pre-proline 0 CA--C 1.531 0.234 0 CA-C-N 116.717 -0.22 . . . . 0.0 111.328 -179.645 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.401 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 88.1 Cg_endo -78.21 169.75 72.14 Favored 'Cis proline' 0 C--N 1.348 0.535 0 C-N-CA 123.422 -1.491 . . . . 0.0 112.112 -0.142 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.8 149.84 18.78 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.74 140.13 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.878 0.371 . . . . 0.0 110.999 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.624 ' HB ' HG23 ' A' ' 224' ' ' VAL . 5.3 p -134.6 158.04 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.264 -179.691 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.481 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.6 OUTLIER -125.01 160.26 29.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.516 179.697 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.83 167.31 10.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.874 0.369 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.748 HD23 ' HG2' ' A' ' 237' ' ' GLU . 1.0 OUTLIER -61.01 159.83 10.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.731 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -55.36 -29.87 59.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.014 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.748 ' HG2' HD23 ' A' ' 235' ' ' LEU . 1.8 pt-20 -117.48 32.35 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -78.19 -176.94 4.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.111 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 -144.16 148.02 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.943 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -96.99 141.84 29.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.822 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 241' ' ' GLY . . . . . 0.573 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -163.07 29.94 0.26 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.595 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.494 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.1 OUTLIER -147.74 130.56 16.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.752 0.31 . . . . 0.0 110.755 179.991 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.67 179.17 4.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.998 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.67 104.7 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.891 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 123.81 -13.64 8.11 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.757 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -67.67 172.98 4.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.809 0.338 . . . . 0.0 110.777 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -123.31 158.24 31.44 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.45 HG22 HG23 ' A' ' 267' ' ' ILE . 19.8 m -155.11 142.66 12.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.198 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 p -109.99 166.13 11.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.303 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.922 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.4 m-30 -99.66 152.24 20.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.863 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.414 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 61.3 m -108.5 -98.77 0.38 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.072 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.498 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.6 OUTLIER -107.09 88.25 2.69 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.592 0.234 . . . . 0.0 110.666 179.892 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.922 HG21 ' CD2' ' A' ' 250' ' ' PHE . 4.1 t -100.93 148.28 7.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.042 0.449 . . . . 0.0 111.625 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.41 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.0 OUTLIER -111.1 108.59 18.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.576 178.955 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.35 -59.92 0.55 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.276 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.804 ' HG2' HD23 ' A' ' 259' ' ' LEU . 21.2 ttm -92.19 54.88 2.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.177 0.513 . . . . 0.0 110.061 179.08 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 9.0 pt -79.25 -33.23 15.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.598 -0.728 . . . . 0.0 112.22 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.42 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 2.5 mm100 -38.64 -34.54 0.15 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.86 -178.677 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.804 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.3 mm? -67.69 -49.68 61.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.979 0.418 . . . . 0.0 110.474 179.403 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -58.65 -34.83 71.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.78 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.43 44.38 2.92 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.468 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.9 t -164.99 162.97 20.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.6 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -54.5 156.73 5.77 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.553 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.446 ' HG3' HG21 ' A' ' 295' ' ' VAL . 32.1 Cg_endo -63.05 169.53 8.96 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.272 1.982 . . . . 0.0 111.821 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.508 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.0 OUTLIER -134.55 -175.59 3.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.856 -179.69 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -99.66 154.66 18.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.417 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.76 HG22 HG22 ' A' ' 277' ' ' ILE . 1.0 OUTLIER -123.02 174.94 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.66 0.743 . . . . 0.0 112.194 -179.271 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.589 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 32.1 mmtm -143.27 129.07 19.39 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.705 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 269' ' ' VAL . 22.3 m -97.54 112.91 30.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.473 0.654 . . . . 0.0 111.48 -178.455 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 270' ' ' LEU . 13.3 mt -91.02 -27.06 18.88 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.569 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.45 -164.01 21.21 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.627 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -63.34 -50.62 3.35 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.585 2.19 . . . . 0.0 112.027 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.408 ' O ' HG23 ' A' ' 233' ' ' THR . 57.5 m-85 -114.1 12.47 17.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.047 179.665 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -118.83 147.32 44.06 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.636 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.613 ' CZ ' HG13 ' A' ' 232' ' ' VAL . 10.4 p90 -177.95 158.54 1.26 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.959 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.0 t -112.84 170.12 8.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.647 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.865 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.5 pp -135.93 -179.01 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.986 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.865 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.1 OUTLIER -55.56 -178.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.891 -179.982 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -68.13 110.32 3.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.44 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.9 t -110.33 32.97 4.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.4 m -87.78 -22.6 24.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -95.43 38.0 1.17 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.984 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.457 ' CE2' HD11 ' A' ' 259' ' ' LEU . 25.0 m-85 -137.76 -171.48 3.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.728 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -88.85 -166.93 1.72 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.83 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -96.75 145.23 26.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -85.89 139.58 31.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.733 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.87 HG22 ' HD3' ' A' ' 288' ' ' ARG . 68.4 mt -124.27 -71.16 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.87 ' HD3' HG22 ' A' ' 287' ' ' ILE . 3.4 mpt_? -138.93 -178.22 5.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.421 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 57.16 160.59 0.02 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.389 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.585 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 128.99 102.11 1.04 Allowed Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.923 179.109 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.414 ' CD1' ' HB2' ' A' ' 251' ' ' SER . 4.5 mp -109.25 129.04 64.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.738 0.304 . . . . 0.0 110.193 179.363 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.618 HG13 ' HB3' ' A' ' 219' ' ' ALA . 14.3 p -99.61 108.83 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.051 0.453 . . . . 0.0 111.474 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -109.11 173.15 6.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.585 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -99.42 101.98 13.41 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.998 0.428 . . . . 0.0 111.032 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.714 ' CG1' HG12 ' A' ' 297' ' ' VAL . 0.5 OUTLIER -61.75 -39.31 82.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.989 179.99 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 4.0 tmtt? 62.79 48.6 4.05 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.368 179.489 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.714 HG12 ' CG1' ' A' ' 295' ' ' VAL . 11.8 p -106.62 88.34 3.36 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.96 0.409 . . . . 0.0 111.108 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.28 -47.46 1.61 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.509 2.139 . . . . 0.0 112.248 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 2.7 mttp -164.74 69.97 0.17 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.88 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.33 176.92 8.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.858 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.1 tp -178.98 -37.71 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.154 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -54.24 171.31 0.11 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.077 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -97.62 84.58 3.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 7.9 mmtt -101.98 102.09 12.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.97 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.26 -166.67 2.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.91 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 24.6 tp 63.47 64.87 1.34 Allowed Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.965 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.55 -48.45 21.83 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.551 2.168 . . . . 0.0 112.242 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -132.14 -178.85 5.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.051 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 17.7 m -155.0 121.02 5.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.899 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 3.8 mt -82.41 148.37 28.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.986 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 31.4 m -116.19 31.19 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.158 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 22.8 tp10 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.165 -0.921 . . . . 0.0 110.938 179.975 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 120.772 0.32 . . . . 0.0 111.22 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -98.59 30.67 3.17 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.965 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -157.81 125.77 1.61 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.494 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.8 mp0 -102.68 30.53 4.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.83 0.347 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -125.85 -80.38 0.61 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.91 179.877 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 171.83 41.01 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.937 0.399 . . . . 0.0 110.819 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.592 ' O ' HG13 ' A' ' 207' ' ' VAL . 11.5 p -92.01 109.63 21.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.06 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 5.9 tt -172.01 -60.36 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.563 HG23 ' O ' ' A' ' 209' ' ' THR . 9.0 t -106.14 106.32 16.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.873 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -131.83 114.49 14.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.962 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 2.2 t -71.07 -38.56 72.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.813 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 6.9 t30 60.78 -174.71 0.12 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.045 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 169.06 83.44 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.384 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 61.12 98.72 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.887 0.375 . . . . 0.0 110.881 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -176.9 93.81 0.24 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.896 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -49.66 -61.66 0.54 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.596 2.198 . . . . 0.0 112.382 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.409 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.1 OUTLIER -172.46 -176.83 1.63 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.947 179.969 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 p -162.57 141.74 9.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.948 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.506 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -137.4 154.66 49.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.101 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.7 mmm -101.23 156.61 17.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 44.6 t -100.67 138.94 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.973 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 15.0 t -110.24 -39.99 4.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.898 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.3 mmm -169.37 138.96 2.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.496 HG23 ' HB ' ' A' ' 232' ' ' VAL . 8.2 p -139.26 151.17 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.08 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.8 p -102.06 148.08 25.82 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.005 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? -92.19 85.55 5.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.747 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.45 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.8 t0 -132.31 -154.79 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.758 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.423 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 31.4 p30 -159.04 90.77 2.0 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-O 120.445 0.164 . . . . 0.0 111.234 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.45 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 72.8 Cg_endo -74.96 169.03 75.65 Favored 'Cis proline' 0 C--N 1.348 0.543 0 C-N-CA 123.387 -1.505 . . . . 0.0 112.081 -0.282 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.42 151.31 17.14 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 16.9 t -99.9 131.86 46.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 111.074 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.584 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 6.3 p -128.87 158.02 41.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.253 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.489 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -123.77 164.59 18.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.686 179.703 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.3 m -99.94 168.81 9.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.871 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 5.8 tp -64.88 151.25 46.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -58.71 -26.23 63.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.197 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -114.91 32.23 6.16 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -133.07 155.91 48.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.256 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.29 158.6 33.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.883 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -92.31 145.16 24.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 241' ' ' GLY . . . . . 0.409 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -136.97 42.45 1.31 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.579 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.46 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.4 OUTLIER -137.99 138.92 39.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.779 0.323 . . . . 0.0 110.775 179.889 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -88.68 171.9 9.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.924 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.5 m -62.72 101.88 0.29 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.868 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 117.24 0.32 18.9 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.85 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.407 ' CB ' ' HB3' ' A' ' 242' ' ' PHE . 0.4 OUTLIER -65.6 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.658 0.266 . . . . 0.0 110.777 179.923 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.56 ' HA ' ' O ' ' A' ' 265' ' ' MET . 38.2 m-85 -134.41 143.37 47.55 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.896 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.471 HG22 ' CG2' ' A' ' 267' ' ' ILE . 3.4 m -149.99 142.33 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.609 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 25.1 p -115.79 165.91 12.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.452 179.469 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.925 ' CD2' HG21 ' A' ' 253' ' ' VAL . 3.9 m-30 -99.71 148.67 24.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.992 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.42 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 58.7 m -99.89 -90.32 0.31 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.09 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.496 ' O ' ' N ' ' A' ' 290' ' ' GLY . 5.1 pt-20 -113.22 88.03 2.74 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 120.519 0.199 . . . . 0.0 110.768 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.925 HG21 ' CD2' ' A' ' 250' ' ' PHE . 12.1 t -100.02 148.09 6.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 111.6 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.406 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.9 OUTLIER -116.24 110.45 18.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.77 -62.21 0.53 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.627 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.726 ' SD ' HG21 ' A' ' 280' ' ' THR . 25.9 ttm -91.79 61.78 4.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.227 0.537 . . . . 0.0 110.225 179.237 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 23.8 pt -80.03 -32.3 13.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.336 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.445 ' HB2' ' CE2' ' A' ' 283' ' ' PHE . 3.8 tp-100 -37.61 -34.44 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -178.124 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.767 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.1 mm? -67.65 -52.08 42.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.973 0.416 . . . . 0.0 110.414 179.457 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -64.61 -34.95 79.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.119 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.27 38.56 3.16 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.836 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 3.2 t -157.99 36.39 0.25 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.766 0.317 . . . . 0.0 111.08 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 263' ' ' GLN . . . . . 0.449 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 11.8 mt-30 59.05 169.16 0.07 OUTLIER Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.488 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.473 ' HG3' HG12 ' A' ' 295' ' ' VAL . 14.2 Cg_endo -56.97 -164.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.253 1.969 . . . . 0.0 111.593 179.812 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.767 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -169.44 -173.2 1.63 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.791 -179.713 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.55 143.23 30.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.407 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.471 ' CG2' HG22 ' A' ' 248' ' ' VAL . 1.1 pp -118.59 176.81 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.665 0.745 . . . . 0.0 112.388 -179.225 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.522 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -149.87 129.64 13.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.374 178.596 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 269' ' ' VAL . 29.3 m -97.59 112.11 28.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.507 0.67 . . . . 0.0 111.546 -178.255 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 40.4 mt -86.14 -29.78 23.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.476 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.9 -167.23 21.09 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -61.61 -43.52 26.54 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.508 2.139 . . . . 0.0 111.826 179.799 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -117.5 -5.1 11.23 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.049 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.3 p -100.2 148.26 24.81 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.841 0.353 . . . . 0.0 111.006 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.584 ' CZ ' HG13 ' A' ' 232' ' ' VAL . 6.7 p90 -178.58 162.62 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.566 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.409 ' HB3' ' HG3' ' A' ' 268' ' ' LYS . 3.7 t -112.39 167.37 10.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.993 0.425 . . . . 0.0 111.354 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.592 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.2 pp -137.9 -173.42 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.751 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.592 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -52.0 179.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.932 0.396 . . . . 0.0 111.159 -179.939 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -94.69 140.59 29.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.998 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.726 HG21 ' SD ' ' A' ' 256' ' ' MET . 11.7 t -151.21 39.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.78 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 28.9 t -73.93 -7.57 52.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.574 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -108.33 5.94 25.99 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.522 0.201 . . . . 0.0 111.53 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.445 ' CE2' ' HB2' ' A' ' 258' ' ' GLN . 0.2 OUTLIER -110.73 -158.44 0.65 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.594 0.235 . . . . 0.0 110.883 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 2.2 m -96.49 156.62 16.26 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.856 0.36 . . . . 0.0 111.077 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -74.29 151.9 39.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.416 ' HB2' HG13 ' A' ' 224' ' ' VAL . 32.1 t80 -58.86 124.48 19.99 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.927 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 29.5 mt -102.77 -47.79 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.005 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.406 ' O ' ' N ' ' A' ' 254' ' ' GLN . 1.1 mmt-85 -176.97 175.37 1.59 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.167 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 289' ' ' GLY . . . . . 0.406 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 60.39 158.42 0.06 OUTLIER Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.178 -1.01 . . . . 0.0 111.966 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 131.76 115.84 1.73 Allowed Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.723 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.7 mp -125.26 128.38 72.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.775 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.53 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.5 p -100.0 118.79 47.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.175 -179.685 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.9 m -129.58 168.19 16.79 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.121 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.488 ' C ' HG23 ' A' ' 295' ' ' VAL . 1.4 tp60 -67.44 84.68 0.17 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.104 0.478 . . . . 0.0 111.034 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.488 HG23 ' C ' ' A' ' 294' ' ' GLN . 0.2 OUTLIER 55.03 167.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.553 -0.748 . . . . 0.0 111.474 179.387 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 27.5 tttt -82.99 -34.58 26.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.926 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.6 t 64.21 131.62 0.03 OUTLIER Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.961 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -72.37 -168.42 0.39 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.485 2.123 . . . . 0.0 112.361 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.64 84.76 0.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.974 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -166.12 155.86 12.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.891 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.442 HD12 ' H ' ' A' ' 303' ' ' PHE . 2.0 pp -117.48 152.81 19.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.119 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 66.8 m -120.0 37.66 4.16 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.878 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 303' ' ' PHE . . . . . 0.442 ' H ' HD12 ' A' ' 301' ' ' ILE . 2.8 m-85 61.21 166.73 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.863 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 2.0 mmtp -60.47 154.82 19.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.962 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 305' ' ' SER . . . . . 0.49 ' O ' HD23 ' A' ' 306' ' ' LEU . 0.5 OUTLIER -149.99 94.7 2.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.95 179.885 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.49 HD23 ' O ' ' A' ' 305' ' ' SER . 11.8 mt -137.85 106.74 8.21 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.84 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -68.43 -44.1 3.64 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.422 2.081 . . . . 0.0 112.251 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -108.32 160.07 16.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.094 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.32 79.05 1.34 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.895 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 65.4 mt -88.12 -39.37 14.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.939 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.2 p -176.1 149.42 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.077 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.237 -0.887 . . . . 0.0 110.971 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 . . . . . 0 N--CA 1.485 1.321 0 CA-C-O 120.789 0.328 . . . . 0.0 111.239 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -92.2 96.33 10.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.965 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -157.72 129.53 2.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.522 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -103.7 -27.14 12.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.8 0.334 . . . . 0.0 111.065 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -64.87 81.16 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.031 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -161.93 -53.2 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.882 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 6.0 m -105.71 -30.6 2.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.074 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -107.78 29.87 6.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.85 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 2.7 t -93.59 -39.32 10.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.911 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -142.72 -74.56 0.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.944 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 16.5 m 60.05 162.19 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.935 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -175.66 38.89 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -100.64 -140.62 11.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.477 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -167.48 -169.82 1.3 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.756 0.312 . . . . 0.0 110.881 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 60.69 98.64 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.83 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -49.39 176.14 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.493 2.129 . . . . 0.0 112.48 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -97.92 -171.09 2.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.926 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 11.2 t -166.53 155.67 11.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.796 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.585 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -149.1 166.8 27.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.019 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.557 ' HE1' HD22 ' A' ' 235' ' ' LEU . 10.9 mtp -107.63 147.48 30.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 40.5 t -105.93 139.56 26.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.995 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 8.3 t -106.61 -31.9 8.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.976 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.1 ptm -168.16 163.94 13.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.968 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.644 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.6 p -162.36 118.62 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.037 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 76.9 p -76.48 140.59 41.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.828 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -90.17 68.15 7.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.795 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.408 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 5.0 t0 -106.69 -148.0 0.41 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.781 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -160.26 88.88 1.82 Allowed Pre-proline 0 CA--C 1.531 0.227 0 CA-C-O 120.536 0.208 . . . . 0.0 111.305 -179.67 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.408 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 97.2 Cg_endo -76.4 169.52 74.23 Favored 'Cis proline' 0 C--N 1.347 0.488 0 C-N-CA 123.27 -1.554 . . . . 0.0 111.945 -0.148 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -100.43 147.63 18.08 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.501 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.2 t -99.81 118.89 47.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.847 0.356 . . . . 0.0 111.058 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.644 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.8 p -110.37 154.24 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.058 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.403 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -128.32 161.8 28.56 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.691 179.731 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -100.04 169.63 9.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.92 0.39 . . . . 0.0 110.845 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.655 HD23 ' HG2' ' A' ' 237' ' ' GLU . 0.4 OUTLIER -60.26 161.6 6.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.794 179.891 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -54.63 -32.86 59.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.074 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.655 ' HG2' HD23 ' A' ' 235' ' ' LEU . 9.3 pt-20 -119.16 32.19 6.24 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.824 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -82.81 -175.74 5.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.082 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.41 136.12 23.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.933 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 2.8 t60 -105.9 137.24 44.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -149.83 26.73 1.17 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.674 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.618 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -114.52 138.39 50.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.813 0.339 . . . . 0.0 110.679 179.899 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 165.0 14.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.03 87.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 138.51 -12.72 3.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.718 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -57.46 -179.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.771 0.32 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.451 ' HA ' ' O ' ' A' ' 265' ' ' MET . 51.1 m-85 -125.07 146.77 49.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.057 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.436 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -148.47 147.86 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.173 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.5 p -115.95 167.88 10.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.623 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 1.038 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.6 m-30 -99.64 146.65 26.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.077 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.412 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 53.8 m -109.46 -89.94 0.47 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.77 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.2 87.59 2.56 Favored 'General case' 0 C--O 1.221 -0.397 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 179.416 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 1.038 HG21 ' CD2' ' A' ' 250' ' ' PHE . 8.0 t -109.47 134.98 49.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.92 0.39 . . . . 0.0 111.873 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 21.2 mt-30 -100.32 114.38 27.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.815 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.05 -58.6 0.61 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.672 -178.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.681 ' HG2' HD23 ' A' ' 259' ' ' LEU . 1.4 ttm -91.04 59.9 4.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.128 0.489 . . . . 0.0 110.359 179.358 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.6 pp -79.52 -33.37 15.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.985 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -39.1 -34.61 0.18 Allowed 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.876 -178.823 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.857 HD11 ' CE2' ' A' ' 283' ' ' PHE . 2.8 mm? -77.76 -44.45 27.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.87 0.366 . . . . 0.0 110.504 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -60.03 -34.84 73.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.851 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.52 42.92 2.38 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.324 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -165.42 171.14 13.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.803 0.335 . . . . 0.0 110.764 -179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 11.3 mt-30 -57.63 167.7 1.29 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.64 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.494 ' HG3' HG21 ' A' ' 295' ' ' VAL . 39.9 Cg_endo -66.5 -166.68 0.11 Allowed 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.38 2.053 . . . . 0.0 112.005 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.59 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -156.07 -175.84 5.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.575 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -99.71 148.08 24.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.771 0.319 . . . . 0.0 110.628 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.707 HG22 HG22 ' A' ' 277' ' ' ILE . 1.6 pp -119.76 172.84 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.528 0.68 . . . . 0.0 112.263 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.627 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.3 mmtm -143.47 127.97 17.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 114.71 -1.132 . . . . 0.0 108.736 178.864 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.618 HG11 ' O ' ' A' ' 242' ' ' PHE . 35.9 m -97.6 114.56 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.471 0.653 . . . . 0.0 111.503 -178.556 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.402 HD23 ' HA ' ' A' ' 270' ' ' LEU . 16.1 mt -92.5 -28.72 16.63 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.567 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.76 -163.66 18.38 Favored Glycine 0 N--CA 1.453 -0.202 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.593 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.08 -49.29 3.95 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.639 2.226 . . . . 0.0 111.992 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -114.82 11.58 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.101 179.773 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.95 148.54 42.84 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.856 0.36 . . . . 0.0 110.704 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.627 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.9 p90 -177.5 161.73 1.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 12.2 t -123.38 170.27 10.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.01 0.433 . . . . 0.0 111.218 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.707 HG22 HG22 ' A' ' 267' ' ' ILE . 1.6 pp -133.9 -179.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.844 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.484 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.4 OUTLIER -56.42 -170.1 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.076 -179.915 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -55.8 132.69 50.03 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.026 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.57 7.24 8.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.404 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -86.04 5.28 34.21 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.749 -0.205 . . . . 0.0 111.463 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -111.67 -23.48 10.63 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.684 0.278 . . . . 0.0 111.177 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.857 ' CE2' HD11 ' A' ' 259' ' ' LEU . 29.5 m-85 -85.43 -170.41 3.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 64.1 m -88.56 -175.43 4.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.86 137.27 32.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.582 ' CE1' HG13 ' A' ' 253' ' ' VAL . 70.0 t80 -78.13 146.61 35.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.773 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 27.1 mt -125.02 -67.87 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.186 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.55 176.43 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.559 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.96 158.25 0.05 OUTLIER Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.287 -0.958 . . . . 0.0 112.068 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.13 108.83 0.9 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.98 178.66 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.412 ' HB ' ' HB2' ' A' ' 251' ' ' SER . 14.8 mm -106.5 130.98 57.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.727 0.299 . . . . 0.0 110.479 179.505 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.597 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.5 p -99.72 109.75 25.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.916 0.389 . . . . 0.0 111.322 -179.59 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -111.77 156.34 22.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.654 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 -90.39 108.44 19.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.032 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.511 HG13 ' N ' ' A' ' 296' ' ' LYS . 0.5 OUTLIER -58.62 167.08 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.876 179.942 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.511 ' N ' HG13 ' A' ' 295' ' ' VAL . 3.9 tttp -151.09 -71.54 0.17 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.026 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.448 ' O ' HG23 ' A' ' 297' ' ' VAL . 5.7 m -141.5 96.44 6.96 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.115 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.39 115.73 4.18 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.43 2.087 . . . . 0.0 112.269 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 35.6 tptt -151.47 31.69 0.58 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.861 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 3.4 ptmt -122.66 109.1 13.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 33.5 mt -85.72 -67.98 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.168 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 50.4 p 179.77 163.05 0.99 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.889 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 63.37 -79.02 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.021 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -115.93 89.2 3.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.008 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 305' ' ' SER . . . . . 0.444 ' OG ' HD12 ' A' ' 306' ' ' LEU . 2.5 p -97.17 -35.77 10.67 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.818 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.617 ' H ' ' HD2' ' A' ' 307' ' ' PRO . 0.6 OUTLIER -147.18 -60.13 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.217 179.69 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.617 ' HD2' ' H ' ' A' ' 306' ' ' LEU . 34.6 Cg_endo -63.62 77.32 0.14 Allowed 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 122.069 1.846 . . . . 0.0 112.236 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -176.23 -73.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.142 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 3.3 p 50.22 86.33 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.234 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 15.5 tp -164.86 91.4 0.55 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.886 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 311' ' ' VAL . . . . . 0.479 HG12 ' N ' ' A' ' 312' ' ' GLU . 21.5 t 62.52 158.85 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.136 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 312' ' ' GLU . . . . . 0.479 ' N ' HG12 ' A' ' 311' ' ' VAL . 37.9 mt-10 . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.858 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.4 tp . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.803 0.335 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 90.1 p -151.56 167.05 29.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.04 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.703 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -157.15 164.7 37.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.962 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -109.89 154.55 22.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.013 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 90.3 t -99.92 123.2 52.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.794 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 31.2 t -100.14 -31.45 11.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.118 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -169.14 135.12 1.65 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.675 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.0 p -142.56 149.37 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.027 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 81.6 p -107.34 149.46 27.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.921 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -95.91 79.48 3.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.412 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -129.07 -161.43 1.11 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.789 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.442 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 0.8 OUTLIER -152.49 87.51 4.15 Favored Pre-proline 0 C--N 1.331 -0.203 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.292 -179.609 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 74.6 Cg_endo -82.7 169.6 59.52 Favored 'Cis proline' 0 C--N 1.348 0.513 0 C-N-CA 123.49 -1.462 . . . . 0.0 112.271 -0.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -111.9 153.01 17.57 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.24 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.87 121.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.83 0.348 . . . . 0.0 111.018 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 224' ' ' VAL . 3.3 p -117.27 156.68 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.133 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.453 ' N ' HG22 ' A' ' 232' ' ' VAL . 87.8 m -122.2 160.6 24.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.564 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . 0.407 ' N ' HG22 ' A' ' 233' ' ' THR . 1.6 m -99.9 170.04 8.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.816 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.67 140.93 36.88 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.848 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -53.6 -36.02 61.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.39 . . . . 0.0 110.823 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -94.09 44.85 1.13 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.074 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -159.85 159.59 32.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.218 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -127.47 146.59 50.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.007 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -101.28 149.42 24.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.776 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -143.83 43.74 0.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.688 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.696 ' O ' HG11 ' A' ' 269' ' ' VAL . 1.6 m-85 -127.1 145.32 50.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.712 0.291 . . . . 0.0 110.651 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -108.65 173.29 6.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.974 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.526 HG22 ' HG3' ' A' ' 268' ' ' LYS . 0.7 OUTLIER -59.58 94.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 -179.967 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.62 -15.58 3.84 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.714 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -63.13 -178.36 0.23 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.738 0.304 . . . . 0.0 110.859 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 265' ' ' MET . 33.6 m-85 -131.79 146.46 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.985 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.525 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -144.85 150.43 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.282 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.0 p -120.86 164.28 16.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.74 ' HD2' HG21 ' A' ' 253' ' ' VAL . 4.2 m-30 -99.74 143.59 29.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.75 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . 0.418 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 58.1 m -99.97 -90.77 0.31 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.408 -179.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.5 OUTLIER -116.3 88.75 2.96 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 120.505 0.193 . . . . 0.0 111.109 -179.851 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.744 HG22 ' HA2' ' A' ' 290' ' ' GLY . 2.4 t -100.24 155.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.977 0.418 . . . . 0.0 111.268 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -111.61 102.59 10.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.901 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.7 -53.71 0.81 Allowed Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.553 -178.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.638 ' HG2' HD23 ' A' ' 259' ' ' LEU . 39.2 ttm -93.04 49.35 1.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.982 0.42 . . . . 0.0 110.483 179.367 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -79.19 -34.01 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.78 -179.557 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.6 mm-40 -39.33 -34.74 0.22 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.936 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.678 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.8 mm? -59.7 -45.28 92.58 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.325 . . . . 0.0 110.792 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 47.3 t30 -64.02 -34.93 79.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.24 39.6 2.79 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.292 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.3 t -151.54 30.53 0.6 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.686 0.279 . . . . 0.0 110.945 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 61.31 156.16 0.11 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.545 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.1 168.06 6.57 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.37 2.046 . . . . 0.0 112.035 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.678 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.8 OUTLIER -132.67 -175.24 3.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.769 -179.859 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -99.67 134.85 41.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.543 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.525 HG23 HG22 ' A' ' 248' ' ' VAL . 1.0 OUTLIER -103.8 172.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.627 0.727 . . . . 0.0 112.311 -179.239 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.606 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 10.0 ttpp -140.34 127.42 20.91 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.641 178.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.696 HG11 ' O ' ' A' ' 242' ' ' PHE . 6.4 m -97.58 115.0 36.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 0.0 111.709 -178.297 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 51.1 mt -92.93 -28.83 16.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.385 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.23 -167.92 26.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.543 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.98 -49.6 9.38 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.534 2.156 . . . . 0.0 111.921 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -115.06 14.15 17.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.915 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.7 p -120.04 147.28 45.01 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.623 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.606 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.9 p90 -177.87 161.74 1.62 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.98 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.66 170.08 9.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.946 0.403 . . . . 0.0 111.113 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.725 HD12 ' O ' ' A' ' 278' ' ' CYS . 1.7 pp -133.41 176.89 7.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.931 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.725 ' O ' HD12 ' A' ' 277' ' ' ILE . 31.0 p -58.83 -177.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.922 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -66.63 110.12 3.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 10.2 t -108.03 31.71 5.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.6 m -87.12 -15.49 38.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.194 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.06 33.6 1.7 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.771 0.319 . . . . 0.0 111.021 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -144.05 175.64 9.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.797 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.61 174.27 6.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.729 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -83.56 137.11 33.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -64.97 121.32 14.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.866 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 23.0 mt -105.99 -55.59 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 6.9 mtt180 -158.98 -171.33 3.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.378 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 53.34 177.62 0.08 OUTLIER Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.344 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.744 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 116.05 106.01 2.5 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.98 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' A' ' 251' ' ' SER . 7.6 mm -114.58 129.69 70.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.703 HG13 ' HB3' ' A' ' 219' ' ' ALA . 9.1 p -99.74 117.89 45.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.982 0.42 . . . . 0.0 111.484 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -120.45 175.72 5.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.629 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.747 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.054 0 CA-C-O 120.828 0.347 . . . . 0.0 110.875 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 2.2 m -157.6 134.42 9.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.428 ' HB2' ' O ' ' A' ' 239' ' ' ARG . . . -136.71 159.6 41.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.038 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.2 mtt -105.09 155.36 19.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 45.2 t -100.67 137.02 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.002 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.2 t -112.18 -37.8 4.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.72 150.77 25.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.92 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.438 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.2 p -159.96 142.79 5.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.047 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 51.5 p -106.62 146.33 30.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.948 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 31.1 tttt -90.72 64.57 5.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.437 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -106.32 -156.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.811 -179.92 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.458 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 9.3 t-20 -157.07 89.52 2.55 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.567 0.223 . . . . 0.0 111.389 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 91.2 Cg_endo -77.69 169.12 74.5 Favored 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 123.347 -1.522 . . . . 0.0 112.012 -0.273 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.72 148.67 16.54 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.429 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 30.7 t -99.92 120.48 49.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.907 0.384 . . . . 0.0 111.029 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.523 HG13 ' CE2' ' A' ' 275' ' ' PHE . 2.6 p -112.99 155.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.12 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.439 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -119.83 162.23 19.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.63 179.817 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.9 m -99.95 166.58 10.99 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.954 0.407 . . . . 0.0 110.935 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.812 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 11.2 tp -59.28 153.66 18.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.701 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -51.68 -27.12 10.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.095 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.481 ' HG3' HD23 ' A' ' 235' ' ' LEU . 2.5 pt-20 -134.79 42.69 2.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.853 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.812 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -91.32 -176.65 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.428 ' O ' ' HB2' ' A' ' 219' ' ' ALA . 1.3 tpm_? -130.62 135.46 47.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 38.5 p-80 -109.66 110.67 21.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . 0.747 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -126.13 -0.48 7.53 Favored Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.991 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.401 ' HB3' ' HB3' ' A' ' 246' ' ' ASP . 1.5 m-85 -80.45 139.67 36.33 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.866 0.365 . . . . 0.0 110.705 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . 0.449 ' O ' HD11 ' A' ' 267' ' ' ILE . 0.8 OUTLIER -92.49 169.4 10.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.928 -179.919 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 4.6 m -59.83 91.57 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.85 23.98 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.685 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.401 ' HB3' ' HB3' ' A' ' 242' ' ' PHE . 1.5 t70 -78.74 170.03 17.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 110.879 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 47.9 m-85 -104.36 122.39 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.903 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 267' ' ' ILE . 30.2 m -128.07 143.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.345 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.2 p -119.82 165.85 14.04 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.739 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.509 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.0 m-30 -99.58 145.24 27.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.96 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . 0.402 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 0.5 OUTLIER -105.0 -88.29 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.988 -179.93 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.606 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.63 90.99 3.45 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.233 0.54 . . . . 0.0 109.769 179.765 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.754 HG22 ' CA ' ' A' ' 290' ' ' GLY . 17.3 t -116.08 139.26 43.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.607 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 119.68 38.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.219 179.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.09 -65.67 0.5 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.778 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.67 ' HG2' HD23 ' A' ' 259' ' ' LEU . 6.4 ttm -85.75 59.73 5.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.089 0.471 . . . . 0.0 110.396 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.41 HG13 ' N ' ' A' ' 258' ' ' GLN . 29.9 pt -80.14 -33.39 14.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.977 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.416 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.1 OUTLIER -38.94 -34.72 0.17 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.897 -178.87 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.838 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.1 mm? -75.15 -44.71 45.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.838 0.351 . . . . 0.0 110.614 179.587 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -57.45 -34.89 69.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.892 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.71 38.64 3.07 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.43 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -158.46 165.2 35.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.755 0.312 . . . . 0.0 110.759 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -56.55 167.66 0.94 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.669 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -67.98 169.37 16.58 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.335 2.023 . . . . 0.0 111.999 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.638 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.7 OUTLIER -129.39 -176.99 4.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.716 179.929 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.37 140.7 33.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.757 0.313 . . . . 0.0 110.649 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.449 HD11 ' O ' ' A' ' 243' ' ' GLU . 1.2 pp -106.77 171.91 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.55 0.691 . . . . 0.0 112.212 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.622 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -143.05 125.58 15.78 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.617 178.797 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.66 115.53 37.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.598 0.714 . . . . 0.0 111.43 -178.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 50.1 mt -94.27 -27.7 15.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.789 -1.096 . . . . 0.0 110.503 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -163.9 -170.67 29.14 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -62.96 -35.34 66.99 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.52 2.147 . . . . 0.0 112.056 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -123.93 2.44 8.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.169 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -112.24 149.94 31.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.798 0.333 . . . . 0.0 110.791 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.622 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.9 p90 -177.44 162.27 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.767 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 5.1 t -118.19 170.17 9.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.933 0.397 . . . . 0.0 111.332 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.456 HD12 ' O ' ' A' ' 278' ' ' CYS . 1.2 pp -133.95 179.3 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.947 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.456 ' O ' HD12 ' A' ' 277' ' ' ILE . 1.2 m -58.51 -173.41 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.9 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.407 ' O ' ' CE2' ' A' ' 283' ' ' PHE . 1.7 m-20 -54.12 126.58 23.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.98 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.541 HG22 ' CE ' ' A' ' 256' ' ' MET . 0.3 OUTLIER -110.02 -30.15 7.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.968 -179.898 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 2.9 m -59.44 -30.49 68.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.019 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -71.8 -31.01 66.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.998 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.838 ' CE2' HD11 ' A' ' 259' ' ' LEU . 50.7 m-85 -89.51 -172.92 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 75.4 m -78.63 -178.32 5.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.993 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -93.26 135.39 34.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.855 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.722 ' CE2' HG13 ' A' ' 253' ' ' VAL . 39.3 t80 -74.94 138.09 42.1 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.746 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.2 mt -117.05 -66.81 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.197 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 -152.65 170.68 19.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.664 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.77 149.72 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.143 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.754 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 142.81 116.64 1.18 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.801 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.437 HD12 ' N ' ' A' ' 291' ' ' ILE . 3.9 mp -117.44 133.56 63.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.755 0.312 . . . . 0.0 110.711 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.481 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.8 p -99.88 122.08 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.219 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.7 m -131.48 158.19 41.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.94 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.745 HD23 ' CE1' ' A' ' 242' ' ' PHE . 29.7 tp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.844 0.355 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 13.7 t -147.42 154.71 41.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.834 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.44 155.98 40.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.043 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -94.26 143.44 26.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 39.1 t -99.92 145.04 11.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.058 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 38.7 t -112.79 -32.96 6.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.073 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 14.7 ptm -169.5 159.05 8.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.559 HG12 ' CG ' ' A' ' 286' ' ' TYR . 8.5 p -158.87 149.21 7.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.062 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 63.3 p -99.46 147.56 25.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.948 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.04 81.44 3.7 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.435 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.6 t0 -127.76 -157.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.796 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.464 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 1.6 p30 -154.68 90.59 3.09 Favored Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 -179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 97.3 Cg_endo -77.13 169.39 74.38 Favored 'Cis proline' 0 C--N 1.347 0.477 0 C-N-CA 123.369 -1.513 . . . . 0.0 112.011 -0.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.76 151.3 17.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.45 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.6 t -99.87 140.25 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.843 0.354 . . . . 0.0 111.008 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.574 HG13 ' CE1' ' A' ' 275' ' ' PHE . 3.3 p -130.88 151.96 36.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.141 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 4.9 m -114.19 158.12 21.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.67 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.1 m -99.97 166.64 10.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.819 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 7.2 tp -59.11 152.25 20.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.789 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -50.95 -27.21 7.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.143 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -132.79 38.35 3.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.819 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -87.68 -169.0 2.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.158 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.2 ttm180 -145.35 106.84 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.924 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.492 ' CE1' ' CD2' ' A' ' 275' ' ' PHE . 27.5 t60 -107.61 143.64 35.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.82 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 177.04 68.79 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.678 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.745 ' CE1' HD23 ' A' ' 217' ' ' LEU . 15.3 m-85 -116.32 149.26 39.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.861 0.362 . . . . 0.0 110.762 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -69.28 151.33 46.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.5 m -57.86 97.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.78 15.35 9.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.721 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -64.9 -178.67 0.45 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.657 0.265 . . . . 0.0 110.743 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.495 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.8 m-85 -120.24 132.06 55.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.789 0.328 . . . . 0.0 110.982 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.419 HG22 HG23 ' A' ' 267' ' ' ILE . 17.8 m -137.32 154.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.421 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.4 p -125.59 165.0 19.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.556 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.665 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.6 m-30 -99.74 140.59 33.73 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.041 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 62.2 m -99.96 -94.09 0.26 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.033 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.54 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.2 OUTLIER -109.66 87.74 2.58 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 121.27 -0.172 . . . . 0.0 110.636 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.665 HG21 ' CD2' ' A' ' 250' ' ' PHE . 15.5 t -107.21 144.72 15.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.928 0.394 . . . . 0.0 111.726 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -107.92 114.94 29.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.912 179.161 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.6 -63.52 0.51 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.671 -0.776 . . . . 0.0 111.458 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.64 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.9 ttm -89.24 54.57 3.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.133 0.492 . . . . 0.0 110.152 179.035 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.415 HG22 ' O ' ' A' ' 253' ' ' VAL . 14.2 pt -79.04 -33.35 15.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.045 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -38.76 -34.71 0.16 Allowed 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.933 -178.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.64 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.2 mm? -71.08 -47.03 60.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.943 0.401 . . . . 0.0 110.49 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -55.86 -34.85 65.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.896 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.14 46.37 3.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -169.1 166.34 10.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.784 0.326 . . . . 0.0 110.663 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -55.91 164.19 1.83 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.9 168.54 13.43 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.242 1.961 . . . . 0.0 112.078 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.497 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -128.35 -172.29 2.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.516 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -99.37 151.43 21.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.758 0.313 . . . . 0.0 110.654 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.419 HG23 HG22 ' A' ' 248' ' ' VAL . 2.1 pp -123.1 174.0 8.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.593 0.711 . . . . 0.0 112.316 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.569 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.2 OUTLIER -147.43 127.77 13.95 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.738 178.919 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 269' ' ' VAL . 34.9 m -97.88 112.75 30.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.434 0.635 . . . . 0.0 111.539 -178.535 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 270' ' ' LEU . 17.6 mt -89.04 -28.0 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.449 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.63 -164.17 24.9 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.583 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 -44.25 9.06 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.586 2.191 . . . . 0.0 112.099 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -117.03 18.34 14.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.029 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.97 146.66 51.67 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.92 0.391 . . . . 0.0 110.794 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.574 ' CE1' HG13 ' A' ' 232' ' ' VAL . 2.2 p90 -178.62 154.12 0.74 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.639 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.7 t -105.58 170.06 8.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.014 0.435 . . . . 0.0 111.441 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.61 -178.02 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.84 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.31 175.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.987 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.38 133.2 50.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 62.9 p -118.07 28.57 8.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.06 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 80.3 p -82.21 -30.05 31.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.921 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.405 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 77.5 m-20 -100.1 31.23 3.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.999 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 259' ' ' LEU . 24.9 m-85 -138.12 -175.05 3.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.04 178.78 6.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.94 150.88 21.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.929 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.559 ' CG ' HG12 ' A' ' 224' ' ' VAL . 67.3 t80 -81.43 136.39 35.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.5 mt -120.0 -56.81 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.199 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.8 mmt85 -162.48 178.11 8.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.372 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.29 162.58 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.269 -0.967 . . . . 0.0 111.932 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.636 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 130.8 116.37 1.81 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.793 179.002 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.2 mt -120.51 133.59 66.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.747 0.308 . . . . 0.0 110.597 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.549 ' O ' HG13 ' A' ' 292' ' ' VAL . 12.1 p -99.6 117.21 44.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.325 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.31 142.54 50.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.812 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.927 -179.938 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 4.0 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.89 0.376 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 63.8 m -134.02 160.22 38.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.991 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.62 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -148.0 153.25 38.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.57 155.97 17.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.055 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.401 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 41.0 t -105.19 135.31 43.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.021 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.6 t -111.52 -34.75 6.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -164.53 151.91 11.67 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.82 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.536 HG12 ' CD1' ' A' ' 286' ' ' TYR . 9.8 p -157.86 148.58 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.023 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 64.5 p -101.96 145.36 29.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.913 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -93.65 77.92 4.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.729 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.411 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.5 t70 -121.59 -153.68 0.56 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.773 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.431 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 37.1 t-20 -157.39 90.19 2.43 Favored Pre-proline 0 CA--C 1.531 0.232 0 CA-C-O 120.452 0.168 . . . . 0.0 111.256 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 97.4 Cg_endo -76.97 169.8 73.43 Favored 'Cis proline' 0 C--N 1.348 0.5 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.15 -0.253 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.4 149.58 16.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.458 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.2 t -99.88 138.72 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.832 0.348 . . . . 0.0 110.874 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.632 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 3.6 p -131.63 156.9 43.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.463 ' N ' HG22 ' A' ' 232' ' ' VAL . 94.3 m -120.92 161.68 21.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.368 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . 0.415 ' N ' HG22 ' A' ' 233' ' ' THR . 2.4 m -99.9 169.86 8.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.908 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.61 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 3.2 tp -68.08 153.67 43.24 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.807 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -53.67 -28.3 32.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.97 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.544 ' CG ' HD23 ' A' ' 235' ' ' LEU . 9.6 pt-20 -121.68 30.64 6.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.891 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.61 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -92.14 -176.42 4.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.122 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -124.87 -175.89 3.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.563 ' CE1' HG12 ' A' ' 269' ' ' VAL . 6.2 t-80 -174.12 113.32 0.18 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -144.78 25.71 1.94 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.819 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.502 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.5 OUTLIER -99.04 138.64 35.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.861 0.362 . . . . 0.0 110.595 179.808 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -92.78 168.8 10.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 58.7 p -59.44 102.39 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 120.6 11.7 6.46 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.898 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -73.83 -176.14 2.34 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.732 0.301 . . . . 0.0 110.767 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.441 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -132.75 121.82 23.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.798 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.49 HG22 HG23 ' A' ' 267' ' ' ILE . 20.2 m -129.1 154.84 40.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 0.0 111.325 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.8 p -123.76 165.51 17.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.862 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 1.012 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.0 m-30 -99.61 144.27 28.89 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.96 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 28.7 t -102.88 -94.35 0.31 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.011 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -110.29 88.29 2.73 Favored 'General case' 0 C--O 1.225 -0.195 0 CA-C-O 120.511 0.196 . . . . 0.0 110.54 179.684 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 1.012 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.9 t -104.32 143.54 15.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.988 0.423 . . . . 0.0 111.745 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.06 110.81 23.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.924 179.152 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.73 -63.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.701 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.472 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.1 ttm -86.25 58.58 5.13 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 110.33 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.401 HG13 ' N ' ' A' ' 258' ' ' GLN . 16.2 pt -79.32 -33.33 15.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.9 -179.362 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.449 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 4.2 mp0 -38.99 -34.59 0.16 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.859 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.764 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.0 mm? -73.16 -46.82 48.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.938 0.399 . . . . 0.0 110.495 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -58.38 -34.94 71.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.788 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.62 45.35 2.74 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.346 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -165.92 163.96 18.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.775 0.321 . . . . 0.0 110.714 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -56.01 167.65 0.83 Allowed Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.599 179.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -68.68 154.39 71.47 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.302 2.002 . . . . 0.0 112.017 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.463 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.1 ptp -115.11 -177.03 3.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.574 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -99.7 138.67 36.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.773 0.321 . . . . 0.0 110.784 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.502 HD11 ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -106.79 174.72 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.573 0.702 . . . . 0.0 112.2 -179.473 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.713 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -144.04 128.77 18.27 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.508 178.716 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.563 HG12 ' CE1' ' A' ' 240' ' ' HIS . 27.7 m -97.43 118.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.523 0.678 . . . . 0.0 111.495 -178.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 44.5 mt -92.42 -30.78 15.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.662 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.44 -158.99 32.17 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.312 -0.947 . . . . 0.0 113.097 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -63.89 112.13 1.74 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.71 2.273 . . . . 0.0 112.338 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 66.27 14.99 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.08 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -128.73 138.33 52.06 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.484 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.713 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.4 p90 -174.21 169.42 3.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.872 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.0 t -123.42 170.11 10.68 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.98 0.419 . . . . 0.0 111.415 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.67 HD11 ' CG2' ' A' ' 280' ' ' THR . 11.6 pt -123.58 -177.53 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.802 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 m -57.5 -82.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.983 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -150.15 140.69 22.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.801 0.334 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.67 ' CG2' HD11 ' A' ' 277' ' ' ILE . 71.5 p -113.22 -26.92 8.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 t -54.53 -24.21 19.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.292 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.401 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 3.3 m120 -94.47 20.91 7.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.23 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.764 ' CE2' HD11 ' A' ' 259' ' ' LEU . 35.7 m-85 -143.78 -179.61 6.57 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.774 0.321 . . . . 0.0 110.825 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.81 -171.79 0.74 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.893 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -98.87 125.86 44.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.536 ' CD1' HG12 ' A' ' 224' ' ' VAL . 26.9 t80 -69.98 120.67 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.797 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.2 mt -106.88 -68.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.185 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -138.48 -178.84 5.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.508 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.81 166.67 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.238 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.665 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 122.87 111.32 2.05 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.532 -0.842 . . . . 0.0 113.126 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.455 HD12 ' N ' ' A' ' 291' ' ' ILE . 4.8 mp -118.69 128.35 75.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.62 HG13 ' HB3' ' A' ' 219' ' ' ALA . 12.6 p -99.55 113.1 33.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.017 0.437 . . . . 0.0 111.531 -179.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.4 m -115.28 -176.81 2.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.641 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.826 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.806 0.336 . . . . 0.0 110.832 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.2 p -168.52 97.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.024 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.743 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -102.49 167.49 9.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.986 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 4.5 mmt -105.54 146.46 29.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.015 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.446 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 96.0 t -100.06 130.58 49.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 40.0 t -109.39 -34.88 6.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.066 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -157.0 148.29 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.043 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 224' ' ' VAL . 11.0 p -155.93 113.09 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.005 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 68.8 p -70.81 135.69 48.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.05 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.54 82.96 6.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.726 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -129.85 -147.94 0.35 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.498 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -145.96 102.77 4.16 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 120.342 0.115 . . . . 0.0 110.881 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.449 ' HB2' ' O ' ' A' ' 277' ' ' ILE . 36.2 Cg_endo -68.24 -74.26 0.0 OUTLIER 'Cis proline' 0 C--N 1.349 0.555 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.656 0.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 154.42 139.73 2.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.18 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.3 t -99.83 127.85 52.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.895 0.378 . . . . 0.0 111.025 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.543 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.7 p -116.85 153.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.165 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 90.3 m -117.93 157.86 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.508 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -99.97 168.65 9.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.664 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 3.5 tp -68.95 150.81 47.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.781 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -48.5 -28.38 3.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.176 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -133.75 47.42 2.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.85 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.664 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -90.85 174.19 7.58 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.163 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -118.38 107.4 13.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.912 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 12.9 p80 -92.57 131.58 37.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.824 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -151.4 26.36 0.97 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.566 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.711 ' O ' HG11 ' A' ' 269' ' ' VAL . 1.4 m-85 -112.3 140.86 46.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 110.719 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.66 175.48 5.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -61.18 88.67 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.773 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.18 -16.47 3.9 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.818 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.09 165.39 3.41 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.658 0.266 . . . . 0.0 110.708 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 265' ' ' MET . 5.0 m-85 -113.61 150.15 33.52 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.883 0.373 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 267' ' ' ILE . 10.1 m -147.48 144.31 19.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.21 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 p -115.78 163.67 15.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.671 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.955 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.0 m-30 -99.44 142.78 30.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.77 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . 0.411 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 65.3 m -99.82 -100.12 0.24 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.108 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 1.7 pt-20 -103.1 88.01 3.04 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.605 0.24 . . . . 0.0 110.641 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.955 HG21 ' CD2' ' A' ' 250' ' ' PHE . 9.8 t -100.9 136.71 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.853 0.358 . . . . 0.0 111.522 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -99.92 107.88 19.98 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.883 179.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.65 -66.02 0.46 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.79 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.596 ' HG2' HD23 ' A' ' 259' ' ' LEU . 32.1 ttm -84.04 59.65 5.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.164 0.506 . . . . 0.0 110.673 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 12.4 pt -80.23 -33.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.989 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -38.57 -34.5 0.14 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.647 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.4 mm? -61.64 -53.9 49.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.907 0.384 . . . . 0.0 110.613 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -57.39 -34.94 69.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.884 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.05 46.09 2.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 2.2 t -162.06 30.2 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.69 0.281 . . . . 0.0 110.981 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . 0.41 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 2.4 mt-30 58.33 167.66 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.773 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.41 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 30.1 Cg_endo -63.39 165.8 16.69 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.31 2.007 . . . . 0.0 112.067 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.647 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -134.52 -171.69 2.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.643 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -99.68 138.63 36.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.857 0.36 . . . . 0.0 110.568 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.442 HD13 ' HB2' ' A' ' 242' ' ' PHE . 1.6 pp -109.71 172.72 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.5 0.666 . . . . 0.0 112.181 -179.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 8.5 tttm -143.54 125.51 15.29 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.788 -1.096 . . . . 0.0 108.833 178.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.711 HG11 ' O ' ' A' ' 242' ' ' PHE . 27.4 m -97.61 108.9 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.459 0.647 . . . . 0.0 111.525 -178.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.1 mt -86.02 -30.57 22.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.451 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.61 -168.53 27.91 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.615 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -60.1 -50.57 7.14 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.59 2.194 . . . . 0.0 111.816 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -112.91 21.87 15.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.723 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -130.33 145.93 51.85 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.736 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.554 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -179.18 155.68 0.73 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.4 t -104.3 170.08 8.11 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.162 0.506 . . . . 0.0 111.35 -179.249 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.547 ' CD1' HG21 ' A' ' 280' ' ' THR . 3.8 pt -124.67 -171.22 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.643 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -74.27 -168.46 0.65 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.623 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -69.77 105.6 2.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.547 HG21 ' CD1' ' A' ' 277' ' ' ILE . 4.4 t -132.89 74.25 1.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.932 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 10.1 p -125.76 -33.51 2.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.593 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 -95.14 25.4 4.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.647 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.426 ' CD1' ' HA ' ' A' ' 280' ' ' THR . 21.6 m-85 -117.36 -167.48 1.32 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.739 0.304 . . . . 0.0 110.739 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 31.0 t -74.56 175.95 7.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.842 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -99.4 131.71 45.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.433 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 24.7 t80 -69.01 117.56 10.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.029 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 6.0 mt -102.98 -60.06 3.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.47 -178.75 6.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.459 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . 0.401 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 57.87 158.31 0.02 OUTLIER Glycine 0 C--N 1.331 0.29 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.427 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.534 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 129.37 106.13 1.21 Allowed Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.513 -0.851 . . . . 0.0 112.865 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.481 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.7 mp -111.54 135.87 49.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.743 ' CG1' ' HB3' ' A' ' 219' ' ' ALA . 12.2 p -99.64 112.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.964 0.411 . . . . 0.0 111.549 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 49.8 m -107.2 171.91 7.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.701 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.42 ' HG3' ' CD1' ' A' ' 242' ' ' PHE . 2.2 tt0 . . . . . 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.086 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.579 HD23 ' CE1' ' A' ' 242' ' ' PHE . 8.1 tp . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.793 0.33 . . . . 0.0 110.834 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 25.6 p -145.25 172.28 13.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.511 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -162.98 169.95 18.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.05 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.3 156.08 22.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.939 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 41.0 t -108.21 127.39 64.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.003 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 17.2 t -106.06 -34.68 7.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.974 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.76 137.33 10.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.74 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.1 p -142.8 122.08 8.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.064 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 31.0 p -81.7 138.67 35.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.112 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -90.56 78.32 6.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.77 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.428 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.9 t0 -123.07 -150.96 0.46 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.723 -179.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.422 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 17.2 p30 -159.44 90.49 1.93 Allowed Pre-proline 0 CA--C 1.532 0.255 0 CA-C-O 120.471 0.177 . . . . 0.0 111.202 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 81.2 Cg_endo -75.13 169.34 74.82 Favored 'Cis proline' 0 C--N 1.347 0.451 0 C-N-CA 123.322 -1.533 . . . . 0.0 111.937 -0.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -103.86 146.13 16.29 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.377 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.1 t -99.76 125.35 53.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.74 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.7 p -122.55 155.25 27.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.214 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.426 ' N ' HG22 ' A' ' 232' ' ' VAL . 4.7 m -123.52 166.9 14.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.577 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -100.0 170.05 8.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.745 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.564 HD23 ' HG2' ' A' ' 237' ' ' GLU . 0.4 OUTLIER -72.16 160.46 32.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.7 179.867 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -55.08 -29.81 58.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.992 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.564 ' HG2' HD23 ' A' ' 235' ' ' LEU . 9.3 pt-20 -119.13 34.64 5.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.829 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.94 159.6 15.22 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.019 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -124.65 140.02 53.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.977 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.4 t60 -118.76 144.19 46.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.82 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . 0.496 ' HA3' HD21 ' A' ' 217' ' ' LEU . . . -159.57 26.39 0.34 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.739 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.579 ' CE1' HD23 ' A' ' 217' ' ' LEU . 1.6 m-85 -100.53 142.34 32.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.66 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -95.94 170.07 9.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.24 101.07 0.11 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.8 19.26 5.35 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.696 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -84.9 169.27 14.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.758 0.313 . . . . 0.0 110.702 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.454 ' HA ' ' O ' ' A' ' 265' ' ' MET . 62.5 m-85 -108.28 141.81 39.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.912 0.387 . . . . 0.0 111.033 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.451 HG22 HG23 ' A' ' 267' ' ' ILE . 32.5 m -146.21 143.5 21.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.1 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.5 p -121.24 162.52 20.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.93 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.0 m-30 -99.76 149.61 23.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.1 m -108.5 -85.17 0.53 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.919 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.602 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.72 92.58 3.85 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.128 0.49 . . . . 0.0 109.828 179.678 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.93 HG21 ' CD2' ' A' ' 250' ' ' PHE . 3.3 t -112.46 140.63 31.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.479 -179.196 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 68.3 mt-30 -103.79 110.84 23.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.091 179.331 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.88 -57.75 0.64 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.591 -179.021 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.676 ' HG2' HD23 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -90.27 53.78 2.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.11 0.481 . . . . 0.0 110.353 179.334 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 18.8 pt -78.91 -33.79 16.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.843 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -39.24 -34.73 0.2 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.294 -0.412 . . . . 0.0 112.068 -178.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.807 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.5 mm? -66.47 -45.07 80.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 110.685 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -57.68 -38.86 75.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.994 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.7 50.22 1.14 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.511 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.2 t -161.67 30.12 0.13 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.711 0.291 . . . . 0.0 110.905 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 10.2 mt-30 58.82 166.22 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.762 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.34 166.01 13.94 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.441 2.094 . . . . 0.0 112.148 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.807 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.2 ptp -130.97 -174.84 3.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.713 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.52 136.53 39.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.801 0.334 . . . . 0.0 110.616 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.451 HG23 HG22 ' A' ' 248' ' ' VAL . 1.2 pp -103.15 175.77 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.662 0.744 . . . . 0.0 112.315 -179.317 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.649 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -148.89 128.84 13.46 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.621 178.805 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.504 HG11 ' O ' ' A' ' 242' ' ' PHE . 26.1 m -97.73 122.89 49.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.528 0.68 . . . . 0.0 111.577 -178.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 48.4 mt -101.95 -29.1 12.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.504 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.49 -172.35 27.64 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.513 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.56 -33.98 65.79 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.556 2.171 . . . . 0.0 112.053 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -124.63 1.92 8.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.166 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -113.98 153.3 29.57 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.85 0.357 . . . . 0.0 110.805 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.649 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.53 169.05 2.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.831 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -124.1 170.08 11.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.993 0.425 . . . . 0.0 111.242 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.3 pt -125.73 -179.21 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.773 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.04 -173.37 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.865 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.67 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.827 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -99.85 33.47 2.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.979 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 31.2 t -109.21 30.78 6.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.406 ' OD1' ' CZ ' ' A' ' 283' ' ' PHE . 28.2 p30 -150.09 30.71 0.7 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.851 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.406 ' CZ ' ' OD1' ' A' ' 282' ' ' ASN . 20.0 m-85 -138.04 -168.42 2.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.462 ' O ' ' HE3' ' A' ' 256' ' ' MET . 0.1 OUTLIER -91.61 175.25 6.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.84 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -85.43 121.04 27.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.426 ' HE1' HG13 ' A' ' 253' ' ' VAL . 64.8 t80 -56.67 136.52 54.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.879 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 30.9 mt -114.16 -59.83 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.301 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.01 173.3 11.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.734 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.36 150.51 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.31 112.53 0.95 Allowed Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.895 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.2 mp -109.22 128.87 64.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.806 0.336 . . . . 0.0 110.614 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.7 p -99.88 114.93 39.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.359 -179.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 75.6 m -109.42 -178.03 3.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.638 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 31.9 tt0 . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.001 -179.905 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.745 0.307 . . . . 0.0 110.774 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.7 m -162.19 169.6 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.972 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -162.25 148.39 13.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.951 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.4 mtt -93.45 160.93 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.002 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.425 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 47.9 t -108.73 123.88 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.025 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 28.8 t -102.22 -30.68 10.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.52 143.21 5.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.955 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.651 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.2 p -149.2 137.33 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.087 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 43.8 p -90.22 145.51 24.95 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.83 78.28 4.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.813 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.71 -160.74 1.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.824 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.424 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 7.3 p-10 -154.4 90.04 3.22 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.277 -179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 92.5 Cg_endo -80.1 169.72 68.61 Favored 'Cis proline' 0 C--N 1.348 0.503 0 C-N-CA 123.501 -1.458 . . . . 0.0 112.168 -0.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -113.76 157.13 15.16 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.334 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.0 t -99.79 125.45 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.858 0.361 . . . . 0.0 110.911 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.651 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.5 p -123.72 155.79 30.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.196 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 232' ' ' VAL . 89.1 m -124.16 159.11 30.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.615 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.0 m -99.97 165.9 11.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.86 0.362 . . . . 0.0 110.905 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 3.7 tp -59.92 150.12 29.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.741 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -52.24 -27.79 16.22 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.261 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -99.92 -26.74 13.9 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.04 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.405 ' O ' ' CE2' ' A' ' 273' ' ' TYR . . . -74.4 140.81 44.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.243 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 27.5 ttt180 -120.59 145.31 47.5 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.902 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -86.24 131.53 34.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.935 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -119.52 -19.38 4.19 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.995 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.485 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -78.9 145.93 33.85 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.777 0.322 . . . . 0.0 110.737 -179.879 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -101.92 179.66 4.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.538 HG23 HG22 ' A' ' 269' ' ' VAL . 0.7 OUTLIER -63.72 105.44 0.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.997 -179.995 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 128.24 -5.39 6.78 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.967 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.418 ' CB ' ' HB3' ' A' ' 242' ' ' PHE . 2.3 t70 -80.21 172.34 13.9 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.841 0.353 . . . . 0.0 110.98 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.444 ' HA ' ' O ' ' A' ' 265' ' ' MET . 4.4 m-85 -122.19 152.75 39.64 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.055 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.537 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -156.55 154.76 5.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.256 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 t -125.61 170.19 11.73 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.725 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.809 ' CD2' HG21 ' A' ' 253' ' ' VAL . 5.5 m-30 -99.6 159.45 15.03 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.13 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 29.3 t -113.37 -87.66 0.56 Allowed 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.065 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -114.66 88.57 2.89 Favored 'General case' 0 CA--C 1.521 -0.15 0 CA-C-O 120.54 0.209 . . . . 0.0 110.852 179.785 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.809 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.0 t -99.96 158.36 3.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.004 0.431 . . . . 0.0 111.462 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.431 ' N ' HG12 ' A' ' 253' ' ' VAL . 2.2 mm-40 -119.04 106.11 12.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.941 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -56.55 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.482 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.457 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.2 ttm -96.59 51.53 1.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.153 0.502 . . . . 0.0 110.315 179.166 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.7 pp -75.74 -33.66 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.563 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.433 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 5.1 mm-40 -39.25 -34.64 0.2 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.695 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.53 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.4 mm? -59.22 -47.32 85.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 110.59 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -57.54 -46.41 83.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.871 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.82 47.56 2.98 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.538 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 5.1 t -152.14 34.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . 0.404 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 4.3 mt-30 59.74 168.49 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.404 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 43.8 Cg_endo -67.55 151.34 79.77 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.349 2.033 . . . . 0.0 112.067 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.53 ' SD ' HD12 ' A' ' 259' ' ' LEU . 3.1 ptp -118.69 -178.01 3.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.711 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -99.75 157.25 16.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.504 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.537 HG23 HG22 ' A' ' 248' ' ' VAL . 1.8 pp -125.93 170.5 15.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.625 0.726 . . . . 0.0 112.312 -179.539 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.628 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 14.4 mtpt -145.06 126.79 15.25 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.564 -1.198 . . . . 0.0 108.532 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.538 HG22 HG23 ' A' ' 244' ' ' THR . 29.4 m -97.54 120.36 46.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.595 0.712 . . . . 0.0 111.587 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.2 mt -99.11 -30.25 12.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.809 -1.087 . . . . 0.0 110.601 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -162.31 -173.81 31.44 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.565 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.82 -59.27 1.31 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.611 2.208 . . . . 0.0 112.243 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CE2' ' O ' ' A' ' 238' ' ' ALA . 10.0 m-85 -109.39 5.19 23.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.3 p -106.57 149.5 27.1 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.628 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -177.65 166.88 2.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.755 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.4 t -117.21 170.09 8.95 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.7 pt -131.11 179.89 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.16 -179.55 0.78 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.89 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.34 109.23 0.83 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.799 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.6 t -122.5 30.08 6.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.026 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 p -98.66 31.42 2.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.942 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.26 -45.95 1.0 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.453 ' CD2' HD21 ' A' ' 259' ' ' LEU . 30.5 m-85 -59.81 -168.21 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.878 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.2 176.77 9.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.913 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -83.79 125.99 32.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.976 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.401 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 20.7 t80 -61.12 135.04 57.64 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.81 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.7 mt -118.26 -64.71 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.008 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.85 -173.74 4.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.438 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.14 170.38 0.1 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.251 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.62 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 118.95 106.83 2.25 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.0 179.261 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.411 ' CD1' ' HG3' ' A' ' 252' ' ' GLU . 2.9 mp -116.94 125.3 73.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.739 0.304 . . . . 0.0 110.191 179.357 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.505 ' O ' HG13 ' A' ' 292' ' ' VAL . 9.8 p -99.68 120.1 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.551 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.5 m -125.58 170.23 11.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.726 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.421 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 27.7 tt0 . . . . . 0 C--N 1.329 -0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.896 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.7 tp . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.872 0.368 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 36.3 p -152.53 146.39 25.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -141.8 145.24 34.5 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.026 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.606 ' HB3' HD13 ' A' ' 235' ' ' LEU . 1.0 OUTLIER -82.8 151.27 26.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.983 -179.942 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 83.7 t -104.25 143.85 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.065 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.2 t -117.32 -38.52 3.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.774 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.7 mtp -159.63 143.61 14.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 224' ' ' VAL . 10.5 p -143.68 121.32 6.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.028 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 32.9 p -79.89 142.76 34.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.007 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.56 78.54 4.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.799 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.43 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 4.7 t0 -127.84 -158.91 0.91 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.749 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.428 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 17.1 t-20 -153.53 90.8 3.37 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.543 0.211 . . . . 0.0 111.325 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.43 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 96.9 Cg_endo -77.23 169.17 74.85 Favored 'Cis proline' 0 C--N 1.348 0.512 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.949 -0.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.27 17.53 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.453 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 21.4 t -99.84 136.09 32.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.844 0.355 . . . . 0.0 111.19 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.566 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 6.3 p -127.67 138.12 55.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.014 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.46 162.33 13.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.65 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.99 165.88 11.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.887 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.712 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 0.5 OUTLIER -58.76 158.0 8.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.701 179.768 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.76 -27.64 29.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.109 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.32 38.51 3.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.804 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.712 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -99.22 169.54 9.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.096 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 4.0 tpt180 -150.02 135.71 18.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.001 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.441 ' HB2' ' CE2' ' A' ' 242' ' ' PHE . 27.1 p-80 -137.78 135.96 36.82 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.766 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -122.15 65.07 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.669 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 240' ' ' HIS . 0.9 OUTLIER -111.87 142.1 44.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.848 0.356 . . . . 0.0 110.656 179.856 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.55 172.26 9.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 27.0 m -64.17 99.54 0.28 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.003 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.26 17.89 6.97 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.902 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.01 -175.46 2.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.704 0.288 . . . . 0.0 110.687 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.47 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.0 m-85 -120.93 151.95 39.08 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.909 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.478 ' HB ' HG23 ' A' ' 292' ' ' VAL . 35.0 m -156.04 152.2 8.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.374 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.9 p -128.45 168.91 14.95 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.952 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.5 m-30 -99.79 140.94 33.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.135 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.8 m -104.09 -81.38 0.52 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.899 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.761 ' HG3' HD12 ' A' ' 291' ' ' ILE . 0.4 OUTLIER -119.56 88.17 2.88 Favored 'General case' 0 C--O 1.216 -0.661 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.61 179.567 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.952 HG21 ' CD2' ' A' ' 250' ' ' PHE . 9.2 t -114.72 134.17 58.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 120.934 0.397 . . . . 0.0 111.882 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 64.2 mt-30 -99.65 119.82 38.7 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.028 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -62.91 0.51 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.366 -178.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.638 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.3 ttm -87.9 58.84 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.156 0.503 . . . . 0.0 110.162 179.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.433 ' O ' ' N ' ' A' ' 260' ' ' ASN . 1.0 OUTLIER -77.46 -33.34 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.961 -179.437 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.438 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 37.9 mm-40 -39.14 -34.65 0.18 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.788 HD11 ' CE2' ' A' ' 283' ' ' PHE . 2.7 mm? -76.87 -39.89 49.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.873 0.368 . . . . 0.0 110.69 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.433 ' N ' ' O ' ' A' ' 257' ' ' ILE . 0.6 OUTLIER -57.09 -36.99 71.27 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.91 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.54 29.1 10.15 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.325 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -144.18 158.42 43.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.767 0.317 . . . . 0.0 110.762 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 12.7 mt-30 -54.42 165.75 0.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.754 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -64.05 174.63 3.8 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.427 2.085 . . . . 0.0 111.826 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.3 OUTLIER -133.86 -177.75 4.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.753 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -99.51 132.83 44.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.455 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.467 HG23 HG22 ' A' ' 248' ' ' VAL . 1.2 pp -102.61 172.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.8 0.81 . . . . 0.0 112.591 -179.08 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.598 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 43.8 mmtt -142.13 129.69 21.41 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.302 -1.317 . . . . 0.0 108.299 178.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 5.8 m -97.48 113.55 32.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.457 0.646 . . . . 0.0 111.567 -178.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.8 mt -93.77 -27.77 16.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.707 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.59 -170.93 34.68 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.811 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -66.99 -27.25 42.89 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.636 2.224 . . . . 0.0 112.309 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 44.5 m-85 -129.42 18.31 5.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.03 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.79 148.85 47.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.843 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.598 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 6.6 p90 -178.55 149.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.611 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 268' ' ' LYS . 1.6 t -107.49 170.14 8.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.275 -179.353 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.553 HD11 HG23 ' A' ' 280' ' ' THR . 2.7 pp -123.7 -175.85 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.739 179.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.401 ' C ' HD12 ' A' ' 277' ' ' ILE . 42.7 t -56.87 -77.36 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.038 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.458 ' N ' HD12 ' A' ' 277' ' ' ILE . 21.1 p-10 -150.06 133.39 16.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.06 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.553 HG23 HD11 ' A' ' 277' ' ' ILE . 0.7 OUTLIER -118.2 -28.23 5.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.195 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 22.5 p -60.38 -18.61 51.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.373 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -94.49 29.72 2.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.213 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.788 ' CE2' HD11 ' A' ' 259' ' ' LEU . 58.4 m-85 -150.07 -174.89 4.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.944 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.5 m -70.74 175.32 5.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.967 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -90.98 136.91 32.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.961 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 11.9 t80 -64.73 142.88 58.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.77 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.7 -61.72 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 2.1 mmt-85 -165.35 171.45 13.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.405 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 62.53 153.04 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.095 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.28 132.96 2.86 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.299 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.761 HD12 ' HG3' ' A' ' 252' ' ' GLU . 3.2 mt -135.45 136.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.566 -0.317 . . . . 0.0 110.3 179.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.478 HG23 ' HB ' ' A' ' 248' ' ' VAL . 11.8 p -99.83 127.2 52.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.192 -179.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.4 m -130.7 135.43 47.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.85 -179.987 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.826 0.346 . . . . 0.0 110.819 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.8 m -146.43 176.84 9.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.002 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -164.15 141.99 7.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.073 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 7.6 mtm -79.32 156.47 28.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.994 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 58.9 t -100.23 137.3 28.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.996 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.4 t -109.75 -31.21 7.53 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.824 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -171.9 131.66 0.67 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.57 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.9 p -133.91 115.88 22.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.118 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 34.0 p -75.43 141.77 43.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.079 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.77 87.39 6.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.869 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.419 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.8 OUTLIER -136.96 -160.41 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.765 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 37.4 t-20 -155.77 92.58 2.65 Favored Pre-proline 0 CA--C 1.531 0.228 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.263 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.419 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 87.1 Cg_endo -76.11 169.59 74.08 Favored 'Cis proline' 0 C--N 1.348 0.549 0 C-N-CA 123.389 -1.504 . . . . 0.0 112.098 -0.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.56 145.74 18.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.335 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 28.1 t -99.84 125.92 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.99 0.424 . . . . 0.0 111.067 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.667 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.1 p -115.82 157.29 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.483 ' N ' HG22 ' A' ' 232' ' ' VAL . 86.5 m -119.56 161.85 19.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.503 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . 0.423 ' N ' HG22 ' A' ' 233' ' ' THR . 4.4 m -99.87 164.75 11.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 110.867 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.674 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 24.1 tp -57.44 157.88 6.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . 0.401 ' N ' ' HG ' ' A' ' 235' ' ' LEU . 0.4 OUTLIER -53.88 -26.91 27.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.046 179.953 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.474 ' HG2' HD23 ' A' ' 235' ' ' LEU . 0.0 OUTLIER -125.28 29.75 5.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.946 179.976 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.674 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -90.81 -178.13 5.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.193 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 3.6 tpt85 -150.09 139.42 21.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.78 ' CE1' HG12 ' A' ' 269' ' ' VAL . 10.5 t-160 -106.64 127.26 53.2 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.746 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -135.8 24.57 3.3 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.967 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.538 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -106.9 138.66 42.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.575 179.774 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -90.81 172.45 8.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.977 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.614 HG23 HG22 ' A' ' 269' ' ' VAL . 3.2 p -63.54 101.62 0.35 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.802 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 119.66 7.14 9.92 Favored Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.851 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.58 -174.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.723 0.297 . . . . 0.0 110.769 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.456 ' HA ' ' O ' ' A' ' 265' ' ' MET . 90.1 m-85 -129.85 142.64 50.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.881 0.372 . . . . 0.0 111.167 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.496 HG22 HG23 ' A' ' 267' ' ' ILE . 18.6 m -151.32 154.71 7.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.63 170.5 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.879 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.989 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.3 m-30 -99.1 142.47 30.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.4 m -100.39 -82.49 0.45 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.944 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.6 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -123.75 91.17 3.41 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.299 0.571 . . . . 0.0 109.793 179.575 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.989 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.6 t -114.39 138.05 45.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.568 -178.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -101.57 118.1 36.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.094 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.54 -62.43 0.54 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.858 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.622 ' HG3' HD23 ' A' ' 259' ' ' LEU . 23.3 tpp -88.54 57.45 4.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.167 0.508 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.593 HD13 ' H ' ' A' ' 257' ' ' ILE . 0.2 OUTLIER -77.09 -33.3 20.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.977 -179.355 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.417 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.5 OUTLIER -39.03 -34.7 0.17 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.983 -178.756 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.813 HD12 ' SD ' ' A' ' 265' ' ' MET . 2.8 mm? -74.76 -43.16 56.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.035 0.445 . . . . 0.0 110.385 179.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.556 ' ND2' HG23 ' A' ' 253' ' ' VAL . 0.6 OUTLIER -50.49 -40.01 49.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.112 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -106.79 46.5 1.16 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 12.9 t -144.07 26.38 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.313 . . . . 0.0 111.085 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 58.14 166.41 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.835 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -61.4 144.9 98.53 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.421 2.081 . . . . 0.0 112.102 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.813 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.3 ptp -115.36 -171.85 2.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.51 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -99.81 149.74 23.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.761 0.315 . . . . 0.0 110.572 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 277' ' ' ILE . 1.2 pp -119.87 175.76 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.569 0.7 . . . . 0.0 112.441 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.703 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 2.2 tttp -146.18 131.27 18.32 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.6 -1.182 . . . . 0.0 108.475 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.78 HG12 ' CE1' ' A' ' 240' ' ' HIS . 27.5 m -97.55 119.77 46.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.369 0.604 . . . . 0.0 111.537 -178.415 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.463 ' HA ' HD23 ' A' ' 270' ' ' LEU . 14.5 mt -95.48 -29.51 14.35 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.779 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 165.71 -159.81 33.1 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 113.108 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.84 112.66 1.88 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.81 2.34 . . . . 0.0 112.301 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 65.46 15.8 10.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.104 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -130.74 134.66 47.08 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.494 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.703 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.2 p90 -171.85 169.86 5.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.94 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.8 t -124.74 170.07 11.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 267' ' ' ILE . 2.6 pp -135.28 -179.87 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.928 179.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.712 ' O ' HD12 ' A' ' 277' ' ' ILE . 29.8 p -55.77 -172.47 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.005 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -62.14 119.68 9.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.647 HG21 HD11 ' A' ' 277' ' ' ILE . 10.0 t -135.33 30.74 3.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.956 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 35.3 t -97.37 -34.06 11.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.923 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -70.21 -25.39 63.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.055 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.604 ' CD2' HD21 ' A' ' 259' ' ' LEU . 20.7 m-85 -77.48 -170.66 1.86 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.918 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.27 -160.54 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.762 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -117.98 131.18 56.51 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.839 0.352 . . . . 0.0 110.715 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.47 ' CG ' HG12 ' A' ' 224' ' ' VAL . 17.3 t80 -57.82 131.05 49.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.983 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.0 mt -111.89 -64.85 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.031 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.06 164.84 36.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.724 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.81 151.73 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.199 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.549 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 141.06 122.29 1.84 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.721 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 26.8 mt -125.85 131.6 71.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.776 0.322 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.2 p -99.98 108.82 23.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.031 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 62.3 m -103.51 169.12 8.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.82 179.97 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.781 0.324 . . . . 0.0 110.85 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.8 p -137.79 152.08 48.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.951 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -137.34 147.82 45.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.06 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.733 ' HB3' HD13 ' A' ' 235' ' ' LEU . 0.0 OUTLIER -86.57 151.17 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.887 -179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 59.0 t -99.94 136.24 32.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.009 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.0 t -111.61 -34.27 6.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.974 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.4 mtp -163.99 153.75 14.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.992 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.41 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.0 p -157.14 135.61 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.05 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.3 140.75 29.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -86.75 74.06 9.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.861 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.4 t0 -122.09 -156.73 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.68 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 1.4 p30 -158.91 91.18 2.01 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-O 120.516 0.198 . . . . 0.0 111.307 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 80.2 Cg_endo -76.06 169.72 73.71 Favored 'Cis proline' 0 C--N 1.348 0.527 0 C-N-CA 123.451 -1.479 . . . . 0.0 112.074 -0.108 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.21 151.8 17.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.501 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.9 t -99.98 114.69 39.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 0.0 111.109 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.509 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.3 p -106.15 157.1 6.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.108 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.471 ' N ' HG22 ' A' ' 232' ' ' VAL . 1.7 m -121.81 165.02 16.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.581 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.03 169.98 8.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.908 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.733 HD13 ' HB3' ' A' ' 220' ' ' MET . 0.6 OUTLIER -68.86 158.66 34.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.754 179.829 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -54.21 -33.53 58.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.044 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.544 ' HG3' HD23 ' A' ' 235' ' ' LEU . 0.1 OUTLIER -122.38 29.98 6.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.892 179.88 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.605 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -82.24 -175.66 5.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -148.45 107.62 3.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.952 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.563 ' CE1' HG12 ' A' ' 269' ' ' VAL . 34.5 t-80 -97.29 136.64 37.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.767 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -164.48 62.94 0.24 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.697 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.462 ' CD2' ' CE1' ' A' ' 240' ' ' HIS . 3.8 m-85 -122.6 143.81 49.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.817 0.341 . . . . 0.0 110.759 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.26 156.7 36.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 5.7 m -58.48 97.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.96 10.37 12.34 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.826 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -60.04 174.11 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.747 0.274 . . . . 0.0 110.724 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 265' ' ' MET . 54.7 m-85 -115.99 130.93 57.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.813 0.34 . . . . 0.0 111.066 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.507 HG21 ' CG2' ' A' ' 292' ' ' VAL . 15.0 m -144.96 159.36 13.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.019 0.438 . . . . 0.0 111.399 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.21 170.71 14.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.983 ' CD2' HG21 ' A' ' 253' ' ' VAL . 3.6 m-30 -99.08 145.49 27.07 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.967 -179.581 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -100.37 -86.6 0.39 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.088 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -119.33 88.32 2.91 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-O 120.535 0.207 . . . . 0.0 110.664 179.627 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.983 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.8 t -102.16 149.9 6.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.55 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.59 30.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.811 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 100.1 -73.29 0.45 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.431 -178.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.436 ' HE1' ' HA ' ' A' ' 285' ' ' ASP . 3.3 tpp -83.71 60.28 5.65 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.2 0.524 . . . . 0.0 110.215 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 16.1 pt -78.63 -33.0 16.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.498 -0.774 . . . . 0.0 112.001 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -38.32 -34.39 0.13 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.897 -178.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.493 HD22 ' N ' ' A' ' 259' ' ' LEU . 3.1 mm? -63.7 -50.25 69.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.979 0.419 . . . . 0.0 110.239 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -53.32 -34.73 58.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.998 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -85.84 45.06 3.42 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.808 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 4.6 t -165.78 150.21 8.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.743 0.306 . . . . 0.0 110.767 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.64 159.95 0.5 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.849 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -53.35 149.13 30.62 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.449 2.099 . . . . 0.0 111.87 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 5.7 ptp -111.91 -173.04 2.16 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.476 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -99.75 155.32 17.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.762 0.315 . . . . 0.0 110.792 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.48 HG23 HG22 ' A' ' 248' ' ' VAL . 1.8 pp -123.47 169.64 14.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.5 0.667 . . . . 0.0 112.127 -179.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.607 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -142.36 125.44 16.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.825 -1.079 . . . . 0.0 108.818 178.707 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 269' ' ' VAL . 33.0 m -97.65 112.61 30.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.53 0.681 . . . . 0.0 111.499 -178.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.5 mt -90.77 -27.72 18.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.522 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -167.31 -166.24 26.06 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.582 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.55 -52.88 3.31 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.573 2.182 . . . . 0.0 111.857 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 20.8 m-85 -112.86 18.92 17.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.87 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.88 145.65 49.7 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.67 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.607 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.8 p90 -178.07 159.2 1.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -108.92 170.05 8.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.158 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.2 pt -131.2 -179.98 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.803 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.33 172.85 1.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.905 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.74 118.91 7.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.857 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.9 t -141.17 51.2 1.6 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.984 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 7.2 p -102.69 -22.08 14.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.171 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -96.51 31.4 2.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.748 0.309 . . . . 0.0 111.089 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -128.77 -175.47 3.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.777 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.04 125.76 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.717 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.436 ' HA ' ' HE1' ' A' ' 256' ' ' MET . 0.2 OUTLIER -42.56 149.17 0.19 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.553 -179.688 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -78.14 137.36 38.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.853 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.3 mt -119.11 -65.18 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.102 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -148.71 -174.48 4.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.44 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 55.76 169.02 0.07 OUTLIER Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.258 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.653 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 122.09 116.75 2.4 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.981 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 2.8 mp -128.79 127.31 66.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.729 0.3 . . . . 0.0 110.252 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.59 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.7 p -99.65 111.06 28.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.992 0.425 . . . . 0.0 111.369 -179.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -106.36 158.31 16.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.706 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.968 -179.828 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.6 tp . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.819 0.342 . . . . 0.0 110.828 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 55.9 p -158.0 160.51 37.57 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.025 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.422 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -159.11 170.08 22.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.079 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 6.6 mtm -105.88 157.04 17.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.8 t -109.51 130.6 62.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.836 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 22.9 t -109.94 -35.1 6.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.162 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.46 148.51 27.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.936 0.398 . . . . 0.0 111.067 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.447 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.3 p -158.31 137.04 3.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.969 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 144.63 29.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.01 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.2 ttmt -89.68 72.63 7.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.815 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.1 t70 -122.49 -160.77 0.9 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.858 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.404 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 8.0 p-10 -156.08 90.91 2.7 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.175 -179.687 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.406 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 83.6 Cg_endo -78.87 169.9 70.92 Favored 'Cis proline' 0 C--N 1.349 0.577 0 C-N-CA 123.495 -1.46 . . . . 0.0 112.179 -0.102 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.17 153.01 17.87 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.444 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.3 t -99.85 122.35 51.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.883 0.373 . . . . 0.0 111.0 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.587 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.8 p -114.34 153.81 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.165 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 273' ' ' TYR . 1.7 m -123.33 155.73 36.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.486 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.85 170.02 8.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.83 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.764 HD23 ' H ' ' A' ' 237' ' ' GLU . 0.3 OUTLIER -71.83 143.43 49.46 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.764 179.883 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -24.86 30.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.399 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.764 ' H ' HD23 ' A' ' 235' ' ' LEU . 6.5 mt-10 -100.54 -18.07 16.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.364 -179.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -79.57 168.01 19.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.824 0.345 . . . . 0.0 111.247 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.08 -167.83 1.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.864 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 9.3 p80 -171.96 155.33 3.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.847 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 179.26 54.33 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.872 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.435 ' HB2' HD11 ' A' ' 267' ' ' ILE . 1.1 m-85 -103.74 141.05 36.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.823 0.344 . . . . 0.0 110.575 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -71.69 153.44 42.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.7 m -57.08 97.44 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.12 9.44 15.67 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.746 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.17 -165.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.772 0.286 . . . . 0.0 110.545 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.563 ' HA ' ' O ' ' A' ' 265' ' ' MET . 86.9 m-85 -128.9 143.06 50.78 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.916 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.5 HG22 HG23 ' A' ' 267' ' ' ILE . 15.9 m -149.58 134.87 10.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.731 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.1 p -111.95 166.47 11.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.434 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 1.003 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.7 m-30 -99.85 143.93 29.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.02 -179.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 25.7 m -99.93 -86.28 0.39 Allowed 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.988 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.598 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -120.02 92.76 3.85 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.266 0.555 . . . . 0.0 110.006 179.896 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 1.003 HG21 ' CD2' ' A' ' 250' ' ' PHE . 4.6 t -111.43 139.02 37.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.383 -179.264 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -99.93 116.27 31.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.194 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.23 -65.53 0.5 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.629 -0.795 . . . . 0.0 111.897 -179.253 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 1.5 ttt -89.91 59.38 4.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.487 . . . . 0.0 110.534 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 15.0 pt -77.99 -33.94 18.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.67 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.7 mm100 -39.24 -34.64 0.2 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.81 -179.091 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.468 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.3 mm? -60.6 -49.54 77.12 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.884 0.373 . . . . 0.0 110.576 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -64.75 -34.82 79.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.835 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -93.1 39.38 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.496 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.5 t -159.26 34.25 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 0.0 110.716 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 61.88 168.41 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.597 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -61.46 -153.15 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 111.702 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.563 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.9 ptp -172.78 -175.89 1.36 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.805 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.58 147.37 25.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.656 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.644 HG22 HG22 ' A' ' 277' ' ' ILE . 1.2 pp -119.73 174.99 4.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.675 0.75 . . . . 0.0 112.482 -179.49 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.674 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.0 mttt -147.33 131.07 16.95 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.401 178.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.443 HG23 ' O ' ' A' ' 269' ' ' VAL . 34.6 m -97.54 122.33 49.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.433 0.635 . . . . 0.0 111.63 -178.279 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 270' ' ' LEU . 15.0 mt -96.77 -30.87 12.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.651 -179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.29 -171.81 42.09 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.245 -0.979 . . . . 0.0 113.214 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_exo -51.75 112.96 0.96 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.793 2.328 . . . . 0.0 112.475 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.532 ' O ' HG23 ' A' ' 233' ' ' THR . 67.9 m-85 64.71 19.41 11.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.054 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.5 p -133.0 139.35 47.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.459 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.674 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.3 p90 -176.97 166.48 2.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 -179.57 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -118.56 170.05 9.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.992 0.425 . . . . 0.0 111.161 -179.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.644 HG22 HG22 ' A' ' 267' ' ' ILE . 1.0 OUTLIER -134.62 -178.63 2.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.848 179.814 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 29.9 p -57.35 -177.55 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -72.56 124.06 24.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.428 ' HA ' ' CD1' ' A' ' 283' ' ' PHE . 8.6 t -137.69 51.88 1.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.971 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 96.5 p -88.37 -54.8 4.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -67.4 -19.62 65.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.192 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.428 ' CD1' ' HA ' ' A' ' 280' ' ' THR . 23.5 m-85 -59.49 -176.94 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.748 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 48.1 t -78.18 -175.81 4.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.895 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.79 127.25 48.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.907 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.495 ' CE1' HG13 ' A' ' 253' ' ' VAL . 65.4 t80 -72.21 140.97 48.99 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 26.1 mt -125.45 -63.51 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.09 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 5.7 mmt180 -153.94 175.56 13.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.655 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.48 149.65 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.424 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.06 115.47 1.19 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.768 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 18.4 mm -114.29 133.43 60.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 120.743 0.306 . . . . 0.0 110.821 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.55 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.1 p -99.89 114.65 38.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.035 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.3 m -119.56 154.44 33.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.051 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 12.9 tt0 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.962 179.898 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.851 0.357 . . . . 0.0 110.747 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 50.2 p -136.21 127.87 28.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -122.18 148.8 44.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.079 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -78.31 145.97 35.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.948 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.0 t -99.94 140.6 18.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 6.5 t -105.93 -29.66 9.83 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.016 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.81 158.69 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.027 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.481 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.6 p -160.93 122.08 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 65.0 p -84.31 143.25 29.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.037 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.42 56.34 3.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.473 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.6 t0 -91.61 -151.02 0.26 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.818 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -159.85 90.57 1.84 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-O 120.489 0.185 . . . . 0.0 111.372 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.473 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 71.8 Cg_endo -73.24 169.11 74.02 Favored 'Cis proline' 0 C--N 1.347 0.493 0 C-N-CA 123.244 -1.565 . . . . 0.0 111.836 -0.132 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -101.41 147.28 17.59 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.436 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.1 t -99.81 145.65 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.87 0.367 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.539 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.4 p -139.2 151.15 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.22 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.412 HG22 ' N ' ' A' ' 234' ' ' CYS . 63.6 m -122.5 161.01 24.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.412 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . 0.412 ' N ' HG22 ' A' ' 233' ' ' THR . 3.1 m -99.84 169.29 9.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.879 0.371 . . . . 0.0 110.86 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 2.9 tp -70.69 148.16 48.32 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.834 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -56.26 -30.83 62.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -106.36 50.76 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -178.35 152.79 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.25 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 20.7 ttm105 -135.89 155.41 50.34 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.857 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 23.4 p-80 -111.23 148.37 32.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.792 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -130.27 70.4 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.723 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.61 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.9 OUTLIER -126.55 141.54 51.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.766 0.317 . . . . 0.0 110.746 179.78 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.61 166.97 12.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.941 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 13.2 m -59.58 100.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.9 18.42 5.58 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.856 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.52 174.75 10.78 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.715 0.293 . . . . 0.0 110.767 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.4 m-85 -114.3 134.06 55.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 267' ' ' ILE . 19.1 m -138.24 153.44 26.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.053 0.454 . . . . 0.0 111.359 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 11.1 p -124.2 165.11 18.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.577 179.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 1.055 ' CD2' HG21 ' A' ' 253' ' ' VAL . 1.9 m-30 -99.8 141.3 32.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.045 -179.69 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . 0.415 ' CB ' ' HB ' ' A' ' 291' ' ' ILE . 31.3 t -99.91 -101.65 0.23 Allowed 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.7 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' A' ' 290' ' ' GLY . 3.3 pt-20 -102.52 87.58 3.04 Favored 'General case' 0 C--O 1.223 -0.333 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 1.055 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.4 t -105.74 134.38 47.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.869 0.366 . . . . 0.0 111.786 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 18.8 mt-30 -99.9 116.02 30.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.777 178.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.35 -69.02 0.42 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.542 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.608 ' HG3' HD23 ' A' ' 259' ' ' LEU . 10.8 tpp -82.74 62.18 6.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.111 0.481 . . . . 0.0 110.235 179.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 37.2 pt -80.09 -33.34 14.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.274 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -38.64 -34.63 0.15 Allowed 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -178.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.792 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.2 mm? -72.8 -46.48 52.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.892 0.377 . . . . 0.0 110.703 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 24.2 t30 -57.57 -34.92 69.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.934 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.83 46.27 2.5 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.367 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.66 161.66 13.61 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.858 0.361 . . . . 0.0 110.898 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -54.99 156.83 6.44 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.682 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -57.38 157.11 23.17 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.508 2.138 . . . . 0.0 111.941 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.635 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -117.07 -171.19 1.98 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -99.48 153.17 19.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.755 0.312 . . . . 0.0 110.615 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 248' ' ' VAL . 1.7 pp -121.84 173.62 7.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.643 0.735 . . . . 0.0 112.312 -179.315 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 6.1 tttt -144.43 127.14 16.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.749 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.61 HG11 ' O ' ' A' ' 242' ' ' PHE . 15.5 m -97.75 115.18 37.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.436 0.636 . . . . 0.0 111.598 -178.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.418 HD23 ' HA ' ' A' ' 270' ' ' LEU . 15.7 mt -94.96 -28.14 15.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.49 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.53 -178.95 39.5 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.576 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -50.61 -48.5 20.21 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.635 2.223 . . . . 0.0 112.217 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 80.8 m-85 -115.95 15.09 16.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.112 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.92 147.72 45.66 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.692 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.611 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.5 p90 -178.35 159.59 1.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.725 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 9.4 t -114.3 170.13 8.53 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.975 0.417 . . . . 0.0 111.32 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.06 -179.17 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.929 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 179.96 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.934 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -60.92 134.49 57.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 1.1 p -116.25 -19.92 10.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.372 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 93.0 p -52.92 -27.63 19.69 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 111.332 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -77.76 -25.87 49.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.142 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.792 ' CE2' HD11 ' A' ' 259' ' ' LEU . 13.1 m-85 -91.09 -168.3 2.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.976 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 8.5 p -83.4 -147.09 0.08 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.568 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -119.07 147.11 44.5 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.831 0.348 . . . . 0.0 110.844 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.453 ' CD2' ' CG1' ' A' ' 224' ' ' VAL . 44.5 t80 -80.02 141.49 35.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 30.3 mt -120.45 -59.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.998 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 4.3 mmt85 -163.32 176.63 9.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.408 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.02 155.55 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.935 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.64 119.24 1.77 Allowed Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.867 178.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.415 ' HB ' ' CB ' ' A' ' 251' ' ' SER . 10.9 mt -122.25 134.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.812 0.339 . . . . 0.0 110.557 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.608 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.4 p -99.73 107.35 20.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.252 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 71.0 m -115.12 123.22 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.771 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.445 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.025 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 3.9 tp . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.806 0.336 . . . . 0.0 110.857 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.5 p -162.34 107.7 1.21 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.48 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -100.08 153.77 18.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.978 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.686 ' SD ' HD22 ' A' ' 235' ' ' LEU . 38.8 mtt -90.68 145.77 24.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.935 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.424 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 98.8 t -99.87 136.62 30.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.815 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.1 t -105.95 -35.75 7.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.024 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -163.21 143.6 9.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.444 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.8 p -146.5 130.58 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.053 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 11.4 p -92.29 146.18 23.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.043 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.8 tttm -92.17 86.61 5.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.732 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.423 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.5 OUTLIER -132.96 -158.07 0.86 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.787 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 9.5 p-10 -158.73 91.87 2.01 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-O 120.503 0.192 . . . . 0.0 111.203 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.423 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 86.9 Cg_endo -75.86 169.52 74.28 Favored 'Cis proline' 0 C--N 1.347 0.498 0 C-N-CA 123.327 -1.53 . . . . 0.0 112.083 -0.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.97 146.9 17.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.471 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.9 t -99.85 126.87 53.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.973 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.566 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 3.8 p -121.09 155.32 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.275 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.438 ' N ' HG22 ' A' ' 232' ' ' VAL . 6.7 m -118.25 161.3 20.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.648 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.85 161.68 13.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.881 0.372 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.686 HD22 ' SD ' ' A' ' 220' ' ' MET . 8.2 tp -60.26 154.35 20.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.825 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -52.62 -27.12 15.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.032 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.497 ' HG3' HD23 ' A' ' 235' ' ' LEU . 3.2 pt-20 -128.48 37.37 4.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -94.77 -167.41 1.64 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.151 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.62 176.57 8.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.011 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -155.08 114.0 3.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.711 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -133.28 26.38 3.54 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.817 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 0.1 OUTLIER -106.4 135.32 48.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 179.799 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -89.85 174.34 7.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.071 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.28 101.33 0.3 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 113.97 15.86 8.27 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.732 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -76.4 -175.75 3.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.728 0.299 . . . . 0.0 110.653 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.483 ' HA ' ' O ' ' A' ' 265' ' ' MET . 63.1 m-85 -121.95 141.45 51.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.983 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.652 ' HB ' HG23 ' A' ' 292' ' ' VAL . 22.5 m -137.4 155.28 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.504 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.2 p -129.29 161.42 30.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.693 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.521 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.6 m-30 -99.85 137.11 38.76 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.999 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . 0.408 ' CB ' ' HB ' ' A' ' 291' ' ' ILE . 72.4 m -99.77 -104.85 0.22 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.671 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.3 OUTLIER -100.18 87.47 3.46 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.687 HG22 ' CA ' ' A' ' 290' ' ' GLY . 21.8 t -109.91 138.1 39.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.883 0.373 . . . . 0.0 111.707 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -100.73 118.66 37.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.935 179.145 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.45 -65.57 0.48 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.673 -179.049 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.653 ' HG2' HD23 ' A' ' 259' ' ' LEU . 6.3 ttm -85.11 58.95 5.32 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.053 0.454 . . . . 0.0 110.357 179.209 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 4.8 pt -79.99 -33.36 14.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.037 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -39.06 -34.75 0.18 Allowed 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.653 HD23 ' HG2' ' A' ' 256' ' ' MET . 2.7 mm? -79.86 -42.09 24.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.872 0.368 . . . . 0.0 110.701 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 44.8 t30 -54.99 -34.88 63.78 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.063 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.88 28.22 13.41 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.293 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -142.24 165.08 28.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 110.753 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -58.04 166.26 2.14 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.595 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.48 158.39 53.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.363 2.042 . . . . 0.0 112.094 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.483 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.1 ptp -116.61 -174.17 2.52 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.517 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -99.56 151.26 21.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.719 0.295 . . . . 0.0 110.705 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.482 HG21 HG11 ' A' ' 248' ' ' VAL . 1.8 pp -122.22 174.96 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.612 0.72 . . . . 0.0 112.376 -179.542 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.625 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.3 tptt -146.86 130.71 17.1 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.576 -1.193 . . . . 0.0 108.5 178.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 269' ' ' VAL . 31.0 m -97.74 120.17 46.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.494 0.664 . . . . 0.0 111.585 -178.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.432 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.4 mt -98.2 -29.99 12.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.462 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.55 -175.3 36.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.524 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.85 -53.91 6.01 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.638 2.226 . . . . 0.0 112.387 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -112.77 23.22 13.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -133.23 148.45 52.0 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.751 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.625 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -175.33 167.3 3.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -117.58 170.15 8.98 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.473 HD12 HG21 ' A' ' 280' ' ' THR . 14.3 pt -133.09 -179.38 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.843 179.753 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.622 ' O ' HG23 ' A' ' 280' ' ' THR . 32.0 p -63.6 171.0 2.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.83 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.9 p-10 -58.73 112.22 1.55 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.966 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.622 HG23 ' O ' ' A' ' 278' ' ' CYS . 11.2 p -115.81 24.94 11.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.058 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 91.6 p -90.48 9.78 27.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.357 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 62.4 m-20 -111.38 -32.05 6.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.348 . . . . 0.0 110.801 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.552 ' CE2' HD11 ' A' ' 259' ' ' LEU . 12.3 m-85 -78.17 -165.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.802 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.96 -179.78 6.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.868 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -94.1 130.86 40.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.449 ' CE2' HG13 ' A' ' 253' ' ' VAL . 54.4 t80 -60.12 136.33 57.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.838 179.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 47.7 mt -115.73 -67.92 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.09 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -151.91 174.01 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.297 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.82 155.98 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.911 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.687 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 138.78 116.12 1.38 Allowed Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.901 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.469 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.1 mp -121.98 138.33 52.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.8 0.334 . . . . 0.0 110.573 179.599 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.652 HG23 ' HB ' ' A' ' 248' ' ' VAL . 13.4 p -99.7 124.95 53.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.517 -179.404 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -121.76 131.94 54.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.528 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.449 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.317 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.754 HD21 ' O ' ' A' ' 241' ' ' GLY . 1.1 mp . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.8 0.333 . . . . 0.0 110.747 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.87 150.11 22.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.086 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.45 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -156.63 154.19 29.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 3.4 mtt -95.23 164.19 12.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.112 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 36.5 t -114.72 140.43 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 4.3 t -114.42 -26.33 8.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.255 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -166.73 162.63 16.33 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.851 0.358 . . . . 0.0 111.042 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.444 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.8 p -168.02 151.64 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.176 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 40.1 p -113.93 150.53 33.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 7.5 ttmt -92.53 84.82 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.859 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.414 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.3 t0 -134.67 -160.16 1.03 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.823 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.403 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 14.1 p-10 -156.28 89.7 2.74 Favored Pre-proline 0 CA--C 1.531 0.233 0 CA-C-O 120.506 0.193 . . . . 0.0 111.371 -179.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.414 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 85.1 Cg_endo -79.36 169.45 71.28 Favored 'Cis proline' 0 C--N 1.349 0.591 0 C-N-CA 123.448 -1.48 . . . . 0.0 112.202 -0.078 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.65 155.24 16.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.391 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.5 t -99.87 111.09 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.9 0.381 . . . . 0.0 111.028 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.619 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.0 p -102.9 151.95 5.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.059 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.12 139.73 52.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.312 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 61.3 m -99.91 170.07 8.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.023 0.44 . . . . 0.0 111.133 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.638 HD23 ' H ' ' A' ' 237' ' ' GLU . 3.6 tt -49.68 161.27 0.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.923 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -42.05 -31.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.242 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.638 ' H ' HD23 ' A' ' 235' ' ' LEU . 7.3 pt-20 -165.5 51.1 0.1 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.816 0.341 . . . . 0.0 111.239 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -121.33 30.99 6.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.484 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -150.15 131.76 14.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.866 0.365 . . . . 0.0 111.121 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 170.04 90.16 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.852 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . 0.754 ' O ' HD21 ' A' ' 217' ' ' LEU . . . 179.79 -35.69 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.779 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.45 ' CD1' HD23 ' A' ' 217' ' ' LEU . 0.1 OUTLIER -85.63 134.5 33.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.922 0.391 . . . . 0.0 110.719 -179.86 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -105.61 171.39 7.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.83 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 62.8 m -53.06 102.03 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.37 25.36 4.7 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.593 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -93.89 166.61 12.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.777 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 265' ' ' MET . 94.6 m-85 -110.86 135.48 51.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.832 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.477 HG22 HG23 ' A' ' 267' ' ' ILE . 14.7 m -143.18 145.58 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.436 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 16.9 p -116.27 170.27 8.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.571 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 1.024 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.5 m-30 -99.46 139.61 34.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.938 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -104.73 -87.95 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.222 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -108.14 88.06 2.64 Favored 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 116.848 -0.16 . . . . 0.0 110.826 179.802 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 1.024 HG21 ' CD2' ' A' ' 250' ' ' PHE . 11.2 t -113.95 132.13 63.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.945 0.403 . . . . 0.0 111.803 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -99.77 115.89 30.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.925 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.94 -59.55 0.59 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.552 -178.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.538 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.5 ttm -92.14 54.63 2.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.107 0.479 . . . . 0.0 110.163 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.438 HG22 ' O ' ' A' ' 253' ' ' VAL . 33.2 pt -77.21 -33.55 20.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.763 -179.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -39.14 -34.66 0.18 Allowed 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.835 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.538 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.5 mm? -66.65 -47.11 73.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.915 0.388 . . . . 0.0 110.618 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -56.37 -34.78 66.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.909 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.54 46.24 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.318 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.7 t -167.61 163.83 14.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.749 0.309 . . . . 0.0 110.596 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.28 166.33 0.9 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.586 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -68.82 178.61 3.83 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.311 2.007 . . . . 0.0 112.013 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.532 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.0 OUTLIER -136.89 176.18 8.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.78 -179.957 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -99.49 125.07 45.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.477 HG23 HG22 ' A' ' 248' ' ' VAL . 1.4 pp -88.7 163.88 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.546 0.689 . . . . 0.0 112.229 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.655 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.5 OUTLIER -137.88 125.52 22.25 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.744 -1.117 . . . . 0.0 108.586 178.445 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.53 HG23 ' O ' ' A' ' 269' ' ' VAL . 30.3 m -97.29 114.77 35.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.547 0.689 . . . . 0.0 111.573 -178.287 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.0 mt -92.03 -28.45 17.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.494 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -161.59 -163.52 14.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.589 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.47 -48.67 4.15 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.572 2.182 . . . . 0.0 112.111 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -115.27 7.77 15.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.212 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.67 152.73 30.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.764 0.316 . . . . 0.0 110.676 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.655 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.1 p90 -179.78 162.44 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.821 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.7 t -118.64 169.99 9.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.07 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.517 HD11 ' CG2' ' A' ' 280' ' ' THR . 1.3 pp -134.22 -177.51 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.911 179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.406 ' HB2' ' HB2' ' A' ' 265' ' ' MET . 0.1 OUTLIER -54.88 -176.4 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 0.0 111.048 -179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -71.89 99.77 2.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.517 ' CG2' HD11 ' A' ' 277' ' ' ILE . 3.2 t -102.83 56.57 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 59.8 p -104.85 -26.38 12.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.988 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -96.54 31.53 2.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.98 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -126.08 -175.66 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.79 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.45 170.97 12.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.91 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -83.96 122.09 28.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.521 ' CE2' HG13 ' A' ' 253' ' ' VAL . 37.5 t80 -59.25 142.81 50.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.722 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 33.7 mt -119.92 -69.21 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.237 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.2 173.82 14.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.729 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.41 153.81 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.216 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.0 124.38 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.904 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 30.8 mt -123.04 134.45 66.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.789 0.328 . . . . 0.0 110.797 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.645 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.1 p -99.94 102.42 13.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.963 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.7 m -113.72 150.89 32.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.022 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.916 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.808 0.337 . . . . 0.0 110.7 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 52.8 p -124.47 146.91 48.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.04 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.658 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -128.38 167.05 17.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.001 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.423 ' SD ' HD22 ' A' ' 235' ' ' LEU . 11.6 mtt -94.09 148.56 22.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.923 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 49.1 t -99.91 139.32 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.953 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.3 t -106.77 -32.94 7.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.053 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.4 mtp -168.89 144.28 3.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.973 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.595 HG23 ' HB ' ' A' ' 232' ' ' VAL . 10.8 p -142.78 140.87 27.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.047 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 15.6 p -95.91 144.31 26.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.028 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.6 tttt -94.1 83.01 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.456 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.2 t0 -128.67 -158.17 0.87 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.738 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 1.6 p30 -154.27 89.62 3.3 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-O 120.472 0.177 . . . . 0.0 111.336 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.456 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 93.7 Cg_endo -77.71 169.16 74.37 Favored 'Cis proline' 0 C--N 1.347 0.491 0 C-N-CA 123.437 -1.485 . . . . 0.0 111.996 -0.162 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.76 149.77 17.01 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.598 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.8 141.81 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.72 0.295 . . . . 0.0 110.905 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.61 HG13 ' CE1' ' A' ' 275' ' ' PHE . 5.3 p -134.43 157.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.246 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.482 ' N ' HG22 ' A' ' 232' ' ' VAL . 91.8 m -122.11 156.79 32.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.582 179.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.94 166.14 11.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.919 0.39 . . . . 0.0 110.721 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.556 HD23 ' HB2' ' A' ' 237' ' ' GLU . 2.5 tp -66.98 148.15 52.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.785 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -55.38 -26.73 43.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.556 ' HB2' HD23 ' A' ' 235' ' ' LEU . 3.2 mm-40 -98.05 -26.28 14.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.016 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.658 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -68.85 172.68 6.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.21 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -145.97 145.25 30.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.967 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.417 ' CE1' HG12 ' A' ' 269' ' ' VAL . 17.2 t-80 -98.36 135.65 39.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -137.09 27.82 2.86 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.525 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.576 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.1 OUTLIER -116.34 146.34 42.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.584 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -102.55 173.26 6.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.141 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.522 ' CG2' HG22 ' A' ' 269' ' ' VAL . 80.6 p -59.87 103.17 0.19 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.84 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 127.87 -17.78 6.0 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.531 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.09 -178.8 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.739 0.304 . . . . 0.0 110.808 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' A' ' 265' ' ' MET . 49.1 m-85 -122.99 162.08 23.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.07 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.622 ' HB ' HG23 ' A' ' 292' ' ' VAL . 28.8 m -151.74 155.06 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.5 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.8 p -129.66 159.31 36.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.501 179.627 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 1.028 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.3 m-30 -99.65 136.3 39.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.0 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 35.1 t -99.78 -92.49 0.28 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.543 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.73 87.77 2.61 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.468 179.499 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 1.028 HG21 ' CD2' ' A' ' 250' ' ' PHE . 3.9 t -106.3 137.59 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.939 0.4 . . . . 0.0 111.809 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -99.97 112.83 25.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.813 179.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.04 -60.28 0.56 Allowed Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.69 -178.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.646 ' HG2' HD23 ' A' ' 259' ' ' LEU . 3.0 ttm -87.88 59.15 5.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.144 0.497 . . . . 0.0 110.478 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.409 HG13 ' N ' ' A' ' 258' ' ' GLN . 28.7 pt -79.95 -33.57 14.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.922 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.409 ' N ' HG13 ' A' ' 257' ' ' ILE . 1.8 mp0 -38.89 -34.64 0.16 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.36 -0.382 . . . . 0.0 112.021 -178.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.849 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.1 mm? -73.01 -46.01 54.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.901 0.381 . . . . 0.0 110.634 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -56.23 -34.85 66.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.864 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.03 46.61 2.89 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.351 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -170.35 160.99 7.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -56.22 156.26 11.17 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.704 179.792 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.22 171.76 1.61 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.318 2.012 . . . . 0.0 112.062 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.674 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.6 OUTLIER -131.75 -174.36 3.39 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.628 -179.892 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -99.51 148.86 23.82 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.724 0.297 . . . . 0.0 110.698 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.561 HD11 ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -118.64 177.36 2.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.637 0.732 . . . . 0.0 112.376 -179.2 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.658 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.44 130.27 19.27 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.473 -1.239 . . . . 0.0 108.27 178.585 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.576 HG11 ' O ' ' A' ' 242' ' ' PHE . 31.9 m -97.49 117.61 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.588 0.708 . . . . 0.0 111.691 -178.243 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.464 ' HA ' HD23 ' A' ' 270' ' ' LEU . 14.3 mt -91.16 -28.31 17.95 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.846 -1.07 . . . . 0.0 110.545 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 162.64 -166.57 36.75 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.224 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -52.83 112.66 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.785 2.323 . . . . 0.0 112.506 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 62.4 m-85 63.07 18.02 10.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.107 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -128.42 136.95 51.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.454 179.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.658 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.77 160.64 1.94 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.806 -179.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.1 t -112.61 170.11 8.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.998 0.428 . . . . 0.0 111.179 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.558 HG22 HG22 ' A' ' 267' ' ' ILE . 0.9 OUTLIER -130.88 -179.5 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.919 179.83 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -55.5 -173.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.983 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -58.67 122.56 13.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.5 24.19 13.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.081 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 34.0 t -98.31 -26.6 14.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.031 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.404 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 17.8 t30 -97.41 34.83 1.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.969 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.849 ' CE2' HD11 ' A' ' 259' ' ' LEU . 24.5 m-85 -137.75 -175.5 4.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.852 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 28.7 t -86.35 176.98 7.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -85.62 132.2 34.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.964 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.467 ' CE2' HG13 ' A' ' 253' ' ' VAL . 16.3 t80 -77.49 144.44 37.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.66 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 35.7 mt -126.24 -68.43 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -146.91 -179.87 7.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.602 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.5 161.57 0.05 OUTLIER Glycine 0 C--N 1.332 0.324 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.27 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 132.56 116.22 1.73 Allowed Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.919 178.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 20.6 mt -118.66 133.92 63.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.798 0.332 . . . . 0.0 110.592 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.622 HG23 ' HB ' ' A' ' 248' ' ' VAL . 12.5 p -99.77 120.9 49.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.567 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 20.8 m -119.64 136.69 54.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.67 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.475 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 7.4 tt0 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.187 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.481 HD22 ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.938 0.399 . . . . 0.0 111.056 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.4 m -138.37 103.62 4.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.507 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.407 ' HB3' ' CZ ' ' A' ' 242' ' ' PHE . . . -102.12 157.7 16.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.973 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 34.1 mtp -101.73 167.98 9.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.9 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.39 128.6 70.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.992 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.6 t -104.31 -29.42 10.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -167.5 152.66 7.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.001 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.675 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.0 p -158.72 145.37 7.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 7.1 p -106.52 146.38 30.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.853 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.31 80.57 3.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.838 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.439 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.6 OUTLIER -126.22 -157.9 0.82 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -154.02 91.0 3.22 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.355 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.439 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 80.2 Cg_endo -76.3 169.07 75.44 Favored 'Cis proline' 0 C--N 1.348 0.516 0 C-N-CA 123.345 -1.523 . . . . 0.0 112.044 -0.143 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.9 151.9 17.59 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.494 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.1 t -99.98 145.86 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 111.135 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.7 p -142.7 150.2 18.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.097 -179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 273' ' ' TYR . 81.0 m -124.98 143.27 50.98 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.492 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 26.2 m -100.0 170.07 8.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.977 0.418 . . . . 0.0 111.054 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.736 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 1.2 tp -56.5 140.49 45.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.996 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -54.16 -26.7 29.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.984 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.6 mt-10 -114.84 34.49 4.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.736 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -166.41 76.44 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.204 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.48 HH22 HG12 ' A' ' 269' ' ' VAL . 38.3 tpt85 -150.06 87.07 1.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.828 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.481 ' O ' HD22 ' A' ' 217' ' ' LEU . 1.0 OUTLIER -178.8 106.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.107 179.986 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 162.11 -14.96 0.14 Allowed Glycine 0 CA--C 1.52 0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 113.562 179.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.568 ' HB2' HD13 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -131.75 132.19 43.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 117.17 0.485 . . . . 0.0 111.258 -179.41 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . 0.439 ' O ' HD11 ' A' ' 267' ' ' ILE . 0.7 OUTLIER -124.09 -169.58 1.99 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.778 179.863 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.2 m -61.32 106.07 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.068 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 100.67 26.94 7.79 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.684 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.55 169.75 8.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.765 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.481 ' HA ' ' O ' ' A' ' 265' ' ' MET . 76.8 m-85 -108.17 148.96 29.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.803 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.577 ' HB ' HG23 ' A' ' 292' ' ' VAL . 34.3 m -149.71 144.26 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 111.578 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.7 p -123.67 156.88 35.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.462 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.552 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.8 m-30 -99.52 139.09 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -99.7 -91.86 0.29 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.11 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.06 87.74 2.59 Favored 'General case' 0 C--O 1.224 -0.278 0 C-N-CA 121.21 -0.196 . . . . 0.0 110.822 179.703 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.704 HG22 ' CA ' ' A' ' 290' ' ' GLY . 21.2 t -109.31 143.69 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.871 0.367 . . . . 0.0 111.491 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -105.72 114.93 29.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.087 179.326 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.36 -64.07 0.52 Allowed Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.596 -179.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.903 ' HG2' HD23 ' A' ' 259' ' ' LEU . 31.1 ttm -88.91 54.54 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.165 0.507 . . . . 0.0 110.283 179.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.58 HG22 ' O ' ' A' ' 253' ' ' VAL . 2.2 pp -80.04 -33.76 14.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.928 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.463 ' HB3' ' CE2' ' A' ' 283' ' ' PHE . 5.7 mm-40 -39.07 -34.47 0.17 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 112.006 -178.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.903 HD23 ' HG2' ' A' ' 256' ' ' MET . 2.9 mm? -64.02 -48.36 76.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.839 0.352 . . . . 0.0 110.682 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.0 t-20 -55.66 -35.06 65.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.94 49.38 1.02 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.71 28.96 0.13 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.104 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . 0.402 ' HB3' ' HD2' ' A' ' 264' ' ' PRO . 6.7 mt-30 60.86 156.67 0.11 Allowed Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.525 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 263' ' ' GLN . 13.3 Cg_endo -55.77 176.33 0.17 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.35 2.033 . . . . 0.0 111.991 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.727 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.5 ptp -142.76 -173.9 4.01 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.632 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -99.39 137.33 38.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.345 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.568 HD13 ' HB2' ' A' ' 242' ' ' PHE . 1.1 pt -106.07 176.45 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.727 0.775 . . . . 0.0 112.472 -179.063 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.5 tttt -148.21 129.95 15.11 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.162 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.48 HG12 HH22 ' A' ' 239' ' ' ARG . 29.0 m -97.3 123.83 49.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.583 0.706 . . . . 0.0 111.423 -178.251 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 55.1 mt -96.41 -28.17 14.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.82 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 169.59 -160.78 34.06 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.417 -0.897 . . . . 0.0 113.14 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.7 111.49 1.92 Allowed 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.711 2.274 . . . . 0.0 112.294 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.824 ' O ' HG23 ' A' ' 233' ' ' THR . 16.2 m-85 71.1 9.37 6.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.23 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.6 p -124.52 145.0 49.81 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.754 0.312 . . . . 0.0 110.617 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.688 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -178.61 170.04 1.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.744 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.9 t -120.35 169.93 9.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.15 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.861 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.1 pp -138.54 -177.91 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.025 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.861 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -54.89 163.65 0.96 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.974 179.962 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -58.41 140.4 53.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.007 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 6.2 t -145.67 31.83 1.06 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 19.9 p -71.24 -46.8 60.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.89 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 12.1 t30 -76.98 -22.53 53.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.059 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.463 ' CE2' ' HB3' ' A' ' 258' ' ' GLN . 3.3 m-85 -67.83 -176.15 0.63 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.3 m -87.29 151.14 23.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.2 142.23 50.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.006 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.444 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 17.6 t80 -72.1 144.96 48.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.88 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.5 mt -124.49 -63.96 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.4 mmt180 -152.8 178.85 9.19 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.434 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.33 164.53 0.08 OUTLIER Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.283 -0.961 . . . . 0.0 112.085 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.704 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 127.89 114.97 1.86 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.038 178.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.651 HD12 ' N ' ' A' ' 291' ' ' ILE . 3.2 mp -121.56 131.06 73.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.79 0.329 . . . . 0.0 110.151 179.228 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.577 HG23 ' HB ' ' A' ' 248' ' ' VAL . 12.9 p -99.83 118.13 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.389 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 58.0 m -121.32 146.95 46.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 6.6 tm0? . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.962 -179.928 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.462 HD23 ' HA3' ' A' ' 241' ' ' GLY . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.352 . . . . 0.0 110.816 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.3 m -125.22 159.95 30.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.038 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.478 ' O ' HG23 ' A' ' 291' ' ' ILE . . . -143.96 162.0 37.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.031 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.72 146.39 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.065 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.0 137.59 27.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.91 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.6 t -108.84 -42.07 4.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -151.03 153.74 35.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.109 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.527 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.5 p -161.87 140.28 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.989 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 1.5 p -95.32 148.13 22.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.08 55.86 2.42 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.445 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -102.79 -158.32 0.66 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.708 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 7.0 p-10 -156.97 91.81 2.43 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 120.504 0.193 . . . . 0.0 111.307 -179.693 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.445 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 73.3 Cg_endo -75.54 169.6 74.08 Favored 'Cis proline' 0 C--N 1.348 0.529 0 C-N-CA 123.436 -1.485 . . . . 0.0 112.002 -0.182 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.54 17.47 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.558 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.98 124.69 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.885 0.374 . . . . 0.0 110.974 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.634 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.9 p -117.51 154.39 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.207 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.593 HG23 ' O ' ' A' ' 273' ' ' TYR . 1.3 m -120.57 155.51 33.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.567 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.0 m -99.94 162.58 12.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.844 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.498 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 4.3 tp -60.11 147.69 38.64 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.794 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -64.94 -26.95 68.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.084 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -95.47 -15.12 23.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.054 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.498 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -97.15 171.07 8.69 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.865 0.364 . . . . 0.0 111.172 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -135.1 160.58 37.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.923 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.5 p-80 -96.81 146.81 24.57 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . 0.462 ' HA3' HD23 ' A' ' 217' ' ' LEU . . . -138.12 25.05 2.93 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.69 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.452 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.4 OUTLIER -128.3 147.57 50.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.803 0.335 . . . . 0.0 110.732 179.875 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -105.13 174.78 5.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.972 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.6 t -62.49 97.23 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.82 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 137.44 -17.43 3.53 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.561 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.54 -171.24 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.753 0.311 . . . . 0.0 110.8 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -138.46 141.99 39.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.787 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.43 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 33.8 m -148.71 146.03 17.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.039 0.447 . . . . 0.0 111.545 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 21.3 p -112.73 170.08 8.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.33 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.863 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.2 m-30 -99.62 143.07 30.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.082 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -99.97 -86.64 0.38 Allowed 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.134 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.6 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.84 92.62 3.85 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-O 121.127 0.489 . . . . 0.0 110.008 179.997 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.863 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.0 t -109.15 149.03 12.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.349 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 288' ' ' ARG . 18.1 mm-40 -110.36 109.33 19.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.026 179.136 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.57 -53.47 0.83 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.6 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.496 ' HG2' HD23 ' A' ' 259' ' ' LEU . 11.0 ttm -95.63 54.03 1.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.988 0.423 . . . . 0.0 110.333 179.456 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 43.7 pt -80.03 -34.35 15.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.71 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.0 mp0 -39.63 -34.62 0.25 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.748 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.724 HD12 ' SD ' ' A' ' 265' ' ' MET . 2.3 mm? -61.02 -46.44 90.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.38 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -61.55 -36.43 80.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.893 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.5 42.93 2.26 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.362 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.4 t -156.06 31.06 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.817 0.342 . . . . 0.0 110.934 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . 0.421 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 0.4 OUTLIER 59.67 168.03 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.622 -179.898 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.421 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 28.9 Cg_endo -62.78 -173.03 0.13 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.372 2.048 . . . . 0.0 112.04 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.724 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.4 OUTLIER -156.03 -177.95 6.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.635 -179.917 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -99.85 135.07 41.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.611 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.74 HG22 HG22 ' A' ' 277' ' ' ILE . 1.0 OUTLIER -105.67 178.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 0.0 112.087 -179.604 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.679 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 29.7 mttt -149.01 131.02 15.3 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.659 178.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 10.5 m -97.33 121.8 48.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.473 0.654 . . . . 0.0 111.367 -178.494 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.435 ' HA ' HD23 ' A' ' 270' ' ' LEU . 15.3 mt -96.81 -30.29 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.868 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 164.76 -166.79 38.21 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.074 -1.06 . . . . 0.0 113.404 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_exo -51.16 112.93 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.897 2.398 . . . . 0.0 112.696 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.593 ' O ' HG23 ' A' ' 233' ' ' THR . 31.9 m-85 60.37 20.59 10.17 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.036 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -130.86 139.47 50.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.586 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.679 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.6 p90 -177.17 166.13 2.35 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.734 -179.615 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.9 t -114.83 170.08 8.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.997 0.427 . . . . 0.0 111.133 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.74 HG22 HG22 ' A' ' 267' ' ' ILE . 0.8 OUTLIER -138.56 -179.69 2.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.916 179.923 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.44 160.5 3.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.999 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 13.5 p30 -56.81 138.03 53.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.024 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.432 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.6 p -133.09 27.11 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.954 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -69.54 -30.31 68.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.95 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -84.94 -31.11 23.78 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.432 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 21.3 m-85 -70.1 -175.51 0.97 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.829 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.99 179.83 6.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -89.63 124.93 35.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.47 ' CE2' HG13 ' A' ' 253' ' ' VAL . 15.1 t80 -59.41 139.55 56.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.776 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.8 mt -117.33 -62.2 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.021 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.414 ' O ' ' HB2' ' A' ' 254' ' ' GLN . 2.8 mmt180 -158.2 175.8 13.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.581 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.52 151.44 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.443 -0.884 . . . . 0.0 112.408 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.23 115.66 1.31 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.642 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 219' ' ' ALA . 3.4 mp -113.24 134.12 56.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.797 0.332 . . . . 0.0 110.954 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.559 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.5 p -99.81 115.04 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.124 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.0 m -119.05 143.49 47.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.15 -179.665 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 . . . . . 0 C--N 1.331 -0.205 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.948 179.871 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.573 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.052 0 CA-C-O 120.785 0.326 . . . . 0.0 110.837 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.5 p -149.52 124.21 9.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.618 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -115.7 170.06 8.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.56 165.76 11.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.895 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.405 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 88.0 t -115.4 125.96 72.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 27.9 t -108.13 -31.15 8.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.27 135.1 7.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.624 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.5 p -142.86 150.26 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 66.3 p -107.42 148.16 29.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.1 tmtt? -99.28 70.18 1.73 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.2 t0 -120.52 -159.64 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 20.4 p30 -153.6 91.03 3.32 Favored Pre-proline 0 CA--C 1.531 0.234 0 CA-C-N 116.717 -0.22 . . . . 0.0 111.328 -179.645 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.401 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 88.1 Cg_endo -78.21 169.75 72.14 Favored 'Cis proline' 0 C--N 1.348 0.535 0 C-N-CA 123.422 -1.491 . . . . 0.0 112.112 -0.142 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.8 149.84 18.78 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.74 140.13 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.878 0.371 . . . . 0.0 110.999 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.624 ' HB ' HG23 ' A' ' 224' ' ' VAL . 5.3 p -134.6 158.04 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.264 -179.691 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.481 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.6 OUTLIER -125.01 160.26 29.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.516 179.697 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.83 167.31 10.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.874 0.369 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.748 HD23 ' HG2' ' A' ' 237' ' ' GLU . 1.0 OUTLIER -61.01 159.83 10.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.731 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -55.36 -29.87 59.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.014 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.748 ' HG2' HD23 ' A' ' 235' ' ' LEU . 1.8 pt-20 -117.48 32.35 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -78.19 -176.94 4.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.111 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 -144.16 148.02 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.943 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -96.99 141.84 29.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.822 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . 0.573 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -163.07 29.94 0.26 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.595 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.494 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.1 OUTLIER -147.74 130.56 16.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.752 0.31 . . . . 0.0 110.755 179.991 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.67 179.17 4.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.998 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.67 104.7 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.891 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 123.81 -13.64 8.11 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.757 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -67.67 172.98 4.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.809 0.338 . . . . 0.0 110.777 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -123.31 158.24 31.44 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.45 HG22 HG23 ' A' ' 267' ' ' ILE . 19.8 m -155.11 142.66 12.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.198 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 p -109.99 166.13 11.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.303 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.922 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.4 m-30 -99.66 152.24 20.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.863 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . 0.414 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 61.3 m -108.5 -98.77 0.38 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.072 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.498 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.6 OUTLIER -107.09 88.25 2.69 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.592 0.234 . . . . 0.0 110.666 179.892 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.922 HG21 ' CD2' ' A' ' 250' ' ' PHE . 4.1 t -100.93 148.28 7.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.042 0.449 . . . . 0.0 111.625 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.41 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.0 OUTLIER -111.1 108.59 18.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.576 178.955 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.35 -59.92 0.55 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.276 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.804 ' HG2' HD23 ' A' ' 259' ' ' LEU . 21.2 ttm -92.19 54.88 2.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.177 0.513 . . . . 0.0 110.061 179.08 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 9.0 pt -79.25 -33.23 15.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.598 -0.728 . . . . 0.0 112.22 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.42 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 2.5 mm100 -38.64 -34.54 0.15 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.86 -178.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.804 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.3 mm? -67.69 -49.68 61.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.979 0.418 . . . . 0.0 110.474 179.403 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -58.65 -34.83 71.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.78 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.43 44.38 2.92 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.468 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.9 t -164.99 162.97 20.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.6 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -54.5 156.73 5.77 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.553 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -63.05 169.53 8.96 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.272 1.982 . . . . 0.0 111.821 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.508 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.0 OUTLIER -134.55 -175.59 3.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.856 -179.69 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -99.66 154.66 18.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.417 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.76 HG22 HG22 ' A' ' 277' ' ' ILE . 1.0 OUTLIER -123.02 174.94 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.66 0.743 . . . . 0.0 112.194 -179.271 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.589 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 32.1 mmtm -143.27 129.07 19.39 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.705 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 269' ' ' VAL . 22.3 m -97.54 112.91 30.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.473 0.654 . . . . 0.0 111.48 -178.455 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 270' ' ' LEU . 13.3 mt -91.02 -27.06 18.88 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.569 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.45 -164.01 21.21 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.627 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -63.34 -50.62 3.35 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.585 2.19 . . . . 0.0 112.027 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.408 ' O ' HG23 ' A' ' 233' ' ' THR . 57.5 m-85 -114.1 12.47 17.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.047 179.665 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -118.83 147.32 44.06 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.636 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.613 ' CZ ' HG13 ' A' ' 232' ' ' VAL . 10.4 p90 -177.95 158.54 1.26 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.959 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.0 t -112.84 170.12 8.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.865 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.5 pp -135.93 -179.01 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.986 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.865 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.1 OUTLIER -55.56 -178.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.891 -179.982 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -68.13 110.32 3.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.44 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.9 t -110.33 32.97 4.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.4 m -87.78 -22.6 24.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -95.43 38.0 1.17 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.984 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.457 ' CE2' HD11 ' A' ' 259' ' ' LEU . 25.0 m-85 -137.76 -171.48 3.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.728 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -88.85 -166.93 1.72 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.83 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -96.75 145.23 26.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -85.89 139.58 31.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.733 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.87 HG22 ' HD3' ' A' ' 288' ' ' ARG . 68.4 mt -124.27 -71.16 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.87 ' HD3' HG22 ' A' ' 287' ' ' ILE . 3.4 mpt_? -138.93 -178.22 5.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.421 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 57.16 160.59 0.02 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.389 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.585 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 128.99 102.11 1.04 Allowed Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.923 179.109 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.414 ' CD1' ' HB2' ' A' ' 251' ' ' SER . 4.5 mp -109.25 129.04 64.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.738 0.304 . . . . 0.0 110.193 179.363 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.618 HG13 ' HB3' ' A' ' 219' ' ' ALA . 14.3 p -99.61 108.83 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.051 0.453 . . . . 0.0 111.474 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -109.11 173.15 6.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.585 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 . . . . . 0 C--N 1.328 -0.368 0 CA-C-O 120.998 0.428 . . . . 0.0 111.032 -179.937 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.409 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.1 OUTLIER . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.748 0.308 . . . . 0.0 110.947 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 p -162.57 141.74 9.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.948 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.506 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -137.4 154.66 49.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.101 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.7 mmm -101.23 156.61 17.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 44.6 t -100.67 138.94 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.973 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 15.0 t -110.24 -39.99 4.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.898 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.3 mmm -169.37 138.96 2.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.496 HG23 ' HB ' ' A' ' 232' ' ' VAL . 8.2 p -139.26 151.17 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.08 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.8 p -102.06 148.08 25.82 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.005 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? -92.19 85.55 5.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.747 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.45 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.8 t0 -132.31 -154.79 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.758 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.423 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 31.4 p30 -159.04 90.77 2.0 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-O 120.445 0.164 . . . . 0.0 111.234 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.45 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 72.8 Cg_endo -74.96 169.03 75.65 Favored 'Cis proline' 0 C--N 1.348 0.543 0 C-N-CA 123.387 -1.505 . . . . 0.0 112.081 -0.282 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.42 151.31 17.14 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 16.9 t -99.9 131.86 46.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 111.074 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.584 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 6.3 p -128.87 158.02 41.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.253 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.489 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -123.77 164.59 18.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.686 179.703 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.3 m -99.94 168.81 9.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.871 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 5.8 tp -64.88 151.25 46.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -58.71 -26.23 63.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.197 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -114.91 32.23 6.16 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -133.07 155.91 48.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.256 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.29 158.6 33.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.883 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -92.31 145.16 24.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . 0.409 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -136.97 42.45 1.31 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.579 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.46 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.4 OUTLIER -137.99 138.92 39.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.779 0.323 . . . . 0.0 110.775 179.889 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -88.68 171.9 9.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.924 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.5 m -62.72 101.88 0.29 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.868 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 117.24 0.32 18.9 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.85 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.407 ' CB ' ' HB3' ' A' ' 242' ' ' PHE . 0.4 OUTLIER -65.6 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.658 0.266 . . . . 0.0 110.777 179.923 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.56 ' HA ' ' O ' ' A' ' 265' ' ' MET . 38.2 m-85 -134.41 143.37 47.55 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.896 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.471 HG22 ' CG2' ' A' ' 267' ' ' ILE . 3.4 m -149.99 142.33 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.609 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 25.1 p -115.79 165.91 12.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.452 179.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.925 ' CD2' HG21 ' A' ' 253' ' ' VAL . 3.9 m-30 -99.71 148.67 24.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.992 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . 0.42 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 58.7 m -99.89 -90.32 0.31 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.09 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.496 ' O ' ' N ' ' A' ' 290' ' ' GLY . 5.1 pt-20 -113.22 88.03 2.74 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 120.519 0.199 . . . . 0.0 110.768 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.925 HG21 ' CD2' ' A' ' 250' ' ' PHE . 12.1 t -100.02 148.09 6.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 111.6 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.406 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.9 OUTLIER -116.24 110.45 18.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.77 -62.21 0.53 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.627 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.726 ' SD ' HG21 ' A' ' 280' ' ' THR . 25.9 ttm -91.79 61.78 4.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.227 0.537 . . . . 0.0 110.225 179.237 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 23.8 pt -80.03 -32.3 13.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.336 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.445 ' HB2' ' CE2' ' A' ' 283' ' ' PHE . 3.8 tp-100 -37.61 -34.44 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -178.124 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.767 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.1 mm? -67.65 -52.08 42.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.973 0.416 . . . . 0.0 110.414 179.457 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -64.61 -34.95 79.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.119 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.27 38.56 3.16 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.836 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 3.2 t -157.99 36.39 0.25 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.766 0.317 . . . . 0.0 111.08 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . 0.449 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 11.8 mt-30 59.05 169.16 0.07 OUTLIER Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.488 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.449 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 14.2 Cg_endo -56.97 -164.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.253 1.969 . . . . 0.0 111.593 179.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.767 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -169.44 -173.2 1.63 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.791 -179.713 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.55 143.23 30.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.407 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.471 ' CG2' HG22 ' A' ' 248' ' ' VAL . 1.1 pp -118.59 176.81 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.665 0.745 . . . . 0.0 112.388 -179.225 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.522 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -149.87 129.64 13.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.374 178.596 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 269' ' ' VAL . 29.3 m -97.59 112.11 28.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.507 0.67 . . . . 0.0 111.546 -178.255 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 40.4 mt -86.14 -29.78 23.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.476 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.9 -167.23 21.09 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -61.61 -43.52 26.54 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.508 2.139 . . . . 0.0 111.826 179.799 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -117.5 -5.1 11.23 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.049 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.3 p -100.2 148.26 24.81 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.841 0.353 . . . . 0.0 111.006 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.584 ' CZ ' HG13 ' A' ' 232' ' ' VAL . 6.7 p90 -178.58 162.62 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.566 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.409 ' HB3' ' HG3' ' A' ' 268' ' ' LYS . 3.7 t -112.39 167.37 10.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.993 0.425 . . . . 0.0 111.354 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.592 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.2 pp -137.9 -173.42 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.751 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.592 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -52.0 179.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.932 0.396 . . . . 0.0 111.159 -179.939 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -94.69 140.59 29.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.998 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.726 HG21 ' SD ' ' A' ' 256' ' ' MET . 11.7 t -151.21 39.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.78 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 28.9 t -73.93 -7.57 52.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.574 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -108.33 5.94 25.99 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.522 0.201 . . . . 0.0 111.53 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.445 ' CE2' ' HB2' ' A' ' 258' ' ' GLN . 0.2 OUTLIER -110.73 -158.44 0.65 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.594 0.235 . . . . 0.0 110.883 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 2.2 m -96.49 156.62 16.26 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.856 0.36 . . . . 0.0 111.077 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -74.29 151.9 39.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.416 ' HB2' HG13 ' A' ' 224' ' ' VAL . 32.1 t80 -58.86 124.48 19.99 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.927 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 29.5 mt -102.77 -47.79 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.005 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.406 ' O ' ' N ' ' A' ' 254' ' ' GLN . 1.1 mmt-85 -176.97 175.37 1.59 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.167 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . 0.406 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 60.39 158.42 0.06 OUTLIER Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.178 -1.01 . . . . 0.0 111.966 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 131.76 115.84 1.73 Allowed Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.723 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.7 mp -125.26 128.38 72.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.775 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.53 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.5 p -100.0 118.79 47.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.175 -179.685 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.9 m -129.58 168.19 16.79 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.121 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 . . . . . 0 C--N 1.33 -0.265 0 CA-C-O 121.104 0.478 . . . . 0.0 111.034 -179.993 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.806 0.336 . . . . 0.0 110.926 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 11.2 t -166.53 155.67 11.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.796 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.585 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -149.1 166.8 27.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.019 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.557 ' HE1' HD22 ' A' ' 235' ' ' LEU . 10.9 mtp -107.63 147.48 30.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 40.5 t -105.93 139.56 26.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.995 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 8.3 t -106.61 -31.9 8.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.976 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.1 ptm -168.16 163.94 13.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.968 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.644 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.6 p -162.36 118.62 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.037 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 76.9 p -76.48 140.59 41.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.828 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -90.17 68.15 7.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.795 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.408 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 5.0 t0 -106.69 -148.0 0.41 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.781 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -160.26 88.88 1.82 Allowed Pre-proline 0 CA--C 1.531 0.227 0 CA-C-O 120.536 0.208 . . . . 0.0 111.305 -179.67 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.408 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 97.2 Cg_endo -76.4 169.52 74.23 Favored 'Cis proline' 0 C--N 1.347 0.488 0 C-N-CA 123.27 -1.554 . . . . 0.0 111.945 -0.148 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -100.43 147.63 18.08 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.501 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.2 t -99.81 118.89 47.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.847 0.356 . . . . 0.0 111.058 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.644 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.8 p -110.37 154.24 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.058 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.403 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -128.32 161.8 28.56 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.691 179.731 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -100.04 169.63 9.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.92 0.39 . . . . 0.0 110.845 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.655 HD23 ' HG2' ' A' ' 237' ' ' GLU . 0.4 OUTLIER -60.26 161.6 6.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.794 179.891 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -54.63 -32.86 59.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.074 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.655 ' HG2' HD23 ' A' ' 235' ' ' LEU . 9.3 pt-20 -119.16 32.19 6.24 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.824 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -82.81 -175.74 5.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.082 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.41 136.12 23.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.933 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 2.8 t60 -105.9 137.24 44.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -149.83 26.73 1.17 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.674 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.618 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -114.52 138.39 50.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.813 0.339 . . . . 0.0 110.679 179.899 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 165.0 14.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.03 87.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 138.51 -12.72 3.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.718 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -57.46 -179.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.771 0.32 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.451 ' HA ' ' O ' ' A' ' 265' ' ' MET . 51.1 m-85 -125.07 146.77 49.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.057 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.436 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -148.47 147.86 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.173 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.5 p -115.95 167.88 10.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.623 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 1.038 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.6 m-30 -99.64 146.65 26.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.077 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . 0.412 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 53.8 m -109.46 -89.94 0.47 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.77 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.2 87.59 2.56 Favored 'General case' 0 C--O 1.221 -0.397 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 179.416 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 1.038 HG21 ' CD2' ' A' ' 250' ' ' PHE . 8.0 t -109.47 134.98 49.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.92 0.39 . . . . 0.0 111.873 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 21.2 mt-30 -100.32 114.38 27.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.815 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.05 -58.6 0.61 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.672 -178.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.681 ' HG2' HD23 ' A' ' 259' ' ' LEU . 1.4 ttm -91.04 59.9 4.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.128 0.489 . . . . 0.0 110.359 179.358 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.6 pp -79.52 -33.37 15.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.985 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -39.1 -34.61 0.18 Allowed 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.876 -178.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.857 HD11 ' CE2' ' A' ' 283' ' ' PHE . 2.8 mm? -77.76 -44.45 27.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.87 0.366 . . . . 0.0 110.504 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -60.03 -34.84 73.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.851 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.52 42.92 2.38 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.324 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -165.42 171.14 13.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.803 0.335 . . . . 0.0 110.764 -179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 11.3 mt-30 -57.63 167.7 1.29 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.64 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -66.5 -166.68 0.11 Allowed 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.38 2.053 . . . . 0.0 112.005 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.59 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -156.07 -175.84 5.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.575 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -99.71 148.08 24.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.771 0.319 . . . . 0.0 110.628 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.707 HG22 HG22 ' A' ' 277' ' ' ILE . 1.6 pp -119.76 172.84 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.528 0.68 . . . . 0.0 112.263 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.627 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.3 mmtm -143.47 127.97 17.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 114.71 -1.132 . . . . 0.0 108.736 178.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.618 HG11 ' O ' ' A' ' 242' ' ' PHE . 35.9 m -97.6 114.56 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.471 0.653 . . . . 0.0 111.503 -178.556 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.402 HD23 ' HA ' ' A' ' 270' ' ' LEU . 16.1 mt -92.5 -28.72 16.63 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.567 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.76 -163.66 18.38 Favored Glycine 0 N--CA 1.453 -0.202 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.593 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.08 -49.29 3.95 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.639 2.226 . . . . 0.0 111.992 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -114.82 11.58 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.101 179.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.95 148.54 42.84 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.856 0.36 . . . . 0.0 110.704 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.627 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.9 p90 -177.5 161.73 1.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 12.2 t -123.38 170.27 10.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.01 0.433 . . . . 0.0 111.218 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.707 HG22 HG22 ' A' ' 267' ' ' ILE . 1.6 pp -133.9 -179.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.844 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.484 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.4 OUTLIER -56.42 -170.1 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.076 -179.915 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -55.8 132.69 50.03 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.026 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.57 7.24 8.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.404 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -86.04 5.28 34.21 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.749 -0.205 . . . . 0.0 111.463 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -111.67 -23.48 10.63 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.684 0.278 . . . . 0.0 111.177 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.857 ' CE2' HD11 ' A' ' 259' ' ' LEU . 29.5 m-85 -85.43 -170.41 3.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 64.1 m -88.56 -175.43 4.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.86 137.27 32.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.582 ' CE1' HG13 ' A' ' 253' ' ' VAL . 70.0 t80 -78.13 146.61 35.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.773 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 27.1 mt -125.02 -67.87 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.186 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.55 176.43 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.559 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.96 158.25 0.05 OUTLIER Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.287 -0.958 . . . . 0.0 112.068 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.13 108.83 0.9 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.98 178.66 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.412 ' HB ' ' HB2' ' A' ' 251' ' ' SER . 14.8 mm -106.5 130.98 57.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.727 0.299 . . . . 0.0 110.479 179.505 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.597 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.5 p -99.72 109.75 25.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.916 0.389 . . . . 0.0 111.322 -179.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -111.77 156.34 22.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.654 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.032 -179.799 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.892 0.377 . . . . 0.0 111.203 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -95.85 -178.82 4.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -83.62 -27.91 37.32 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.481 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.59 168.41 1.65 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.8 0.333 . . . . 0.0 110.831 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 -152.83 29.14 0.52 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.039 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . 0.495 ' O ' HG13 ' A' ' 207' ' ' VAL . 0.4 OUTLIER 57.67 -175.72 0.07 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.023 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.495 HG13 ' O ' ' A' ' 206' ' ' MET . 11.9 m -158.12 34.31 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.112 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -81.45 -171.14 3.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.853 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 50.6 p -98.86 179.32 4.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -66.79 134.28 51.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.838 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.46 -67.6 0.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 15.5 p30 -66.72 165.68 14.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.881 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 135.39 131.97 3.1 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.496 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 60.35 179.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.784 0.326 . . . . 0.0 110.9 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 17.0 mt-30 60.01 160.12 0.1 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -52.51 174.11 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.531 2.154 . . . . 0.0 112.264 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.4 tp -98.53 154.2 18.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.889 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 90.1 p -151.56 167.05 29.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.04 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.703 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -157.15 164.7 37.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.962 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -109.89 154.55 22.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.013 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 90.3 t -99.92 123.2 52.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.794 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 31.2 t -100.14 -31.45 11.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.118 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -169.14 135.12 1.65 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.675 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.0 p -142.56 149.37 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.027 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 81.6 p -107.34 149.46 27.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.921 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -95.91 79.48 3.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.412 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -129.07 -161.43 1.11 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.789 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.442 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 0.8 OUTLIER -152.49 87.51 4.15 Favored Pre-proline 0 C--N 1.331 -0.203 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.292 -179.609 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 74.6 Cg_endo -82.7 169.6 59.52 Favored 'Cis proline' 0 C--N 1.348 0.513 0 C-N-CA 123.49 -1.462 . . . . 0.0 112.271 -0.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -111.9 153.01 17.57 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.24 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.87 121.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.83 0.348 . . . . 0.0 111.018 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 224' ' ' VAL . 3.3 p -117.27 156.68 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.133 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.453 ' N ' HG22 ' A' ' 232' ' ' VAL . 87.8 m -122.2 160.6 24.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.564 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . 0.407 ' N ' HG22 ' A' ' 233' ' ' THR . 1.6 m -99.9 170.04 8.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.816 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -79.67 140.93 36.88 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.848 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -53.6 -36.02 61.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.39 . . . . 0.0 110.823 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -94.09 44.85 1.13 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.074 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -159.85 159.59 32.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.218 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -127.47 146.59 50.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.007 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -101.28 149.42 24.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.776 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -143.83 43.74 0.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.688 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.696 ' O ' HG11 ' A' ' 269' ' ' VAL . 1.6 m-85 -127.1 145.32 50.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.712 0.291 . . . . 0.0 110.651 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -108.65 173.29 6.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.974 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.526 HG22 ' HG3' ' A' ' 268' ' ' LYS . 0.7 OUTLIER -59.58 94.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.918 -179.967 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.62 -15.58 3.84 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.714 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -63.13 -178.36 0.23 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.738 0.304 . . . . 0.0 110.859 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 265' ' ' MET . 33.6 m-85 -131.79 146.46 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.985 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.525 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -144.85 150.43 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.282 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.0 p -120.86 164.28 16.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.74 ' HD2' HG21 ' A' ' 253' ' ' VAL . 4.2 m-30 -99.74 143.59 29.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.75 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . 0.418 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 58.1 m -99.97 -90.77 0.31 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.408 -179.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.5 OUTLIER -116.3 88.75 2.96 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 120.505 0.193 . . . . 0.0 111.109 -179.851 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.744 HG22 ' HA2' ' A' ' 290' ' ' GLY . 2.4 t -100.24 155.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.977 0.418 . . . . 0.0 111.268 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -111.61 102.59 10.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.901 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.7 -53.71 0.81 Allowed Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.553 -178.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.638 ' HG2' HD23 ' A' ' 259' ' ' LEU . 39.2 ttm -93.04 49.35 1.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.982 0.42 . . . . 0.0 110.483 179.367 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -79.19 -34.01 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.78 -179.557 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.6 mm-40 -39.33 -34.74 0.22 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.936 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.678 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.8 mm? -59.7 -45.28 92.58 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.325 . . . . 0.0 110.792 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 47.3 t30 -64.02 -34.93 79.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.24 39.6 2.79 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.292 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.3 t -151.54 30.53 0.6 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.686 0.279 . . . . 0.0 110.945 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 61.31 156.16 0.11 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.545 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.527 ' HG3' HG11 ' A' ' 295' ' ' VAL . 20.7 Cg_endo -60.1 168.06 6.57 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.37 2.046 . . . . 0.0 112.035 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.678 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.8 OUTLIER -132.67 -175.24 3.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.769 -179.859 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -99.67 134.85 41.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.543 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.525 HG23 HG22 ' A' ' 248' ' ' VAL . 1.0 OUTLIER -103.8 172.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.627 0.727 . . . . 0.0 112.311 -179.239 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.606 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 10.0 ttpp -140.34 127.42 20.91 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.641 178.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.696 HG11 ' O ' ' A' ' 242' ' ' PHE . 6.4 m -97.58 115.0 36.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 0.0 111.709 -178.297 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 51.1 mt -92.93 -28.83 16.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.385 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.23 -167.92 26.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.543 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.98 -49.6 9.38 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.534 2.156 . . . . 0.0 111.921 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -115.06 14.15 17.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.915 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.7 p -120.04 147.28 45.01 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.623 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.606 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.9 p90 -177.87 161.74 1.62 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.98 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.66 170.08 9.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.946 0.403 . . . . 0.0 111.113 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.725 HD12 ' O ' ' A' ' 278' ' ' CYS . 1.7 pp -133.41 176.89 7.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.931 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.725 ' O ' HD12 ' A' ' 277' ' ' ILE . 31.0 p -58.83 -177.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.922 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -66.63 110.12 3.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 10.2 t -108.03 31.71 5.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.6 m -87.12 -15.49 38.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.194 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.06 33.6 1.7 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.771 0.319 . . . . 0.0 111.021 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -144.05 175.64 9.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.797 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.61 174.27 6.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.729 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -83.56 137.11 33.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -64.97 121.32 14.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.866 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 23.0 mt -105.99 -55.59 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 6.9 mtt180 -158.98 -171.33 3.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.378 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 53.34 177.62 0.08 OUTLIER Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.344 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.744 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 116.05 106.01 2.5 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.98 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' A' ' 251' ' ' SER . 7.6 mm -114.58 129.69 70.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.703 HG13 ' HB3' ' A' ' 219' ' ' ALA . 9.1 p -99.74 117.89 45.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.982 0.42 . . . . 0.0 111.484 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -120.45 175.72 5.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.629 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.64 99.6 9.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.527 HG11 ' HG3' ' A' ' 264' ' ' PRO . 14.8 m -59.41 162.03 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.191 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.8 68.68 1.31 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.81 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.487 HG13 HG23 ' A' ' 295' ' ' VAL . 31.1 m -59.65 152.26 57.92 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.206 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -47.53 134.09 21.08 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.774 2.316 . . . . 0.0 112.403 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 14.5 tttt -154.52 36.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.863 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 3.9 tttm -114.77 177.02 4.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.77 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.1 pt -78.6 76.99 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.095 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 1.4 m -95.16 125.36 39.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -135.74 160.12 39.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.988 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 61.3 mttm -132.28 142.18 49.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.83 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -139.06 97.51 3.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.025 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.472 ' N ' ' HD2' ' A' ' 307' ' ' PRO . 0.4 OUTLIER -77.04 -49.36 2.44 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.229 179.965 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.472 ' HD2' ' N ' ' A' ' 306' ' ' LEU . 87.5 Cg_endo -78.84 177.6 8.52 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.32 2.013 . . . . 0.0 112.352 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -111.12 135.28 51.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.197 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 72.4 m -154.13 103.03 2.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 4.0 mt -99.33 -65.64 0.95 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.897 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 5.7 m -128.2 124.49 62.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.834 -179.981 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.407 0 CA-C-O 120.815 0.341 . . . . 0.0 111.19 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -128.71 32.77 4.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.829 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -173.92 143.61 7.14 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.532 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -124.51 66.02 1.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.922 0.391 . . . . 0.0 110.869 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -84.99 173.55 10.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.917 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -128.99 147.05 50.83 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -121.09 -42.32 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.089 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -68.72 119.12 12.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.838 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 209' ' ' THR . 4.2 t -138.03 92.28 2.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.891 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -157.76 147.69 20.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.893 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 35.4 p -131.42 31.39 4.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.935 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -111.03 161.7 15.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 121.1 -130.88 8.4 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.394 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -81.58 111.14 17.61 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.81 0.338 . . . . 0.0 110.872 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.49 ' N ' ' HD2' ' A' ' 216' ' ' PRO . 3.4 mt-30 -67.23 -49.48 44.16 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.236 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.49 ' HD2' ' N ' ' A' ' 215' ' ' GLN . 71.6 Cg_endo -77.33 138.56 17.84 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.283 1.989 . . . . 0.0 112.39 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.747 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.3 OUTLIER -147.01 167.76 23.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 2.2 m -157.6 134.42 9.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.428 ' HB2' ' O ' ' A' ' 239' ' ' ARG . . . -136.71 159.6 41.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.038 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.2 mtt -105.09 155.36 19.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 45.2 t -100.67 137.02 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.002 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.2 t -112.18 -37.8 4.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.72 150.77 25.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.92 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.438 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.2 p -159.96 142.79 5.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.047 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 51.5 p -106.62 146.33 30.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.948 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 31.1 tttt -90.72 64.57 5.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.437 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -106.32 -156.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.811 -179.92 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.458 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 9.3 t-20 -157.07 89.52 2.55 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.567 0.223 . . . . 0.0 111.389 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 91.2 Cg_endo -77.69 169.12 74.5 Favored 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 123.347 -1.522 . . . . 0.0 112.012 -0.273 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.72 148.67 16.54 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.429 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 30.7 t -99.92 120.48 49.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.907 0.384 . . . . 0.0 111.029 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.523 HG13 ' CE2' ' A' ' 275' ' ' PHE . 2.6 p -112.99 155.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.12 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.439 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -119.83 162.23 19.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.63 179.817 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.9 m -99.95 166.58 10.99 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.954 0.407 . . . . 0.0 110.935 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.812 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 11.2 tp -59.28 153.66 18.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.701 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -51.68 -27.12 10.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.095 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.481 ' HG3' HD23 ' A' ' 235' ' ' LEU . 2.5 pt-20 -134.79 42.69 2.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.853 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.812 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -91.32 -176.65 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.428 ' O ' ' HB2' ' A' ' 219' ' ' ALA . 1.3 tpm_? -130.62 135.46 47.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 38.5 p-80 -109.66 110.67 21.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . 0.747 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -126.13 -0.48 7.53 Favored Glycine 0 CA--C 1.518 0.278 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.991 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.401 ' HB3' ' HB3' ' A' ' 246' ' ' ASP . 1.5 m-85 -80.45 139.67 36.33 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.866 0.365 . . . . 0.0 110.705 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . 0.449 ' O ' HD11 ' A' ' 267' ' ' ILE . 0.8 OUTLIER -92.49 169.4 10.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.928 -179.919 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 4.6 m -59.83 91.57 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.85 23.98 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.685 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.401 ' HB3' ' HB3' ' A' ' 242' ' ' PHE . 1.5 t70 -78.74 170.03 17.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 110.879 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 47.9 m-85 -104.36 122.39 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.903 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 267' ' ' ILE . 30.2 m -128.07 143.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.345 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.2 p -119.82 165.85 14.04 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.739 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.509 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.0 m-30 -99.58 145.24 27.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.96 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . 0.402 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 0.5 OUTLIER -105.0 -88.29 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.988 -179.93 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.606 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.63 90.99 3.45 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.233 0.54 . . . . 0.0 109.769 179.765 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.754 HG22 ' CA ' ' A' ' 290' ' ' GLY . 17.3 t -116.08 139.26 43.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.607 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 119.68 38.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.219 179.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.09 -65.67 0.5 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.778 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.67 ' HG2' HD23 ' A' ' 259' ' ' LEU . 6.4 ttm -85.75 59.73 5.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.089 0.471 . . . . 0.0 110.396 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.41 HG13 ' N ' ' A' ' 258' ' ' GLN . 29.9 pt -80.14 -33.39 14.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.977 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.416 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.1 OUTLIER -38.94 -34.72 0.17 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.897 -178.87 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.838 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.1 mm? -75.15 -44.71 45.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.838 0.351 . . . . 0.0 110.614 179.587 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -57.45 -34.89 69.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.892 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.71 38.64 3.07 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.43 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -158.46 165.2 35.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.755 0.312 . . . . 0.0 110.759 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -56.55 167.66 0.94 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.669 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.55 ' HG3' HG11 ' A' ' 295' ' ' VAL . 48.7 Cg_endo -67.98 169.37 16.58 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.335 2.023 . . . . 0.0 111.999 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.638 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.7 OUTLIER -129.39 -176.99 4.06 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.716 179.929 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.37 140.7 33.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.757 0.313 . . . . 0.0 110.649 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.449 HD11 ' O ' ' A' ' 243' ' ' GLU . 1.2 pp -106.77 171.91 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.55 0.691 . . . . 0.0 112.212 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.622 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -143.05 125.58 15.78 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.617 178.797 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.66 115.53 37.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.598 0.714 . . . . 0.0 111.43 -178.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 50.1 mt -94.27 -27.7 15.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.789 -1.096 . . . . 0.0 110.503 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -163.9 -170.67 29.14 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -62.96 -35.34 66.99 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.52 2.147 . . . . 0.0 112.056 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -123.93 2.44 8.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.169 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -112.24 149.94 31.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.798 0.333 . . . . 0.0 110.791 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.622 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.9 p90 -177.44 162.27 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.767 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 5.1 t -118.19 170.17 9.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.933 0.397 . . . . 0.0 111.332 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.456 HD12 ' O ' ' A' ' 278' ' ' CYS . 1.2 pp -133.95 179.3 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.947 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.456 ' O ' HD12 ' A' ' 277' ' ' ILE . 1.2 m -58.51 -173.41 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.9 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.407 ' O ' ' CE2' ' A' ' 283' ' ' PHE . 1.7 m-20 -54.12 126.58 23.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.98 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.541 HG22 ' CE ' ' A' ' 256' ' ' MET . 0.3 OUTLIER -110.02 -30.15 7.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.968 -179.898 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 2.9 m -59.44 -30.49 68.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.019 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -71.8 -31.01 66.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.998 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.838 ' CE2' HD11 ' A' ' 259' ' ' LEU . 50.7 m-85 -89.51 -172.92 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 75.4 m -78.63 -178.32 5.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.993 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -93.26 135.39 34.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.855 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.722 ' CE2' HG13 ' A' ' 253' ' ' VAL . 39.3 t80 -74.94 138.09 42.1 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.746 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.2 mt -117.05 -66.81 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.197 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 -152.65 170.68 19.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.664 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.77 149.72 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.143 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.754 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 142.81 116.64 1.18 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.801 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.437 HD12 ' N ' ' A' ' 291' ' ' ILE . 3.9 mp -117.44 133.56 63.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.755 0.312 . . . . 0.0 110.711 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.481 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.8 p -99.88 122.08 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.219 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.7 m -131.48 158.19 41.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.94 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -90.5 118.81 30.25 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.55 HG11 ' HG3' ' A' ' 264' ' ' PRO . 3.5 m -57.75 122.32 7.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.27 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -98.29 -43.51 6.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.924 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.431 HG13 ' HD2' ' A' ' 298' ' ' PRO . 34.3 t 65.14 136.14 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.037 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.431 ' HD2' HG13 ' A' ' 297' ' ' VAL . 55.5 Cg_endo -69.72 97.53 0.64 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 122.511 2.14 . . . . 0.0 112.274 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 8.7 tttt -99.13 -24.36 14.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.101 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 7.1 tmtm? 65.0 32.05 10.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.921 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 19.0 tt -96.41 128.58 47.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.097 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 6.9 p 62.26 117.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.947 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -154.07 33.05 0.43 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.921 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -142.88 -70.9 0.32 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.828 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 51.4 p -143.47 33.26 1.3 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.962 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.5 mp 61.02 56.11 3.44 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.939 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -78.55 -44.01 0.16 Allowed 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.684 2.256 . . . . 0.0 112.313 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -98.51 110.11 22.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.106 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.1 m -146.88 127.71 14.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER 61.67 174.48 0.12 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.838 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.2 p -64.67 138.29 23.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.07 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.233 -0.889 . . . . 0.0 110.869 179.995 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.486 1.364 0 CA-C-O 120.856 0.36 . . . . 0.0 111.187 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . 0.4 ' O ' ' CD1' ' A' ' 202' ' ' PHE . 15.0 p90 -161.37 117.66 2.17 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.909 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -177.2 36.05 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.457 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -63.27 -176.2 0.13 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.814 0.34 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -129.3 119.1 23.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.855 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -89.38 113.39 24.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.883 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 207' ' ' VAL . 7.4 p -146.08 95.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.077 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 7.4 mt -139.58 86.71 2.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.84 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.438 HG22 ' H ' ' A' ' 210' ' ' ASP . 0.2 OUTLIER 60.18 179.66 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 180.0 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.438 ' H ' HG22 ' A' ' 209' ' ' THR . 5.3 t0 -113.23 -36.22 5.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.92 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 3.6 m 60.67 90.77 0.06 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -81.06 112.93 18.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.931 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -92.17 -66.81 1.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.471 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 62.1 mt-10 -96.88 174.27 6.88 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.81 0.338 . . . . 0.0 110.933 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.402 ' CB ' ' CD ' ' A' ' 216' ' ' PRO . 0.4 OUTLIER -68.17 -60.82 4.63 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.931 179.943 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.402 ' CD ' ' CB ' ' A' ' 215' ' ' GLN . 61.3 Cg_endo -73.12 -168.68 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.468 2.112 . . . . 0.0 112.341 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.745 HD23 ' CE1' ' A' ' 242' ' ' PHE . 29.7 tp -160.04 141.97 12.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.889 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 13.7 t -147.42 154.71 41.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.834 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.44 155.98 40.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.043 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -94.26 143.44 26.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 39.1 t -99.92 145.04 11.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.058 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 38.7 t -112.79 -32.96 6.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.073 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 14.7 ptm -169.5 159.05 8.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.559 HG12 ' CG ' ' A' ' 286' ' ' TYR . 8.5 p -158.87 149.21 7.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.062 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 63.3 p -99.46 147.56 25.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.948 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.04 81.44 3.7 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.435 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.6 t0 -127.76 -157.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.796 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.464 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 1.6 p30 -154.68 90.59 3.09 Favored Pre-proline 0 CA--C 1.531 0.223 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 -179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 97.3 Cg_endo -77.13 169.39 74.38 Favored 'Cis proline' 0 C--N 1.347 0.477 0 C-N-CA 123.369 -1.513 . . . . 0.0 112.011 -0.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.76 151.3 17.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.45 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.6 t -99.87 140.25 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.843 0.354 . . . . 0.0 111.008 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.574 HG13 ' CE1' ' A' ' 275' ' ' PHE . 3.3 p -130.88 151.96 36.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.141 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 4.9 m -114.19 158.12 21.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.67 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.1 m -99.97 166.64 10.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.819 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 7.2 tp -59.11 152.25 20.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.789 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -50.95 -27.21 7.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.143 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -132.79 38.35 3.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.819 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -87.68 -169.0 2.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.158 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.2 ttm180 -145.35 106.84 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.924 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.492 ' CE1' ' CD2' ' A' ' 275' ' ' PHE . 27.5 t60 -107.61 143.64 35.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.82 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 177.04 68.79 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.678 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.745 ' CE1' HD23 ' A' ' 217' ' ' LEU . 15.3 m-85 -116.32 149.26 39.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.861 0.362 . . . . 0.0 110.762 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -69.28 151.33 46.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.5 m -57.86 97.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.78 15.35 9.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.721 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -64.9 -178.67 0.45 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.657 0.265 . . . . 0.0 110.743 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.495 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.8 m-85 -120.24 132.06 55.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.789 0.328 . . . . 0.0 110.982 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.419 HG22 HG23 ' A' ' 267' ' ' ILE . 17.8 m -137.32 154.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.421 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 4.4 p -125.59 165.0 19.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.556 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.665 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.6 m-30 -99.74 140.59 33.73 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.041 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 62.2 m -99.96 -94.09 0.26 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.033 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.54 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.2 OUTLIER -109.66 87.74 2.58 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 121.27 -0.172 . . . . 0.0 110.636 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.665 HG21 ' CD2' ' A' ' 250' ' ' PHE . 15.5 t -107.21 144.72 15.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.928 0.394 . . . . 0.0 111.726 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -107.92 114.94 29.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.912 179.161 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.6 -63.52 0.51 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.671 -0.776 . . . . 0.0 111.458 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.64 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.9 ttm -89.24 54.57 3.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.133 0.492 . . . . 0.0 110.152 179.035 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.415 HG22 ' O ' ' A' ' 253' ' ' VAL . 14.2 pt -79.04 -33.35 15.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.045 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -38.76 -34.71 0.16 Allowed 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.933 -178.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.64 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.2 mm? -71.08 -47.03 60.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.943 0.401 . . . . 0.0 110.49 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -55.86 -34.85 65.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.896 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.14 46.37 3.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -169.1 166.34 10.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.784 0.326 . . . . 0.0 110.663 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -55.91 164.19 1.83 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.644 ' HG3' HG21 ' A' ' 295' ' ' VAL . 36.6 Cg_endo -64.9 168.54 13.43 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.242 1.961 . . . . 0.0 112.078 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.497 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -128.35 -172.29 2.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.516 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -99.37 151.43 21.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.758 0.313 . . . . 0.0 110.654 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.419 HG23 HG22 ' A' ' 248' ' ' VAL . 2.1 pp -123.1 174.0 8.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.593 0.711 . . . . 0.0 112.316 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.569 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.2 OUTLIER -147.43 127.77 13.95 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.738 178.919 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 269' ' ' VAL . 34.9 m -97.88 112.75 30.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.434 0.635 . . . . 0.0 111.539 -178.535 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 270' ' ' LEU . 17.6 mt -89.04 -28.0 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.449 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.63 -164.17 24.9 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.583 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 -44.25 9.06 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.586 2.191 . . . . 0.0 112.099 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -117.03 18.34 14.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.029 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.97 146.66 51.67 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.92 0.391 . . . . 0.0 110.794 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.574 ' CE1' HG13 ' A' ' 232' ' ' VAL . 2.2 p90 -178.62 154.12 0.74 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.639 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.7 t -105.58 170.06 8.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.014 0.435 . . . . 0.0 111.441 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.61 -178.02 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.84 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.31 175.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.987 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.38 133.2 50.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 62.9 p -118.07 28.57 8.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.06 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 80.3 p -82.21 -30.05 31.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.921 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.405 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 77.5 m-20 -100.1 31.23 3.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.999 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 259' ' ' LEU . 24.9 m-85 -138.12 -175.05 3.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.04 178.78 6.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.94 150.88 21.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.929 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.559 ' CG ' HG12 ' A' ' 224' ' ' VAL . 67.3 t80 -81.43 136.39 35.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.5 mt -120.0 -56.81 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.199 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.8 mmt85 -162.48 178.11 8.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.372 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.29 162.58 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.269 -0.967 . . . . 0.0 111.932 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.636 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 130.8 116.37 1.81 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.793 179.002 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 10.2 mt -120.51 133.59 66.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.747 0.308 . . . . 0.0 110.597 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.549 ' O ' HG13 ' A' ' 292' ' ' VAL . 12.1 p -99.6 117.21 44.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.325 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -122.31 142.54 50.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.812 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -80.7 101.59 9.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.927 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.644 HG21 ' HG3' ' A' ' 264' ' ' PRO . 27.1 m -57.05 132.76 21.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.135 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -169.73 77.95 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.874 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.614 HG13 ' O ' ' A' ' 297' ' ' VAL . 11.1 p 34.91 90.5 0.07 OUTLIER Pre-proline 0 N--CA 1.467 0.388 0 CA-C-N 115.977 -0.556 . . . . 0.0 112.032 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.8 128.92 31.55 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.618 2.212 . . . . 0.0 112.231 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.38 173.04 12.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -81.68 153.25 26.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.913 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 32.5 mm -70.65 148.66 10.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.044 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.2 154.02 17.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.962 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -159.86 118.49 2.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.849 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -99.88 -75.41 0.57 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.964 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.93 117.46 7.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.971 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 59.1 91.08 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.937 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -83.68 46.07 1.96 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.784 2.323 . . . . 0.0 112.73 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 50.55 97.0 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.85 0.357 . . . . 0.0 111.351 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 1.4 m -170.83 115.66 0.45 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.032 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 2.6 pp -83.11 121.17 26.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.82 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.2 p -59.19 130.83 23.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.885 -179.986 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 120.831 0.348 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 61.38 105.52 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.861 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -132.36 124.16 3.8 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.515 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -135.62 30.14 3.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.816 0.341 . . . . 0.0 110.883 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -158.52 166.02 33.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 64.15 -79.08 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -65.08 80.29 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.059 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -105.83 107.87 19.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.89 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 9.0 t -127.65 -176.11 3.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.829 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 1.7 t70 60.39 110.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.933 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.6 -32.23 7.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.893 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -176.64 -40.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.844 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 177.99 -92.53 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.496 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 59.39 94.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.832 0.349 . . . . 0.0 110.876 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.413 ' N ' ' CD ' ' A' ' 216' ' ' PRO . 0.0 OUTLIER -69.07 -52.45 15.99 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.947 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.413 ' CD ' ' N ' ' A' ' 215' ' ' GLN . 52.8 Cg_exo -54.63 134.28 61.42 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.447 2.098 . . . . 0.0 112.188 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 4.0 tp -129.74 139.73 51.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.87 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 63.8 m -134.02 160.22 38.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.991 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.62 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -148.0 153.25 38.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.57 155.97 17.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.055 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.401 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 41.0 t -105.19 135.31 43.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.021 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.6 t -111.52 -34.75 6.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -164.53 151.91 11.67 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.82 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.536 HG12 ' CD1' ' A' ' 286' ' ' TYR . 9.8 p -157.86 148.58 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.023 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 64.5 p -101.96 145.36 29.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.913 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -93.65 77.92 4.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.729 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.411 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.5 t70 -121.59 -153.68 0.56 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.773 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.431 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 37.1 t-20 -157.39 90.19 2.43 Favored Pre-proline 0 CA--C 1.531 0.232 0 CA-C-O 120.452 0.168 . . . . 0.0 111.256 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 97.4 Cg_endo -76.97 169.8 73.43 Favored 'Cis proline' 0 C--N 1.348 0.5 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.15 -0.253 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.4 149.58 16.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.458 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.2 t -99.88 138.72 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.832 0.348 . . . . 0.0 110.874 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.632 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 3.6 p -131.63 156.9 43.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.463 ' N ' HG22 ' A' ' 232' ' ' VAL . 94.3 m -120.92 161.68 21.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.368 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . 0.415 ' N ' HG22 ' A' ' 233' ' ' THR . 2.4 m -99.9 169.86 8.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.908 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.61 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 3.2 tp -68.08 153.67 43.24 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.807 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -53.67 -28.3 32.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.97 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.544 ' CG ' HD23 ' A' ' 235' ' ' LEU . 9.6 pt-20 -121.68 30.64 6.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.891 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.61 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -92.14 -176.42 4.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.122 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -124.87 -175.89 3.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.563 ' CE1' HG12 ' A' ' 269' ' ' VAL . 6.2 t-80 -174.12 113.32 0.18 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -144.78 25.71 1.94 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.819 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.502 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.5 OUTLIER -99.04 138.64 35.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.861 0.362 . . . . 0.0 110.595 179.808 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -92.78 168.8 10.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 58.7 p -59.44 102.39 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 120.6 11.7 6.46 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.898 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -73.83 -176.14 2.34 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.732 0.301 . . . . 0.0 110.767 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.441 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -132.75 121.82 23.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.798 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.49 HG22 HG23 ' A' ' 267' ' ' ILE . 20.2 m -129.1 154.84 40.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 0.0 111.325 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.8 p -123.76 165.51 17.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.862 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 1.012 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.0 m-30 -99.61 144.27 28.89 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.96 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 28.7 t -102.88 -94.35 0.31 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.011 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -110.29 88.29 2.73 Favored 'General case' 0 C--O 1.225 -0.195 0 CA-C-O 120.511 0.196 . . . . 0.0 110.54 179.684 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 1.012 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.9 t -104.32 143.54 15.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.988 0.423 . . . . 0.0 111.745 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.06 110.81 23.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.924 179.152 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.73 -63.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.701 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.472 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.1 ttm -86.25 58.58 5.13 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 110.33 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.401 HG13 ' N ' ' A' ' 258' ' ' GLN . 16.2 pt -79.32 -33.33 15.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.9 -179.362 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.449 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 4.2 mp0 -38.99 -34.59 0.16 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.859 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.764 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.0 mm? -73.16 -46.82 48.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.938 0.399 . . . . 0.0 110.495 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -58.38 -34.94 71.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.788 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.62 45.35 2.74 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.346 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -165.92 163.96 18.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.775 0.321 . . . . 0.0 110.714 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -56.01 167.65 0.83 Allowed Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.599 179.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.599 ' HG3' HG21 ' A' ' 295' ' ' VAL . 54.0 Cg_endo -68.68 154.39 71.47 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.302 2.002 . . . . 0.0 112.017 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.463 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.1 ptp -115.11 -177.03 3.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.574 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -99.7 138.67 36.46 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.773 0.321 . . . . 0.0 110.784 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.502 HD11 ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -106.79 174.72 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.573 0.702 . . . . 0.0 112.2 -179.473 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.713 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -144.04 128.77 18.27 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.508 178.716 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.563 HG12 ' CE1' ' A' ' 240' ' ' HIS . 27.7 m -97.43 118.18 43.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-O 121.523 0.678 . . . . 0.0 111.495 -178.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 44.5 mt -92.42 -30.78 15.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.662 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.44 -158.99 32.17 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.312 -0.947 . . . . 0.0 113.097 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -63.89 112.13 1.74 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.71 2.273 . . . . 0.0 112.338 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 66.27 14.99 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.08 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -128.73 138.33 52.06 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.484 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.713 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.4 p90 -174.21 169.42 3.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.872 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.0 t -123.42 170.11 10.68 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.98 0.419 . . . . 0.0 111.415 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.67 HD11 ' CG2' ' A' ' 280' ' ' THR . 11.6 pt -123.58 -177.53 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.802 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 m -57.5 -82.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.983 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -150.15 140.69 22.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.801 0.334 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.67 ' CG2' HD11 ' A' ' 277' ' ' ILE . 71.5 p -113.22 -26.92 8.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 t -54.53 -24.21 19.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.292 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.401 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 3.3 m120 -94.47 20.91 7.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.23 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.764 ' CE2' HD11 ' A' ' 259' ' ' LEU . 35.7 m-85 -143.78 -179.61 6.57 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.774 0.321 . . . . 0.0 110.825 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.81 -171.79 0.74 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.893 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -98.87 125.86 44.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.536 ' CD1' HG12 ' A' ' 224' ' ' VAL . 26.9 t80 -69.98 120.67 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.797 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.2 mt -106.88 -68.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.185 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -138.48 -178.84 5.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.508 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.81 166.67 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.238 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.665 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 122.87 111.32 2.05 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.532 -0.842 . . . . 0.0 113.126 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.455 HD12 ' N ' ' A' ' 291' ' ' ILE . 4.8 mp -118.69 128.35 75.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.62 HG13 ' HB3' ' A' ' 219' ' ' ALA . 12.6 p -99.55 113.1 33.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.017 0.437 . . . . 0.0 111.531 -179.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.4 m -115.28 -176.81 2.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.641 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -112.59 106.6 15.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.826 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.599 HG21 ' HG3' ' A' ' 264' ' ' PRO . 4.7 m -58.47 133.94 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.114 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -126.02 19.79 7.68 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.255 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.5 t 53.36 91.49 0.07 OUTLIER Pre-proline 0 C--N 1.331 -0.202 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.404 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.56 138.81 39.35 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.456 2.104 . . . . 0.0 112.278 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.37 175.02 5.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.952 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -71.89 124.5 24.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.918 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.9 pt -104.39 131.66 52.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.192 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 88.9 p -102.46 27.94 6.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.004 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 56.78 178.55 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.93 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -107.96 -36.06 6.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.8 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 1.4 m -154.27 158.44 40.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.905 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 60.39 82.74 0.22 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.92 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.95 -46.56 0.71 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.642 2.228 . . . . 0.0 112.357 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -142.14 -176.56 4.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.134 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 10.0 m -157.97 31.51 0.26 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -149.0 124.59 10.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.805 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.94 -30.12 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.23 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.207 -0.902 . . . . 0.0 110.857 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.768 0.318 . . . . 0.0 111.257 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -111.82 141.75 45.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.901 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 104.95 97.86 2.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.452 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -140.62 -66.16 0.44 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.794 0.33 . . . . 0.0 110.902 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -147.9 -46.55 0.16 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.962 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 1.4 ttp 62.61 29.44 16.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.981 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.461 HG13 ' HE1' ' A' ' 303' ' ' PHE . 21.5 t 63.34 124.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.11 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.604 HD12 ' O ' ' A' ' 208' ' ' LEU . 2.3 pp -158.37 103.77 1.81 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.469 HG22 ' CD1' ' A' ' 306' ' ' LEU . 0.0 OUTLIER -138.13 -169.55 2.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.852 -179.991 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -116.86 -171.72 2.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.966 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.7 t -92.1 150.7 20.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.984 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -109.93 -23.69 11.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.13 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -54.04 108.08 0.78 Allowed Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.631 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -142.72 -47.44 0.33 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.881 0.372 . . . . 0.0 110.94 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 2.4 pt20 -104.27 112.65 65.49 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.83 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -68.51 130.19 20.44 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.439 2.093 . . . . 0.0 112.296 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.94 -179.27 4.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.832 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.2 p -168.52 97.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.024 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.743 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -102.49 167.49 9.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.986 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 4.5 mmt -105.54 146.46 29.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.015 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.446 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 96.0 t -100.06 130.58 49.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 40.0 t -109.39 -34.88 6.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.066 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -157.0 148.29 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.043 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 224' ' ' VAL . 11.0 p -155.93 113.09 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.005 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 68.8 p -70.81 135.69 48.29 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.05 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.54 82.96 6.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.726 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -129.85 -147.94 0.35 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.498 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -145.96 102.77 4.16 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-O 120.342 0.115 . . . . 0.0 110.881 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.449 ' HB2' ' O ' ' A' ' 277' ' ' ILE . 36.2 Cg_endo -68.24 -74.26 0.0 OUTLIER 'Cis proline' 0 C--N 1.349 0.555 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.656 0.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 154.42 139.73 2.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.18 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.3 t -99.83 127.85 52.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.895 0.378 . . . . 0.0 111.025 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.543 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.7 p -116.85 153.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.165 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 90.3 m -117.93 157.86 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.508 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -99.97 168.65 9.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.664 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 3.5 tp -68.95 150.81 47.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.781 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -48.5 -28.38 3.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.176 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -133.75 47.42 2.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.85 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.664 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -90.85 174.19 7.58 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.163 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -118.38 107.4 13.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.912 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 12.9 p80 -92.57 131.58 37.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.824 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -151.4 26.36 0.97 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.566 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.711 ' O ' HG11 ' A' ' 269' ' ' VAL . 1.4 m-85 -112.3 140.86 46.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 110.719 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.66 175.48 5.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -61.18 88.67 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.773 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 136.18 -16.47 3.9 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.818 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.09 165.39 3.41 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.658 0.266 . . . . 0.0 110.708 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 265' ' ' MET . 5.0 m-85 -113.61 150.15 33.52 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.883 0.373 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 267' ' ' ILE . 10.1 m -147.48 144.31 19.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.21 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 p -115.78 163.67 15.49 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.671 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.955 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.0 m-30 -99.44 142.78 30.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.77 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . 0.411 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 65.3 m -99.82 -100.12 0.24 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.108 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 1.7 pt-20 -103.1 88.01 3.04 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.605 0.24 . . . . 0.0 110.641 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.955 HG21 ' CD2' ' A' ' 250' ' ' PHE . 9.8 t -100.9 136.71 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.853 0.358 . . . . 0.0 111.522 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -99.92 107.88 19.98 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.883 179.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.65 -66.02 0.46 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.79 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.596 ' HG2' HD23 ' A' ' 259' ' ' LEU . 32.1 ttm -84.04 59.65 5.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.164 0.506 . . . . 0.0 110.673 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 12.4 pt -80.23 -33.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.989 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -38.57 -34.5 0.14 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.647 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.4 mm? -61.64 -53.9 49.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.907 0.384 . . . . 0.0 110.613 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -57.39 -34.94 69.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.884 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.05 46.09 2.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 2.2 t -162.06 30.2 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.69 0.281 . . . . 0.0 110.981 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . 0.41 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 2.4 mt-30 58.33 167.66 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.773 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.651 ' HB3' HG11 ' A' ' 295' ' ' VAL . 30.1 Cg_endo -63.39 165.8 16.69 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.31 2.007 . . . . 0.0 112.067 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.647 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -134.52 -171.69 2.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.643 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -99.68 138.63 36.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.857 0.36 . . . . 0.0 110.568 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.442 HD13 ' HB2' ' A' ' 242' ' ' PHE . 1.6 pp -109.71 172.72 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.5 0.666 . . . . 0.0 112.181 -179.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 8.5 tttm -143.54 125.51 15.29 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.788 -1.096 . . . . 0.0 108.833 178.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.711 HG11 ' O ' ' A' ' 242' ' ' PHE . 27.4 m -97.61 108.9 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.459 0.647 . . . . 0.0 111.525 -178.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.1 mt -86.02 -30.57 22.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.451 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -165.61 -168.53 27.91 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.615 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -60.1 -50.57 7.14 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.59 2.194 . . . . 0.0 111.816 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -112.91 21.87 15.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.723 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -130.33 145.93 51.85 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.736 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.554 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -179.18 155.68 0.73 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.4 t -104.3 170.08 8.11 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.162 0.506 . . . . 0.0 111.35 -179.249 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.547 ' CD1' HG21 ' A' ' 280' ' ' THR . 3.8 pt -124.67 -171.22 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.643 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -74.27 -168.46 0.65 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.623 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -69.77 105.6 2.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.547 HG21 ' CD1' ' A' ' 277' ' ' ILE . 4.4 t -132.89 74.25 1.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.932 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 10.1 p -125.76 -33.51 2.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.593 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 -95.14 25.4 4.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.608 -0.269 . . . . 0.0 111.647 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.426 ' CD1' ' HA ' ' A' ' 280' ' ' THR . 21.6 m-85 -117.36 -167.48 1.32 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.739 0.304 . . . . 0.0 110.739 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 31.0 t -74.56 175.95 7.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.842 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -99.4 131.71 45.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.433 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 24.7 t80 -69.01 117.56 10.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.029 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 6.0 mt -102.98 -60.06 3.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.47 -178.75 6.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.459 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . 0.401 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 57.87 158.31 0.02 OUTLIER Glycine 0 C--N 1.331 0.29 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.427 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.534 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 129.37 106.13 1.21 Allowed Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.513 -0.851 . . . . 0.0 112.865 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.481 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.7 mp -111.54 135.87 49.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.743 ' CG1' ' HB3' ' A' ' 219' ' ' ALA . 12.2 p -99.64 112.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.964 0.411 . . . . 0.0 111.549 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 49.8 m -107.2 171.91 7.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.701 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.42 ' HG3' ' CD1' ' A' ' 242' ' ' PHE . 2.2 tt0 -110.04 94.96 5.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.086 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.815 ' O ' HG22 ' A' ' 297' ' ' VAL . 32.1 m -59.48 -171.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.013 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.575 ' O ' HG13 ' A' ' 297' ' ' VAL . 0.0 OUTLIER -52.88 90.24 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.861 0.362 . . . . 0.0 111.238 -179.833 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.815 HG22 ' O ' ' A' ' 295' ' ' VAL . 3.7 m -160.27 156.34 22.97 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.087 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.25 164.15 31.54 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.53 2.153 . . . . 0.0 112.265 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.03 -64.58 1.06 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 13.8 tttm -149.49 136.25 19.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.87 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 28.2 mm -81.58 137.75 20.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.18 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 10.1 m -113.77 162.68 16.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.89 179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . 0.461 ' HE1' HG13 ' A' ' 207' ' ' VAL . 23.7 t80 -150.83 164.62 35.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.831 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 12.0 mttt 61.84 113.83 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.79 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 62.65 148.13 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.469 ' CD1' HG22 ' A' ' 209' ' ' THR . 0.6 OUTLIER -153.66 87.61 3.74 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 179.993 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -69.23 -35.38 14.32 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.586 2.191 . . . . 0.0 112.309 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 61.1 114.04 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.1 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 19.4 t -74.84 101.64 4.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.88 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . 0.642 ' O ' HD12 ' A' ' 310' ' ' LEU . 0.5 OUTLIER -140.9 79.16 1.68 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.848 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.67 -36.01 4.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.063 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.274 -0.87 . . . . 0.0 110.931 179.956 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 . . . . . 0 N--CA 1.486 1.335 0 CA-C-O 120.859 0.361 . . . . 0.0 111.174 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -157.41 -47.57 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.937 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -84.35 -106.17 0.59 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.48 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -156.87 68.2 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.841 0.353 . . . . 0.0 110.912 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 61.99 117.59 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.914 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 61.27 112.03 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.476 HG13 ' N ' ' A' ' 208' ' ' LEU . 10.8 p -153.02 -44.56 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.071 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.476 ' N ' HG13 ' A' ' 207' ' ' VAL . 5.1 mp -101.44 -31.46 10.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.957 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 76.6 p -83.85 122.47 28.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.85 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -136.46 -51.83 0.7 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.992 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 9.0 t -98.69 122.51 42.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.95 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.95 151.46 45.43 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -148.44 -92.51 0.1 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.377 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -162.84 154.33 17.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.807 0.337 . . . . 0.0 110.853 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.86 132.93 21.73 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.71 -62.44 0.32 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.395 2.063 . . . . 0.0 112.242 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.579 HD23 ' CE1' ' A' ' 242' ' ' PHE . 8.1 tp -147.7 133.53 19.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.834 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 25.6 p -145.25 172.28 13.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.511 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -162.98 169.95 18.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.05 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.3 156.08 22.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.939 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 41.0 t -108.21 127.39 64.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.003 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 17.2 t -106.06 -34.68 7.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.974 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.76 137.33 10.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.74 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.1 p -142.8 122.08 8.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.064 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 31.0 p -81.7 138.67 35.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.112 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -90.56 78.32 6.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.77 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.428 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.9 t0 -123.07 -150.96 0.46 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.723 -179.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.422 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 17.2 p30 -159.44 90.49 1.93 Allowed Pre-proline 0 CA--C 1.532 0.255 0 CA-C-O 120.471 0.177 . . . . 0.0 111.202 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 81.2 Cg_endo -75.13 169.34 74.82 Favored 'Cis proline' 0 C--N 1.347 0.451 0 C-N-CA 123.322 -1.533 . . . . 0.0 111.937 -0.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -103.86 146.13 16.29 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.377 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.1 t -99.76 125.35 53.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.74 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.7 p -122.55 155.25 27.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.214 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.426 ' N ' HG22 ' A' ' 232' ' ' VAL . 4.7 m -123.52 166.9 14.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.577 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -100.0 170.05 8.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.745 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.564 HD23 ' HG2' ' A' ' 237' ' ' GLU . 0.4 OUTLIER -72.16 160.46 32.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.7 179.867 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -55.08 -29.81 58.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.992 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.564 ' HG2' HD23 ' A' ' 235' ' ' LEU . 9.3 pt-20 -119.13 34.64 5.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.829 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.94 159.6 15.22 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.019 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -124.65 140.02 53.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.977 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.4 t60 -118.76 144.19 46.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.82 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . 0.496 ' HA3' HD21 ' A' ' 217' ' ' LEU . . . -159.57 26.39 0.34 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.739 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.579 ' CE1' HD23 ' A' ' 217' ' ' LEU . 1.6 m-85 -100.53 142.34 32.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.788 0.328 . . . . 0.0 110.66 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -95.94 170.07 9.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.24 101.07 0.11 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.8 19.26 5.35 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.696 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -84.9 169.27 14.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.758 0.313 . . . . 0.0 110.702 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.454 ' HA ' ' O ' ' A' ' 265' ' ' MET . 62.5 m-85 -108.28 141.81 39.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.912 0.387 . . . . 0.0 111.033 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.451 HG22 HG23 ' A' ' 267' ' ' ILE . 32.5 m -146.21 143.5 21.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.1 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.5 p -121.24 162.52 20.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.93 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.0 m-30 -99.76 149.61 23.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.1 m -108.5 -85.17 0.53 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.919 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.602 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.72 92.58 3.85 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.128 0.49 . . . . 0.0 109.828 179.678 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.93 HG21 ' CD2' ' A' ' 250' ' ' PHE . 3.3 t -112.46 140.63 31.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.479 -179.196 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 68.3 mt-30 -103.79 110.84 23.1 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.091 179.331 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.88 -57.75 0.64 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.591 -179.021 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.676 ' HG2' HD23 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -90.27 53.78 2.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.11 0.481 . . . . 0.0 110.353 179.334 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 18.8 pt -78.91 -33.79 16.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.843 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -39.24 -34.73 0.2 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.294 -0.412 . . . . 0.0 112.068 -178.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.807 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.5 mm? -66.47 -45.07 80.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 110.685 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -57.68 -38.86 75.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.994 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.7 50.22 1.14 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.511 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.2 t -161.67 30.12 0.13 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.711 0.291 . . . . 0.0 110.905 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 10.2 mt-30 58.82 166.22 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.762 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.71 ' HG3' HG21 ' A' ' 295' ' ' VAL . 27.6 Cg_endo -62.34 166.01 13.94 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.441 2.094 . . . . 0.0 112.148 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.807 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.2 ptp -130.97 -174.84 3.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.713 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.52 136.53 39.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.801 0.334 . . . . 0.0 110.616 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.451 HG23 HG22 ' A' ' 248' ' ' VAL . 1.2 pp -103.15 175.77 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.662 0.744 . . . . 0.0 112.315 -179.317 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.649 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.1 OUTLIER -148.89 128.84 13.46 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.621 178.805 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.504 HG11 ' O ' ' A' ' 242' ' ' PHE . 26.1 m -97.73 122.89 49.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.528 0.68 . . . . 0.0 111.577 -178.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 48.4 mt -101.95 -29.1 12.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.504 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.49 -172.35 27.64 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.513 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.56 -33.98 65.79 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.556 2.171 . . . . 0.0 112.053 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -124.63 1.92 8.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.166 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -113.98 153.3 29.57 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.85 0.357 . . . . 0.0 110.805 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.649 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.53 169.05 2.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.831 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -124.1 170.08 11.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.993 0.425 . . . . 0.0 111.242 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.3 pt -125.73 -179.21 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.773 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.04 -173.37 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.865 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.67 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.827 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -99.85 33.47 2.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.979 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 31.2 t -109.21 30.78 6.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.406 ' OD1' ' CZ ' ' A' ' 283' ' ' PHE . 28.2 p30 -150.09 30.71 0.7 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.851 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.406 ' CZ ' ' OD1' ' A' ' 282' ' ' ASN . 20.0 m-85 -138.04 -168.42 2.35 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.462 ' O ' ' HE3' ' A' ' 256' ' ' MET . 0.1 OUTLIER -91.61 175.25 6.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.84 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -85.43 121.04 27.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.877 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.426 ' HE1' HG13 ' A' ' 253' ' ' VAL . 64.8 t80 -56.67 136.52 54.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.879 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 30.9 mt -114.16 -59.83 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.301 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.01 173.3 11.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.734 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.36 150.51 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.31 112.53 0.95 Allowed Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.895 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 4.2 mp -109.22 128.87 64.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.806 0.336 . . . . 0.0 110.614 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.7 p -99.88 114.93 39.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.359 -179.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 75.6 m -109.42 -178.03 3.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.638 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 31.9 tt0 -119.31 102.89 9.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.001 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.71 HG21 ' HG3' ' A' ' 264' ' ' PRO . 28.8 m -73.48 64.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.0 179.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 7.5 tttm -127.2 94.35 3.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 4.7 m -135.03 111.98 11.17 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.227 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.408 ' O ' ' CG ' ' A' ' 299' ' ' LYS . 45.7 Cg_exo -56.22 -19.22 26.68 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.466 2.111 . . . . 0.0 112.505 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.408 ' CG ' ' O ' ' A' ' 298' ' ' PRO . 5.7 ptmt 46.17 101.29 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.026 0.441 . . . . 0.0 111.659 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.691 ' O ' HG22 ' A' ' 301' ' ' ILE . 10.8 mttt 66.78 179.62 0.22 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.936 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.691 HG22 ' O ' ' A' ' 300' ' ' LYS . 7.4 tt 51.81 160.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.92 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 95.9 p -153.23 -46.52 0.1 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.015 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -142.06 151.22 42.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.891 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 23.6 mtmt 62.09 117.93 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.953 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 23.1 t -142.12 31.25 1.57 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.922 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 1.6 mp -97.59 150.37 36.71 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.46 -170.46 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.586 2.191 . . . . 0.0 112.193 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -118.17 137.19 53.15 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.135 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 55.9 p -118.3 148.0 42.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.942 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -105.62 -35.01 7.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.837 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . 0.434 HG12 ' N ' ' A' ' 312' ' ' GLU . 27.7 t -124.13 155.76 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.009 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . 0.434 ' N ' HG12 ' A' ' 311' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.849 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.354 0 CA-C-O 120.839 0.352 . . . . 0.0 111.243 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -100.84 -31.07 11.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.93 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 145.97 138.26 3.19 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.463 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -79.82 -39.82 29.9 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.877 0.37 . . . . 0.0 110.94 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 60.34 94.29 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.937 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -176.72 123.41 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.607 ' O ' HG13 ' A' ' 207' ' ' VAL . 9.9 p -124.52 69.33 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.998 0.428 . . . . 0.0 111.097 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.4 HD13 ' HA ' ' A' ' 208' ' ' LEU . 3.7 mm? 63.73 -79.81 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.073 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 21.8 p -99.52 -41.69 7.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.055 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 3.1 t70 64.35 95.91 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -157.97 143.2 16.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.849 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -155.55 112.18 3.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.959 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 73.89 -135.23 19.97 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.51 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -104.98 150.41 24.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.884 0.373 . . . . 0.0 110.895 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 -156.44 122.55 2.55 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.765 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -54.14 121.9 10.48 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.454 2.103 . . . . 0.0 112.257 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp -119.9 178.21 4.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.774 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.7 m -162.19 169.6 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.972 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -162.25 148.39 13.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.951 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 2.4 mtt -93.45 160.93 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.002 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.425 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 47.9 t -108.73 123.88 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.025 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 28.8 t -102.22 -30.68 10.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.52 143.21 5.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.955 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.651 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.2 p -149.2 137.33 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.087 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 43.8 p -90.22 145.51 24.95 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.83 78.28 4.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.813 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.71 -160.74 1.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.824 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.424 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 7.3 p-10 -154.4 90.04 3.22 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-N 116.694 -0.23 . . . . 0.0 111.277 -179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 92.5 Cg_endo -80.1 169.72 68.61 Favored 'Cis proline' 0 C--N 1.348 0.503 0 C-N-CA 123.501 -1.458 . . . . 0.0 112.168 -0.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -113.76 157.13 15.16 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.334 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.0 t -99.79 125.45 53.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.858 0.361 . . . . 0.0 110.911 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.651 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.5 p -123.72 155.79 30.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.196 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 232' ' ' VAL . 89.1 m -124.16 159.11 30.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.615 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 4.0 m -99.97 165.9 11.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.86 0.362 . . . . 0.0 110.905 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 3.7 tp -59.92 150.12 29.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.741 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -52.24 -27.79 16.22 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.261 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -99.92 -26.74 13.9 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.04 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.405 ' O ' ' CE2' ' A' ' 273' ' ' TYR . . . -74.4 140.81 44.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.243 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 27.5 ttt180 -120.59 145.31 47.5 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.902 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -86.24 131.53 34.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.935 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -119.52 -19.38 4.19 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.995 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.485 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -78.9 145.93 33.85 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.777 0.322 . . . . 0.0 110.737 -179.879 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -101.92 179.66 4.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.538 HG23 HG22 ' A' ' 269' ' ' VAL . 0.7 OUTLIER -63.72 105.44 0.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.997 -179.995 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 128.24 -5.39 6.78 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.967 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.418 ' CB ' ' HB3' ' A' ' 242' ' ' PHE . 2.3 t70 -80.21 172.34 13.9 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.841 0.353 . . . . 0.0 110.98 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.444 ' HA ' ' O ' ' A' ' 265' ' ' MET . 4.4 m-85 -122.19 152.75 39.64 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.055 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.537 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -156.55 154.76 5.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.256 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 t -125.61 170.19 11.73 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.725 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.809 ' CD2' HG21 ' A' ' 253' ' ' VAL . 5.5 m-30 -99.6 159.45 15.03 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.13 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 29.3 t -113.37 -87.66 0.56 Allowed 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.065 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.492 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -114.66 88.57 2.89 Favored 'General case' 0 CA--C 1.521 -0.15 0 CA-C-O 120.54 0.209 . . . . 0.0 110.852 179.785 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.809 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.0 t -99.96 158.36 3.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.004 0.431 . . . . 0.0 111.462 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.431 ' N ' HG12 ' A' ' 253' ' ' VAL . 2.2 mm-40 -119.04 106.11 12.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.941 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -56.55 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.482 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.457 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.2 ttm -96.59 51.53 1.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.153 0.502 . . . . 0.0 110.315 179.166 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.7 pp -75.74 -33.66 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.563 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.433 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 5.1 mm-40 -39.25 -34.64 0.2 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.695 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.53 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.4 mm? -59.22 -47.32 85.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 110.59 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -57.54 -46.41 83.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.871 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.82 47.56 2.98 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.538 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 5.1 t -152.14 34.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . 0.404 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 4.3 mt-30 59.74 168.49 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.583 ' HB3' HG21 ' A' ' 295' ' ' VAL . 43.8 Cg_endo -67.55 151.34 79.77 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.349 2.033 . . . . 0.0 112.067 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.53 ' SD ' HD12 ' A' ' 259' ' ' LEU . 3.1 ptp -118.69 -178.01 3.44 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.711 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -99.75 157.25 16.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.504 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.537 HG23 HG22 ' A' ' 248' ' ' VAL . 1.8 pp -125.93 170.5 15.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.625 0.726 . . . . 0.0 112.312 -179.539 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.628 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 14.4 mtpt -145.06 126.79 15.25 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.564 -1.198 . . . . 0.0 108.532 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.538 HG22 HG23 ' A' ' 244' ' ' THR . 29.4 m -97.54 120.36 46.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.595 0.712 . . . . 0.0 111.587 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.2 mt -99.11 -30.25 12.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.809 -1.087 . . . . 0.0 110.601 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -162.31 -173.81 31.44 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.565 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.82 -59.27 1.31 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.611 2.208 . . . . 0.0 112.243 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CE2' ' O ' ' A' ' 238' ' ' ALA . 10.0 m-85 -109.39 5.19 23.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.3 p -106.57 149.5 27.1 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.628 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -177.65 166.88 2.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.755 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.4 t -117.21 170.09 8.95 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 19.7 pt -131.11 179.89 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.16 -179.55 0.78 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.89 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.34 109.23 0.83 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.799 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.6 t -122.5 30.08 6.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.026 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 18.2 p -98.66 31.42 2.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.942 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.26 -45.95 1.0 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.453 ' CD2' HD21 ' A' ' 259' ' ' LEU . 30.5 m-85 -59.81 -168.21 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.878 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.2 176.77 9.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.913 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -83.79 125.99 32.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.976 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.401 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 20.7 t80 -61.12 135.04 57.64 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.81 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.7 mt -118.26 -64.71 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.008 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.85 -173.74 4.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.438 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.14 170.38 0.1 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.391 -0.909 . . . . 0.0 112.251 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.62 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 118.95 106.83 2.25 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.0 179.261 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.411 ' CD1' ' HG3' ' A' ' 252' ' ' GLU . 2.9 mp -116.94 125.3 73.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.739 0.304 . . . . 0.0 110.191 179.357 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.505 ' O ' HG13 ' A' ' 292' ' ' VAL . 9.8 p -99.68 120.1 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.551 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.5 m -125.58 170.23 11.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.726 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.421 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 27.7 tt0 -86.3 118.33 25.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.896 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.583 HG21 ' HB3' ' A' ' 264' ' ' PRO . 0.4 OUTLIER -78.63 164.45 3.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.086 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -161.23 30.21 0.14 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.985 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.509 ' N ' ' CD ' ' A' ' 298' ' ' PRO . 3.6 t -81.91 -45.82 1.04 Allowed Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.467 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.509 ' CD ' ' N ' ' A' ' 297' ' ' VAL . 25.7 Cg_exo -62.58 -26.99 76.11 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.521 2.147 . . . . 0.0 112.234 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.22 154.02 14.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.044 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.605 ' C ' HD12 ' A' ' 301' ' ' ILE . 0.0 OUTLIER 59.52 30.01 19.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.045 -179.958 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.605 HD12 ' C ' ' A' ' 300' ' ' LYS . 3.7 mp 63.82 134.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 66.4 p -132.39 174.43 10.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.9 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -134.47 168.95 18.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.873 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -98.92 31.62 2.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 5.6 m -107.03 -178.51 3.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -132.63 87.22 42.22 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_exo -51.21 -25.67 18.02 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.535 2.157 . . . . 0.0 112.46 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 61.66 110.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.074 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.453 ' O ' HD22 ' A' ' 310' ' ' LEU . 22.8 t -98.62 117.4 32.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . 0.453 HD22 ' O ' ' A' ' 309' ' ' SER . 2.2 mm? -124.86 31.35 5.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 17.2 m -94.89 43.51 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.85 179.955 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 120.789 0.328 . . . . 0.0 111.234 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -105.48 134.34 48.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.908 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 73.95 -105.12 1.75 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.522 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 61.22 112.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.864 0.364 . . . . 0.0 110.881 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -95.63 -31.6 13.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.901 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.07 109.26 2.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.3 m -114.94 31.23 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.128 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.504 HD12 ' H ' ' A' ' 208' ' ' LEU . 0.9 OUTLIER -85.98 160.7 19.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.52 154.43 42.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.932 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.9 t0 62.73 146.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.966 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 59.94 30.39 19.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 41.7 t30 -68.98 -31.2 69.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.896 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -111.07 167.49 12.53 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.568 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -76.74 -30.0 56.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.745 0.307 . . . . 0.0 110.972 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.423 ' N ' ' HD2' ' A' ' 216' ' ' PRO . 7.9 mt-30 -58.69 -60.72 9.49 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.065 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.423 ' HD2' ' N ' ' A' ' 215' ' ' GLN . 45.8 Cg_endo -68.76 150.89 74.46 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.464 2.109 . . . . 0.0 112.328 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.7 tp -130.49 -173.88 3.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 36.3 p -152.53 146.39 25.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -141.8 145.24 34.5 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.026 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.606 ' HB3' HD13 ' A' ' 235' ' ' LEU . 1.0 OUTLIER -82.8 151.27 26.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.983 -179.942 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 83.7 t -104.25 143.85 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.065 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.2 t -117.32 -38.52 3.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.774 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.7 mtp -159.63 143.61 14.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 224' ' ' VAL . 10.5 p -143.68 121.32 6.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.028 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 32.9 p -79.89 142.76 34.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.007 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.56 78.54 4.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.799 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.43 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 4.7 t0 -127.84 -158.91 0.91 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.749 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.428 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 17.1 t-20 -153.53 90.8 3.37 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.543 0.211 . . . . 0.0 111.325 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.43 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 96.9 Cg_endo -77.23 169.17 74.85 Favored 'Cis proline' 0 C--N 1.348 0.512 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.949 -0.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.27 17.53 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.453 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 21.4 t -99.84 136.09 32.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.844 0.355 . . . . 0.0 111.19 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.566 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 6.3 p -127.67 138.12 55.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.014 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.46 162.33 13.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.65 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.99 165.88 11.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.887 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.712 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 0.5 OUTLIER -58.76 158.0 8.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.701 179.768 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.76 -27.64 29.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.109 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.32 38.51 3.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.804 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.712 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -99.22 169.54 9.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.096 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 4.0 tpt180 -150.02 135.71 18.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.001 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.441 ' HB2' ' CE2' ' A' ' 242' ' ' PHE . 27.1 p-80 -137.78 135.96 36.82 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.766 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -122.15 65.07 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.669 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 240' ' ' HIS . 0.9 OUTLIER -111.87 142.1 44.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.848 0.356 . . . . 0.0 110.656 179.856 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.55 172.26 9.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 27.0 m -64.17 99.54 0.28 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.003 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.26 17.89 6.97 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.902 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.01 -175.46 2.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.704 0.288 . . . . 0.0 110.687 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.47 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.0 m-85 -120.93 151.95 39.08 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.909 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.478 ' HB ' HG23 ' A' ' 292' ' ' VAL . 35.0 m -156.04 152.2 8.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.374 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 15.9 p -128.45 168.91 14.95 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.923 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.952 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.5 m-30 -99.79 140.94 33.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.135 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.8 m -104.09 -81.38 0.52 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.899 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.761 ' HG3' HD12 ' A' ' 291' ' ' ILE . 0.4 OUTLIER -119.56 88.17 2.88 Favored 'General case' 0 C--O 1.216 -0.661 0 CA-C-N 116.57 -0.286 . . . . 0.0 110.61 179.567 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.952 HG21 ' CD2' ' A' ' 250' ' ' PHE . 9.2 t -114.72 134.17 58.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 120.934 0.397 . . . . 0.0 111.882 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 64.2 mt-30 -99.65 119.82 38.7 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.028 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.86 -62.91 0.51 Allowed Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.366 -178.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.638 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.3 ttm -87.9 58.84 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.156 0.503 . . . . 0.0 110.162 179.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.433 ' O ' ' N ' ' A' ' 260' ' ' ASN . 1.0 OUTLIER -77.46 -33.34 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.961 -179.437 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.438 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 37.9 mm-40 -39.14 -34.65 0.18 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.788 HD11 ' CE2' ' A' ' 283' ' ' PHE . 2.7 mm? -76.87 -39.89 49.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.873 0.368 . . . . 0.0 110.69 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.433 ' N ' ' O ' ' A' ' 257' ' ' ILE . 0.6 OUTLIER -57.09 -36.99 71.27 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.91 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.54 29.1 10.15 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.325 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -144.18 158.42 43.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.767 0.317 . . . . 0.0 110.762 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 12.7 mt-30 -54.42 165.75 0.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.754 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.774 ' HG3' HG21 ' A' ' 295' ' ' VAL . 35.6 Cg_endo -64.05 174.63 3.8 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.427 2.085 . . . . 0.0 111.826 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 0.3 OUTLIER -133.86 -177.75 4.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.753 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -99.51 132.83 44.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.455 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.467 HG23 HG22 ' A' ' 248' ' ' VAL . 1.2 pp -102.61 172.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.8 0.81 . . . . 0.0 112.591 -179.08 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.598 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 43.8 mmtt -142.13 129.69 21.41 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.302 -1.317 . . . . 0.0 108.299 178.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 5.8 m -97.48 113.55 32.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.457 0.646 . . . . 0.0 111.567 -178.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.8 mt -93.77 -27.77 16.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.707 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -169.59 -170.93 34.68 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.811 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -66.99 -27.25 42.89 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.636 2.224 . . . . 0.0 112.309 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 44.5 m-85 -129.42 18.31 5.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.03 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.79 148.85 47.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.843 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.598 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 6.6 p90 -178.55 149.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.611 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 268' ' ' LYS . 1.6 t -107.49 170.14 8.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.275 -179.353 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.553 HD11 HG23 ' A' ' 280' ' ' THR . 2.7 pp -123.7 -175.85 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.739 179.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.401 ' C ' HD12 ' A' ' 277' ' ' ILE . 42.7 t -56.87 -77.36 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.038 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.458 ' N ' HD12 ' A' ' 277' ' ' ILE . 21.1 p-10 -150.06 133.39 16.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.06 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.553 HG23 HD11 ' A' ' 277' ' ' ILE . 0.7 OUTLIER -118.2 -28.23 5.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.195 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 22.5 p -60.38 -18.61 51.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.373 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -94.49 29.72 2.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.213 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.788 ' CE2' HD11 ' A' ' 259' ' ' LEU . 58.4 m-85 -150.07 -174.89 4.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.944 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.5 m -70.74 175.32 5.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.967 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -90.98 136.91 32.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.961 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 11.9 t80 -64.73 142.88 58.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.77 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.7 -61.72 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 2.1 mmt-85 -165.35 171.45 13.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.405 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 62.53 153.04 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.095 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.28 132.96 2.86 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.299 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.761 HD12 ' HG3' ' A' ' 252' ' ' GLU . 3.2 mt -135.45 136.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.566 -0.317 . . . . 0.0 110.3 179.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.478 HG23 ' HB ' ' A' ' 248' ' ' VAL . 11.8 p -99.83 127.2 52.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.192 -179.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.4 m -130.7 135.43 47.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -77.62 105.4 8.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.85 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.774 HG21 ' HG3' ' A' ' 264' ' ' PRO . 16.1 m -58.8 149.52 5.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.192 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -72.92 -67.32 0.57 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.987 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.637 HG13 ' O ' ' A' ' 297' ' ' VAL . 7.7 p -130.64 99.59 18.59 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.07 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.415 ' HB3' ' HG2' ' A' ' 264' ' ' PRO . 55.8 Cg_endo -69.9 -38.52 7.37 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.53 2.153 . . . . 0.0 112.413 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.17 131.7 6.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -148.5 28.36 0.88 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.922 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.52 ' N ' HD13 ' A' ' 301' ' ' ILE . 0.2 OUTLIER -51.77 177.47 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.434 -179.885 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 3.5 t 63.46 128.9 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.007 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 60.61 52.36 4.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.907 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.99 -169.16 0.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.78 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -104.64 -66.04 0.99 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.933 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.5 mt -148.77 112.71 3.65 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.77 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -68.19 -40.51 8.55 Favored 'Trans proline' 0 C--N 1.347 0.459 0 C-N-CA 122.446 2.097 . . . . 0.0 112.389 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -168.43 -67.45 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.11 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 91.5 p -166.08 125.67 1.64 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.845 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 14.1 mt -69.42 136.23 51.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.921 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 12.3 p -114.46 153.13 16.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.069 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.342 -0.837 . . . . 0.0 110.877 -179.975 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.738 0.304 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 63.33 109.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.828 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 129.66 -37.01 2.25 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.453 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -67.15 -49.98 62.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.784 0.326 . . . . 0.0 110.86 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -126.01 119.73 28.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.86 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 2.8 ptp -106.47 117.11 33.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.846 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -83.17 96.04 3.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.141 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.569 HD22 ' HB2' ' A' ' 210' ' ' ASP . 0.6 OUTLIER -166.07 135.61 3.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.941 179.905 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.53 ' O ' HG22 ' A' ' 209' ' ' THR . 25.8 m -109.08 38.47 2.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.872 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.569 ' HB2' HD22 ' A' ' 208' ' ' LEU . 1.3 m-20 -123.49 156.88 34.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.868 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -165.37 -45.13 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 17.2 m-80 -89.54 163.1 15.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.985 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -176.22 115.85 0.54 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.467 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -97.11 135.34 39.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.892 0.377 . . . . 0.0 110.856 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.17 89.74 6.34 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.807 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.51 146.87 63.09 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.493 2.128 . . . . 0.0 112.327 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.31 147.66 35.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.819 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 14.8 m -146.43 176.84 9.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.002 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -164.15 141.99 7.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.073 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 7.6 mtm -79.32 156.47 28.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.994 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 58.9 t -100.23 137.3 28.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.996 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 10.4 t -109.75 -31.21 7.53 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.824 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -171.9 131.66 0.67 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.57 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.9 p -133.91 115.88 22.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.118 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 34.0 p -75.43 141.77 43.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.079 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.77 87.39 6.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.869 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.419 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.8 OUTLIER -136.96 -160.41 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.765 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 37.4 t-20 -155.77 92.58 2.65 Favored Pre-proline 0 CA--C 1.531 0.228 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.263 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.419 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 87.1 Cg_endo -76.11 169.59 74.08 Favored 'Cis proline' 0 C--N 1.348 0.549 0 C-N-CA 123.389 -1.504 . . . . 0.0 112.098 -0.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.56 145.74 18.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.335 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 28.1 t -99.84 125.92 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.99 0.424 . . . . 0.0 111.067 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.667 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.1 p -115.82 157.29 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.483 ' N ' HG22 ' A' ' 232' ' ' VAL . 86.5 m -119.56 161.85 19.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.503 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . 0.423 ' N ' HG22 ' A' ' 233' ' ' THR . 4.4 m -99.87 164.75 11.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 110.867 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.674 ' HB3' ' HB2' ' A' ' 238' ' ' ALA . 24.1 tp -57.44 157.88 6.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . 0.401 ' N ' ' HG ' ' A' ' 235' ' ' LEU . 0.4 OUTLIER -53.88 -26.91 27.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.046 179.953 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.474 ' HG2' HD23 ' A' ' 235' ' ' LEU . 0.0 OUTLIER -125.28 29.75 5.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.946 179.976 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.674 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -90.81 -178.13 5.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.193 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 3.6 tpt85 -150.09 139.42 21.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.78 ' CE1' HG12 ' A' ' 269' ' ' VAL . 10.5 t-160 -106.64 127.26 53.2 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.746 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -135.8 24.57 3.3 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.967 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.538 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -106.9 138.66 42.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.575 179.774 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -90.81 172.45 8.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.977 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.614 HG23 HG22 ' A' ' 269' ' ' VAL . 3.2 p -63.54 101.62 0.35 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.802 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 119.66 7.14 9.92 Favored Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.851 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -70.58 -174.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.723 0.297 . . . . 0.0 110.769 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.456 ' HA ' ' O ' ' A' ' 265' ' ' MET . 90.1 m-85 -129.85 142.64 50.64 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.881 0.372 . . . . 0.0 111.167 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.496 HG22 HG23 ' A' ' 267' ' ' ILE . 18.6 m -151.32 154.71 7.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.63 170.5 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.879 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.989 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.3 m-30 -99.1 142.47 30.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.4 m -100.39 -82.49 0.45 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.944 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.6 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -123.75 91.17 3.41 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.299 0.571 . . . . 0.0 109.793 179.575 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.989 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.6 t -114.39 138.05 45.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.568 -178.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -101.57 118.1 36.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.094 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.54 -62.43 0.54 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.858 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.622 ' HG3' HD23 ' A' ' 259' ' ' LEU . 23.3 tpp -88.54 57.45 4.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.167 0.508 . . . . 0.0 110.295 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.593 HD13 ' H ' ' A' ' 257' ' ' ILE . 0.2 OUTLIER -77.09 -33.3 20.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.977 -179.355 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.417 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 0.5 OUTLIER -39.03 -34.7 0.17 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.983 -178.756 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.813 HD12 ' SD ' ' A' ' 265' ' ' MET . 2.8 mm? -74.76 -43.16 56.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.035 0.445 . . . . 0.0 110.385 179.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.556 ' ND2' HG23 ' A' ' 253' ' ' VAL . 0.6 OUTLIER -50.49 -40.01 49.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.112 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -106.79 46.5 1.16 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 12.9 t -144.07 26.38 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.313 . . . . 0.0 111.085 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 58.14 166.41 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.835 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.704 ' CB ' HG21 ' A' ' 295' ' ' VAL . 22.1 Cg_endo -61.4 144.9 98.53 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.421 2.081 . . . . 0.0 112.102 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.813 ' SD ' HD12 ' A' ' 259' ' ' LEU . 2.3 ptp -115.36 -171.85 2.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.51 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -99.81 149.74 23.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.761 0.315 . . . . 0.0 110.572 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 277' ' ' ILE . 1.2 pp -119.87 175.76 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.569 0.7 . . . . 0.0 112.441 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.703 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 2.2 tttp -146.18 131.27 18.32 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.6 -1.182 . . . . 0.0 108.475 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.78 HG12 ' CE1' ' A' ' 240' ' ' HIS . 27.5 m -97.55 119.77 46.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.369 0.604 . . . . 0.0 111.537 -178.415 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.463 ' HA ' HD23 ' A' ' 270' ' ' LEU . 14.5 mt -95.48 -29.51 14.35 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.779 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 165.71 -159.81 33.1 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 113.108 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.84 112.66 1.88 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.81 2.34 . . . . 0.0 112.301 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 65.46 15.8 10.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.104 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.0 p -130.74 134.66 47.08 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.494 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.703 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.2 p90 -171.85 169.86 5.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.94 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.8 t -124.74 170.07 11.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 267' ' ' ILE . 2.6 pp -135.28 -179.87 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.928 179.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.712 ' O ' HD12 ' A' ' 277' ' ' ILE . 29.8 p -55.77 -172.47 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.005 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -62.14 119.68 9.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.647 HG21 HD11 ' A' ' 277' ' ' ILE . 10.0 t -135.33 30.74 3.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.956 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 35.3 t -97.37 -34.06 11.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.923 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -70.21 -25.39 63.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.055 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.604 ' CD2' HD21 ' A' ' 259' ' ' LEU . 20.7 m-85 -77.48 -170.66 1.86 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.918 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.27 -160.54 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.762 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -117.98 131.18 56.51 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.839 0.352 . . . . 0.0 110.715 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.47 ' CG ' HG12 ' A' ' 224' ' ' VAL . 17.3 t80 -57.82 131.05 49.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.983 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.0 mt -111.89 -64.85 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.031 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.06 164.84 36.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.724 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.81 151.73 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.199 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.549 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 141.06 122.29 1.84 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.721 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 26.8 mt -125.85 131.6 71.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.776 0.322 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.2 p -99.98 108.82 23.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.031 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 62.3 m -103.51 169.12 8.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -106.08 100.9 10.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.82 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.704 HG21 ' CB ' ' A' ' 264' ' ' PRO . 17.2 m -68.34 143.93 14.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.28 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 31.6 mttp -95.53 -55.23 3.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.895 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 4.5 m 41.24 80.72 0.27 Allowed Pre-proline 0 N--CA 1.464 0.237 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.779 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.24 -22.67 25.27 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.521 2.147 . . . . 0.0 112.401 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -172.28 -39.25 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.048 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 18.6 mtpt 66.74 173.32 0.25 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.798 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 31.5 mt -96.95 85.97 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 50.6 m -145.23 123.62 12.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.93 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -141.11 -48.95 0.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.946 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.22 93.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.913 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -98.09 119.38 36.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.936 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -104.36 105.38 49.35 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.837 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.73 120.14 7.15 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.384 2.056 . . . . 0.0 112.25 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -59.28 177.47 0.18 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.132 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -112.48 145.13 40.75 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.884 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 4.4 mt -107.17 124.39 49.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.856 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . 0.434 ' O ' HG23 ' A' ' 311' ' ' VAL . 5.9 m -99.88 86.33 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.099 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.947 179.915 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 . . . . . 0 N--CA 1.487 1.416 0 CA-C-O 120.843 0.354 . . . . 0.0 111.209 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 63.33 124.95 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.96 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -102.67 -89.98 2.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.404 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 60.44 86.35 0.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.783 0.325 . . . . 0.0 110.943 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -175.08 151.35 1.3 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.904 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 25.3 mtt -100.72 -55.3 2.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.914 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.562 HG22 ' O ' ' A' ' 207' ' ' VAL . 10.8 p -176.21 51.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.081 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 2.4 mp 61.69 152.97 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 8.6 t -138.79 31.37 2.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.91 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.25 164.63 11.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.85 40.85 1.13 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.936 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -171.14 103.44 0.21 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.927 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 128.25 100.66 1.03 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.515 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -117.33 127.1 53.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.815 0.34 . . . . 0.0 110.912 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -99.48 131.85 24.21 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.854 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.87 152.38 23.3 Favored 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.471 2.114 . . . . 0.0 112.328 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -111.71 143.1 43.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.85 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.8 p -137.79 152.08 48.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.951 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -137.34 147.82 45.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.06 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.733 ' HB3' HD13 ' A' ' 235' ' ' LEU . 0.0 OUTLIER -86.57 151.17 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.887 -179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 59.0 t -99.94 136.24 32.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.009 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.0 t -111.61 -34.27 6.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.974 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.4 mtp -163.99 153.75 14.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.992 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.41 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.0 p -157.14 135.61 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.05 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.3 140.75 29.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -86.75 74.06 9.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.861 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.4 t0 -122.09 -156.73 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.68 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 1.4 p30 -158.91 91.18 2.01 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-O 120.516 0.198 . . . . 0.0 111.307 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 228' ' ' ASN . 80.2 Cg_endo -76.06 169.72 73.71 Favored 'Cis proline' 0 C--N 1.348 0.527 0 C-N-CA 123.451 -1.479 . . . . 0.0 112.074 -0.108 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.21 151.8 17.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.501 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 17.9 t -99.98 114.69 39.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 0.0 111.109 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.509 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.3 p -106.15 157.1 6.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.108 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.471 ' N ' HG22 ' A' ' 232' ' ' VAL . 1.7 m -121.81 165.02 16.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.581 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.03 169.98 8.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.908 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.733 HD13 ' HB3' ' A' ' 220' ' ' MET . 0.6 OUTLIER -68.86 158.66 34.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.754 179.829 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -54.21 -33.53 58.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.044 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.544 ' HG3' HD23 ' A' ' 235' ' ' LEU . 0.1 OUTLIER -122.38 29.98 6.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.892 179.88 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.605 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -82.24 -175.66 5.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -148.45 107.62 3.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.952 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.563 ' CE1' HG12 ' A' ' 269' ' ' VAL . 34.5 t-80 -97.29 136.64 37.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.767 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -164.48 62.94 0.24 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.697 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.462 ' CD2' ' CE1' ' A' ' 240' ' ' HIS . 3.8 m-85 -122.6 143.81 49.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.817 0.341 . . . . 0.0 110.759 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.26 156.7 36.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 5.7 m -58.48 97.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.96 10.37 12.34 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.826 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -60.04 174.11 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.747 0.274 . . . . 0.0 110.724 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 265' ' ' MET . 54.7 m-85 -115.99 130.93 57.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.813 0.34 . . . . 0.0 111.066 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.507 HG21 ' CG2' ' A' ' 292' ' ' VAL . 15.0 m -144.96 159.36 13.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.019 0.438 . . . . 0.0 111.399 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.21 170.71 14.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.983 ' CD2' HG21 ' A' ' 253' ' ' VAL . 3.6 m-30 -99.08 145.49 27.07 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.967 -179.581 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -100.37 -86.6 0.39 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.088 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -119.33 88.32 2.91 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-O 120.535 0.207 . . . . 0.0 110.664 179.627 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.983 HG21 ' CD2' ' A' ' 250' ' ' PHE . 2.8 t -102.16 149.9 6.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.55 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.59 30.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.811 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 100.1 -73.29 0.45 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.431 -178.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.436 ' HE1' ' HA ' ' A' ' 285' ' ' ASP . 3.3 tpp -83.71 60.28 5.65 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.2 0.524 . . . . 0.0 110.215 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 16.1 pt -78.63 -33.0 16.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.498 -0.774 . . . . 0.0 112.001 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -38.32 -34.39 0.13 Allowed 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.897 -178.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.493 HD22 ' N ' ' A' ' 259' ' ' LEU . 3.1 mm? -63.7 -50.25 69.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.979 0.419 . . . . 0.0 110.239 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -53.32 -34.73 58.6 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.998 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -85.84 45.06 3.42 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.808 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 4.6 t -165.78 150.21 8.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.743 0.306 . . . . 0.0 110.767 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.64 159.95 0.5 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.849 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.608 ' CB ' HG21 ' A' ' 295' ' ' VAL . 10.4 Cg_endo -53.35 149.13 30.62 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.449 2.099 . . . . 0.0 111.87 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 5.7 ptp -111.91 -173.04 2.16 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.476 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -99.75 155.32 17.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.762 0.315 . . . . 0.0 110.792 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.48 HG23 HG22 ' A' ' 248' ' ' VAL . 1.8 pp -123.47 169.64 14.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.5 0.667 . . . . 0.0 112.127 -179.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.607 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -142.36 125.44 16.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.825 -1.079 . . . . 0.0 108.818 178.707 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 269' ' ' VAL . 33.0 m -97.65 112.61 30.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.53 0.681 . . . . 0.0 111.499 -178.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.5 mt -90.77 -27.72 18.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.522 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -167.31 -166.24 26.06 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.582 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.55 -52.88 3.31 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.573 2.182 . . . . 0.0 111.857 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 20.8 m-85 -112.86 18.92 17.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.87 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.88 145.65 49.7 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.67 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.607 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.8 p90 -178.07 159.2 1.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.8 t -108.92 170.05 8.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.158 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.2 pt -131.2 -179.98 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.803 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.33 172.85 1.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.905 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.74 118.91 7.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.857 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 9.9 t -141.17 51.2 1.6 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.984 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 7.2 p -102.69 -22.08 14.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.171 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -96.51 31.4 2.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.748 0.309 . . . . 0.0 111.089 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -128.77 -175.47 3.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.777 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.04 125.76 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.717 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.436 ' HA ' ' HE1' ' A' ' 256' ' ' MET . 0.2 OUTLIER -42.56 149.17 0.19 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.553 -179.688 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -78.14 137.36 38.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.853 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 32.3 mt -119.11 -65.18 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.102 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -148.71 -174.48 4.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.44 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 55.76 169.02 0.07 OUTLIER Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.258 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.653 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 122.09 116.75 2.4 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.981 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 2.8 mp -128.79 127.31 66.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.729 0.3 . . . . 0.0 110.252 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.59 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.7 p -99.65 111.06 28.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.992 0.425 . . . . 0.0 111.369 -179.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -106.36 158.31 16.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.706 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -95.04 92.64 6.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.968 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.608 HG21 ' CB ' ' A' ' 264' ' ' PRO . 13.3 m -58.83 175.07 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.094 179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.78 32.89 0.49 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.889 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.6 t 59.17 84.04 0.21 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.053 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.09 159.14 54.21 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.624 2.216 . . . . 0.0 112.324 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.86 162.65 13.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -136.91 156.82 47.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.826 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 22.6 mm -113.99 144.06 22.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.076 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 27.3 t 63.25 152.38 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.935 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 60.68 109.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.738 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.72 83.01 1.16 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.977 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 27.6 t -111.57 128.97 56.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.691 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.512 ' HB2' ' HD3' ' A' ' 307' ' ' PRO . 14.8 mt -88.28 -48.45 0.44 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.452 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.512 ' HD3' ' HB2' ' A' ' 306' ' ' LEU . 49.9 Cg_endo -91.37 -78.35 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 122.75 2.3 . . . . 0.0 112.674 -179.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -176.67 -165.96 0.14 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.827 0.346 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -118.92 -44.74 2.6 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.819 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -130.12 157.17 43.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.768 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.41 -61.09 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.141 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.95 179.97 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 120.873 0.368 . . . . 0.0 111.177 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -137.61 157.28 46.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.01 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 88.82 63.74 1.33 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.495 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -62.34 -66.08 0.59 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.816 0.341 . . . . 0.0 110.904 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -116.57 80.19 1.43 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 2.1 mtt -125.17 -44.27 1.9 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.868 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 31.0 m -65.96 -30.33 49.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.171 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 2.2 tt -86.65 61.18 6.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -118.35 130.01 55.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.814 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.5 t0 74.3 -58.73 0.58 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.025 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 75.65 -62.56 0.43 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.905 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -162.41 -69.5 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.96 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -139.21 175.61 21.51 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.557 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -83.61 130.02 34.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.88 0.371 . . . . 0.0 110.826 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -102.58 157.75 33.1 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.928 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.04 -61.72 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.548 2.165 . . . . 0.0 112.256 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 1.6 tp -149.45 157.66 43.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 55.9 p -158.0 160.51 37.57 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.025 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.422 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -159.11 170.08 22.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.079 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 6.6 mtm -105.88 157.04 17.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.8 t -109.51 130.6 62.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.836 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 22.9 t -109.94 -35.1 6.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.162 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.46 148.51 27.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.936 0.398 . . . . 0.0 111.067 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.447 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.3 p -158.31 137.04 3.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.969 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 144.63 29.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.01 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.2 ttmt -89.68 72.63 7.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.815 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.1 t70 -122.49 -160.77 0.9 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.858 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.404 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 8.0 p-10 -156.08 90.91 2.7 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.175 -179.687 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.406 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 83.6 Cg_endo -78.87 169.9 70.92 Favored 'Cis proline' 0 C--N 1.349 0.577 0 C-N-CA 123.495 -1.46 . . . . 0.0 112.179 -0.102 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.17 153.01 17.87 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.444 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 24.3 t -99.85 122.35 51.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.883 0.373 . . . . 0.0 111.0 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.587 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.8 p -114.34 153.81 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.165 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 273' ' ' TYR . 1.7 m -123.33 155.73 36.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.486 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.85 170.02 8.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.83 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.764 HD23 ' H ' ' A' ' 237' ' ' GLU . 0.3 OUTLIER -71.83 143.43 49.46 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.764 179.883 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -24.86 30.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.399 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.764 ' H ' HD23 ' A' ' 235' ' ' LEU . 6.5 mt-10 -100.54 -18.07 16.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.364 -179.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -79.57 168.01 19.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.824 0.345 . . . . 0.0 111.247 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.08 -167.83 1.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.864 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 9.3 p80 -171.96 155.33 3.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.847 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 179.26 54.33 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.872 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.435 ' HB2' HD11 ' A' ' 267' ' ' ILE . 1.1 m-85 -103.74 141.05 36.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.823 0.344 . . . . 0.0 110.575 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -71.69 153.44 42.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.7 m -57.08 97.44 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.12 9.44 15.67 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.746 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.17 -165.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.772 0.286 . . . . 0.0 110.545 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.581 ' HB2' HG22 ' A' ' 295' ' ' VAL . 86.9 m-85 -128.9 143.06 50.78 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.916 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.5 HG22 HG23 ' A' ' 267' ' ' ILE . 15.9 m -149.58 134.87 10.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.731 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.1 p -111.95 166.47 11.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.434 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 1.003 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.7 m-30 -99.85 143.93 29.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.02 -179.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 25.7 m -99.93 -86.28 0.39 Allowed 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.988 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.598 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -120.02 92.76 3.85 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.266 0.555 . . . . 0.0 110.006 179.896 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 1.003 HG21 ' CD2' ' A' ' 250' ' ' PHE . 4.6 t -111.43 139.02 37.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.383 -179.264 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -99.93 116.27 31.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.194 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.23 -65.53 0.5 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.629 -0.795 . . . . 0.0 111.897 -179.253 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . . . . . . . . . 1.5 ttt -89.91 59.38 4.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.487 . . . . 0.0 110.534 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 15.0 pt -77.99 -33.94 18.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.67 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.7 mm100 -39.24 -34.64 0.2 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.81 -179.091 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.468 ' HB2' ' CD2' ' A' ' 250' ' ' PHE . 3.3 mm? -60.6 -49.54 77.12 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.884 0.373 . . . . 0.0 110.576 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -64.75 -34.82 79.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.835 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -93.1 39.38 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.496 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.5 t -159.26 34.25 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 0.0 110.716 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 61.88 168.41 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.597 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.546 ' HG2' HG12 ' A' ' 295' ' ' VAL . 24.1 Cg_exo -61.46 -153.15 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 111.702 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.563 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.9 ptp -172.78 -175.89 1.36 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.805 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.58 147.37 25.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.656 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.644 HG22 HG22 ' A' ' 277' ' ' ILE . 1.2 pp -119.73 174.99 4.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.675 0.75 . . . . 0.0 112.482 -179.49 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.674 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.0 mttt -147.33 131.07 16.95 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.401 178.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.443 HG23 ' O ' ' A' ' 269' ' ' VAL . 34.6 m -97.54 122.33 49.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.433 0.635 . . . . 0.0 111.63 -178.279 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 270' ' ' LEU . 15.0 mt -96.77 -30.87 12.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.651 -179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 167.29 -171.81 42.09 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.245 -0.979 . . . . 0.0 113.214 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_exo -51.75 112.96 0.96 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.793 2.328 . . . . 0.0 112.475 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.532 ' O ' HG23 ' A' ' 233' ' ' THR . 67.9 m-85 64.71 19.41 11.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.054 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.5 p -133.0 139.35 47.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.459 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.674 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.3 p90 -176.97 166.48 2.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 -179.57 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -118.56 170.05 9.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.992 0.425 . . . . 0.0 111.161 -179.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.644 HG22 HG22 ' A' ' 267' ' ' ILE . 1.0 OUTLIER -134.62 -178.63 2.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.848 179.814 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 29.9 p -57.35 -177.55 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -72.56 124.06 24.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.428 ' HA ' ' CD1' ' A' ' 283' ' ' PHE . 8.6 t -137.69 51.88 1.9 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.971 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 96.5 p -88.37 -54.8 4.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -67.4 -19.62 65.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.192 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.428 ' CD1' ' HA ' ' A' ' 280' ' ' THR . 23.5 m-85 -59.49 -176.94 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.748 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 48.1 t -78.18 -175.81 4.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.895 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.79 127.25 48.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.907 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.495 ' CE1' HG13 ' A' ' 253' ' ' VAL . 65.4 t80 -72.21 140.97 48.99 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 26.1 mt -125.45 -63.51 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.09 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 5.7 mmt180 -153.94 175.56 13.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.655 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.48 149.65 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.424 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 141.06 115.47 1.19 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.768 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 18.4 mm -114.29 133.43 60.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 120.743 0.306 . . . . 0.0 110.821 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.55 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.1 p -99.89 114.65 38.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.035 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.3 m -119.56 154.44 33.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.051 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.481 ' C ' HG23 ' A' ' 295' ' ' VAL . 12.9 tt0 -66.53 85.85 0.11 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.962 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.581 HG22 ' HB2' ' A' ' 247' ' ' PHE . 0.0 OUTLIER 51.17 -179.47 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.414 179.746 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.48 -65.19 0.18 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 16.3 m -141.08 130.94 13.02 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.041 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.66 -168.37 0.49 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.49 2.126 . . . . 0.0 112.372 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.92 154.35 25.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.72 33.03 5.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.882 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.555 ' O ' HG23 ' A' ' 301' ' ' ILE . 2.5 tt -171.07 114.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.099 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.82 -66.9 0.19 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.874 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -138.85 -55.56 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 61.0 106.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 3.0 p -175.09 134.47 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.964 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.8 mp -131.93 68.95 80.89 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.835 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.79 -172.28 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.561 2.174 . . . . 0.0 112.242 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -131.16 161.45 32.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.118 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 93.3 p -70.16 88.31 0.61 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.88 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -115.6 110.39 19.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t 59.73 86.91 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.152 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.174 -0.917 . . . . 0.0 110.878 179.999 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.841 0.353 . . . . 0.0 111.169 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -79.48 95.2 5.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.872 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 179.03 -36.74 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -123.5 75.86 1.36 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.85 0.357 . . . . 0.0 110.949 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 22.0 mm-40 -151.88 137.27 17.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.945 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 5.3 mtp -108.11 127.66 54.0 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.583 ' O ' HG13 ' A' ' 207' ' ' VAL . 8.1 p -133.49 69.43 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.002 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.12 114.73 28.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.787 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.42 HG22 ' H ' ' A' ' 210' ' ' ASP . 2.3 m -128.88 168.3 16.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.896 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.42 ' H ' HG22 ' A' ' 209' ' ' THR . 1.8 t0 -63.58 -172.9 0.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.928 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 27.9 m -78.3 -35.89 47.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.824 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -106.69 143.55 34.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.826 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -103.08 -95.03 2.31 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.534 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 60.01 96.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.943 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -73.2 124.07 90.2 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.815 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -54.97 -171.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.407 2.071 . . . . 0.0 112.28 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.83 126.04 35.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.747 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 50.2 p -136.21 127.87 28.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -122.18 148.8 44.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.079 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -78.31 145.97 35.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.948 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.0 t -99.94 140.6 18.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 6.5 t -105.93 -29.66 9.83 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.016 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.81 158.69 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.027 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.481 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.6 p -160.93 122.08 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 65.0 p -84.31 143.25 29.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.037 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.42 56.34 3.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.473 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.6 t0 -91.61 -151.02 0.26 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.818 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -159.85 90.57 1.84 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-O 120.489 0.185 . . . . 0.0 111.372 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.473 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 71.8 Cg_endo -73.24 169.11 74.02 Favored 'Cis proline' 0 C--N 1.347 0.493 0 C-N-CA 123.244 -1.565 . . . . 0.0 111.836 -0.132 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -101.41 147.28 17.59 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.436 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 19.1 t -99.81 145.65 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.87 0.367 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.539 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 4.4 p -139.2 151.15 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.22 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.412 HG22 ' N ' ' A' ' 234' ' ' CYS . 63.6 m -122.5 161.01 24.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.412 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . 0.412 ' N ' HG22 ' A' ' 233' ' ' THR . 3.1 m -99.84 169.29 9.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.879 0.371 . . . . 0.0 110.86 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 2.9 tp -70.69 148.16 48.32 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.834 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -56.26 -30.83 62.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -106.36 50.76 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -178.35 152.79 0.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.25 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 20.7 ttm105 -135.89 155.41 50.34 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.857 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 23.4 p-80 -111.23 148.37 32.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.792 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -130.27 70.4 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.723 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.61 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.9 OUTLIER -126.55 141.54 51.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.766 0.317 . . . . 0.0 110.746 179.78 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.61 166.97 12.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.941 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 13.2 m -59.58 100.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 116.9 18.42 5.58 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.856 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.52 174.75 10.78 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.715 0.293 . . . . 0.0 110.767 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.4 m-85 -114.3 134.06 55.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.44 HG22 HG23 ' A' ' 267' ' ' ILE . 19.1 m -138.24 153.44 26.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.053 0.454 . . . . 0.0 111.359 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 11.1 p -124.2 165.11 18.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.577 179.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 1.055 ' CD2' HG21 ' A' ' 253' ' ' VAL . 1.9 m-30 -99.8 141.3 32.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.045 -179.69 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . 0.415 ' CB ' ' HB ' ' A' ' 291' ' ' ILE . 31.3 t -99.91 -101.65 0.23 Allowed 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.7 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' A' ' 290' ' ' GLY . 3.3 pt-20 -102.52 87.58 3.04 Favored 'General case' 0 C--O 1.223 -0.333 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 1.055 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.4 t -105.74 134.38 47.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.869 0.366 . . . . 0.0 111.786 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 18.8 mt-30 -99.9 116.02 30.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.777 178.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.35 -69.02 0.42 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.542 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.608 ' HG3' HD23 ' A' ' 259' ' ' LEU . 10.8 tpp -82.74 62.18 6.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.111 0.481 . . . . 0.0 110.235 179.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 37.2 pt -80.09 -33.34 14.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.274 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -38.64 -34.63 0.15 Allowed 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -178.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.792 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.2 mm? -72.8 -46.48 52.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.892 0.377 . . . . 0.0 110.703 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 24.2 t30 -57.57 -34.92 69.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.934 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.83 46.27 2.5 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.367 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.66 161.66 13.61 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.858 0.361 . . . . 0.0 110.898 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -54.99 156.83 6.44 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.682 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.794 ' HG3' HG11 ' A' ' 295' ' ' VAL . 19.6 Cg_endo -57.38 157.11 23.17 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.508 2.138 . . . . 0.0 111.941 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.635 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.7 ptp -117.07 -171.19 1.98 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -99.48 153.17 19.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.755 0.312 . . . . 0.0 110.615 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 248' ' ' VAL . 1.7 pp -121.84 173.62 7.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.643 0.735 . . . . 0.0 112.312 -179.315 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 6.1 tttt -144.43 127.14 16.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.749 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.61 HG11 ' O ' ' A' ' 242' ' ' PHE . 15.5 m -97.75 115.18 37.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.436 0.636 . . . . 0.0 111.598 -178.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.418 HD23 ' HA ' ' A' ' 270' ' ' LEU . 15.7 mt -94.96 -28.14 15.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.49 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.53 -178.95 39.5 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.576 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -50.61 -48.5 20.21 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.635 2.223 . . . . 0.0 112.217 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 80.8 m-85 -115.95 15.09 16.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.112 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.92 147.72 45.66 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.692 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.611 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 4.5 p90 -178.35 159.59 1.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.725 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 9.4 t -114.3 170.13 8.53 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.975 0.417 . . . . 0.0 111.32 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.06 -179.17 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.929 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 179.96 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.934 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -60.92 134.49 57.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 1.1 p -116.25 -19.92 10.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.372 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 93.0 p -52.92 -27.63 19.69 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.717 0.294 . . . . 0.0 111.332 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -77.76 -25.87 49.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.142 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.792 ' CE2' HD11 ' A' ' 259' ' ' LEU . 13.1 m-85 -91.09 -168.3 2.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.976 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 8.5 p -83.4 -147.09 0.08 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.568 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -119.07 147.11 44.5 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.831 0.348 . . . . 0.0 110.844 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.453 ' CD2' ' CG1' ' A' ' 224' ' ' VAL . 44.5 t80 -80.02 141.49 35.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 30.3 mt -120.45 -59.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.998 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 4.3 mmt85 -163.32 176.63 9.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.408 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.02 155.55 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.152 -1.023 . . . . 0.0 111.935 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.64 119.24 1.77 Allowed Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.867 178.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.415 ' HB ' ' CB ' ' A' ' 251' ' ' SER . 10.9 mt -122.25 134.56 65.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.812 0.339 . . . . 0.0 110.557 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.608 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.4 p -99.73 107.35 20.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.252 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 71.0 m -115.12 123.22 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.771 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.445 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 0.0 OUTLIER -72.65 111.15 7.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.025 -179.865 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.794 HG11 ' HG3' ' A' ' 264' ' ' PRO . 12.5 m -54.52 157.78 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.312 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.25 79.77 6.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.064 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.756 HG12 HG23 ' A' ' 295' ' ' VAL . 10.7 p -167.69 63.66 0.65 Allowed Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.208 179.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.455 ' HD3' ' N ' ' A' ' 297' ' ' VAL . 5.7 Cg_exo -78.05 -51.62 0.07 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.922 2.415 . . . . 0.0 112.335 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.5 149.64 16.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.182 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 1.2 ttmt -144.61 88.53 1.93 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.749 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 4.7 mt 66.35 92.39 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.016 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 4.8 t -110.95 110.81 21.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.934 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 65.97 -75.37 0.05 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.966 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 14.9 pttt -178.16 -176.17 0.52 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.885 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.24 113.89 6.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 60.72 101.49 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.833 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -49.59 166.21 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.487 2.125 . . . . 0.0 112.339 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 61.54 45.0 8.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.033 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -136.65 104.78 5.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.968 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 2.7 tp -82.83 -53.83 5.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.836 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . 0.59 HG12 ' O ' ' A' ' 311' ' ' VAL . 15.0 t -111.12 24.7 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.207 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.216 -0.897 . . . . 0.0 110.964 179.936 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 120.789 0.328 . . . . 0.0 111.151 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 65.7 m-85 59.53 92.85 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.015 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -152.79 134.34 4.43 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.517 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -139.67 153.17 47.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.774 0.321 . . . . 0.0 110.937 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -108.73 -31.61 7.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.956 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . 0.631 ' HG3' HG23 ' A' ' 207' ' ' VAL . 21.0 ptt? -94.53 172.65 8.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.009 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.631 HG23 ' HG3' ' A' ' 206' ' ' MET . 27.6 t 64.67 83.37 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.095 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -142.09 178.89 7.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.819 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 12.7 t -176.46 -160.77 0.07 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.851 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 75.23 106.71 0.08 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.891 0.377 . . . . 0.0 110.821 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.98 148.46 45.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.987 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -118.72 -43.43 2.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 111.01 -119.14 5.11 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.512 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 60.74 23.91 13.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.75 0.309 . . . . 0.0 111.01 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 8.8 mm100 -143.5 86.2 9.0 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.959 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.12 -177.6 2.07 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.663 2.242 . . . . 0.0 112.272 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 3.9 tp -87.55 162.27 17.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.857 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 19.5 p -162.34 107.7 1.21 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.48 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -100.08 153.77 18.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.978 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.686 ' SD ' HD22 ' A' ' 235' ' ' LEU . 38.8 mtt -90.68 145.77 24.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.935 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.424 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 98.8 t -99.87 136.62 30.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.815 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.1 t -105.95 -35.75 7.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.024 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -163.21 143.6 9.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.444 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.8 p -146.5 130.58 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.053 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 11.4 p -92.29 146.18 23.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.043 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.8 tttm -92.17 86.61 5.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.732 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.423 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.5 OUTLIER -132.96 -158.07 0.86 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.787 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 9.5 p-10 -158.73 91.87 2.01 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-O 120.503 0.192 . . . . 0.0 111.203 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.423 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 86.9 Cg_endo -75.86 169.52 74.28 Favored 'Cis proline' 0 C--N 1.347 0.498 0 C-N-CA 123.327 -1.53 . . . . 0.0 112.083 -0.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -109.97 146.9 17.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.471 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 20.9 t -99.85 126.87 53.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.973 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.566 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 3.8 p -121.09 155.32 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.275 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.438 ' N ' HG22 ' A' ' 232' ' ' VAL . 6.7 m -118.25 161.3 20.13 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.648 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.85 161.68 13.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.881 0.372 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.686 HD22 ' SD ' ' A' ' 220' ' ' MET . 8.2 tp -60.26 154.35 20.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.825 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -52.62 -27.12 15.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.032 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.497 ' HG3' HD23 ' A' ' 235' ' ' LEU . 3.2 pt-20 -128.48 37.37 4.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' A' ' 235' ' ' LEU . . . -94.77 -167.41 1.64 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.151 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.62 176.57 8.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.011 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -155.08 114.0 3.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.711 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -133.28 26.38 3.54 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.817 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 0.1 OUTLIER -106.4 135.32 48.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 179.799 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -89.85 174.34 7.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.071 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.28 101.33 0.3 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.861 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 113.97 15.86 8.27 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.732 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -76.4 -175.75 3.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.728 0.299 . . . . 0.0 110.653 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.483 ' HA ' ' O ' ' A' ' 265' ' ' MET . 63.1 m-85 -121.95 141.45 51.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.983 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.652 ' HB ' HG23 ' A' ' 292' ' ' VAL . 22.5 m -137.4 155.28 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.504 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.2 p -129.29 161.42 30.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.693 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.521 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.6 m-30 -99.85 137.11 38.76 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.999 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . 0.408 ' CB ' ' HB ' ' A' ' 291' ' ' ILE . 72.4 m -99.77 -104.85 0.22 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.671 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.505 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.3 OUTLIER -100.18 87.47 3.46 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.687 HG22 ' CA ' ' A' ' 290' ' ' GLY . 21.8 t -109.91 138.1 39.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.883 0.373 . . . . 0.0 111.707 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -100.73 118.66 37.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.935 179.145 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.45 -65.57 0.48 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.673 -179.049 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.653 ' HG2' HD23 ' A' ' 259' ' ' LEU . 6.3 ttm -85.11 58.95 5.32 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.053 0.454 . . . . 0.0 110.357 179.209 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 4.8 pt -79.99 -33.36 14.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.037 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -39.06 -34.75 0.18 Allowed 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.653 HD23 ' HG2' ' A' ' 256' ' ' MET . 2.7 mm? -79.86 -42.09 24.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.872 0.368 . . . . 0.0 110.701 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 44.8 t30 -54.99 -34.88 63.78 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.063 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.88 28.22 13.41 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.293 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -142.24 165.08 28.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 110.753 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -58.04 166.26 2.14 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.595 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.507 ' HG3' HG21 ' A' ' 295' ' ' VAL . 37.2 Cg_endo -65.48 158.39 53.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.363 2.042 . . . . 0.0 112.094 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.483 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 2.1 ptp -116.61 -174.17 2.52 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.517 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -99.56 151.26 21.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.719 0.295 . . . . 0.0 110.705 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.482 HG21 HG11 ' A' ' 248' ' ' VAL . 1.8 pp -122.22 174.96 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.612 0.72 . . . . 0.0 112.376 -179.542 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.625 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.3 tptt -146.86 130.71 17.1 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.576 -1.193 . . . . 0.0 108.5 178.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 269' ' ' VAL . 31.0 m -97.74 120.17 46.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.494 0.664 . . . . 0.0 111.585 -178.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.432 HD23 ' HA ' ' A' ' 270' ' ' LEU . 14.4 mt -98.2 -29.99 12.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.462 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.55 -175.3 36.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.524 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.85 -53.91 6.01 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.638 2.226 . . . . 0.0 112.387 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -112.77 23.22 13.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.126 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -133.23 148.45 52.0 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.751 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.625 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 3.3 p90 -175.33 167.3 3.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.888 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -117.58 170.15 8.98 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.473 HD12 HG21 ' A' ' 280' ' ' THR . 14.3 pt -133.09 -179.38 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.843 179.753 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.622 ' O ' HG23 ' A' ' 280' ' ' THR . 32.0 p -63.6 171.0 2.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.83 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.9 p-10 -58.73 112.22 1.55 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.966 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.622 HG23 ' O ' ' A' ' 278' ' ' CYS . 11.2 p -115.81 24.94 11.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.058 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 91.6 p -90.48 9.78 27.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.357 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 62.4 m-20 -111.38 -32.05 6.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.348 . . . . 0.0 110.801 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.552 ' CE2' HD11 ' A' ' 259' ' ' LEU . 12.3 m-85 -78.17 -165.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.802 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.96 -179.78 6.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.868 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -94.1 130.86 40.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.449 ' CE2' HG13 ' A' ' 253' ' ' VAL . 54.4 t80 -60.12 136.33 57.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.838 179.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 47.7 mt -115.73 -67.92 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.09 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -151.91 174.01 14.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.297 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 60.82 155.98 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.911 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.687 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 138.78 116.12 1.38 Allowed Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.901 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.469 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.1 mp -121.98 138.33 52.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.8 0.334 . . . . 0.0 110.573 179.599 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.652 HG23 ' HB ' ' A' ' 248' ' ' VAL . 13.4 p -99.7 124.95 53.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.517 -179.404 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -121.76 131.94 54.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.528 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.449 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER -86.06 97.82 10.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.317 -179.584 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.507 HG21 ' HG3' ' A' ' 264' ' ' PRO . 35.9 m -58.79 143.18 13.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.753 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -134.17 24.72 3.87 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.339 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.445 ' HB ' ' HD3' ' A' ' 298' ' ' PRO . 2.0 t -90.12 -50.21 0.36 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.406 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.445 ' HD3' ' HB ' ' A' ' 297' ' ' VAL . 3.7 Cg_exo -80.83 -168.23 0.6 Allowed 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.998 2.465 . . . . 0.0 112.219 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 18.5 tttt -179.13 -50.99 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.766 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 3.6 tptt -140.97 -63.8 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.836 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 2.5 pp -71.56 -179.06 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.085 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 99.0 p -161.9 -49.72 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.948 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -68.23 172.8 5.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -133.44 154.52 50.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.909 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 59.5 p -157.38 94.66 1.4 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 5.7 mp -112.03 87.09 8.3 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.881 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.58 139.76 41.67 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.576 2.184 . . . . 0.0 112.406 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -147.81 -55.17 0.22 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.06 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.87 -76.52 0.6 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.89 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 13.6 mt 58.9 -178.94 0.08 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.907 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t -116.74 -39.28 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.094 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.888 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 . . . . . 0 N--CA 1.486 1.328 0 CA-C-O 120.86 0.362 . . . . 0.0 111.202 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -110.88 162.8 14.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.876 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 162.63 -145.92 11.24 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.539 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -157.16 102.71 1.97 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.847 0.356 . . . . 0.0 110.9 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -142.0 -53.64 0.43 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.877 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -78.47 161.25 27.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.908 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t -151.97 -49.12 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.13 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 1.4 mp -112.79 142.88 44.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.924 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.65 -30.73 7.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.918 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 61.56 170.77 0.11 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 16.1 m 60.8 84.47 0.13 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.93 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -174.4 144.47 0.91 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.968 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -165.02 -52.16 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.49 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -94.43 -170.74 2.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.732 0.301 . . . . 0.0 110.815 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.61 75.64 0.39 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.88 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.04 -29.27 22.79 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.69 2.26 . . . . 0.0 112.254 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.754 HD21 ' O ' ' A' ' 241' ' ' GLY . 1.1 mp -91.09 127.72 36.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.747 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.87 150.11 22.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.086 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.45 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -156.63 154.19 29.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 3.4 mtt -95.23 164.19 12.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.112 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 36.5 t -114.72 140.43 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 4.3 t -114.42 -26.33 8.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.255 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -166.73 162.63 16.33 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.851 0.358 . . . . 0.0 111.042 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.444 ' CG1' ' CG ' ' A' ' 286' ' ' TYR . 11.8 p -168.02 151.64 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.176 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 40.1 p -113.93 150.53 33.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 7.5 ttmt -92.53 84.82 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.859 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.414 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 1.3 t0 -134.67 -160.16 1.03 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.823 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.403 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 14.1 p-10 -156.28 89.7 2.74 Favored Pre-proline 0 CA--C 1.531 0.233 0 CA-C-O 120.506 0.193 . . . . 0.0 111.371 -179.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.414 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 85.1 Cg_endo -79.36 169.45 71.28 Favored 'Cis proline' 0 C--N 1.349 0.591 0 C-N-CA 123.448 -1.48 . . . . 0.0 112.202 -0.078 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.65 155.24 16.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.391 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.5 t -99.87 111.09 28.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.9 0.381 . . . . 0.0 111.028 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.619 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.0 p -102.9 151.95 5.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.059 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -128.12 139.73 52.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.312 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 61.3 m -99.91 170.07 8.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.023 0.44 . . . . 0.0 111.133 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.638 HD23 ' H ' ' A' ' 237' ' ' GLU . 3.6 tt -49.68 161.27 0.23 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.923 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -42.05 -31.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.109 -0.496 . . . . 0.0 112.242 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.638 ' H ' HD23 ' A' ' 235' ' ' LEU . 7.3 pt-20 -165.5 51.1 0.1 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.816 0.341 . . . . 0.0 111.239 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -121.33 30.99 6.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.484 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -150.15 131.76 14.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.866 0.365 . . . . 0.0 111.121 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 170.04 90.16 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.852 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . 0.754 ' O ' HD21 ' A' ' 217' ' ' LEU . . . 179.79 -35.69 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.779 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.45 ' CD1' HD23 ' A' ' 217' ' ' LEU . 0.1 OUTLIER -85.63 134.5 33.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.922 0.391 . . . . 0.0 110.719 -179.86 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -105.61 171.39 7.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.83 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 62.8 m -53.06 102.03 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 112.37 25.36 4.7 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.593 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -93.89 166.61 12.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.777 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 265' ' ' MET . 94.6 m-85 -110.86 135.48 51.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.832 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.477 HG22 HG23 ' A' ' 267' ' ' ILE . 14.7 m -143.18 145.58 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.436 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 16.9 p -116.27 170.27 8.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.571 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 1.024 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.5 m-30 -99.46 139.61 34.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.938 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -104.73 -87.95 0.44 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.222 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.4 OUTLIER -108.14 88.06 2.64 Favored 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 116.848 -0.16 . . . . 0.0 110.826 179.802 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 1.024 HG21 ' CD2' ' A' ' 250' ' ' PHE . 11.2 t -113.95 132.13 63.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 120.945 0.403 . . . . 0.0 111.803 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -99.77 115.89 30.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.925 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.94 -59.55 0.59 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.552 -178.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.538 ' HG2' HD23 ' A' ' 259' ' ' LEU . 2.5 ttm -92.14 54.63 2.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.107 0.479 . . . . 0.0 110.163 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.438 HG22 ' O ' ' A' ' 253' ' ' VAL . 33.2 pt -77.21 -33.55 20.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.763 -179.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -39.14 -34.66 0.18 Allowed 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.835 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.538 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.5 mm? -66.65 -47.11 73.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.915 0.388 . . . . 0.0 110.618 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -56.37 -34.78 66.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.909 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.54 46.24 2.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.318 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.7 t -167.61 163.83 14.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.749 0.309 . . . . 0.0 110.596 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.28 166.33 0.9 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.586 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.441 ' HG3' HG21 ' A' ' 295' ' ' VAL . 51.5 Cg_endo -68.82 178.61 3.83 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.311 2.007 . . . . 0.0 112.013 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.532 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.0 OUTLIER -136.89 176.18 8.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.78 -179.957 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -99.49 125.07 45.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.56 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.477 HG23 HG22 ' A' ' 248' ' ' VAL . 1.4 pp -88.7 163.88 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.546 0.689 . . . . 0.0 112.229 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.655 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.5 OUTLIER -137.88 125.52 22.25 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.744 -1.117 . . . . 0.0 108.586 178.445 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.53 HG23 ' O ' ' A' ' 269' ' ' VAL . 30.3 m -97.29 114.77 35.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.547 0.689 . . . . 0.0 111.573 -178.287 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 14.0 mt -92.03 -28.45 17.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.494 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -161.59 -163.52 14.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.589 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.47 -48.67 4.15 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.572 2.182 . . . . 0.0 112.111 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -115.27 7.77 15.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.212 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.67 152.73 30.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.764 0.316 . . . . 0.0 110.676 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.655 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.1 p90 -179.78 162.44 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.821 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.7 t -118.64 169.99 9.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.07 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.517 HD11 ' CG2' ' A' ' 280' ' ' THR . 1.3 pp -134.22 -177.51 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.911 179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.406 ' HB2' ' HB2' ' A' ' 265' ' ' MET . 0.1 OUTLIER -54.88 -176.4 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 0.0 111.048 -179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -71.89 99.77 2.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.517 ' CG2' HD11 ' A' ' 277' ' ' ILE . 3.2 t -102.83 56.57 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 59.8 p -104.85 -26.38 12.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.988 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -96.54 31.53 2.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.98 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -126.08 -175.66 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.79 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.45 170.97 12.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.91 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -83.96 122.09 28.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.521 ' CE2' HG13 ' A' ' 253' ' ' VAL . 37.5 t80 -59.25 142.81 50.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.722 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 33.7 mt -119.92 -69.21 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.237 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.2 173.82 14.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.729 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 61.41 153.81 0.03 OUTLIER Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.216 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.0 124.38 2.2 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.904 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 30.8 mt -123.04 134.45 66.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.789 0.328 . . . . 0.0 110.797 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.645 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.1 p -99.94 102.42 13.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.963 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.7 m -113.72 150.89 32.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.022 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 -79.62 121.63 25.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.441 HG21 ' HG3' ' A' ' 264' ' ' PRO . 2.0 m -57.38 163.01 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.27 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 1.4 pttt -139.0 30.05 2.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.93 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 29.8 m 41.67 53.24 7.26 Favored Pre-proline 0 CA--C 1.531 0.23 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.704 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.27 64.83 3.56 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.538 2.159 . . . . 0.0 112.289 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -113.72 40.71 2.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.929 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.43 33.92 4.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.952 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -68.76 -32.71 55.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.07 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 37.9 t -69.82 140.99 53.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.92 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.55 -46.35 7.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.939 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 3.9 tptm -137.12 -62.14 0.64 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.908 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 1.8 m -148.14 128.33 13.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.623 HD11 HD22 ' A' ' 310' ' ' LEU . 0.2 OUTLIER -112.29 103.62 55.49 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.819 179.951 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -50.32 -62.78 0.35 Allowed 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.449 2.099 . . . . 0.0 112.424 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -179.54 -71.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -85.08 91.65 8.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.945 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . 0.623 HD22 HD11 ' A' ' 306' ' ' LEU . 1.6 tp -111.17 -47.28 3.22 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.862 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.1 p -101.41 -29.09 3.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.087 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.937 -179.974 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.831 0.348 . . . . 0.0 111.184 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -94.04 -169.15 2.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.845 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 135.64 -111.6 0.91 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.491 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 62.79 -79.84 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.708 0.289 . . . . 0.0 111.02 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -102.26 -44.88 5.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.974 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 69.2 -64.39 0.33 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.977 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 9.8 t 73.5 91.2 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -127.7 -176.86 3.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.77 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.406 HG23 ' O ' ' A' ' 209' ' ' THR . 3.7 t -109.89 76.7 1.01 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.865 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -108.45 141.37 40.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.92 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 4.4 m -150.89 35.88 0.61 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.942 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 15.8 p-10 -164.78 -43.95 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.938 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -143.05 174.15 23.81 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.564 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 59.64 21.05 9.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.677 0.275 . . . . 0.0 111.218 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.529 ' CB ' ' HD3' ' A' ' 216' ' ' PRO . 2.5 mm-40 -122.41 -60.4 0.03 OUTLIER Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.326 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.529 ' HD3' ' CB ' ' A' ' 215' ' ' GLN . 32.5 Cg_exo -58.18 -161.83 0.02 OUTLIER 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.164 1.91 . . . . 0.0 112.215 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 2.1 tp -138.31 100.97 4.26 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.7 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 52.8 p -124.47 146.91 48.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.04 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.658 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -128.38 167.05 17.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.001 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.423 ' SD ' HD22 ' A' ' 235' ' ' LEU . 11.6 mtt -94.09 148.56 22.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.923 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 49.1 t -99.91 139.32 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.953 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.3 t -106.77 -32.94 7.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.053 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.4 mtp -168.89 144.28 3.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.973 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.595 HG23 ' HB ' ' A' ' 232' ' ' VAL . 10.8 p -142.78 140.87 27.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.047 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 15.6 p -95.91 144.31 26.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.028 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 1.6 tttt -94.1 83.01 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.456 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.2 t0 -128.67 -158.17 0.87 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.738 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 1.6 p30 -154.27 89.62 3.3 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-O 120.472 0.177 . . . . 0.0 111.336 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.456 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 93.7 Cg_endo -77.71 169.16 74.37 Favored 'Cis proline' 0 C--N 1.347 0.491 0 C-N-CA 123.437 -1.485 . . . . 0.0 111.996 -0.162 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -108.76 149.77 17.01 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.598 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.8 141.81 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.72 0.295 . . . . 0.0 110.905 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.61 HG13 ' CE1' ' A' ' 275' ' ' PHE . 5.3 p -134.43 157.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.246 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.482 ' N ' HG22 ' A' ' 232' ' ' VAL . 91.8 m -122.11 156.79 32.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.582 179.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.7 m -99.94 166.14 11.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.919 0.39 . . . . 0.0 110.721 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.556 HD23 ' HB2' ' A' ' 237' ' ' GLU . 2.5 tp -66.98 148.15 52.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.785 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -55.38 -26.73 43.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.556 ' HB2' HD23 ' A' ' 235' ' ' LEU . 3.2 mm-40 -98.05 -26.28 14.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.016 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.658 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -68.85 172.68 6.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.21 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -145.97 145.25 30.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.967 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.417 ' CE1' HG12 ' A' ' 269' ' ' VAL . 17.2 t-80 -98.36 135.65 39.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -137.09 27.82 2.86 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.525 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.576 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.1 OUTLIER -116.34 146.34 42.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.584 179.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -102.55 173.26 6.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.141 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.522 ' CG2' HG22 ' A' ' 269' ' ' VAL . 80.6 p -59.87 103.17 0.19 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.84 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 127.87 -17.78 6.0 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.531 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -58.09 -178.8 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.739 0.304 . . . . 0.0 110.808 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' A' ' 265' ' ' MET . 49.1 m-85 -122.99 162.08 23.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.07 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.622 ' HB ' HG23 ' A' ' 292' ' ' VAL . 28.8 m -151.74 155.06 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.5 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.8 p -129.66 159.31 36.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.501 179.627 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 1.028 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.3 m-30 -99.65 136.3 39.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.0 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 35.1 t -99.78 -92.49 0.28 Allowed 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.543 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.73 87.77 2.61 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.468 179.499 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 1.028 HG21 ' CD2' ' A' ' 250' ' ' PHE . 3.9 t -106.3 137.59 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.939 0.4 . . . . 0.0 111.809 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -99.97 112.83 25.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.813 179.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.04 -60.28 0.56 Allowed Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.69 -178.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.646 ' HG2' HD23 ' A' ' 259' ' ' LEU . 3.0 ttm -87.88 59.15 5.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.144 0.497 . . . . 0.0 110.478 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.409 HG13 ' N ' ' A' ' 258' ' ' GLN . 28.7 pt -79.95 -33.57 14.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.922 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.409 ' N ' HG13 ' A' ' 257' ' ' ILE . 1.8 mp0 -38.89 -34.64 0.16 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.36 -0.382 . . . . 0.0 112.021 -178.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.849 HD11 ' CE2' ' A' ' 283' ' ' PHE . 3.1 mm? -73.01 -46.01 54.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.901 0.381 . . . . 0.0 110.634 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -56.23 -34.85 66.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.864 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.03 46.61 2.89 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.351 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.8 t -170.35 160.99 7.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -56.22 156.26 11.17 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.704 179.792 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.796 ' CG ' HG21 ' A' ' 295' ' ' VAL . 19.3 Cg_endo -58.22 171.76 1.61 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.318 2.012 . . . . 0.0 112.062 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.674 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.6 OUTLIER -131.75 -174.36 3.39 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.628 -179.892 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -99.51 148.86 23.82 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.724 0.297 . . . . 0.0 110.698 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.561 HD11 ' HB2' ' A' ' 242' ' ' PHE . 1.0 OUTLIER -118.64 177.36 2.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.637 0.732 . . . . 0.0 112.376 -179.2 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.658 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.44 130.27 19.27 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.473 -1.239 . . . . 0.0 108.27 178.585 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.576 HG11 ' O ' ' A' ' 242' ' ' PHE . 31.9 m -97.49 117.61 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.588 0.708 . . . . 0.0 111.691 -178.243 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.464 ' HA ' HD23 ' A' ' 270' ' ' LEU . 14.3 mt -91.16 -28.31 17.95 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.846 -1.07 . . . . 0.0 110.545 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 162.64 -166.57 36.75 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.224 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -52.83 112.66 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.785 2.323 . . . . 0.0 112.506 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 62.4 m-85 63.07 18.02 10.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.107 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -128.42 136.95 51.58 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.454 179.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.658 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 7.1 p90 -176.77 160.64 1.94 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.806 -179.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.1 t -112.61 170.11 8.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.998 0.428 . . . . 0.0 111.179 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.558 HG22 HG22 ' A' ' 267' ' ' ILE . 0.9 OUTLIER -130.88 -179.5 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.919 179.83 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -55.5 -173.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.983 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -58.67 122.56 13.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.5 24.19 13.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.081 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 34.0 t -98.31 -26.6 14.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.031 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.404 ' O ' ' CD1' ' A' ' 283' ' ' PHE . 17.8 t30 -97.41 34.83 1.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.969 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.849 ' CE2' HD11 ' A' ' 259' ' ' LEU . 24.5 m-85 -137.75 -175.5 4.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.852 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 28.7 t -86.35 176.98 7.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -85.62 132.2 34.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.964 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.467 ' CE2' HG13 ' A' ' 253' ' ' VAL . 16.3 t80 -77.49 144.44 37.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.66 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 35.7 mt -126.24 -68.43 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -146.91 -179.87 7.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.602 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.5 161.57 0.05 OUTLIER Glycine 0 C--N 1.332 0.324 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.27 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 132.56 116.22 1.73 Allowed Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.919 178.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 20.6 mt -118.66 133.92 63.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.798 0.332 . . . . 0.0 110.592 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.622 HG23 ' HB ' ' A' ' 248' ' ' VAL . 12.5 p -99.77 120.9 49.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.567 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 20.8 m -119.64 136.69 54.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.67 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.475 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 7.4 tt0 -82.13 96.62 7.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.187 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.796 HG21 ' CG ' ' A' ' 264' ' ' PRO . 31.0 m -71.47 64.59 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.017 179.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 2.7 ttpp -148.75 -66.12 0.23 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.97 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.3 t 67.51 73.76 0.35 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.429 ' C ' HD11 ' A' ' 301' ' ' ILE . 45.3 Cg_exo -56.18 95.72 0.06 OUTLIER 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.529 2.152 . . . . 0.0 112.237 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.99 137.67 53.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.992 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 43.48 82.28 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.552 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.429 HD11 ' C ' ' A' ' 298' ' ' PRO . 3.5 mp -120.3 -41.21 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.13 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 9.8 p 61.65 32.78 18.4 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.958 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 59.53 -171.14 0.13 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.034 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -146.52 124.34 11.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.936 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 14.5 p -138.02 50.12 1.92 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.677 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.449 ' N ' ' CD ' ' A' ' 307' ' ' PRO . 2.8 mp -79.61 -49.14 1.39 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.312 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.449 ' CD ' ' N ' ' A' ' 306' ' ' LEU . 92.4 Cg_endo -83.13 11.59 3.22 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.602 2.202 . . . . 0.0 113.087 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -55.68 123.73 15.07 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.797 0.332 . . . . 0.0 111.227 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.06 -56.81 1.1 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.959 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 1.1 mt -87.0 55.78 3.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.916 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . 0.426 HG12 ' N ' ' A' ' 312' ' ' GLU . 21.4 t -78.69 156.21 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.185 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . 0.426 ' N ' HG12 ' A' ' 311' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.794 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.486 1.372 0 CA-C-O 120.816 0.341 . . . . 0.0 111.16 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 13.5 t80 -103.48 -35.62 8.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.9 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 163.27 176.04 34.87 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.497 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -70.63 142.33 51.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.768 0.318 . . . . 0.0 110.962 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -165.26 137.91 4.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.89 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -148.5 -69.01 0.22 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.847 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.578 HG22 ' O ' ' A' ' 207' ' ' VAL . 14.5 p -177.84 45.23 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.025 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -159.02 74.89 0.67 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.88 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -113.41 -51.18 2.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.863 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 60.16 -176.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.892 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.98 -177.75 4.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.895 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -86.2 133.07 33.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -102.89 45.33 1.35 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.48 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -151.97 172.25 16.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.829 0.347 . . . . 0.0 110.847 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.05 94.51 4.0 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -66.97 154.14 75.61 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.432 2.088 . . . . 0.0 112.084 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.481 HD22 ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -150.44 -175.04 4.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.056 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.4 m -138.37 103.62 4.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.507 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.407 ' HB3' ' CZ ' ' A' ' 242' ' ' PHE . . . -102.12 157.7 16.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.973 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 34.1 mtp -101.73 167.98 9.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.9 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.39 128.6 70.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.992 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 7.6 t -104.31 -29.42 10.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -167.5 152.66 7.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.001 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.675 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.0 p -158.72 145.37 7.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 7.1 p -106.52 146.38 30.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.853 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.31 80.57 3.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.838 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.439 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.6 OUTLIER -126.22 -157.9 0.82 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -154.02 91.0 3.22 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.355 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.439 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 80.2 Cg_endo -76.3 169.07 75.44 Favored 'Cis proline' 0 C--N 1.348 0.516 0 C-N-CA 123.345 -1.523 . . . . 0.0 112.044 -0.143 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.9 151.9 17.59 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.494 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 22.1 t -99.98 145.86 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 111.135 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.7 p -142.7 150.2 18.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.097 -179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 273' ' ' TYR . 81.0 m -124.98 143.27 50.98 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.492 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 26.2 m -100.0 170.07 8.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.977 0.418 . . . . 0.0 111.054 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.736 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 1.2 tp -56.5 140.49 45.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.996 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -54.16 -26.7 29.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.984 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 13.6 mt-10 -114.84 34.49 4.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.736 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -166.41 76.44 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.204 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.48 HH22 HG12 ' A' ' 269' ' ' VAL . 38.3 tpt85 -150.06 87.07 1.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.828 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.481 ' O ' HD22 ' A' ' 217' ' ' LEU . 1.0 OUTLIER -178.8 106.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.107 179.986 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 162.11 -14.96 0.14 Allowed Glycine 0 CA--C 1.52 0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 113.562 179.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.568 ' HB2' HD13 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -131.75 132.19 43.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 117.17 0.485 . . . . 0.0 111.258 -179.41 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . 0.439 ' O ' HD11 ' A' ' 267' ' ' ILE . 0.7 OUTLIER -124.09 -169.58 1.99 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.778 179.863 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.2 m -61.32 106.07 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.068 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 100.67 26.94 7.79 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.684 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.55 169.75 8.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.765 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.481 ' HA ' ' O ' ' A' ' 265' ' ' MET . 76.8 m-85 -108.17 148.96 29.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.803 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.577 ' HB ' HG23 ' A' ' 292' ' ' VAL . 34.3 m -149.71 144.26 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 111.578 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.7 p -123.67 156.88 35.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.462 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.552 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.8 m-30 -99.52 139.09 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.3 m -99.7 -91.86 0.29 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.11 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.06 87.74 2.59 Favored 'General case' 0 C--O 1.224 -0.278 0 C-N-CA 121.21 -0.196 . . . . 0.0 110.822 179.703 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.704 HG22 ' CA ' ' A' ' 290' ' ' GLY . 21.2 t -109.31 143.69 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.871 0.367 . . . . 0.0 111.491 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -105.72 114.93 29.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.087 179.326 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.36 -64.07 0.52 Allowed Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.596 -179.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.903 ' HG2' HD23 ' A' ' 259' ' ' LEU . 31.1 ttm -88.91 54.54 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.165 0.507 . . . . 0.0 110.283 179.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.58 HG22 ' O ' ' A' ' 253' ' ' VAL . 2.2 pp -80.04 -33.76 14.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.928 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.463 ' HB3' ' CE2' ' A' ' 283' ' ' PHE . 5.7 mm-40 -39.07 -34.47 0.17 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 112.006 -178.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.903 HD23 ' HG2' ' A' ' 256' ' ' MET . 2.9 mm? -64.02 -48.36 76.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.839 0.352 . . . . 0.0 110.682 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.0 t-20 -55.66 -35.06 65.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.94 49.38 1.02 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.71 28.96 0.13 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.104 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . 0.402 ' HB3' ' HD2' ' A' ' 264' ' ' PRO . 6.7 mt-30 60.86 156.67 0.11 Allowed Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.525 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.475 ' HG3' HG21 ' A' ' 295' ' ' VAL . 13.3 Cg_endo -55.77 176.33 0.17 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.35 2.033 . . . . 0.0 111.991 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.727 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.5 ptp -142.76 -173.9 4.01 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.632 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -99.39 137.33 38.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.345 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.568 HD13 ' HB2' ' A' ' 242' ' ' PHE . 1.1 pt -106.07 176.45 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.727 0.775 . . . . 0.0 112.472 -179.063 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 5.5 tttt -148.21 129.95 15.11 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.162 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.48 HG12 HH22 ' A' ' 239' ' ' ARG . 29.0 m -97.3 123.83 49.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.583 0.706 . . . . 0.0 111.423 -178.251 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 55.1 mt -96.41 -28.17 14.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.82 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 169.59 -160.78 34.06 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.417 -0.897 . . . . 0.0 113.14 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.7 111.49 1.92 Allowed 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.711 2.274 . . . . 0.0 112.294 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.824 ' O ' HG23 ' A' ' 233' ' ' THR . 16.2 m-85 71.1 9.37 6.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.23 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.6 p -124.52 145.0 49.81 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.754 0.312 . . . . 0.0 110.617 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.688 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.1 p90 -178.61 170.04 1.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.744 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 4.9 t -120.35 169.93 9.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.15 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.861 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.1 pp -138.54 -177.91 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.025 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.861 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -54.89 163.65 0.96 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.974 179.962 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -58.41 140.4 53.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.007 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 6.2 t -145.67 31.83 1.06 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 19.9 p -71.24 -46.8 60.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.89 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 12.1 t30 -76.98 -22.53 53.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.059 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.463 ' CE2' ' HB3' ' A' ' 258' ' ' GLN . 3.3 m-85 -67.83 -176.15 0.63 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.3 m -87.29 151.14 23.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -71.2 142.23 50.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.006 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.444 ' CG ' ' CG1' ' A' ' 224' ' ' VAL . 17.6 t80 -72.1 144.96 48.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.88 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 20.5 mt -124.49 -63.96 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.4 mmt180 -152.8 178.85 9.19 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.434 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 58.33 164.53 0.08 OUTLIER Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.283 -0.961 . . . . 0.0 112.085 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.704 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 127.89 114.97 1.86 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.038 178.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.651 HD12 ' N ' ' A' ' 291' ' ' ILE . 3.2 mp -121.56 131.06 73.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.79 0.329 . . . . 0.0 110.151 179.228 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.577 HG23 ' HB ' ' A' ' 248' ' ' VAL . 12.9 p -99.83 118.13 46.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.389 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 58.0 m -121.32 146.95 46.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 6.6 tm0? -84.57 98.33 10.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.962 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.475 HG21 ' HG3' ' A' ' 264' ' ' PRO . 30.3 m -60.59 122.55 11.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.162 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.58 -48.17 1.81 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.6 t -110.53 96.52 27.91 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.052 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -49.31 -56.65 2.95 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.523 2.149 . . . . 0.0 112.467 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.38 130.77 6.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.982 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 13.2 tptt -175.28 74.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.833 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.641 HD12 ' O ' ' A' ' 301' ' ' ILE . 2.4 pp -148.45 123.73 2.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.117 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 67.7 m -97.27 129.8 44.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.951 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -100.72 124.17 45.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.87 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.34 148.31 28.67 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.936 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 33.4 m -140.17 175.9 9.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.963 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 2.9 mp -99.42 126.77 36.45 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.835 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -73.46 166.08 30.8 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.466 2.11 . . . . 0.0 112.317 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . 59.49 164.75 0.05 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.174 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 5.8 m -146.77 -56.66 0.26 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.858 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -123.78 74.01 1.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.897 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 7.8 m -120.21 171.19 8.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.126 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.21 -0.9 . . . . 0.0 110.899 -179.966 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 120.802 0.334 . . . . 0.0 111.19 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -95.89 -37.23 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.86 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 169.05 -165.51 38.98 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.485 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -147.08 40.54 1.05 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.841 0.353 . . . . 0.0 110.878 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 62.5 mt-10 -59.84 171.4 0.93 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.918 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 3.7 mtm -89.91 118.22 29.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.866 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.486 ' O ' HG13 ' A' ' 207' ' ' VAL . 12.2 p -140.29 120.5 13.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.094 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 11.9 mt -131.32 52.21 2.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 2.9 m 61.85 114.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.823 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -73.86 164.95 25.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 16.8 p -154.39 113.49 3.68 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -125.76 103.05 7.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.874 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 124.09 -152.03 17.23 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.471 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -131.13 147.07 52.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.885 0.374 . . . . 0.0 110.928 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -164.79 142.44 5.23 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.849 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.93 -175.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.556 2.171 . . . . 0.0 112.243 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.462 HD23 ' HA3' ' A' ' 241' ' ' GLY . 0.2 OUTLIER -83.24 111.6 19.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.816 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.3 m -125.22 159.95 30.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.038 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.478 ' O ' HG23 ' A' ' 291' ' ' ILE . . . -143.96 162.0 37.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.031 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.72 146.39 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.065 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.0 137.59 27.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.91 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.6 t -108.84 -42.07 4.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -151.03 153.74 35.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.109 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.527 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.5 p -161.87 140.28 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.989 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 1.5 p -95.32 148.13 22.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.08 55.86 2.42 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.445 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -102.79 -158.32 0.66 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.708 179.966 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 7.0 p-10 -156.97 91.81 2.43 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 120.504 0.193 . . . . 0.0 111.307 -179.693 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.445 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 73.3 Cg_endo -75.54 169.6 74.08 Favored 'Cis proline' 0 C--N 1.348 0.529 0 C-N-CA 123.436 -1.485 . . . . 0.0 112.002 -0.182 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -110.96 152.54 17.47 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.558 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 25.5 t -99.98 124.69 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.885 0.374 . . . . 0.0 110.974 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.634 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 2.9 p -117.51 154.39 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.207 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.593 HG23 ' O ' ' A' ' 273' ' ' TYR . 1.3 m -120.57 155.51 33.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.567 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.0 m -99.94 162.58 12.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.844 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.498 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 4.3 tp -60.11 147.69 38.64 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.794 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -64.94 -26.95 68.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.084 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -95.47 -15.12 23.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.054 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.498 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -97.15 171.07 8.69 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.865 0.364 . . . . 0.0 111.172 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -135.1 160.58 37.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.923 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 14.5 p-80 -96.81 146.81 24.57 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . 0.462 ' HA3' HD23 ' A' ' 217' ' ' LEU . . . -138.12 25.05 2.93 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.69 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.452 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.4 OUTLIER -128.3 147.57 50.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.803 0.335 . . . . 0.0 110.732 179.875 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -105.13 174.78 5.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.972 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 1.6 t -62.49 97.23 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.82 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 137.44 -17.43 3.53 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.561 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.54 -171.24 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.753 0.311 . . . . 0.0 110.8 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 265' ' ' MET . 88.7 m-85 -138.46 141.99 39.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.787 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.43 ' HB ' ' CG2' ' A' ' 292' ' ' VAL . 33.8 m -148.71 146.03 17.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.039 0.447 . . . . 0.0 111.545 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 21.3 p -112.73 170.08 8.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.33 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.863 ' CD2' HG21 ' A' ' 253' ' ' VAL . 4.2 m-30 -99.62 143.07 30.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.082 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 58.1 m -99.97 -86.64 0.38 Allowed 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.134 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.6 ' CG ' ' O ' ' A' ' 252' ' ' GLU . 0.0 OUTLIER -118.84 92.62 3.85 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-O 121.127 0.489 . . . . 0.0 110.008 179.997 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.863 HG21 ' CD2' ' A' ' 250' ' ' PHE . 5.0 t -109.15 149.03 12.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.349 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 288' ' ' ARG . 18.1 mm-40 -110.36 109.33 19.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.026 179.136 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.57 -53.47 0.83 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.6 -179.096 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.496 ' HG2' HD23 ' A' ' 259' ' ' LEU . 11.0 ttm -95.63 54.03 1.51 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.988 0.423 . . . . 0.0 110.333 179.456 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 43.7 pt -80.03 -34.35 15.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.71 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.0 mp0 -39.63 -34.62 0.25 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.748 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.724 HD12 ' SD ' ' A' ' 265' ' ' MET . 2.3 mm? -61.02 -46.44 90.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.38 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -61.55 -36.43 80.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.893 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -95.5 42.93 2.26 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.362 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.4 t -156.06 31.06 0.35 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.817 0.342 . . . . 0.0 110.934 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . 0.421 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 0.4 OUTLIER 59.67 168.03 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.622 -179.898 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.421 ' HD2' ' CB ' ' A' ' 263' ' ' GLN . 28.9 Cg_endo -62.78 -173.03 0.13 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.372 2.048 . . . . 0.0 112.04 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.724 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.4 OUTLIER -156.03 -177.95 6.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.635 -179.917 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -99.85 135.07 41.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.611 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.74 HG22 HG22 ' A' ' 277' ' ' ILE . 1.0 OUTLIER -105.67 178.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 0.0 112.087 -179.604 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.679 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 29.7 mttt -149.01 131.02 15.3 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.659 178.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 10.5 m -97.33 121.8 48.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.473 0.654 . . . . 0.0 111.367 -178.494 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.435 ' HA ' HD23 ' A' ' 270' ' ' LEU . 15.3 mt -96.81 -30.29 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.868 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 164.76 -166.79 38.21 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.074 -1.06 . . . . 0.0 113.404 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_exo -51.16 112.93 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.897 2.398 . . . . 0.0 112.696 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.593 ' O ' HG23 ' A' ' 233' ' ' THR . 31.9 m-85 60.37 20.59 10.17 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.036 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.6 p -130.86 139.47 50.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.586 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.679 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 2.6 p90 -177.17 166.13 2.35 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.734 -179.615 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 2.9 t -114.83 170.08 8.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.997 0.427 . . . . 0.0 111.133 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.74 HG22 HG22 ' A' ' 267' ' ' ILE . 0.8 OUTLIER -138.56 -179.69 2.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.916 179.923 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.44 160.5 3.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.999 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 13.5 p30 -56.81 138.03 53.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.024 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.432 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.6 p -133.09 27.11 4.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.954 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -69.54 -30.31 68.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.95 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -84.94 -31.11 23.78 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.432 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 21.3 m-85 -70.1 -175.51 0.97 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.829 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.99 179.83 6.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -89.63 124.93 35.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.47 ' CE2' HG13 ' A' ' 253' ' ' VAL . 15.1 t80 -59.41 139.55 56.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.776 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 31.8 mt -117.33 -62.2 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.021 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.414 ' O ' ' HB2' ' A' ' 254' ' ' GLN . 2.8 mmt180 -158.2 175.8 13.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.581 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.52 151.44 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.443 -0.884 . . . . 0.0 112.408 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 139.23 115.66 1.31 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.642 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 219' ' ' ALA . 3.4 mp -113.24 134.12 56.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.797 0.332 . . . . 0.0 110.954 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.559 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.5 p -99.81 115.04 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.124 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 69.0 m -119.05 143.49 47.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.15 -179.665 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -64.86 83.76 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.948 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER 39.88 92.83 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.844 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -80.18 -7.41 58.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.402 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.4 t 67.12 110.1 0.03 OUTLIER Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.578 0.228 . . . . 0.0 111.076 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_exo -51.45 179.43 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.486 2.124 . . . . 0.0 112.376 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -117.35 -39.55 3.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.972 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 5.5 ttmm -58.54 129.01 40.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.993 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 8.9 mt 59.7 100.51 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.064 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 37.1 p -135.57 143.6 45.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.816 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -98.87 32.88 2.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.915 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.59 141.45 47.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.842 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 1.1 m 59.83 172.47 0.08 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.925 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.728 ' O ' HD22 ' A' ' 306' ' ' LEU . 0.0 OUTLIER -51.77 139.06 31.78 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.271 -179.865 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -78.66 115.73 3.67 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.535 2.157 . . . . 0.0 112.347 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -89.72 76.53 7.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.001 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.0 m -131.81 151.19 51.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.002 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 4.9 tp -140.93 112.06 7.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.884 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.17 -48.68 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.07 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.258 -0.877 . . . . 0.0 110.878 179.979 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.484 1.275 0 CA-C-O 120.877 0.37 . . . . 0.0 111.172 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 57.7 m-85 -119.11 132.04 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.818 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 60.15 -178.97 2.6 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.529 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -87.96 89.62 8.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.886 0.374 . . . . 0.0 110.892 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -79.89 -67.64 0.74 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.872 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.96 -178.27 5.26 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.5 t 64.14 112.16 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.057 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -157.63 162.57 38.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.947 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 59.5 p -141.42 30.21 1.75 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.897 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -177.92 171.82 1.73 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -148.93 27.64 0.86 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.983 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -177.53 161.7 1.75 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 66.89 -155.79 52.12 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.62 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 61.39 152.89 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.913 0.387 . . . . 0.0 110.971 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.43 ' CB ' ' HD3' ' A' ' 216' ' ' PRO . 0.0 OUTLIER -179.02 -52.21 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.959 179.809 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.43 ' HD3' ' CB ' ' A' ' 215' ' ' GLN . 15.7 Cg_exo -67.88 84.33 0.42 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.537 2.158 . . . . 0.0 112.201 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.573 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.2 OUTLIER -68.01 163.29 22.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.837 -179.924 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 7.5 p -149.52 124.21 9.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.618 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -115.7 170.06 8.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.05 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.56 165.76 11.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.895 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.405 ' HB ' ' O ' ' A' ' 290' ' ' GLY . 88.0 t -115.4 125.96 72.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.908 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 27.9 t -108.13 -31.15 8.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.27 135.1 7.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.624 HG23 ' HB ' ' A' ' 232' ' ' VAL . 11.5 p -142.86 150.26 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 66.3 p -107.42 148.16 29.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 2.1 tmtt? -99.28 70.18 1.73 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.828 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 3.2 t0 -120.52 -159.64 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 20.4 p30 -153.6 91.03 3.32 Favored Pre-proline 0 CA--C 1.531 0.234 0 CA-C-N 116.717 -0.22 . . . . 0.0 111.328 -179.645 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.401 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 88.1 Cg_endo -78.21 169.75 72.14 Favored 'Cis proline' 0 C--N 1.348 0.535 0 C-N-CA 123.422 -1.491 . . . . 0.0 112.112 -0.142 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -114.8 149.84 18.78 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 23.7 t -99.74 140.13 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.878 0.371 . . . . 0.0 110.999 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.624 ' HB ' HG23 ' A' ' 224' ' ' VAL . 5.3 p -134.6 158.04 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.264 -179.691 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.481 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.6 OUTLIER -125.01 160.26 29.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.516 179.697 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.83 167.31 10.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.874 0.369 . . . . 0.0 110.903 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.748 HD23 ' HG2' ' A' ' 237' ' ' GLU . 1.0 OUTLIER -61.01 159.83 10.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.731 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -55.36 -29.87 59.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.014 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.748 ' HG2' HD23 ' A' ' 235' ' ' LEU . 1.8 pt-20 -117.48 32.35 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -78.19 -176.94 4.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.111 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 -144.16 148.02 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.943 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -96.99 141.84 29.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.822 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . 0.573 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -163.07 29.94 0.26 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.595 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.494 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.1 OUTLIER -147.74 130.56 16.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.752 0.31 . . . . 0.0 110.755 179.991 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.67 179.17 4.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.998 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.67 104.7 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.891 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 123.81 -13.64 8.11 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.757 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -67.67 172.98 4.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.809 0.338 . . . . 0.0 110.777 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -123.31 158.24 31.44 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.45 HG22 HG23 ' A' ' 267' ' ' ILE . 19.8 m -155.11 142.66 12.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.198 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.4 p -109.99 166.13 11.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.303 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.922 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.4 m-30 -99.66 152.24 20.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.863 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . 0.414 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 61.3 m -108.5 -98.77 0.38 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.072 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.498 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.6 OUTLIER -107.09 88.25 2.69 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.592 0.234 . . . . 0.0 110.666 179.892 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.922 HG21 ' CD2' ' A' ' 250' ' ' PHE . 4.1 t -100.93 148.28 7.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.042 0.449 . . . . 0.0 111.625 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.41 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.0 OUTLIER -111.1 108.59 18.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.576 178.955 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.35 -59.92 0.55 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.276 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.804 ' HG2' HD23 ' A' ' 259' ' ' LEU . 21.2 ttm -92.19 54.88 2.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.177 0.513 . . . . 0.0 110.061 179.08 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 9.0 pt -79.25 -33.23 15.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.598 -0.728 . . . . 0.0 112.22 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.42 ' HB3' ' CD1' ' A' ' 283' ' ' PHE . 2.5 mm100 -38.64 -34.54 0.15 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.86 -178.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.804 HD23 ' HG2' ' A' ' 256' ' ' MET . 3.3 mm? -67.69 -49.68 61.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.979 0.418 . . . . 0.0 110.474 179.403 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -58.65 -34.83 71.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.78 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -90.43 44.38 2.92 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.468 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 1.9 t -164.99 162.97 20.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.6 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -54.5 156.73 5.77 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.553 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.446 ' HG3' HG21 ' A' ' 295' ' ' VAL . 32.1 Cg_endo -63.05 169.53 8.96 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.272 1.982 . . . . 0.0 111.821 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.508 ' SD ' HD12 ' A' ' 259' ' ' LEU . 0.0 OUTLIER -134.55 -175.59 3.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.856 -179.69 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -99.66 154.66 18.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.417 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.76 HG22 HG22 ' A' ' 277' ' ' ILE . 1.0 OUTLIER -123.02 174.94 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.66 0.743 . . . . 0.0 112.194 -179.271 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.589 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 32.1 mmtm -143.27 129.07 19.39 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.705 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 269' ' ' VAL . 22.3 m -97.54 112.91 30.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.473 0.654 . . . . 0.0 111.48 -178.455 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 270' ' ' LEU . 13.3 mt -91.02 -27.06 18.88 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.569 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -166.45 -164.01 21.21 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.627 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -63.34 -50.62 3.35 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.585 2.19 . . . . 0.0 112.027 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.408 ' O ' HG23 ' A' ' 233' ' ' THR . 57.5 m-85 -114.1 12.47 17.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.047 179.665 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -118.83 147.32 44.06 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.636 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.613 ' CZ ' HG13 ' A' ' 232' ' ' VAL . 10.4 p90 -177.95 158.54 1.26 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.959 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.0 t -112.84 170.12 8.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.865 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.5 pp -135.93 -179.01 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.986 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.865 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.1 OUTLIER -55.56 -178.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.891 -179.982 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -68.13 110.32 3.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.44 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 6.9 t -110.33 32.97 4.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.4 m -87.78 -22.6 24.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -95.43 38.0 1.17 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.984 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.457 ' CE2' HD11 ' A' ' 259' ' ' LEU . 25.0 m-85 -137.76 -171.48 3.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.728 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -88.85 -166.93 1.72 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.83 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -96.75 145.23 26.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -85.89 139.58 31.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.733 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.87 HG22 ' HD3' ' A' ' 288' ' ' ARG . 68.4 mt -124.27 -71.16 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.87 ' HD3' HG22 ' A' ' 287' ' ' ILE . 3.4 mpt_? -138.93 -178.22 5.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.421 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 57.16 160.59 0.02 OUTLIER Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.389 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.585 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 128.99 102.11 1.04 Allowed Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.923 179.109 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.414 ' CD1' ' HB2' ' A' ' 251' ' ' SER . 4.5 mp -109.25 129.04 64.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.738 0.304 . . . . 0.0 110.193 179.363 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.618 HG13 ' HB3' ' A' ' 219' ' ' ALA . 14.3 p -99.61 108.83 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.051 0.453 . . . . 0.0 111.474 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.3 m -109.11 173.15 6.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.585 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -99.42 101.98 13.41 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.998 0.428 . . . . 0.0 111.032 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.714 ' CG1' HG12 ' A' ' 297' ' ' VAL . 0.5 OUTLIER -61.75 -39.31 82.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.989 179.99 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 4.0 tmtt? 62.79 48.6 4.05 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.368 179.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.714 HG12 ' CG1' ' A' ' 295' ' ' VAL . 11.8 p -106.62 88.34 3.36 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.96 0.409 . . . . 0.0 111.108 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.28 -47.46 1.61 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.509 2.139 . . . . 0.0 112.248 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 2.7 mttp -164.74 69.97 0.17 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.88 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.33 176.92 8.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.858 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 1.1 tp -178.98 -37.71 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.154 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -54.24 171.31 0.11 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.077 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -97.62 84.58 3.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 7.9 mmtt -101.98 102.09 12.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.97 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.26 -166.67 2.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.91 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 24.6 tp 63.47 64.87 1.34 Allowed Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.965 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.55 -48.45 21.83 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.551 2.168 . . . . 0.0 112.242 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -132.14 -178.85 5.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.051 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 17.7 m -155.0 121.02 5.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.899 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 3.8 mt -82.41 148.37 28.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.986 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 31.4 m -116.19 31.19 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.158 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 22.8 tp10 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.165 -0.921 . . . . 0.0 110.938 179.975 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 120.772 0.32 . . . . 0.0 111.22 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -98.59 30.67 3.17 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.965 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -157.81 125.77 1.61 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.494 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 5.8 mp0 -102.68 30.53 4.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.83 0.347 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -125.85 -80.38 0.61 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.91 179.877 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 171.83 41.01 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.937 0.399 . . . . 0.0 110.819 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.592 ' O ' HG13 ' A' ' 207' ' ' VAL . 11.5 p -92.01 109.63 21.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.06 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 5.9 tt -172.01 -60.36 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.563 HG23 ' O ' ' A' ' 209' ' ' THR . 9.0 t -106.14 106.32 16.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.873 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -131.83 114.49 14.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.962 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 2.2 t -71.07 -38.56 72.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.813 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 6.9 t30 60.78 -174.71 0.12 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.045 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 169.06 83.44 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.384 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 61.12 98.72 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.887 0.375 . . . . 0.0 110.881 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -176.9 93.81 0.24 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.896 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -49.66 -61.66 0.54 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.596 2.198 . . . . 0.0 112.382 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.409 HD22 ' HA3' ' A' ' 241' ' ' GLY . 0.1 OUTLIER -172.46 -176.83 1.63 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.947 179.969 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 p -162.57 141.74 9.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.948 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.506 ' HB3' HG13 ' A' ' 292' ' ' VAL . . . -137.4 154.66 49.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.101 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.7 mmm -101.23 156.61 17.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 44.6 t -100.67 138.94 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.973 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 15.0 t -110.24 -39.99 4.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.898 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 4.3 mmm -169.37 138.96 2.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.496 HG23 ' HB ' ' A' ' 232' ' ' VAL . 8.2 p -139.26 151.17 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.08 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.8 p -102.06 148.08 25.82 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.005 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 11.3 tmtt? -92.19 85.55 5.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.747 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.45 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 2.8 t0 -132.31 -154.79 0.64 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.758 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.423 ' HA ' ' HA ' ' A' ' 229' ' ' PRO . 31.4 p30 -159.04 90.77 2.0 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-O 120.445 0.164 . . . . 0.0 111.234 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.45 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 72.8 Cg_endo -74.96 169.03 75.65 Favored 'Cis proline' 0 C--N 1.348 0.543 0 C-N-CA 123.387 -1.505 . . . . 0.0 112.081 -0.282 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -105.42 151.31 17.14 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 16.9 t -99.9 131.86 46.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 111.074 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.584 HG13 ' CZ ' ' A' ' 275' ' ' PHE . 6.3 p -128.87 158.02 41.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.253 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.489 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -123.77 164.59 18.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.686 179.703 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.3 m -99.94 168.81 9.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.871 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 5.8 tp -64.88 151.25 46.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.9 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -58.71 -26.23 63.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.197 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -114.91 32.23 6.16 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -133.07 155.91 48.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.256 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.29 158.6 33.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.883 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -92.31 145.16 24.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . 0.409 ' HA3' HD22 ' A' ' 217' ' ' LEU . . . -136.97 42.45 1.31 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.579 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.46 ' HB2' HD11 ' A' ' 267' ' ' ILE . 0.4 OUTLIER -137.99 138.92 39.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.779 0.323 . . . . 0.0 110.775 179.889 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -88.68 171.9 9.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.924 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 3.5 m -62.72 101.88 0.29 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.868 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 117.24 0.32 18.9 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.85 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.407 ' CB ' ' HB3' ' A' ' 242' ' ' PHE . 0.4 OUTLIER -65.6 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.658 0.266 . . . . 0.0 110.777 179.923 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.56 ' HA ' ' O ' ' A' ' 265' ' ' MET . 38.2 m-85 -134.41 143.37 47.55 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.896 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.471 HG22 ' CG2' ' A' ' 267' ' ' ILE . 3.4 m -149.99 142.33 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.609 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 25.1 p -115.79 165.91 12.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.452 179.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.925 ' CD2' HG21 ' A' ' 253' ' ' VAL . 3.9 m-30 -99.71 148.67 24.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.992 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . 0.42 ' HB2' ' CD1' ' A' ' 291' ' ' ILE . 58.7 m -99.89 -90.32 0.31 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.09 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.496 ' O ' ' N ' ' A' ' 290' ' ' GLY . 5.1 pt-20 -113.22 88.03 2.74 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 120.519 0.199 . . . . 0.0 110.768 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.925 HG21 ' CD2' ' A' ' 250' ' ' PHE . 12.1 t -100.02 148.09 6.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.948 0.404 . . . . 0.0 111.6 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.406 ' N ' ' O ' ' A' ' 288' ' ' ARG . 0.9 OUTLIER -116.24 110.45 18.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 101.77 -62.21 0.53 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.627 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.726 ' SD ' HG21 ' A' ' 280' ' ' THR . 25.9 ttm -91.79 61.78 4.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.227 0.537 . . . . 0.0 110.225 179.237 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 23.8 pt -80.03 -32.3 13.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.336 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.445 ' HB2' ' CE2' ' A' ' 283' ' ' PHE . 3.8 tp-100 -37.61 -34.44 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 112.222 0.453 . . . . 0.0 112.222 -178.124 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.767 HD12 ' SD ' ' A' ' 265' ' ' MET . 3.1 mm? -67.65 -52.08 42.36 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.973 0.416 . . . . 0.0 110.414 179.457 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -64.61 -34.95 79.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.119 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.27 38.56 3.16 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.836 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 3.2 t -157.99 36.39 0.25 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.766 0.317 . . . . 0.0 111.08 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . 0.449 ' CB ' ' HD2' ' A' ' 264' ' ' PRO . 11.8 mt-30 59.05 169.16 0.07 OUTLIER Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.488 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.473 ' HG3' HG12 ' A' ' 295' ' ' VAL . 14.2 Cg_endo -56.97 -164.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.253 1.969 . . . . 0.0 111.593 179.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.767 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -169.44 -173.2 1.63 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.791 -179.713 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.55 143.23 30.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.407 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.471 ' CG2' HG22 ' A' ' 248' ' ' VAL . 1.1 pp -118.59 176.81 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.665 0.745 . . . . 0.0 112.388 -179.225 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.522 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -149.87 129.64 13.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.374 178.596 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 269' ' ' VAL . 29.3 m -97.59 112.11 28.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.507 0.67 . . . . 0.0 111.546 -178.255 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 40.4 mt -86.14 -29.78 23.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.476 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -160.9 -167.23 21.09 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -61.61 -43.52 26.54 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.508 2.139 . . . . 0.0 111.826 179.799 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -117.5 -5.1 11.23 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.049 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.3 p -100.2 148.26 24.81 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.841 0.353 . . . . 0.0 111.006 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.584 ' CZ ' HG13 ' A' ' 232' ' ' VAL . 6.7 p90 -178.58 162.62 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.566 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.409 ' HB3' ' HG3' ' A' ' 268' ' ' LYS . 3.7 t -112.39 167.37 10.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.993 0.425 . . . . 0.0 111.354 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.592 HD12 ' O ' ' A' ' 278' ' ' CYS . 2.2 pp -137.9 -173.42 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.751 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.592 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -52.0 179.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.932 0.396 . . . . 0.0 111.159 -179.939 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -94.69 140.59 29.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.998 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.726 HG21 ' SD ' ' A' ' 256' ' ' MET . 11.7 t -151.21 39.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.78 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 28.9 t -73.93 -7.57 52.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.574 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -108.33 5.94 25.99 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 120.522 0.201 . . . . 0.0 111.53 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.445 ' CE2' ' HB2' ' A' ' 258' ' ' GLN . 0.2 OUTLIER -110.73 -158.44 0.65 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.594 0.235 . . . . 0.0 110.883 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 2.2 m -96.49 156.62 16.26 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.856 0.36 . . . . 0.0 111.077 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -74.29 151.9 39.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.416 ' HB2' HG13 ' A' ' 224' ' ' VAL . 32.1 t80 -58.86 124.48 19.99 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.927 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 29.5 mt -102.77 -47.79 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.005 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.406 ' O ' ' N ' ' A' ' 254' ' ' GLN . 1.1 mmt-85 -176.97 175.37 1.59 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.167 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . 0.406 ' O ' ' CE2' ' A' ' 286' ' ' TYR . . . 60.39 158.42 0.06 OUTLIER Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.178 -1.01 . . . . 0.0 111.966 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 131.76 115.84 1.73 Allowed Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.586 -0.816 . . . . 0.0 112.723 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 219' ' ' ALA . 4.7 mp -125.26 128.38 72.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.843 0.354 . . . . 0.0 110.775 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.53 ' O ' HG13 ' A' ' 292' ' ' VAL . 14.5 p -100.0 118.79 47.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.175 -179.685 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.9 m -129.58 168.19 16.79 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.121 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.488 ' C ' HG23 ' A' ' 295' ' ' VAL . 1.4 tp60 -67.44 84.68 0.17 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.104 0.478 . . . . 0.0 111.034 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.488 HG23 ' C ' ' A' ' 294' ' ' GLN . 0.2 OUTLIER 55.03 167.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.553 -0.748 . . . . 0.0 111.474 179.387 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 27.5 tttt -82.99 -34.58 26.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.926 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 21.6 t 64.21 131.62 0.03 OUTLIER Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.961 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -72.37 -168.42 0.39 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.485 2.123 . . . . 0.0 112.361 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.64 84.76 0.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.974 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -166.12 155.86 12.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.891 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.442 HD12 ' H ' ' A' ' 303' ' ' PHE . 2.0 pp -117.48 152.81 19.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.119 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 66.8 m -120.0 37.66 4.16 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.878 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . 0.442 ' H ' HD12 ' A' ' 301' ' ' ILE . 2.8 m-85 61.21 166.73 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.863 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 2.0 mmtp -60.47 154.82 19.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.962 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . 0.49 ' O ' HD23 ' A' ' 306' ' ' LEU . 0.5 OUTLIER -149.99 94.7 2.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.95 179.885 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.49 HD23 ' O ' ' A' ' 305' ' ' SER . 11.8 mt -137.85 106.74 8.21 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.84 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -68.43 -44.1 3.64 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.422 2.081 . . . . 0.0 112.251 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -108.32 160.07 16.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.094 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.32 79.05 1.34 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.895 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 65.4 mt -88.12 -39.37 14.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.939 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.2 p -176.1 149.42 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.077 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.237 -0.887 . . . . 0.0 110.971 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 . . . . . 0 N--CA 1.485 1.321 0 CA-C-O 120.789 0.328 . . . . 0.0 111.239 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -92.2 96.33 10.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.965 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -157.72 129.53 2.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.522 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -103.7 -27.14 12.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.8 0.334 . . . . 0.0 111.065 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -64.87 81.16 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.031 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -161.93 -53.2 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.882 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 6.0 m -105.71 -30.6 2.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.074 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -107.78 29.87 6.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.85 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 2.7 t -93.59 -39.32 10.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.911 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -142.72 -74.56 0.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.944 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 16.5 m 60.05 162.19 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.935 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -175.66 38.89 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . -100.64 -140.62 11.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.477 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -167.48 -169.82 1.3 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.756 0.312 . . . . 0.0 110.881 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 60.69 98.64 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.83 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -49.39 176.14 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.493 2.129 . . . . 0.0 112.48 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -97.92 -171.09 2.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.926 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 11.2 t -166.53 155.67 11.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.796 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.585 ' HB3' ' CG1' ' A' ' 292' ' ' VAL . . . -149.1 166.8 27.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.019 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.557 ' HE1' HD22 ' A' ' 235' ' ' LEU . 10.9 mtp -107.63 147.48 30.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 40.5 t -105.93 139.56 26.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.995 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 8.3 t -106.61 -31.9 8.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.976 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.1 ptm -168.16 163.94 13.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.968 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.644 HG23 ' HB ' ' A' ' 232' ' ' VAL . 12.6 p -162.36 118.62 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.037 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 76.9 p -76.48 140.59 41.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.828 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -90.17 68.15 7.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.795 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.408 ' HB3' ' O ' ' A' ' 229' ' ' PRO . 5.0 t0 -106.69 -148.0 0.41 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.781 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -160.26 88.88 1.82 Allowed Pre-proline 0 CA--C 1.531 0.227 0 CA-C-O 120.536 0.208 . . . . 0.0 111.305 -179.67 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.408 ' O ' ' HB3' ' A' ' 227' ' ' ASP . 97.2 Cg_endo -76.4 169.52 74.23 Favored 'Cis proline' 0 C--N 1.347 0.488 0 C-N-CA 123.27 -1.554 . . . . 0.0 111.945 -0.148 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -100.43 147.63 18.08 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.501 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 26.2 t -99.81 118.89 47.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.847 0.356 . . . . 0.0 111.058 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.644 ' HB ' HG23 ' A' ' 224' ' ' VAL . 2.8 p -110.37 154.24 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.058 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.403 ' N ' HG22 ' A' ' 232' ' ' VAL . 0.2 OUTLIER -128.32 161.8 28.56 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.691 179.731 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 3.2 m -100.04 169.63 9.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.92 0.39 . . . . 0.0 110.845 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.655 HD23 ' HG2' ' A' ' 237' ' ' GLU . 0.4 OUTLIER -60.26 161.6 6.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.794 179.891 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -54.63 -32.86 59.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.074 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.655 ' HG2' HD23 ' A' ' 235' ' ' LEU . 9.3 pt-20 -119.16 32.19 6.24 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.824 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -82.81 -175.74 5.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.082 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.41 136.12 23.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.933 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . . . . . . . . . 2.8 t60 -105.9 137.24 44.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . -149.83 26.73 1.17 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.674 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.618 ' O ' HG11 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -114.52 138.39 50.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.813 0.339 . . . . 0.0 110.679 179.899 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 165.0 14.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.03 87.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 138.51 -12.72 3.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.718 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -57.46 -179.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.771 0.32 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.451 ' HA ' ' O ' ' A' ' 265' ' ' MET . 51.1 m-85 -125.07 146.77 49.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.057 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.436 HG22 HG23 ' A' ' 267' ' ' ILE . 19.5 m -148.47 147.86 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.173 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 6.5 p -115.95 167.88 10.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.623 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 1.038 ' CD2' HG21 ' A' ' 253' ' ' VAL . 2.6 m-30 -99.64 146.65 26.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.077 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . 0.412 ' HB2' ' HB ' ' A' ' 291' ' ' ILE . 53.8 m -109.46 -89.94 0.47 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.77 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.559 ' O ' ' N ' ' A' ' 290' ' ' GLY . 0.0 OUTLIER -110.2 87.59 2.56 Favored 'General case' 0 C--O 1.221 -0.397 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 179.416 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 1.038 HG21 ' CD2' ' A' ' 250' ' ' PHE . 8.0 t -109.47 134.98 49.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.92 0.39 . . . . 0.0 111.873 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 21.2 mt-30 -100.32 114.38 27.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.815 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 102.05 -58.6 0.61 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.672 -178.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.681 ' HG2' HD23 ' A' ' 259' ' ' LEU . 1.4 ttm -91.04 59.9 4.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.128 0.489 . . . . 0.0 110.359 179.358 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 1.6 pp -79.52 -33.37 15.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.985 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -39.1 -34.61 0.18 Allowed 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.876 -178.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.857 HD11 ' CE2' ' A' ' 283' ' ' PHE . 2.8 mm? -77.76 -44.45 27.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.87 0.366 . . . . 0.0 110.504 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -60.03 -34.84 73.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.851 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.52 42.92 2.38 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.324 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -165.42 171.14 13.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.803 0.335 . . . . 0.0 110.764 -179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 11.3 mt-30 -57.63 167.7 1.29 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.64 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.494 ' HG3' HG21 ' A' ' 295' ' ' VAL . 39.9 Cg_endo -66.5 -166.68 0.11 Allowed 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.38 2.053 . . . . 0.0 112.005 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.59 ' SD ' HD12 ' A' ' 259' ' ' LEU . 1.0 OUTLIER -156.07 -175.84 5.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.575 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -99.71 148.08 24.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.771 0.319 . . . . 0.0 110.628 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.707 HG22 HG22 ' A' ' 277' ' ' ILE . 1.6 pp -119.76 172.84 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.528 0.68 . . . . 0.0 112.263 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.627 ' O ' ' HB2' ' A' ' 275' ' ' PHE . 4.3 mmtm -143.47 127.97 17.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 114.71 -1.132 . . . . 0.0 108.736 178.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.618 HG11 ' O ' ' A' ' 242' ' ' PHE . 35.9 m -97.6 114.56 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.471 0.653 . . . . 0.0 111.503 -178.556 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.402 HD23 ' HA ' ' A' ' 270' ' ' LEU . 16.1 mt -92.5 -28.72 16.63 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.567 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.76 -163.66 18.38 Favored Glycine 0 N--CA 1.453 -0.202 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.593 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -64.08 -49.29 3.95 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.639 2.226 . . . . 0.0 111.992 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -114.82 11.58 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.101 179.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -118.95 148.54 42.84 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.856 0.36 . . . . 0.0 110.704 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.627 ' HB2' ' O ' ' A' ' 268' ' ' LYS . 1.9 p90 -177.5 161.73 1.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 12.2 t -123.38 170.27 10.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.01 0.433 . . . . 0.0 111.218 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.707 HG22 HG22 ' A' ' 267' ' ' ILE . 1.6 pp -133.9 -179.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.844 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.484 ' O ' HD12 ' A' ' 277' ' ' ILE . 0.4 OUTLIER -56.42 -170.1 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.076 -179.915 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -55.8 132.69 50.03 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.026 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.57 7.24 8.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.404 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 8.6 t -86.04 5.28 34.21 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.749 -0.205 . . . . 0.0 111.463 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -111.67 -23.48 10.63 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.684 0.278 . . . . 0.0 111.177 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.857 ' CE2' HD11 ' A' ' 259' ' ' LEU . 29.5 m-85 -85.43 -170.41 3.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.946 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 64.1 m -88.56 -175.43 4.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.86 137.27 32.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.582 ' CE1' HG13 ' A' ' 253' ' ' VAL . 70.0 t80 -78.13 146.61 35.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.773 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 27.1 mt -125.02 -67.87 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.186 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.55 176.43 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.559 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 59.96 158.25 0.05 OUTLIER Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.287 -0.958 . . . . 0.0 112.068 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 252' ' ' GLU . . . 137.13 108.83 0.9 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.98 178.66 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.412 ' HB ' ' HB2' ' A' ' 251' ' ' SER . 14.8 mm -106.5 130.98 57.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.727 0.299 . . . . 0.0 110.479 179.505 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.597 ' O ' HG13 ' A' ' 292' ' ' VAL . 13.5 p -99.72 109.75 25.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.916 0.389 . . . . 0.0 111.322 -179.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.1 m -111.77 156.34 22.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.654 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 -90.39 108.44 19.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.032 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.511 HG13 ' N ' ' A' ' 296' ' ' LYS . 0.5 OUTLIER -58.62 167.08 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.876 179.942 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.511 ' N ' HG13 ' A' ' 295' ' ' VAL . 3.9 tttp -151.09 -71.54 0.17 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.026 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.448 ' O ' HG23 ' A' ' 297' ' ' VAL . 5.7 m -141.5 96.44 6.96 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.115 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.39 115.73 4.18 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.43 2.087 . . . . 0.0 112.269 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 35.6 tptt -151.47 31.69 0.58 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.861 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 3.4 ptmt -122.66 109.1 13.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 33.5 mt -85.72 -67.98 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.168 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 50.4 p 179.77 163.05 0.99 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.889 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 63.37 -79.02 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.021 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -115.93 89.2 3.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.008 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . 0.444 ' OG ' HD12 ' A' ' 306' ' ' LEU . 2.5 p -97.17 -35.77 10.67 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.818 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.617 ' H ' ' HD2' ' A' ' 307' ' ' PRO . 0.6 OUTLIER -147.18 -60.13 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.217 179.69 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.617 ' HD2' ' H ' ' A' ' 306' ' ' LEU . 34.6 Cg_endo -63.62 77.32 0.14 Allowed 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 122.069 1.846 . . . . 0.0 112.236 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -176.23 -73.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.142 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 3.3 p 50.22 86.33 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.234 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 15.5 tp -164.86 91.4 0.55 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.886 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . 0.479 HG12 ' N ' ' A' ' 312' ' ' GLU . 21.5 t 62.52 158.85 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.136 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . 0.479 ' N ' HG12 ' A' ' 311' ' ' VAL . 37.9 mt-10 . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.858 -179.949 . . . . . . . . 1 1 . 1 stop_ save_